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Morphological characteristics Young 
(age <55) 
patients with 
cryptogenic 
stroke
(n=33)
Older
(age q55)
patients with 
cryptogenic 
stroke
(n=25)
P value
PFO Size (mm) 3.6 ± 1.5 4.3 ± 1.8 0.14
Large PFO (size q4mm) (%) 41 52 0.39
Presence of atrial septal aneurysm (ASA) (%) 36 56 0.14
Tunnel Length (mm) 14 ± 7 14 ± 4 0.82
Long Tunnel (q 1cm) (%) 73 84 0.31
Degree of shunting (%)
mild
moderate
severe
58
18
9
44
24
24
0.31
0.59
0.12
Prominent Eustachian valve (%) 24 16 0.44
Prominent Chiari network (%) 3 0 0.38
11:15 a.m.
2602-8 Association of Patent Foramen Ovale With Obstructive 
Sleep Apnea
Brian K. Whisenant, Benjamin D. Horne, Sherman G. Sorenson, Jeffrey L. Anderson, Heidi 
T. May, Tami L. Bair, Joseph B. Muhlestein, Intermountain Medical Center, Murray, UT
Background: Preliminary investigations have identiﬁed an increased prevalence of 
patent foramen ovale (PFO) among patients with sleep apnea when compared with 
controls. Sleep apnea induced pulmonary hypertension has been hypothesized to open 
PFOs. Hypoxic or peptide signals traversing the PFO may inhibit the central respiratory 
center. PFOs may also exacerbate sleep hypoxia as apnea induced thoracic pressure 
changes induce right to left shunting. Transcatheter PFO closure has been reported to 
diminish sleep hypoxia. We sought to compare the incidence of sleep apnea diagnosis in 
a population of patients with and without PFO.
Methods: Patients from the Intermountain Heart Collaborative Study (IHCS) with a PFO 
(n=245) conﬁrmed by a history of transcatheter PFO closure were compared with IHCS 
patients (n=11,302) undergoing cardiac catheterization who were found to be free from 
coronary artery disease, unstable angina, or myocardial infarction. The PFO and control 
patients were queried for ICD-9 diagnoses (327.2, 780.51, 780.53, 780.57) that indicate 
the presence of clinically-diagnosed sleep apnea.
Results: Signiﬁcant demographic differences were detected among the PFO and control 
populations. PFO patients were younger (51 years vs. 61 years, p<0.001), more likely 
to be women (61% vs. 43%, p<0.001), less likely to have hypertension (HTN) (10% vs. 
51%, p<0.001), or to use tobacco (4% vs. 16%, p<0.001). Sleep apnea occurred among 
PFO patients more than among controls (30% vs. 21%, p=0.009). After adjusting for 
age, sex, HTN, smoking history, chronic obstructive pulmonary disease, and body mass 
index, PFO remained signiﬁcantly associated with sleep apnea (odds ratio= 1.59, 95% 
conﬁdence interval=1.19, 2.12; p=0.002).
Conclusions: PFO was associated with sleep apnea among non-coronary cardiac 
patients. Further investigation is warranted to determine if a causative relationship exists 
between PFO and sleep apnea and if PFO closure beneﬁts sleep disordered breathing 
or sleep hypoxia.
I2.SYMPOSIUM
2627
i2.Interventional Pharmacology
Saturday, March 28, 2009, 10:00 a.m.-Noon
Orange County Convention Center, Room W415D
11:30 a.m.
2627-10 Platelet Response to Clopidogrel Assessed With Point-
of-Care Analysis and Drug-Eluting Stent Thrombosis
Dirk Sibbing, Siegmund Braun, Tanja Morath, Julinda Mehilli, Wolfgang Vogt, Albert 
Schomig, Adnan Kastrati, Nicolas von Beckerath, Deutsches Herzzentrum Munchen, 
Munich, Germany
Background: Prospective studies implementing different methods of platelet function 
testing have reported that an attenuated response to clopidogrel is associated with an 
increased risk of ischemic events following percutaneous coronary intervention (PCI) 
including stent thrombosis (ST). Light transmission aggregometry (LTA) has been the 
most widely used technique in this setting. However, LTA is time- and labor-intensive and 
a point-of-care assay with similar predictive power would be of great value. The aim of this 
prospective trial was to assess whether platelet response to clopidogrel measured with 
multiple electrode platelet aggregometry (MEA), a newly developed point-of-care assay, 
correlates with the risk of drug-eluting stent thrombosis.
Methods: Between February 2007 and April 2008, a total of 1608 consecutive patients 
with coronary artery disease and planned drug-eluting stent implantation were enrolled. 
Before PCI all patients received 600 mg clopidogrel. Blood was obtained directly before 
PCI. Adenosine diphosphate (ADP)-induced platelet aggregation was assessed in whole 
blood with MEA on a Multiplate analyzer (Dynabyte, Munich, Germany). The primary 
I2.SYMPOSIUM
2601
i2.Carotid Artery Disease
Saturday, March 28, 2009, 10:00 a.m.-Noon
Orange County Convention Center, Room W414C
11:30 a.m.
2601-10 The SAPPHIRE Worldwide Registry: 30-Day Outcomes 
of 4,005 Patients Undergoing Carotid Artery Stenting 
With Distal Embolic Protection
Christopher Metzger, Maurice Solis, Majdi Ashchi, Rasesh Shah, Ravish Sachar, 
William Bachinsky, Farrell Mendelsohn, Robert Hibbard, Greg Schultz, Holston Valley 
Medical Center, Kingsport, TN
Background: Periprocedural outcomes after carotid artery stenting (CAS) 
continue to improve over time as reported with current CAS registries. A decrease 
in periprocedural events could be attributed to increased operator experience, 
improvements in procedural technique and better patient selection. The primary 
objective of this study is to evaluate 30-day outcomes after CAS performed at multiple 
centers by physicians with varied experience and utilizing a formal training program.
Methods: SAPPHIRE Worldwide is a multicenter, prospective, post-approval, 
observational study. CAS was performed using the Cordis PRECISE® Stent and 
ANGIOGUARD™ Emboli Capture Guidewire. The primary endpoint is 30-day 
major adverse events (MAE), including death, stroke, and myocardial infarction.
Results: Enrollment began October 2006, and presently 4,005 patients have 
been enrolled and completed 30-day follow up. Among these patients, the mean 
age was 72.1 years, 26.5% of patients were q80 years of age, and 27.9% are 
symptomatic. Preliminary 30-day MAE rate for the overall population was 3.3% (table). 
MAE was signiﬁcantly lower in asymptomatic patients vs. symptomatic patients. 
Periprocedural stroke or death rate was below recommended AHA guidelines.
Conclusions: Results from SAPPHIRE Worldwide along with other contemporary CAS 
registries will continue to provide evidence in support of optimal patient selection, lesion 
criteria, and operator experience in performing CAS in patients at high-surgical risk.
Efﬁcacy Measures Symptomatic(N1 = 1117)
Asymptomatic
(N2 = 2887)
Total
(N = 4005)
Fisher
P-value
MAE 5.4% (60/1117) 2.5% (71/2887) 3.3% (131/4004) < 0.0001
Any Death or Stroke 5.1% (57/1117) 2.2% (63/2887) 3.0% (120/4004) < 0.0001
Any Death 1.7% (19/1117) 0.5% (15/2887) 0.8% (34/4004) 0.0007
MI 0.7% (8/1117) 0.5% (13/2887) 0.5% (21/4004) 0.3296
Any Stroke 4.1% (46/1117) 1.8% (52/2887) 2.4% (98/4004) < 0.0001
I2.SYMPOSIUM
2602
i2.Congenital I: ASD / PFO Closure
Saturday, March 28, 2009, 10:00 a.m.-Noon
Orange County Convention Center, Room W414A-B
11:00 a.m.
2602-7 PFO Morphology in Young and Older Patients 
With Cryptogenic Stroke on Transesophageal 
Echocardiography
Sachin S. Goel, E Murat Tuzcu, Eduardo I. de Oliveira, Mehdi H. Shishehbor, Leonardo 
L. Rodriguez, Richard Krasuski, Samir R. Kapadia, Cleveland Clinic, Cleveland, OH
Background: Recently patent foramen ovale (PFO) was shown to be associated with 
cryptogenic stroke (CS) in older patients (q55 years).
Methods: We blindly compared pre-closure TEEs of 33 young patients with 25 older 
patients who had PFO closure for CS. We also compared these with TEEs of consecutive 
asymptomatic 18 young and 40 older controls with incidentally detected PFO. We 
analyzed data for PFO size (maximum separation of septum primum and secundum), 
tunnel length (maximum overlap of the two septa), atrial septal aneurysm (ASA) (>11 
mm mobility), shunt severity (mild: 3-9, moderate: 10-30, severe >30 microbubbles), 
prominent Eustachian valve and Chiari network.
Results: There were no differences in PFO morphology between young and older 
patients with CS. However, young CS group had larger PFOs (3.6 ± 1.5 mm vs. 2.5 ± 1.1, 
p=0.007), greater proportion of large PFOs (q 4 mm) (41% vs. 11%, p=0.03) and higher 
frequency of ASA (36% vs. 11%, p =0.05) compared to the young asymptomatic controls. 
Similarly, the older CS group had larger PFOs (4.3 ± 1.8 vs. 3.1 ± 1.6, p=0.007), greater 
proportion of large PFOs (52% vs. 20%, p=0.007), long tunnels (q1 cm) (84% vs. 58%, 
p=0.03), higher frequency of ASA (56% vs. 25%, p=0.01) and severe shunting (24% vs. 
5%, p=0.02) compared to older asymptomatic controls.
Conclusion: Young and older patients with cryptogenic stroke have similar PFO 
morphology on TEE. Compared to asymptomatic controls, both young and older patients 
with cryptogenic stroke have larger PFO and ASA more frequently. 
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endpoint was deﬁnite ST at 30 days.
Results: The upper quintile of patients according to MEA measurements (n=323) were 
deﬁned as clopidogrel low-responders. Compared with normal-responders (n=1285), low-
responders had a signiﬁcantly higher risk of deﬁnite ST within 30 days [2.2% vs. 0.2%; 
odds ratio (OR) 9.4; 95% conﬁdence interval (CI) 3.1-28.4; P<0.0001]. The composite 
of death or ST was higher in low- vs. normal-responders [3.1% vs. 0.6%; OR 5.1; 95% 
CI 2.2-11.6; P<0.001]. In a multivariate Cox proportional hazards model, low-response 
to clopidogrel assessed with MEA was found to be an independent predictor for the 
occurrence of ST [Hazard Ratio 10.95; 95% CI 2.31-51.99; P=0.003]. At the ACC meeting 
2009, 6 month follow-up data will be presented as well.
Conclusions: Low-response to clopidogrel assessed with MEA is signiﬁcantly associated 
with an increased risk of ST. Further studies are warranted to evaluate the ability of MEA 
to guide antiplatelet therapy in patients undergoing PCI.
I2.ORAL CONTRIBUTIONS
2901
DES Outcomes
Saturday, March 28, 2009, 10:00 a.m.-Noon
Orange County Convention Center, Room W414D
10:00 a.m.
2901-5 Four-Year Clinical Outcomes After Drug-Eluting and 
Bare-Metal Stents in Patients With Diabetes Mellitus: 
Pooled Analysis From 10 Randomized Clinical Trials
Adriano Caixeta, Roxana Mehran, Eugenia Nikolsky, Alexandra Lansky, George Dangas, 
Jeffrey W. Moses, Ajay Kirtane, Martin Fahy, Gregg Stone, Martin Leon, Columbia 
University Medical Center and the Cardiovascular Research Foundation, New York, NY
Background: Drug-eluting stents (DES) reduce the need for repeat revascularization, 
but their long-term safety has recently been called into question, particularly in pts with 
diabetes mellitus (DM). We sought to compare the clinical outcome of patients with DM 
treated with DES vs. BMS.
Methods: Patient-level data were pooled from 10 prospective, double-blind, randomized 
trials of DES (TAXUS I, II, IV, V and VI; SIRIUS, C-SIRIUS, E-SIRIUS, RAVEL, and 
ENDEAVOR II) vs. BMS. Safety and efﬁcacy outcomes through 4-year follow-up were 
assessed in 1,493 patients with DM.
Results: Baseline angiographic and demographic characteristics were similar between 
the 2 groups. Four-year outcomes are shown in Table. 
Variable Description DES BMS Hazard Ratio[95% C.I.] P-value
Death 10.5% 8.7% 1.22 [0.86,1.75] 0.2649
Cardiac Death 5.9% 4.1% 1.40 [0.85,2.31] 0.1781
MI* 7.0% 8.1% 0.80 [0.55,1.19] 0.2720
TLR** 12.0% 26.1% 0.40 [0.31,0.52] <.0001
Any ST† 4.9% 3.5% 1.24 [0.73,2.11] 0.4223
Deﬁnite/Probable ST 1.7% 1.8% 0.80 [0.35,1.79] 0.5804
Death/MI 15.9% 14.5% 1.01 [0.77,1.34] 0.9158
Death/MI/TLR 25.2% 36.1% 0.59 [0.49,0.72] <.0001
MI*: myocardial infarction, TLR**: target lesion revascularization, ST†: stent thrombosis by 
Academic Research Consortium deﬁnition
Conclusions: In patients with diabetes mellitus, treatment with DES was associated with 
similar rates of death, MI, composite of death/MI, and stent thrombosis compared with 
BMS. DES was also associated with signiﬁcant and durable reduction in TLR at 4-year 
follow-up.
10:12 a.m.
2901-6 Cardiovascular Outcomes in Patients With Drug Eluting 
Coronary Stents Undergoing Noncardiac Surgery
Nicholas Cruden, Scott Harding, Andrew D. Flapan, Cat Graham, Sarah Wild, Rachel 
Slack, Jill Pell, David E. Newby, University of Edinburgh, Edinburgh, United Kingdom
Background: Noncardiac surgery within 6 weeks of bare metal coronary stent (BMS) 
implantation is associated with an increased risk of stent thrombosis. It is unclear whether 
this risk extends beyond 6 weeks for drug eluting stents (DES).
Methods: We examined perioperative cardiovascular outcomes in patients treated with 
DES or BMS in Scotland between 01/04/03 and 31/03/07 who subsequently underwent 
noncardiac surgery.
Results: 570 patients receiving a DES and 1383 receiving only BMS underwent noncardiac 
surgery. There were no differences in perioperative mortality (0.7% vs 0.6%; p=0.8), or rates 
of myocardial infarction (AMI) (1.2 vs 0.7%; p=0.3) or any ischaemic cardiac (IHD) event (13% 
versus 14%; p=0.8) between the DES and BMS groups. Compared to surgery performed 
after 42 days, perioperative mortality, AMI and IHD events were all signiﬁcantly greater when 
noncardiac surgery was performed within 42 days of stent implantation (Table 1). There were 
no temporal differences in cardiovascular outcomes between the DES and BMS groups. 
Following multivariate regression, previous coronary bypass grafting (OR 1.55 [1.07-2.26] and 
increasing age (OR 1.02[1.01-1.03]/yr) were associated with adverse cardiac outcomes.
Conclusion:Patients undergoing noncardiac surgery within 6 weeks of coronary stent 
implantation are at increased risk of death, myocardial infarction and ischaemia. Cardiac 
event rates were similar for DES and BMS, irrespective of the timing of surgery relative 
to stent implantation. 
10:24 a.m.
2901-7 Perioperative Cardiac Risk of Noncardiac Surgery After 
Drug Eluting Stent Implantation
Yohei Ohno, Akio Kawamura, Takahide Arai, Ayaka Endo, Toshimi Kageyama, Takaharu 
Katayama, Kimi Koide, Yusuke Jo, Kentaro Hayashida, Shinsuke Yuasa, Yuichiro Maekawa, 
Satoshi Ogawa, Keio University School of Medicine, Division of Cardiology, Tokyo, Japan
Background: Perioperative coronary stent thrombosis is a life-threatening complication 
that can occur in patients receiving drug-eluting stents (DES). Noncardiac surgery (NCS) 
appears to increase the risk of stent thrombosis, especially when it is performed early 
after stenting, and particularly if dual antiplatelet therapy is discontinued. The guideline 
recommends 12 months of dual antiplatelet therapy, however little is known about cardiac 
risk of patients with DES who are undergoing NCS. This study was aimed to investigate 
the incidence and outcome of NCS after DES implantation.
Methods: This single-center, retrospective study examined the incidence and outcome of 
NCS performed within 3 years after DES placement and examined whether this risk changed 
based on the timing of surgery, timing of antiplatelet agent discontinuation, and patient 
characteristics. Outcome measures included postoperative myocardial infarction (MI), stent 
thrombosis, major bleeding, and all-cause mortality during the hospitalization for NCS.
Results: From June 2004 to October 2007, 519 patients received Sirolimus-eluting stent 
(SES) and we identiﬁed 76 (14.6%) patients who underwent NCS a median of 401 days 
(IQR 229-866) after SES implantation. NCS included 10 endoscopic procedures (13%), 
29 minor surgery (38%), and 37 major surgery (49%).Thirteen patients (17%) underwent 
surgery within 180 days of stenting, 4 of whom (5%) underwent surgery within 90 days. In 42 
patients (55%), all antiplatelet agents were discontinued a median of 5 days before surgery. 
Intravenous antiplatelet agent or anticoagulant was not used for substitution. In 34 patients 
(45%), single or dual antiplatelet therapy was continued. No patients died nor suffered MI/
stent thrombosis. One patient developed major bleeding which required transfusion (1.3%).
The majority (79%) of patients were consulted to cardiologists before NCS.
Conclusions: A considerable number of patients face the need of NCS after DES 
implantation. Although NCS is performed safely after discontinuation of single or dual 
antiplatelet agents, more cardiologists should be involved in the perioperative care of 
these patients.
10:36 a.m.
2901-8 Unique Distributions of Stent Fracture and Stent 
Fracture With Restenosis After Sirolimus-Eluting Stent 
Implanattion
Kazushige Kadota, Kazuaki Mitsudo, Katsumi Inoue, Tsuyoshi Goto, Satoki Fujii, 
Hiroyuki Yamamoto, Harumi Kato, Yasushi Fuku, Shingo Hosogi, Hiroyuki Tanaka, Seiji 
Habara, Daiji Hasegawa, Masao Imai, Suguru Ootsuru, Masakazu Miyamoto, Kurashiki 
Central Hospital, Kurashiki, Japan
Background: Stent fracture (SF) after drug-eluting stent implantation has been reported 
to occur more frequently at RCA than other native coronary arteries. However, further 
information on common sites of SF and SF-related restenosis remain unclear. Thus, we 
evaluated the sites of SF and SF with restenosis according to the coronary branches after 
Sirolimus-eluting stent (SES).
Methods: Between November 2002 and December 2006, a total of 2417 consecutive 
patients with 3888 lesions underwent SES implantation. Of these, 2291 patients with 
3621 lesions were treated with SES exclusively and successfully. A total of 1979 patients 
with 3090 lesions who were followed by angiography constituted the study population.
Angiographic SF was deﬁned as apparent complete separation of stent segments at any 
view of angiogram.
Results: SF was observed at 163 lesions and SF with restenosis at 59. Prevalence of 
stent fracture of RCA, LMT, LAD, LCX and SVG were 8.0 % (97/1207), 2.8 % (4/142), 
3.3 % (34/1032), 3.3 % (23/688) and 25 % (5/20) respectively. Prevalence of SF with 
restenosis of RCA, left main trunk LMT, LAD, LCX and SVG were 3.0 % (36/1207), 0.7 
% (1/142), 1.3 % (13/1032), 0.6 % (4/688) and 25 % (5/20) respectively. Prevalence of 
SF and SF with restenosis at various branches of native coronary artery and SVG was 
shown in Figure. Conclusions:Unique distributions of SF and SF with restenosis after 
SES implantation were observed. These ﬁndings could be useful to prevent SF with or 
without restenosis. 
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2901-9 Randomised Trial of 3 Rapamycin-Eluting Stents With 
Different Coating Strategies for the Reduction of 
Coronary Restenosis - Two-year Follow-Up Results
Robert A. Byrne, Julinda Mehilli, Anna Wieczorek, Raisuke Iijima, Stefanie Schulz, Olga 
Bruskina, Jürgen Pache, Rainer Wessely, Adnan Kastrati, Albert Schömig, Deutsches 
Herzzentrum, Munich, Germany, 1. Medizinische Klinik rechts der Isar, Munich, 
Germany
Background: Drug-eluting stent platforms devoid of durable polymer may potentially be 
associated with enhanced long-term safety and efﬁcacy outcomes. The ISAR-TEST-3 
study was a randomized trial comparing 3 rapamycin-eluting stents with different coating 
strategies incorporating angiographic follow up at 6-8 months and clinical follow up to one 
year. The purpose of the current study was to examine 2-year outcomes of these patients.
Methods: Patients with de novo coronary lesions in native vessels were randomly assigned 
to receive one of 3 types of rapamycin-eluting stents: biodegradable polymer (BP), permanent 
polymer (PP; Cypher) and polymer-free (PF) stents. Additional follow-up coronary angiography 
was scheduled at 2 years. We assessed late lumen loss (LLL), target lesion revascularization 
(TLR), death or myocardial infarction and deﬁnite stent thrombosis.
Results: A total of 605 patients were enrolled: 202 patients received BP stents, 202 were 
treated with PP stents and 201 received PF stents. As previously reported LLL at 6-8 
months differed across the groups: 0.17±0.45 mm with BP, 0.23±0.46 mm with PP stent 
and 0.47±0.56 with PF stent (p<0.001). Repeat angiography at 2 years was available 
for 574 patients (94.9%). LLL was signiﬁcantly different across the treatment groups: 
0.21±0.48 mm in the BP stent group, 0.34±0.53 mm in the PP group and 0.48±0.58 
mm in the PF stent group (p<0.001). TLR was required in 17 (8.4%), 21 (10.4%) and 28 
(13.9%) cases in BP, PP and PF groups respectively (p=0.20). There were no differences 
in safety outcomes which occurred infrequently after 1 year: death or myocardial infarction 
occurred in 14 cases (6.9%) with BP stent, 14 cases (6.4%) in PP stent and 13 cases 
(7.0%) with PF stent (p=0.97); deﬁnite stent thrombosis occurred in 0 cases with the BP 
stent, 1 case with the PP stent and 2 cases with the PF stent (p=0.36).
Conclusions: At 2 years, inhibition of neo-intimal formation (late loss) may be more 
durable with a biodegradable polymer stent. At this time point, there was no signal of a 
differential safety proﬁle between the 3 stent platforms, though investigation with larger 
patient numbers should be the subject of future studies.
11:00 a.m.
2901-10 Deﬁning the Incidence of Late Major Cardiac Adverse 
Events (MACE) in a Non-Selected, Complex, Real-World 
Population: Very Long-Term Outcomes (q 4 years) of 
Patients in the DESIRE-Late Registry
Jose de Ribamar Costa Jr, Amanda Sousa, Adriana C. Moreira, Ricardo A. Costa, Galo 
Maldonado, Manuel N. Cano, Mariana Carballo, Cantídio Campos, Maria Helena Bib, 
Abrão Cury, Otávio Berwanger, J. Eduardo Sousa, Instituto de Ensino e Pesquisa do 
Hospital do Coração, São Paulo, Brazil
Background: Despite the efﬁcacy of DES in reducing repeat TLR, concerns regarding 
the occurrence of stent thrombosis (ST), mainly after the 1st year of the procedure, have 
partially obscured the beneﬁts of this novel technology. We sought to access the incidence 
of late MACE and ST in non-selected, complex pts followed for a minimum 4-year period.
Methods: Since the ﬁrst DES was marked approved in our country (May 2002) all pts 
treated solely with these devices were included in this prospective, non-randomized, 
single center registry. In order to access the very long-term clinical impact of DES, we 
included in the present analysis pts treated until October 2004 (minimum 4-year period 
from the index procedure). Virtually all subsets of patients and lesions were included. Pts 
were followed at 1, 6 and 12 months and then yearly up to 6 years.
Results: 976 consecutive pts were enrolled. Most were men (77%) with mean age of 
64±12 years-old. 28% had DM. SVG were treated in 7% of the cases and STEMI was the 
initial clinical presentation in 12%. Stent/patient rate was 1.4. Pts were kept in dual anti-
platelet therapy for 3 and 6 months after Cypher and Taxus, respectively. FU was obtained 
in 98% of the cohort (median 5.2 years). Survival-free of MACE and deﬁnite/probable ST 
are displayed on the chart. Five of the 14 ST occurred after the 4th year of FU.
Conclusions: The deployment of DES in complex, real-world pts resulted in a low rate 
of very long-term MACE (<15%)and ST (<2%). However, ST still occurs very long after 
the index procedure. 
11:12 a.m.
2901-11 Clinical Outcome and Prognosis of Patients who 
Present With Early Versus Late Stent Thrombosis
Gilles Lemesle, Laurent Bonello, Axel De Labriolle, Sara D. Collins, Asmir I. Syed, 
Gabriel Maluenda, Itsik Ben-Dor, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. 
Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Late stent thrombosis (ST) is a major complication of drug eluting stents. 
The prognosis of late ST is still poorly described. This study aimed to compare the 
outcome of patients presenting with early versus late deﬁnite ST after percutaneous 
coronary intervention (PCI).
Methods: Between 2003 and 2007, 91 patients presenting with deﬁnite ST were 
included. We compared patients with an early ST (n=51) to patients with a late ST (n=40) 
as deﬁned by the ARC deﬁnition.
Results: Baseline characteristics were similar between the 2 groups. The indication 
of the initial PCI was more often an acute MI in the early ST group than in the late 
ST group (43% vs 18%, p=0.007). The ST presented as STEMI with high and equal 
frequency in both groups (73% vs 77%, p=0.6), but the rate of cardiogenic shock was 
higher in the early ST group (39% vs 20%, p=0.04). There was no difference in the ST 
treatment between the groups except for intra-aortic balloon pump use. The angiographic 
success rate was similar between the groups (83% vs 87%, p=0.5). The incidence of the 
composite endpoint death-MI-recurrent ST at 1 year was 53% in the early ST group vs 
30% in the late ST group (p=0.03).
Conclusion: Patients with early deﬁnite ST have worse prognosis when compared to 
patients with late deﬁnite ST. This could be attributed to the occurrence of a subsequent 
MI within 30 days from the ﬁrst one in 45% of the patients with early ST, leading to 
a higher rate of cardiogenic shock. Special efforts should be taken to minimize the 
occurrence of early ST.
11:24 a.m.
2901-12 Revascularization With Cardiac Surgery Versus 
Paclitaxel-Eluting Stents in Patients With Diabetes and 
Metabolic Syndrome: 1-Year Results From the SYNTAX 
Study
Adrian P. Banning, Stephen Westaby, Friedrich W. Mohr, A. Pieter Kappetein, Marie-
Claude Morice, Katrin Leadley, Keith D. Dawkins, Patrick W. Serruys, John Radcliffe 
Hospital, Oxford, United Kingdom, Boston Scientiﬁc Corporation, Natick, MA
Background: Optimal revascularization strategy in diabetic patients with multivessel coronary 
disease is under debate. TAXUS paclitaxel-eluting stents yield comparable outcomes in 
diabetic and nondiabetic patients with 1- and 2-vessel disease. SYNTAX is a contemporary 
worldwide randomized comparison of surgery (CABG) versus TAXUS Express.
Methods: SYNTAX enrolled only patients with left main and/or 3-vessel disease--the most 
complex patient group ever studied in a coronary artery revascularization trial. Of 1800 
randomized patients, 452 had medically treated diabetes and 656 had metabolic syndrome.
Results: There were no signiﬁcant differences in composite safety in any cohort but 
revascularization was increased in TAXUS-treated patients compared to surgery. MACCE 
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in nondiabetic patients was 11.8% in the CABG arm and 15.1% in the TAXUS arm 
(P=0.08). In diabetic and metabolic syndrome patients, the MACCE difference increased 
with SYNTAX score; MACCE was not different between arms in the lowest SYNTAX score 
tercile but was higher in TAXUS in the intermediate and high terciles.
Conclusion: Cardiovascular complications are the leading cause of death in diabetes. 
However, optimal revascularization strategy in patients with diabetes is unclear. This 
analysis provides a treatment algorithm for physicians to determine the patient risk proﬁle 
based on co-morbidity, diabetes severity, and lesion characteristics, and choose the most 
safe and effective revascularization option for each patient. 
CABG TAXUS P Value
Nondiabetic Patients (N=1348)†
Death/CVA/ MI 6.8% (44/645) 6.8% (45/664) 0.97
Revascularization 5.7% (37/645) 11.1% (74/664) <0.001
Medically Treated Diabetes‡ (N=452)
Death/CVA/ MI 10.3% (21/204) 10.1% (23/227) 0.96
Revascularization 6.4% (13/204) 20.3% (46/227) <0.001
Metabolic Syndrome (N=656)
Death/CVA/ MI 8.8% (27/307) 7.8% (26/333) 0.65
Revascularization 6.5% (20/307) 14.7% (49/333) <0.001
HbA1cq7.0% (N=246)
Death/CVA/ MI 7.6% (9/119) 10.2% (12/118) 0.48
Revascularization 7.6% (9/119) 19.5% (23/118) 0.007
Composite safety = death, CVA (cerebrovascular accident), myocardial infarction (MI).
MACCE = death, CVA, MI, and revascularization (any vessel)
†Includes 59 patients treated with diet control for hyperglycemia.
‡Treatment with oral hypoglycemic agents or insulin at enrollment; randomization was 
stratiﬁed by presence or absence of medically treated diabetes.
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i2.09 Complex Lesions I: Bifurcations/LM
Saturday, March 28, 2009, 1:00 p.m.-3:00 p.m.
Orange County Convention Center, Room W415D
1:40 p.m.
2604-7 Angiographic Restenosis at 9 Months in the DIVERGE 
Trial, a Multi-Center Investigation of a Dedicated Drug-
Eluting Bifurcation Lesion Stent
Alexandra J. Lansky, Stefan Verheye, Christophe Dubois, Josef Dens, John Ormiston, 
Stephen Worthley, Ecaterina Cristea, Ovidiu Dressler, Martin Fahy, Iulian Benetato 
Giuran, Roxana Mehran, The Cardiovascula Research Foundation, New York, NY
Background: The AXXESS™ stent is a self-expandable bifurcation drug eluting stent 
(DES). In this multicenter study, 9 month angiographic outcomes were assessed after 
complex bifurcation treatment of 150 pts.
Methods: The DIVERGE study enrolled 302 pts with bifurcation lesions treated with 
AXXESS DES and Cypher stents in the distal parent vessel (PV) and side branch 
(SB) as needed for optimal outcomes. Follow up angiography was performed in a pre-
speciﬁed subgroup of 150 pts. Restenosis was measured in the PV and SB and results 
were compiled to reﬂect total bifurcation lesion outcomes per patient. Outcomes by SB 
treatment mode (PTCA or stent) were also evaluated. There was 100% source document 
monitoring independent core laboratory and independent clinical events committee.
Results: Angiographic follow up was completed in 140 patients (93.3%) at 9 months. 
Overall bifurcation restenosis was 6.4%, of which 3.6% was in PV and 4.3% in SB. Within 
the stented segments, restenosis most frequently occurred within the ﬁrst 5mm distal 
to the carina. Overall results by vessel segment are presented in Table 1. At 9 months, 
MACE in this subgroup was 9.4% and TLR was 5.4%.
Conclusion: In the DIVERGE Trial, an optimal stenting strategy combining the AXXESS 
and Cypher stents demonstrated markedly low MACE, TLR and restenosis rates in both 
PV and SB.
Table 1: Bifurcation Restenosis Segmental Analysis in 140 Patients 
Location Restenosis Rate 
All Bifurcation (per patient)* 6.4% (9/140)
PV 3.6% (5/140)
Proximal Edge 2.1% (3/140)
Axxess Stent 0.7% (1/140)
Distal Stent 2.3% (3/128)
Ostial-5mm location 1.4% (2/128)
Distal Edge 0% (0/140)
SB 4.3% (6/140)
In-stent 4.8% (5/105)
PTCA 2.9% (1/35)
Ostial-5mm location 3.6% (5)
Distal Edge 0
*Two patients had RS in both PV and SB
2:35 p.m.
2604-12 Syntax Score in Patients With Left Main Disease: 
Prediction of Long-Term Clinical Outcome Following 
Percutaneous Coronary Intervention
Chrysaﬁos Girasis, Yoshinobu Onuma, Neville Kukreja, Ron van Domburg, Patrick 
W. Serruys, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands, 
Cardialysis BV, Rotterdam, The Netherlands
Background: The Syntax score was developed as an angiographic scoring system 
to grade the complexity of coronary artery disease and to risk-stratify patients before 
treatment. To appreciate its long-term prognostic value, we applied it retrospectively to 
the Left Main (LM) population of the Thoraxcenter.
Methods: Between January 1, 2000 and December 31, 2005, 207 consecutive patients 
underwent PCI for unprotected LM disease; 77 (37.2%) of them due to stable angina, 79 
and 51 for unstable angina and myocardial infarction (MI) respectively. Cineangiograms 
of patients were reviewed and lesion-speciﬁc data were entered into a custom-made 
software application to compute the individual scores. Annual follow-up on the occurrence 
of death and clinical events were collected for 3 years. The primary end-point was all-
cause mortality. Secondary endpoints included MI, target vessel revascularization (TVR) 
and composite major adverse events (MACE: all-cause death, MI or TVR).
Results: Syntax score, calculated for 196 out of 207 patients, varied considerably 
(minimum 10, maximum 118.5) displaying a median value of 32.5 (21.25-49.75). Values 
for Syntax score tertiles were a25, 26-43 and q44 respectively. Intertertile differences in 
3-year clinical event rates were considerable (table).
Conclusion: Syntax score varied considerably within this Left Main cohort. However, 
when stratiﬁed into tertiles, it succeeds in predicting long-term clinical events. 
3-year clinical event rates _ Syntax score
SS a 25 SS=26-43 SSq44 P value1st vs. 2nd tertile
P value
1st vs. 3rd tertile
All-cause mortality 11.0% 28.8% 50.0% 0.015 <0.001
MI 0.0% 6.4% 14.4% 0.039 0.002
TVR 20.0% 13.0% 21.1% 0.41 0.80
Death+MI 11.0% 33.7% 51.4% 0.003 <0.001
MACE 29.9% 44.6% 59.3% 0.066 <0.001
Log rank test, pairwise comparisons over strata, p<0.05 signiﬁcant
I2.ORAL CONTRIBUTIONS
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Aortic and Pulmonic Valve Disease
Saturday, March 28, 2009, 1:00 p.m.-3:00 p.m.
Orange County Convention Center, Room W414D
1:00 p.m.
2902-5 Clinical Outcomes After Transcatheter Aortic Valve 
Replacement: An Interim Report From the Pooled 
REVIVE II and REVIVAL II Clinical Studies
Susheel Kodali, William O’Neill, Helene Eltchaninoff, Murat Tuzcu, Thierry Lefevre, Craig 
Smith, Lars Svensson, Mathew Williams, John Webb, Jeffrey Moses, Martin B. Leon, 
Columbia University, New York, NY
Background: There is limited long-term clinical follow-up after transcatheter aortic valve 
replacement (TAVR) in patients with severe aortic stenosis (AS) who are at high surgical 
risk or are non-operable.
Methods: All patients undergoing transfemoral TAVR using the Edwards Sapien valve 
in the REVIVE II (EU) or REVIVAL II (US IDE) non-randomized feasibility studies were 
followed at 1,3,6,12,18,and 24 months. Patients were symptomatic with severe AS (valve 
area < 0.7 cm2) and were either non-operative or high-risk for conventional AVR.
Results: TAVR was attempted in 161 patients with successful valve deployed in 142 
(88.2%). Thirty day MACCE was 18.6%; 18 (11.2%) deaths, 5 (3.1%) MIs and 7 (4.3%) 
CVAs. Other major complications included vascular events (15.5%) and permanent 
pacemakers (4.9%). One-year survival was 73.8% (ﬁgure). Additional MACCE endpoints 
between one and twelve months included 3 CVAs and 1 MI. Multivariate analysis indicated 
that signiﬁcant predictors of one-year mortality were prior CABG, baseline NYHA class 
and procedural vascular complications.
Conclusions: TAVR was successfully performed (~90%) in a high risk patient population 
during these early clinical trials. Long-term survival is inﬂuenced by both patient co-
morbidities and procedural complications. Ongoing randomized trials will establish the 
role of TAVR in this high risk patient population. 
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2902-6 Effectiveness of Percutaneous Aortic Valve 
Replacement to Improve Left Ventricular 
Hemodynamics and Reduce Hypertrophy: Serial 
Echocardiographic Data From the Italian CoreValve 
Registry
Marco De Carlo, Angelo Ramondo, Federica Ettori, Gian Paolo Ussia, Cristina Giannini, 
Massimo Napodano, Claudia Fiorina, Giuseppe Tarantini, Ermanna Chiari, Anna S. 
Petronio, Corrado Tamburino, University of Pisa, Pisa, Italy, University of Padova, 
Padova, Italy
Background: Percutaneous aortic valve replacement (PAVR) represents a major 
breakthrough in the treatment of patients with severe aortic valve stenosis. Our aim is 
to evaluate the effects of the implantation of the CoreValve prosthesis (CoreValve Inc., 
Irvine, CA) by means of serial echocardiographic examinations.
Methods: In September 2007 we started the implantation of the 3rd generation CoreValve 
prosthesis at 4 sites in Italy. Inclusion criteria were: 1) symptomatic, severe aortic valve 
stenosis (area index <0.6cm2/m2); 2) aortic valve annulus between 20 and 27 mm; 3) 
aortic sino-tubular junction <44 mm; 4) at least one of the following: (a) age >74 years; 
(b) logistic EuroSCORE >14%; (c) age >64 years plus severe prespeciﬁed comorbidities. 
The procedure was performed under general or local anesthesia, with fully percutaneous 
approach, and without hemodynamic support. Changes in echographic parameters from 
baseline to 1- and 3-month follow-up was performed with repeated measures ANOVA.
Results: 138 patients were treated, 82 with the small device (26mm), and 56 with the large 
one (29mm). Twelve in-hospital deaths (9.1%) occurred. Baseline, 1-month, and 3-month 
echocardiographic data are reported in the Table. A highly signiﬁcant improvement in all 
parameters was observed.
Conclusion: serial echocardiographic examination showed evident hemodynamic 
improvement at 1- and 3-month after CoreValve implantation, entailing improvement in 
LV ejection fraction and reduction in LV hypertrophy. 
Before PAVR
(n=138)
1-month
(n=107)
3-month
(n=72) P
NYHA class (mean) 2.7±0.7 1.4±0.6 1.3±0.5 <0.001
LV Ejection fraction, % 51±12 54±11 55±11 <0.001
Peak gradient, mmHg 84±27 18±8 18±7 <0.001
Mean gradient, mmHg 54±19 10±4 10±4 <0.001
LV mass index, g/m2 149±45 123±37 129±41 <0.001
Pulmonary artery pressure, mmHg 43±14 38±10 38±11 <0.001
1:24 p.m.
2902-7 Use of Transesophageal Echocardiography to Assist 
Positioning of a Balloon Expandable Transcatheter 
Heart Valve
Stamatios Lerakis, Vasilis Babaliaros, Zahid Junagadhwalla, Vinod Thourani, Robert 
Guyton, Thomas Vassiliades, Jacob Green, Kush Agrawal, Roy Abrahamian, Collins 
Kwarteng, William Whitley, Stephen Clements, Randolph Martin, Peter Block, Emory 
University, ATLANTA, GA
Background: The ideal positioning of a Transcatheter Heart Valve (THV) before 
deployment is primarily done by ﬂuoroscopic guidance. The use of transesophageal 
echocardiography (TEE) to aid the optimal placement of THV has not been fully studied 
because of the inability to differentiate the THV from the balloon it is mounted upon.
Methods: Patients (pts, n=26) underwent balloon expandable trans-femoral THV for 
aortic stenosis. Both 2 and 3-Dimensional TEE were utilized to determine the optimal 
location for deployment in the 120-130 degrees long axis view. The ideal position of THV 
by TEE was conﬁrmed by two separate operators and ﬂuoroscopy prior to implantation.
Results: In 26/26 pts, the proximal end of the THV could be visualized and in 20/26 pts, 
the distal end was visualized (FIGURE 1). When the larger THV (26mm) was implanted, 
the proximal and distal ends could be visualized (n=14/14 pts). With the smaller THV 
(23mm), the distal end was only seen in 6/12 pts. 3-D TEE was able to better visualize 
the distal end of the 23 mm THV (3/12 vs 6/12 pts). Using TEE guidance conﬁrmed by 
ﬂuoroscopy, THV deployment resulted in no occurrence of coronary artery occlusion, 
valve embolization, or signiﬁcant paravalvular leak.
Conclusion: TEE guidance can assist in the placement of THV, though the distal end of the 
smaller THV is more difﬁcult to visualize. 3D and 2D TEE are complementary techniques for 
THV visualization. More experience with TEE and THV implantation is needed.
1:36 p.m.
2902-8 Increase in Diastolic and Systolic Coronary Flow After 
Percutaneous Aortic Valve Replacement in Patients 
With Severe Aortic Stenosis
Itsik Ben-Dor, Augusto Pichard, Ron Waksman, Satler Lowell, Petros Okubagzi, Zuyue 
Wang, Steven.A Goldstein, Washington Hospital Center, Washington DC, DC
Background: In patients with severe aortic stenosis and normal coronary angiogram the 
coronary ﬂow is reduce. Doppler evaluation of proximal coronary ﬂow is feasible using 
transesophageal echocardiography (TEE).
We aimed to assess the change in coronary ﬂow in patients with severe aortic stenosis 
undergoing percutaneous aortic valve replacement (PAVR).
Methods: The left main coronary artery was visualized clearly using TEE in 9 patients 
undergoing PAVR using EDWARDS SAPIEN transcathether heart valve. Peak systolic 
and diastolic velocity of the coronary ﬂow and the time-velocity integral were obtained 
before and after PAVR using pulsed wave Doppler Results: The mean age was 86.8±6.0 
years. Mean aortic gradients decreased from 53.4±20.7 mmHg before and 1.7±1.9 mmHg 
after valve implantation. The aortic valve area increased from 0.5±0.2 cm2 to 2.0±0.6cm2.
Cardiac output decreased from 3.3±1.5 to 3.2±1.1 l/min.
The coronary ﬂow parameter pre and post PHV are presented in Table 1.
Conclusions: After PAVR there is a signiﬁcant increase in coronary ﬂow as measured 
by peak systolic velocity, diastolic velocity and velocity time integral using pulse wave 
Doppler by TEE. This may improve anginal symptoms in this subset of patients.
Table 1
Pre PAVR Post PAVR P
Peak systolic velocity cm/s 21.5±7.5 38.6± 18.6 0.03
Peak diastolic velocity cm/s 51.1±18.6 76.1±38.2 0.03
Total velocity time integral cm 22.0±7.9 28.1±12.9 0.03
Systolic velocity time integral cm 3.1± 5.4 6.5±8.2 0.09
Diastolic velocity time integral cm 18.9±7.2 21.8±9.1 0.3
1:48 p.m.
2902-9 True Percutaneous Implantation of the Edwards Aortic 
Valve Prosthesis Using a Suture-Mediated Closure 
Device. Results of a Multicenter Study
Thierry Lefevre, John Webb, Alaide Chieffo, David Wood, Iassen Michev, Francesco 
Maesano, Mauro Romano, Antonio Colombo, Marie-Claude Morice, Institut Hospitalier 
Jacques Cartier, Massy, France
Objectives -To evaluate the feasibility, safety and efﬁcacy of suture-mediated closure 
devices (Prostar XL) for access site management after percutaneous aortic valve 
implantation (PAVI) with the Edwards valve.
Background: - PAVI has recently emerged as a new therapeutic option in high-risk patients 
(Pts) with severe aortic stenosis. With the retrograde approach, femoral artery access is 
commonly demanding surgical closure and general anaesthesia. A truly percutaneous 
intervention may reduce procedural complexity and decrease complications.
Methods - After direct puncture of the common femoral artery, 1 or 2 Prostar XL were deployed. 
A 12 or 14F was inserted for predilatation of the aortic valve. A 22 or 24 French sheath was then 
inserted and the aortic valve deployed. At the end of the procedure, the preloaded sutures were 
tied and an angiogram was performed from the controlateral approach.
Results - A total of 87 Pts were included in 3 centers, age 80.3+7.0 years, logistic 
euroscore 24.4+13.8%. The right femoral approach was used in 59.8% of cases using 
a 24 Fr sheath in 60.9% and two closure devices in 82.7%. Minimal femoral size was 
7.75+0.86 mm, calciﬁcation score (0 to 3) 0.94+0.74 and tortuosity score (0 to 3) 
0.96+0.82.. Complete closure success was obtained in 91.8% of cases (87.2% for the ﬁrst 
47 cases and 95.0% for the last 40 cases, p=NS). Femoral surgical repair of the femoral 
access was necessary in 9.2% and of controlateral access in 1.1%. Femoral stenosis or 
occlusion at the closure site was observed in 5.7% and successfully treated with stents in 
4/5 cases and with surgery in one. Other access site complication not related to closure 
were iliac or femoral dissection treated by stent in 5.1% of case and iliac rupture treated by 
covered stents in 6.3%. Before hospital discharge signiﬁcant hematoma were observed in 
10.8% of cases, pseudoaneurysm in 1.1% and local infection 2.3%. There was 3 deaths 
at discharge (3.4%). No deaths were related to the use of closure devices.
Conclusions - Access site management still remains an issue when using 22 or 24 
French sheaths for PAVI. However, percutaneous approach using suture-mediated 
closure devices is a promising technique.
2:00 p.m.
2902-10 The Clinical Outcome of Patients With Severe Aortic 
Stenosis Who Were Not Eligible to Participate in a 
Clinical Trial Evaluation Percutaneous Aortic Valve 
Replacement
Itsik Ben-Dor, Augusto Pichard, Lowell Satler, Petros Okubagzi, Rebecca Torguson, 
Sara Collins, Asmir Syed, William O. Suddath, Kenneth Kent, Ron Waksman, 
Washington Hospital Center, Washington DC, DC
Background: Percutaneous aortic valve replacement (PAVR) is currently under 
evaluation in clinical trials for pts with severe aortic stenosis (AS), who are high-risk 
surgical candidates. However, many pts are not eligible to participate in these trials. We 
aimed to study the demographics and the outcome of the pts who could not enter a trial.
Methods: The study cohort consisted of 195 pts with severe AS referred to participate in 
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a clinical trial of PAVR. All pts were evaluated based on the protocol-speciﬁc inclusion /
exclusion criteria and the group deferred from a study was followed clinically. 
Results: Of the 195 pts, 143 (73.3%) were not eligible. The major reasons for non-
eligibility were signiﬁcant PVD in 25.9%, STS <10% in 20.3%, and aortic valve area (AVA) 
>0.8 cm2 in 13.2%. This cohort was divided into 3 groups: 1) medically treated 31.4%; 2) 
balloon aortic valvuloplasty (BAV) 47.5%; and 3) surgery 21.0%. The pts’ mean age was 
similar among the groups. The STS and Euro scores were lower in the surgical group. The 
mean AVA was higher and the mean gradients were lower in the medically treated group. 
The EF was lower in the BAV group. Death was lower in surgical treated group. (Table)
Conclusion: The most common reason for exclusion in a PAVR clinical trial was 
concomitant peripheral artery disease. The mortality rate for the excluded group treated 
with the current alternative modalities is high. Efforts should be directed to minimize the 
proﬁle of the PAVR delivery systems to increase the eligibility of pts with PVD.
TABLE
Medically
treated
N=45
Balloon
valvuloplasty
N= 68
Surgical
aortic valve 
replacement
N=30
P
Age years 81.7±8.7 81.0±9.6 80.7±9.0 0.69
Thoracic Surgeons score (%) 10.7±5.1 10.6±4.5 5.9±2.7 0.001
Logistic Euro score (%) 30.8±21.3 35.9±12.8 18.7±8.6 0.001
Ejection fraction (%) 52.2±16.6 46.0±18.1 60.0±13.9 0.02
Aortic valve area(cm2) 0.81±0.24 0.65±0.09 0.73±0.21 0.01
Mean gradient (mmHg) 40.5±14.6 45.0±10.2 43.1±21.4 0.33
Mean duration follow up (days) 269.4±179.8 307.5±194.0 216.7±135.1 0.009
Mean time from screening to 
mortality (days) 87.0±91.1 80.5±75.3 25.6±22.3 0.04
Mortality (%) 33.3 38.2 10 0.001
2:12 p.m.
2902-11 Percutaneous Pulmonary Valve Replacement in Thirty 
Patients
K. AL SENAIDI, D. TAYLOR, J. RUTLEDGE, F. DICKE, G. MACK, JY COE, University of 
Alberta, Edmonton, AB, Canada
Background: Percutaneous pulmonary valve replacement (PPVR) is gaining popularity 
in patients with failed pulmonary homografts (PH) or prosthetic valves (PV). The Melody 
valve is a stent mounted bovine jugular vein valve.
Method: We reviewed our experince with PPVR at the University of Alberta.The patients 
pre and post PPVR data presented as median (range) and analyzed by paired t-test. p 
<0.05 is considered signiﬁcant.
Result: PPVR was successful in 32 of 33 procedures (30 patients, 22 male). The median 
age was 17 (8-39) years & median weight 60 (17-97) kg. Femoral vein was used in 31 and 
jugular in 2. There were 11 homografts &19 prosthetic valves in patients with tetralogy of 
Fallot (n= 16), pulmonary atresia-VSD (n=9), transposition of the great arteries-Rastelli, 
(n=2), AS-Ross (n=2), truncus arteriosus (n=1). Pulmonary stenosis was present in 
all and signiﬁcant regurgitation in 25. Median duration from surgery to PPVR was 8 
(3-12) years. Exertional dyspnea was present in 16, and 13 had exercise intolerance. 
The Median procedural time was 100 (50-180) minutes. All patients had a statistically 
signiﬁcant decrease in right ventricular systolic and end diastolic pressure and Right 
ventricular to pulmonary artery gradient after PPVR. All Melody valves were competent 
post PPVR. All except 3 patients were discharged home the next day. Replacement failed 
in one, signiﬁcant bleeding in another, and surgical valve replacement in two patients 
with signiﬁcant post PPVR gradient. On follow up at median of 10 ( 1-23) months (n=24), 
PV regurgitation mild in 2 with no mortality. Second valve (n: 2) There was no statistically 
signiﬁcant change in tricuspid regurgitation gradient and right ventricular to pulmonary 
artery gradient by echocardiography immediately post PPVR and on last follow-up.
Conclusion:
PPVR is not only an effective alternative to surgical replacement of pulmonary valve, 
but signiﬁcantly shortened the hospital stay, rarely required blood transfusion, and 
accomplished without thoracotomy. The short term result is remarkable. Long term 
outcome remains to be evaluated.
2:24 p.m.
2902-12 The Safety and Efﬁcacy of Cutting Balloon Versus 
High Pressure Balloon Therapy for the Treatment of 
Resistant Pulmonary Artery Stenosis: A Multi-Center 
Randomized Trial
Lisa Bergersen, Kimberlee Gauvreau, Jonathan Rome, Jackie Kreutzer, David Nykanen, 
Evan Zahn, Larry Latson, Jonathan Rhodes, Alan Nugent, Henri Justino, Phillip Moore, 
James Lock, Kathy Jenkins, Childrens Hospital Boston, Boston, MA
Background: We sought to determine the safety and efﬁcacy of Cutting Balloon (CB) 
versus conventional high pressure balloon (HPB) therapy for the treatment of pulmonary 
artery stenosis.
Methods: A prospective, randomized, multi-center, IDE trial compared CB to HPB therapy. 
Patient eligibility was determined at the pre-catheterization assessment; for each patient, 
only native pulmonary vessels with favorable anatomy for balloon delivery, and without 
an associated stent, or recent surgical intervention were evaluated. In these vessels a 
balloon was inﬂated to 8 ATM, low pressure balloon dilation (LPB); if the waist in the 
balloon was not eliminated the vessel was randomized to CB vs HPB. The primary study 
outcome was percent change in minimum lumen diameter. A core laboratory performed 
all vessel measurements and angiographic assessment of vessel damage. A Data and 
Safety Monitoring Board reviewed all adverse events. Three changes were made to the 
study design during the enrollment period: 1) cross-over treatment permitted, 2) 1 cm 
peripheral CB replaced by 2 cm length peripheral CB, and 3) randomization changed from 
1:1 to 2:1 (CB:HPB). Multiple vessels within a patient could be randomized, and analytical 
methods accounted for this clustering.
Results: 73 patients from 8 pediatric hospitals in the United States were enrolled between 
2004 and 2008. In these patients, 71 vessels responded to LPB dilation. 172 vessels met 
eligibility criteria; 106 were randomized to CB and 66 to HPB. In vessels randomized to 
HPB, the balloon waist was eliminated in 29% vs 97% CB, p<0.001. Vessels randomized 
to CB had a greater percent increase in lumen diameter (86% vs 53% HPB, p=0.003). 
After cross-over was introduced, 25 of 47 vessels treated with HPB underwent CB therapy 
and experienced an additional 39% increase in lumen diameter, ﬁnal 105%. Neither 
treatment arm experienced a serious adverse event attributed to CB or HPB therapy. 
There was no difference in total events due to balloon angioplasty in a study vessel: 18 
(17%) randomized to CB versus 9 (14%) HPB, p = 0.7.
Conclusions: CB therapy for pulmonary artery stenosis not responsive to LPB is more 
effective than HPB therapy and has an equivalent safety proﬁle.
I2.POSTER CONTRIBUTIONS
2501
PCI - DES I
Sunday, March 29, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2501-501 Fractional Flow Reserve versus Angiography in 
Multivessel Evaluation
Pim A.L. Tonino, Bernard De Bruyne, Nico H.J. Pijls, Uwe Siebert, Fumiaki Ikeno, 
Marcel van ‘t Veer, Volker Klauss, Ganesh Manoharan, Thomas Engstrom, Keith G. 
Oldroyd, Peter N. Verlee, Philip A. MacCarthy, William F. Fearon, for the FAME Study 
Investigators, Catharina Hospital, Eindhoven, The Netherlands, Stanford University 
Medical Center, Stanford, CA
Background In patients with multivessel coronary artery disease (CAD) undergoing 
percutaneous coronary intervention (PCI) it is unclear whether routine measurement of 
fractional ﬂow reserve (FFR) in addition to angiography improves outcomes.
Methods At 20 U.S. and European medical centers, 1005 patients with multivessel CAD 
were randomized to PCI with drug-eluting stents (DES) guided by angiography alone 
or guided by FFR measurements. Prior to randomization, lesions requiring PCI were 
identiﬁed based on their angiographic appearance. Patients randomized to angiography-
guided PCI underwent stenting of all indicated lesions, while those randomized to 
FFR-guided PCI underwent stenting of indicated lesions only if the FFR was a 0.80. 
The primary endpoint was the rate of death, nonfatal myocardial infarction or repeat 
revascularization at 1 year.
Results Baseline characteristics were similar. The 1-year event rate was 18.4% in 
the angiography-guided group and 13.2% in the FFR-guided group (P=0.02). The rate 
of death or myocardial infarction was 11.1% and 7.3%, respectively (P=0.04). In the 
angiography-guided group 78% of patients were free from angina, as compared to 81% 
in the FFR-guided group (P=0.20).
Conclusions Routine measurement of FFR in patients with multivessel CAD undergoing 
PCI with DES signiﬁcantly reduces the rate of death, nonfatal myocardial infarction or 
repeat revascularization at 1 year. (ClinicalTrials.gov Identiﬁer: NCT00267774) 
Angiography-group
N= 496
FFR-group
N= 509 P Value 
Age - yr 64.2±10.2 64.6±10.3 0.47
Previous PCI 129(26) 146(29) 0.34
Diabetes 125(25) 123(24) 0.65
Indicated lesions per patient - no. 2.7±0.9 2.8±1.0 0.34
Drug eluting stents used per patient- no. 2.7±1.2 1.9±1.3 <0.001
Procedure time - min. 70±44 71±43 0.51
Contrast agent used - ml. 302±127 272±133 <0.001
Lesions with FFR a 0.80 - no. (%) n/a 874(63%)
Lesions with FFR > 0.80 - no. (%) n/a 513(37%)
Death, myocardial infarction, CABG or 
repeat PCI 91(18.4) 67(13.2) 0.02
Death 15(3.0) 9(1.8) 0.19
Myocardial infarction 43(8.7) 29(5.7) 0.07
Death or myocardial infarction 55(11.1) 37(7.3) 0.04
CABG or repeat PCI 47(9.5) 33(6.5) 0.08
Patients free from angina - no. (%) 374(78) 399(81) 0.20
Patients without event and free from angina 326(68) 360(73) 0.07
Materials - USD 6007±2819 5332±3261 <0.001
Hospital stay at baseline admission - days 3.7±3.5 3.4±3.3 0.05
JACC March 10, 2009 ABSTRACTS - Angiography and Interventional Cardiology (i2 Summit)  A7
A
ngiography and Interventional C
ardiology (i2
 S
um
m
it)
9:30 a.m.
2501-502 Long Term Outcome of Paclitaxel- and Sirolimus-
Eluting Stents Versus Bare Metal Stents. From Western 
Denmark Heart Registry
Per Thayssen, Anne Kaltoft, Hans Henrik Tilsted, Lisette Okkels Jensen, Michael 
Maeng, Jens Flensted Lassen, Knud Noerregaard Hansen, Klaus Rasmussen, Morten 
Madsen, Soeren Paaske Johnsen, Lars Pedersen, Henrik Toft Soerensen, Leif Thuesen, 
Odense University Hospital, Odense, Denmark
Background: The long term effectiveness and safety of drug-eluting stent (DES) outside 
clinical trials is controversial. Therefore, we examined stent thrombosis, myocardial 
infarction (MI), mortality and target vessel revascularisation (TLR) in patients treated 
with percutaneous coronary intervention (PCI) and paclitaxel- (PES) or sirolimus-eluting 
(SES) or bare metal (BMS) stent implantations in Western Denmark.
Methods: From January 2002 to June 2005 all consecutive patients, who had SES, PES 
or BMS implantation where identiﬁed in the population based Western Denmark Heart 
Registry. All patients received were followed for 36 months. We used Cox regression 
analysis to estimate relative risk controlled for potential confounding.
Results: A total of 12,374 patients were treated: 1,304 with PES, 2,212 with SES and 
8,858 with BMS. Very late deﬁnite stent thrombosis (between 12 and 36 months after 
implantation) was seen more often in DES treated compared to BMS treated patients 
[adjusted RR=2.89 (95% CI: 1.48-6.78)]. Compared to BMS treated patients an elevated 
risk of very late deﬁnite stent thrombosis was seen in PES treated patients [adjusted RR 
4.23 (95%CI: 1.97-9.09)].The risk was not signiﬁcantly increased in SES treated patients 
[adjusted RR 1.81 (95%CI: 0.78-4.20)]. The risk of MI was slightly increased in DES 
treated patients [adjusted RR 1.27 (95%CI: 1.07-1.51)]. Compared to BMS treatment an 
elevated risk of MI was seen in PES treated patients [adjusted RR 1.38 (95%CI: 1.09-
1.74)] and SES treated patients [adjusted RR 1.23 (95%CI: 1.00-1.51)]. Mortality did not 
differ between DES and BMS treated patients [adjusted RR=0.94 (95% CI: 0.82-1.08)].
TLR was reduced signiﬁcantly in DES treated patients [adjusted RR=0.71 (95% CI: 
0.63-0.81)]. Compared to BMS treated patients SES reduced TLR signiﬁcantly [adjusted 
RR=0.61 (95% CI: 0.52-0.72)], whereas this association became weaker after 3 years in 
PES treated patients [adjusted RR=0.86 (95% CI: 0.73-1.03)].
Conclusion: After 3 years an increased risk of deﬁnite stent thrombosis and MI were 
seen in PES treated patients compared with BMS treated patients. A sustained better 
outcome was seen after SES treatment.
9:30 a.m.
2501-503 Does African-American Race Inﬂuence Development of 
Stent Thrombosis in the Drug-Eluting Stent Era?
Sara D. Collins, Michael A. Gaglia, Jr., Asmir Syed, Itsik Ben-Dor, Yanlin Li, Gilles Lemesle, 
Gabriel Manuela, Mickey Scheinowitz, Rebecca Torguson, Kimberly Kaneshige, Zhenyi 
Xue, Joseph Lindsay, Kenneth Kent, Lowell Satler, William O. Suddath, Augusto Pichard, 
Ron Waksman, Washington Hospital Center, Washington, DC
Background: It has been suggested that African American (AA) race predicts stent 
thrombosis after drug-eluting stent (DES) implantation. Whether socioeconomic status 
or comorbid conditions confound the contribution of AA race to the development of stent 
thrombosis is unclear.
Methods: 104 patients with deﬁnite DES thrombosis (ST) were compared to 5862 patients 
with DES implantation who did not develop stent thrombosis (NoST). Multivariable Cox 
regression analysis was performed adjusting for comorbities, including median household 
income, to assess the impact of AA race on development of stent thrombosis.
Results: On univariate analysis, patients with stent thrombosis were more likely to be 
AA (41.3% ST vs. 22.1% NoST, p<0.001), and have a history of diabetes (50.5% ST vs. 
34.5% NoST, p<0.001). Clopidogrel compliance at the time of the ST event was similar in 
the AA versus Non-AA population (AA 66.7%, Non-AA 63.4%, p=0.936). After multivariate 
analysis, including adjustment for median income (Table 1), AA race emerged as the 
strongest predictor of cumulative deﬁnite stent thrombosis at 3 years.
Conclusion: African American race is an independent predictor of cumulative stent 
thrombosis. As clopidogrel compliance was similar, and household income did not predict 
ST, further investigation into potential mechanisms of this inﬂuence must be pursued. 
Hazard Ratio 95% Conﬁdence Interval p value
African American race 2.3 1.5-3.5 <0.001
Previous PCI 1.8 1.2-2.7 0.006
History of diabetes 1.8 1.2-2.7 0.007
Median household income (zip code) 1.0 1.0-1.0 0.582
History of CRI 0.8 0.4-1.5 0.557
Table 1: Multivariate Cox proportional hazard model of deﬁnite DES thrombosis at 3 years 
follow-up
9:30 a.m.
2501-504 Delayed Arterial Healing Is Associated With Late Stent 
Thrombosis in Off-Label Use of Drug-Eluting Stents: A 
Pathologic Study
Gaku Nakazawa, Andrew Farb, Marc Vorpahl, Aloke V. Finn, Frank D. Kolodgie, Renu 
Virmani, CVPath Institute, Inc., Gaithersburg, MD
Background: Currently > 60% drug-eluting stents (DES) are implanted beyond the 
labeled indications for use (“off-label”). Observational studies show that off-label use 
is associated with an increased risk of stent thrombosis, but the mechanism of DES 
thrombosis when used off-label is poorly understood.
Methods: A total of 158 lesions (implant duration >30 days) from 108 patients in the 
CVPath DES autopsy registry were divided into on- and off-label use. On-label was 
deﬁned as de novo native coronary lesion of length <30mm in patients with symptomatic 
ischemic disease. Pathologic comparisons between on- versus off-label were performed 
for DES implanted 12 months separately.
Results: DES were placed off-label in 84 of 158 lesions (53%). The indications for off-
label use were acute MI (45%), long lesion stenting (44%), bifurcations (23%), bypass 
grafts (11%), and left main lesions (4%). The rate of late stent thrombosis (>30 days) 
was signiﬁcantly higher (p<0.0001) in off-label (43%) as compared to on-label use (4%). 
Morphometric analysis showed higher prevalence of uncovered struts and greater ﬁbrin 
score in off-label as compared to on-label not only within 12 months but also beyond 12 
months (Table).
Conclusions: A higher rate of late stent thrombosis was observed in off-label as 
compared to on-label use at autopsy. Delayed arterial healing in off-label use remained 
discernable beyond 12 months.
Morphometric and pathologic analysis (>30days)
< 12 months > 12 months
On-label
(n=47)
Off-label
(n=48) p value
On-label
(n=27)
Off-label
(n=36) p value
Duration, day; 
Median (IQR)
120 (57, 
240)
126 (60, 
213) 0.75
558 (465, 
990)
645 (450, 
848) 0.94
Stent length, mm 17.7±7.0 27.0±11.6 <0.0001 18.9±5.7 29.8±16.2 0.004
Stent area, mm2 6.9±3.7 7.2±2.3 0.72 7.2±2.3 7.0±2.0 0.67
Max Neointimal 
thickness, mm 0.22±0.21 0.20±0.17 0.52 0.27±0.22 0.28±0.18 0.88
Inﬂammation score 1.1±1.1 1.1±0.9 0.87 1.2±1.2 1.7±1.5 0.19
Fibrin score 1.4±1.3 2.1±1.1 0.01 0.8±0.9 1.3±1.1 0.11
%Uncovered struts 31±32 46±34 0.03 13±17 25±23 0.03
Thrombosis (%) 2 (4) 21 (44) <0.0001 1 (4) 15 (42) 0.0009
9:30 a.m.
2501-505 The Homozygous LDL Receptor Deﬁcient Swine 
Predicts Efﬁcacy Following DES Implantation: A 
Prospective Endovascular Imaging Feasibility Study.
Armando Tellez, Christian G. Krueger, Michael S. Aboodi, Yanping Cheng, Shigenobu 
Inami, Genghua Yi, Jennifer McGregor, Tom Crenshaw, Jess D. Reed, Greg L. Kaluza, 
Juan F. Granada, Skirball Center for Cardiovascular Research, Cardiovascular Research 
Foundation, New York, NY, Department of Animal Sciences, University of Wisconsin, 
Madison, WI
Background: To date, most of coronary DES technology is tested using the normal 
juvenile swine model. Although reliable in demonstrating the safety proﬁle of these 
devices, this model has not been particularly useful in demonstrating device efﬁcacy. 
In this study, we aimed to compare the vascular response occurring following DES 
implantation in the homozygous LDL receptor deﬁcient swine (FHS) compared to weight-
matched domestic swine controls (DS).
Methods: A total of 25 coronary (11 Taxus stents, 14 BMS stents) and 22 peripheral 
stents (11 Paclitaxel eluting stents and 11 BMS stents) were implanted in 12 swine (6 DS 
versus 6 FHS) using a 10% overstretch ratio. All animals were fed with regular cholesterol 
diet to the completion of the study. At 28 days follow up, OCT analysis was performed in 
the coronaries and IVUS analysis in the peripheral arteries. Stents were harvested and 
sent for histological evaluation.
Results: At sacriﬁce the mean LDL cholesterol levels were 415±45 mg/dl in the FHS 
group and 100±14 mg/dl in the DS group (P=<0.001). In the DS group, the neointimal 
area measured with OCT in the coronary arteries was similar between the two stent types 
(BMS=21.9%±10% versus DES=16.9%±8%; P=0.1). On the contrary, in the FHS group, 
there was more than 50% reduction in neointimal area compared to the DS controls 
(BMS=25.4%±12% versus DES=11%±3%; P=<0.001). In addition, OCT analysis of both 
DES groups demonstrated complete strut coverage in the DS group compared to 86% 
coverage in the FHS group (P=<0.001). In the peripheral arteries, IVUS analysis showed 
similar neointimal areas in both stent types in the DS group (BMS=6.3%±9.2% versus 
DES=4.8%±6%; P=0.9) compared to a more than 50% reduction in the FHS group 
(BMS=6.5%±2.6% versus DES=2.9%±1.5%; P=0.015).
Conclusions: The FHS seems to provide a more favorable vascular environment for 
the testing of DES technologies compared to the DS. In this particular model, the hyper-
proliferative effect commonly seen in the juvenile DS appears not to be present, allowing 
the evaluation of efﬁcacy outcomes following DES implantation. Histological correlates 
among groups will be presented at the meeting.
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9:30 a.m.
2501-506 Vasomotor Dysfunction in Pig Coronary Arteries with 
Paclitaxel-Eluting Stents is Associated with Increased 
Inﬂammation and Oxidative Stress
Lakshmana K. Pendyala, Jinsheng Li, Toshiro Shinke, Sarah Geva, Xinhua Yin, Joseph 
P. Chen, Spencer King, III, Keith Robinson, Nicolos Chronos, Dongming Hou, Saint 
Joseph’s Translational Research Institute, Atlanta, GA
Background: Underlying mechanisms of vasomotor dysfunction after paclitaxel-eluting stent 
(PES) implantation remain unknown. We evaluated coronary arterial vasomotor function, 
local inﬂammatory reaction, and superoxide anion (O2·−) production after PES implantation.
Methods: Nine pigs received overlapping PES and bare metal stents (BMS), and 3 sham 
animals were naïve. At one month, inﬂammatory response at the overlapped region 
was assessed by histopathology and scanning electron microscopy (SEM). Endothelial 
vasomotor function and O2·− at non-stented coronary reference segments (NSRS) were 
measured by angiography and organ chamber tensiometry, and lucigenin luminometry.
Results: PES showed reduced late lumen loss, but inﬂammation and luminal inﬂammatory 
cell adherence were higher than for BMS (p < 0.001 respectively) at overlapped segments. 
Endothelium-dependent relaxation (EDdR) to substance P and A23187 was signiﬁcantly 
impaired in PES at NSRS (p < 0.05 vs. BMS and naïve, respectively). Local O2·− production
at both proximal and distal NSRS was elevated for PES compared to BMS and naive 
arteries (proximal: PES 36 ± 3 vs. BMS 15 ± 2 and naïve 12 ± 1, p < 0.001 Distal: PES 77 
± 4 vs. BMS 23 ± 5 and naïve 19 ± 1 RLU/s/mg tissue, p < 0.001, respectively).
Conclusions: Abnormal endothelium-dependent relaxation was demonstrated after 
overlapping PES implantation. Profound localized inﬂammatory reaction, as well as 
enhanced local oxidative stress, may contribute to vasomotor dysfunction. 
9:30 a.m.
2501-507 Stent Related Death Rates are higher in Drug Eluting 
Stents than Bare Metal Stents at Autopsy
Marc Vorpahl, Gaku Nakazawa, Andrew Farb, Aloke Finn, Elena Ladich, Renu Virmani, 
CV Path Institute, Gaithersburg, MD
Background: Recent clinical studies have shown a higher rate of complications including 
in-stent restenosis, myocardial infarction, and death in bare metal stents (BMS) versus 
drug eluting stent (DES). No pathologic study of cause of death from a large number of 
patients implanted with DES and BMS have been reported.
Methods: CVPath registry of coronary arteries with DES and BMS implantation involving 
270 autopsy cases >30 days were reviewed to determine the incidence of stent related 
death. Stent related death was classiﬁed as either stent-thrombosis or in stent restenosis 
(>75%) or chronic total occlusion (CTO) in the absence of other coronary disease in non-
stent related regions with or without myocardial infarction.
Results: A total of 106 cases of DES (21 female vs. 85 male, 148 lesions) and 164 
cases of BMS (48 female vs. 116 male, 254 lesions) were included in the analysis. No 
differences in age (60±12 vs. 63±13 years; n.s.), stents per patient (1.9±1.2 vs. 1.9±1.5, 
n.s.), vessels diseased (2.2±0.8 vs. 2.4±9; n.s.) and lesion distribution (LAD: 41.1% vs. 
42.1%, LCx: 23.4% vs. 18.9%, RCA: 29.1% vs. 39%; n.s.) were present between DES 
and BMS. Signiﬁcant differences were observed in the neointima formation (37±16% vs. 
60±24 %; p<0.0001), number of stents per lesion (1.4±0.7 vs. 1.3±0.6; p=0.04), stent 
length per lesion (24±12 vs. 18±9 mm; p<0.0001) and the time of duration of implantation 
(370±351 vs. 742±932; p<0.0001). The duration to death was signiﬁcantly less in females 
than males in both DES (248±196, 397±373; p=0.04) and BMS (422±543, 852±1011; 
p= 0.001). The cause of stent related death in DES was 32.1% versus BMS 14.6% 
(p=0.0007). The main cause of death in DES and BMS was thrombosis (28.3% vs. 4.9% 
p<0.0001 ) and restenosis/CTO (3.8% vs. 9.8%, p= 0.05).
Conclusions: DES result in a signiﬁcant reduction in neointima formation (37±16% 
vs. 60±24 % BMS; p<0.05). Whereas overall stent related death is lower in BMS than 
DES (14.6% vs. 32.1% p=0.0007) with females dying earlier after coronary stenting then 
males. DES stenting results in a reduction of death by in-stent restenosis/CTO (3.8% vs 
9.8% BMS; p=0.05) but a signiﬁcant increase in death by late stent thrombosis (28.3% 
vs. 4.9% BMS; p<0.0001).
9:30 a.m.
2501-508 Thrombosis in Real Practice With Second Generation 
Drug-Eluting Stents. Results from the ESTROFA-2 
Spanish Registry.
Jose M. de la Torre Hernandez, Federico Gimeno, Jose A. Diarte, Ramon Lopez-Palop, 
Armando Perez de Prado, Fernando Rivero, Juan Sanchis, Mariano Larman, Javier Martin-
Moreiras, Jose M. Hernandez, Josepa Mauri, Juan A. Bullones, Jose R. Rumoroso, Jose A. 
Baz, Javier Botas, Jose Diaz-Fernandez, Jose Moreu, Francisco Bosa, Rafael Melgares, 
Felipe Hernandez, Bruno Garcia del Blanco, Jose M. Vazquez, Jaime Elizaga, Iñigo Lozano, 
Angel Sanchez-Recalde, Grupo ESTROFA, Coordination in Santander, Spain
Background: First generation drug-eluting stents are associated to a variable incidence 
of late thrombosis (0.4-0.6% /yr up to 4 years), specially in off-label indications. There is no 
data regarding incidence and predictors for thrombosis with the second drug-eluting stent 
generation, zotarolimus-eluting stent (ZES) ENDEAVOR® and everolimus-eluting stents 
(EES) XIENCE V® and PROMUS®, in real practice with frequent off-label indications.
Methods: We have designed a large-scale, nonindustry-linked multicentered prospective 
registry in order to evaluate thrombosis (ARC deﬁnitions) of second generation DES in 
clinical practice. Complete clinical-procedural data of all patients treated with these stents 
is reported and a systematic follow up is done every year (up to 3 yrs) in a web-based 
registry supported by the Spanish Working Group on Interventional Cardiology.
Results: Up to now 3709 pts have been included in 34 centers, 2104 treated with ZES 
and 1605 with EES, 61% in off-label indications.Nowadays median follow up is 395 days 
(212-605) for pts with ZES and 245 days (128-365) for pts with EES. The cumulative 
incidence of deﬁnite + probable stent thrombosis for ZES was 1% at 30 days, 1.5% at 12 
months and 1.8% at 18 months and for EES was 0.6% at 30 days and 1.4% at one year. 
In STEMI cases (n=752, 74% with ZES) incidence was 0.8% at 30 days, 1.2% at 1 yr and 
1.7% at 18 months. Early discontinuation of antiplatelet dual therapy was observed in 8% 
of cases with thrombosis (all due to bleeding). Univariant predictors for thrombosis were: 
age, diabetes, renal failure, high blood pressure, ejection fraction, stent length and stent 
diameter. Multivariant analysis yielded as independent predictors for thrombosis: ejection 
fraction (HR 0.96; 95% CI 0.94-0.99: p=0.03), high blood pressure (HR 7; 95% CI 1.6-
28:p=0.008) and stent diameter (HR 0.35; 95%CI 0.16-0.87:p=0.02).
Conclusions: In a real practice setting with frequent off-label indications the incidence 
of stent thrombosis at 1 year with second generation drug-eluting stents, ZES and EES, 
was similarly low. However, a longer follow up is needed to determine the incidence of 
thrombosis over following years.
9:30 a.m.
2501-509 Efﬁcacy and safety of drug eluting stents versus bare 
metal stents in ST-elevation myocardial infarction: a 
meta-analysis of randomized clinical trials
Henri Roukoz, Basel Al Aloul, Shashank Vats, Anthony A. Bavry, University of 
Minnesota, Minneapolis, MN, University of Florida, Gainesville, FL
Background: Some registry reports have suggested decreased mortality with drug eluting 
stents, while others have documented increased adverse events in patients with ST-
elevation myocardial infarction (MI). We sought to evaluate the safety and efﬁcacy of drug-
eluting stents (DES) compared with bare metal stents (BMS) in this patient population.
Methods: We performed a comprehensive meta-analysis of randomized clinical trails 
comparing DES versus BMS in ST-elevation MI.
Results: We identiﬁed 14 trials with a total of 7,439 patients (76.6% males, 14.9% 
diabetics). The trials’ follow-up ranged from 8 to 36 months, with a weighted mean duration 
of follow-up of 13.2 months. The incidence of all cause mortality for DES vs. BMS was 
3.9 % vs. 4.4 %, RR=0.91 (0.72-1.15), p=0.43, cardiovascular mortality was 2.8% vs. 3.3 
%, RR=0.93 (0.69-1.27), p=0.67, MI was 3.4% vs. 3.9 %, RR=0.81 (0.63-1.04), p=0.09, 
and target vessel revascularization was 5.5 % vs. 11.9 %, RR=0.44 (0.35-0.54), p<0.001. 
The incidence of deﬁnite stent thrombosis (ST) was 2.1% vs. 2.4 %, RR=0.79 (0.57-1.10), 
p=0.17, and deﬁnite or probable ST was 2.8% vs. 3.1 %, RR=0.88 (0.65-1.19), p=0.39.
Conclusion: With the available data, there appears to be similar all-cause and cardiovascular 
mortality, recurrent MI, and stent thrombosis between DES and BMS in patients with ST-
elevation MI. Target vessel revascularization is signiﬁcantly reduced with DES.
9:30 a.m.
2501-510 Vasomotion and endothelial function 2-year after 
implantation of an Everolimus-eluting bioabsorbable 
stent
Yoshinobu Onuma, John A. Ormiston, Evelyn Regar, Dariusz Dudek, Leif Thussen, 
Nieves Gonzalo, Hector Garcia-Garcia, Mark Webster, Susan Veldhof, Patrick W. 
Serruys, Thorax center, Erasmus MC, Rotterdam, The Netherlands
Background: The BVS stent is a fully absorbable drug-eluting stent with a backbone 
of poly-L-lactic acid and a coating of poly-DL-lactic acid that controls the release of 
everolimus. In ﬁrst-in-man study (ABSORB), the BVS demonstrated an acceptable in-
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stent loss with alteration or disappearance of stent struts at 6 month. It is unclear whether 
vasomotor function is restored after absorption of the polymeric strut.
Methods: In the ABSORB study, 30 patients underwent implantation of a BVS stent 
(Abbott Vascular, Santa Clara, CA). In 16 patients who underwent follow-up angiography 
at 2 years, vasomotion was assessed with quantitative coronary angiography before 
and after intracoronary infusion of acetylcholine (Ach) in 9 patients, or before and after 
intravenous administration of Methylergonovine Maleate (Meth) in 7 patients.
Results: There is methergine-induced non-endothelium dependent vasoconstriction 
in the proximal (pre 2.7±0.43 vs. post 2.49±0.46 mm, p=0.02) and stented segments 
(2.64±0.22 vs. 2.44±0.33mm, p=0.03) (ﬁgure). Non-signiﬁcant Ach-induced endothelium 
dependent vasodilation was observed in the stented segments (pre 1.81±0.33 vs. post 
1.86±0.40 mm, p=0.3) as well as in the distal segment (1.76±0.11vs. 1.85±0.19mm).
Conclusion: Two years after implantation of the BVS, vasomotion tests suggest a 
restoration of vasoconstrictive ability in the proximal and the stented segments and a 
potential for normalization of endothelial function in the stented and distal segments.
9:30 a.m.
2501-511 Stent Strut Distribution at Implantation and 9-Month 
Follow-up in TAXUS and Bare Metal Stents and Its 
Effect on Neointimal Hyperplasia. An Intravascular 
Ultrasound Integrated Analysis of the Randomized 
TAXUS IV, V and VI Trials
Maksymilian P. Opolski, Radoslaw Pracon, Gary S. Mintz, Neil J. Weissman, Lazar 
Mandinov, Jerzy Pregowski, Mariusz Kruk, Adam Witkowski, Hong Wang, Stephen G. 
Ellis, Eberhard Grube, Keith D. Dawkins, Gregg W. Stone, Cardiovascular Research 
Institute/Medstar Research Institute, Washington Hospital Center, Washington, DC, 
Cardiovascular Research Foundation, New York, NY
Background: Stent strut fracture (1) affects neointimal hyperplasia (NIH) after drug-
eluting stent implantation and (2) is identiﬁed by an increase in interstrut angle from 
implantation to follow-up.
Methods: In 445 patients with serial (post-implantation and follow-up) volumetric 
intravascular ultrasound (IVUS) from TAXUS IV, V and VI, the # of stent struts was 
counted and the largest interstrut angle was measured at 1mm intervals along the stent. 
IVUS binary restenosis was deﬁned as NIH >50%.
Results: After stent implantation, both the interstrut angles and the # of visible stent struts 
were comparable between TAXUS and bare metal stents (BMS, Table). During follow-up, 
the maximal interstrut angle for BMS (n=117 paired cases) increased from 71.8±0.8º 
to 84.5±20.8º (p<0.0001), while in TAXUS stents (n=125 paired cases) the maximal 
interstrut angle increased from 73.7±17.9º to 95.1±23.6º (p<0.0001) leading to a larger 
maximal interstrut angle and fewer visible stent struts as compared with BMS. Receiver-
operating characteristic (ROC) analysis showed that a maximal interstrut angle of 81° 
at 9-month follow-up best distinguished 9-month IVUS restenosis from no restenosis in 
TAXUS stents (c=0.75). These relationships were not seen for BMS.
Conclusions: Serial IVUS analysis (1) showed that stent strut fracture was more common 
in TAXUS compared to BMS as evidenced by a greater increase in the maximal interstrut 
angle in TAXUS stents and (2) identiﬁed the threshold that lead to IVUS restenosis.
TAXUS BMS P-Value
Post-Implantation N=141 N=126
Min No of Struts per Stent 7 ± 1 7 ± 1 0.41
Max Interstrut Angle per Stent 73.5 ± 17.5 71.3 ± 19.1 0.32
Mean Interstrut Angle 43.2 ± 6.8 41.7 ± 7.4 0.10
At 9-Month Follow-up N=225 N=220
Min No of Struts per Stent 6 ± 1 6.5 ± 1 0.0032
Max Interstrut Angle per Stent 91.4 ± 23.9 84.3 ± 22.9 0.0015
Mean Interstrut Angle 51.4 ± 9.7 47.4 ± 9.0 <0.0001
9:30 a.m.
2501-512 Safety and Efﬁcacy of Biodegradable-Polymer Coated 
Sirolimus-Eluting Stents in “Real-World” Practice: 
18-month Clinical and 9-month Angiographic Outcomes
Yaling Han, Quanmin Jing, Bo Xu, Lixia Yang, Huiliang Liu, Xiaoming Shang, Tieming 
Jiang, Zhanquan Li, Hua Zhang, Hui Li, Jian Qiu, Xingfeng Liu, Yi Li, Xuezhi Chen, 
Runlin Gao, Shenyang Northern Hospital, Shenyang, People’s Republic of China
Background: It has been hypothesized that persistent presence of polymer may 
compromise the safety of drug-eluting stents, and that therefore biodegradable polymer 
coatings might reduce late adverse events. The aim of the present study was to evaluate 
the safety and efﬁcacy of a biodegradable-polymer coated sirolimus-eluting stent (EXCEL) 
with 6-month dual antiplatelet therapy in daily practice.
Methods: Between June and November 2006, 2077 patients, exclusively treated 
with EXCEL stents at 59 centers from 4 countries, were enrolled in this prospective, 
multicenter registry. Recommended antiplatelet regimen included clopidogrel and aspirin 
for 6 months followed by chronic aspirin therapy.
Results: The average duration of clopidogrel treatment was 199.8±52.7 days and 80.5% of 
discharged patients discontinued clopidogrel at 6 months. The cumulative rates of major adverse 
cardiac events (MACE) were 0.9% at 30 days, 2.7% at 1 year and 3.1% at 18-month. Overall 
rate of stent thrombosis was 0.87% at 18-month and the rates of acute, subacute and late stent 
thrombosis were 0.1%, 0.38% and 0.39%, respectively. Angiographic follow-up, performed 
in 974 (31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss of 
0.21±0.39mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment.
Conclusions: This multicenter registry documents satisfactory safety and efﬁcacy 
proﬁles, as evidenced by low rates of MACE and stent thrombosis up to 18 months, for the 
EXCEL biodegradable-polymer based SES when used with 6 months of dual antiplatelet 
therapy in a “real-world” setting.
9:30 a.m.
2501-513 Relative Dose and Vascular Response After 
Drug-Eluting Stent Implantation: A Dosimetric 
3D-Intravascular Ultrasound Study
Katsuhisa Waseda, Takao Hasegawa, Daisaku Nakatani, Bon-Kwon Koo, Hiromasa 
Otake, Takao Shimohama, Hyeonsoo Chang, Junya Ako, Paul G. Yock, Peter J. 
Fitzgerald, Yasuhiro Honda, Stanford University, Stanford, CA
Background: In DES implantation, a ﬁxed loading dose per metal surface area may result in a 
considerable variability in actual delivered dose, due to difference in spacing of the struts once 
expanded. The aim of this study was to evaluate the effect of different local dose concentration, 
as measured by 3D-IVUS dosimetry, on neointimal suppression among DESs.
Method: Follow-up 3D-IVUS was analyzed in 613 coronary lesions treated with sirolimus- 
(SES, n=148), paclitaxel- (PES, n=162), zotarolimus- (ZES, n=187) and everolimus-eluting 
stent (EES, n=116). In each lesion, local drug concentration was calculated as known loading 
dose divided by measured stented segment surface area at follow-up. Lesions were divided 
into tertiles according to calculated local dose: high, medium, and low dose groups.
Results: The calculated local dose ranged from 0.74 to 1.76μg/mm2 for SES, 0.41 to 
1.18μg/mm2 for PES, 0.71 to 1.57μg/mm2 for ZES and 0.45 to 0.84μg/mm2 for EES. 
Although SES, PES and EES showed no signiﬁcant difference of neointimal growth and 
neointimal thickness among 3 dosimetry groups, ZES showed signiﬁcantly less neointimal 
hyperplasia and neointimal thickness in high dose group.
Conclusion: Detailed 3D-IVUS dosimetry suggested a signiﬁcant lesion-to-lesion 
variability in local dose concentration after DES implantation. However, within each stent 
type, current DES appears to yield equally effective neointimal suppression, regardless of 
the varying delivered dose intensity, except for ZES. 
High dose Medium Dose Low Dose p
SES Neointimal volume Index (mm3/mm) 0.1±0.2 0.1±0.2 0.2±0.2 NS
%NVI* (%) 2.5±4.7 2.2±3.2 2.3±2.9 NS
Intimal thickness (mm) 0.02±0.04 0.02±0.02 0.02±0.02 NS
PES Neointimal volume Index (mm3/mm) 0.6±0.5 0.8±0.8 0.9±07 NS
%NVI* (%) 11.9±9.4 11.2±10.4 9.5±8.3 NS
Intimal thickness (mm) 0.08±0.07 0.09±0.09 0.09±0.08 NS
ZES Neointimal volume Index (mm3/mm) 0.8±0.6 1.3±0.7 1.5±1.0 <0.01
%NVI* (%) 16.6±12.0 18.3±10.8 16.5±10.2 NS
Intimal thickness (mm) 0.11±0.08 0.15±0.11 0.15±0.10 <0.05
EES Neointimal volume Index (mm3/mm) 0.3±0.2 0.3±0.3 0.2±0.2 NS
%NVI* (%) 5.7±5.1 4.9±5.3 2.9±3.0 <0.05
Intimal thickness (mm) 0.04±0.03 0.04±0.04 0.02±0.02 NS
* %NVI=neointimal volume / stent volume
9:30 a.m.
2501-514 Randomized Comparison of Everolimus-eluting and 
Paclitaxel-eluting Stents: Pooled analysis of Two-Year 
Clinical Follow-up from the SPIRIT II and III Trials
Yoshinobu Onuma, Patrick W. Serruys, Neville Kukureja, Gregg W. Stone, SPIRIT II and 
III investigators, Thorax center, Erasmus MC, Rotterdam, The Netherlands
Background: In the multicenter randomized trials of SPIRIT II (SII) and III (SIII), the 
XIENCE V everolimus-eluting stent (EES) demonstrated superiority to the TAXUS 
paclitaxel-eluting stent (PES) for angiographic late loss and non-inferiority for Target 
Vessel Failure (TVF) at 1 year. In SII, a late catch-up of in-stent neointimal hyperplasia 
was observed between 1 and 2 years in EES but not in PES. In SIII, among those who 
ﬁrst discontinued thienopyridine after 6 months, stent thrombosis rate was relatively lower 
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in EES than in PES. To further corroborate these observations in a larger population, we 
performed a pooled analysis of 2-year clinical data from SII and SIII.
Methods: The SII (n=300) and SIII (n=1,002) trials randomized 1,302 patients with 
a maximum of 2 de novo coronary artery lesions either to EES or PES. Poolability 
was justiﬁed on the basis of comparable inclusion and exclusion criteria with similar 
demographic, and angiographic characteristics and endpoint deﬁnitions. Major adverse 
cardiac events (MACE) were deﬁned as the composite of cardiac death, MI, or ischemia-
driven TLR, TVF as cardiac death, MI or ischemia-driven TVR.
Results: At 2 years, MACE rates were 7.4% for EES vs. 13.2% for PES (p=0.002) and TVF 
rates were 10.4% for EES vs. 14.7% for PES (p=0.03). The observed reduction in MACE 
and TVF were driven by lower rates of ischemia-driven TLR by PCI (3.3% vs. 6.3%, p=0.02) 
and non-QMI (2.6% vs 5.0%, p=0.04) in EES patients. Between 1 and 2 years, there were 
no differences in occurrence of MACE in both groups (EES 2.3% vs. PES 3.0%, p= 0.55). At 
two years, ARC deﬁnite or probable stent thrombosis occurred in 1.2% with EES vs. 1.6% 
with PES. (p=0.59) Amongst those who ﬁrst discontinued thienopyridine after 6 months , 
deﬁnite or probable stent thrombosis was 1.1% in EES vs. 1.3% in PES.
Conclusions: In the pooled 2 year data from SII and SIII, EES demonstrated superiority 
over PES for MACE, MI, TLR and TVF. Despite a late catch-up observed in EES, this may 
not be representative of the whole population as there is no difference in occurrence of 
MACE between 1 and 2 years. In addition, there are no difference in occurrence of stent 
thrombosis among those who ﬁrst discontinued thienopyridine after 6 months.
9:30 a.m.
2501-515 Correlation of Stented Segment Length on Target 
Lesion Revascularization and Stent Thrombosis: From 
Two-Year Clinical Outcome of The j-Cypher Registry
Shinichi Shirai, Kenji Ando, Yoshimitsu Soga, Katsuhiro Kondo, Koyu Sakai, Takeshi 
Arita, Kyohei Yamaji, Masahiko Goya, Hiroyoshi Yokoi, Masashi Iwabuchi, Hideyuki 
Nosaka, Masakiyo Nobuyoshi, Takeshi Kimura, Kazuaki Mitsudo, Kokura Memorial 
Hospital, Kitakyushu, Japan
Background: A longer stented segment resulted in a high restenosis rate in Bare Metal 
Stent (BMS). The advent of Sirolimus Eluting Stent (SES) reduced the rate of restenosis as 
compared with BMS. In this sub-analysis of the j-Cypher registry, we evaluate the relation 
between the total stented segment length (TSL) and target lesion revascularization (TLR), 
and between TSL and stent thrombosis.
Methods: Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients (pts) receiving SES from 39 centers in Japan. By the end of March, 
2008, two-year clinical follow-up data was completed in 11323 pts (14712 lesions) 
underwent successful implantation of SES.
Results: Angiographical follow-up was completed in 9507 lesions (64.6%). Overall 
angiographic restenosis rate through 2years was 699 lesions/ 9507 lesions (7.4%). 
Overall TLR rate was 886 lesions/ 14712 lesions (6.0%). Stent thrombosis was occurred 
in 57 pts (early in 36 pts, late in 18 pts and very late in 3 pts). Each 1mm of stented 
segment length increased TLR rate by 0.1% (Figure-1). Stent thrombosis rate was not 
accociated with stented segment length (Figure-2).
Conclusions:Total stented segment length affected the restenosis rates and the need for 
TLR. However, stent thrombosis rate was not related to the total stented segment length. 
9:30 a.m.
2501-516 Abluminal Deposition of Sirolimus on Anti-CD34 Coated 
Stents Controls Neointimal Proliferation and Promotes 
Enhanced Endothelialization in Porcine Coronary 
Arteries
Michael S. Aboodi, Juan F. Granada, Carlos Alviar, Martin B. Leon, Greg L. Kaluza, 
Stephen Rowland, Sherry Parker, Frank Kolodgie, Gaku Nakazawa, Renu Virmani, 
Cardiovascular Research Foundation, Orangeburg, NY
Background: There is substantial clinical potential for stents integrating the 
antiproliferative effect of sirolimus elution with endothelial progenitor cell capture (anti-
CD34). Functional endothelialization increases natural healing while reducing thrombotic 
potential and the need for anti-platelet therapy. We hypothesize that by separating EPC 
capture from sirolimus delivery through application of the drug to the abluminal surface of 
the stent, the safety proﬁle of these devices could be improved.
Methods: 35 stents (18 with anti-CD34 and abluminal sirolimus deposition (AS), 18 with 
anti-CD34 and uniform sirolimus coating (US)) were implanted in 12 pigs using a 10% 
overstretch ratio. Animals were sacriﬁced at 3 (n=4), 14 (n=4), and 28 days (n=4). Terminal 
IVUS analysis was performed in all stents. All stents were harvested and examined by 
conventional histology, surface electron microscopy (SEM) and confocal microscopy to 
assess the degree of neointimal formation and device endothelialization.
Results: SEM analysis demonstrated that the amount of strut coverage was similar 
between both devices at 3 (AS:47±13% versus US:45±21%) and 14 days (AS:97±2.4% 
versus US:96±2.6%). Confocal microscopy (PECAM) analysis at 14 days demonstrated 
an increased presence of functional endothelium in AS stents (70±35%) compared 
to US stents (27±35%, p=0.06). At 28 days, the degree of neointimal thickness 
(AS: 0.094±0.068mm versus US:0.087±0.021mm) and percentage area of stenosis 
(AS:17.19±4.35%, US:18.57±6.43) were similar between both stent groups.
Conclusion: Partitioning sirolimus abluminally effectively maintains its antiproliferative 
effect on neointimal formation while allowing the recruitment of functional endothelial cells 
to the adluminal side of the device. These biological effects could potentially translate to 
a clinical advantage over stents with uniform sirolimus coating.
9:30 a.m.
2501-517 Recurrent Restenosis After Reimplantation With 
Sirolimus-eluting Stent for Restenosis After Sirolimus-
eluting Stent Implantation
Masakazu Miyamoto, Kazushige Kadota, Kazuaki Mitsudo, Tsuyoshi Gotoh, Hiroyuki 
Yamamoto, Satoki Fujii, Yasushi Fuku, Shingo Hosogi, Hiroyuki Tanaka, Seiji Habara, 
Daiji Hasegawa, Masao Imai, Suguru Ohtsuru, Kurashiki Central Hospital, Kurashiki, 
Japan
Background: Reintervention cases for restenosis after implantation of Sirolimus-
eluting stent (SES) have increased as the indication for SES has expanded. However, 
the prevalence and predictors of recurrent restenosis after SES implantation for SES 
restenosis remains unclear. In this study we evaluated the prevalence of recurrent 
restenosis after reintervention with SES for restenosis after SES restenosis.
Methods: From November 2002 to January 2008, 3840 patients with 5049 lesions 
underwent implantation with SES. Of these lesions, 86 patients with 95 lesions were 
treated with SES for recurrent restenosis after SES implantation and underwent the 
follow-up coronary angiography after reintervention at 8 months.
Results: The recurrent restenosis rate was 41.1% (39/95 lesions). The table shows the 
relationships between recurrent restenosis and clinical, angiographical, and procedural 
factors. The recurrent restenosis rate of diffuse restenosis lesion was signiﬁcantly higher 
than that of focal restenosis lesion (61.5% vs. 38.5% p = 0.0032). Of focal restenosis 
lesion, recurrent restenosis rate of lesion treated with shorter stenting (<=13mm) was 
lower than that with longer stenting (=>14mm) (9.1% vs. 43.1% p= 0.0058).
Conclusion: The effect of reimplantation with SES for SES restenosis lesion was limited, 
especially in diffuse restenotic lesion. Considering the stenting length, shorter stenting at 
any procedure could be beneﬁcial to prevent recurrent restenosis. 
9:30 a.m.
2501-518 Zotarolimus-Eluting Stents vs. Sirolimus-Eluting 
Stents or Paclitaxel-Eluting Stents: Meta-Analysis of 
Randomized Trials
Alban Dibra, Antoinette de Waha, Laureta Sulcaj, Tritan Keta, Julinda Mehilli, Albert 
Schömig, Adnan Kastrati, Deutsches Herzzentrum, Munich, Germany, University 
Hospital Center “Nene Tereza”, Tirana, Albania
Background: Clinical trials comparing zotarolimus-eluting stents (ZES-Endeavor) versus 
the most frequently used drug-eluting stents - the sirolimus-eluting stents (SES-Cypher) 
or paclitaxel-eluting stents (PES-Taxus), have reported conﬂicting results regarding their 
relative clinical efﬁcacy and safety.
Methods: We performed a meta-analysis of 4 randomized trials comparing ZES with SES 
or PES and reporting the outcomes of interest during a follow-up period of 9 to 24 months. 
A total of 4635 patients were enrolled in these trials. The primary endpoint was target 
lesion revascularization. Secondary endpoints were mortality, myocardial infarction, and 
stent thrombosis rates. Odds ratios (ORs) were used as summary estimates. The pooled 
ORs were calculated using the DerSimonian and Laird method for random effects.
Results: Use of ZES was associated with a marked increase in the odds of target lesion 
revascularization compared to the use of SES or PES (OR 1.87, 95% conﬁdence interval 
[CI]: 1.36 to 2.56, P<0.001). On the other hand, there was no signiﬁcant difference 
between the respective groups of patients regarding the odds of death (OR 1.20, 95% CI: 
0.70 to 2.04, P=0.52), myocardial infarction (OR 0.69, 95% CI: 0.44 to 1.08, P=0.10) or 
stent thrombosis (OR 1.53, 95% CI: 0.76 to 3.07, P=0.24).
Conclusions: Zotarolimus-eluting stents are less effective and similarly safe compared to 
sirolimus-eluting or paclitaxel-eluting stents. 
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for the procedure through the 2 year interval were 6.6% in the XIENCE V group and 
11.0% in the TAXUS group. According to the ARC deﬁnition, stent thrombosis was 0.9% 
in the XIENCE V group and 1.4% in the Taxus group through 2 year follow-up.
Conclusion: Based on the protocol design and statistics, XIENCE V showed non-
inferiority (primary endpoint) and superiority to TAXUS in terms of late loss. Additionally, 
SPIRIT II 2 year data shows a consistent reduction in clinical events for XIENCE V versus 
TAXUS and low stent thrombosis rate for XIENCE V. The three-year clinical results will 
be presented at ACC.
9:30 a.m.
2501-521 Predictors of Major Adverse Cardiovascular Events in 
a Real-World Population receiving the Zotarolimus-
eluting Stents: Data from the E-Five Registry
Chaim Lotan, Ian T. Meredith, Peter Sick, Nakul Sinha, Praveen Chandra, Fausto Feres, 
Martin T. Rothman, For the E-FIVE Registry Investigators, Hadassah-Hebrew University 
Medical Center, Jerusalem, Israel
Background: Concerns regarding the safety of drug-eluting stents (DES) in patients with 
complex lesions and clinical characteristics typically excluded from randomized clinical 
trials highlight the need to identify predictors of major adverse cardiovascular events 
(MACE) that may guide patient selection for DES implantation.
Methods: E-Five, a prospective, multicenter, global registry enrolled patients with 
symptomatic coronary artery disease who underwent single or multi-vessel percutaneous 
coronary intervention (PCI) with the Endeavor zotarolimus-eluting stent (ZES). MACE 
(death, MI, emergency cardiac bypass surgery, or target lesion revascularization) events 
were adjudicated by a Clinical Events Committee. Multivariate logistic regression was 
used to identify signiﬁcant predictors of MACE at 12 months.
Results: Twelve month data is available for 7832 of the 8314 patients enrolled at 
188 centers across 4 continents. The 12-month rate of MACE was 7.5% (587/7832). 
The majority of these events occurred in complex patients (500/6189, 8.6%). Clinical 
characteristics predicting MACE include increasing age, diabetes, prior PCI, and renal 
impairment. MACE was also signiﬁcantly associated with the presence of multivessel 
disease, long lesions, and bifurcated lesions.
Conclusions: Characteristics predicting MACE in the E-Five registry are consistent with 
observations from other clinical trials and conﬁrm the higher risk of patients with complex 
clinical and lesion characteristics. 
Characteristic Odds Ratio P-Value
Age 1.02 <.001
Diabetes (vs. Non diabetes) 1.52 <.001
Prior PCI (vs. Non) 1.59 <.001
Moderate/ severe renal impairment (vs. mild renal 
impairment) 1.66 <.001
Single lesion (vs. multiple lesions) 0.65 <.001
Lesion length a 27 mm (vs. lesion length > 27 mm) 0.63 <.001
Bifurcation (vs. Non) 1.30 0.022
Logistic regression multivariate analyses were performed using stepwise selection 
with the following covariates: age, sex, smoking, diabetes, prior MI, hypertension, 
hypercholesterolemia, prior PCI, prior CABG, ACS (unstable angina or AMI <72 hr); 
renal impairment with no renal transplant (mod./severe [creatinine q140 μmol/L] vs. 
mild [creatinine < 140 μmol/l]; single vs. multiple lesions, lesion length > 27mm vs. 
lesion length a27mm, bifurcation.
9:30 a.m.
2501-522 Clopidogrel Use and Clinical Events After Drug-Eluting 
Stent Implantation: Findings From the HealthCore 
Integrated Research Database
John L. Petersen, II, John D. Barron, Bradley G. Hammill, Mark J. Cziraky, Kevin J. 
Anstrom, Peter M. Wahl, Eric J. Eisenstein, Mitchell W. Krucoff, Robert M. Califf, Kevin A. 
Schulman, Lesley H. Curtis, Duke University Medical Center, Durham, NC, HealthCore, 
Inc., Wilmington, DE
Background: The relationship between use of dual antiplatelet therapy greater than 12 
months and outcomes after drug-eluting stent implantation has not been well established.
Methods: We performed a retrospective cohort study using administrative data from the 
HealthCore Integrated Research Database from 9256 patients receiving drug-eluting stents 
between January 1, 2003, and August 31, 2006. We classiﬁed patients according to tertiles 
of clopidogrel use based on supply received during the 12-month landmark period after 
stent implantation. We adjusted for differences in baseline characteristics using Inverse 
Propensity Weighted models and adjusted for intervening clinical events and concomitant 
medication use between baseline and 12 months using Cox proportional hazards models to 
evaluate death, death or nonfatal myocardial infarction, and bleeding events. .
Results: There were 3102 (33.5%) patients in the high-use clopidogrel group, 3069 
(33.2%) in the medium-use group, and 3085 (33.3%) in the low-use group. Use of 
clopidogrel in the 12 months after stent implantation was highly correlated with clopidogrel 
use at 24 and 36 months. Compared with the high-use clopidogrel group, risk of death or 
nonfatal myocardial infarction was signiﬁcantly greater in the medium-use group (hazard 
ratio [HR], 1.46; 95% conﬁdence interval [CI], 1.09-1.99; P = .01) and the low-use group 
(HR, 1.59; 95% CI, 1.18-2.14; P = .002) (Table). There were no signiﬁcant differences for 
mortality alone. Compared with the high-use clopidogrel group, the risk of bleeding events 
was signiﬁcantly lower in the medium-use group (HR, 0.84; 95% CI, 0.71-0.98; P = .03) 
and the low-use group (HR, 0.77; 95% CI, 0.65-0.90; P = .002).
9:30 a.m.
2501-519 Incidence, Correlates and Predictors of Stent 
Thrombosis (ST) up to 6 Years Follow-up Following 
Implantation of Drug-Eluting Stents (DES) in 
Unselected Patients with Complex Coronary Lesions 
- Results from the Large, Prospective DESIRE (DES In 
the REal World) Registry
Ricardo A. Costa, Amanda Sousa, Adriana Moreira, J. Ribamar Costa, Jr., Galo 
Maldonado, Manuel Cano, Fausto Feres, Luiz A. Mattos, Rodolfo Staico, Alexandre 
Abizaid, Mariana T. Carballo, Cantídio Campos, Ricardo Pavanello, Otávio Berwanger, J. 
Eduardo Sousa, Hospital do Coração - Associação do Sanatório Sírio, São Paulo, Brazil
Background: Recent reports have suggested that ST after DES could be increased in 
complex subsets and overtime. 
Methods: In the DESIRE trial, 2,500 unselected undergoing routine or emergency PCI 
with DES implantation were consecutively enrolled at 1 center from Mar/02-May/08. 
Clinical FU (98%) was performed at 1 and 6 months, and yearly up to 6 years. ST was 
deﬁned according to the ARC propositions.
Results: Mean age was 64 years, 29% had diabetes, 22% had prior MI, and 52% had 
prior revascularization; 41% presented with ACS (15% STEMI); and 66% of lesions were 
type B2/C, including 27% mod/severe calcium, 5% ISR, 6% SVG, 5% ostial location, 
and 3% thrombus. Overall, there were 40 cases of ST (1.6%) during the follow-up period 
(median time: 3.4 years). Of the 40 ST, 9 (23%) were classiﬁed as subacute (1-30 days), 
18 (45%) late (1-12 months), and 13 (33%) very late (>12 months). The majority of ST 
were angiographically documented (60% deﬁnite ST), and 53% (21/40) were associated 
to a fatal event.
Conclusions: In this large, prospective “real-world” registry, unselected patients with 
complex coronary lesions undergoing DES implantation had low cumulative incidence 
of ST (1.6%) up to 6 years FU; however, a fatal event was associated in half of pts. In 
this study, signiﬁcant predictors of ST were acute MI at presentation, smoking, diabetes, 
multiple stenting procedure, complex lesion morphology, and stent underexpansion. 
Variable HazardRatio
95% Conﬁdence 
Interval P value
Acute MI 3.58 1.35 - 9.52 0.010
Smoking (current) 2.58 1.19 - 5.61 0.017
Multiple DES implanted 2.11 1.28 - 3.47 0.003
Diabetes mellitus 1.95 1.03 - 3.69 0.041
Lesion postdilatation 0.50 0.29 - 0.86 0.013
Calcium (mod/severe) 1.97 1.17 - 3.34 0.011
Eccentric lesion morphology 1.60 0.95 - 2.71 0.079
In-stent residual stenosis (per % unit 
increase) 1.04 1.02 - 1.07 <0.001
9:30 a.m.
2501-520 SPIRIT II Study: A Clinical Evaluation of the XIENCE V 
Everolimus Eluting Stent
Patrick W. Serruys, on behalf of the SPIRIT II Investigators, Erasmus University Thorax 
Center, Rotterdam, The Netherlands
Background: SPIRIT FIRST results demonstrated continued safety of the XIENCE 
V Everolimus Eluting Stent in a limited number of patients. The SPIRIT II study is a 
continuation in the assessment of the safety and performance of the XIENCE V Stent in 
the treatment of patients with a maximum of 2 de novo native coronary artery lesions.
Methods: The XIENCE V stent is compared to the TAXUS Paclitaxel-Eluting Stent. The 
primary endpoint is in-stent late loss at 180 days. Ischemia Driven Major Adverse Cardiac 
Events (MACE) are assessed through 5 years.
Results: Three hundred patients were randomised in the proportion of 3:1 (XIENCE 
V: TAXUS) at 28 sites in Europe, New Zealand and India. At 180 days, the mean in-
stent Late Loss (analysis lesion, intent-to-treat population) was signiﬁcantly lower for the 
XIENCE V group compared to the TAXUS group, 0.11±0.27mm vs. 0.36±0.39mm (non-
inferiority p<0.0001, superiority p<0.0001). Hierarchical analysis of 1-year clinical results 
showed that the total MACE rates for the procedure through the 1 year interval were 2.7% 
in the XIENCE V group and 9.2% in the TAXUS group [p=0.04 from two-sided Fishers’s 
Exact]. At 2 year serial follow up the in-stent late loss was no longer signiﬁcantly different; 
0.33±0.37mm in the XIENCE V arm vs. 0.34±0.34mm in the TAXUS arm. IVUS results 
showed that in the XIENCE V arm the neo-intimal volume was 8.4 mm and the % volume 
obstruction was 5.2% vs 11.6 mm and 5.8 % in the TAXUS arm. However despite this 
modest increase in late loss and neo-intima in the XIENCE V arm, the total MACE rates 
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9:30 a.m.
2501-524 Long-Term Outcome of Sirolimus-Eluting Stents for 
Off-Label Indications. Data from the Randomized 
SCANDSTENT Trial.
Henning Kelbæk, Lene Kløvgaard, Steffen Helqvist, Jens Lassen, Lars Krusell, Thomas 
Engstrøm, Hans Erik Bøtker, Erik Jørgensen, Kari Saunamäki, Samir Aljabbari, Per Thayssen, 
Anders Galløe, Gunnar Jensen, Leif Thuesen, Rigshospitalet, Copenhagen, Denmark
Background: While sirolimus-eluting stents (SES) have proved to be effective in patients 
with simple coronary artery lesions, there are limited data of long-term outcome of their 
use in patients with off-label lesion characteristics.
Methods: We randomly assigned 322 patients with total coronary occlusions or lesions 
located in bifurcations, ostial or angulated segments of the coronary arteries to have SES 
or bare-metal stents (BMS) implanted.
Results: At 3 years, major adverse cardiac events had occurred in 20 patients (12%) 
in the SES group and in 59 patients (38%) in the BMS group (p<0.001). Four versus 2 
patients suffered a cardiac death in the SES versus the BMS group (NS). Six patients 
in the SES group versus 15 patients in the BMS group suffered a myocardial infarction 
(p<0.05) during the 3-year observation period, and target lesion revascularization was 
performed in 8 patients (4.9%) versus 53 patients (33.8%), respectively (p<0.001)
(Figure); of these 4 in the SES versus 7 in the BMS group was performed between 1 and 
3 years after the index treatment (NS). Stent thrombosis occurred in 5 patients (3.1%) in 
the SES group and in 7 patients (4.4%) in the BMS group (NS). The lower rate of events 
was recorded in all subgroups of patients who had a SES implanted and in all types of 
lesions albeit most pronounced in occluded lesions.
Conclusions: Implantation of SES for off-label lesion indications can be done with a high level 
of efﬁcacy and safety as indicated from these 3 years results of the SCANDSTENT Trial. 
9:30 a.m.
2501-525 Comparison of Vessel Response Between Zotarolimus- 
and Paclitaxel-eluting Stents: Global and Focal Vessel 
Responses as Assessed by Serial Intravascular Ultrasound
Katsuhisa Waseda, Akiyoshi Miyazawa, Takao Hasegawa, Ichizo Tsujino, Ryota Sakurai, 
Junya Ako, Paul G. Yock, David E. Kandzari, Martin B. Leon, Peter J. Fitzgerald, Yasuhiro 
Honda, The ENDEAVOR IV Trial Investigators, Stanford University, Stanford, CA
Background: The aim of this study was to compare chronic vessel responses to 
zotarolimus-(ZES) versus paclitaxel-eluting stent (PES) implantation.
Methods: In ENDEAVOR IV (a randomized trial of zotarolimus-eluting, phosphorylcholine-
coated, DRIVER stent for the treatment of de novo coronary lesions), serial IVUS analyses 
(baseline and 8 months) were available in 38 ZES and 32 PES. Volumetric analyses were 
performed for vessel (VVI), lumen, plaque (PVI), stent, and neointima. Changes in vessel 
and plaque areas were analyzed at every matched 1-mm sub-segment throughout the 
stent. Signiﬁcant focal positive remodeling was deﬁned as >20% vessel area increase 
during follow-up in at least 3 consecutive subsegments.
Results: In overall analysis, ZES had no signiﬁcant change in peri-stent vessel 
dimensions, whereas PES showed a signiﬁcant increase in VVI and PVI during follow-
up. Delta VVI was signiﬁcantly larger in PES than ZES (0.7±0.9 mm3/mm versus 0.1±0.9 
mm3/mm, p<0.05). In subsegment analysis, signiﬁcant focal positive remodeling was 
observed in 5% of ZES and 25% of PES (p<0.01). Delta VVI at maximum remodeling 
site was signiﬁcantly larger in PES than ZES (2.2±1.4 mm3/mm versus 1.6±0.8 mm3/mm,
p<0.05). When compared with in-stent vessel response, changes in peri-stent dimensions 
did not correlate with neointimal volume in either stent type.
Conclusions: Global and focal vessel responses appear to be different between ZES 
and PES, particularly within the vessel wall surrounding the stent. 
ZES (N=38) PES (N=32) p*
Entire Stent Segment Analysis 
(mm3/mm)
Baseline Follow-up Baseline Follow-up
VVI 12.8±3.6 13.0±3.5 13.8±4.0 14.5±4.2† NS
PVI 6.2±2.2 6.3±2.1 6.5±2.6 7.2±2.7† NS
Subsegment Analysis
Incidence of focal positive 
remodeling (%) 5 25 <0.01
%VVI change at max. remodeling 
site (%) 13.7±6.8 18.2±9.2 <0.05
%PVI change at max. remodeling 
site (%) 28.3±20.3 47.2±29.8 <0.01
* p value for ZES vs. PES
† p<0.05 for baseline vs. follow up
Conclusion: High use of clopidogrel in the 12 months after drug-eluting stent implantation 
is associated with a higher risk of bleeding events. Low use of clopidogrel is associated 
with a greater risk of death or nonfatal myocardial infarction.
Table 
Characteristic Adjusted HR(95% CI)* P Value
Death
Clopidogrel use
Low 1.28 (0.79-2.06) .31
Medium 1.36 (0.86-2.15) .18
High 1.00
Other medication use
ACE inhibitor 0.82 (0.55-1.22) .327
Beta-blocker 0.90 (0.61-1.30) .57
Statin 1.02 (0.70-1.49) .93
Events during landmark period
Bleeding event 2.30 (1.49-3.53) <.001
Myocardial infarction 2.62 (1.41-4.88) .002
Revascularization 0.80 (0.48-1.33) .39
Transfusion 4.34 (2.23-8.45) <.001
Death or Nonfatal Myocardial Infarction
Clopidogrel use
Low 1.59 (1.18-2.14) .002
Medium 1.46 (1.09-1.96) .01
High 1.00
Other medication use
ACE inhibitor 1.04 (0.82-1.33) .73
Beta-blocker 0.91 (0.72-1.15) .45
Statin 0.83 (0.65-1.04) .11
Events during landmark period
Bleeding event 1.69 (1.27-2.25) <.001
Myocardial infarction 2.19 (1.44-3.33) <.001
Revascularization 0.97 (0.71-1.31) .82
Transfusion 2.41 (1.39-4.17) .002
Bleeding Events
Clopidogrel use
Low 0.77 (0.65-0.90) .002
Medium 0.84 (0.71-0.98) .03
High 1.00
Other medication use
ACE inhibitor 1.01 (0.88-1.17) .84
Beta-blocker 0.88 (0.77-1.01) .08
Statin 0.82 (0.71-0.94) .004
Events during landmark period
Bleeding event 2.79 (2.40-3.25) <.001
Myocardial infarction 0.91 (0.66-1.27) .60
Revascularization 1.05 (0.88-1.25) .58
Transfusion 2.12 (1.50-2.98) <.001
9:30 a.m.
2501-523 Late Progression After Sirolimus-Eluting Stent 
Implantation: Comparison with Bare Metal Stent 
Implantation
Nobuo Shiode, Kinya Shirota, Yukihiro Fukuda, Yasuko Katou, Fumiyo Tsunoda, Mai 
Fujiwara, Asao Mimura, Matsue Red Cross Hospital, Matsue, Japan
Background: In previous studies, minimal luminal diameter (MLD) of lesions treated 
with bare metal stent (BMS) was shown to improve from 6 months to 3 years. However 
the long-term response to Sirolimus-Eluting Stent (SES) implantation remains unclear. 
Methods: To evaluate 6-month, 12-month and 3-year outcomes, angiographic follow-
up data were analyzed for 531 patients (812 lesions) who underwent successful SES 
implantation compared to follow-up data for 703 patients (903 lesions) who underwent 
BMS implantation. Results: Angiographic follow-up was performed at both 6 and 12 
months for 655 SES-treated lesions and 628 BMS-treated lesions and at 3 years for 
148 SES-treated lesions and 210 BMS-treated lesions. The angiographic restenosis rate 
within 12 months was signiﬁcantly lower for SES-treated lesions than for BMS-treated 
lesions (8.4% vs. 26.4%, p < 0.01), but from 12 months to 3 years, the new restenosis 
rate was signiﬁcantly higher for SES-treated lesions than for BMS-treated lesions (11.5% 
vs. 4.8%, p < 0.05). Among lesions without revascularization neither at 6 and 12 months, 
MLD increased signiﬁcantly from 2.01 ± 0.62 mm at 6 months, to 2.09 ± 0.58 mm at 12 
months (p < 0.05) and to 2.20 ± 0.57 mm at 3 years (p < 0.05) in BMS lesions. However, 
MLD decreased signiﬁcantly from 2.60 ± 0.50 mm at 6 months to 2.44 ± 0.55 mm at 12 
months (p < 0.01) and to 2.35 ± 0.58 mm at 3 years (p < 0.01) in SES-treated lesions.
Conclusions: From 6 months to 3 years, stenosis of BMS-treated lesions regressed, but 
stenosis of SES-treated lesions progressed.
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2501-528 Impact of Drug-Eluting Stents on the Peristent Plaque 
Compositions: A Serial Volumetric Analysis Using 
Quantitative Integrated Backscatter Intravascular 
Ultrasound
Mitsuaki Endo, Kiyoshi Hibi, Naohiro Komura, Fumiyuki Otsuka, Takayuki Mitsuhashi, 
Noriaki Iwahashi, Naoki Nozawa, Jun Okuda, Kengo Tsukahara, Masami Kosuge, 
Toshiaki Ebina, Tsutomu Endo, Satoshi Umemura, Kazuo Kimura, Saiseikai Yokohama-
city Southern Hospital, Yokohama, Japan, Yokohama City University Medical Center, 
Yokohama, Japan
Background: Although drug-eluting stents (DES) are effective in inhibiting neointimal 
hyperplasia, concern about vasculo-toxic effects of DES still remains to be resolved. 
Several autopsy studies revealed enhanced inﬂammatory responses of peristent plaque 
when treated with DES. However, little data are available regarding tissue characteristics 
of peristent plaque after DES implantation in vivo. Recently, integrated backscatter 
intravascular ultrasound (IB IVUS) was developed for tissue characterization of coronary 
plaques. The aim of this study was to investigate serial change in peristent plaque 
compositions after DES implantation using quantitative IB IVUS.
Methods: We enrolled 42 consecutive patients (pts) with angina pectoris who received 
elective stenting with DES (22 pts; 16 sirolimus-eluting and 6 paclitaxel-eluting stents) 
and bare-metal stents (BMS) (20 pts). Serial IB IVUS analyses were performed after 
stent implantation and at 10 month follow-up (f/u). The tissue characterization of peristent 
plaque was analyzed in the 10 mm stent segment with the largest peristent plaque 
volume at baseline, and the occupancy rate of four tissue types (lipid, ﬁbrous, dense 
ﬁbrous, calciﬁed) within peristent plaque was evaluated.
Results: In the DES group, a signiﬁcant increase in vessel volume (143 to 154 mm3,
p<0.001), which was mainly caused by an increase in peristent plaque volume (56 to 
65 mm3, p<0.001), was observed during f/u. %lipid volume of peristent plaque became 
greater from baseline to f/u (28 to 35%, p=0.02), whereas %ﬁbrous volume (58 to 56%, 
p=0.08), %dense ﬁbrous volume (10 to 8%, p=0.01), and %calciﬁed volume (4 to 3%, 
p=0.003) decreased. In contrast, vessel volume (144 to 140 mm3, p=0.21), peristent 
plaque volume (53 to 50 mm3, p=0.17), and each tissue compositions of peristent plaque 
in the BMS group did not change during f/u.
Conclusions: DES caused expansive remodeling and altered tissue characteristics of 
peristent plaque as assessed by IB IVUS, which may represent inﬂammatory response 
and delayed healing process around stent struts. Development of new generation 
DES without this potentially deleterious effect is required to reduce long term adverse 
outcomes.
9:30 a.m.
2501-529 Elevated Circulating Endothelial Progenitor Cells in 
Stent Thrombosis Patients is not Correlated With 
Platelet Reactivity Index
Mickey Scheinowitz, Tina L. Pinto Slottow, Rajbabu Pakala, Richard Baffour, Laurent 
Bonello, Rebecca Torguson, Augusto D. Pichard, Lowell Satler, Rekha Gavini, Patricia 
Beauzile, Shari Lawler, Udaya Tantry, Paul Gurbel, Ron Waksman, Washington Hospital 
Center, Washington DC, DC
Background: Limited data is available regarding the association between endothelial 
progenitor cells (EPCs) and platelet reactivity among patients post drug-eluting stent 
(DES) implantation. We aimed to investigate the level of circulating EPCs in post stent 
thrombosis (ST) patients treated with clopidogrel and correlate these data with platelet 
reactivity index (PRI). Methods: Forty patients (19 ST - ARC deﬁnition, 21 controls) with 
prior DES implantation in the past 3 years were enrolled in this study. The number of 
circulating EPCs (positive for CD34/CD133; CD34/VEGFR; and CD133/VEGFR) were 
counted using ﬂow cytometry. PRI (%), as a measure of clopidogrel responsiveness, was 
assessed using vasodilator stimulated phosphoprotein (VASP)/P2Y12 assay.
Results: Baseline characteristics were similar between groups. The average time to 
presentation with ST was 157±308 days (ranging between 0 to 1148 days) post DES 
implantation. PRI were similar: 66.5%±20.0% and 57.4%±20.7%, for ST and control 
patients, respectively (p=0.408). No correlation was found between elevated EPCs 
among ST patients and PRI values at any given time during the follow-up.
Conclusion: Stent thrombosis is associated with signiﬁcant elevation of circulating 
EPCs, however, this is not correlated with the responsiveness to clopidogrel therapy. The 
increased EPCs even long after stent implementation suggest an active, ongoing process 
which may be unrelated to initial thrombus formation. 
Variables
Acute ST 
patients
n=5
Sub-acute ST 
patients
n=7
Late ST 
patients
n=7
Control
patients
n=21
p value
Days to thrombosis 0.8±1.1 10.3±5.4 416.1±401.9 -----
PRI, % 60.6±14.4 67.5±28.4 69.8±14.7 57.4±20.7 0.408
CD34/CD133, % 1.7±2.3 1.0±1.2 0.9±0.8 0.17±0.23 0.001
CD133/VEGFR, % 3.0±2.7 2.3±1.2 2.4±2.5 0.34±0.61 0.004
CD34/VEGFR, % 11.7±6.4 8.7±8.8 5.2±4.7 0.34±0.64 0.0001
9:30 a.m.
2501-526 Effect of Gender on One Year Outcomes in the Synergy 
between Percutaneous Coronary Intervention and 
Cardiac Surgery (SYNTAX) Trial
Marie-Claude Morice, Helene Eltchaninoff, Patrick Serruys, Pieter Kappetein, Friedrich 
Mohr, Katrin Leadley, Keith Dawkins, Elisabeth Stahle, Institut Cardiovasculaire - Paris 
Sud, Massy, France, Boston Scientiﬁc Corporation, Natick, MA
Background: Women undergoing coronary revascularization are at an increased risk for 
adverse outcomes compared with men due to a higher prevalence of risk factors and co-
morbidity. This study assesses gender differences in one year outcomes between coronary 
artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in the SYNTAX 
trial which enrolled the most challenging patients with three vessel and/or left main disease.
Methods: SYNTAX is a prospective, multinational trial with an intended ‘all-comers’ 
design. Consecutive patients were screened by a Heart Team (cardiothoracic surgeon 
and interventional cardiologist) to determine suitability for PCI or CABG. Patients 
amenable for equivalent revascularization using either treatment option were randomized 
1:1 to TAXUS Express² paclitaxel-eluting stent system or CABG. The primary endpoint 
was 12-month MACCE (major adverse cardiac and cerebrovascular events; death, stroke, 
MI, and revascularization).
Results: A total of 1800 patients were randomized, of which 402 (22%) were women. 
Although the baseline characteristics were well matched between the treatment groups, 
women were older, had more unstable angina, diabetes, hypertension, metabolic 
syndrome, and chronic lung disease compared with men. Similar to the men, the 12-month 
MACCE rate in women was signiﬁcantly higher in the TAXUS group compared with CABG 
(men, 12.7% vs 17.5%, P=0.0132; women, 11.1% vs 19.0%, P=0.0348). The rate of 
revascularization was signiﬁcantly higher in the TAXUS group compared with CABG in 
both cohorts (men, 6.2% vs 13.2%, P<0.001; women 4.7% vs 14.2%, P=0.0020). The 
overall safety (death, stroke and MI) rate was comparable in CABG and TAXUS for men 
and women (men, 7.8% vs. 6.8%, P=0.46; women 7.0% vs 10.4%, P=0.24). The rate 
of stroke however was higher in the CABG group for men (2.5% vs 0.3%, P<0.001 but 
comparable in both groups for women (1.2% vs 1.4%, P<0.99).
Conclusions: In the most challenging group of patients with three vessel and/or left main 
disease in the SYNTAX trial, relative differences in outcomes between CABG and PCI 
at 12 months were similar for men and women despite gender related differences in 
baseline co-morbidity.
9:30 a.m.
2501-527 Long-Term Outcomes by Clopidogrel Duration in a 
Diabetic Patients treated with Drug-eluting stent
Jeong-Sook Seo, Duk-Woo Park, Sung Sik Kim, Sung-Hwan Kim, Myung-Zoon Yi, 
Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: Data are limited regarding uniform evaluation of stent thrombosis (ST) and 
the inﬂuence of clopidogrel continuation beyond 12 months on late events after drug-
eluting stent (DES) treatment in diabetic patients. Therefore, this study evaluated the 
long-term risk of ST, cardiovascular events, and the beneﬁts of extended clopidogrel use 
after DES implantation in these patients.
Methods: We identiﬁed 865 patients with diabetes who received DES implantation 
between February 21, 2003 and March 16, 2006. A total of 833 patients surviving 12 
months without adverse cardiovascular events event were analyzed according to 
clopidogrel continuation at 12 months after the procedure. We compared long-term 
adverse outcomes including death, MI, and ST up to 4 years.
Results: Patients with extended use of clopidogrel beyond 12 months had more complex clinical 
and angiographic characteristics as compared to those with limited duration of clopidogrel <12 
months after the procedure. During the 4 years of follow-up, extended continuing clopidogrel 
beyond 12 months was not associated with a reduced risk for ST (deﬁnite or probable, HR: 1.12, 
95% CI: 0.37-3.42). In addition, the adjusted-risk of death (HR: 1.24, 95% CI: 0.62-2.47) and 
death or MI (HR: 1.02, 95% CI: 0.54-1.94) were also similar in the both groups.
Conclusion: In diabetic patients treated with DES, extended continuation of clopidogrel 
beyond 1 year did not appear to reduce ST and death or MI during the long-term clinical 
follow-up.
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eluting stent (ZES) and paclitaxel-eluting stent (PES) using OCT.
Methods: Sixty-one patients (33 ZES vs. 28 PES) undergoing follow-up coronary 
angiography at 9 months after stent implantation were enrolled on the list of study 
population. We performed OCT to evaluate the degree of NIH inside each strut and stent 
apposition.
Results: 15,190 struts in 1,492 mm single-stented segments in total were analyzed. OCT 
analysis showed trend that ZES had greater mean NIH thickness (247 ± 111 μm vs. 210 
± 119 μm, p = 0.06) and percentage of mean NIH area (28 ± 9% vs. 24 ± 14%, p = 0.05). 
In addition, there were signiﬁcant differences in percentage of malapposition (ZES 0.1 ± 
0.5% vs. PES 1.4 ± 3.9%, p = 0.02) and exposed struts (0.50 ± 1.37% vs. 4.62 ± 7.85%, 
p = 0.001). Interestingly, thrombi were more frequently observed in ZES than in PES [3 
patients (9 %) vs. 8 patients (30 %), p = 0.05].
Conclusions: The magnitude of NIH was greater in ZES while malapposition, exposure 
of stent struts and thrombi were more frequently observed in PES at 9 months follow-up. 
These ﬁndings might elucidate higher rate of late stent thrombosis in PES than ZES.
9:30 a.m.
2501-533 The Safety and Efﬁcacy of the Zotarolimus-eluting Stent 
in Elderly Patients: 12-Month Outcomes from the E-Five 
Registry
Chaim Lotan, Eulogio Garcia-Fernandez, Nakul Sinha, Ian T. Meredith, Martin T. 
Rothman, For the E-FIVE Registry Investigators, Hadassah University Hospital, 
Jerusalem, Israel
Background: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in 
the elderly has not been well studied and outcomes are conﬂicting. The clinical outcomes 
of PCI with the Endeavor zotarolimus-eluting stent in a real-world population of elderly 
patients were examined.
Methods: The E-FIVE Registry, a prospective, multicenter, nonrandomized, global 
registry, enrolled 8314 patients at 188 centers. All patients with symptomatic coronary 
artery disease suitable for stenting were eligible. Patient characteristics and clinical 
outcomes at 12 months were stratiﬁed by age and analyzed for patients >75 and 
>85 years. Logistic regression analysis was used to adjust for differences in baseline 
characteristics. All MACE events, death, myocardial infarction (MI), and ARC deﬁned 
stent thrombosis events were adjudicated by a Clinical Events Committee.
Results: Data was available for 1172 and 56 patients over age 75 years and 85 years 
respectively. Elderly patients were more likely to be female and for those >75 years, more likely 
to have complex lesions, and comorbid conditions. Patients >75 and >85 years had signiﬁcantly 
more cardiac deaths. Among patients >75 there was a greater proportion of MACE, cardiac 
death, non-Q wave MI, and cardiac death plus MI, but similar TLR rates. (Table)
Conclusions: We found that patients over 75 in the E-Five Registry experienced a higher 
rate of MACE and its components, consistent with other reports of DES in this age group, 
however TLR rates were similar.
Clinical Outcome a75 years N=7142
>75 years
N=1172 P-value*
a85 years
N=8258
>85
years
N=56
P-value*
MACE, % 6.8 11.5 <.001 7.5 12.0 0.250
Cardiac death, % 1.3 4.2 <.001 1.7 6.0 0.027
MI (all), % 1.5 2.4 0.077 1.6 2.0 0.819
Q-wave MI, % 0.4 0.3 0.604 0.4 0.0 0.989
Non-Q-wave MI, % 1.1 2.2 0.028 1.2 2.0 0.647
Cardiac death + 
MI, % 2.5 6.0 <.001 3.0 6.0 0.227
ARC Def/Prob 
ST, % 1.0 1.9 0.054 1.1 2.0 0.495
TLR 4.4 4.8 0.875 4.4 8.0 0.242
*P-values were calculated using logistic regression adjusted for propensity scores 
for age > 75 vs. a75, or age >85 vs. a85. Propensity scores were calculated using: 
sex, prior MI, prior PTCA, prior CABG, diabetes, acute MI (<72hrs), hypertension, 
hypercholesterolemia, smoking, LAD (vs. Non LAD), B2C (vs. AB1), lesion length ( 
q27mm vs. <27mm), RVD (> 3.5mm, vs. a 3.5mm).
9:30 a.m.
2501-534 Paclitaxel-Eluting Stents for the Treatment of Bare Metal 
Stent Restenosis: Three-Year Results of the TAXUS V 
ISR Trial
Stephen G. Ellis, Saif Anwaruddin, Charles D. O’Shaughnessy, Kenneth M. Kent, 
Kenneth M. Kent, Steven L. Martin, Thomas F. McGarry, Dean J. Kereiakes, Donald S. 
Baim, Gregg W. Stone, Cleveland Clinic, Cleveland, OH
Introduction: In the TAXUS V-ISR trial at 2 years, TAXUS Express, a paclitaxel-eluting 
stent (PES), demonstrated similar safety and less clinical restenosis than vascular 
brachytherapy (VBT) for treatment of bare metal stent (BMS) in-stent restenosis (ISR). 
Whether these beneﬁts are sustained long-term at the 3-year follow-up is unknown.
Methods: Patients (N=396) with BMS ISR were prospectively randomized to either beta 
source VBT or PCI with PES. The primary endpoint was ischemia-driven target vessel 
revascularization (TVR) at 9 months. Thienopyridine use at 3 years was 59.3% in the PES 
group and 66.3% in the VBT group.
Results: At 3 years, PES compared to VBT resulted in a decrease in TVR (21.5% vs 
32.6%, P=0.02) and target lesion revascularization (TLR) (11.2% vs 25.6%, P<0.001). 
This reﬂects a further differential reduction with PES vs. VBT in TVR (3.8% vs 9.9%, 
P=0.02) and TLR (1.1% vs 6.6%, P=0.006) between 2 to 3 years. No differences in 
9:30 a.m.
2501-530 Outcomes of Small Vessel Stenting in the Bare Metal 
Stent vs. Drug Eluting Stent Eras: Results from the 
NHLBI Dynamic Registry
Shailja V. Parikh, Tayo Addo, Faith Selzer, Oscar C. Marroquin, Suresh Mulukutla, J. 
Dawn Abbott, Elizabeth Holper, University of Texas - Southwestern, Dallas, TX
Background: While randomized trials of drug-eluting stents (DES) vs bare metal stents 
(BMS) demonstrate reduced target vessel revascularization, it is unclear if similar 
outcomes are seen in unselected patients after PCI for small vessel disease.
Methods: Utilizing patients from the NHLBI Dynamic Registry Waves 1-3 for BMS (1997-
2002) and Waves 4-5 for DES (2004 and 2006), demographic, angiographic, and one 
year outcome data of patients with small vessel disease treated with BMS (n= 550) vs 
DES (n= 643) were evaluated. Small vessel was deﬁned as 2.5 - 2.75 mm in diameter.
Results: Patients undergoing small vessel PCI with DES vs BMS had a higher prevalence 
of diabetes (38.5% vs 31.0%, p = 0.007) and were more likely to have a prior PCI (35.9% vs 
26.9%, p<0.001), but less likely to have a prior MI (24.1% vs 32.1%, p=0.003). Compared to 
BMS-treated patients, the mean number of signiﬁcant lesions was higher in the DES-treated 
group (3.0 vs 2.8, p=0.04). Among DES-treated lesions, the mean lesion length was longer 
(16.7 vs 13.6 mm, p<0.001) and the mean reference vessel size was smaller (2.56 vs 2.59 
mm, p<0.001) vs BMS-treated lesions. Adjusted one year adverse outcomes are in Table 1.
Conclusions: Despite a higher clinical and angiographic risk proﬁle, in this real-world 
registry, patients with small vessel disease treated with DES had lower rates of repeat 
revascularization and lower rates of death and MI vs patients treated with BMS. These 
data conﬁrm the efﬁcacy and safety of DES over BMS in common clinical practice.
Adjusted HR of One Year Adverse Events for pts w/ Small Vessel 
Disease Undergoing PCI w/ DES vs. BMS
Hazard Ratios 95% CI p-value
Death 0.82 0.41 - 1.61 0.56
MI 0.55 0.29 - 1.05 0.07
CABG 0.20 0.10 - 0.41 <0.001
Death or MI 0.58 0.36 - 0.93 0.02
Repeat PCI 0.48 0.32 - 0.70 <0.001
Repeat Revascularization 0.44 0.31 - 0.61 <0.001
9:30 a.m.
2501-531 Incidence and Predictor of Stent Thrombosis in 
Japanese Patients with Acute Coronary Syndrome in 
the Real World. -From the j-CYPHER Registry-
Ren Kawaguchi, Shigeru Oshima, Takeshi Kimura, Kazuaki Mitsudou, j-CYPHER 
Registry Investigators, Gunma Prefectural Cardiovascular Center, Maebashi, Japan
Background: Acute coronary syndrome (ACS) has been identiﬁed as a strong predictor 
of stent thrombosis (ST) after Sirolimus-Eluting Stent (SES) implantation. We aimed to 
estimate the incidence and predictors of ST for the ACS lesions after SES implantation in 
the real world of Japanese intervention.
Methods: 2440 Patients with 2800 lesions of ACS (ST-elevation myocardial infarction: 
666, Non ST-elevation myocardial infarction: 318, unstable angina: 1816) which enrolled in 
j-Cypher Registry were investigated. ST was deﬁned as deﬁnite or probable of Academic 
Research Consortium.
Results: One year and two years follow up have completed for 96% and 86 % of the 
patients respectively. Emergent procedure was performed in 1146 cases (47.0%). Dual 
antiplatelet therapy (APT) before procedure had given in 1328 cases (54.4%), oppositely 
272 cases (11.1%) had not given either both aspirin and thienopiridine before procedure. 
All course of death was observed in 184 patients (7.5%) and cardiac death was 114 
cases (4.7%). TLR was performed in 155 cases (8.3%). Overall ST occurred in 38 lesions 
(1.36%) and late ST (LST) was observed in 12 lesions (0.43%) through 2 years. Diabetes, 
severe renal insufﬁciency, hemodialysis, low EF (<40%) and two stent approach to the 
bifurcation lesion were signiﬁcantly associated to the overall ST in univariate analysis. 
Discontinuation of both APT, premature discontinuation of thienopiridine, severe renal 
insufﬁciency and LMT lesion were signiﬁcantly associated to the LST in the univariate 
analysis. Furthermore, the multivariate analysis identiﬁed that discontinuation of both APT 
(O.R. 5.47 95%CI: 1.08-23.29) was the strongest predictor of the LST. The pretreatment of 
dual APT before procedure was not associated to either ST or LST.
Conclusions: The incidence of ST seems lower in Japanese patients with ACS than 
previously reported in the world. Pretreatment of APT was not associated to ST. However, 
similar to the previous report, discontinuation of dual APT is the strong predictor of both 
overall ST and LST for the ACS lesion treated with SES.
9:30 a.m.
2501-532 Comparison of Neointimal Coverage of Zotarolimus-
Eluting Stents With Paclitaxel-Eluting Stents Using 
Optical Coherence Tomography at 9 Months After 
Implantation
Sang Min Park, Jung-Sun Kim, Chunyu Fan, Tae Hoon Kim, Young-Guk Ko, Donghoon 
Choi, Yangsoo Jang, Yonsei cardiovascular center, Seoul, South Korea
Background: Optical coherence tomography (OCT) could afford the detection of thin 
layer of neointimal hyperplasia (NIH) and malapposition of stent with high-resolution. We 
intended to compare the stent strut coverage and malapposition between Zotarolimus-
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(UA and MI) showed no signiﬁcant correlation with %NIV (B=0.044, P=0.702) or max CSN 
(B=0.094, P=0.382). The incidence of late acquired incomplete stent apposition (ISA) was 
also similar among the 3 groups.
Conclusion: The efﬁcacy of ZES in patients with ACS on neointimal hyperplasia appears 
to be comparable to those with stable angina. 
Stable AP Unstable AP AMI P value
Baseline (BL)
VVI (mm3/mm) 12.9±4.1 14.4±3.6 16.6±5.0 0.001
PVI (mm3/mm) 6.3±2.7 7.1±2.4 8.6±3.1 0.004
LVI (mm3/mm) 6.7±1.9 7.3±2 7.7±2.3 0.022
Follow-up (FU)
VVI (mm/mm3) 13.2±4.1 14.9±3.6 15.8±4.8 0.002
Delta-VVI (mm3/mm) 0.203±1.027 0.174±1.18 -0.276±1.208 0.279
PVI (mm3/mm) 6.5±2.5 7.4±2.3 8.2±3.3 0.006
Delta-PVI (mm3/mm) 0.163±0.932 0.119±0.935 -0.159±0.671 0.436
LVI (mm3/mm) 5.7±1.9 6.0±1.8 6.6±1.8 0.032
Delta-LVI (mm3/mm) -1.007±1.007 -1.351±1.054 -1.216±1.362 0.066
% NIV (%) 16.9±11.8 18.9±10.7 16.6±9.5 0.292
% Max CSN (%) 31.7±14.9 35.4±14.9 34.0±16.5 0.135
Patinets with Max CSN >=50% (%) 12.0 15.2 16.7 0.666
Late acquired ISA (%) 1.5 0 0 0.322
9:30 a.m.
2501-537 Six-Month Clinical Outcomes of Sirolimus-Eluting 
Stents with a Biodegradable Polymer for the Treatment 
of Unselected Patients with Complex Coronary Lesions 
- Preliminary Results from the Prospective, Multicenter 
E-Series Registry
Ricardo A. Costa, Alexandre Abizaid, Andrea S. Abizaid, J. Ribamar Costa, Jr., Dimytri 
Siqueira, Fausto Feres, Costantino Costantini, Ayrton Arruda, Fábio S. Brito, Maurício 
Prudente, Expedito Ribeiro, Cadiovascular Research Center, São Paulo, Brazil, Institudo 
Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: The Supralimus sirolimus-eluting stent, S-SES (Sahajanand Medical 
Technologies Pvt. Ltd., Surat, India), is a new DES technology incorporating a 
biodegradable drug-carrier component. Preliminary data with the S-SES has shown 
promising results, however, its impact in unselected pts is still unknown.
Methods: Between Nov/2006-Sep/2008, 1,045 pts were prospectively enrolled in 35 sites 
in South America. Inclusion criteria were all comers for routine or emergency PCI. Clinical 
follow-up was scheduled at 1, 6, 12, and 24 months. We report the preliminary outcomes 
at 6-month.
Results: Baseline characteristics included mean age 64 years, 32% female, 79% 
hypertension, 40% diabetes, 32% smoking, 23% previous MI, and 35% previous PCI. 
Overall, 37% presented with ACS (5% AMI). Lesion morphology included 29% mod/
severe calcium, 16% in-stent restenosis, 12% bifurcation, 6% total occlusion, 5% ostial, 
4% thrombus, and 63% classiﬁed as type B2/C. LAD was the predominant location (43%); 
glycoprotein inhibitors were used in 11%, there were 1.03 lesions per patient, and ﬁnal 
TIMI 3 ﬂow was achieved in 97%. Baseline reference diameter and lesion length were 
2.92 and 23.26 mm, respectively. Clinical outcomes are shown in the Table.
Conclusions: The novel S-SES DES with a biodegradable polymer demonstrated 
excellent results in unselected pts with complex lesions. In the mid-term FU, there were 
only 2% TLR, and no safety concerns including stent thrombosis <1%. Longer-term 
follow-up is warranted. 
Outcome In-hospital 6-month (Out-of-hospital)
Death (all cause) 0.3% 2.1%
MI 1.7% 1.2%
TLR 0.1% 2.2%
Stent thrombosis 0% 0.8%
9:30 a.m.
2501-538 The Initial Extent of Incomplete Stent Apposition in 
ST-Elevation Myocardial Infarction Treated with Drug-
Eluting Stent: The Usefulness of Optical Coherence 
Tomography
Ung Kim, Jung-Sun Kim, Jin-Sun Kim, Jung-Myung Lee, Jung-Woo Son, Jaedeok Kim, 
Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Inje University Paik hospital, Busan, 
South Korea
Background: The aim is to identify the extent of initial incomplete stent apposition (ISA) 
using optical coherence tomography (OCT) in ST-elevation myocardial infarctions (STEMI) 
treated with different types of drug-eluting stents (DES) and to compare the results.
Methods: Twenty four STEMI patients underwent primary percutaneous coronary 
intervention (PCI) were enrolled. The OCT was performed within 72 hours after the 
primary PCI. Distances between the endo-luminal surface of the strut reﬂection and the 
vessel wall and the extent of ISA were measured and analyzed.
Results: Sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES) and zotarolimus-
eluting stents (ZES) were deployed in 7 patients (29%), 7 patients (29%) and 10 patients 
(42%). In total, 4951 struts in 620 mm single-stent segments were analyzed. 1463 struts 
in SES, 1522 in PES, and 1966 in ZES were analyzed and measured distances were 
found to be signiﬁcantly different (134±48 μm in SES, 89±29 μm in PES and 76±26 μm 
in ZES, p=0.001) and the frequency of ISA were also signiﬁcantly different (28% in SES, 
11% in PES, 10% in ZES, p=0.001).
estimated rates of cardiac death (2.8% PES vs 2.2% VBT, P=0.76), myocardial infarction 
(4.2% PES vs 7.6% VBT, P=0.20) or target vessel thrombosis (2.7% PES vs 4.3% VBT, 
P=0.40) were observed at 3 years. The signiﬁcant decrease in MACE (cardiac death, 
MI or TVR) with PES (24.7%) over VBT (34.5%, P=0.04) appears driven primarily by a 
progressive relative reduction in TVR throughout follow-up (Figure).
Conclusion: The treatment of BMS ISR using PES rather than VBT improves event free 
survival through 3 years, with beneﬁts improving over time due to reduced late catch-up.
9:30 a.m.
2501-535 “Late catch-up” in Restenosis Following Sirolimus-
Eluting Stent Implantation
Masashi Kimura, Osamu Matsuda, Nobuyoshi Tanaka, Kenya Nasu, Mariko Ehara, 
Yoshihisa Kinoshita, Mitsuyasu Terashima, Etsuo Tsuchikane, Hitoshi Matsuo, Yasushi 
Asakura, Osamu Katoh, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Despite the suppression of intimal hyperplasia (IH) in coronary arteries with 
drug eluting stents (DES) compared with bare-metal stents at 6 months postprocedure, 
there appears to be a “late catch-up” in IH growth among patients treated with DES after 
1 year. However, late restenosis after sirolimus-eluting stent (SES) implantation has 
not been sufﬁciently evaluated. The aim of our study was to determine whether in-stent 
restenosis (ISR) occurring >1 year after SES implantation is a real clinical entity.
Methods: We analyzed data on all SES implanted in patients treated from June 2004 
to April 2007 and evaluated the incidence, clinical presentation, and angiographic ISR 
pattern after SES implantation. “Late catch-up” required demonstration of a patent stent at 
6 to 9 months, with restenosis demonstrated on repeat angiography after 1 year.
Results: There were 3,420 lesions in 2,414 patients treated with SES over the length 
of the study period at our institution. Of this population, angiographic follow-up was 
performed in 1,763 patients (73.0%) with 2,506 lesions (73.3%). Angiography was 
performed after 1 year because of patient symptoms or to treat other vessels. Overall, 
ISR occurred in 265 lesions (10.6%). “Late catch-up” in ISR was observed in 20 lesions 
(0.80%) at second angiographic follow-up (median 23.5 months; range of 17.7 to 29.3 
months). Of 20 lesions, 13 (65%) were located at the stent edge. Almost all cases of “late 
catch-up” (92.8%) expressed a focal angiographic ISR pattern. Clinical presentation of 
late target lesion revascularization (TLR) included silent ischemia (43%) and recurrent 
angina (57%). Late TLR was performed in 18 patients with 19 lesions. Serial quantitative 
coronary angiographic analysis of these lesions showed a minimal lumen diameter of 
2.71±0.55 mm immediately after SES implantation, 2.44±0.59 mm at 9-month follow-up, 
and 1.04±0.26 mm at second follow up (p<0.001).
Conclusions: “Late catch-up” is an infrequent but real entity. The clinical presentation of 
late TLR was either silent ischemia or recurrent angina, but not acute coronary syndrome. 
Careful clinical and angiographic follow-up 1 year after SES implantation should be 
considered.
9:30 a.m.
2501-536 Intravascular Ultrasound Analysis of Vessel Response 
in Acute Coronary Syndrome Treated with Zotarolimus-
Eluting Stents
Daisaku Nakatani, Katsuhisa Waseda, Hiromasa Otake, Bon-Kwon Koo, Ryota Sakurai, 
Akiyoshi Miyazawa, Masao Yamasaki, Junya Ako, Hyeonsoo Chang, Jean Fajadet, 
Richard E. Kuntz, William Wijns, David E. Kandzari, Martin B. Leon, Paul G. Yock, 
Yasuhiro Honda, Peter J. Fitzgerald, Stanford University Medical Center, Palo Alto, CA, 
Clinique Pasteur, Toulouse, France
Background: First-generation drug-eluting stents demonstrated conﬂicting results in the 
treatment of acute coronary syndrome (ACS). The aim of this IVUS study was to elucidate 
detailed vessel response to Endeavor zotalolimus-eluting stents (ZES) in patients with 
ACS versus stable angina.
Methods: We analyzed serial (baseline and 8-9 month follow-up) volumetric IVUS in 297 
patients treated with a ZES for de novo coronary lesions. Volume index (volume/length) 
was calculated for vessel (VVI), plaque (PVI), neointima (NIV), and lumen (LVI). Percent 
neointimal volume (%NIV) was calculated as (NIV/SVI)×100. Cross-sectional narrowing 
(CSN) was deﬁned as neointimal area divided by stent area (%).
Results: Despite larger VVI, PVI, and SVI in ACS patients, %NIV and max CSN at 
follow-up were similar among groups with stable angina (SA, n=142), unstable angina 
(UA, n=125), and recent myocardial infarction (MI, n=30) (Table). The rate of signiﬁcant 
narrowing (maximum %CSN >50%) was also comparable among the 3 groups. With 
adjustment for difference in baseline characteristics by multiple regression analysis, ACS 
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presented with death.
Methods: Between March 2003 and July 2006, a total of 6,592 patients underwent 
percutaneous coronary intervention with DES in a Korean Multicenter Angioplasty 
Team (KOMATE) Registry. Of these patients, using the database from Korea National 
Statistical Ofﬁce and hospital network, we identiﬁed 97 patients with ST, by Academic 
Research Consortium deﬁnition. The ST presented with a death, which developed 
initially or during the in-hospital periods, occurred in 60 (62%) patients. We compared the 
clinical, angiographic, and procedural variables of these patients with other patients with 
ST without deaths (n=37), who survived after ST. Multivariate regression analysis was 
performed to determine the correlates of ST presented with a death.
Results: The patients with deaths after ST were older [mean age; 69 vs. 62, p=0.002], 
more female gender [25 (42%) vs. 8 (22%), p=0.040], and lower left ventricular ejection 
fraction [45±16 vs. 53±14 %, p=0.019] and had a higher frequency of chronic renal failure 
[16 (27%) vs. 2 (5%), p=0.014] and acute myocardial infarction [35(58%) vs. 14 (38%), 
p=0.042], as compared with those without deaths after ST. There was no difference in 
the frequency of diabetes or hypertension between the 2 groups. In angiographic and 
procedural variables, the patients with ST presented with deaths were treated more 
frequently for chronic total obstructive lesions (20% vs. 7%, p=0.044), compared with 
those without death after ST. The types, length, and diameter of used DES did not differ 
between the groups. The most independent predictor for the occurrence of a death in 
patients with ST after DES implantation was older age [odds ratio (OR) = 1.08, 95% 
conﬁdence interval (CI)=1.01-1.15, p=0.029].
Conclusions: This study suggested that the patients with ST following DES might be 
frequently presented with death. The major determinant for death after ST was older 
age.
9:30 a.m.
2501-542 Two Year Outcomes Following Off-Label Use of Drug-
Eluting Stents in the Real-World: Insights from the HMO 
Research Network- Stent Registry (HMORN-Stent)
Thomas T. Tsai, P. Michael Ho, Nikki M. Carroll, Susan M. Shetterly, Stanley Xu, J. David 
Powers, Alan S. Go, Karen Margolis, David J. Magid, Denver VA Medical Center, Denver, 
CO, University of Colorado Denver, Denver, CO
Background: Most drug-eluting stents (DES) are implanted for non-FDA-approved “off-
label indications”. The degree to which off label use and clopidogrel treatment duration 
impacts long term post-stent outcomes remains unclear.
Methods: We evaluated 5679 patients from the HMORN-Stent Registry from January 
2004-June 2006 stratiﬁed by on versus off-label indications. Off-label DES indications 
included use in bypass grafts, chronic total occlusions, left main artery, bifurcations, multi-
vessel intervention, myocardial infarction (MI), and vessel diameter <2.5 mm or >4.0 mm 
or lesion length >30 mm.
Results: Of 5679 patients with DES, 3893 (68.6%) received stents for off-label indications. 
At 2 years of follow-up, those receiving off label DES had signiﬁcantly higher rates of 
death and MI (12.6% vs 7.2%)[Figure]. After adjustment for confounders, off-label use 
was associated with a signiﬁcantly higher risk of death, MI, or revascularization (adjusted 
HR, 1.32; 95% CI, 1.15-1.53; P=0.005). Mean duration of clopidogrel therapy was longer 
in off-label patients (264 days vs. 222 days, P<0.0001).
Conclusion: Most DES in real world practice are placed for off-label indications. There 
are increased adverse events with off-label DES implantation at 2 years despite longer 
clopidogrel treatment. Optimal clopidogrel duration and DES use in this patient subset 
requires further study. 
9:30 a.m.
2501-543 Outcome of Non-cardiac Surgical Procedure and 
Brief Interruption of Dual Anti-platelet Agents within 
12 Months Following ENdeavorTM Stent (Zotarolimus-
eluting Stent) Implantation (SENS): a Multicenter Study
Jin Won Kim, Woong Chol Kang, Ki Seok Kim, Soo Joong Kim, Chang-Wook Nam, 
Chul-Min Ahn, Bong-Ki Lee, Sang Yup Lim, Hyun Sook Jung, Jin Ho Choi, Young Joon 
Hong, Dong Joo Oh, Korea Univ Guro Hosp, Seoul, South Korea
Background: Bare-metal stent is preferable to 1st generation drug-eluting stent (DES) in 
patients who need non-cardiac surgery within 12 months from coronary stenting despite 
restenosis. However, data are lacking regarding the safety of EndeavorTM stent which has 
been known to carry a lower risk of stent thrombosis due to rapid re-endothelialization.
Methods: A total of 3099 consecutive patients treated with EndeavorTM stent (Zotarolimus-
eluting stent;ZES) since January 2006 were retrospectively analyzed in Korean 11 teaching 
hospitals. The primary endpoint was the 30-day major adverse cardiac events (MACE) 
including death, non-fatal myocardial infarction (MI) and target lesion revascularization.
Results: 194 patients (6.2 %, 194/3099) (male 54.9 %, mean age 63.5 years, diabetes 
Conclusions: Considerable rates of ISA using OCT were detected in STEMI after primary 
PCI with DES implantation and SES has especially higher rates of ISA.
9:30 a.m.
2501-539 Stent fracture after “full metal jacket” using drug-eluting 
stents as cause of in-stent restenosis
Masashi Kimura, Tsuyoshi Ito, Mariko Ehara, Nobuyoshi Tanaka, Kenya Nasu, Yoshihisa 
Kinoshita, Etsuo Tsuchikane, Yasushi Asakura, Hitoshi Matsuo, Mitsuyasu Terashima, 
Osamu Katoh, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Stented segment length and multiple stents are predictive factors for restenosis 
after drug-eluting stent (DES) implantation; coronary stent fracture has been noticed as a cause 
of in-stent restenosis (ISR). Nonetheless, clear visualization of in-vivo stent structure is not 
currently feasible with conventional technology. Therefore, we investigated the morphological 
characteristics of the stent fracture site and the correlation with ISR using multislice computed 
tomography (MSCT). Speciﬁcally, we looked at very long segments (ie, q64 mm of stented 
length) treated by DES, an approach colloquially referred to as a “full metal jacket.”
Methods: From January 2007 to April 2008, we performed MSCT coronary angiography 
in 512 consecutive patients. In these patients, a total of 21 stented lesions were treated, 
with at least 64 mm of overlapping DES scanned using MSCT. Stent fracture was deﬁned 
as a spontaneous injury to the structure of the in vivo stent strut in the absence of any 
artiﬁcial process. Lesions were divided according to the presence or absence of fracture. 
Frequency of overlapping, vessel bending and severe calciﬁcation of the native artery 
were compared between the 2 groups, as well as the ISR rate.
Results: Of the entire population, lesions with “full metal jacket” had more stent fractures 
than those without “full metal jacket” (30% vs. 7%, P<0.0001). The average stented length 
in these lesions was 83.9 ± 19.0 mm, with stent fracture detected in 10 sites (30%) and 
observed more frequently in the right coronary artery (RCA). There were no signiﬁcant 
differences between groups in the rate of bending of the native coronary artery or in severe 
calciﬁcation. The ISR rate was higher in the fracture group (73% vs. 30%, P=0.03.
Conclusion: Coronary stent fracture was detected in 30% of stented lesions after 
aggressive stenting. “Full metal jacket” was the main predictor of stent fracture, resulting in 
in-stent restenosis. MSCT is a feasible modality capable of providing essential information 
regarding stent fracture.
9:30 a.m.
2501-540 The Impact of Age on One Year Outcomes in the 
Synergy Between Percutaneous Coronary Intervention 
and Cardiac Surgery (SYNTAX) Trial
Antonio Colombo, Pieter Kappetein, Patrick Serruys, Marie-Claude Morice, Katrin 
Leadley, Keith Dawkins, Friedrich Mohr, Ospedale San Raffaele, Milan, Italy, Boston 
Scientiﬁc Corporation, Natick, MA
Background: Although advanced age is known to induce adverse outcomes following 
percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), 
limited data are available on the relative differences in outcomes between these 
procedures as a function of age. This study compares one year outcomes between CABG 
and PCI in patients a70 and >70 years in the SYNTAX trial which enrolled the most 
challenging patients with three vessel and/or left main disease.
Methods: SYNTAX is a prospective, multinational trial with an intended ‘all-comers’ 
design. Consecutive patients with de novo three vessel and/or left main disease were 
screened by a Heart Team (cardiothoracic surgeon and interventional cardiologist) to 
determine suitability for PCI or CABG. Patients amenable for equivalent revascularization 
using either treatment option were randomized 1:1 to TAXUS Express² paclitaxel-eluting 
stent system or CABG. Patients deemed amenable for only one treatment option were 
entered into the appropriate registry. The primary
endpoint was 12-month MACCE (major adverse cardiac and cerebrovascular events; 
death, stroke, MI and revascularization).
Results: Of the 1800 randomized patients, 1225 (68%) were a70 (CABG, 612; TAXUS, 
613) and 575 patients were >70 (CABG, 285; TAXUS, 290). The12-month, MACCE rate 
was signiﬁcantly higher in the TAXUS group (11.4% vs 17.4%, P=0.0034) in patients a70 
but was comparable between CABG and TAXUS in patients >70 (14.4% vs 18.8%, P=0.18). 
The overall safety (death, stroke, MI) rate was comparable between the groups in both 
cohorts (a70, 6.1% vs 5.8%, P=0.81; >70, 11.0% vs 11.5%, P=0.87). The rate of stroke 
however was signiﬁcantly higher in the CABG group (1.7% vs 0.2%, P=0.0055) in patients 
a70 but comparable between the two groups in patients >70 (3.4% vs 1.4%, P=0.12). The 
revascularization rate was signiﬁcantly higher in the TAXUS group compared with CABG in 
both cohorts (a70, 6.5% vs 13.9%, P<0.001; >70, 4.6% vs. 12.5%, P=0.001).
Conclusions: In the SYNTAX trial, patients a 70 had a signiﬁcantly higher MACCE rate 
in the Taxus group compared with CABG. However, patients >70 years had comparable 
MACCE rates in TAXUS and CABG at 12 months.
9:30 a.m.
2501-541 To Be Dead or Alive After Stent Thrombosis? Clinical 
and Angiographic Correlates of Drug-eluting Stent 
Thrombosis Presented with Deaths
Byeung-Keuk Kim, Seung Jin Oh, Dong Woon Jeon, Joo Young Yang, Jung-Sun Kim, 
Young-Guk Ko, Donghoon Choi, Yangsoo Jang, Bum Kee Hong, Hyuck Moon Kwon, 
Kyung-Hoon Lee, Seung-Hwan Lee, Byoung Kwon Lee, Choong Won Goh, Jae-Hun 
Jung, National Health Insurance Corporation Ilsan Hospital, Goyang-si, South Korea
Background: The stent thrombosis (ST) following drug-eluting stents (DES) implantation 
has a fatal clinical course and shows the various initial clinical presentations including 
deaths. The aim of this study is to evaluate the clinical and angiographic correlates of ST 
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Results: Of 75 patients enrolled, the device was implanted successfully in 66. Anatomic 
limitations prevented implantation in 7, failure of venous access and an earlier generation 
delivery cable resulted in the other 2. Mean follow up was 46 ± 14 months. Mean age 
was 68.5±8.0 years. The acute results have been published previously. After 6 months, 
91% had discontinued warfarin therapy. On routine 6 month TEE follow-up, 4 patients 
were noted to have a thrombus layer along the atrial face of the implant, one of whom 
developed a transient ischemic attack (TIA). Warfarin was restarted in these patients and 
stopped 3 months later without further evidence of thrombus. In long term follow up, 63 of 
66 patients (95%) were off anticoagulation. There was one additional TIA. One patient had 
an embolic stroke at 39 months in the setting of severe concurrent carotid disease. These 
data reﬂect an actual stroke rate of 1 in 251 patient years (0.4%); the expected stroke rate 
given a mean CHADS2 Score of 1.8 ± 1.1 would have been 5.75%. Eight patients have 
died (mean 36± 15 months), all deaths were non-device and non-procedure related.
Conclusions: The data suggest that WATCHMAN LAA Closure is safe and feasible, 
with one embolic stroke through 5 year follow up. A randomized study comparing the 
WATCHMAN device with warfarin for stroke prevention in NVAF is ongoing.
9:30 a.m.
2502-546 Novel Fully Bioabsorbable Salicylate-Based Sirolimus-
Eluting Stent: OCT Assessment of Stent Degradation in 
Pig Coronary Artery Implants
Daisuke Matsumoto, Toshiro Shinke, Sarah Geva, Nicolas Chronos, Keith Robinson, 
Refat Jabara, Saint Joseph’s Translational Research Institute, Atlanta, GA, Saint 
Joseph’s Hospital of Atlanta, Atlanta, GA
Background: Fully biodegradable stent is an attractive alternative strategy for current 
permanent metallic stents. We evaluated a novel, fully bioabsorbable sirolimus-eluting 
stent (8.3μg sirolimus/mm stent) synthesized entirely from salicylic-acid polymer in a 
clinically relevant animal model.
Methods: Bioabsorbable balloon-expandable stents (n=21) were implanted in pig 
coronaries using QCA to optimize stent apposition. In vitro studies demonstrated sirolimus 
elution over 30 days and complete stent degradation in 9-12 months. Animals underwent 
restudy and terminated at 1 month (1M), 3 month (3M), and 6 month (6M). Thickness 
and area of each strut (implantation: 1273 struts, 1M: 689 struts, 3M: 585 struts, and 6M: 
292struts) were measured. Brightness of struts was semiquantitatively classiﬁed into 3 
groups: 1) high 2) moderate 3) low signal intensity with or without clear strut border.
Results: Average strut thickness and area at 1M was similar to post implantation (implant: 
0.27±0.025mm, 0.14±0.018mm2, 1M: 0.26±0.002mm, 0.12±0.002mm2, respectively, 
P=NS,). Strut Thickness and area gradually decreased over time (3M: 0.230±0.002mm 
and 0.093±0.002mm2, P<0.0001; 6M: 0.227±0.003mm and 0.085±0.002mm2, respectively, 
P<0.0001). OCT signal intensity was decreased with higher frequency of unclear border 
at 6M (P<0.01).
Conclusions: Degradation of a novel fully bioabsorbable salicylate-based stent was 
demonstrated by OCT. The size of this stent was remarkably decreased from 1M to 3M 
and 6M.
9:30 a.m.
2502-547 In-Vivo Intravascular Imaging of Novel Fully 
Bioabsorbable Salicylate-Based Sirolimus-Eluting Stent 
Refat Jabara, Daisuke Matsumoto, Toshiro Shinke, Sarah Geva, Nicolas Chronos, 
Nicolas Chronos, Keith Robinson, Hadassah-Hebrew University Medical Center, 
Jerusalem, Israel, Saint Joseph’s Translational Research Institute, Atlanta, GA
Background: Recent advances in bioabsorbable stent technology have contributed to 
awakened interest in their role as alternatives to current metallic drug-eluting stents. We 
sought to evaluate a novel, fully bioabsorbable sirolimus-eluting stent (SES) synthesized 
entirely from salicylic-acid polymer, in a clinically relevant animal model.
Methods: Bioabsorbable balloon-expandable stents (n=32) were implanted in pig 
coronaries using quantitative coronary angiography (QCA) and intravascular ultrasound 
(IVUS) to optimize stent apposition. Dose density of sirolimus was 8.3 μg/mm stent length 
with in-vitro studies demonstrating elution over 30 days and complete stent degradation 
in 9-12 months. Animals underwent QCA and IVUS restudy and were terminated at 7, 14, 
30, 90, and 180 days for histologic assessment. Optical coherence tomography (OCT) 
was also performed for the 90- and 180-days samples.
Results: All stents were deployed successfully without notable mechanical difﬁculties. 
No edge dissection or vasospasm was observed during implant. No stent migration was 
observed at any time. Angiographic diameter stenosis (DS) was 20±16%, 24±4%, and 
23±17%, at 1, 3, and 6 months, respectively. In parallel, IVUS showed good apposition of 
the stent to the vessel wall with DS of 21±9%, 25±7%, and 18±3%; and area stenosis (AS) 
of 35±13%, 33±7%, and 32±4% at 1, 3, and 6 months, respectively. OCT demonstrated 
good apposition of the stent with DS of 28±7% and 20±6%, and AS of 37±10% and 
33±13% at 3 and 6 months, respectively. OCT showed reduction of stent thickness by 
23% from 3 to 6 months. Histologic analysis conﬁrmed these in-vivo ﬁndings and revealed 
a favorable healing process of absorbable stent incorporation into the arterial wall, without 
excessive thrombotic or inﬂammatory reactions. 
29.7 %) with brief interruption of dual anti-platelet agents (DAP; both aspirin and 
clopidogrel) due to non-cardiac surgical procedure within 12 months following ZES 
implantation were identiﬁed. Four patients (2.1 %) experienced a MACE (2 patients: fatal, 
2 patients: non-fatal MI with identiﬁed thrombus). The incidence of MACE was higher in 
the early-surgery group (within 3 months following stent implantation) than in the late-
surgery group (3 months to 12 months after stent implantation) (p<0.001, Table).
Conclusion: ZES appears to be safe and feasible in patients undergoing non-cardiac 
surgical procedure after 3 months following stent implantation. 
Variables Early surgery group (0-3 
months, n=34)
Late surgery group (3-12 
months, n=160) p-value
Age(yrs)/Male(%) 62.2/63.5 63.1/50.9 NS
Lesion type (B2/C) 
(%) 73.6 72.8 NS
Stent number 1.4 1.5 NS
Mean stent diameter 
(mm) 3.11±0.52 3.08±0.47 NS
Total stent length 
(mm) 33.0±16.7 29.2±19.5 NS
Major surgery (%) 20.5 22.8 NS
Days from stenting to 
surgery 56.5 233.7 <0.001
DAP withdrawal (days) 13.4 14.8 NS
MACE (%) 8.9(2 Death, 1 MI)
0.6
(1 MI) <0.001
9:30 a.m.
2501-544 A Year of Drug Eluting Stent Failure: Results From a 
Single Institution Registry
Giuseppe Gioia, MariaFrancesca Gioia, Dawn Christensen, Jackie White, Howard 
Levite, William Mathhai, AtlantiCare Regional Medical Center, Pomona, NJ
Background: In January 2007 we created a prospective registry of patients presenting to 
AtlantiCare Regional Medical Center with DES in-stent restenosis or thrombosis (DES failure) to 
identify potential risk factors, and to assess the early and long term outcome of these patients.
Methods: Patients previously implanted with any DES who presented to the cath lab from 
January to December 2007 with a DES failure (deﬁned as either in-stent restenosis or 
thrombosis) were enrolled.
Results: Fifty-ﬁve patients were identiﬁed and treated for DES failure. Mean age was 
61 ± 13 years. Mean time to DES failure was 550 ±389 days. Twenty-eight patients 
(51%) presented with angiographic evidence of stent thrombosis (ST cohort) and clinical 
presentation with either STEMI (22 patients, 79%), non-STEMI (5 patients, 18%) or 
unstable angina (1 patient, 4%). Twenty-seven patients (49%) presented with in-stent 
restenosis (ISR cohort) and clinical presentation with either unstable angina (16 patients, 
59%) or stable angina (11 patients, 41%). Thirteen (46%) patients with ST were still on 
dual antiplatelets therapy (DAT). A strong association was noted between the initial DES 
clinical indication and subsequent clinical DES failure presentation. Out of 22 patients 
presenting with ST and STEMI, 19 (86%) were initially implanted because of a STEMI. 
and only 3 (14%) were implanted for a non-MI syndrome (p<0.001). In contrast out of 
27 patients presenting with ISR, 22 (81%) of them were initially implanted for a non-MI 
syndrome (stable or unstable angina) and only ﬁve of them were implanted because 
of a STEMI (p<0.001). Patients with ST were younger (55±12 vs. 66±10 yrs, p=0.001), 
more frequently current smokers (50% vs. 15%, p=0.008) and less likely to be on dual 
antiplatelets therapy (DAT) than patients with ISR (45% vs. 78%, p=0.02).
Conclusions: A strong association was noted between the initial DES clinical indication 
and subsequent clinical DES failure presentation. Patients presenting with ST were likely 
to have had their implant because of a STEMI and patients with ISR likely to have had 
their implant because a non-MI syndrome, suggesting that the implantation of DES for 
STEMI is a risk factor for subsequent stent thrombosis
I2.POSTER CONTRIBUTIONS
2502
New Technologies/Innovations
Sunday, March 29, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2502-545 Stroke Prevention in Non-valvular Atrial Fibrillation: 
Long-Term Results of the WATCHMAN Left Atrial 
Appendage Occlusion Pilot Study
Peter B. Sick, Zoltan G. Turi, Eberhard Grube, Gerhard Schuler, Karl E. Hauptmann, 
Gregory Mishkel, Steven Yakubov, Steven Almany, David R. Holmes, Hospital 
Barmherzige Brüder, Regensburg, Germany
Background: Patients with non-valvular atrial ﬁbrillation (NVAF) are at enhanced risk 
of embolic stroke; 90 % of left atrial thrombi in NVAF patients are found in the left atrial 
appendage (LAA).
Methods: The WATCHMAN LAA Closure device (Atritech, Plymouth, MN) is made of 
nitinol, incorporates ﬁxation barbs around its perimeter and has a porous membrane on 
its atrial surface. A multi-center pilot study commenced in August 2002. Patients were 
assessed at 45 days, 6 months and one year with transesophageal echo (TEE) and 
clinically assessed annually for up to 5 years.
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2502-550 Long Term Safety, Angina Relief and Improvement 
in Quality of Life in Patients with Refractory Angina 
Treated with the Neovasc Coronary Sinus Reducer
Keyur H. Parikh, Milan Chag, Urmil Shah, Hemang Baxi, Anish Chanadarana, Ajay Naik, 
Satya Gupta, Shmuel Banai, The Heart Care Clinic, Ahmedabad, India, Cardiology 
Department, Tel Aviv Medical Center, Tel Aviv, Israel
Background: Increased coronary sinus (CS) pressure redistributes collateral blood ﬂow 
into ischemic territories of the myocardium, reduces ischemic damage and infarct size. 
First-in-Man Study for the feasibility and short term (12 months) safety for CS ReducerTM
(Neovasc Inc, Canada) in patients with refractory angina have demonstrated promising 
results. The following study was conducted to assess the long term safety, quality of life 
(QoL) and cardiac status among patients implanted with CS ReducerTM.
Methods: Ten patients with coronary artery disease (CAD), severe angina, and reversible 
ischemia were electively implanted with the CS ReducerTM. Angina class assessment, 
echocardiography, exercise stress test, and quality of life assessed by the Seattle Angina 
Questionnaire (SAQ) were performed at baseline and at 3 year follow-up.
Results: At 3 years after implantation of the CS ReducerTM, all 10 patients were alive. 
Average angina class (by Canadian Cardiovascular Class, (CCS)) was signiﬁcantly 
improved compared to baseline (P<0.0001). SAQ at 3 year follow-up demonstrated 
signiﬁcant (P<0.001) improvement compared to baseline in physical limitation, angina 
frequency, treatment satisfaction and QoL. Improvement in the Angina Stability was 
also statistically signiﬁcant at 3 years follow up (P=0.0288). Mean ejection fraction by 
echocardiography and exercise duration by stress test were unchanged as compared with 
baseline (P=0.9627 and P=0.3097 respectively)
Conclusions: Long term follow up after implantation of the Neovasc CS ReducerTM in 10 
patients with refractory angina demonstrates the safety and efﬁcacy of the ReducerTM. No 
mortality was recorded, and the improvement in CCS class, angina relief and QoL was 
sustained for 3 years after implantation of the ReducerTM.
9:30 a.m.
2502-551 A Novel Transcatheter Suture Technique for PFO 
Closure: The Heart Stitch Pilot Study
Anita W. Asgar, Arif Khan, Niki Walker, Anthony Nobles, Michael J. Mullen, Royal 
Brompton Hospital and Hareﬁeld HNS Trust, London, United Kingdom
Background: Patent foramen ovale (PFO) has been implicated in the etiology of embolic 
stroke, transient ischemic attack, migraine with aura, and decompression sickness in 
divers. Transcatheter PFO closure is a safe procedure however, current devices implant 
material that may obstruct future access to the left atrium. The Sutura Heart Stitch is a 
novel bidirectional suture device which allows direct suturing of the PFO without the need 
for an open surgical approach. We describe our preliminary results.
Methods: The study was a prospective non-randomized feasibility study of the Heart 
Stitch to determine safety and efﬁcacy of the device in patients with a PFO and indication 
for closure. Inclusion criteria were as follows: patients 18 years and older, diagnosis of a 
PFO and indication for closure, and no previous history of device closure for PFO. The 
procedure was performed in the cardiac catheterization lab using general anesthetic and 
transesophageal echocardiographic guidance. If device implantation failed, closure was 
performed using another device at the discretion of the operator.
Results: From April 2008 to October 2008, sixteen patients underwent attempted PFO 
closure using the Sutura Heart Stitch device. Indications for PFO closure were; previous 
thromboembolic stroke or transient ischemic attack (11 patients), intractable migraine 
headaches (4 patients) and cryptogenic MI (one patient). Of those enrolled, the Heart 
Stitch was successfully deployed in ten patients . Inability to deploy the device was 
secondary to failure to capture the secundum septum in four patients, and the suture 
being pulled through the septum in two patients. In those patients, the PFO was closed 
using a Biostar (n=5) and Premere device (n=1). One procedural complication, a 
hemothorax occurred was managed successfully. Follow up contrast echocardiography in 
device success patients (n=10) following the procedure demonstrated; no residual shunt 
(n=5), Grade 1 (n=2), and Grade 3 shunt (n=3) at rest and no shunt (n=2), Grade 1 (n=3) 
and Grade 2 shunt (n=1) at valsalva.
Conclusions: This feasibility study demonstrates that the Heart Stitch is both safe and 
effective for PFO closure and provides a novel option for patients.
9:30 a.m.
2502-552 Mid-term Safety and Efﬁcacy of Patent Foramen Ovale 
Closure Using the Bioabsorbable Septal Repair Implant
Ben Van den Branden, Marco Post, Jurrien ten Berg, Maarten-Jan Suttorp, St. Antonius 
Hospital, Nieuwegein, The Netherlands
Background: The use of permanent synthetic implants for closure of a patent foramen 
ovale (PFO) has a number of possible disadvantages including erosions, thrombus 
formation and allergic reactions. These might be absent using a bioabsorbable closure 
device because it will be absorbed and replaced by healthy native tissue.
Methods: All consecutive patients who underwent a percutaneous PFO closure with 
the bioabsorbable closure device between November 2007 and September 2008 were 
included. We report the safety and efﬁcacy of closure in-hospital and at 1 month and 6 
months follow up.
Results: In total 44 patients (50% female, mean age 49.1±10.9 years) underwent a PFO 
closure. The in-hospital complications were a surgical device retrieval from the femoral 
vein in one patient (2%) and a minimal inguinal haematoma in four patients (9%). The 
short-term complications at one month follow up (n=34) were a transient ischemic attack 
in the presence of a residual shunt in one patient (3.0 %) and paroxysmal supraventricular 
Conclusions: This study shows favorable vascular compatibility and efﬁcacy for a novel 
fully bioabsorbable salicylate-based SES. This device has good mechanical performance 
during deployment and stays well-apposed to the vessel wall at long term follow-up. 
These initial results are highly encouraging and support progress into more extensive 
preclinical studies as well as early clinical testing.
9:30 a.m.
2502-548 A Novel Technique For Endovascular Detection and 
Automated Removal of Radiographic Contrast During 
Angiography
Hyeonsoo Chang, Ali H.M. Hassan, Young L. Kim, Bon-Kwon Koo, Junya Ako, Yasuhiro 
Honda, Peter J. Fitzgerald, Center for Cardiovascular Technology, School of Medicine, 
Stanford University, Stanford, CA
Background: Increasing complexity of current PCI may be associated with growing 
incidence of contrast-induced nephropathy. To address this clinical problem, a novel 
method of endovascular detection and automated removal of contrast has been 
developed, comprised of a catheter-based system with a reﬂectance-type optical sensor.
Methods: To test the feasibility of in-vivo detection and removal of contrast, a prototype 
aspiration catheter equipped with a ﬁber-optic sensor (Figure) was inserted into the 
coronary sinus (CS) of 5 canines. Contrast (5 cc per injection) was administered into the 
coronary artery, and reﬂectance signals were recorded at the CS (n=33 signal samples). 
The removal rate was analyzed through 10 blood specimen collections using spectro-
photometric absorbance assay.
Results: Upon detection of contrast in the CS, the sensor signal dropped by 79.5±9.9% 
(range 54.1~92.9%) from the baseline reﬂectance signal at pre-injection (Plot, left axis). 
The signal change was highly reproducible and was signiﬁcantly greater than the baseline 
noise level (2.5±0.9%; range 0.9~4.3%), enabling automatic activation of the aspiration 
system (Plot, right axis). Quantiﬁcation of contrast removal ranged from 46~76% of the 
total injection volume.
Conclusions: The present study demonstrated the feasibility of an in-vivo, catheter-based 
detection and automated removal of contrast using reﬂectance sensing technology. 
9:30 a.m.
2502-549 Responders and Mechanism of Clinical Beneﬁt in 
AMADEUS Trial of the CARILLONTM Mitral Contour 
SystemTM to Treat Functional Mitral Regurgitation
Steven L. Goldberg, Joachim Schofer, Tomasz Siminiak, Uta C. Hoppe, Michael Haude, 
Jean-Paul Herrman, Richard Van Bibber, Ludwik Firek, David Reuter, Justina C. Wu, 
Cardiac Dimensions, Inc, Kirkland, WA
AMADEUS evaluated pts with CHF (NYHA > 2), cardiomyopathy (EF < 40%), and 
functional mitral regurgitation > 2+. The CARILLONTM Mitral Contour SystemTM (CMCS) 
is a device placed percutaneously into the coronary sinus/great cardiac vein, and manual 
tension applied to “cinch” the posterior annulus of the mitral valve. This analysis compares 
improvements in clinical and echo parameters at 1 mo fu after placing a CSMC.
Methods: 30 pts successfully received a CMCS. 1 patient died 3 weeks after implant of 
progressive CHF. The others returned at 1 month for clinical and echo fu. Quantitative 
measurements were performed on baseline and 1 mo echos, including mitral jet area to 
left atrial area, vena contracta, EROA, regurgitant volume, regurgitant fraction as well as 
MR grade. A pt was identiﬁed as a responder (RESP) by 2 different echo criteria or by 3 
different clinical criteria (see TABLE below):
Results: The Table shows the different RESP rate per the different deﬁnition of RESP. 
There were 21 pts who improved their NYHA class by > 1 and 8 who did not. The MR 
grade in the 21 pts who improved their NYHA class decreased from a mean of 3.1 to 2.0, 
whereas those that did not improve their NYHA decreased from a mean of 3.1 to 2.7 (p = 
0.03 comparing the RESP and non-RESP).
Conclusions: There were similar numbers of RESP using echo and clinical deﬁnitions. 
There was a correlation between echo and clinical improvement, suggesting a mechanistic 
explanation for the clinical beneﬁts which were seen after a CARILLON implant was 
performed.
Responders in AMADEUS
Deﬁnition of Responder Percent Responder
Improvement in > 1 MR grade 67%
Improvement in > 1 grade in 2 or more quantitative MR 
measurements 76%
Improvement in > 1 NYHA class 75%
Improvement in 6 MWT > 30 meters 75%
Increase in KCCQ by > 5 points 81%
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2502-555 Novel Sirolimus-Eluting Stent Coated with 
Bioabsorbable Salicylate-Based Polymer: Optical 
Coherence Tomography and Angioscopic Evaluation of 
Pig Coronary Artery Stent Implants
Daisuke Matsumoto, Toshiro Shinke, Sarah Geva, Nicolas Chronos, Keith Robinson, 
Refat Jabara, Saint Joseph’s Translational Research Institute, Atlanta, GA, Saint 
Joseph’s Hospital of Atlanta, Atlanta, GA
Background: Permanent polymers used in current DES can trigger chronic inﬂammation 
and hypersensitivity reactions, which may contribute to late thrombosis and rebound 
restenosis. We evaluated sirolimus-eluting stent coated with novel bioabsorbable 
salicylate-based polymer using OCT, angioscopy and histology.
Methods: Bare metal stents (BMS, n=14), salicylic acid/adipic acid bioabsorbable 
polymer-only coated metal stents (SA/AA, n=15), biostable polymeric sirolimus-eluting 
stents (Cypher®, n=13) and SA/AA containing sirolimus (SA/AA+S, n=17) were randomly 
implanted in pig coronary arteries using QCA to optimize stent apposition. Diameter 
stenosis (DS) was evaluated by angiography, OCT, and histology (aDS, oDS, and 
hDS). Intimal area was assessed by OCT and histology (oIA and hIA). Angioscopic and 
histological mural thrombus (aMTand hMT) was also assessed.
Results: aDS was signiﬁcantly lower in SA/AA+S (-13.2±4.3%) than the other groups 
(BMS: 6.7±5.6%, SA/AA: 8.1±4.2%, and Cypher: -3.4±6.2%, respectively, P=0.01). oIA 
and hIA were lower in SA/AA+S and Cypher compared to SA/AA group (SA/AA+S: 
1.65±0.18mm2, BMS: 2.11±0.32mm2, SA/AA: 2.99±0.36mm2, and Cypher: 1.88±0.34mm2,
P=0.017). aMT and hMT were observed slightly higher in SA/AA+S and Cypher compared 
to BMS and SA/AA.
Conclusions: This sirolimus-eluting stent coated with novel bioabsorbable salicylate-
based polymer showed favorable vascular compatibility and suppression of neointimal 
growth by different modalities.
9:30 a.m.
2502-556 TIMI Myocardial Perfusion Grade Predicts Abnormal 
Single Photon Emission Computed Tomography 
and Endocardial Electrical Activity in Patients with 
Advanced Chronic Coronary Artery Disease
Ricardo Sanz-Ruiz, Pilar Jimenez-Quevedo, Guilherme Silva, Marlos Fernandes, 
Cristiano Cardoso, Fred Braimbridge, Edie Oliveira, Yi Zheng, James Willerson, 
Emerson Perin, Texas Heart Institute, Houston, TX
Background: in the setting of chronic CAD, we aimed to assess the ability of abnormal 
TIMI Myocardial Perfusion Grade (TMPG) scores to identitfy patients with impaired 
myocardial perfusion by SPECT imaging and decreased endocardial voltage at 
electromechanical mapping (EMM). Methods: Nineteen consecutive pts with chronic 
stable CAD were included. TMPG was assessed from coronary angiography utilizing a 
17-segment polar map of the LV (normal, TMPG=3; impaired, TMPG=0-1-2). Perfusion 
was studied with Tc-99m sestamibi (normal: grades 3-4; impaired: grades 0-1-2) and 
EMM was performed with the NOGA system. All studies were performed and analyzed by 
independent observers blinded to the results of the other techniques.
Results: Mean age was 59±7 years and 73% were male. A total of 357 SPECT and EMM 
segments were correlated with the corresponding angiographic data. Abnormal TMPG 
was associated with impaired perfusion by SPECT and segments with normal TMPG 
showed normal SPECT perfusion more frequently (ﬁgure 1A). Segments with abnormal 
TMPG had lower unipolar voltage (UV) than segments with normal TMPG (ﬁgure 1B). 
Moreover, segments with impaired perfusion by SPECT had lower UV (9.6±4.3mV vs 
11.9±4.7mV, p<0.01) and local shortening (8.4±7.1% vs 11.4±6.8%, p<0.01) than 
segments with normal perfusion.
Conclusions: For the ﬁrst time, we have demonstrated that TMPG may be a reliable 
method to study myocardial perfusion in chronic CAD pts, and that TMPG is associated 
with voltage values as assessed by EMM.
tachycardia in three patients (9.0 %). There were no mid-term complications at six months 
follow up (n=21). Using contrast transthoracic echocardiography, a mild or moderate residual 
shunt was present in 49%, 40%, and 32% at 0, 1, and 6 months follow up respectively. A 
large shunt was present in 9%, 6%, and 0% at 0, 1, and 6 months follow up respectively.
Conclusion: Percutaneous PFO closure using the bioabsorbable device seems to be 
safe during mid-term follow up. A high percentage of residual shunting is present at short-
term follow up which decreased importantly at mid-term follow up. Long-term follow up 
data are necessary to evaluate the residual shunting and safety of this new device.
9:30 a.m.
2502-553 Clinical Experience with a Novel Multi-functional 
Percutaneous Assist Device
Ehab S. Kasasbeh, David Webb, Jayant Bagai, Joseph Salloum, Marshall Crenshaw, 
David X. Zhao, Vanderbilt University Medical Center, Nashville, TN
Background: In 1968, the ﬁrst clinical application of the intra-aortic balloon pump -the ﬁrst 
mechanical assist device- was reported in treating patients with cardiogenic shock after 
acute myocardial infarction. Since then, multiple mechanical assist devices have been 
developed. Percutaneous ventricular assist devices (pVAD) have been in use since 2003.
Objective: Here, we present our clinical experience with a newly developed pVAD, named 
the Vanderbilt multifunctional percutaneous heart (MPH). Our objective is to evaluate 
the feasibility and safety of implanting the Vanderbilt MPH in comparison to a currently 
available pVAD, the TandemHeart.
Methods: From February to September 2008, we used the Vanderbilt MPH device in 18 
patients. All patients were clinically assessed to be at high of a risk for circulatory collapse 
without maximal hemodynamic support. In 9 of these patients, the device was used as an 
extra-corporeal membrane oxygenator (ECMO) device. In the remaining 9 patients, it was 
used as a left pVAD. Procedural success was 100%. During the same period, Tandem 
Heart pVAD was used in 20 patients.
Results: Average age was similar between the two groups (65.1 in the TandemHeart 
group versus 61.8 in the Vanderbilt MPH group). Death at 5 and 21 days was 10% (2 
patients) and 25% (5 patients) respectively in the TandemHeart group versus 11% (2 
patients) and 28% (5 patients) respectively in the Vanderbilt MPH group. One patient who 
underwent TandemHeart implantation developed a stroke and two patients required renal 
replacement therapy. Vascular complications were similar in both groups (one in each).
Conclusions: Our clinical experience with this device has shown that it is simple and 
easy to deploy. Our device is unique because it can function as an ECMO as well as a 
VAD. The switch can be made quickly and with a few short steps. Its small size and few 
components make it portable and it can be utilized at the referring institution or in the ﬁeld 
if needed. It is signiﬁcantly cheaper than currently available pVADs. Therefore, it is an 
effective, versatile, and economical VAD, and can aid in providing the necessary support 
required to enhance procedural success and safety during high risk cardiac procedures.
9:30 a.m.
2502-554 Does The Absence of Polymer Really Impact The 
Efﬁcacy of Drug-Eluting Stents? A Serial Angiography 
and Intravascular Ultrasound Comparison of Sirolimus-
Eluting Stents With and Without Polymeric Coating
Daniel Chamié, J. Ribamar Costa, Jr., Alexandre Abizaid, J. Fábio Almiro, Fausto Feres, 
Luiz Alberto Piva Mattos, Rodolfo Staico, Ricardo Costa, Andréa Abizaid, Luiz Fernando 
Tanajura, Amanda G.M.R. Sousa, J. Eduardo Sousa, Instituto Dante Pazzanese de 
Cardiologia, São Paulo, Brazil
Background: Although synthetic polymers in DES may provide better release kinetics of 
the drug, their long-term presence in the vessel has been related to intense inﬂammatory 
response and late adverse events. Moreover, it is believed that the lesser the drug dose, 
the lower the toxic effect to the vessel wall. However, absence of polymer may compromise 
drug dose and release kinetics, leading to some efﬁcacy issues. The Vestasync Sirolimus-
eluting stent (VES) combines a stainless-steel platform with a nanothin-microporous 
hydroxiapatite surface coating, impregnated with a polymer-free, low-dose Sirolimus 
formulation (55 μg), eluting the drug for 3 months. We aimed to compare, by means of 
serial QCA and IVUS, the efﬁcacy of this novel device with the permanent polymer, high-
dose (140 μg) Cypher sirolimus-eluting stent (CYP).
Methods: 15 pts with single, de novo lesions <14 mm length, in native vessels of 3.0-3.5 
mm in diameter, were consecutively treated with VES in May/2007, and compared to a 
historical cohort of 15 pts treated with the CYP with the same inclusion criteria. QCA and 
IVUS data were obtained post-procedure and serially at 4- and 10-month FU, and were 
analyzed by 2 operators blinded to the type of DES used. Primary end-points were the 
comparison of in-stent late loss (LL) by QCA and % of intimal hyperplasia (IH) by IVUS.
Results: Clinical characteristics were similar between groups. The VES group had smaller 
vessels (2.67 ± 0.32 vs. 2.98 ± 0.4 mm, p=0.02). Success of the procedure was obtained 
in all pts. At 4-month FU, the VES group had similar in-stent LL (0.30 ± 0.25 vs. 0.09 ± 0.3, 
p=0.08) and IVUS % IH obstruction (2.8 ± 2.2 vs. 2.2 ± 3.8, p=0.60). At mean 10.5 ± 1.5 
months, in-stent LL was 0.37 ± 0.24 (VES) vs. 0.16 ± 0.36 (CYP), p=0.074, and the IVUS 
% IH obstruction was 3.8 ± 2.3 (VES) vs. 2.37 ± 3.8 (CYP), p=0.22. There were no cases 
of binary restenosis in both groups.
Conclusions: This analysis shows that the VES is safe and effective in reducing IH 
formation up to 10-month FU. The absence of polymer, as well as the lower drug dose, 
did not impact on the efﬁcacy of the VES compared to the CYP. Whether these changes 
will impact the safety proﬁle of this novel DES has to be conﬁrmed in a larger cohort of 
pts and a longer FU.
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2502-559 Quantitative Analysis of Myocardial Perfusion After 
Primary Percutaneous Coronary Intervention in 
Patients With ST-Elevation Myocardial Infarction: 
Computer Assisted Myocardial Blush Results From a 
Randomized Controlled Trial
Youlan L. Gu, Marieke L. Fokkema, Mathijs Vogelzang, Pieter J. Vlaar, Felix Zijlstra, 
University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Background: Although visually scored myocardial blush grade (MBG) is an established marker 
of myocardial perfusion after primary percutaneous coronary intervention (PCI) in patients with 
ST-elevation myocardial infarction (STEMI), computer assisted quantitative analysis may allow 
better reproducibility, and a more ﬁne-grained evaluation. We sought to validate the applicability 
of the Quantitative Blush Evaluator (QuBE) in a randomized clinical trial.
Methods: In the ADenosine Administration during Primary percutaneous coronary 
intervention in acute myocardial infarction Trial, patients were randomized to 2 
intracoronary (IC) injections of adenosine (2x0.12mg in 20ml sodium chloride) or placebo 
(2x20ml sodium chloride), administered before and after stenting. QuBE values were 
quantiﬁed on angiograms recorded before and after the second injection.
Results: QuBE values had an excellent intra- and interobserver variability (see Figures). 
In total, 448 patients were randomized to IC adenosine (n=226) or placebo (n=222). 
So far, paired angiograms have been analyzed in 318 (71%) patients. There was no 
difference in QuBE values before and after the ﬁrst injection between the adenosine and 
placebo groups (-0.067±2.3 versus -0.15±1.9, p=0.738).
Conclusions: QuBE provides a reproducible quantitative measure of myocardial 
perfusion, and is an attractive method in future studies in STEMI patients. IC adenosine 
does not improve MBG as assessed by QuBE (Dutch trial register ID NTR1073). 
9:30 a.m.
2502-560 Coronary Revascularization Approaches Combining 
Total Endoscopic Bypass Grafting and Percutaneous 
Interventions using Different Timing Protocols
Guy J. Friedrich, Nicos Bonaros, Thomas Schachner, Guenther Laufer, Otmar 
Pachinger, Johannes O. Bonatti, Medical University Innsbruck, Innsbruck, Austria
Background: LIMA grafting is known to be the optimal revascularization strategy in 
LAD lesions unsuitable for PCI. Total endoscopic bypass surgery (TECAB) is a minimal 
invasive procedure reducing surgical trauma. The sequence of both strategies has not yet 
been deﬁned or compared regarding follow up (FU). We sought to investigate this “hybrid” 
approach combining PCI and TECAB using different timing protocols.
Methods: Patients (pts, n=57, mean age 58, 47 male, mean EuroSCORE 1) with stable 
angina and 2 - or 3 vessel disease were included. All presented type C lesions of the LAD, 
type A/B lesions of non LAD vessels. PCI timing in relation to TECAB was investigated 
using 4 timing protocols. LIMA bypass (54 LAD, 6 DG, 4 CX, including jump grafts) was 
performed using the robotically assisted TECAB technique ( da VINCI™, Intuitive Surgical 
Inc., Sunnyvale, Ca). The non LAD lesions were treated by PCI either simultaneously 
9:30 a.m.
2502-557 First In Man Assessment of Orbital Atherectomy 
System in Treating De Novo Calciﬁed Coronary Lesions 
(ORBIT I)
Keyur H. Parikh, Ashok Seth, Hemang Baxi, Anish Chandarana, Satya Gupta, 
Urmil Shah, Milan Chag, Sandhya Nair, Praveen Chandra, The Heart Care Clinic, 
Ahmedabad, India, Max Heart and Vascular Institute, New Delhi, India
Background: Calciﬁc coronary artery disease (CCAD) remains a signiﬁcant clinical 
problem for interventional cardiologists, requiring different treatment strategies. Various 
debulking strategies have been tried over the years with mixed results. This study was 
sought to evaluate the safety and performance of the Diamondback 360°TM Orbital 
Atherectomy System (OAS) in treating de novo calciﬁed coronary lesions
Methods: ORBIT I study is a prospective, non randomized, multi-center trial. Fifty 
patients with de novo calciﬁed coronary lesions were enrolled in the study. The Orbital 
Atherectomy included a sterile single use device, guidewire and a console. The diameter 
of the crowns used in the study was 1.25, 1.5, 1.75 and 2 mm. All devices had 30 μ
grit size. Angiographic and intravascular ultrasound (IVUS) images before and post 
procedure were recorded. The primary end point was target vessel failure (TVF) whereas 
secondary end points were target lesion revascularization (TLR), procedural success and 
device performance.
Results: Of the ﬁfty patients enrolled in the study, one patient was withdrawn since 
the IVUS catheter could not pass the lesion. Debulking measured by percent change 
in diameter stenosis using angiography and IVUS were signiﬁcantly achieved. No 
major angiographic complications were seen while in 9 cases minor complications 
were observed (minor dissection- 5, minor perforation- 2 and bradycardia-2). TVF was 
observed in 3 cases (Q wave MI in 1 and non Q wave MI in 2 patients) and TLR (PTCA) 
was done in 1 case at 30 days. Both procedural success as well as device success were 
achieved in 48 out of 49 cases .There were no serious acute in-hospital complications 
such as deaths and emergency coronary artery bypass graft surgery.
Conclusion: 
This study demonstrates that the Diamondback 360°TM Orbital Atherectomy System 
safely and effectively debulks heavily calciﬁed plaque in patients with de novo calciﬁed 
coronary lesions improving stent expansion and apposition .
9:30 a.m.
2502-558 Long-Term Results (> 1 Year) of the Vestasync I 
Trial With a Novel, Third-Generation, Hydroxyapatite 
Polymer-Free Sirolimus-Eluting Stent
Jose de Ribamar Costa Jr, Alexandre Abizaid, Ricardo A. Costa, Fausto Feres, Luiz 
Fernando Tanajura, Andrea Abizaid, Rodolfo Staico, Dimytri Siqueira, Galo Maldonado, 
Raoul Bonan, Amanda Sousa, J. Eduardo Sousa, Instituto Dante Pazzanese de 
Cardiologia, São Paulo, Brazil, Cardiovascular Research Center, São Paulo, Brazil
Background: Durable polymers in 1st-generation DES have been linked to local 
inﬂammatory reactions. Stent thrombosis (ST) secondary to positive vessel remodeling 
and late-acquired incomplete stent apposition (ISA) is a possible clinical translation 
of this local adverse effect. We sought to assess the safety, and efﬁcacy of the novel 
VESTAsync Eluting Stent (VES) combining a SS platform with a nanothin-microporous 
hydroxyapatite surface coating impregnated with a polymer-free low-dose of Sirolimus 
(55μg). All sirolimus is released within 3 months of the procedure.
Methods: 15 pts with single de novo lesions in native coronary arteries with 3.0-3.5mm 
diameter and a 14mm in length were enrolled in this FIM study. Primary endpoint was 
in-stent late lumen loss (LL) at 4 and 9 months.
Results: Baseline characteristics included mean age of 63 years-old and 33% of diabetics. 
RVD and lesion length were 2.7 ± 0.3mm and 10 ± 2.0mm, respectively. Procedure 
success was obtained in all cases. Lifelong AAS and 6-month clopidogrel were prescribed 
to all pts. At 4 months, in-stent LL and % of NIH were 0.3±0.25mm and 2.6±2.2%, with 
a non-signiﬁcant increase at 9 months (0.36 ± 0.23mm and 4.0 ± 2.2%). Serial IVUS did 
not show late ISA. The chart displays the variation of MLD and % of stenosis along the 
months. There was no MACE within 1 year of FU.
Conclusion: The novel VES was effective in reducing LL and NIH at 4 and 9 months, with 
no evidence of late catch-up by QCA or IVUS. Two-year clinical results will be available 
during the meeting.
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2502-563 Development of Novel Adenosine Polymers for Coating 
Medical Devices
Mervyn B. Forman, Jianying Zhang, Zaichuan Mi, Edwin K. Jackson, St. Joseph 
Translational Research Institute, Atlanta, GA
Background: Percutaneous coronary intervention (PCI) procedures in ST segment 
elevation myocardial infarction (STEMI) and acute coronary syndromes (ACS) are 
frequently complicated by vascular and organ damage secondary to reperfusion 
injury, no-reﬂow phenomenon (NRF), and microembolization. Adenosine (ADO) is an 
endogenous nucleoside that ameliorates many of the adverse processes activated 
during PCI and signiﬁcantly reduces infarct size in STEMI. ADO’s therapeutic potential 
is compromised during PCI due to its ultra-short half life (~ 1-2 seconds) and dilutional 
effects with catheter administration. Prophylactic and continuous local infusion of ADO 
during PCI would optimize its cardioprotective effects.
Methods: We embarked on a project to develop a number of unique polymers with 
special characteristics to allow ADO to be covalently bonded. The goals were: (i) the 
polymers should consist of physiological components, rapidly release ADO, and degrade 
into non-toxic substances; (ii) the polymers can be coated onto medical devices such 
as guide wires and stents; (iii) a continual release of pharmacological amounts of ADO 
should occur during the duration of a PCI procedure (30-60 minutes).
Results: A number of unique polymers were developed composed of adenosine, lysine 
methyl esters, and either glycerol or cysteine. These polymers undergo non-enzymatic 
hydrolysis rapidly in contact with aqueous solutions. A signiﬁcant release of ADO 
occurred in an in vitro system with coated guide wires within 10 minutes and continued for 
another 50 minutes. In vivo experiments utilizing a small animal model infused with potent 
vasoconstrictors to mimic NRF exhibited a signiﬁcant increase in arterial blood ﬂow over 
50 minutes with the ADO-coated wire compared to controls. Pilot studies in the porcine 
model revealed that the coated wire produced a striking increase in coronary blood ﬂow 
and prevented vasoconstriction induced by intracoronary infusion of endothelin-1.
Conclusion: The development of unique polymers containing adenosine and non-toxic 
monomers that can be coated onto guide wires and stents may signiﬁcantly improve 
outcomes in patients with STEMI and ACS undergoing PCI procedures.
9:30 a.m.
2502-564 Percutaneous Coronary Intervention using a Novel 
4-French Coronary Accessor “KIWAMI”
Satoshi Takeshita, Shinji Tanaka, Takaaki Shiono, Saeko Takahashi, Shigeru Saito, 
Shonan Kamakura General Hospital, Kamakura, Japan, Shonan Atsugi Hospital, Atsugi, 
Japan
Background: Percutaneous coronary intervention (PCI) using a guiding catheter with 
small diameters may have a favorable impact on vascular access complications and 
patient morbidity. Here, we report the initial results of PCI using a 4-Fr coronary accessor 
“KIWAMI”.
Methods: Between July 2007 and September 2008, a total of 58 patients underwent 
4-Fr PCI. Exclusion criteria were (1) lesions associated with side branches requiring wire 
protection and (2) planned use of angioplasty devices not compatible with 4-Fr catheter.
Results: Forty six patients were male (79%) and the average age was 71.6 ± 9.7 years 
(range, 38 to 85 years). Sixty eight lesions, including 6 chronic total occlusions (CTO), 
were treated. Access sites included radial artery in 43 patients (74%), brachial artery in 
8 (14%), and femoral artery in 7 (12%). PCI was successful in 64 of 68 lesions (94%) in 
56 of 58 patients (97%). Reasons for unsuccessful PCI included 2 CTOs,1 tortuous right 
coronary artery, and 1 cannulation failure. Among successfully treated 64 lesions of the 
56 patients, coronary stents were deployed in 58 lesions (91%). There were no stent 
dislodgements or inadequate contrast opaciﬁcation. No access-site related complications 
including radial artery occlusion were observed.
Conclusions: PCI using a 4-Fr coronary accessor is a viable alternative to the use of 
or in a staged intervention protocol (7 PCI before,16 after TECAB,16 simultaneously). 
One group (n = 18) underwent TECAB only, PCI(small caliber of non LAD vessels, no 
robust evidence of related ischemia) was postponed and planned to be performed only 
in clinically driven indications.
Intraoperative coronary angiography (ICA) in simultaneous revascularization was 
performed with a mobile C-arm (OEC 9800™, GE Healthcare).
Results: Surgery was performed as 1 vessel arrested heart (1V-AH) TECAB in 45 pts, 2 
V-AH TECAB in 8 and 1 V beating heart TECAB in 4 pts. In 30/39 pts PCI with stenting 
was performed (13 BMS, 17 DES). Mean PCI timing in pts before TECAB was 60 days, 
after TECAB 90 days. ICA showed patent TECAB grafts in 50 pts, 7 were converted to 
open surgery (12.3%). Peri-and postoperative mortality was 0%. Mean FU time was 24 
months including clinical investigation and invasive CA: mortality rate was 0%, freedom 
from angina 97%, MACCE rate 9%, PCI target vessel reintervention rate 4%.
Conclusions: Our preliminary experience shows that TECAB LIMA bypass surgery 
combined with PCI, performed using different timing protocols, is feasible and safe. 
Intermediate term survival and freedom from angina are excellent.
9:30 a.m.
2502-561 Safety and Feasibility of a New Biodegradable Drug 
Eluting Stent for the Inhibition of Neovascularization: 
Assessment with Optical Coherence Tomography
Konstantinos Toutouzas, Andreas Synetos, Antonis Karanasos, Eleutherios Tsiamis, Elli 
Stefanadi, Christodoulos Stefanadis, 1st Cardiology Clinic, University of Athens, Medical 
School, Hippokration Hospital, Athens, Greece
Background: Neovascularization seems to play an important role in the development of 
the vulnerable plaque. Vascular endothelial growth factor (VEGF) appears to be the most 
important mediator of neovascularisation. We assumed that inhibition of VEGF, using 
local delivery of bevacizumab, a monoclonal antibody speciﬁc for VEGF, could affect 
neovascularization and intimal hyperplasia in hypercholesterolemic rabbits.
Methods: We used 12 New Zealand white rabbits under atherogenic diet for 3 weeks. 
Thirteen bevacizumab-eluting stents were implanted in the distal aorta. The stents were 
coated with a biodegradable polymer which was loaded with bevacizumab, after immersion 
into a solution of 4 ml of the drug. All animals were treated with aspirin and clopidogrel for 
4 weeks. Follow-up angiography and Optical Coherence Tomography (OCT) study were 
performed at 4 weeks. OCT images of each stent taken at 1 mm intervals were analysed 
and each strut was examined for apposition. A strut was deﬁned as embedded when it 
was buried in the intima for more than half its thickness, protruding when apposed to the 
intima but not embedded, and malapposed when there was no intimal contact. A stent 
was deﬁned as well apposed when all struts were either embedded or protruding. Mean 
neointimal area for each arterial segment was measured.
Results: Angiography in all stented arteries revealed no acute or subacute thrombosis or 
restenosis. OCT image acquisition was successful in all cases. OCT revealed no severe 
stenosis or thrombus. We acquired 143 cross-sectional images from 130 mm of 13 stents 
in 12 arteries. Images with poor quality and images located in a major side branch were 
excluded. From the total of 1303 struts analysed, 1271 (97.5%) were embedded, while 
only 32 (2.5%) struts were protruding and none malapposed. All stents were well apposed. 
Mean neointimal area was 0.30±0.30 mm2 comprising 5.31% of the lumen area.
Conclusions: This study demonstrated the safety of the bevacizumab-eluting stent 
implantation in animal models. The bevacizumab-eluting stent inhibits intimal hyperplasia. 
Further clinical trials are needed in order to show its efﬁcacy as a potential treatment of 
vulnerable plaques.
9:30 a.m.
2502-562 Fully Automated Iterative 3D Reconstruction of 
Rotational Coronary X-Ray Angiograms: A Feasibility 
Study
Anne M. Neubauer, Joel A. Garcia, John C. Messenger, Eberhard Hansis, Michael S. 
Kim, Andrew J. Klein, Gert A. F. Schoonenberg, John D. Carroll, Michael Grass, Philips 
Research, Briarcliff Manor, NY, University of Colorado, Denver, CO
Background: The lack of 3D data from typical angiography has limited its use for 
accurate lesion characterization, quantiﬁcation of vessel properties (curvature and 
bifurcation angles) and interventional roadmapping. Existing methods for generating 3D 
representations require user interaction or suffer from signiﬁcant motion artifacts. We 
describe and evaluate a strategy which overcomes these limitations.
Methods: 23 patients referred for diagnostic coronary angiography underwent a 7.2 s 
acquisition of the LCA and RCA during a 180° rotational run (Philips Allura Xper FD20). 
Fully automatic processing of the images consisted of: least motion cardiac phase 
determination, gated iterative reconstruction, and 2D motion compensation within the 
gating window (see Figure). Two interventional cardiologists qualitatively evaluated the 2D 
and 3D images of 23 LCAs and 17 RCAs for image quality and clinical utility.
Results: No adverse events resulted from the extended injection and the 2D images were 
adequate for CAD screening. The quality of the reconstructions was rated 3.7±1.1 (LCA) 
and 4.3±0.9 (RCA) and the average clinical utility score was 3.0±1.4 (LCA) and 3.0±0.92 
(RCA) out of 5 with good agreement between the two observers. The 3D reconstructions 
allowed the evaluation of more segments than the 2D data in 85% of cases.
Conclusion
These results show the that the 3D reconstruction algorithm is not only feasible but also 
helps compensate for the limitations of 2D angiography. 
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Conclusions: Using the present strut-level malapposition criteria, OCT demonstrates 
more accuracy than IVUS in detecting stent strut malapposition. However, the extent of 
malapposition associated with increased risk of adverse outcome is still unknown.
9:30 a.m.
2502-567 How Do Intracardiac Devices Integrate into the Heart? 
Histopathologic Healing in Left Atrial Appendage 
Closure is Analogous to Intravascular Stent Healing
Robert S. Schwartz, David R. Holmes, Robert A. Van Tassel, Ray Matthews, Shepal 
Doshi, Renu Virmani, Minneapolis Heart Institute Foundation, Minneapolis, MN
Background: Intracardiac devices integrate into the heart through poorly understood 
mechanisms. We studied healing of Left Atrial Appendage (LAA) obliteration and 
compared results with stent healing.
Methods: 9 dog hearts were examined at 3, 49 and 91 days after LAA implant, and the 
results compared with 2 human necropsy hearts with LAA obliteration.
Results: At 3 days, struts were apposed to the LAA wall. The atrial fabric mesh was 
covered by a ﬁbrin ﬁlm. Fibrin sealed gaps between the LA wall and the device. Thrombus 
ﬁlled the LAA body. Device contact sites showed submyocardial hemorrhage and 
edema. At 49 days, endocardial cells completely covered exposed surfaces. Continuous 
endocardial growth effectively sealed the device-LA interface. Prior ﬁbrin deposition 
was replaced by endocardium that surrounded metal and fabric elements. Disorganized 
thrombus occurred within the device in the LAA body and at the periphery near the 
appendage walls. Granulation tissue and neovascularization occurred at the periphery. 
Mild inﬂammation was seen as the thrombus resorbed. No inﬂammation was found at 
metal strut contact sites. At 91 days, ﬁbrous connective tissue covered the former LAA 
ostium with complete endocardial lining. Organizing thrombus had transformed into 
ﬁbrous connective tissue, and no residual inﬂammation was evident.
The human necropsy hearts had similar ﬁndings. In both hearts (139 and 200 days post 
procedure) the fabric membrane was covered with organized endocardium. Organizing 
thrombus covered the under-surface. No signiﬁcant inﬂammation occurred at the struts or 
fabric. Organizing ﬁbrous tissue was seen inside the LAA, prominent at and near the atrial 
wall. The device interior contained RBC and organizing ﬁbrin thrombus.
Conclusions: This temporal study of intracardiac device integration delineated stages 
of 1) early thrombus deposition, 2) thrombus organization, inﬂammation and granulation 
tissue, and 3) ﬁnal healing by mature ﬁbrous connective tissue, and endocardialization. 
These healing histopathologic stages are similar to those of intravascular stents that 
integrate into coronary and peripheral arteries.
9:30 a.m.
2502-568 “Cool It”: Therapeutic Hypothermia as a New Standard 
of Care in Treating Transfer Patients Following Out-of-
Hospital Cardiac Arrest
Leah Swanson, Kalie Edelstein, William Parham, Daniel O’Laughlin, Barbara T. Unger, 
David Page, Tony Sundholm, Eric Gage, James Hodges, Wes R. Pedersen, William 
T. Katsiyiannis, Timothy D. Henry, Michael R. Mooney, Minneapolis Heart Institute 
Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: Recent trials have shown that therapeutic hypothermia (TH) reduces 
mortality and improves neurological outcome in comatose survivors out-of-hospital 
cardiac arrest (OOHCA). Widespread implementation of TH in the United States is limited 
by the lack of data supporting the safe transfer and treatment of these high risk pts by 
organized systems of emergency care.
Methods: The Cool It program established a regional TH system transferring pts up to 200 
miles from the TH capable center. OOHCA pts were cooled to 33ºC for 24 hours. Cerebral 
function after TH was measured by the ﬁve point Pittsburgh Cerebral Performance 
Category (CPC) scale. CPC 1 and 2 are positive neurological outcomes.
Results: From 2/06 to 5/08, 85 pts were treated with TH; 63 were transferred from outstate 
hospitals. Comparing non-transfer pts to transfer pts, no difference occurs in survival rate 
(50% vs. 54%, p=0.81) or positive neurological outcome among survivors (82% vs. 97%, 
p=0.14). For each hour TH was delayed, the relative risk of death increased by 20%.
Conclusions: The transfer of TH pts does not compromise survival or neurological 
recovery following OOHCA. This program relies on rapid initiation of TH with ice packs in 
the ﬁeld, organized protocols, and intensivist management. With this data, TH becomes a 
more relevant standard of care for OOHCA and should be a part of every large acute MI 
and cardiovascular emergency transfer program. 
larger guide catheters. The advent of this system may afford a less invasive approach for 
the treatment of patients with coronary artery disease.
Procedural Characteristics
Number of lesions treated per patient 1.2+0.4
Ad hoc coronary intervention 7 (12%)
Number of catheters used per patient 1.1+0.4
Number of pts crossed-over to 5 or 6 Fr 3 (5%)
Stent diameter (mm) 2.9+0.5
Stent length (mm) 18.1+7.2
Deep vessel intubation 48 (63%)
Direct stenting 5 (7%)
Fluoroscopy time (min) 12.1+12.2
Contrast dye volume (mL) 80.3+46.1
9:30 a.m.
2502-565 An Innovative Non-Invasive Respiratory Stress Test 
Indicates Signiﬁcant Coronary Artery Disease
Ron Waksman, Steven Sushinsky, Petros Okubagzi, Patricia Landry, Rebecca Torguson, 
Anh Bui, Arthur Shiyovich, Amos Katz, Washington Hospital Center, Washington, DC
Background: Respiratory maneuvers can uncover manifestations of myocardial ischemia. 
Some pulse wave (PW) characteristics are strongly associated with signiﬁcant coronary 
artery disease (S-CAD). An innovative test, using the respiratory stress response (RSR), 
has been developed for the detection of S-CAD. It is based on spectral analysis of 
ﬁnger pulse wave oscillations measured by photoplethysmography (PPG) during deep, 
paced breathing at a rate of 6 breaths per minute (0.1Hz) over 70 seconds. We aimed to 
investigate the value of RSR as a noninvasive tool for identiﬁcation of S-CAD.
Methods: RSR was assessed, prior to the procedure, in 150 consecutive patients referred 
for coronary angiography. It was calculated by analyzing the relative spectral power of the 
respiratory peak area at 0.1 Hz using proprietary software. The coronary angiograms 
were analyzed by quantitative coronary angiography (QCA) by a cardiologist who was 
blinded to the RSR results. S-CAD was deﬁned as luminal stenosis >70% of at least 1 
coronary artery with a diameter q2 mm, or left main stenosis >50%.
Results: A valid RSR was obtained in 150/153 patients (98%) with a mean age of 58.7 
± 10.6 years (67% males). S-CAD was found in 36 patients (24%). S-CAD patients had 
signiﬁcantly lower RSR compared to patients without S-CAD, (6.7% ± 5.1 vs. 17.4% ± 
10.6, p<0.001, respectively). RSR a10.2% yielded a sensitivity of 86%, a speciﬁcity of 
81%, and positive and negative predictive values of 59% and 95%, respectively for the 
detection of S-CAD. Multivariate logistic regression analysis, adjusted for known CAD risk 
factors, showed that RSR is a strong independent indicator of S-CAD (OR 41.2, 95% CI 
12.2-139.3, p<0.001).
Conclusion: The innovative RSR test is a simple, non-invasive bedside or ofﬁce-based 
tool for the detection of S-CAD.
Figure 1. Reduced Respiratory Stress Response in Signiﬁcant CAD.
9:30 a.m.
2502-566 Comparison of Intravascular Ultrasound and Optical 
Coherence Tomography for the Evaluation of Stent 
Segment Malapposition
Noah Rosenthal, Giulio Guagliumi, Vasile Sirbu, Giuseppe B. Zoccai, Luigi Fioca, 
Giuseppe Musumeci, Alexandre Mathiasvili, Antonio Trivisonno, Hiro Kyono, Satoko 
Tahara, Daniel I. Simon, Marco Costa, Hiram G. Bezerra, University Hospitals Case 
Medical Center, Cleveland, OH
Background: Stent malapposition has been associated with stent thombosis. IVUS can 
be used to evaluate stent apposition, but has weaker resolution than Optical Coherence 
Tomography (OCT) which allows in-vivo evaluation of stent struts and coronary lumen 
to 10 microns.
Methods: Data were obtained from the ODESSA trial, a single center, randomized, 
controlled OCT study comparing luminal impact of overlapping drug eluting stents 
vs. bare metal stents. IVUS and OCT of stented vessels were performed 6 months 
post-implantation. Each stent was divided into proximal, overlap and distal segments. 
Malapposition by IVUS was deﬁned as visible blood between a strut and luminal contour. 
Two methods were used by OCT: qualitatively (every 0.067mm) counting free struts 
without luminal apposition; and quantitatively (every 0.33mm), using a strut-to-lumen 
distance corrected for strut thickness. An arbitrary threshold to detect malapposition was 
used: q5 free ﬂoating struts in q3 frames. Cross sections at bifurcations were excluded. 
When OCT and IVUS disagreed, 3 experienced independent observers reviewed images 
for consensus. Sensitivity of IVUS and OCT to detect malapposition was evaluated 
against cases where both IVUS and OCT agreed.
Results: 43 coronary segments with matched IVUS and OCT images for analysis. 
IVUS identiﬁed 17/43 (40%) segments with strut malapposition vs. 40/43 (93%) by OCT. 
IVUS failed to identify malapposition in 23 cases (57%) detected by OCT. There were 5 
segments with malapposition by IVUS but not by OCT: in 2, OCT identiﬁed struts at a 
bifurcation missed by IVUS; OCT missed malapposed struts in 2 cases from poor images; 
1 was due to bridging coverage of malapposed struts.
The sensitivity of IVUS to detect malapposition was 39.5% with a speciﬁcity of 99.2% 
vs. OCT with 93.0% and 100.0% respectively. IVUS was 25.0% sens. and 99.0% spec. 
for malapposition in stent overlap segments, and 45.2% sens. and 99.4% spec. at non-
overlapping sites.
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2503-571 Cerebral Embolism is Related to Access Site at 
Coronary Angiography
Juliane Jurga, Jesper Nyman, Nondita Sarkar, Per Tornvall, Maria N. Mannila, Peter 
Svenarud, Jan van der Linden, Dep of Cardiology, Karolinska University Hospital, 
Karolinska Institutet, Stockholm, Sweden, Dep of Cardiothoracic Surgery and 
Anesthesiology, Karolinska University Hospital, Karolinska Institu, Stockholm, Sweden
Background: Stroke is an unusual but severe complication of coronary angiography (CA). 
Its cause is not entirely explained, but the choice of access site might be of importance. The 
aim of this study was to investigate if the number of particulate cerebral emboli during CA is 
related to the access site. Methods: Fifty patients with stable angina pectoris referred for CA 
and with normal hand collateral blood ﬂow were randomized to right femoral or right radial 
access site. A transcranial Doppler with bilateral probes was used to automatically register the 
number of particulate emboli passing each middle cerebral artery (MCA) during every part of 
the procedure. The Mann-Whitney U test was used for comparisons. Results: Eight patients 
were converted to the femoral approach due to problems cannulating the left coronary artery. 
The number of particulate emboli was signiﬁcantly higher with radial than with femoral access 
site 10.9±6.3 (n=19) versus 6.9± 4.7 (n=23, p= 0.036, Figure). More emboli passed the right 
MCA with radial (6.8±4.7) than with femoral access (3.0±2.4, p=0.007), whereas there was no 
difference on the left side. Speciﬁc parts of the CA procedure showed to be embogenic such 
as change of catheters. Conclusion: The present study provides novel evidence indicating 
that the vascular access site and certain procedural steps have a substantial impact on the 
number of particulate cerebral emboli. The ﬁnding that more particles passed the right MCA 
with the right radial approach denotes a causal linkage. 
9:30 a.m.
2503-572 Are neurologic complications following percutaneous 
coronary diagnostic or interventions more common in 
transfemoral versus transradial approach?
Helena Tizon-Marcos, Gerald barbeau, Jacques Rouleau, Louis Roy, onil gleeton, Guy 
proulx, J-Pierre Dery, olivier Bertand, cM nguyen, bernard Noel, josep Rodés-Cabau, 
eric larose, stephane Rinfret, robert De Larochellière, Laval hospital, quebec, QC, 
Canada
Introduction: Neurologic complications (NC) have been described as a rare but 
potentially catastrophic complication following transfemoral coronary angiography and 
interventions. Recently, transradial approach is showing less incidence of complications 
with similar per-procedural succeed.
Objectives: Determine the incidence and characteristics of neurological complications 
between transradial and transfemoral approach.
Methods: Retrospective review of all charts of patients with coronary angiography or 
interventions from April 1990 to October 2007 and per-procedural NC in our center. 
Analysis was performed comparing multiple clinical and procedural variables.
Results: NC occurred in 54 of the 83,409 patients (0.06%). 
Radial patients Femoral patients p
N patients with NC 26/52191 28/31218 0.029
% of entire population (0.05%) (0.09%)
NC in diagnostic procedures 9/28411 (0.03%) 24/23607 (0.1%) 0.0024
NC in interventional procedures 17/23780 (0.07%) 4/7611 (0.05%) 0.799
Type of NC,%
- Non hemorrhagic stroke 65.5 68
- Hemorrhagic stroke 11 3.5
- AIT 23.5 28.5
Inhospital mortality, % 23 3.6 0.047
Conclusions: In this large series, per-procedural cerebrovascular accident was an 
uncommon complication of both coronary angiography and interventions. Compared to 
transfemoral approach, transadial approach is associated with a lower incidence of per-
procedural CVA (0.049% vs 0.089%, p= 0.029). No differences between type of stroke 
and approach were found. Mortality of patients with transradial approach and NC was 
higher in our series.
9:30 a.m.
2502-569 The Same Day Discharge after Coronary and Peripheral 
Percutaneous Interventions. Bivalirudin and Catalyst II 
Wire System Strategy (GO HOME Study)
R. Stefan Kiesz, Pawel E. Buszman, Barbara K. Wiernek, Szymon L. Wiernek, Martin 
G. Radvany, George V. Nazarewicz, Jack L. Martin, San Antonio Endovascular & Heart 
Institute, San Antonio, TX
Background: The majority of coronary and peripheral interventions are performed with 
an overnight stay. That increases the cost and adds little if any to patient safety. Bivalirudin 
has been shown to decrease bleeding complications in comparison to heparin. Cardiva 
Catalyst II Wire device facilitates site closure after intervention and leaves nothing behind. 
We hypothesized that by combining Bivalirudin with the Catalyst II Wire System we can 
safely discharge patients within 5 hours after interventions.
Methods: Since January 2008 in our outpatient cath lab we performed 110 interventions 
on 71 consecutive patients (46 male, mean age 62.4 ± 10.2, range 43-83). All procedures, 
45 (40.1%) coronary, and 65 (59.9%) peripheral were performed exclusively with 
Bivalirudin. Thirty three (46.5%) patients were diabetic, 15 (21.1%) on dialysis, 65 (91.5%) 
had hypertension, 64 (90.1%) had hyperlipidemia and the average BMI was 30.3 ± 6.5 
(range 20.1-47.9). The primary endpoint was assessment of major adverse events (death, 
stroke, myocardial infarction [MI], target lesion revascularization [TLR], severe GUSTO 
bleeding) in short term follow-up.
Results: The average time of observation was 4.9 ± 2.6 months. Procedural success 
was achieved in 44 (97.7%) coronary and 63 (96.9%) peripheral procedures. Thirty two 
(96.7%) procedures below the knee, were done with antegrade 4 French access. The 
Catalyst II Wire System device was applied successfully after 107 (97.2%) procedures. All 
patients were discharged home the same day in up to 5 hours after the intervention. No 
major adverse events were noted in short term follow-up. Site echymosis was noted after 
30 (27.2%) procedures, haematoma (2-5cm) after 5 (4.54%), retroperitoneal bleeding 
after 1 (0.9%) and pseudoaneurysm after 1 (0.9%).
Conclusions: The same day discharge after coronary and peripheral percutaneous 
interventions in a selected group of patients appears to not increase the risk of the procedure. 
The Catalyst II Wire System is a safe and effective device in achieving hemostasis and in 
combination with Bivalirudin allows patients to go home the same day.
I2.POSTER CONTRIBUTIONS
2503
Vascular Access, Closure Devices and 
Complications
Sunday, March 29, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2503-570 A Clinical Risk Prediction Tool for Post-PCI Bleeding From 
the National Cardiovascular Data Registry® (NCDR®)
Jason B. Lindsey, Sameer K. Mehta, Andrew D. Frutkin, John A. Spertus, Sunil V. Rao, 
Fang-Shu Ou, Matthew T. Roe, Eric D. Peterson, Steven P. Marso, Mid America Heart 
Institute, Kansas City, MO, Duke Clinical Research Institute, Durham, NC
Background: Bleeding after percutaneous coronary intervention (PCI) is associated with 
increased morbidity and mortality. A clinical tool to estimate bleeding risk may enable 
physicians to tailor peri-PCI therapy and mitigate risk.
Methods: PCI procedural data at 440 U.S. centers in the NCDR® from 2004-06 were 
examined. Bleeding was deﬁned as resulting in transfusion, increased length of stay, 
and/or >3gm/dL decrease in hemoglobin occurring at vascular entry site, retroperitoneal, 
gastrointestinal, genitourinary or other location. A random sample of 80% of patients 
was used to develop a model to estimate risk of post-PCI bleeding; the remaining 20% 
comprised a validation cohort. Variables in the risk model were assigned a weighted 
integer based on the z-score to develop a simpliﬁed risk score.
Results: There were 302,152 patients with a bleeding rate of 2.4%. The model using pre-
PCI variables associated with post-PCI bleeding performed adequately overall (c-statistic 
= 0.73). Independent predictors of bleeding and risk score assignment are shown in the 
ﬁgure (left). Bleeding rates increased with increasing risk score category (ﬁgure, right).
Conclusions: Using data from the NCDR, we developed a clinical tool that estimates 
post-PCI bleeding. This tool is potentially actionable, enabling physicians to consider 
alternative strategies in high risk patients that are associated with lower rates of bleeding 
e.g., radial PCI, smaller sheath size and alternative anticoagulation strategies. 
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catheterization. Major vascular complications was deﬁned as any retroperitoneal 
hemorrhage, limb ischemia, or any surgical repair. Minor vascular complications was 
deﬁned as any groin bleeding, hematoma (>=5 cm), pseudoaneurysm, and arteriovenous 
ﬁstula. ‘Any’ vascular complications was deﬁned as either a major or minor vascular 
complication.
Results: Among the 3398 patients, 2600 (76.5%) received a VCD while the rest had 
manual compression. Compared to manual compression, VCDs were associated with a 
signiﬁcant reduction in the risk of any, major or minor vascular complications (Figure). Use 
of VCDs was the strongest predictor [Chi2 = 22.6; OR = 0.43 (0.30-0.61); P <0.0001] for 
decrease in the risk of any vascular complications even after controlling for age, female 
gender, history of peripheral arterial disease, chronic renal insufﬁciency, use of GP IIB/
IIIA, a emergent or an urgent procedure, MI on presentation and using a 7.0 Fr or greater 
arterial sheath size, which were all multivariable predictors of vascular complications.
Conclusions: VCD use is the strongest predictor of decrease (57%) in the risk of 
vascular access site complication in patients with diabetes. VCD beneﬁt extends beyond 
mere reducing the time to ambulation in patients with diabetes.
9:30 a.m.
2503-576 Left Radial Versus Femoral Approach in Primary 
Percutaneous Coronary Intervention - Prospective 
Comparison
Ivo Bernat, Jiri Koza, Jan Pesek, Jitka Tesarova, Richard Rokyta, University Hospital, 
Plzen, Czech Republic
Background: Transradial approach reduces access site bleeding complications. Right 
radial artery is routinely used for coronary interventions although 90% of the population is 
right handed. The aim of this study was to compare left radial (LR) and femoral approach 
(FA) in primary percutaneous coronary intervention (PCI).
Methods: From January to December 2007, 297 consecutive patients (pts) with acute 
myocardial infarction (STEMI) were treated by primary PCI in our institution. 255 pts 
were enrolled to this prospective non randomized study: LR 129 pts versus (vs) FA 126 
pts. Exclusion criteria were: cardiogenic shock (n=22), right radial approach (n=18) and 
brachial approach (n=2). Both groups did not differ signiﬁcantly in age (63,7±11,3 vs 
64,4±10,9 years), gender (75% vs 67% males), body mass index (28±4 vs 29±5) and 
Killip class I (105 vs 107), II (21 vs 12), III (3 vs 7).
Results: Procedural duration (45±21 vs 43±19 min), ﬂuoroscopy time (10,3±7,4 vs 9,2 
±6,3 min) and technical procedural success (96% vs 97%) were not signiﬁcantly different 
(p=NS). Contrast consumption was lower in LR group (144±52 vs 162±53ml, p<0,05). 
Serious access site bleeding complications occured only in FA group (0 vs 5 pts, p<0,05). 
In hospital mortality was 2,3% in LR and 4,0% in FA group (p=NS). Conversion to FA was 
necessary in two (1,6%) pts. At discharge three (2,3%) pts had asymptomatic loss of the 
left artery pulsation.
Conclusions: Left radial approach for primary PCI is safe, feasible and effective in 
STEMI patients without cardiogenic shock. Minimal risk of serious access site bleeding 
complications is the main advantage in comparison with femoral approach. Postprocedural 
immediate normal right hand mobility is an added beneﬁt for right handed patients.
9:30 a.m.
2503-577 Quality of Life after Same-day Discharge or Overnight 
Hospitalization after Transradial Coronary Stenting 
and Maximal Antiplatelet Therapy. Results of the 
Randomized EASY Trial.
Olivier F. Bertrand, Javier Courtis, Stéphane Rinfret, Olivier Costerousse, Éric Larose, 
Rodrigo Bagur, Helena Tizon-Marcos, Can M. Nguyen, Robert De Larochellière, Paul 
Poirier, Louis Roy, Josep Rodes-Cabau, Laval Hospital, Quebec Heart-Lung Institute, 
Quebec, QC, Canada
Background: : It is unknown whether same-day home discharge after PCI impacts 
differently health-related quality of life (HRQOL) measures compared to standard 
overnight hospitalisation.
Objective : To compare early and late HRQOL in acute coronary syndrome (ACS) patients 
discharged home the same-day (SD) or after overnight hospitalisation (OH) after transradial 
coronary stenting and maximal antiplatelet therapy in the randomized EASY trial.
Methods : We administered the Medical Outcomes Study Short-Form Survey (SF-36) at 
baseline, 1, 6, and 12 months after uncomplicated transradial PCI in patients randomized 
to SD (n =504) or OH (n = 501). The questionnaire contains 36 items that, when scored, 
yields 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social 
functioning, role emotional, and mental health). All patients were pretreated with ASA and 
9:30 a.m.
2503-573 Lower Concentration of Heparinized Flush Solution is 
Associated With a Higher Incidence of Femoral Sheath 
Clot Following Diagnostic Cardiac Catheterization
Kristen E. Casale, Michael A. Horst, Angela S. Anderson, Richard B. Devereux, 
Lancaster General Hospital, Lancaster, PA, Weill Cornell Medical College, New York, NY
Background: The concentration of heparinized saline ﬂush solution used in catheters 
and sheaths during diagnostic cardiac catheterization varies by laboratory. It is unknown 
if lower heparin concentration in ﬂush solution is associated with a higher incidence of 
femoral sheath clot.
Methods: 853 patients (pts) undergoing diagnostic cardiac catheterization were 
randomized to receive either 2 unit/ml (group 1) or 6 unit/ml (group 2) of heparin in the 
saline ﬂush solution for catheters and sheaths. Clinical and procedural variables were 
analyzed by multiple logistic regression analysis to identify independent predictors of 
post-procedure femoral sheath clot.
Results: 212 of 404 pts.(52.5%) in group 1 developed femoral sheath clot compared 
to 133 of 448 pts.(29.7%) in group 2, p<.001. Of the clinical and procedural variables 
analyzed, procedure time q16 minutes, sheath size q5 French, no ﬂushing of sheath 
between catheter exchanges and older age were associated with a higher incidence of 
femoral sheath clot. After adjustment for these variables, lower heparin concentration was 
associated with a 2.7-fold higher incidence of femoral sheath clot (Table 1).
Conclusions: Femoral sheath clot was identiﬁed more frequently when 2 unit/ml 
heparinized saline ﬂush solution was used compared to 6 unit/ml after adjusting for 
clinical and procedural variables. The 63% lower incidence of sheath clot with 6 unit/ml 
heparin may help guide decisions regarding heparin concentration for ﬂush solutions.
Table 1: Multivariate Logistic Regression Analysis
Variable odds ratio conﬁdenceinterval p value
2 unit/ml heparin 2.67 1.97-3.63 <.001
sheath size q5 French 6.00 2.87-12.52 <.001
procedure time q16 min. 1.56 1.14-2.13 <.001
no ﬂushing of sheath between catheter 
exchanges 3.75 2.66-5.28 <.001
age (per 10 yrs) 1.22 1.07-1.38 <.01
9:30 a.m.
2503-574 Unsuccessful Transradial Approach for Percutaneous 
Coronary Interventions: Predictors and Mechanisms of 
Radial Access Failure
Payam Dehghani, Tony Hong, Colin M. Suen, Waseem Sharieff, Atif Muhammad, Robert 
J. Chisholm, Michael J.B. Kutryk, Neil P. Fam, Asim N. Cheema, St. Michael’s Hospital, 
Toronto, ON, Canada
Background: Radial access for percutaneous coronary intervention (PCI) results in 
early ambulation and a lower risk of vascular access site complications. However, the 
mechanism and predictors of radial access failure (RF) in a diverse patient population are 
poorly understood. In this study, we sought to determine the mechanisms and predictors 
RF in a large cohort of patients undergoing transradial PCI.
Methods: All patients undergoing transradial PCI at our center between June 2002 and 
June 2005 were included in the study. Baseline clinical characteristics, procedural details, 
and clinical outcomes were prospectively collected. RF was deﬁned as an inability to 
complete PCI procedure by the radial approach. Logistic regression analysis was applied 
to determine the predictors of RF.
Results: A total of 2100 patients underwent transradial PCI during the study period 
and were included in the analysis. The mean age was 62±10 years, 83% were male, 
38% presented with an acute coronary syndrome and 66% were treated with GPIIb/
IIIa antagonist. Vascular complications occurred in 18 (0.9%) and 9 (0.5%) patients 
received blood transfusion. A total of 98 (4.7%) patients experienced RF. This was due 
to unsuccessful arterial puncture in 13 (13%), inability to advance equipment beyond 
brachial artery in 50 (51%) due to spasm in 33 (66%) followed by radial artery dissection 
in 10 (20%), inability to maneuver the tortuous subclavian artery in 18 (18%), and 
poor guide catheter support for PCI in 17 (17%) patients. Of those with RF, the PCI 
was completed successfully in 94 (96%) of patients through a femoral approach. On 
multivariate regression analysis, age >75 (OR=3.86; CI=2.33, 6.40, p<0.0001), previous 
CABG (OR=7.48; CI=3.45, 16.19, p<0.0001) and short stature (OR=2.55; CI=1.22, 5.32, 
p = 0.02) were independent predictors of RF.
Conclusions: Radial access for PCI in a diverse patient population is associated with a 
low rate of failure (<5%) and vascular complications (<1%). Predominant mechanisms of 
RF were radial artery spasm, subclavian artery tortuosity, and an anatomy with unsuitable 
back-up for PCI. Advanced age, precious CABG and short stature were independent 
predictors of RF.
9:30 a.m.
2503-575 Prevention of Vascular Access Site Complications with 
Vascular Closure Devices in Patients with Diabetes 
Undergoing Cardiac Catheterization
Sripal Bangalore, Nipun Arora, Kevin Bainey, Thomas Todoran, Pallav Garg, Pinak B. 
Shah, Frederick S. Resnic, Brigham and Women’s Hospital, Boston, MA
Background: The efﬁcacy of VCDs in patients with diabetes, who are considered to be at 
increased risk of vascular complications, is not well deﬁned.
Methods: We evaluated 3398 consecutive diabetic patients undergoing cardiac 
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Aortic and Pulmonic Valve Intervention
Sunday, March 29, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2504-580 Assessment of Aortic Valve Performance After 
Transcatheter Aortic Valve Replacement: Interim Report 
from the REVIVE II and REVIVAL II Clinical Trials
Mathew Williams, William O’Neal, Helene Eltchaninoff, Susheel Kodali, George Hanzel, 
Thierry Lefevre, Michael Pichard, Craig Smith, Linda Gillam, Samir Kapadia, John 
Webb, Jeffrey Moses, Martin Leon, Columbia University, New York, NY
Background: Transcatheter aortic valve replacement (TAVR) has been an investigational 
procedure for several years and although clinical outcomes have been encouraging, little is 
known about bioprosthetic valve function over time. This analysis was designed to examine 
a consecutive series of TAVR patients (Edwards-Sapien valve) with serial echocardiographic 
studies to assess mean valve gradients (MVG), effective oriﬁce areas (EOA), paravalvular 
aortic regurgitation (pAR), and other signs of prosthetic valve deterioration.
Methods: All patients were enrolled in the REVIVE II (EU) and REVIVAL II (US IDE) non-
randomized feasibility studies for high surgical risk or non-operable patients with severe 
aortic stenosis (AS). Patients had transfemoral implantation of the balloon-expandable 
bovine pericardial Edwards-Sapien stent valve (sizes = 23mm and 26mm). Bioprosthetic 
valve function was assessed by serial echocardiograms which were interpreted in a 
single core laboratory.
Results: 161 patients were enrolled of whom 61 had echo data available at one year. 
Patients had a signiﬁcant reduction in MVG and improvement in EOA (MVG: from 42.8±17.1 
to 10.7±4.0 mmHg, p<0.001 and EOA: from 0.57±0.14 to 1.54±0.46 cm2, p<0.001) which 
was sustained at one year (MVG: 9.5±3.6 mmHg and EOA: 1.54±0.46 cm2). After TAVR, 
62.4% had 0/1+, 34.6% had 2+, and 3% had 3/4+ pAR, which was unchanged at mean 
follow-up of 268 days (53.5% 0/1+, 36.6% 2+, and 9.9% 3/4+ pAR). Of those patients with 2+ 
or greater pAR, LV diastolic and systolic volumes trended to become smaller (LVEDS: 99.5 
ml v. 86.5 mm, p=0.18 and LVESV: 46.8 ml v. 35.8 mm, p=0.22) and LVEF improved (51.8% 
v. 57.6%, p=0.05) over time. There were no cases of bioprosthetic valve deterioration.
Conclusion: TAVR using the Edwards-Sapien valve results in excellent hemodynamic 
valve performance which is sustained for at least one year. pAR does not progress over 
time and there is no evidence of LV remodeling or dysfunction in patients with > 2+ pAR. 
Continued echocardiographic surveillance is required to assess long-term TAVR durability.
9:30 a.m.
2504-581 Percutaneous Mitral Valvuloplasty During Pregnancy
Hung Manh Pham, Oanh Ngoc Pham, Hieu Lan Nguyen, Quang Ngoc Nguyen, Loi 
Doan Do, Viet Lan Nguyen, Khai Gia Pham, Hanoi Medical School, Hanoi, Viet Nam, 
Vietnam Heart Insitute, Bachmai Hospital, Hanoi, Viet Nam
Background: Circulatory changes in gestation, a hyperdynamic adaptive state in 
general, cause an additional burden on the cardiovascular system of women with 
rheumatic mitral stenosis (MS). Percutaneous Mitral Valvuloplasty (PMV) has emerged 
as an effective nonsurgical technique for the treatment of patients with symptomatic MS 
during pregnancy.
Methods: From November 1999 to Dec. 2007, 95 pregnant women (among 4700 PMV 
patients) were performed PMV using Inoue balloon at Vietnam Heart Institute. The 
transthoracic echocardiography was used in combination with intermittent ﬂuoroscopy to limit 
the radiation exposure time. A detailed clinical, echocardiographic, hemodynamic assessment 
was analyzed pre, post procedure, at every 3 months for the ﬁrst year and at 6-month interval 
thereafter. The pregnancy and newborn babies outcomes were also followed.
Results: MS pregnant women were 27,6 years old on average (ranged 22-42) and the 
mean length of pregnancy was 24,2 ± 5,6 weeks. Echo score of mitral valve was 7,1 ± 
2,3. The procedure was technically successful in all cases without any complications. 
The good result (MVA post PMV greater than 1.5cm2) was obtained in 85 cases 
(89.5%). The total mean duration of the procedure was 35,25 ± 14,28 min and that of 
ﬂuoroscopy 2,55 ± 1,28 min (from 1 min 59 sec to 3 min 15 sec). The ﬂuoroscopy time 
was signiﬁcantly shorter than that of usual patients not using echo guided (2 min 23 sec 
vs. 7 min 23 sec, p< 0.01). The mitral valve area increased from 0,7 ± 0,3 to 1,9 ± 0,4 
cm2 (on 2D echocardiography) and from 0,8 ± 0,4 to 2,0 ± 0,4 cm2 (on PHT) (p< 0.01). 
A reduction in mean transmitral valve gradient (MVG) was from 22 ± 6 to 8 ± 2 mmHg. 
There were no maternal or fetal deaths. All patients delivered at full term but 9 (without 
major complications), 37 vaginally and 49 by caesarean section. After average 36 months 
follow-up (range, 3 to 60) all children had normal growth.
Conclusions: During pregnancy, Percutaneous Mitral Valvuloplasty could be considered 
as the treatment of choice of severe pliable mitral stenosis which are refractory to medical 
treatment. Using echocardiography guided can reduce the ﬂuoroscopy time.
clopidogrel (90% > 12h) and received abciximab bolus prior the ﬁrst balloon inﬂation.
Results : At baseline, no differences were noted between the 2 groups. After 1 month, 
signiﬁcant improvement was observed in 7 domains in both randomized groups (P < 0.05) 
but no change was detected in the general health domain. The amplitude of improvement 
was similar in both groups. Between, 1 month and 6 months, further signiﬁcant (P < 
0.05) and similar improvement was observed in role-physical and -emotional and social-
functioning domains whereas other domains remained stable until 12 months. There was 
no change in any domain between 6-months and 12-months.
Conclusion: After transradial PCI and maximal antiplatelet therapy in ACS patients, 
several dimensions of health status improve during the ﬁrst 6 months of follow-up and 
remained stable up to 1 year after PCI. The duration of hospitalization after uncomplicated 
trans-radial PCI has no impact on health recovery.
9:30 a.m.
2503-578 Impact of Micropuncture on Vascular Access Site-
Related Complication Rates in Percutaneous Coronary 
Interventions
Louie Kostopoulos, Babak Haddadian, Mohamed Rahman, Alfred J. Anderson, Joaquin 
Solis, Ramagopal Tumuluri, Anjan Gupta, Tanvir Bajwa, Suhail Allaqaband, Aurora Sinai/
Aurora St. Luke’s Med Ctrs, Univ Wisconsin School of Medicine and Public Health-MCC, 
Milwaukee, WI
Background: Vascular access site-related complications during percutaneous coronary 
interventions (PCI) are known to increase morbidity and mortality. In spite of its widespread 
use, the ability of micropuncture to lower these complication rates has not been validated. 
We reviewed our access-site complication rates from 2005 to 2007 in patients undergoing 
PCI; access via the traditional 18-gauge thin-wall needle (TWN) versus the 21-gauge 
micropuncture kit (MPK).
Methods: Data was extracted from the ACC-NCDR CathPCI Registry. Event rates of 1,706 
patients who underwent PCI with TWN access from 1/05 to 1/06, and 1,997 patients with 
MPK from 7/06 to 7/07 were reviewed. Primary endpoints included ACC-deﬁned vascular 
complications of bleeding and pseudoaneurysm conﬁrmed by ultrasound.
Results: Overall bleeding rates using TWN versus MPK were 1.5% (26/1706) and 1.9% 
(41/1997) (p=0.5) and pseudoaneurysm rates were 0.8% (14/1680) and 1.3% (25/1974) 
(p=0.25), respectively. There was a trend towards a higher mean clopidogrel loading dose 
in the MPK group (360 mg for MPK vs. 297mg for TWN); the highest loading dose of 600 
mg was observed more frequently in the MPK group (39% versus 8%). Test for linear 
trend in proportions among the varied loading doses between the two groups was not 
found to be statistically signiﬁcant (p<0.08).
Conclusion: Use of MPK for gaining vascular access in PCI did not contribute to reduced 
site-related complication rates.
BLEEDING EVENT RATES
Hematoma >10cm diameter + either Thin-Walled Needle(n=26)
Micropuncture
(n=41) p-value
Need for transfusion 12 (46.2%) 19 (46.3%) 0.47 (ns)
Prolonged length of stay 10 (38.5%) 18 (43.9%) 0.35 (ns)
Hb decrease > 3g/dl 4 (15.4%) 4 (9.8%) 1.0 (ns)
9:30 a.m.
2503-579 Randomized comparison of Angio-seal vs. Starclose 
for closure of femoral artery access in coronary 
catheterization
Jong-Young Lee, Sung Sik Kim, Myung-Zoon Yi, Sung-Hwan Kim, Duk-Woo Park, 
Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Seong-Wook 
Park, Seung-Jung Park, Asan medical center, Seoul, South Korea
Background: Percutaneous vascular closure devices (VCDs) decrease the time to 
ambulation and decrease complications for patients undergoing invasive cardiovascular 
procedures via femoral artery access. Currently, the collagen-anchor-suture mediated 
device (Angio-Seal) and clip-mediated device (Starclose) were most commonly used. 
We compare the safety and efﬁcacy of these two devices for patients receiving cardiac 
cauterization via femoral access.
Methods: Patients undergoing coronary intervention via femoral approach were randomly 
assigned to receive either AngioSeal or StarClose VCD. Study end points were success of 
hemostasis and major vascular complication within 1 month. Success of hemostasis was 
deﬁned as absence of pulsatile blood leakage directly after device placement. Major vascular 
complication was deﬁned as puncture site bleeding necessary transfusion, distal device 
embolization, aggravated claudication, AVF, pseudoaneurysm and femoral artery compromise.
Results: Total 238 patients (Angioseal, N = 116 versus Starclose, N = 122) were 
enrolled from August 2007 through February 2008 in Asan Medical Center. There was 
no signiﬁcant differences in baseline characteristics including antiplatelet medication, 
baseline coagulation level, and sheath size. Successful hemostasis was not achieved in 4 
(3.2%) patients of Starclose group and no in Angioseal group (p=0.12). The rate of oozing 
necessitating immediate manual compression was signiﬁcantly higher in Starclose group 
than in Angioseal group (37.4% vs. 20.0%, p=0.003). The incidence of early hematoma 
(a12 hours) (13.8% vs. 11.3%, p=0.56) and bruising area (67 ± 70cm2 vs 31 ± 29 cm2,
p=0.08) were not signiﬁcantly different. However, late hematoma formation (q12 hours) 
was signiﬁcantly higher in Angioseal group than in Starclose group (8.7% vs. 0, p=0.001). 
There were no signiﬁcant major vascular complications.
Conclusions:Two different VCD are simialry safe and effective for percutaneous occlusion 
of femoral access. However, the rate of oozing with additive manual compression was 
signiﬁcantly higher in Starclosure group than Angioseal group, whereas the incidence of 
late hematoma was vice versa.
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2609
i2.Iliofemoral Disease: Evaluation, 
Treatment, Follow-up
Sunday, March 29, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W414C
11:30 a.m.
2609-8 In-Hospital Outcomes and Cost Comparison of 
Femoropopliteal Revascularization Strategies
David M. Saﬂey, Jason B. Lindsey, John A. House, Katherine Robertus, Keith B. Allen, 
Elizabeth Mahoney, David J. Cohen, Mid America Heart Institute, Kansas City, MO, 
University of Missouri - Kansas City, Kansas City, MO
Background: For patients undergoing femoropopliteal (FP) revascularization, 
atherectomy (ATH) has recently emerged as an alternative to angioplasty (PTA) with 
or without stenting or bypass surgery. Despite the increased use of ATH, there are few 
comparative studies of these alternative approaches to FP revascularization and no direct 
cost comparisons.
Methods: Consecutive patients (n=199) undergoing FP PTA (n=70), ATH (n=91) or 
surgical bypass (n=42) from 1/05 - 4/06 were included in this analysis. Hospital costs 
were calculated from detailed hospital cost accounting records. Professional fees were 
calculated from CPT codes and the Medicare Physician Fee Schedule. Between group 
differences were evaluated using Fisher’s Exact Test for complication rates and the 
Wilcoxon rank-sum test for costs.
Results: Among the 3 treatment groups, there were no signiﬁcant differences in baseline 
characteristics. Complication rates did not differ between groups except for higher rates 
of urgent repeat procedures after bypass (table). Total costs were similar for PTA and ATH 
but higher for bypass (table), due to longer length of stay.
Conclusions: For patients undergoing FP revascularization, initial clinical outcomes are 
comparable for PTA, ATH, and surgery but costs are higher with surgery. These ﬁndings 
suggest that either PTA or ATH may be acceptable initial treatment strategies if the 
anatomy is suitable. Long-term follow-up will be needed to determine if an initial surgical 
strategy can be justiﬁed. 
In-Hospital Outcomes and Costs of Femoropopliteal Revascularization
In-Hospital Outcomes PTA(n=70)
Atherectomy
(n=91)
p
value*
Surgical
Bypass
(n=42)
p
value†
Bleeding 8.7% 4.3% 0.33 7.1% 0.90
Urgent Revascularization 0.0% 2.2% 0.51 9.5% 0.02
Costs
Total Costs $10,945 $10,783 0.57 $14,947 <0.0001
Procedural $7,396 $7556 0.75 $3,564 <0.0001
Non-Procedural $2,655 $2347 0.57 $9,519 <0.0001
Professional Fees $893 $880 0.78 $1,863 <0.0001
Length of Stay (procedural 
related)
0.46 ± 
1.82 0.27 ± 0.96 0.40 3.48 ± 4.44 0.0001
*p-value is PTA vs atherectomy
†p-value is PTA vs surgical bypass
I2.SYMPOSIUM
2613
i2.Vascular Access and Closure
Sunday, March 29, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W315B
11:30 a.m.
2613-8 Vascular Closure Device Failure: Frequency and 
Implications
Sripal Bangalore, Nipun Arora, Thomas M. Todoran, Kevin Bainey, Pallav Garg, Piotr S. 
Sobieszczyk, Frederic S. Resnic, Brigham and Women’s Hospital, Boston, MA
Background: The frequency and consequence of failure of VCDs is not well deﬁned.
Methods: 9838 consecutive patients who received either a collagen-plug (Angioseal) 
based or a suture-based (Perclose) VCD were selected. VCD failure was deﬁned as 
unsuccessful deployment or failure to achieve hemostasis. Major vascular complications 
was deﬁned as any retroperitoneal hemorrhage, limb ischemia, or need for surgical repair. 
Minor vascular complications was deﬁned as any groin bleeding, hematoma (>=5 cm), 
pseudoaneurysm, or AV ﬁstula. ‘Any’ vascular complication was deﬁned as either a major 
or minor vascular complication.
Results: VCD failed in 268 (2.7%) patients. The VCD failure group had signiﬁcantly 
increased risk of any (10.8% vs. 3.7%), major (1.9% vs. 0.6%) or minor (5.2% vs. 0.9%) 
vascular complications compared with the group with successful deployment of VCD 
(Figure). Univariable predictors of VCD failures were older age, female sex, history 
9:30 a.m.
2504-582 Comparison of Transapical and Transfemoral Aortic 
Valve Replacement for High Risk Patients With Severe 
Aortic Stenosis Using the Edwards Sapien Balloon-
Expandable Bioprosthesis: In-Hospital and Medium 
Term Outcomes
Mark D. Osten, Christopher Feindel, Barry Rubin, Kristeen Chamberlain, Joan Ivanov, 
Massimiliano Meineri, Melitta Mezody, Eric M. Horlick, University Health Network, 
Toronto General Hospital., Toronto, Canada
Background: Transcatheter aortic valve replacement (TCAVR) is an emerging alternative 
therapy to conventional open heart surgery in high risk surgical patients with symptomatic 
aortic stenosis. We sought to compare our experience with the transfemoral (TF) and 
transapical ( TA) Edwards Sapien bioprosthesis (Edwards lifesciences, Irvine,Calif).
Methods: Patients with severe aortic stenosis (area<0.8cm2 and/or mean gradient 
>40mmHg) with NYHA class >2 and an operative mortality risk of >15% as assessed by a 
cardiologist and two surgeons were eligible for TCAVR. Two valve sizes were available:23- 
and 26-mm diameter using a 22Fr and 24Fr sheath system via the TF approach and a 
24Fr sheath via the TA approach. Results: :A total of 30 patients(18-TA, 12-TF) with a 
mean valve area of 0.6+/-0.1cm2,a mean age of 80.8+/-7.9,a mean logistic euroscore of 
25.3+/-10.7, and a mean STS score of 8.0+/-4.4 were analyzed. Discharge home occurred 
at a median of 8 days in the TA group (range 5 to 47) and 14 days in the TF group (range 
6 to 21). The mean follow up period was 164 days. Procedural success was 89% in the 
TA group and 92% in the TF group. There were 2 (1-TA, 1-TF) procedural deaths. Overall 
in-hospital mortality was 16% (2-TA, 3-TF). There was 1 procedural stroke in the TF group. 
Successful valve replacement was associated with an increase in valve area from 0.6+/-
0.1cm2 to 1.4+/-0.1cm2 in the TA group and 0.6+/-0.1cm2 to 1.2+/-0.1cm2 in the TF group. 
At discharge, there was a signiﬁcant improvement in mean gradient (p<0.0001), mitral 
regurgitation (p<0.01) and NYHA functional class (p<0.0001) in both groups. At medium 
term follow up the valve area was maintained (1.4cm2 in both groups) (p<0.0001),and 
there remained an improvement in functional class in both groups compared to baseline 
(p<0.0001). At medium term follow up, there were no cardiac related deaths in either 
group. There were two late strokes in the TA group. Mild paravalvular regurgitation was 
common in both groups.Conclusions::We observed similar in-hospital and medium 
term outcomes using the two currently available TCAVR techniques with the Edward 
Sapien bioprosthesis for the treatment of severe aortic valve stenosis in this high-risk 
population.
9:30 a.m.
2504-583 Use of Balloon Aortic Valvuloplasty to Size the Aortic 
Annulus Prior to Implantation of a Balloon Expandable 
Transcatheter Heart Valve
Vasilis Babaliaros, David Liff, Vinod Thourani, Edward Chen, Robert Guyton, Zahid 
Junagadhwalla, Stamatios Lerakis, Jacob Green, Kush Agrawal, Collins Kwarteng, 
Jason Guyotte, Ateet Patel, Roy Abrahamian, Thomas Vassiliades, Peter Block, Emory 
University, ATLANTA, GA
Background: Annulus sizing by balloon aortic valvuloplasty (BAV) during transcatheter 
heart valve (THV) procedures has not been studied and may aid in selecting appropriate 
THV size.
Methods: Patients (pts, n=20) with aortic stenosis (< 1.0cm2) scheduled for THV 
implantation were enrolled. Pre and post procedure echo measurements were made by 
TEE. A valvuloplasty balloon of known size and inﬂatable pressure was inserted into 
the aortic valve and inﬂated. The development of intra-balloon pressure in addition to 
the nominal inﬂation pressure (AIBP) reﬂected apposition of balloon and aortic annulus. 
THV implantation with a device q 1mm than the balloon size that generated AIBP was 
subsequently performed.
Results: Intra-balloon pressure measurements were performed in 18 pts during BAV 
(unable to stabilize balloon for measurement, n=2), Table 1. In 1 pt, no AIBP was 
generated during BAV and THV size was chosen >3mm than TEE annulus size. Using 
the THV size based on balloon results, no valve embolization occurred or signiﬁcant 
paravalvular leak was observed.
Conclusions: Intra-balloon pressure measurements during BAV can help size the aortic 
annulus and may help select the size THV that should be implanted. These data suggest 
a strategy of THV sizing q 1mm + the Balloon size that generates AIBP.
Table 1. Patients Undergoing Aortic Annulus Sizing by BAV Before THV Implantation 
Patient Number TEE Annulus (mm) Balloon Size (mm) AIBP (atm) THV Size (mm)
1 20 20 1 23
2 21 22 2 23
3 20 20 1 23
4 22 23 2 26
5 19 20 1 23
6 20 21 2 23
7 22 23 0.5 26
8 20 20 N/A 23
9 20 20 0.5 23
10 23 23 0 26
11 20 20 0.5 23
12 24 24 0.5 26
13 23 22 N/A 26
14 22 22 0.5 23
15 20 22 1 23
16 22 22 0.75 23
17 24 24.5 0.5 26
18 24 24 0.5 26
19 20 23 0.5 26
20 24 24.5 0.5 26
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infarction - stent thrombosis at 30 days after the clopidogrel cessation.
Results: Baseline characteristics were similar among groups. The rate of the composite 
criteria at 30 days after clopidogrel cessation was signiﬁcantly higher in group 1 vs groups 
2 and 3: 2.7% vs 0.2% and 0.3%, respectively (p=0.001).
Conclusion: This study conﬁrms that clopidogrel cessation is strongly associated with 
an increased short-term risk of adverse events when it occurred within the ﬁrst 6 months 
after the PCI. By contrast, clopidogrel cessation was no longer associated with such a 
risk after 6 months. This suggests that cardiac events seen immediately after clopidogrel 
cessation are not related to a rebound phenomenon.
10:54 a.m.
2903-7 Proton Pump Inhibitor and Clopidogrel Combination Is 
not Associated With Adverse Clinical Outcomes After 
PCI: The NHLBI Dynamic Registry
Jose F. Ramirez, Faith Selzer, Rinita Chakaprani, William D. Anderson, Joon S. Lee, 
Conrad Smith, Suresh R. Mulukutla, Kevin E. Kip, Sheryl F. Kelsey, Oscar C. Marroquin, 
Cardiovascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA
Background: In vitro studies have suggested that Proton Pump Inhibitors (PPI’s) could 
inﬂuence the antiplatelet effect of Clopidogrel, by decreasing its inhibitory effect on the 
platelet P2Y12 ADP receptor. The clinical impact of this combination has not been well 
characterized. Therefore, we investigated the effect of this therapeutic combination on 
clinical outcomes in patients undergoing percutaneous coronary intervention (PCI).
Methods: Data from 535 patients enrolled at the University of Pittsburgh as part of the 
NHLBI Dynamic Registry waves 4 (2004) and 5 (2006) was analyzed. Patients discharged 
alive from their index PCI and on clopidogrel were included. They were divided onto 
those PPI users and those PPI nonusers. One-year rates of death, MI, and repeat 
revascularization were collected.
Results: Of the 535 patients taking clopidogrel, 138 (25.80%) were PPI users and 397 
(74.20 %) patients were PPI nonusers. There were no signiﬁcant baseline differences 
between PPI users and nonusers in age, baseline prevalence of diabetes, hypertension, 
renal dysfunction, smoking habits, or procedural success. At one year, there were no 
differences between PPI users and nonusers in univariate rates of death, MI, death/MI, or 
repeat revascularization.(table)
Conclusion: In patients undergoing PCI and discharged on clopidogrel therapy, the 
concomitant use of PPI’s did not result in adverse cardiovascular outcomes at one year. 
This suggests that this combination is safe in patients who have undergone PCI.
Cumulative 1-year outcomes
Adverse Outcome (%) PPI non-users(n=397) PPI users(n=138) p-value
Death 5.9 3.0 0.18
MI 4.2 3.7 0.83
CABG 4.1 3.1 0.53
Death/MI 9.6 6.7 0.32
Repeat PCI 10.1 13.4 0.23
Repeat Revascularization 14.2 15.8 0.65
11:06 a.m.
2903-8 Carriage of the CYP2C19*2 Allele Increases One-Year 
Risk of Myocardial Infarction Among Recipients of 
Drug-Eluting Stents Treated With Clopidogrel.
Jeffrey L. Anderson, Chrissa P. Mower, Benjamin D. Horne, Joseph B. Muhlestein, 
James J. Park, Tami L. Bair, John F. Carlquist, Intermountain Medical Center, Murray, UT
Background: Drug-eluting stents (DES) reduce the rate of restenosis but increase 
the risk of in-stent thrombosis with consequent myocardial infarction (MI) from delayed 
endothelialization. At least 1 y dual anti-platelet therapy (clopidogrel plus aspirin) is 
recommended after DES as premature thienopyridine discontinuation (at < 6 months 
post-DES) increases risk for late stent thrombosis and MI. From 29-56% of the population 
achieve suboptimal inhibition of platelet aggregation (IPA) with clopidogrel and up to a 
three-fold increase in risk for MI or death (D) at 1 y. The reduced-function *2 variant 
of the p450 cytochrome oxidase CYP2C19 gene was shown to predict impaired IPA 
with clopidogrel (5.4% reduction for carriers vs. 27.3% for non-carriers). However, a 
CYP2C19*2 association with clinical risk has not been shown. We prospectively tested 
the hypothesis that carriage of the CYP2C19*2 allele increases risk for myocardial 
infarction (MI) in the ﬁrst y after DES in a large cohort.
Methods: Consenting patients (pts; N=1250) enrolled in the Intermountain Heart Collaborative 
Study, receiving a DES, and discharged with a prescription for clopidogrel from January 1 
of diabetes, peripheral arterial disease, presentation with NSTEMI, lower creatinine 
clearence, use of suture-based VCD (8.9% vs. 1.5%) and undergoing PCI. Multivariable 
predictors were older age, use of suture-based VCD (OR = 7.30; 95% CI = 5.59-9.52; 
P<0.0001) and undergoing PCI.
Conclusions: In contemporary practice, VCD failure is rare but when it does fail, it is 
associated with signiﬁcant increase in the risk of vascular complications. Patients with 
VCD failure should be closely monitored.
I2.ORAL CONTRIBUTIONS
2903
Interventional Pharmacology
Sunday, March 29, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W414D
10:30 a.m.
2903-5 Impact of Different Antithrombotic Regimens on Ischemic 
and Hemorrhagic Outcomes Following Percutaneous 
Coronary Intervention in Elderly: Pooled Analysis from 
the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Eugenia Nikolsky, Roxana Mehran, Helen Parise, Alexandra J. Lansky, George D. 
Dangas, Steven V. Manoukian, Michele Voeltz, Karen P. Alexander, E. Magnus Ohman, 
Darius Dudek, A. Michael Lincoff, Gregg W. Stone, Columbia University Medical Center 
and the Cardiovascular Research Foundation, New York, NY
Background: Among patients (pts), undergoing percutaneous coronary interventions 
(PCI), elderly represent vulnerable population due to higher rates of ischemic and bleeding 
complications. Our aim was to assess impact of different antithrombotic regimens on 
outcomes of elderly pts with stable or acute coronary syndromes treated with bivalirudin (Biv) 
alone versus heparin+GPIIb/IIIa inhibitors (Hep+GPI) in three contemporary PCI trials.
Methods and Results: Among a total of 14,325 pts undergoing PCI in the patient-based 
pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI trials, 2,235 (15.6%) 
were elderly (q 75 years of age). Elderly compared to younger pts had signiﬁcantly higher 
rates of composite ischemic endpoint (death, myocardial infarction, or revascularization) 
[10% vs. 6.7% p<0.001] and protocol-deﬁned major bleeding (8.3% vs. 3.8%, p<0.001). 
At 30 days, elderly assigned to Biv vs. Hep+GPI had similar rates of composite ischemic 
endpoint but signiﬁcantly lower rates of bleeding (Table).
Conclusions: Older age is associated with notably increased risk of PCI-related ischemic 
and bleeding complications. Elderly patients beneﬁt from bivalirudin by a marked reduction 
in bleeding with similar rates of ischemic complications. 
Clinical endpoints (%) Heparin + GPI(N=1,144)
Bivalirudin
(N=1,091) P value
Composite ischemia 9.5% 10.5% 0.43
Death 2.5% 3.3% 0.23
Myocardial infarction 6.3% 7.0% 0.58
Revascularization 2.3% 2.0% 0.69
Non-CABG TIMI bleeding (major + minor) 9.5% 7.0% 0.03
10:42 a.m.
2903-6 Is There a Rebound Effect After Clopidogrel Cessation 
in Patients Undergoing Percutaneous Coronary 
Intervention and Drug-Eluting Stent Implantation?
Gilles Lemesle, Laurent Bonello, Axel De Labriolle, Itsik Ben-Dor, Gabriel Maluenda, 
Sara D. Collins, Asmir I. Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. 
Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Clopidogrel discontinuation within the ﬁrst 6 months after percutaneous coronary 
intervention (PCI) with drug-eluting stent (DES) implantation has been reported to be a strong 
predictor of early events. Nevertheless, it is currently debated if clopidogrel cessation after 6 
months is also related to an increased short-term risk of adverse events. This study aimed to 
determine the link between clopidogrel cessation and adverse cardiovascular events after PCI.
Methods: From 2002 to 2007, 2254 patients underwent PCI with DES implantation. 
We compared patients who stopped their clopidogrel within the ﬁrst 6 months (group 
1, n=442), between 6 and 12 months (group 2, n=510) and after 12 months after the 
PCI (group 3, n=1302). We indexed the primary composite endpoint death - myocardial 
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Conclusions: Although infrequent, GIB is a serious complication of contemporary 
antithrombotic therapy, associated with high rates of transfusion, reinfarction and strikingly 
increased mortality at 30 days and 1 year. Future investigation is warranted to determine 
effective measures to prevent GIB in high-risk populations.
I2.SYMPOSIUM
2612
i2. Acute Myocardial Infarction
Sunday, March 29, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W415D
3:00 p.m.
2612-9 Randomized Comparison of Primary Percutaneous 
Coronary Intervention With Combined Proximal 
Embolic Protection and Thrombus Aspiration and 
Primary Percutaneous Coronary Intervention Alone in 
ST-segment Elevation Myocardial Infarction
Joost D. Haeck, Karel T. Koch, Luc Bilodeau, René J. Van der Schaaf, José P. Henriques, 
Jan Baan, Jr., Marije M. Vis, Krischan D. Sjauw, Jan J. Piek, Jan G. Tijssen, Mitchell W. 
Krucoff, Robbert J. De Winter, Academic Medical Center – University of Amsterdam, 
Amsterdam, The Netherlands, Duke Clinical Research Institute, Duke University Medical 
Center, Durham, NC
Background: Distal embolization during primary percutaneous coronary intervention (PCI) 
occurs in at least 15% of patients and is a strong predictor of more extensive myocardial 
damage and a poor prognosis. A novel approach of preventing distal embolization is the 
use of the Proxis system (St. Jude Medical, St Paul, MN, USA), a combination of proximal 
embolic protection and thrombus aspiration, during primary PCI.
Methods: We performed a randomized trial assessing whether primary PCI with 
combined proximal embolic protection and thrombus aspiration was superior compared 
to primary PCI alone. A total of 284 patients were randomly assigned to primary PCI with 
Proxis system or primary PCI alone after coronary angiography. The primary endpoint 
was complete (q 70%) ST-segment resolution (STR) after the procedure, performed in 
a blinded manner at Duke Clinical Research Institute Virtual Electrocardiogram Core 
Laboratory (Durham, North Carolina, USA).
Results: Complete STR at time of last contrast occurred in 66% (85/129) of patients 
receiving combined proximal embolic protection and aspiration and in 50% (67/135) of 
control patients (absolute difference, 16.3% [95% conﬁdence interval, 4.3% to 28.2%]; 
P=0.009).The difference between the 2 groups in the rate of complete STR at the time of 
last contrast injection was statistically signiﬁcant. The mean percent STR at last contrast 
in the both arms was also statistically signiﬁcant different (73.2% vs 63.4%, respectively; 
P=0.009). A signiﬁcant lower ST-segment curve area (0 - 3 hours after primary PCI) was 
observed in the Proxis arm (5192 μV-minutes vs 6250 μV-minutes, P=0.037). Debris was 
conﬁrmed on pathology in 75% (84/112) of patients.
Conclusions: The results of the PREPARE trial showed that primary PCI with combined 
proximal embolic protection and thrombus aspiration is feasible and safe and leads to more 
complete STR which suggest better immediate microvascular ﬂow in STEMI patients.
I2.SYMPOSIUM
2614
i2.Infrapopliteal Disease: Evaluation, 
Treatment, Follow-up
Sunday, March 29, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W414C
3:00 p.m.
2614-8 Presence of Critical Limb Ischemia Rather Than Vessel 
Run-off Determines Restenosis in the Femoro-popliteal 
Artery in the New Nitinol Stent Era
Kuniyasu Ikeoka, Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, 
Tetsuya Watanabe, Masaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, 
Shin Okamoto, Seiki Nagata, Kansai Rosai Hospital, Hyogo, Japan
Background: Severity of limb ischemia, lesion length, and outﬂow lesions are raised as 
restenosis factors following endovascular therapy (EVT) in the superﬁcial femoral artery 
(SFA) in TASC 2. However, factors inﬂuencing restenosis in the new era of nitinol stents 
are unclear. We sought to investigate factors inﬂuencing restenosis following EVT with 
nitinol stents in the femoro-popliteal artery (FPA). Methods: Provisional stenting was 
performed with a nitinol stent (Smart Control, Cordis)in the FPA of 163 patients (227 
limbs), including diabetes mellitus (DM, 63%), hemodialysis (20%), critical limb ischemia 
(CLI, 24%). Thirty-seven % of patients showed less than 1 vessel distal run-off below the 
knee. Mean lesion length was 139±90mm; TASC classiﬁcation A/B/C/D was 91/42/23/71; 
46% of lesions were chronic total occlusion (CTO); 40% were with severe calciﬁcation; 
43% received multiple stents. Either angiography (diameter stenosis > 50%) or duplex 
ultrasound (peak systolic velocity ratio >2.5) were used at follow up to deﬁne restenosis. 
Results: Restenosis rate at 15±6.7 months of follow up was 17%. Seventeen % of the 
lesions had stent fractures. Presence of CLI, TASC C/D, CTO, multiple stenting, lesion 
2003 - June 30, 2006 were studied. Pts were genotyped for CYP2C19*2 using 5’ nuclease 
technology. Electronic medical records and national databases were analyzed at 1 year for 
incident MI, D, and combined MI/D following stent placement and at 2 y.
Results: Pt age averaged 63 y, and 27% were women. Genotype frequencies were 
*1*1=72%, *1*2=27%, and *2*2=1%. By 1 y, MI had occurred in 11.9% of *2 carriers and 
8.3% of non-carriers (OR=1.50, 95% CI=1.00, 2.24; p=0.048) and was not affected by 
adjustment for age and sex (OR=1.49, CI=0.99, 2.23; p=0.054); a similar trend was found 
for MI/D (13.7% vs. 9.9%, OR=1.43, CI=0.98, 2.09; p=0.06). Rates of D were low (2.0% 
vs. 1.9%, p=0.86). The effect of *2 carriage on MI risk was maintained at 2 y (OR=1.42, 
CI=0.99, 2.02; p=0.055).
Conclusion: Carriage of a CYP2C19*2 allele not only decreases in vitro (IPA) 
responsiveness to clopidogrel, but increases (by 50%) the 1-2 y risk of MI or MI/D among 
DES recipients. If conﬁrmed, these ﬁndings may lead to pre-DES stent genotyping to 
optimize DAT therapy and reduce MI risk.
11:18 a.m.
2903-9 Modiﬁed Clopidogrel Desensitization Following 
Percutaneous Coronary Intervention (PCI): A Novel 
Approach to the Management of Clopidogrel Allergy
Hasan Jilaihawi, Rose-Pascale Paul, Martin Blaquière, Denis Brouillette, Marc-André 
Lavoie, Pierre Théroux, Raoul Bonan, Philippe L’Allier, Réda Ibrahim, Montreal Heart 
Institute, Montreal, QC, Canada
Background: Allergic reactions to clopidogrel affect around 6% of patients. In patients 
after PCI, where a period of dual antiplatelet therapy is fundamental to reduce the risk of 
stent thrombosis, ticlopidine is used as a traditional replacement drug when clopidogrel 
allergy is seen. We sought to assess the safety and efﬁcacy of a locally modiﬁed 
clopidogrel desensitization protocol.
Methods: Patients post PCI were regarded as having probable clopidogrel reaction in the 
absence of alternative causes. They were treated symptomatically in the ﬁrst instance by 
a modiﬁed desensitization approach, with a course of oral corticosteroid/antihistamine 
combination with continued clopidogrel. In the setting of a persistent rash despite this, the 
clopidogrel was temporarily changed to ticlopidine and a graded rechallenge protocol was 
initiated. This consisted of rapidly incremental doses of plavix given at 30 min intervals; 
0.75mg, then 7.5 mg, then 75 mg. Clopidogrel was continued thereafter and patients were 
assessed for symptoms at 1-2 weeks and 3 months follow-up.
Results: 45 consecutive patients with probable clopidogrel allergy underwent modiﬁed 
desensitization (steroids/antihistamines with continued clopidogrel) between March and 
June 2008; these comprised 13 STEMI (29%), 14 UA/NSTEMI (31%) and 18 stable angina 
(40%) cases. 37 (82%) were male and mean age was 61.9 years (SD 12.4). Of these 
cases, 20 had undergone PCI with DES (44%), 21 with BMS (47%), 1 POBA (2%) and 3 
diagnostic coronary angiograms only (7%). Reactions were observed a mean of 7.6 days 
(SD 5.4, range 1-21) post clopidogrel exposure and in all cases were cutaneous reactions 
with no anaphylactic reactions observed. Full graded rechallenge was necessary in 4 
patients (9%). At 1-2 weeks, 5 cases had minimal residual rash or pruritis (11%) with 40 
no residual symptoms (89%). Of the 30 cases with documented 3 month follow-up thus 
far, only 2 had minimal residual rash/pruritis (7%).
Conclusion: A modiﬁed desensitization approach to clopidogrel allergy, with continued 
clopidogrel and a course of a corticosteroid/antihistamine combination, is a safe and 
effective strategy to this important clinical problem.
11:30 a.m.
2903-10 Impact of Gastrointestinal Bleeding on Outcomes of 
Patients Treated With Contemporary Antithrombotic 
Strategies: Pooled Analysis From 3 Randomized Trials
Eugenia Nikolsky, Roxana Mehran, Alexandra Lansky, Adriano Caixeta, George 
D. Dangas, Giora Weisz, Iulian Benetato Giuran, Martin Fahy, A. Michael Lincoff, 
Bernhard Witzenbichler, Gregg W. Stone, Columbia University Medical Center and the 
Cardiovascular Research Foundation, New York, NY
Background: Gastrointestinal bleeding (GIB) is a potential complication of antithrombotic 
therapy. Our aim was to assess incidence and impact of GIB on outcomes of patients with 
coronary artery disease treated with contemporary antithrombotic regimens.
Methods: We performed a patient-level pooled analysis from 3 contemporary multicenter, 
randomized trials (REPLACE-2, ACUITY and HORIZONS-AMI) assessing outcomes of 
patients assigned to heparin+GP IIb/IIIa inhibitors, bivalirudin+GP IIb/IIIa inhibitors, or 
bivalirudin monotherapy. GIB events adjudicated to CABG were excluded from analysis.
Results: Of the 22,283 patients in the dataset, in-hospital GIB occurred in 253 patients 
(1.1%). Multivariable predictors of major bleeding included older age (OR=1.03, 
P=0.0004), prior cerebrovascular accident (OR=2.20, P=0.008), baseline hematocrit 
(OR=0.91, P<0.0001), positive biomarker (OR=1.55, P=0.023), and treatment with 
any GP IIb/IIIa inhibitors regimen (OR=2.17, P=0.003). Thirty-day and 1-year clinical 
outcomes are presented in the Table. At 1 year, GIB was an independent predictor of 
death (OR=4.66, P<0.0001). 
Clinical outcomes, % GIB (+)N=253
GIB (-)
N=22,030 P-value
30-day events
Death 7.8% 1.1% <0.0001
Reinfarction 11.0% 4.6% <0.0001
Q Wave 2.8% 0.8% 0.0003
Non-Q Wave 8.6% 3.8% 0.0002
Target vessel revascularization 2.4% 1.2% 0.09
Blood product transfusion 36.6% 0.2% <0.0001
1-year death 16.4% 2.9% <0.0001
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Adjusted Hazard Ratios of One Year Adverse Events for Patients with 
Pulmonary Disease
HR 95% CI p-value
Death 1.30 1.01-1.67 0.04
MI 0.96 0.70-1.30 0.77
CABG 1.28 0.94-1.76 0.12
Death or MI 1.16 0.95-1.42 0.14
Repeat PCI 1.12 0.91-1.38 0.27
Repeat Revascularization 1.22 1.02-1.46 0.03
2:24 p.m.
2904-7 Safety and Efﬁcacy of Three Strategies of Multi-Vessel 
Percutaneous Coronary Intervention: Same Session vs. 
Multi-Session vs. Multi-Hospitalization
James C. Blankenship, Richard E. Shaw, Joseph D. Babb, Geisinger Medical Center, 
Danville, PA, Sutter Paciﬁc Heart Centers, San Francisco, CA
Background: Multi-vessel coronary intervention (MVPCI) may be performed during 
1 session, different sessions during 1 hospitalization, or different hospitalizations. US 
federal agencies are concerned that economic factors may bias treatment strategies 
toward multiple admissions.
Methods: The American College of Cardiology National Cardiovascular Data Registry 
(NCDR) was queried to identify all patients undergoing elective MVPCI during 2001-2003. 
Patients were assigned to groups based on strategy: 1 session (1-session, N = 32,246), 
2 sessions during 1 hospitalization (2-session, N = 1,932), or sessions during different 
hospitalizations (2-hosp, N = 6,474). Complications and success rates were calculated 
on a per-patient basis. Expected mortality was calculated using a model based on 
demographic and angiographic characteristics.
Results: 2-session patients (vs 1-session vs 2-hosp) had more co-morbidities: current 
CHF: 10.6% vs 7.7% vs. 5.6%; unstable angina: 58.8% vs. 49.2% vs 40.0%; prior renal 
failure: 7.0% vs. 4.6% vs. 4.7%, EF<40%: 19.5% vs. 14.4% vs. 13.4%. Lesions/ patient 
were 2.1 vs 2.5 vs 2.3. Observed/expected mortality was lower for 2-hosp (0.27) than for 
1-session (1.17) or 2-session (1.28) (p <0.0001).
Conclusions: A strategy of 2-session MVPCI, used in the sickest patients, does not 
reduce mortality below expected levels. MVPCI on different hospitalizations, used in the 
least sick patients, is effective and may be safer than MVPCI during 1 admission.
Complications and Success Rates of Multi-Vessel PCI Strategies
1 Session 2 Sessions, 1 Hospitalization 2 Hospitalizations
In-hospital mortality 0.54% 0.69% 0.08%
Expected mortality 0.46% 0.53% 0.29%
Peri-procedural MI 1.69% 1.55% 0.82%
Unplanned CABG 0.47% 0.41% 0.36%
Vascular site bleeding 1.58% 1.50% 0.69%
Success in all lesions 91.1% 93.4% 94.0%
2:36 p.m.
2904-8 Patients With Coronary Artery Disease not Amenable 
to Traditional Revascularization: Prevalence and 3-Year 
Mortality
Benjamin Williams, Madhav Menon, Daniel Hayward, Daniel Satran, James Hodges, 
Timothy D. Henry, Minneapolis Heart Institute Foundation at Abbott Northwestern 
Hospital, Minneapolis, MN
Background: A growing number of patients have severe coronary artery disease (CAD) 
not amenable to traditional revascularization. Many have ongoing angina despite optimal 
medical therapy. Prevalence and mortality data for these patients are scarce.
Methods: Clinical and angiographic data were reviewed for 493 consecutive patients 
undergoing coronary angiography at the Minneapolis Heart Institute in 2005. Patients 
were categorized into six groups: 1) normal coronary arteries 2) CAD <70%, 3) CAD 
>70% with complete revascularization (CR) by percutaneous intervention (PCI) or 
coronary artery bypass grafting (CABG), 4) CAD >70% with partial revascularization (PR) 
(by PCI or CABG), 5) CAD >70% treated medically and 6) CAD >70% on optimal medical 
therapy with no revascularization option. All-cause mortality at 3 years was determined.
Results: Prevalence and 3 year mortality for each group are shown (Table). Mortality for patients 
not undergoing complete revascularization (groups 4-6, n = 142) was signiﬁcantly higher than 
for completely revascularized patients (groups 1-3, n = 351): 14.8% vs. 6.6% (p=0.004). 
Prevalence and Mortality by CAD Group
Group Total n=493 (% of 493) Deaths (% of group n)
1. Normal 73 (14.8) 2 (2.7)
2. CAD <70% 96 (19.5) 6 (6.3)
3. CAD >70% (CR) 182 (36.9) 15 (8.2)
4. CAD >70% (PR) 63 (12.8) 8 (12.7)
5. CAD >70% (medical) 46 (9.3) 8 (17.4)
6. CAD >70% (“no option”) 33 (6.7) 5 (15.2)
Conclusions: In a contemporary series of patients undergoing coronary angiography, 
28.8% (142/493) of patients had CAD and did not undergo complete revascularization, 
including 12.8% partially revascularized, 9.3% managed medically, and 6.7% with “no 
option.” These patients had higher risk for mortality at 3-years (14.8% vs. 6.6%, p=0.004) 
length > 100mm(P=0.005, 0.001, 0.01, 0.0009, 0.002, respectively) were chosen 
as signiﬁcant variables related to restenosis by single regression analysis, while DM, 
hemodialysis, poor run-off, stent fracture were not chosen (P=0.66, 0.76, 0.71, 0.15, 
respectively). CLI was chosen as the only signiﬁcant variable by multivariate regression 
analysis (P=0.009). Conclusion: Presence of CLI was the strongest independent 
predictor of restenosis in the femoro-popliteal artery in the new nitinol stent era.
I2.ORAL CONTRIBUTIONS
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Complex Patients
Sunday, March 29, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W414D
2:00 p.m.
2904-5 Impact of PCI vs. CABG on the Development of 
Acute Renal Failure in Patients With Acute Coronary 
Syndromes: Insights From the ACUITY Trial
Giora Weisz, Roxana Mehran, George Dangas, Eugenia Nikolsky, Leroy Rabbani, Yanai 
Ben-Gal, Martin Fahy, Varinder Singh, Alexandra Lansky, Jeffrey W. Moses, Gregg W. 
Stone, Center for Interventional Vascular Therapy, Columbia University Medical Center, 
New York, NY, Cardiovascular Research Foundation, New York, NY
Background: In patients with acute coronary syndrome (ACS) and CAD requiring 
revascularization, concerns about contrast induced nephropathy often lead to referral to 
CABG over PCI. We studied the effect of revascularization mode (PCI vs CABG) on the 
rate of in-hospital acute renal failure (ARF) in patients with ACS in the ACUITY trial.
Methods: All patients underwent angiography within 72 hours of presentation, followed 
by triage to PCI or CABG. Serum creatinine (SCr) was measured throughout hospital stay, 
and ARF was deﬁned as SCr increase of q25% or q0.5mg/dl from baseline
Results: Data on revascularization and SCr were available on 8087 patients. Following 
angiography, 6731 patients (83.2%) were managed by PCI, and 1356 (16.8%) with CABG. 
Baseline characteristics and rates of ARF are presented in Table. Independent predictors 
of ARF were CABG (RR 3.92, p<0.0001), female gender (RR 1.43 p<0.0001), diabetes 
(RR 1.41, p<0.0001), ST-segment deviation (RR 1.26, p=0.04), (RR 1.02, p<0.0001) and 
baseline creatinine clearance (RR 1.01, p<0.0001). 
PCI
(n=6731)
CABG
(n=1356) p-value
Mean Age, years 63 65 <0.0001
Diabetes 27.6% 34.2% <0.0001
Baseline Creatinine clearance, ml/min 88.1 84.1% <0.0001
Baseline renal insufﬁciency 18.4% 18.8% 0.726
ST deviation 35.8% 49.5% <0.0001
TIMI Risk score q3 47.5% 50.4% 0.049
# lesions per pt 4.4 ± 2.6 6.1 ± 2.8 <0.0001
LVEF, % 65.2 63.6 <0.003
In-hospital acute renal failure 11.6% 32.2% <0.0001
Conclusions: In patients with moderate and high risk ACS requiring revascularization, the 
patients that were referred to CABG had higher rates of diabetes and more extensive CAD 
than patients treated by PCI. As compared with PCI, surgical revascularization resulted in 
signiﬁcantly higher rates of in-hospital ARF. When considering the mode of revascularization in 
patients with CAD, the signiﬁcantly increased risk of ARF with CABG should be considered.
2:12 p.m.
2904-6 Higher Adverse Events After PCI in Patients With 
Pulmonary Disease: Insights From the NHLBI Dynamic 
Registry
Jonathan R. Enriquez, Shailja V. Parikh, Faith Selzer, Alice K. Jacobs, Elizabeth M. 
Holper, Rush University Medical Center, Chicago, IL, University of Texas Southwestern 
Medical Center, Dallas, TX
Background: Previous studies have demonstrated that patients with pulmonary disease 
are at higher risk for mortality after PCI, but the cause of this association remains poorly 
understood.
Methods: Utilizing Waves 1-5 (1999-2006) of the NHLBI Dynamic Registry, patients with 
pulmonary disease (n= 860) and without (n= 10,048) were compared. Baseline demographics, 
angiographic characteristics, in-hospital and 1-year adverse events were compared.
Results: Patients with pulmonary disease were older (mean age 66.8 vs 63.2, p<0.001), 
more likely to be female, and more likely to present with diabetes, prior MI, peripheral 
arterial disease, renal disease, and smoking. Patients with pulmonary disease also had 
a lower mean ejection fraction (49.1% vs 53.0%, p<0.001) and a greater mean number of 
signiﬁcant lesions (3.2 vs 3.0, p=0.006). Rates of in-hospital death (2.2% vs 1.1%, p=0.003) 
and major entry site complications (6.7% vs 4.4%, p=0.001) were also higher in pulmonary 
patients. At discharge, pulmonary patients were signiﬁcantly less likely to be prescribed 
aspirin (92.4% vs 95.3%, p<0.001), B-blockers (55.7% vs 76.2%, p<0.001), and statins (60. 
0% vs 66.8%, p<0.001). Adjusted one year adverse outcomes are shown in Table 1.
Conclusions: Pulmonary disease is associated with higher mortality and need for 
repeat revascularization 1-year after PCI. Possible causes of these ﬁndings include 
greater unmeasured comorbidities and lower rates of guideline class I recommended 
medications post-procedure.
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PCI - Diabetes
Sunday, March 29, 2009, 3:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
2505-649 Clinical and Angiographic Predictors of Death or 
Myocardial Infarction in Diabetics with Acute Coronary 
Syndromes Undergoing Percutaneous Coronary 
Intervention: An ACUITY Subanalysis
Kenji Goto, Alexandra J. Lansky, Ecatarina Cristea, Martin Fahy, Frederick Feit, Magnus E. 
Ohman, Harvey D. White, Karen P. Alexander, Michel E. Bertrand, Walter Desmet, Martial 
Hamon, Steven V. Manoukian, Ramin Ebrahimi, Carles V. Pollack, Michael J. Attubato, 
Roxana Mehran, Gregg W. Stone, Cardiovascular Research Foundation, New York, NY
Backgrounds Despite pharmacologic and technical advances, diabetic pts with acute 
coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) have 
a poor prognosis. We sought to determine the rates and predictors of cardiac ischemic 
events in diabetics with ACS undergoing contemporary PCI.
Methods The ACUITY trial randomized 13,819 pts with moderate- and high-risk ACS 
to unfractionated or low molecular weight heparin + glycoprotein IIb/IIIa inhibitors (GPI), 
bivalirudin + GPI, or bivalirudin alone; 7000 pts were included in a formal angiographic 
substudy. Clinical and angiographic predictors of death or myocardial infarction (MI) at 
30 days and 1 year were identiﬁed by univariate and multivariable analysis using logistic 
regression analysis.
Results Following angiography, 7,789 (56.4%) pts were treated with PCI, including 2,137 
patients (27.4%) with diabetes. Pts with vs. without diabetes had more hypertension 
(83.5% vs. 58.7%), hyperlipidemia (70.2% vs. 50.8%), renal insufﬁciency (20.7% vs. 
17.6%), and 3-vessel disease (51.8% vs. 44.5%) (all p<0.01). The rates of death/MI 
were similar at 30 days in diabetics compared to non-diabetics (7.3% vs. 6.8%, p=0.56). 
However, death/MI was signiﬁcantly more frequent at 1 year in diabetics (14.3% vs. 
10.7%, p<0.0001). Among diabetics, independent predictors of death/MI at 30 days 
included renal insufﬁciency (OR 1.84 [1.06, 3.19], p=0.03), elevated biomarkers (OR 
1.71 [1.02, 2.86], p=0.04) and the number of diseased vessels (OR 1.18 [1.08, 1.29], 
p=0.0003). Death/MI at 1-year was independently predicted by insulin treatment (OR 1.66 
[1.10, 2.51], p=0.02) and renal insufﬁciency (OR 1.76 [1.11, 2.79], p=0.02).
Conclusions: Among diabetics with ACS undergoing PCI with contemporary techniques 
and pharmacologic regimens, the rates of death or MI are not increased at 30 days 
compared to non-diabetics, but are signiﬁcantly worse at 1 year. While the extent of CAD 
and clinical syndrome acuity contributes to adverse 30 day outcomes in diabetics, at 1 
year renal insufﬁciency and the requirement for insulin are the most powerful factors 
contributing to death and MI in diabetics with ACS undergoing PCI.
3:30 p.m.
2505-650 The Effects of Pioglitazone on Neointima Volume and 
Atherosclerosis Progression at Eight Months after 
Zotarolimus-Eluting Stent Implantation in Diabetic 
Patients
Soon Jun Hong, Wan Joo Shim, Seong Mi Park, Jae Suk Park, Yong Hyun Kim, Chul 
Min Ahn, Do-Sun Lim, Korea University Anam Hospital, Seoul, South Korea
Background: Diabetic patients showed increased late lumen loss and rates of 
restenosis compared with nondiabetic patients even after drug-eluting stent implantation. 
Pioglitazone has been known for anti-inﬂammatory and antiproliferative effects in patients 
with coronary artery disease. We compared the effects of pioglitazone and placebo on 
neointima volume and atherosclerosis progression with intravascular ultrasonography 
(IVUS) after zotarolimus-eluting stent (ZES) implantation in diabetic patients.
Methods: This was a prospective, randomized, single-blinded, 8 months follow-up 
study including diabetic patients with signiﬁcant coronary artery stenosis assigned to 
the Pioglitazone Group (n=44) and the Placebo Group (n=43). Neointima volume and 
atherosclerosis progression beginning 5 mm distal to and extending 5 mm proximal to 
the stented segment were analyzed by repeat IVUS examination. Inﬂammatory markers 
such as IL-6, IL-18, TNF-  and high sensitive C-reactive protein (hsCRP) were measured. 
Major adverse cardiovascular events such as death, myocardial infarction, and target 
vessel failure were evaluated.
Results: Total plaque volume 5 mm proximal (7.7 ± 4.2 vs. 8.3 ± 4.8 mm3 per 1-mm 
vessel segment, p<0.05) and distal to the stent (4.8 ± 3.2 vs. 5.2 ± 2.9 mm3 per 1-mm 
vessel segment, p<0.05) were signiﬁcantly lower in the Pioglitazone Group compared 
with the Placebo Group at 8 months. Neointima volume was also signiﬁcantly lower in 
the Pioglitazone Group (1.5 ± 1.0 vs. 2.0 ± 1.1 mm3 per 1-mm stented segment, p<0.05) 
at 8 months. Inﬂammatory markers such as IL-6 (0.76 ± 0.70 vs. 1.32 ± 1.21 pg/ml, 
p<0.05), IL-18 (153.9 ± 99.1 vs. 172.4 ± 107.4 pg/ml, p<0.05), TNF-  (2.02 ± 1.66 vs. 
2.73 ± 1.93 pg/ml, p<0.05) were signiﬁcantly lower in the Pioglitazone Group at 8 months; 
however, no signiﬁcant differences were found for hsCRP level between the 2 groups. 
Major adverse cardiac events were similar between the 2 groups.
Conclusions:Adding pioglitazone was associated with signiﬁcant decrease in the total 
neointima volume and total plaque volume 5mm proximal and distal to the stent after ZES 
implantation in diabetic patients with signiﬁcant coronary narrowings.
compared to completely revascularized patients.
2:48 p.m.
2904-9 Will the Net Clinical Beneﬁt of the Prophylactic Use 
of the Impella LP 2.5 Device Demonstrate Superiority 
Over the Intra-Aortic Balloon Pump for High-Risk 
Percutaneous Coronary Intervention?
Asmir Syed, Amit Kakkar, Yanlin Li, Sara Collins, Itsik Ben-Dor, Gabriel Manuela, Gilles 
Lemesle, Mickey Scheinowitz, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
Joseph Lindsay, Kenneth Kent, Lowell Satler, William O. Suddath, Augusto Pichard, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: For patients (pts) undergoing non-emergent, high-risk percutaneous 
coronary intervention (HRPCI) the current practice is to use prophylactic intra-aortic 
balloon pump (IABP) (8 Fr) for hemodynamic support. The aim of this analysis was to 
detect the event rates in this population supported with IABP and to evaluate in what 
conditions the prophylactic use of the Impella LP 2.5 device (12 Fr) would demonstrate 
superiority over IABP in the high-risk population.
Methods: Among our general PCI population 73 pts were identiﬁed as receiving 
prophylactic IABP support for HRPCI and who met the inclusion/ exclusion criteria of 
the PROTECT II study, which is evaluating the prophylactic use of the Impella LP 2.5 
device in this population. HRPCI was deﬁned as PCI to the last patent coronary conduit 
or an unprotected left main or EF < 35% with 3-vessel disease. Pts with STEMI, cardiac 
arrest within 24 hours, or cardiogenic shock were excluded. The primary endpoint was 
the composite of death, myocardial infarction, stroke, TIA, revascularization, renal failure, 
severe hypotension, CPR, ventricular arrythmias, and angiographic failure at 30 days.
Results: Baseline characteristics of the cohort included a mean age of 68 years, 78% 
male, 84% with hypertension, 24% acute coronary syndrome, 50% diabetes, and 35% 
chronic renal insufﬁciency. The in hospital and 30 day event rates were low for this 
population (5.7% and 21.4%, respectively) with a low major vascular complication rate 
of 3.0%. With a 30 day event rate of 21.4% and a treatment effect size of 33.3% aimed in 
the PROTECT II trial a total of 924 patients would be required to evaluate superiority with 
80% power. Additionally, with this event rate the PROTECT II, with a total sample size of 
654 patients, would have 60% power to detect a treatment effect size of 33.3%.
Conclusion: Prophylactic use of IABP for HRPCI is associated with a low event rate in 
hospital and at 30 days. The current PROTECT II study will be underpowered to detect 
superiority of the Impella LP 2.5 device over IABP in this high-risk population. These data 
question the net clinical beneﬁt of the relatively high-proﬁle Impella LP 2.5 device over 
IABP for this high-risk population.
3:00 p.m.
2904-10 “Cool It”: Therapeutic Hypothermia for Recovery of 
Neurologic Function in High Risk Patients Following 
Cardiac Arrest
Leah Swanson, Kalie Edelstein, William Parham, Jon Hokanson, Richard Shronts, 
Barbara T. Unger, Wendy George, Ivan J. Chavez, Timothy D. Henry, Michael R. Mooney, 
Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: Survival to discharge following out-of-hospital cardiac arrest (OOHCA) 
is uncommon. Among survivors, neurologic deﬁcits from anoxic encephalopathy are 
common and disabling. The Hypothermia after Cardiac Arrest (HACA) Study Group 
reported that pts randomized to therapeutic hypothermia (TH) had improved survival 
(59% vs. 45%; p=0.02) and neurologic outcome (55% vs. 39%; p=0.009).
Methods: OOHCA pts due to ventricular ﬁbrillation, ventricular tachycardia, asystole, and 
pulseless electrical activity (PEA) were cooled to 33ºC for 24 hrs. Pts in cardiogenic shock 
were included. Cerebral function after TH was measured by the ﬁve point Pittsburgh 
Cerebral Performance Category (CPC) scale. CPC 1 and 2 are positive neurologic 
outcomes, 3 and 4 are poor outcomes, and 5 is death.
Results: From 2/06 to 5/08, 85 pts were treated with TH, and 45 (53%) of pts survived. 
Applying the HACA Study Group exclusion criteria eliminated 43 pts with cardiogenic shock 
or PEA/asystole rhythms. HACA criteria pts had a higher survival rate than non-HACA 
criteria pts (71% vs. 35%; p=0.001). Comparing HACA Study Group survivors with all Cool 
It survivors, 24% vs. 7% were discharged with poor neurologic outcomes, CPC 3 or 4.
Conclusions: In comparison to previous studies, the Cool It protocol extended TH to 
higher risk pts and discharged pts with higher neurologic outcomes. Cool It enhanced 
survival in HACA criteria pts with rapid treatment and preserved neurologic and functional 
status in a broader pt population. 
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NSTE-ACS (in ACUITY), and STEMI (in HORIZONS). However, pts with diabetes mellitus 
(DM) undergoing PCI are at increased risk of ischemic events. A pooled analysis of these 
3 pivotal trials was performed to provide a more accurate estimate of the treatment effects 
of Biv vs Hep+GPI across a broad spectrum of pts with DM undergoing PCI.
Methods: The REPLACE-2, ACUITY, and HORIZONS trials randomized pts to Biv or 
Hep+GPI. We assessed the rates of 30-day composite ischemia (death, MI, or urgent 
revascularization), non-CABG TIMI bleeding (major/minor), and net adverse clinical 
outcomes (NACE, composite ischemia or protocol-deﬁned bleeding) in pts with DM 
undergoing PCI, by randomized treatment.
Results: Of 14,280 randomized pts undergoing PCI, 3540 (24.8%) were diabetic. In 
pts with DM undergoing PCI, Biv vs Hep+GPI resulted in a signiﬁcant reduction in 30-
day NACE due to signiﬁcantly reduced major bleeding with no signiﬁcant difference in 
composite ischemia (Table).
Conclusions: These results indicate that Biv is a safe and effective antithrombotic strategy 
for pts with DM undergoing PCI across a broad spectrum of clinical presentations. 
30-day adverse events Hep + GPI N=1750 BivN=1790 p-value
NACE 12.6% 10.2% 0.03
Composite Ischemia 8.0% 6.8% 0.20
- Death 1.5% 0.9% 0.21
- MI 5.4% 4.9% 0.49
- Revascularization 2.5% 2.7% 0.66
TIMI Major or Minor Bleeding (Non-CABG) 5.9% 3.5% 0.001
3:30 p.m.
2505-654 Three-Year Clinical Outcome of Paclitaxel- and 
Sirolimus-Eluting Stents Versus Bare Metal Stents in 
Patients with Diabetes Mellitus. From Western Denmark 
Heart Registry
Lisette Okkels Jensen, Anne Kaltoft, Per Thayssen, Michael Maeng, Hans Henrik 
Tilsted, Jens Flensted Lassen, Knud Noerregaard Hansen, Klaus Rasmussen, Klaus 
Rasmussen, Morten Madsen, Soeren Paaske Johnsen, Henrik Toft Soerensen, Leif 
Thuesen, Odense University Hospital, Odense, Denmark
Background: Patients with diabetes mellitus have an increased risk of restenosis after 
coronary stent implantation. Drug-eluting stents have reduced this risk of restenosis but 
the long-term outcome after paclitaxel-(PES) or sirolimus-eluting (SES) stents compared 
to bare metal stents (BMS) is unknown. Therefore, we examined stent thrombosis, 
myocardial infarction (MI), mortality and target lesion revascularisation (TLR) in diabetic 
patients treated with PES, SES or BMS implantation in Western Denmark.
Methods: From January 2002 to June 2005 all consecutive diabetic patients who had SES, 
PES or BMS implantation were identiﬁed in the Western Denmark Heart Registry. All patients 
were treated with dual antiplatelet therapy for 12 months and followed for 36 months.
Results: A total of 1,580 diabetic patients were treated: 228 with PES, 370 with SES 
and 982 with BMS. Very late deﬁnite stent thrombosis (between 12 and 36 months after 
implantation) did not differ signiﬁcantly between DES (0.2%) or BMS (0.1%) treated 
patients [adjusted RR=0.53 (95% CI: 0.0.04-6.78)]. MI [adjusted RR 1.11(95%CI: 0.76-
1.62)] and mortality [adjusted RR=0.91 (95% CI: 0.69-1.19)] did likewise not differ 
signiﬁcantly between DES and BMS treated diabetic patients. The risk proﬁles were 
similar according to DES type. TLR was reduced signiﬁcantly in DES treated patients 
[adjusted RR=0.67 (95% CI: 0.50-0.91)]. Compared to BMS treated diabetic patients 
SES reduced TLR signiﬁcantly [adjusted RR=0.62 (95% CI: 0.43-0.89)], whereas this 
attenuated after 36 months in PES treated diabetic patients [adjusted RR=0.77 (95% 
CI: 0.52-1.14)].
Conclusion: In diabetic patients a sustained effectiveness and safety were found after 
SES treatment. TLR was not reduced in PES treated patients after 3 years. The safety 
proﬁles did not differ between DES type and BMS.
3:30 p.m.
2505-655 Lack of Prognostic Value of HbA1C in Diabetic Patients 
Undergoing Percutaneous Coronary Intervention With 
Drug-eluting Stent Implantation
Gilles Lemesle, Laurent Bonello, Axel De Labriolle, Gabriel Maluenda, Sara D. Collins, 
Asmir I. Syed, Yanlin Li, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William 
O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: The optimal HbA1C target among diabetic patients (pts) is a subject of 
ongoing controversy that may be especially pertinent among diabetic pts with coronary 
artery disease (CAD). This study aimed to determine the prognostic value of HbA1C 
levels in diabetic pts undergoing percutaneous coronary intervention (PCI).
Methods: From 2003 to 2007, 952 consecutive diabetic pts underwent PCI with drug-
eluting stent implantation. We compared pts with a normal HbA1C (a7%, n=429) to pts with 
an elevated HbA1C (>7%, n=523). The 1-year rate of major adverse cardiovascular events 
(MACE) including death, myocardial infarction (MI), and target vessel revascularization 
(TVR) was indexed.
Results: Baseline characteristics were similar between both groups except for the body 
mass index that was higher in the High-HbA1C group: 32.2 vs 31.2, p=0.03. Pts in the 
High-HbA1C were more likely insulin dependents: 45.5% vs 26.3%, p<0.001. The rate of 
cardiovascular events was similar between both groups. By multivariate analysis age, renal 
failure, clinical presentation as MI and history of congestive heart failure were independently 
associated with MACE. By contrast, HbA1C was not associated with patient outcome.
Conclusion: This study suggests that HbA1C is not a predictor of cardiac events in 
3:30 p.m.
2505-651 Impact of Longitudinal Geographic Miss in the Clinical 
Outcomes of Diabetes Population Treated With Drug 
Eluting Stent: Sub-analysis of the STLLR Trial.
SATOKO TAHARA, Hiram Grando Bezerra, Hiroyuki Kyono, Noah Rosenthal, Nobuaki 
Suzuki, Marco Aurelio Costa, University Hospitals Harrington-McLaughlin Heart & 
Vascular Institute, Cleveland, OH
Background: Longitudinal geographic miss (LGM) frequently occurs during stent 
implantation and is associated with an increased risk of target lesion revascularization 
(TLR) at 1 year. Diabetes mellitus (DM) is recognized as a risk factor for coronary 
restenosis, even when treated with drug eluting stent
(DES). However it is unknown how technical aspects like longitudinal geographic miss 
inﬂuence the outcomes of DM population.
Methods: The STLLR trial (Stent deployment Techniques on cLinicaL outcomes of 
patients treated with the cypheR stent) was the ﬁrst prospective, multicenter (41 US 
hospitals), large (n=1557) study to evaluate clinical outcomes associated with sirolimus-
eluting stent (SES) deployment techniques in real world practice. Quantitative coronary 
analysis and assessment of LGM, deﬁned as balloon injured or diseased segment 
uncovered by SES, was performed and adjudicated by an independent blinded core lab. 
We analyzed the impact of LGM in a sub-population of DM.
Results: A total of 1336 lesions were assessed and classiﬁed as DM (28.8%) group or 
non-DM (71.2%) group. TLR was only slightly higher in the DM population compared to 
non-DM (4.7% vs. 2.8%, p=NS). However in the LGM population (n=632, 47.3%), TLR 
was signiﬁcantly higher in DM (8.0% vs. 3.8%, p=0.03). When LGM was represented by 
balloon injury, it had a higher impact on TLR in the DM population (8.5% vs. non-DM 1.9%, 
p=0.012). On the other hand when LGM was the result of uncovered diseased segments, it 
did not show signiﬁcant difference between the DM and non-DM (7.3% vs. 7.6%, p=NS).
Conclusion: The higher incidence of TLR in the DM population is mostly explained by 
LGM, especially balloon injury during stent implantation.
3:30 p.m.
2505-652 Similar Prognostic Signiﬁcance of Impaired Glucose 
Tolerance and Diabetes Mellitus in Patients with Acute 
Myocardial Infarction Treated Invasively
Zbigniew Kalarus, Jacek Kowalczyk, Radoslaw Lenarczyk, Teresa Zielinska, Agnieszka 
Sedkowska, Patrycja Pruszkowska-Skrzep, Andrzej Swiatkowski, Beata Sredniawa, 
Joanna Stabryla-Deska, Oskar Kowalski, Lech Polonski, Krzysztof Strojek, 1st and 3rd 
Dept. of Cardiology, Medical University of Silesia, Silesian Center for Heart Diseases, 
Zabrze, Poland, Department of Internal Diseases, Diabetology and Nephrology, Medical 
University of Silesia, Zabrze, Poland
Background: The prognostic role of impaired glucose tolerance (IGT) is still little known. 
The aim of the study was to evaluate the impact of diabetes mellitus (DM) and IGT on long-
term outcome in patients (pts) with acute myocardial infarction (AMI) treated invasively.
Methods: Single-centre study encompassed 2733 survivors of acute AMI phase. In all 
pts without history of DM standard oral glucose tolerance test was performed before 
hospital discharge. Our study population was divided into 3 major groups: 560 pts with 
IGT, 809 pts with DM diagnosed prior or during index hospitalization and 1158 pts without 
IGT and DM, deﬁned as controls. Long-term outcomes were compared with log-rank test. 
Independent predictors of death were selected with multivariate Cox-regression model.
Results: Remote mortality was signiﬁcantly higher in DM and IGT pts compared to 
controls, but not in DM vs. IGT group (Table 1). DM and IGT groups had more unfavorable 
baseline characteristics in comparison with controls. Neither IGT nor DM was independent 
risk factor for death. The independent death predictors in the entire population were: age 
>=70, cardiogenic shock, chronic kidney disease, incomplete revascularization, ejection 
fraction <35%, contrast-induced nephropathy.
Conclusions: Prognosis in AMI pts with IGT, who were treated invasively is similar to 
those with DM. Both DM and IGT are associated with signiﬁcantly reduced long-term 
survival compared to controls. Neither IGT nor DM was independent risk factor for death.
Table 1.
Mortality DM group(n=809)
IGT group
(n=560)
Control group
(n=1158)
P value
(DM and IGT vs. controls)
30-day mortality 1.5% 0.9% 1.0% NS
1-year mortality 7.3% 6.6% 3.3% <0.05
Total mortality 11.6% 9.3% 6.2% <0.05
all P = NS for DM vs. IGT
3:30 p.m.
2505-653 Outcomes of patients with diabetes mellitus 
undergoing PCI treated with bivalirudin versus heparin 
plus a glycoprotein IIb/IIIa inhibitor: Pooled analysis 
from the REPLACE-2, ACUITY and HORIZONS-AMI 
Trials
Frederick Feit, Hitinder S. Gurm, Bernhard Witzenbichler, Helen Parise, A. Michael 
Lincoff, Steven V. Manoukian, Harvey D. White, Stuart J. Pocock, Roxana Mehran, Gregg 
W. Stone, New York University School of Medicine, New York, NY
Background: Bivalirudin monotherapy (Biv) was associated with similar rates of ischemic 
events and signiﬁcantly reduced bleeding compared to Heparin+ GP IIb/IIa inhibitors 
(GPI) in patients (pts) undergoing PCI for stable or unstable angina (in REPLACE-2), 
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WMSI(t) [= WMSI(pre) - WMSI(post)].
Results: 71 patients were recruited. 42 underwent PCI and 29 CABG. 39 PCI patients 
demonstrated ischaemia, 31 had a signiﬁcant improvement in reversibility (79%), 5 
showed no improvement in ischaemia, 3 demonstrated worsening of ischaemia. 23 CABG 
patients demonstrated ischaemia, 20 had a signiﬁcant improvement in reversibility (87%), 
2 showed no improvement in ischaemia, 1 demonstrated worsening of ischaemia.
The mean WMSI(pre) in the PCI group was 1.63 and mean WMSI(post) was 1.32. In the 
CABG group the mean WMSI(pre) was 1.69 and mean WMSI(post) was 1.46. The PCI 
WMSI(t) was 0.31 and CABG WMSI(t) was 0.23, (p=NS).
Conclusion: The optimal form of revascularisation in diabetic patients with multivessel 
disease has been controversial for many years. This subset analysis of the CARDia Trial 
in patients undergoing stress echo at baseline and at 6 months post revascularisation 
shows that both PCI and CABG achieve similar improvement in myocardial function.
3:30 p.m.
2505-658 A Three-year Clinical Outcome after Percutaneous 
Coronary Intervention using Sirolimus-eluting Stent 
versus Off-pump Coronary Artery Bypass Grafting for 
Diabetic Patients with Multivessel Disease
Yu Kataoka, Ken-ichirou Yamagata, Nobuaki Kokubu, Yoichirou Kasahara, Mitsuru Abe, 
Hiroyuki Nakajima, Junjiro Kobayashi, Yoritaka Otsuka, National Cardiovascular Center, 
Osaka, Japan
Background: BARI study showed that diabetic patients with multivessel disease (MVD) 
had the survival beneﬁt by coronary bypass surgery compared with balloon angioplasty. 
Recently, sirolimus-eluting stent (SES) and off-pump coronary artery bypass grafting 
(OPCAB) have improved the outcomes of patients with coronary artery disease. However, 
there are few data to compare the long-term efﬁcacy of SES and OPCAB for diabetic 
patients with MVD.
Methods: Two-hundred and eight diabetic patients with MVD were examined (SES: n=92, 
OPCAB: n=116). The occurrence of major adverse cardiac and cerebral events (MACCE: 
all-cause death, heart failure, non-fatal myocardial infarction, cerebral events, repeat 
revascularization) were compared between 2 groups.
Results: During the follow-up period (mean periods: 36 ± 8 months), the rate of 
revascularization was signiﬁcantly higher in the SES group than the OPCAB group (ﬁgure-
right panel, 20% vs 6%, p=0.005). On the other hand, signiﬁcant high occurrence of in-
hospital cerebral event could be seen in the OPCAB group. In the SES group, there were 
no stent thrombosis. Finally, there were no signiﬁcant differences of MACCE between 2 
groups (ﬁgure-left panel, 21% vs 24%, p=0.290).
Conclusion: At a three-year clinical follow-up, although some signiﬁcant differences exist, 
the prevalence of MACCE was comparable between the SES group and the OPCAB 
group for diabetic patients with MVD, and SES seems to be effective therapeutic option 
for this particular category. 
3:30 p.m.
2505-659 Diabetes Mellitus Is Associated With Inadequate 
Platelet Inhibition After Clopidogrel Measured by a 
Point-of-Care Assay and With Poorer Peri-Procedural 
Outcome in Patients Undergoing Percutaneous 
Coronary Intervention
Fabio Mangiacapra, Giuseppe Patti, Laura Gatto, Annunziata Nusca, Vincenzo 
Vizzi, Elisabetta Ricottini, Andrea D’Ambrosio, Germano Di Sciascio, Department of 
Cardiovascular Sciences, Campus Bio-Medico University of Rome, Rome, Italy
Background: Diabetes mellitus (DM) is associated with high platelet reactivity and 
impaired response to clopidogrel. A threshold of platelet reactivity q240 P2Y12 reaction 
units (PRU) after clopidogrel loading, as measured by the VerifyNowTM assay, is 
associated with a signiﬁcantly higher risk of peri-procedural myocardial infarction (MI) 
in patients undergoing percutaneous coronary intervention (PCI). In this study we 
prospectively evaluated the inﬂuence of diabetes mellitus on residual platelet reactivity 
and peri-procedural outcome after PCI.
Methods: A total of 254 patients (96 diabetics, 38%) receiving clopidogrel and undergoing 
PCI were prospectively enrolled. Platelet reactivity was measured before intervention by 
the VerifyNowTM P2Y12 assay. Creatine kinase-MB and Troponin-I levels were measured 
at baseline and at 8 and 24 hours after the procedure.
Results: Diabetic patients showed higher platelet reactivity by PRU values (210±82 
vs. 190±70 in patients without DM; P=0.040). A PRU value q240 was more frequently 
observed in patients with DM than in non-diabetic patients (34% vs. 21%; P=0.017). 
Patients with pre-procedural PRU levels in the fourth quartile had a higher prevalence of 
DM (49% vs. 34% in quartiles 1 to 3; P= 0.031). Among patients with DM, a PRU value 
q240 was associated with higher incidence of peri-procedural MI (15% vs 2% in those 
diabetic pts with advanced CAD. These results could explain at least in part the recent 
ﬁndings of randomized trials suggesting the absence of beneﬁt in terms of macrovascular 
complications of a strict glycemia control.
3:30 p.m.
2505-656 Comparison of Subsequent Vascular Response in 
Diabetic Patients Following Coronary Stenting Between 
Sirolimus- and Paclitaxel-Eluting Stents: Optical 
Coherence Tomography Analysis
Kenya Nasu, Etsuo Tsuchikane, Osamu Katoh, Masashi Kimura, Yoshihisa Kinoshita, 
Mariko Ehara, Mitsuyasu Terashima, Takahiko Suzuki, Toyohashi Heart Center, 
Toyohashi, Japan
Background: Diabetes mellitus is one of the major predictors for target lesion 
revascularization even in drug-eluting stent era. The aim of this study is to evaluate the 
differences of chronic vascular response in patients with diabetes mellitus (DM) following 
coronary stenting between sirolimus-eluting stent (SES) and paclitaxel-eluting stent 
(PES) using optical coherence tomography (OCT).
Methods: We examined non-restenotic 60 SESs and 60 PESs were imaged with 
motorized OCT pull-back system (1 mm/s) at 9-month follow-up and analyzed at interval 
of 1 mm. Neointimal coverage of stent struts and the incidence of stent malapposition 
were evaluated.
Results: A total of 20526 struts were analyzed (10336 SES struts and 10190 PES struts). 
Exposed struts and malapposed struts of SES were observed more frequently in non-
diabetic patients than those in diabetic patients. However, in PES group, both incidences 
of exposed struts and malapposed struts were not different between diabetic and non-
diabetic patients. SES in diabetic patients also had less averaged neointimal thickness 
compared with SES in non-diabetic patients. However, in PES group, averaged neointimal 
thickness was similar between diabetic and non-diabetic patients (See table).
Conclusions: SES could not prevent neointimal growth in DM group. However, 
subsequent vascular response after PES implantation in DM group was similar to that 
in non DM group.
SES non-
DM SES DM p value
PES non-
DM PES DM p value
No. of patient 29 27 28 25
No. of stent 35 25 36 24
No. of analyzed strut 5650 4686 5503 4687
Exposed strut (%) 17.3 2.1 <0.0001 2.3 2.2 0.67
Malapposed strut (%) 6.3 1.6 0.002 0.7 0.3 0.51
Neointimal thickness 
(μm) 81±83 124±96 0.001 162±123 185±131 0.17
3:30 p.m.
2505-657 Myocardial Function Improves Equally in Diabetes 
following both Multivessel PCI and CABG - Results 
from a CARDia Trial Substudy
Akhil Kapur, Ayesha C. Qureshi, Malcolm Finlay, Jeremy Butts, Iqbal S. Malik, Marcus 
Flather, Jamil Mayet, Kevin J. Beatt, Roger J. Hall, Petros Nihoyannopoulos, Barts and 
the London NHS Trust, London, United Kingdom, Imperial College Healthcare NHS 
Trust, London, United Kingdom
Background: The optimal form of revascularisation in diabetic patients with multivessel 
coronary disease has been controversial since the subset analysis of BARI (Bypass 
Angioplasty Revascularisation Investigation) in 1995. The CARDia (Coronary Artery 
Revascularisation in Diabetes) Trial presented at the ESC in 2008 and is the ﬁrst study in 
patients with diabetes comparing Coronary Artery Bypass Grafting (CABG) and optimal 
Percutaneous Coronary Intervention (PCI) with abciximab and drug eluting stents.
Aim: A sub-study was undertaken in 3 centres recruiting to CARDia. It assessed 
comparative improvement in reversible ischaemia following revascularisation.
Methods: 71 patients underwent stress echo at baseline and 6 months. A wall motion 
score index [WMSI] was assigned at baseline [WMSI(pre)] and six months[WMSI(post)]. 
These were calculated as the sum of individual segment scores (1-4, where 1 = normal 
and 4 = akinetic) divided by the number of segments. Individual patients were deﬁned as: 
improvement in reversible ischaemia, no change from normal, no change from positive 
ischaemia or worsening of reversible ischaemia. An overall score deﬁned this difference: 
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2505-662 Late Outcomes of Patients with Diabetes Mellitus 
and Acute Myocardial Infarction Undergoing Primary 
Angioplasty: One Year Results from The HORIZONS 
AMI trial
Bernhard Witzenbichler, Roxana Mehran, Giulio Guagliumi, Ran Kornowski, Martin 
Desaga, Janusz Kochman, Dennis W. Nilsen, Ariel Finkelstein, Morris Mosseri, Helen 
Parise, Eugenia Nikolsky, Alexandra J. Lansky, Gregg W. Stone, Columbia University 
Medical Center and the Cardiovascular Research Foundation, New York, NY
Background: In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared to 
unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced 
rates of major bleeding, comparable composite major adverse cardiovascular events 
(MACE) (although with decreased cardiac mortality), and enhanced freedom from net 
adverse clinical events (NACE) in pts with AMI undergoing primary PCI. Whether the 
beneﬁcial effects of Biv are independent of diabetic status has not been reported.
Methods and Results: A total of 3602 pts at 123 centers in 11 countries with AMI 
undergoing primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802) and 
followed up to one year. Outcomes were analyzed according to the presence of known 
diabetes mellitus (DM) at the time of admission. At one year in the entire study population, 
Biv compared to UFH+GPI resulted in a 39% reduction in major bleeding (5.8% vs. 9.2%, 
P<0.0001), similar MACE (11.9% vs. 11.9%, P=1.0), and a 16% reduction in NACE 
(15.7% vs. 18.3%, P=0.03). Compared to pts without DM, those with DM (n=593; 16.4%) 
had greater rates of major bleeding (9.8% vs. 7.1%, P=0.027), MACE (15.4% vs. 11.2%, 
P=0.003), mortality (6.3% vs. 3.7%, P=0.003), and NACE (21.3% vs. 16.1%, P=0.002). 
Impact of biv was independent of DM (Table).
Conclusions: In pts with DM and AMI undergoing primary PCI, Biv monotherapy 
signiﬁcantly reduces major bleeding and net adverse clinical events and cardiac 
mortality. 
Diabetes (n=593)
Biv mono UFH+GPI RR [95%CI]
Major bleeding 8.7% 10.7% 0.81 [0.48, 1.36]
MACE* 14.5% 16.2% 0.87 [0.57, 1.32]
NACE** 20.6% 22.0% 0.91 [0.64, 1.31]
Cardiac Death 2.5% 7.1% 0.35 [0.15,0.82]
3:30 p.m.
2505-663 The Efﬁcacy of Sirolimus-eluting Stent in Patients 
with Impaired Glucose Tolerance and Coronary Artery 
Disease
Yu Kataoka, Nobuaki Kokubu, Yoichirou Kasahara, Mitsuru Abe, Yoritaka Otsuka, 
National Cardiovascular Center, Osaka, Japan
Background: Patients with impaired glucose tolerance (IGT) have small vessel, diffuse 
coronary narrowing similar to diabetic patients, and higher cardiovascular events 
compared with patients with normal glucose tolerance. Although sirolimus-eluting stent 
(SES) has improved the outcome of PCI, there are few data about the efﬁcacy of SES for 
this category. In the present study, we examined the clinical efﬁcacy of SES in patients 
with IGT and compared with IGT patients treated by BMS.
Methods: A total of 268 IGT patients with CAD were examined (BMS group n=133, SES 
group n=135). IGT was deﬁned by the oral glucose tolerance test. The occurrence of 
MACE (death, non-fatal myocardial infarction, heart failure and repeat revascularization) 
was compared between 2 groups. In addition, these two groups were divided on the basis 
of median post-2-hour glucose level of oral glucose tolerance test (168mg/dl).
Results: In SES group, reference diameter was smaller and lesion length was longer 
than BMS group. (reference diameter 2.9mm vs 3.2mm, lesion length 55mm vs 28mm, p 
168mg/dl) had higher MACE than that with lower post-2-hour glucose level (< 168mg/dl). 
However, in SES group, this difference of MACE was disappeared (Figure-B).
Conclusions:In BMS group, patients with IGT, especially patients with post-2-hour 
hyperglycemia, have high cardiovascular events. However, SES has improved these 
worse clinical outcomes regardless of post-2-hour glucose level. 
with PRU <240; P=0.017), while this association was not observed in the non-diabetic 
population (P=0.159).
Conclusions: DM is associated with impaired platelet response to clopidogrel, as 
assessed by a point-of-care assay, and poorer peri-procedural outcome in patients 
undergoing PCI. In patients with DM more aggressive antithrombotic strategies may be 
indicated in order to reduce peri-procedural complications in the setting of PCI.
3:30 p.m.
2505-660 Four years follow-up of DIABETES trial
Pilar Jimenez-Quevedo, Lorenzo Hernando, Joan Antoni Gomez-Hospital, Andres 
Iñiguez, Alberto SanRoman, Rosana Hernandez Antolin, Fernando Alfonso, Camino 
Bañuelos, Javier Escaned, Carlos Macaya, Manel Sabate, Hospital Clínico San Carlos, 
Madrid, Spain, Hospital de Bellvitge, Barcelona, Spain
Background: The DIABETES trial is a prospective, multicenter, randomized, controlled 
trial aimed to demonstrate the efﬁcacy of sirolimus-eluting stent (SES) implantation as 
compared to bare metal stent (BMS) in diabetic patients (pts). The aim of this study was 
to assess the 4 years clinical follow-up of the patients included in this trial.
Methods: From January to November 2003, 160 pts (222 lesions) were included in the 
trial: 80 pts were randomized to SES and 80 pts to BMS. Patients were eligible for the 
study if they were identiﬁed as non-insulin or insulin-dependent diabetics, with signiﬁcant 
coronary stenoses in q1 vessel. There was a sub-randomization according to the type of 
diabetes. The use of abciximab during the procedure was recommended per protocol, 
and dual antiplatelet therapy (aspirin indeﬁnitely and clopidogrel for 1 year) was routinely 
prescribed.
Results: Four-year clinical follow-up was obtained in 95% of the pts included in the trial. 
Between 2 and 4 years very few events have been recorded. After the second year follow-
up there was not any additional target lesion revascularization (TLR) due to very late 
restenosis or any new episodes of myocardial infarction (MI) in the SES group. However, 
one additional TLR and MI was observed in the BMS group. One patient in the SES 
group (sudden death) and one patient in the BMS group (refractory heart failure) suffered 
cardiac death . The TLR rate at 4 year was still signiﬁcantly lower in the SES group (8.1% 
vs. 37.7%, p<0.001), whereas the MI rate and the cardiac death rate were similar between 
groups (4,1% vs 10.4;P=0.21), (4.1% vs 6.5%, p=0.50), respectively. In addition, one 
patient presented a possible stent thrombosis in the SES group and 1 patient presented 
a deﬁnitive stent thrombosis in the BMS group.
Conclusions: After 4 years SES implantation continues to demonstrate the safety and 
efﬁcacy in diabetic patients.
3:30 p.m.
2505-661 Triple Versus Dual Antiplatelet Therapy in Diabetic 
Patients with Acute Myocardial Infarction Undergoing 
Percutaneous Coronary Intervention with Drug-Eluting 
Stent
Kang Yin Chen, Seung-Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn*, Myung Ho Jeong*, Other 
KAMIR Investigators, Korea University Guro Hospital, Seoul, South Korea, ChonNam 
National University Hospital*, Gwangju, South Korea
Background: Whether the triple antiplatelet strategy is superior or similar to dual 
antiplatelet strategy in diabetic patients (pts) with acute myocardial infarction (AMI) 
undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) 
remains unclear.
Methods: A total of 2,074 diabetic pts with AMI underwent PCI with DES received either 
dual (aspirin plus clopidogrel, Dual group, n=1,220) or triple antiplatelet therapy (aspirin 
plus clopidogrel plus cilostazol, Triple group, n=854). Total major adverse cardiac events 
(total MACE) included total death, revascularization, and myocardial re-infarction. The 
bleeding complications and clinical outcomes at 7 days, 1 and 8 months were compared 
between these two groups.
Results: Triple group was associated with signiﬁcantly lower incidence of total death 
and total MACE up to 8 months compared with Dual group. However, the incidence of 
myocardial re-infarction, revascularization and TIMI major bleeding were similar between 
these two groups throughout 8 months clinical follow up period (Table).
Conclusions: The triple antiplatelet therapy appears to be superior to the conventional 
dual antiplatelet therapy in reducing early mortality and MACE without increasing the 
major bleeding in diabetic AMI pts undergoing PCI with DES.
Table: Clinical Outcomes at 7 Days, 1 Month and 6 Months 
Variable, n (%) Dual group(n= 1,220 pts)
Triple group
(n= 854 pts) P value
At 7 days
Total death 69 (5.7) 16 (1.9) <0.001
Re-infarction 3 (0.2) 1 (0.1) 0.648
Revascularization 12 (1.0) 6 (0.7) 0.497
Total MACE 84 (6.9) 23 (2.7) <0.001
TIMI-major bleeding 8 (0.7) 4 (0.5) 0.771
At 1 month
Total death 95 (7.8) 23 (2.7) <0.001
Re-infarction 8 (0.7) 5 (0.6) 0.845
Revascularization 24 (2.0) 9 (1.1) 0.102
Total MACE 127 (10.4) 37 (4.3) <0.001
At 8 months
Total death 106 (8.7) 39 (4.6) <0.001
Re-infarction 14 (1.1) 11 (1.3) 0.773
Revascularization 62 (5.1) 36 (4.2) 0.360
Total MACE 182 (14.9) 86 (10.0) 0.001
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3:30 p.m.
2506-610 Comparison of 4 Years Efﬁcacy and Durability of Drug-
Eluting Stent Implantation in Non-Bifurcation and 
Bifurcation Lesion of Unprotected Left Main Coronary 
Arteries: Multicenter Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Aim: The aim of this study is to compare the 4 years safety and durability of drug-eluting 
stent implantation in non-bifurcation (ostium and/or mid shaft) (Non-Bifur) and bifurcation 
(Bifur) lesion of unprotected left main coronary arteries (LMT). Methods: A prospective 
analysis of 448 patients with LMT stenosis (324 Bifur and 124 Non-Bifur) in ﬁve high 
volume Asian centers after successful stenting in LMT was performed. LMT was treated 
with 5 strategies (single stenting 195 cases, T-stenting 47 cases, crush stenting 38 cases, 
Mini-crush stenting 93 cases, culotte stenting 54 cases, kissing stenting 21 cases). 
Complete clinical follow-up to 4 years is being analyzed for all 448 patients. Results: The 
baseline clinical characteristics between 2 groups were similar. Angiographic and clinical 
success were achieved in all patients without any major complication. At 4 years overall 
cardiac events of Non-Bifur (14.5%) were signiﬁcantly lower than Bifur (28.0%) (p=0.011). 
See ﬁgure for clinical results. Conclusion: The use of drug-eluting stent in patients with 
LMT was safe and feasible with low acute complication and low incidence of restenosis. 
Drug-eluting stent implantation in non-bifurcation lesion of LMT showed lesser incidence 
of cardiac events (death, myocardial infarction, CABG and PCI) compared with those of 
bifurcation lesion at 4 years clinical follow-up. 
3:30 p.m.
2506-611 Five-Year Durability of Sirolimus-Eluting Stent in 
Patients with Unprotected Left Main Coronary Arteries 
Compared with Bare Metal Stents: Multicenter Registry 
in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Aim: The aim of this study is to compare the safety and efﬁcacy of Sirolimus-eluting 
stent (SES) and bare metal stent (BMS) on the outcome of patients with unprotected 
left main coronary arteries (LMT). Methods: Complete clinical follow-up to 5 years is 
being analyzed for 241 patients who received 120 SES and 121 BMS in patients with 
LMT (male 71.7%, mean age 70.5 yrs) in ﬁve high volume Asian centers. Lesion location 
of LMT was ostial 24 cases (10.0%), mid shaft 38 cases (15.8%) and distal 179 cases 
(74.3%). Results: The baseline clinical characteristics between 2 groups were similar. 
Angiographic and clinical success were achieved in all patients. At 5 years overall cardiac 
events occurred in 12.5% of SES patients and 38.0% of BMS patients (p<0.001). See 
ﬁgure. Conclusion: The use of Sirolimus-eluting stent is effective in preventing cardiac 
events compared with bare metal stent associated with low acute complication and these 
beneﬁts is durable at least 5 years. 
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3:30 p.m.
2506-608 Comparison of Coronary Artery Bypass Surgery 
(CABG) and Percutaneous Drug-eluting Stent 
Implantation (PCI) for Treatment of Unprotected Left 
Main Coronary Artery (ULMCA) Stenosis: 3-year follow-
up analysis by Propensity Score Adjustment
Tarun Chakravarty, Anthony J. White, James S. Forrester, James M. Mirocha, Hursh 
Naik, Ulrich Luft, Saibal Kar, Lawrence Czer, Gregory Fontana, Alfredo Trento, Prediman 
K. Shah, Raj R. Makkar, Cedars Sinai Medical Center, Los Angeles, CA
Background: ACC/AHA guidelines indicate CABG is the appropriate treatment of ULMCA. 
Recent studies suggest that drug-eluting stents (DES) may achieve comparable outcomes.
Methods: 343 patients undergoing PCI or CABG for ULMCA stenosis were analyzed 
using an 18 variable propensity score model with multivariate logistic regression. Hazard 
ratios (HR) for death and major adverse cardiac and cerebrovascular events (MACCE) 
were calculated by Cox proportional hazards. Freedom from death and MACCE was 
compared in propensity score matched patients. The effect of operative risk on survival 
was assessed, using Parsonnet and Ellis scores.
Results: In 223 CABG (follow-up 1298 days) and 120 PCI patients (follow-up 973 days), 
death (HR 1.60 CI 0.84-3.05, p=0.155) was not statistically signiﬁcant, but there was 
a higher risk of MACCE in the PCI group (HR 2.13, 95% CI 1.32-2.41, p=0.002). In 
the 134 propensity matched individuals, neither survival (log-rank p=0.72, Fig. 1) nor 
MACCE-free survival (log-rank p=0.17) was different. Survival was similar in low-risk 
surgical candidates (Parsonnet score a 15, log-rank p=0.70; Ellis category I, II or III, log-
rank p=0.28), but PCI had a tendency to worse survival in high-risk surgical candidates 
(Parsonnet score >15, log-rank p=0.017; Ellis category IV, log-rank p=0.053).
Conclusions: When ULMCA patients are treated by physician judgment rather than 
randomization, long-term mortality is similar for PCI and CABG, suggesting that ACC/
AHA guidelines should be revisited.
3:30 p.m.
2506-609 Drug-Eluting Stents for the Treatment of Left Main 
Coronary Artery Disease with Sirolimus, Paclitaxel, 
Zotarolimus, EPC Capture and Everolimus-Eluting 
Stent: Multicenter Registry in Asia
Sunao Nakamura, Shotaro Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, 
Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo 
Hospital, Chiba, Japan
Aim: The aim of this study is to compare the safety, efﬁcacy and durability of Sirolimus 
(SES), Paclitaxel (PES), Zotarolimus (ZES), EPC capture (ECS) and Everolimus-eluting 
stent (EES) on the outcome of patients with left main coronary arteries (LMT) stenosis. 
Methods: A prospective analysis of 616 patients with 628 LMT stenosis (248 SES, 172 
PES, 104 ZES, 42 ECS 50 EES) in ﬁve high volume Asian centers after successful stenting 
in LMT stenosis was performed. The study endpoints were 30 days and 9 months major 
adverse cardiac events (MACE), 9 months angiographic restenosis and target lesion 
revascularization (TLR) in those 4 groups and 24 months MACE in SES and PES groups. 
Results: See table for clinical results. 
Conclusion: The use of drug-eluting stents in patients with LMT stenosis was safe 
with low acute complication. Patients treated with SES and EES showed lesser rate of 
restenosis compared with other drug-eluting stents. 
SES PES ZES ECS EES
Number of patients 248 172 104 42 50
Procedural success (%) 100 100 100 100 100
MACE at 30 days (%) 0 0 0 0 0
Proximal reference diameter (mean: mm) 3.6 3.5 3.5 3.7 3.5
Stenting procedure: culotte/single/crush 75/87/86 52/40/80 36/39/29 10/29/3 4/30/16
Minimum lumen diameter post 
procedure (mean: mm) 3.5 3.5 3.3 3.5 3.4
Minimum lumen diameter at 9 
months (mean: mm) 3.4 3.0 2.9 3.1 3.3
Restenosis rate at 9 months (%) 7.3* 9.9 16.3 16.7 6.0*
TLR at 9 months (%) 6.0* 8.7 14.4 14.3 6.0*
MACE at 2 years (%) 6.0* 8.7 14.4 14.3 6.0*
*p<0.05 vs ZES, ECS
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PCI for bifurcation lesions (left main or non left main) between October 2003 and 
December 2007 were evaluated for Major Adverse Cardiac Event (MACE) in one month 
and six month period .The factor studied were matched for other signiﬁcant risk factors.
Results: -In our study population baseline characteristics were similar in left main 
bifurcation and non left main bifurcation groups. Difference in MACE in one month post 
procedure period was not statistically signiﬁcant ( 3 out of 44 pts as compared to 10 out of 
471 pts with p value 0.116 after adjustment , OR 3.317 , CI 0.755-13.030 ).Six month post 
procedure period showed signiﬁcant statistical difference in terms of MACE ( 8 out of 44 
pts as compared to 30 out of 471). Age ( p value - 0.013 , OR 1.048 with 95% CI 1.010-
1.088) and Left main bifurcation lesion ( p value - 0.007 , OR 3.356 with CI 1.399-8.050) 
were independent predictors for MACE in six month period with Left main bifurcation 
lesion a much stronger predictor.
Conclusion: As per our study population , bifurcation lesion at left main is not associated 
with higher adverse cardiac event in short term outcome but is a strong predictor for 
higher adverse cardiac events in mid term outcome as compared to non left main 
bifurcation lesions.
3:30 p.m.
2506-615 Outcome in Very High Risk Patients with Unprotected 
Left Main Coronary Artery Stenosis Treated with 
Percutaneous Coronary Intervention and Stent 
Implantation. Results from the Western Denmark Heart 
Registry.
Lisette Okkels Jensen, Kirsten Vilan Mikkelsen, Michael Maeng, Anne Kaltoft, Hans 
Henrik Tilsted, Per Thayssen, Evald Hoej Christiansen, Knud Erik Pedersen, Jens 
Flensted Lassen, Morten Madsen, Klaus Rasmussen, Knud Noerregaard Hansen, Leif 
Thuesen, Odense University Hospital, Odense, Denmark
Background: Percutaneous coronary intervention (PCI) of left main coronary artery lesions 
may be an alternative to coronary artery bypass grafting in very high risk surgical patients. 
We examined mortality, risk of myocardial infarction and target lesion revascularization rate 
in very high risk patients with unprotected LM PCI in Western Denmark.
Methods: From January 2005 to May 2007 all consecutive patients who had unprotected 
LM PCI with stent implantation where identiﬁed in the Western Denmark Heart Registry. The 
indications for PCI were: (1) ST segment elevation myocardial infarction (STEMI), (2) non-
STEMI or unstable angina, and (3) stable angina. All patients were followed for 18 months
Results: A total of 344 patients were treated with LM PCI. Drug-eluting stents were used 
in 88.4% of the patients. The number of stents pr. lesion was 1.2 ± 0.5. Fifty-six (16.2%) 
patients were diabetics. Glycoprotein IIb/IIIa inhibitors were used in 146 (42.3%) patients. 
Forty-two (12.2%) patients underwent intravascular ultrasound.
Conclusion: Patients with STEMI and LM culprit lesion have a high mortality risk in the 
acute phase whereas long term outcome is comparable to other very high risk surgical 
patients with unprotected left main lesions. Further, TLR rates were low and risk of stent 
thrombosis minimal. 
STEMI Non-STEMI/Unstable Angina
Stable 
Angina p-value
Number of patients 71 157 116
Age, (years) 69.3 ± 12.6 73.3 ± 10.7 68.8 ± 10.8 0.002
Euroscore (Logistic) 28.4 ± 20.4 18.6 ± 17.9 8.4 ± 10.3 <0.001
Euroscore >6, (%) 95.8 68.2 40.5 <0.001
Drug-Eluting stents, (%) 88.7 86.6 91.4 NS
Distal LM Lesion, (%) 60.6 69.4 62.9 NS
Bifurcation stenting, (%) 29.6 22.3 31.0 NS
Endpoints:
Mortality, (%) 40.8 23.1 12.9 <0.001
Mortality < 30-days, (%) 31.0 6.4 3.4 <0.001
Mortality 30 days -18 months, (%) 9.8 16.7 9.5 NS
Myocardial Infarction, (%) 9.9 6.4 5.2 NS
Deﬁnite Stent Thrombosis, (%) 0.6 0 0 NS
Target Vessel 
Revasculariization, (%) 2.8 4.5 5.2 NS
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3:30 p.m.
2507-664 Randomized Clinical Trial to Compare the Nephrotoxic 
Effects of Iso-osmolar vs. Low-osmolar Contrast 
Medium in Patients with Impaired Renal Function 
Undergoing Coronary Angiography
Tobias Koppara, Rainer Wessely, Adnan Kastrati, Christian Bradaric, Stefanie Schulz, 
Marc Vorpahl, Julinda Mehilli, Albert Schömig, Deutsches Herzzentrum München, 
Munich, Germany, Klinikum rechts der Isar der TU München, Munich, Germany
Background: Exposure to contrast medium for coronary angiography increases the risk 
of contrast induced nephropathy (CIN) in patients with renal failure. The purpose of the 
CONTRAST trial (COntrast media and NephroToxicity following coronary Revascularization 
by AngioplaSTy) was to compare the nephrotoxic effect of Iodixanol 320, an iso-osmolar 
3:30 p.m.
2506-612 Comparison of Efﬁcacy and Four-Year Durability 
between Sirolimus-Eluting Stent and Paclitaxel-Eluting 
Stent in Unprotected Left Main Coronary Arteries: 
Multicenter Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Aim: The aim of this study is to compare the safety and durability of Sirolimus-eluting stent 
(SES) and Paclitaxel-eluting stent (PES) on the outcome of patients with unprotected 
left main coronary arteries (LMT). Methods: A prospective analysis of 448 patients with 
LMT stenosis (248 SES and 200 PES) in ﬁve high volume Asian centers after successful 
stenting in LMT was performed. Lesion location of LMT was ostial 38 cases (8.5%), mid 
shaft 56 cases (12.5%) and distal 354 cases (79.0%). Complete clinical follow-up to 4 
years is being analyzed for 448 patients. Results: The baseline clinical characteristics 
between 2 groups were similar. Angiographic and clinical success were achieved in all 
patients without any major complication. At 4 years overall cardiac events of SES (16.5%) 
were lower than PES (25.5%) (p=0.045). See ﬁgure for clinical results. Conclusion:
The use of SES and PES in patients with LMT was safe and feasible with low acute 
complication and low incidence of restenosis. SES showed lesser incidence of cardiac 
events (death, myocardial infarction, CABG and PCI compared with PES). 
3:30 p.m.
2506-613 Drug-Eluting Stents versus Coronary-Artery Bypass 
Grafting for Left Main Coronary Artery Disease: Mid- to 
Long-Term Results of a Two-Center Registry
Si-Hyuck Kang, Kyung Woo Park, Seung-Jung Park, Il-Young Oh, Hae-Young Lee, Hyun-Jae 
Kang, Young-Seok Cho, Tae-Jin Yeon, Bon-Kwon Koo, Woo-Young Chung, In-Ho Chae, Dong-
Ju Choi, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim, Department of Internal Medicine and 
Cardiovascular Center, Seoul National University Hospital, Seoul, South Korea
Background: Recent results from the SYNTAX trial and MAIN-COMPARE registry 
suggest the comparability of percutaneous coronary intervention (PCI) with coronary-
artery bypass grafting (CABG) regarding hard endpoints in patients with left main 
coronary artery disease. This study aimed to compare outcomes of the two strategies in 
an unselected ‘real-world’ two-center registry.
Methods: From March 2003 and June 2007, a total of 463 patients were treated by PCI 
with drug-eluting stents (DES) (N=205) or CABG (N=258) at Seoul National University 
Main and Bundang Hospital in Korea.
Results: Baseline characteristics were mostly comparable between the groups. However, 
patients in the CABG group were older and had more complex coronary anatomy, and 
ST-elevation myocardial infarction was more frequent in the PCI group. After a median 
follow-up of 31.2 months, the composite of death, stroke, and myocardial infarction was 
similar between the two groups (20.2% vs. 20.5%, P=0.662), while the needs of repeat 
revascularization was signiﬁcantly higher in DES group (TVR rate: 21.0% vs. 4.6%, 
P<0.001). Although event rates of repeat revascularization at 6 months did not differ 
signiﬁcantly (3.4% vs. 1.6%, P=0.191), most of the revascularization events occurred 
between at 6 to 12 months in PCI group (13.8% vs. 1.7%; P<0.001). The results were 
similar after adjustment of various factors, (Hazard ratio for death, stroke, MI, 1.03; 95% 
CI, 0.63-1.67, for death, stroke, MI, and TVR, 1.67; 95% CI, 1.13-2.48). Deﬁnite stent 
thrombosis occurred in 6 patients (2.9%) in the PCI group.
Conclusions: PCI using DES in patients with left main coronary artery disease showed 
comparable outcomes compared with CABG especially regarding hard endpoints. However, 
CABG was signiﬁcantly associated with reduced needs for repeat revascularization.
3:30 p.m.
2506-614 Left main bifurcation lesion and non left main 
bifurcation lesions : Comparison in terms of One 
month and six month MACE outcome
Kanhaiya L. Poddar, Seung-Woon Rha, Kang Yin Chen, Yong Jian Li, Jae Hyoung Park, 
Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, 
Hong Seog Seo, Dong Joo Oh, Korea University Guro Hospital, Seoul, South Korea
Background: Bifurcation lesions are a challenging pathology to deal with, during 
intervention procedure. Depending upon the location , vessel size and type of lesions , 
bifurcation lesions may be associated with different early and medium term outcome.
Methods: A total of 515 ( male 69.7%, age 61.61 with SD 10.64) patients who underwent 
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CIN (n=422) No CIN (n=2353) P value
Baseline
Age (yrs, mean) 65.0 59.4 <0.0001
Diabetes mellitus 21.8% 15.2% 0.0007
Baseline SCr (mg/dl) 0.9 1.0% <0.0001
CHF (Killip 2-4) 14.2% 8.1% <0.0001
Multivessel PCI 6.8% 3.8% 0.007
Contrast dose (ml, mean) 248 225 0.0001
30-day events
Death 7.8% 0.9% <0.0001
Cardiac death 7.4% 0.9% <0.0001
Reinfarction 3.6% 1.8% 0.02
Ischemic TVR 5.0% 2.4% 0.003
MACE* 11.8% 4.0% <0.0001
Major Bleeding 17.6% 7.3% <0.0001
1-yr events
Death 11.4% 2.2% <0.0001
Cardiac death 8.8% 1.5% <0.0001
Reinfarction 6.0% 4.0% 0.057
Ischemic TVR 10.3% 6.7% 0.008
MACE* 20.5% 10.2% <0.0001
Major Bleeding 18.6% 7.9% <0.0001
*MACE = Death, reinfarction, ischemic TVR or stroke
Independent predictors of CIN included diabetes (RR 1.43, p<0.005), presentation with 
Killip class 2-4 (RR 1.37, p=0.013), and age (RR 1.03, p<0.0001). By multivariate analysis 
CIN was a powerful independent predictor of death (RR 6.21 and 4.2) and MACE (RR 
2.97 and 1.96) at 30 days and 1 yr follow-up (all p<0.0001) .
Conclusions: CIN develops frequently in patient with STEMI undergoing primary 
PCI, and is more common in the elderly, diabetics, and in pts presented with CHF. The 
development of CIN is associated with markedly increased rates of mortality and adverse 
cardiovascular events and major bleeding in these high risk pts.
3:30 p.m.
2507-667 Prevention of Contrast Induced Nephropathy Using 
High Volume Matched Diuresis Using the RenalGuard 
System: First-In-Man Study
Frederic S. Resnic, Charles J. Davidson, Richard Zelman, Simon R. Dixon, Robert 
Rudko, Jean-Francois Dorval, Brigham and Women’s Hospital, Boston, MA
Background: Studies have suggested that high urine ﬂow can reduce the risk of contrast 
induced nephropathy (CIN) by creating a lower concentration of contrast in the renal 
tubules. However, preventing dehydration and volume overload are challenging.
Methods: : A multicenter study was performed using a novel hydration balancing device, the 
RenalGuard™ System (system), to assess the safety of high urine ﬂow rates with matching 
ﬂuid input in patients at high risk for CIN (with estimated glomerular ﬁltration rate (eGFR) < 
50cc/min) undergoing angiography. The system replaces patient urine output with intravenous 
normal saline. Patients were given 250cc saline over 30min and then 0.5 ml/kg Furosemide. 
After achieving urine rates greater than 300 ml/hr, the patient underwent angiography.
Results: A total of 23 patients with mean sCR of 1.67±.69 mg/dl and eGFR of 46±13 
were enrolled. Mean urine ﬂow rate at initial contrast administration was 584±272 ml/
hr. Mean contrast administered was 184±107 ml. There were no major device related 
complications. At 48-60hrs following the procedure mean sCr=1.82±.78 and eGFR was 
40±12 with 2 patients (9%) developing CIN. The system accurately matched ﬂuid input to 
output with 99.9% as shown.
Conclusions: In this ﬁrst in man study, the system demonstrated effective high volume 
ﬂuid balancing with acceptable safety. Further evaluation of system efﬁcacy at preventing 
CIN is warranted.
3:30 p.m.
2507-668 Impact of Renal Insufﬁciency on Prescription of 
Discharge Medication after Percutaneous Coronary 
Intervention
Andrew O. Maree, Faith Selzer, Hani Jneid, Rene Quiroz, Oscar C. Marroquin, Suresh 
R. Mulukutla, Warren K. Laskey, Alice K. Jacobs, Boston University Medical Center, 
Boston, MA, University of Pittsburgh, Pittsburgh, PA
Background: Renal insufﬁciency strongly predicts death and cardiovascular events in a 
dose-dependent fashion after percutaneous coronary intervention (PCI). Little is known 
about how varying degrees of renal insufﬁciency impact the prescription of cardiovascular 
medication in PCI patients.
contrast medium (IOCM), and Iomeprol 350, an low-osmolar contrast medium (LOCM), 
in 975 patients with impared renal function undergoing coronary angiography (CAG) with 
or without percutaneous coronary intervention (PCI). The outcomes of 324 patients who 
underwent PCI have been presented as a late-breaking clinical trial at ACC 2008.
The present work assesses the outcomes of 651 patients randomly assigned to either 
Iodixanol 320 or Iomeprol 350 who underwent diagnostic CAG without subsequent PCI.
Methods: A prospective, randomized, double blind, comparative clinical trial was 
performed in two university heart centers. Patients with impaired renal function 
(MDRD calculated glomerular ﬁltration rate a 60 ml/min and/or S-creatinine q 1.5 mg/
dl) undergoing CAG were randomized to receive either Iodixanol 320 or Iomeprol 350. 
N-acetylcysteine was not administered.
Primary endpoint of the study is the peak increase in S-creatinine during index 
hospitalization. Secondary endpoints are cardiovascular events within 6 months.
Results: The cohort contained 30% diabetics of whom one third were treated with insulin 
and 65% patients with multivessel disease. Baseline GFR was 49.2 ± 13.0 ml/min in the 
IOCM group and 49.1 ± 10.9ml/min in the LOCM group. The mean change of S-creatinine 
was not signiﬁcantly different between the groups and amounted to 0.08±0.29 mg/dl in 
the iodixanol and 0.06±0.27 mg/dl in the iomeprol group (P=0.47). CIN occurred in 9% in 
the IOCM group and 8% in the the LOCM group. There was no signiﬁcant difference in 
mortality after a 180 days follow-up.
Conclusion: The outcomes of this trial, the largest randomized clinical trial in patients 
with impaired renal function undergoing coronary angiography, do not support a beneﬁt 
of iodixanol to reduce nephrotoxicity associated with contrast medium injection in these 
high-risk patients.
3:30 p.m.
2507-665 Bivalirudin Therapy Reduces 30-Day Bleeding 
Complications in Patients with Chronic Renal 
Insufﬁciency: A Pooled Analysis of the REPLACE-2, 
ACUITY, and HORIZONS Trials
Roxana Mehran, George D. Dangas, Alexandra J. Lansky, Eugenia Nikolsky, Derek P. 
Chew, A. Michael Lincoff, Eric Topol, Stuart J. Pocock, Bernhard Witzenbichler, Helen 
Parise, Gregg W. Stone, Columbia University Medical Center and the Cardiovascular 
Research Foundation, New York, NY
Background: Chronic renal insufﬁciency (CRI) is an independent marker of ischemic and 
hemorrhagic events in patients (pts) undergoing PCI. This analysis assessed impact of 
two different antithrombotic regimens (bivalirudin [Biv] vs. heparin+GP IIb/IIIa inhibitors 
[Hep+GPI]) on outcomes of pts with CRI treated with PCI in 3 contemporary PCI trials 
(REPLACE-2, ACUITY and HORIZONS-AMI).
Methods: We assessed 30-day outcomes including composite ischemic endpoint (death, 
myocardial infarction, or revascularization), non-CABG related major+minor bleeding 
by TIMI deﬁnition, and net adverse clinical events (composite ischemic endpoint + 
protocol-deﬁned major bleeding) in pts with CRI (creatinine clearance [CrCl] <60 mL/
min) undergoing PCI.
Results: Among a total of 13,708 pts with baseline CrCl data, 2,295 pts (16.7%) had CRI. 
Pts with vs. without CRI had signiﬁcantly higher rates of composite ischemia (10.5% vs. 6.6% 
p<0.001) and major bleeding (7.9% vs. 3.8%, p<0.001). Ischemic complications occurred with 
similar frequency in pts assigned to Biv vs. Hep+GPI, while rates of bleeding complications 
were notably lower in the Biv treated pts yielding a relative reduction of 41% (Table).
Conclusions: Presence of CRI is associated with remarkably worse short-term 
prognosis. In a broad spectrum of pts with stable/acute coronary syndromes and CRI, 
treatment with Biv compared with Hep+GPI provides signiﬁcant beneﬁt in reduction of 
bleeding complications without increasing rates of ischemic events. 
Endpoints (%) Heparin + GPI(N=1,179)
Bivalirudin
(N=1,116) p-value
Composite ischemic endpoint 10.0% 11.1% 0.39
Death 3.0% 3.1% 0.74
Myocardial infarction 6.4% 7.0% 0.59
Revascularization 2.8% 2.6% 0.77
Non-CABG TIMI bleeding (major + minor) 9.9% 5.8% 0.0003
Net adverse clinical events 17.9% 16.6% 0.41
3:30 p.m.
2507-666 Contrast-Induced Nephropathy Occurs Frequently and 
is a Powerful Independent Predictor of Morbidity and 
Mortality In Patients With Acute Myocardial Infarction 
Undergoing Primary PCI
Giora Weisz, Roxana Mehran, Leroy Rabbani, Eugenia Nikolsky, Ran Kornowski, Franz 
Hartmann, S. Chiu Wong, Alexandra Lansky, Helen Parise, Gregg W. Stone, Center for 
Interventional Vascular Therapy, Columbia University Medical Center, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Introduction: Patients undergoing primary PCI for ST-elevation myocardial infarction 
(STEMI) may be at increased risk to develop contrast-induced nephropathy (CIN) due to 
insufﬁcient time for protective hydration as well as other high risk features. We studied the 
predictors and outcomes of CIN after PCI in pts enrolled in the HORIZONS-AMI trial.
Methods: In HORIZONS-AMI, pts presenting within 12 hours of symptom onset were 
randomized to different anticoagulation regimens and stent types. Serum creatinine (SCr) 
was assessed at baseline and daily post PCI for at least 2 days. CIN was deﬁned as SCr 
increase of q25% or q0.5 mg/dl from baseline.
Results: Among 2775 pts available for analysis, 422 (15.2%) developed CIN. Baseline 
features and outcomes in pts with and without CIN are presented in the Table. 
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hrs, 48 hrs and 7 days post PCI. Serum electrolytes and hemodynamics were monitored 
during PUF. Incidence of CIN was deﬁned as the increase in Cr from baseline of an 
absolute of 0.5 mg/dL or 25% from baseline.
Results: Nine patients completed the protocol: 78% were male, with mean age of 74.9 
(+10) years. Mean baseline Cr was 2.47 (+ 0.8) mg/dL (Mean GFR 28.5 mL/min/1.73 
m2) with mean contrast received 123 + 52 cc. PUF was conducted for a mean duration 
of 4.8 + 1.1 hr pre-PCI, 1.6 + 0.5 hr during PCI, and 5.2 + 0.6 hr post-PCI. In all patients, 
electrolytes remained stable, with the exception of serum bicarbonate, which decreased 
by a mean of 21% in the ﬁrst 4 patients, prompting the addition of a small amount of 
NaHCO3 to the hydration ﬂuid in the remaining patients. No patients suffered adverse 
reactions, hemodynamic compromise, or signiﬁcant discomfort from the protocol. 3 out of 
8 patients had CIN at 48 hours, where Cr increased by mean 0.77 mg/dL; in 2 of these 
patients Cr normalized at 7 days. No patients required hemodialysis.
Conclusions: Peripheral ultraﬁltration is a safe, well tolerated approach for the prevention 
of CIN. A randomized trial comparing PUF with maximum medical therapy will be 
performed to evaluate its efﬁcacy.
3:30 p.m.
2507-671 Impact of Renal Insufﬁciency on Bleeding Events 
in Patients Undergoing Percutaneous Coronary 
Intervention
Andrew O. Maree, Faith Selzer, Brian Adams, Neal Patel, Hani Jneid, Oscar C. 
Marroquin, Suresh R. Mulukutla, Warren K. Laskey, Alice K. Jacobs, Boston University 
Medical Center, Boston, MA, University of Pittsburgh, Pittsburgh, PA
Background: Access site hematoma requiring blood transfusion predicts mortality in 
patients undergoing PCI. Patients with renal insufﬁciency undergoing PCI have increased 
risk of adverse cardiovascular events. Little is known about the relationship between 
degrees of renal insufﬁciency and bleeding in patients undergoing PCI.
Methods: This was a prospective, multi-center, cohort study of consecutive patients 
undergoing PCI during three NHLBI Dynamic Registry recruitment waves (2001-2006). In-
hospital major and minor bleeding events and access site bleeding requiring transfusion 
were determined based on estimated glomerular ﬁltration rate.
Results: Bleeding events and access site bleeding requiring transfusion were signiﬁcantly 
associated with renal insufﬁciency (table). Patients with renal insufﬁciency were more 
commonly female (p<0.0001) and less likely to receive peri- and post-procedural 
anticoagulation and antiplatelet therapy.
Event Rates and Odds Ratios for Bleeding Events in Patients with 
Renal Insufﬁciency Undergoing PCI
Glomerular Filtration Rate.
(ml/min/1.73m2) Event Rate (%) Adjusted Odds Ratio 95% CI p-value
Bleeding*
<45 (n=661)
45-59 (n=1023)
60-74 (n=1544)
q75 (n=2822)
4.8
5.1
2.8
2.7
1.49
1.58
1.05
1.00
0.94-2.37
1.06-2.36
0.70-1.57
reference
0.09
0.03
0.80
n/a
Access site transfusion*
<45 (n=661)
45-59 (n=1023)
60-74 (n=1544)
q75 (n=2822)
2.7
1.5
1.1
0.6
2.67
1.41
1.50
1.00
1.29-5.52
0.67-2.99
0.74-3.04
reference
0.008
0.37
0.26
n/a
Event rate comparisons (overall and trend): *p<0.001
Conclusions: Renal insufﬁciency predicts in-hospital bleeding events in patients 
undergoing PCI. Even moderate levels of impairment are associated with increased 
bleeding risk after adjustment for all other measured variables. Whether renal insufﬁciency 
imparts an added risk of mortality in patients with bleeding requiring transfusion requires 
further study.
3:30 p.m.
2507-672 Improved Outcomes Post Coronary Revascularization 
with Drug Eluting Stents Compared to Coronary Artery 
Bypass Surgery in Patients with End Stage Renal 
Disease on Hemodialysis
Syed A. Hussain, Alan C. Wilson, Abel E. Moreyra, UMDNJ-Robert Wood Johnson 
Medical School, New Brunswick, NJ
Background: Patients with Stage 5 renal failure on hemodialysis (HD) have increased 
cardiovascular risk and mortality. Historically revascularization with coronary artery 
bypass graft surgery (CABG) as compared to bare metal stents (BMS) has yielded better 
outcomes. There are few data on revascularization using drug eluting stents (DES) in this 
patient population.
Methods: We used the statewide MIDAS data of patients admitted with renal failure on 
HD who also had diagnosis of coronary heart disease (CHD) or myocardial infarction (MI) 
in New Jersey between 2003 and 2006. Outcomes included frequency of readmission for 
revascularization procedures, MI, stroke, 30-day, 1 and 2 year mortality were analyzed.
Results: A total of 9839 patients were identiﬁed. Of these 571 had revascularization 
at the index admission; 227 CABG, 217 DES, 91 BMS and 36 percutaneous balloon 
angioplasty (PTCA). The two-year mortality rate for the DES vs CABG group was 20% vs 
34%, adjusted hazard ratio (HR) of 0.687 (95% CI 0.469 - 1.006). The adjusted two-year 
composite MACE (cardiovascular death, readmission for MI, CABG and stroke) for the 
DES vs CABG group was 24% vs 20%. This difference was not statistically signiﬁcant.
Methods: This was a prospective, multi-center, cohort study of consecutive patients 
undergoing PCI during three NHLBI Dynamic Registry recruitment waves (2001-2006). 
Rates of prescription of statin, aspirin, thienopyridine, beta blocker, ACE inhibitor and 
Coumadin were determined based on estimated glomerular ﬁltration rate (eGFR) in 
discharged patients.
Results: Patients with renal insufﬁciency who underwent PCI were less likely to 
be prescribed cardiovascular medication on discharge. The percentage of patients 
discharged on statins, antiplatelet therapy, beta blockers and ACE inhibitors was inversely 
proportional to the degree of renal insufﬁciency (table). 
Prescription Rates of Discharge Medication in Patients with Renal 
Insufﬁciency Undergoing PCI
eGFR (ml/min/1.73m2)
Medication on discharge <45(n=639)
45-59
(n=1,004)
60-74
(n=1,534)
q 75
(n=2,815)
p-value
overall
p-value
trend
Statin (%) 73.6 76.4 81.9 81.6 <0.001 <0.001
Aspirin (%) 93.7 95.5 96.7 96.9 <0.001 <0.001
Clopidogrel / Ticlopidine (%) 93.4 93.9 95.6 96.4 <0.001 <0.001
Beta blocker (%) 80.8 76.0 80.5 81.5 0.003 0.03
ACE Inhibitor %) 45.9 52.3 52.9 51.5 0.02 0.10
Coumadin (%) 11.7 10.0 7.4 6.3 <0.001 <0.001
Conclusions: Patients with even mild or moderate degrees of renal insufﬁciency are less 
likely to receive optimal discharge pharmacotherapy after PCI despite higher cardiovascular 
risk. An incremental decline in the prescription rate of all guideline recommended Class 
I medications is evident, and not only those with relative contraindication in patients with 
renal impairment.
3:30 p.m.
2507-669 Major Adverse Cardiac Events in Patients With 
Moderate to Severe Renal Insufﬁciency Treated With 
Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent
Tarunjit Singh, Chandrasekar Palaniswamy, Rishi Sukhija, Wilbert S. Aronow, Kumar 
Kalapatapu, Anthony L. Pucillo, Craig E. Monsen, Carmine Sorbera, Fausan Tsai, 
Sastry Prayaga, Diwakar Mohan, Savneek S. Chugh, Melvin B. Weiss, New York Medical 
College, Valhalla, NY, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background: There is a dearth of data comparing the long-term outcome of sirolimus-
eluting stent (SES) versus paclitaxel-eluting stent (PES) in patients with moderate to 
severe renal insufﬁciency.
Methods: The incidence of major adverse cardiac events (MACE) - death, myocardial 
infarction, and target vessel revascularization during long-term follow-up were studied in 
patients with a glomerular ﬁltration rate less than 60 ml/min/1.73 m2 by the Modiﬁcation 
of Diet in Renal Disease (MDRD) study equation, who underwent percutaneous coronary 
intervention (PCI) with either SES or PES. Out of 428 patients studied, PES was placed 
in 287 patients and SES in 141 patients. Stepwise Cox regression analyses were 
performed to identify signiﬁcant independent risk factors for MACE using the variables 
age, gender, race, length of stents, width of stents, indications for PCI, coronary artery 
disease burden, complexity of lesion, prior coronary artery bypass surgery, smoking, 
hypertension, diabetes, dyslipidemia, body mass index, and use of drugs which included 
aspirin, clopidogrel, thrombolytics, glycoprotein IIb/IIIa inhibitors, beta blockers, statins, 
and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
Results: At 47 ± 19-month follow-up, MACE occurred in 49 of 287 patients in the PES group 
(age 71.3 ± 10.5 years, 54.7% males) versus 31 of 141 patients in the SES group (age 70.6 ± 
11.8 years, 53.2% males). There was no signiﬁcant difference in MACE in the PES versus the 
SES group (17% vs. 22%, p value=0.8). This persisted even after controlling for length of the 
stent, complexity of lesion and other co-morbidities. All-cause mortality was not signiﬁcantly 
different in the PES group versus the SES group (7.1% vs. 8.5%, p value = 0.7).
Conclusions: At long-term follow-up of patients with moderate to severe renal 
insufﬁciency, the rate of major adverse cardiac events and the all-cause mortality were 
similar in the PES and SES.
3:30 p.m.
2507-670 Peripheral Ultraﬁltration for the Prevention of Contrast 
Induced Nephropathy: A Pilot Study
Alice A. Perlowski, Michael S. Lee, Jonathan M. Tobis, UCLA Medical Center, Los 
Angeles, CA
Background: Peripheral ultraﬁltration (PUF) is an effective method for ﬂuid removal 
in heart failure patients. This pilot study evaluated the feasibility and safety of a PUF/ 
hydration protocol for the prevention of contrast induced nephropathy (CIN) in patients 
with moderate to severe kidney dysfunction undergoing elective percutaneous coronary 
intervention (PCI).
Methods: Patients with serum creatinine (Cr) > 1.8 mg/dL scheduled for elective PCI 
were recruited. A 16 Ga, 35 cm extended length catheter and 18 Ga IVs were placed in 
peripheral veins for blood withdrawal and return, respectively. PUF was performed with 
the Aquadex FlexFlow system (CHF Solutions, Inc.) at goal rate 500 mL/hour (hr). IV 
hydration with either NS or ½ NS with ½ ampule of NaHCO3 was infused at a rate equal 
the amount of ﬂuid withdrawn. PUF/ hydration was performed for 4-6 hrs before PCI, 
continued during PCI, and for 4-6 hrs post PCI. Serum Cr was measured at baseline, 12 
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Restenosis/Instent Restenosis - 
Prevention and Management
Sunday, March 29, 2009, 3:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
2508-616 Impact of Cilostazol on Angiographic and Clinical 
Outcomes After Cobalt-Chromium Alloy Stent 
Implantation
Hiroshi Ueda, Hiroki Sakamoto, Akira Miura, Japanese Red Cross Society Wakayama 
Medical Center, Wakayama, Japan
Background: The impact of cilostazol on neointimal hyperplasia after cobalt-chromium 
alloy stent (CCS) implantation has not been evaluated. We performed a prospective 
randomized trial to evaluate the angiographic and clinical impact of cilostazol after CCS 
implantation.
Methods: From August 2006 to March 2008, a total of 220 patients who underwent 
CCS (VisionTM or DriverTM) implantation were randomly assigned to receive aspirin plus 
thienopyridine plus cilostazol (triple group, n=110) or aspirin plus thienopyridine (dual 
group, n=110). The primary end point was in-stent late loss at 6 months. The secondary 
end points were in-segment late loss and binary restenosis rate at 6 months, target lesion 
revascularization, target vessel revascularization (TVR), and major adverse cardiac 
events, including death, myocardial infarction, and TVR at 1 year.
Results: Follow-up angiography was performed in 89.5% of patients. Baseline 
clinical and angiographic characteristics were similar between the two groups. The in-
stent (0.49±0.56mm vs. 0.85±0.52mm, p<0.001) and in-segment (0.23±0.51mm vs. 
0.49±0.54mm, p=0.001) late loss were signiﬁcantly smaller in the triple group compared 
with the dual group. The incidence of in-segment binary restenosis was also signiﬁcantly 
lower in the triple group compared with the dual group (4.3% vs. 15.5%, p=0.01). 
Multivariate analysis showed that the use of cilostazol was the only independent predictor 
of 6-month in-segment binary restenosis (OR 0.09, 95% CI 0.02-0.58, p=0.01). One-year 
clinical follow-up data will be presented at the meeting.
Conclusions: Triple antiplatelet therapy with aspirin, thienopyridine, and cilostazol after 
CCS implantation resulted in a signiﬁcantly smaller late loss and a signiﬁcantly lower 
binary restenosis rate compared with standard dual antiplatelet therapy.
3:30 p.m.
2508-617 Predictors of Clinical Restenosis in Real-World Clinical 
Practice: An Analysis of Drug Eluting Stents in the 
EVENT Multicenter Registry
Joshua M. Stolker, Jason B. Lindsey, Steven P. Marso, Kevin F. Kennedy, Michael 
J. Pencina, Donald E. Cutlip, Neal S. Kleiman, David J. Cohen, Mid-America Heart 
Institute, Kansas City, MO, Methodist DeBakey Heart & Vascular, Houston, TX
Background: Drug eluting stents (DES) reduce restenosis compared with bare metal 
stents, but data are limited regarding predictors of target lesion revascularization (TLR) in 
DES-- particularly in the absence of angiographic follow-up.
Methods and Results: We used data from the EVENT study-- a prospective registry of 
the practice and outcomes of contemporary PCI at 50 US centers-- to examine incidence 
and predictors of TLR among DES recipients. Between 7/04 and 6/06, EVENT enrolled 
7,587 patients of whom 6,871 received at least 1 DES. Over 1-year follow-up, the incidence 
of TLR in DES was 3.93% (on a per lesion basis), which decreased to 3.47% when early 
repeat PCI (<30d) and deﬁnite stent thrombosis were excluded. Independent predictors 
of TLR were identiﬁed from 18 candidate clinical and angiographic variables using logistic 
regression and are summarized in the Table. Consistent with studies from the pre-DES 
era, smaller stent diameter and longer stent length were independent predictors of TLR 
along with SVG location, while advanced age and current smoking were associated with a 
lower need for subsequent TLR. Diabetes was not associated with TLR in either univariate 
or multivariate analyses.
Conclusion: Among unselected patients undergoing PCI with DES, the per lesion 
incidence of TLR is <4% and is associated with several clinical and angiographic factors. 
Although several predictors of TLR are conserved from the pre-DES era, the absence of 
diabetes is noteworthy and should be validated in future studies.
Independent predictors of 12-month target lesion revascularizaton
Variable Odds Ratio 95% C.I. p-value
Patient age (per 10-year increment) 0.77 0.68-0.87 <0.0001
Female gender 1.62 1.23-2.14 0.0007
Prior percutaneous coronary intervention 1.58 1.21-2.07 0.0009
Current smoker 0.60 0.42-0.86 0.0050
Average stent diameter (per mm increase) 0.61 0.43-0.88 0.0077
Total stent length (per 10 mm increment) 1.15 1.06-1.25 0.0010
DES placement in saphenous vein graft 3.30 2.25-4.83 <0.0001
Conclusions: Patients with Stage 5 renal failure on hemodialysis have high 
cardiovascular mortality. Revascularization using drug eluting stents has a lower mortality 
with no difference in MACE as compared to coronary artery bypass graft surgery in this 
population.
3:30 p.m.
2507-673 Can Contrast Induced Nephropathy be Prevented via a 
Renal Pleotropism Effect from Statins?
Valentyna Ivanova, Jennifer Spotti, Diane A. Vido, David M. Lasorda, Robert W. 
Biederman, Allegheny General Hospital, The Gerald McGinnis Cardiovascular Institute, 
Pittsburgh, PA
Introduction: Statins are extensively used for treatment of dyslipidemia and CAD 
prevention. Current controversy exists regarding possible pleotropic effect of statins with 
many vascular and nonvascular beds appearing to beneﬁt from their administration. To 
date, little data exists to support possible nephroprotective effects of the non-lipid effects 
of statins.
Hypothesis: We hypothesize that pre-PCI administration of statins may be beneﬁcial in 
preventing contrast induced nephropathy (CIN) post-PCI.
Methods: A retrospective study of 4000 pt charts who underwent PCI for standard clinical 
reasons was performed. Pts were categorized into those who developed CIN (based on 
serum creatinine (SCr) level elevation by q0.5mg/dL from baseline) and those with normal 
renal function after PCI. Pts with CIN were further grouped into statin (_) and statin (+) prior 
to PCI. Multivariate analysis against HTN, DM, age, sex, baseline SCr, BUN, contrast 
dose, WBC and lipid levels was performed and related to statin +/- therapy.
Results: SCr was measured within 1 week prior to or day of PCI in 806 pts: 516 (64%) 
male, 289 (36%) female and within 1 week post PCI. Statin therapy was initiated in 328 
(41%) pts qweek prior to PCI. When classiﬁed by statin therapy ((+) or (-)), there was 
no signiﬁcant difference in the incidence of CIN (29 vs. 39, p=0.8). However there was 
a signiﬁcant number of pts who had rise to over 2.5mg/dL in the statin (_) pts (p<0.05). 
When limited to the absolute rise in SCr, the mean rise in SCr was 0.64 in statin (_) vs. 
0.16mg/dL in statin (+) subgroup, representing a 3-fold nephroprotective effect of statins 
(p<0.001). Interestingly, HTN, age, sex, baseline SCr or BUN, LDL/total cholesterol/
triglyceride level, WBC or contrast load were not a signiﬁcant variable in predicting the 
rise in SCr; while only statin+ therapy was nephroprotective.
Conclusion: Renal pleotropism due to statin therapy to prevent against CIN appears to 
have important clinical beneﬁts. A strong signal supporting additional statin capability as a 
nephroprotective agent emerged. Early pre-PCI use of statins therapy was independently 
reno-protective despite the strong presence of otherwise high risk co-morbidities.
3:30 p.m.
2507-674 Paclitaxel Eluting Versus Sirolimus Eluting Stents for 
Patients with Pre-existing Chronic Renal Insufﬁciency.
Asmir Syed, Itsik Ben-Dor, Sara Collins, Yanlin Li, Gilles Lemesle, Gabriel Manuela, 
Mickey Scheinowitz, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, Joseph 
Lindsay, Kenneth Kent, Lowell Satler, William O. Suddath, Augusto Pichard, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: Chronic renal insufﬁciency (CRI) is associated with increased incidence 
of restenosis and stent thrombosis. Drug Eluting Stents (DES) reduce the incidence of 
restenosis, compared to BMS in these pts. This study aimed was to examine whether 
there are differences in clinical outcomes between paclitaxel eluting stents (PES) versus 
sirolimus eluting stents (SES) in patients with CRI who were subjected to coronary 
intervention.
Methods: A cohort of 570 patients with CRI who underwent intervention with DES (346 
with SES and 224 with PES) were followed clinically up to 1 year and the clinical events 
were recorded and compared between the two groups.
Results: Baseline and procedural characteristics were similar with slightly higher number 
of diseased vessels in the SES group as compared to PES (2.3±0.9 vs. 2.1±0.9, p=0.06). 
The overall MACE and the stent thrombosis were similar between the groups. The PES 
group had less revascularization when compared to SES (Table). However, after covariate 
adjustment there was no difference seen in target vessel revascularization between stent 
types (HR: 2.5 [0.9-6.9], 0.083). The strongest independent predictor of Death and MACE 
at 1 year was number of diseased vessels.
Conclusions: Patients with CRI who are undergoing PCI with either PES or SES have 
low restenosis and acceptable stent thrombosis rates. Patients CRI who present with 
multi-vessel disease should be considered for surgical revascularization. 
Baseline Characteristics (n=1033) Cypher
n=346
Taxus
n=224 p value
Age, years 69.4 +/- 12 68.5 +/- 11.6 0.383
Male, % 59.0 60.7 0.677
Diabetes, % 58.1 57.2 0.826
Hypertension, % 95.7 95.1 0.748
Hyperlipidemia, % 92.8 87.3 0.031
Peripheral Vascular Disease, % 36.4 35.6 0.851
Presnetation with AMI, % 13.6 10.3 0.241
Baseline Creatinine Clearance 2.50 +/- 2.42 2.68 +/- 2.49 0.306
On Dialysis, % 18.8 21.4 0.440
LAD disease, % 35.3 28.6 0.034
Proximal Disease, % 48.1 39.0 0.008
Procedure Related ARF, % 12.2 13.5 0.535
Outcomes at 1 Year
MACE, % 27.2% 20.1% 0.535
Death, % 18.2% 17.9% 0.535
TVR, % 10.6% 2.9% 0.001
Stent Thrombosis, % 1.4 0.4 0.411
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similar between both stents. Angiographic and clinical outcomes are shown in the table.
Conclusions: The use of CCS in patients with de novo coronary lesions is safe and 
effective. Both VisionTM and DriverTM stents provide similar angiographic and clinical 
outcomes in a real-world setting.
Angiographic and Clinical Outcomes
Vision (n=107) Driver (n=113) p-value
In-stent late loss (mm) 0.69±0.64 0.67±0.49 0.82
In-segment late loss (mm) 0.38±0.57 0.35±0.51 0.71
In-stent binary restenosis (%) 10.4 8.9 0.91
In-segment binary restenosis (%) 10.4 9.9 1.00
TLR (%) 3.7 4.4 1.00
TVR (%) 4.7 6.2 0.77
MI (%) 0.0 0.0 N/A
Death (%) 0.0 1.8 0.50
MACE (%) 4.7 8.0 0.41
3:30 p.m.
2508-621 Long-term safety and efﬁcacy of using drug-eluting 
stents to treat previous bare-metal and drug-eluting 
stents restenosis: insights from the DESIRE-ISR 
Registry
Jose de Ribamar Costa Jr, Amanda Sousa, Adriana C. Moreira, Ricardo A. Costa, 
Manuel N. Cano, Galo Maldonado, Cantídio Campos, Mariana Carballo, Marcos 
Barbosa, Ricardo Pavanello, Otávio Berwanger, J. Eduardo Sousa, Instituto de Ensino e 
Pesquisa do Hospital do Coração, São Paulo, Brazil
Background: Currently, DES are the 1st choice to treat BMS restenosis, replacing all 
other available percutaneous approaches. Although markedly reduced, DES restenosis 
still occurs and has been often treated with the another DES, despite the lack of robust 
data supporting the safety and efﬁcacy of this approach. We sought to compare the long-
term clinical outcomes of pts with BMS and DES restesnosis treated with another DES 
deployment.
Methods: Between May 2002 and May 2008 a total of 158 pts with BMS restenosis 
and 58 pts with DES restenosis were consecutively treated with a DES and enrolled 
in this single-center registry. Pts treated in the setting of AMI and lesions in SVG were 
excluded.
Results: Baseline clinical aspects did not signiﬁcantly differ between the groups. The 
exception was the higher incidence of DM in the DES cohort (36% vs. 33%, p=0.04). 
Mean time between ﬁrst procedure and restenosis was signiﬁcant longer in the DES 
population (178±61 days vs. 140±38 days, p=0.02). LAD was the most frequent treated 
vessel (37% in the BMS and 38% in the DES, p=0.7). Main pts characteristics as well as 
clinical outcomes are displayed in the table. Clinical FU was obtained from all pts.
Conclusions: Percutaneous treatment of BMS or DES restenosis with the implant of 
another DES represents a simple, efﬁcient and safe approach with sustained long-term 
results. However, the recurrence of restenosis is considerably higher among patients with 
prior DES restenosis.
Clinical, angiographic and procedural characteristics
-Female gender, %
-Age, years
-DM, %
-Unstable angina, %
27%
62.6±11.5
33%
38%
29%
59.5±9.8
36%
42%
0.2
0.06
0.04
0.09
-Focal ISR(10mm), %
-Diffuse ISR (>10mm),%
36%
58%
83%
17%
<0.01
<0.01
-Lesion length,mm
-RVD,mm
-Use of Cypher to treat ISR,%
16.6±7.3
2.99±0.5
93%
14.33±5.8
2.8±0.5
79%
0.02
0.02
<0.01
Clinical outcomes (median 3.6 years)
-MACE
-Cardiac death
-Non-fatal MI
-TLR
-Stent thrombosis
8.6%
2.8%
2.8%
3.0%
0.6%
13.7%
0.4%
1.8%
11.5%
0
<0.01
0.4
0.8
<0.01
0.8
3:30 p.m.
2508-622 U-Shape Relationship of Pre-procedural Blood Glucose 
Levels With In-stent Restenosis in Patients Undergoing 
Coronary Angioplasty
Annunziata Nusca, Giuseppe Patti, Antonio Abbate, Andrea D’Ambrosio, Fabio 
Mangiacapra, Germano Di Sciascio, Campus Bio-Medico University, Rome, Italy, 
Virginia Commonwealth University, Richmond, VA
Background. Hyperglycemia and hypoglycemia are associated with increased long-
term mortality in patients with acute myocardial infarction, irrespective of diabetic state. 
Moreover, neointimal hyperplasia after coronary stent implantation is increased in the 
presence of suboptimal glycemic control. Both hypoglycemia and hyperglycemia may 
have a pathogenic role in endothelial dysfunction and inﬂammation, potential mechanisms 
for adverse outcome following percutaneous coronary intervention (PCI). The aim of this 
study was to evaluate the relationship between pre-procedural blood glucose levels and 
long-term outcome in patients undergoing PCI.
Methods. We retrospectively enrolled 573 patients who underwent coronary stenting 
at our Institution. In all patients, blood glucose levels were measured before PCI and, 
3:30 p.m.
2508-618 Comparison of Sirolimus versus Paclitaxel-eluting 
Stents for Treatment of Sirolimus-Eluting Stent 
Restenosis
Seiji Habara, Kazushige Kadota, Kazuaki Mitsudo, Tsuyoshi Goto, Satoki Fujii, Hiroyuki 
Yamamoto, Harumi Kato, Naoki Oka, Yasushi Fuku, Shingo Hosogi, Akitoshi Hirono, 
Toru Kawakami, Takeshi Maruo, Hiroyuki Tanaka, Daiji Hasegawa, Masao Imai, Hiroshi 
Tasaka, Chinatsu Yamada, Yoji Okamoto, Suguru Otsuru, Masakazu Miyamoto, Naoki 
Saito, Kentaro Shibayama, Yuki Tsujimoto, Kurashiki central hospital, Kurashiki, Japan
Background: Although the rate of restenosis is quite low after sirolimus-eluting stent (SES) 
implantation, recurrent restenosis may still occur in some cases. The next major question 
is what the effective treatment of recurrent restenosis in a SES will be. We evaluated the 
efﬁcacy of repeat stenting (stent-in-stent) in patients with in-stent restenosis (ISR) of SES.
Methods: From December 2004 to February 2008, 123 consecutive patients (69.2±10.4 
yrs) with 145 lesions after repeat drug-eluting stent (SES or Paclitaxel-eluting stent 
(PES)) implantation for ISR of SES were enrolled. All of the initial SES were implanted 
in de novo lesions. Follow-up angiogram was obtained 8 months after implantation. We 
compared characteristics of lesions between the two groups (the SES group (n=89) and 
the PES group (n=56)).
Results: There were no signiﬁcant differences in clinical, lesional, or procedural 
characteristics between two groups. The incidence of restenosis was higher in SES group 
than PES group (27.0% vs 16.1%, p=0.03).
By multivariate analysis, reference diameter of less than 2.5mm (odds ratio [OR]: 1.54, 
95% conﬁdence interval [CI]: 1.1 to 3.3, p=0.05), the use of SES (OR: 1.82, CI: 1.21 to 
4.56, p=0.01) and diffuse type restenosis (OR: 3.10, CI: 1.29 to 8.36, p=0.002) were 
independent predictors of recurrent restenosis.
Conclusions: PES is superior to SES in reducing the incidence of recurrent restenosis 
in lesions with ISR of SES.
3:30 p.m.
2508-619 Clinical Outcomes of Target Lesion Revascularization 
after Bare-Metal or Sirolimus-Eluting Stenting. Five Year 
Follow-up from SIRIUS
Victor Novack, Michael C. Nguyen, Meredith Mulhearn, Riya Chacko, Lena Novack, 
Michael Pencina, Laura Mauri, Sidney A. Cohen, Jeffrey Moses, Martin B. Leon, Donald 
E. Cutlip, Harvard Clinical Research Institute, Boston, MA
Background: The association of restenosis requiring target lesion revascularization 
(TLR) following either drug-eluting stent (DES) or bare-metal stent (BMS) placement and 
subsequent late cardiac outcomes has not been previously assessed.
Methods: The study objective was to assess the long-term outcomes of patients 
undergoing clinically driven TLR associated with restenosis (TLR group) compared to 
those without TLR (non-TLR group). Of the 1057 patients with one native coronary lesion 
randomized to sirolimus-eluting (SES) or BMS in the SIRIUS trial, those who survived 
free from TLR or MI for the ﬁrst 30 days were followed for the primary outcome of cardiac 
death or MI (deﬁned by the universal deﬁnition) for 5 years (983 subjects). Events either 
occurring at time of or after TLR for restenosis were assigned to TLR group. Events 
related to stent thrombosis occurring before a ﬁrst TLR were assigned to non-TLR group. 
Cox proportional hazard risk model with time dependent variable (TLR) adjusted for 
baseline clinical and demographic covariates was used to assess the independent effect 
of requirement for TLR on the primary outcome.
Results: TLR occurred at least once in 160 (16.3%) patients. Primary endpoint was 
reached by 66 subjects during assignment to non-TLR group (24 MI and 22 cardiac 
deaths) and in 26 subjects in TLR group (21 MI and 5 cardiac deaths) . Of these 26 events 
7 presented at time of ﬁrst TLR, 3 events were periprocedural complications of TLR and 
16 events occurred later during the follow-up. Multivariate analysis showed that TLR was 
an independent predictor of the primary endpoint (Hazard ratio [HR] 2.8, 95% CI 1.7-4.5). 
Other independent predictors of CD/MI were RVD (HR 0.5, 95% CI = 0.3-0.8), diabetes 
(HR 1.5, 95% CI 1.0-2.3) and prior MI (HR 2.1, 95% CI 1.4-3.1) however use of BMS was 
not (HR 0.9, 95% CI = 0.6-1.4). Brachytherapy performed in 77 cases (48.1%) was not 
associated with an increase risk of CD/MI following the TLR.
Conclusions: Restenosis requiring TLR after 30 days following successful initial stenting 
is associated with an increased risk of adverse long-term outcomes such as cardiac 
death/MI in subsequent years.
3:30 p.m.
2508-620 A Prospective Randomized Comparison of Vision 
Versus Driver Stents in De Novo Coronary Lesions
Hiroshi Ueda, Hiroki Sakamoto, Akira Miura, Japanese Red Cross Society Wakayama 
Medical Center, Wakayama, Japan
Aim: The aim of this study was to evaluate the relative efﬁcacy and safety of 2 commonly 
used cobalt-chromium alloy stents (CCS): the VisionTM stent and the DriverTM stent.
Methods: From August 2006 to March 2008, 220 consecutive patients with de novo 
coronary lesions (<30 mm in length, 3.0-4.0 mm in diameter), who had angina pectoris 
or acute coronary syndrome, were randomly assigned to receive a VisionTM stent (n=107) 
or a DriverTM stent (n=113). The primary end point was in-stent late loss at 6 months. 
The secondary end points included in-segment late loss and binary restenosis rate at 
6 months, target lesion revascularization (TLR), target vessel revascularization (TVR), 
and major adverse cardiac events (MACE), including death, myocardial infarction (MI), 
and TVR at 9 months.
Results: Procedural success rate was 100% in both stents. Follow-up angiography was 
performed in 89.5% of patients. Baseline clinical and angiographic characteristics were 
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Figure-1 shows that MM patients had thicker basal septum (1.4mm on average) compared 
to ASA patients. Follow-up septal thickness was similar in two groups.
3:30 p.m.
2509-625 Effects of Alcohol Septal Ablation on Inﬂammation and 
Signal Peptides in Hypertrophic Cardiomyopathy
Francesco Pelliccia, Cinzia Cianfrocca, Lucia Gatta, Vincenzo Pasceri, Antonio Auriti, 
Christian Pristipino, Giulio Speciale, Giuseppe Rosano, San Filippo Neri Hospital, 
Rome, Italy, San Raffaele Pisana, Roma, Italy
Background: Alcohol septal ablation (ASA) has become a diffuse therapeutic approach 
in hypertrophic cardiomyopathy (HC) leading to reduced obstruction, relief of symptoms, 
and improvement in global LV function. It remains unknown, however, if ASA exerts 
favorable effects on markers of inﬂammation and signal peptides. Accordingly, we 
prospectively assessed whether changes in biochemical indexes occur after ASA in HC.
Methods: We studied 20 patients (12 women, 66±13 years) with obstructive HC who 
underwent ASA. Before ASA and 6 months later, erythrocyte sedimentation rate (ESR), 
high-sensitivity C-reactive protein (hsCRP), nuclear factor-kappa B (NF-kB), interleukin 
(IL)-6, tumor necrosis factor-alpha (TNF-alpha), and the glycoprotein carbohydrate 
antigen 125 (CA125) were evaluated in all patients. Measurements were done according 
to standard techniques. NFkB was quantiﬁed by a sensitive multi-well colorimetric assay 
for active NF-kB.
Results: ASA was successful in all patients, with NYHA functional class decreasing from 
3.5±1.1 to 1.6±1.0 and LV outﬂow tract gradient reducing from 101±45 to 18±12 mm Hg. 
Procedural complications included only the need of permanent pace-maker in 3 patients. 
Over follow-up, no death occurred and obstruction recurred in 1 patient who underwent 
myectomy. Hematologic evaluation at 6-month follow-up did not show any signiﬁcant change 
in ESR (from 15±3 to 12±5 mm/h, p<0.05), hsCRP (from 3.2±2.1 to 2.9±2.0 mg/l, p<0.05), 
and IL-6 from 4.2±3.1 to 4.0±2.7 pg/ml, p<0.05). Conversely, there was evidence of signiﬁcant 
decreases in NF-kB (from 10.5±6.5 to 4.1±3.9 ng/μg cell protein, p<0.05), TNF (from 3.5±2.9 
to 1.1±1.9 pg/ml, p<0.05), and CA125 (from 13.4±9.8 to 7.9±8.9 U/ml, p<0.05).
Conclusions: Signal peptides, but not markers of inﬂammation, decrease signiﬁcantly 
after ASA in patients with obstructive HC. These ﬁndings suggest that symptomatic and 
functional improvement after the procedure can be ascribed, at least partly, to favorable 
changes that occur in some biochemical indexes.
3:30 p.m.
2509-626 Combination Stem Cell Therapy for the Treatment of 
Severe Limb Ischemia
Gabriel P. Lasala, Jose A. Silva, Philip A. Gardner, Denise Gonsior, Rebecca Lorino, 
Jose J. Minguell, TCA Cellular Therapy, Covington, LA
Background. A source of endothelial progenitor cells (EPCs) has been used to increase 
blood ﬂow in patients with severe limb ischemia. Results have shown that infusion of this 
single cell type is safe and may stimulate angiogenesis; however the long-term clinical 
beneﬁts have not been established. Vasculogenesis involves the interaction of EPCs 
with many other cell types, including mesenchymal stem cells (MSCs)-derived pericytes. 
Following this rationale, we used a combination of autologous EPCs and MSC to treat 
patients with severe limb ischemia.
Methods. Ten patients (Fontaine, stage 2b-4) were enrolled in a Phase I, randomized, 
open label, safety/efﬁcacy clinical trial. MSC and EPCs, obtained by bone marrow 
aspiration were mixed and infused in the most hypoperfused area of the gastrocnemius 
muscle. Follow-up included evaluation of pain-free walking test (WT), ankle brachial 
pressure index (ABI), transcutaneous oxygen pressure, angiography, 99mTc-TF perfusion 
scintigraphy and Quality of Life (QOL).
Results. No adverse events occurred after infusion. Efﬁcacy assessed periodically 
after infusion demonstrated a time-dependent improvement in all clinical parameters. A 
comparison of baseline values and 6 month follow up showed that ABI improved from 
0.34 ± 0.19 to 0.69 ±18 (p a0.001), QOL increased from 1.09 ± 0.40 to 2.39 ± 0.65 (p 
a0.001) and WT improved 2.92 + 1.64 fold.
Conclusions. Improvement in all variables as well as a concomitant increase in collateral 
vessels suggests that the combination cell therapy is safe and effective. The outcome of 
this study could be due to either a cell-dependent stimulation of pre-existing collateral 
vessels or the development of new mature and stable capillaries (vasculogenesis). The 
latter is strongly supported by the persistence of clinical effects after 8-13 months of cell 
infusion and by an increase in radionuclide uptake in the ischemic areas.
according to these, patients were classiﬁed in four pre-deﬁned groups: hypoglycemia <
80 mg/dl; euglycemia 81-99 mg/dl; mild hyperglycemia 100-149 mg/dl; hyperglycemia >
150 mg/dl. Primary end point was the occurrence of clinically driven in-stent restenosis, 
deﬁned as stenosis of at least 50% of the luminal diameter.
Results. After a median of 15±8 months, incidence of in-stent restenosis was signiﬁcantly 
higher in patients with hypoglycemia (27%) and hyperglycemia (24%) compared with the 
euglycemic (13 %) and mild hyperglycemic groups (8%) (P for trend = 0.006). Incidence 
of death and myocardial infarction was not different between the four groups (P = 0.10 
and P = 0.22). All patients with angiographic evidence of in-stent restenosis were treated 
with re-PCI. A U-shaped relationship of blood glucose with in-stent restenosis was also 
observed both in diabetic and non diabetic subgroups.
Conclusions. In patients undergoing PCI, hypoglycemia and hyperglycemia are 
associated with increased incidence of in-stent restenosis. These results suggest that 
optimal glucose control remains an important target in diabetic and non-diabetic patients 
undergoing PCI.
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2509-623 Hepatocyte Growth Factor Gene Therapy for Patients 
With Critical Limb Ischemia: Results of a Phase I Dose-
Escalation Trial
Timothy D. Henry, JoAnne Goldman, Yale L. Wang, Daniel L. Lips, Daniel Dulas, William 
D. McMillan, Sue Duval, Thomas A. Biggs, Alan T. Hirsch, Minneapolis Heart Institute 
Foundation at Abbott Northwestern Hospital, Minneapolis, MN
Background: Angiogenic growth factors represent a novel treatment for patients with 
critical limb ischemia (CLI) who are not amenable to revascularization. We evaluated the 
safety and tolerability of increasing doses of IM delivery of a novel non-viral plasmid 
encoding 2 isoforms of hepatocyte growth factor (pCK- HGF-X7) in patients with CLI.
Methods: 12 patients with CLI, and not eligible for revascularization based on angiography 
performed within 12 months, were randomly assigned to increasing doses (2 mg to 16 mg) 
of pCK- HGF-X7 at days 0 and 14 administered into the ischemic calf. Serum HGF levels, 
plasmid biodistribution, transcutaneous oxygen (TCPO2), ankle-brachial index (ABI), pain 
severity score by a 100mm visual analog scale (VAS), and ulcer size assessment were 
obtained at baseline and at 1, 2, 3, and 6 months. MRA was performed at baseline, 3 
and 6 months.
Results: pCK- HGF-X7 was well tolerated with no serious adverse effects, amputations, 
or deaths through 1 year of followup. 9 patients have completed 3 months follow-up. A 
signiﬁcant reduction in pain was reported by 8/9 patients, with mean VAS decreasing from 
63.8 to 36.9 (p=.02). ABI increased from 0.34 to 0.44 (p=.056), though TCPO2 decreased 
from 30.2 to 23 (p=NS). HGF levels remained unchanged and there was no HGF plasmid 
detectable via biodistribution studies after 59 days. Complete 6 month results will be 
available by 03/2009.
Conclusions: This ﬁrst trial using HGF gene therapy in CLI patients demonstrates 
excellent safety with encouraging initial subjective and objective clinical results. These 
results support performance of a randomized, double-blind, placebo-controlled trial in 
patients with CLI using pCK-HGF-X7.
3:30 p.m.
2509-624 Hypertrophic Obstructive Cardiomyopathy-Alcohol 
Septal Ablation vs. Myomectomy: A meta-analysis
Mahboob Alam, Hisham Dokainish, Nasser Lakkis, Baylor College of Medicine, 
Houston, TX
Objectives: We conducted a meta-analysis of all published studies comparing alcohol septal 
ablation (ASA) and myomectomy (MM) for hypertrophic obstructive cardiomyopathy (HOCM).
Background: ASA is a less invasive alternative to MM for relief of symptoms in patients 
with drug refractory HOCM.
Methods: An extensive PubMed search identiﬁed 5 studies (351 patients) comparing 
outcomes of patients undergoing ASA and MM.
Results: 183/351 patients underwent ASA and 168/351 underwent MM. ASA group 
was older (54.4±6.3 vs. 45.0±4.4 years, p=0.02). All patients were in NYHA class II-IV. 
Baseline left ventricular outﬂow tract (LVOT) gradient was comparable (81.4 ± 14.3mmHg 
in ASA vs. 77.4±15.5mmHg in MM, p=0.2). Although resting LVOT gradient after ASA or 
MM in both groups was <20mmHg, MM group had lower LVOT gradient (18.2±6.7mmHg 
vs. 10.8±6.3mmHg, p<0.001). Patients in both groups had comparable improvement in 
NYHA class (1.5 ± 0.3 in ASA vs. 1.3 ± 0.2, p=0.2) at follow-up. A higher percentage 
of ASA patients required permanent pacemaker (PPM) implantation for complete heart 
block (18.4 ± 7.9 vs. 3.3 ± 3.9%, p=0.04). There was no signiﬁcant in-hospital mortality 
difference between the 2 groups.
Conclusions: ASA provides similar reduction in NYHA class and LVOT gradient on a 
mid-term follow-up. A higher percentage of patients required PPM after ASA.
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this study was to evaluate 4-year efﬁcacy and LV functional improvement of autologous 
bone marrow mononuclear cells (BMMNC) transplantation in patients with ST-segment 
elevation myocardial infarction.
Methods: 86 patients with STEMI who had successfully undergone percutaneous 
coronary intervention (PCI) were randomized to receive intracoronary injection of BMMNC 
(n=41) or saline (n=45) 7 days after PCI. Left ventricular function and myocardial viability 
were assessed by echocardiography, single-photon emission computed tomography 
(SPECT) and coronary angiography up to 4 years’ follow-up.
Results: LV ejection fraction was markedly improved compared with control group 6 
months after the procedure [(48.4±0.5)% in BMMNC group vs (45.7±0.6)% in control 
group, P<0.05], and this beneﬁt was still evident in 4 years’ follow-up [(50.5±0.8)% in 
BMMNC group vs (47.6±0.9)% in control group, P<0.05] evaluated by echocardiography. 
However, the current cell therapy didn’t improve the myocardial viability of the infarcted 
area assessed by SPECT 4 years after the transplantation (0.263±0.007 in BMMNC group 
vs 0.281±0.008 in control group, P>0.05). During the four years’ follow-up period, 1 case 
(2.2%) of in-stent restenosis in control group was conﬁrmed by coronary angiography 
which subjected to repeat PCI. 1 patient (2.4%) of transient acute heart failure in BMMNC 
group and 1 death (2.2%) in control group were reported.
Conclusions: This study indicates that intracoronary delivery of autologous BMMNC 
is safe and feasible for STEMI patients who have undergone PCI, which can also lead 
to long-term beneﬁts on heart functional improvement. The mechanism by which the 
functional improvement occurs still needs more dedicate investigation.
3:30 p.m.
2509-630 Assessment of Safety, Accuracy and Human CD34+ 
Cell Retention After Intramyocardial Injections With a 
Helical Needle Catheter in a Porcine Model
Arun Kumar, Micah Hughes, Roberto Pacheco, Christian Spies, Didier Rouy, Nate 
Cresswell, Ryan Braun, David Turner, David Amrani, Delara Motlagh, Sharon 
Pokropinski, Gary L. Schaer, Rush University Medical Center, Chicago, IL
Background: Percutaneous intramyocardial delivery of biotherapeutic agents must be 
accomplished in a safe and accurate manner and adequate retention is an important 
goal. A unique delivery system (Helix, Biocardia Inc., S. San Francisco CA) has been 
developed to improve maneuverability and stability of the catheter-needle-myocardium 
intersection using a separate deﬂectable guiding catheter, and an injection catheter with 
a helical needle at its tip and two injection ports.
Methods: In part A, 12 anesthetized swine received 6 intramyocardial injections of colored 
dye (at least 5 mm apart) into prespeciﬁed LV territories using ﬂuoroscopic guidance. 
The hearts underwent gross and histologic evaluation to assess safety and accuracy. In 
part B, cell retention was assessed by labeling human CD34+ cells with iron oxide and 
ﬂuorochrome. The cells were injected into 6 pigs using the same technique as part A. The 
animals were euthanized after 2 hours, and hearts were formalin ﬁxed. MRI was performed 
on the 6 treated hearts and 4 untreated controls. Blinded analysis was performed by 2 MRI 
radiologists. Two treated hearts underwent immunohistologic analysis.
Results: In part A, 71 of 72 total injections (98.6%) were within the pre-speciﬁed target 
zone and 65 of 72 injections (90.3%) were at least 5 mm apart. No malignant arrhythmia, 
perforation, pericardial effusion, or death occurred. In part B, iron-oxide labeled cells were 
identiﬁed by MRI in all treated hearts. Antibody staining and ﬂuorescence microscopy also 
conﬁrmed retention of human CD34+, and histology suggested cell viability.
Conclusions: The Helix percutaneous intramyocardial delivery system was highly 
accurate and safe in this animal model using only ﬂuoroscopic guidance. Retention of 
human CD34+ cells was conﬁrmed by MRI and immunohistology. Future studies are 
needed to conﬁrm accuracy, safety, and cell retention in patients. Further preclinical 
studies are needed to characterize cell retention over time and quantify efﬁciency of cell 
delivery.
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2510-631 Long Term Effectiveness of Drug Eluting Stents in the 
Treatment of In-stent Restenosis
W T Yeo, S G Teo, C H Lee, Y T Lim, H C Tan, A F Low, National University Heart 
Centre, Singapore, Singapore
Background: In-stent restenosis (ISR) rate vary from 20% to 40% following implantation of 
a bare metal stent in coronary intervention. Drug-eluting stents (DES) is now the preferred 
option in managing ISR. Long-term efﬁcacy beyond 2 years is however uncertain.
Methods: We conducted a prospective analysis of a cohort of patients presenting to a 
tertiary hospital with ISR who were treated with DES. All patients were followed-up for 
major adverse cardiac events (MACE), deﬁned as death, myocardial infarction (MI), or 
target lesion revascularization (TLR). Patient’s clinical information, lesion characteristics 
and intervention details were evaluated. They were followed up by telephone and 
outpatient reviews during the study period.
Results: A total of 127 patients with 135 target lesions were evaluated from 1st June 
2002 to 31st July 2006. The average age of the patients was 56.9 ± 10.4 years with a 
male predominance (81.1%). 27.6% of patients had a myocardial infarction and 6.3% had 
3:30 p.m.
2509-627 Oxytocin Accelerates Transmigration of Umbilical Cord 
Blood-derived Mesenchymal Stem Cells via MMP-2 and 
MMP-9
Youngkeun Ahn, Yong Sook Kim, Moon Hwa Hong, Chang Hun Song, Myung Ho Jeong, 
Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National University 
Hospital, Gwangju, South Korea, Gwangju, South Korea
Background: Oxytocin (OT), a cardiac hormone, is reported as the cardiomyogenic 
factor for embryonic stem cells. It also stimulates the differentiation of cardiac progenitor 
cells to cardiomyocytes. We found that oxytocin receptor (OTR) was highly expressed in 
UCB-MSCs in compared with bone marrow (BM)-MSCs, and we designed this study to 
elucidate whether OT play important roles in UCB-MSCs cellular events.
Methods: MSC were isolated and cultured from UCB and BM. MSCs were treated with 
OT (100 nM). Angiogeneic potential was evaluated by tube formation, and cell migration 
was assessed by wound healing assay. The transwell migration activity was determined 
by using modiﬁed Boyden chamber assay. The expressions of OTR, vWF, angiopoietin 
(Ang)-1, vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP)-2 
and MMP-9 were determined by reverse transcriptase-polymerase chain reaction (RT-
PCR) or Western blot analysis. To assay the enzymatic activities of MMP-2 and MMP-9, 
MSCs cultured media were analyzed by zymography.
Results: The expression level of OTR was higher in UCB-MSCs than BM-MSCs. The 
proliferation rate of UCB-MSCs was not changed during treatment with OT (0, 10, 100, 
1000 nM). Tube formation was attenuated by OT, and cell migration rate was not changed by 
OT treatment. On the other hand, transmigration activity was drastically accelerated by OT 
treatment. To examine whether MMP expression was induced by OT, mRNA level of MMP-2 
and MMP-9 was determined by RT-PCR. OT increased the MMP-2 mRNA in proportion to OT 
concentration (10, 100, 1000 nM) in 1 hr. MMP-9 mRNA, not expressed in UCB-MSCs, was 
increased by 100 nM and 1000 nM OT treatment in 1 hr and prolonged to 24 hr. To examine 
whether MMP-2 and MMP-9 activity was increased by OT, the UCB-MSCs were cultured 
for 24 hr in the presence or absence of OT (100 nM), and cultured media was analyzed by 
zymograph. Both MMP-2 and MMP-9 activities were increased by OT treatment.
Conclusions: OT accelerated the transmigration activity of UCB-MSCs, and OT could be 
utilized to improve the efﬁcient targeting of UCM-MSCs to injured heart tissue.
3:30 p.m.
2509-628 Real Time 3D Echo Guided Intramyocardial Delivery of 
Mesenchymal Precursor Cells in a Chronic Myocardial 
Infarct Ovine Model Using a Novel Catheter
Yanping Cheng, Warren Sherman, Genghua Yi, Gerard Conditt, Alexander Sheehy, 
Timothy Martens, Michael Schuster, Silviu Itescu, Armando Tellez, Anguo Gu, Greg 
L Kaluza, Shubhayu Basu, Juan Granada, The Skirball Center for Cardiovascular 
Research Foundation, Orangeburg, NY
Background: Allogeneic mesenchymal precursor cells (MPCs) provide a new treatment 
for heart failure. Previous studies delivered MPCs either surgically or used electromagnetic 
mapping and guidance for percutaneous injection. We evaluated the safety and feasibility of 
3D echo guided, transendocardial delivery of MPCs (Angioblast Systems Inc, NY) in a chronic 
myocardial infarct (MI) ovine model using a novel injection catheter (Abbott Vascular, CA).
Methods: MI was induced by LAD 90 min occlusion-reperfusion. 4wks after MI, the infarct 
area was identiﬁed by echocardiography. Allogeneic MPCs (225x106 cells, n=9) or media 
(n=10) were injected into the infarcted myocardium. The catheter was positioned by 
ﬂuoroscopy and catheter tip location and target area was conﬁrmed by 3D echo. Cardiac 
function was evaluated 8 wks following injections in all animals.
Results: The average procedure time in each animal was 44±10 minutes. No adverse 
cardiac events occurred during and after procedure. 8 wks after cell injection when compared 
to baseline, EF was increased 8±7% while decreased 11±9% in control group (P<0.001). 
Anterior wall circumferential (S
circ) and radial (Srad) strain were improved after MPC treatment.
Conclusions: Transendocardial injection of allogeneic MPCs was safe and effectively 
preserved of cardiac function in a model of chronic myocardial infarction. Real time 3D 
echo guided injections using a novel catheter provides a quick, safe, and effective method 
for percutaneous delivery of cells.
LVEDV(ml) LVESV(ml) EF% Scirc (%) Srad (%)
Baseline (4 wks Post MI) 56±8 33±5 42±4 -8.7±4.8 12.3±9.9
8 wks MI-Media 74±20* 47±15* 37±3* -8.5±3.3 9.2±4.1
Baseline (4 wks Post MI) 63±12 38±9 40±6 -9.9±4.4 4.6±12
8 wks MI-MPCs 74±18* 43±14 43±5*† -15.3±3.6† 17.9±8.9*†
Mean ± SD. *P<0.05 vs. 4 wks post MI; †P<0.05 vs. MI-Media
3:30 p.m.
2509-629 Four Years Follow Up of Intracoronary Delivery 
Autologous Bone Marrow Mononuclear Cells in 
Patients with ST-Segment Elevation Myocardial 
Infarction
Feng Cao, Dongdong Sun, Chengxiang Li, Li Zhao, Haichang Wang, Deparment of 
Cardiology, Xijing Hospital, FMMU, Xi’an, People’s Republic of China
Background: The beneﬁt of current reperfusion therapies for ST-elevation myocardial 
infarction (STEMI) is limited by post-infarction left ventricular (LV) dysfunction. Many 
clinical trials showed the short term outcome of bone marrow stem cell transplantation for 
MI patients, but few report demonstrated the long-term follow-up results.The purpose of 
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All death (%) 2.0 2.3 3.5 3.8
Cardiac death (%) 1.1 1.3 2.4 2.6
MI (%) 0.6(Q-wave) 0.5 (Q-wave) 3.7 2.8
TVR (%) 5.3e 4.9 5.8 5.8
ARC STf (%) 0.9 0.9 3.1 2.6
a: Includes TAXUS I, II-SR, IV, and V-de novo
b: Simple-use cases excluded one or more of the following: AMI; bifurcation, 
cardiogenic shock, chronic total occlusion, failed brachytherapy, vein graft stenting, in-
stent restenosis, large vessel (RVD>3.75), left main disease/stenting, long lesion (>28 
mm), moderate/severe calciﬁcation, multivessel stenting, ostial lesion, renal disease, 
severe tortuosity, small vessel (RVD<2.5 mm).
c: Stone GW, HORIZONS AMI: A prospective, randomized comparison of paclitaxel-
eluting TAXUS stents versus bare metal stents during primary angioplasty in acute 
myocardial infarction-one year results; Presented at TCT 2008; downloaded 16Oct08 
from http://www.crtonline.org
d: ARRIVE AMI population was more inclusive than HORIZONS AMI due to no 
exclusion criteria in the registry.
e: Non-angiographic subset (N=287)
f: ARC deﬁnite plus probable (Cutlip, et al. Circulation. 2007;115:2344)
Abbreviations: AMI=acute myocardial infarction; RCT=randomized clinical trial; 
ST=stent thrombosis; TVR=target vessel revascularization
3:30 p.m.
2510-634 Evaluation of Bioabsorbable Polymer Coated Paclitaxel-
Eluting Stent by Optical Coherence Tomography; 
STELLIUM First-in-Man Study
Amane Kozuki, Junya Shite, Toshiro Shinke, Yusuke Tanino, Daisuke Ogasawara, 
Takahiro Sawada, Hiroyuki Kawamori, Yuki Kato, Naoki Miyoshi, Naoki Yoshino, Damian 
Conway, Ken-ichi Hirata, Kobe University Graduate School of Medicine, kobe, Japan, 
Disa Vascular Ltd, Cape Town, South Africa
Background: Recent reports suggest durable polymers used for ﬁrst generation drug-
eluting stent (DES) as potential contributors to persistent inﬂammation and late DES 
thrombosis. In this study, we evaluated the vascular response to STELLIUM stent, which 
is coated with absorbable polymer for slow releases of low dose paclitaxel.
Methods: Sixteen patients with stable angina were implanted with 21 STELLIUM stents 
in South Africa. Quantitative coronary angiography (QCA) was performed at baseline and 
QCA and optical coherence tomography (OCT) analysis were done at 6 months post-
implant on 12 of these patients (15 stents). Ofﬂine OCT analyze was fulﬁlled with every 1 
mm cross section. Strut apposition to the vessel wall and thickness of neointima on each 
strut surface was evaluated. Frequency of intravascular thrombus was also evaluated.
Results: In-stent and analyzed late luminal loss was 15.33±10.22mm and 17.33±6.60mm 
(binary restenosis: 0%). By OCT, 3015 struts were visualized and average neointimal 
thickness was 148.93±154.44μm . Well-apposed strut with and without neointima overlay 
was 2725 (90.38%) and 273 (9.05%). Malapposed struts were observed in 7 (0.23%), 5 of 
those (0.17%) were uncovered with neointima. Thrombus attached to struts was observed 
in 1 stent but no angiographic obstruction.
Conclusions:This ﬁrst-in-man study of STELLIUM shows feasibility and safety of 
bioabsorbable polymeric surface coating paclitaxel-eluting stent. Additional large clinical 
trials are warranted.
3:30 p.m.
2510-635 Difference in Neointimal Coverage on the Stent Strut 
Between Sirolimus- and Paclitaxel-Eluting Stents: 
Optical Coherence Tomography Analysis
Kenya Nasu, Etsuo Tsuchikane, Osamu Katoh, Mariko Ehara, Yoshihisa Kinoshita, 
Masashi Kimura, Sudhir Rathore, Mitsuyasu Terashima, Takahiko Suzuki, Toyohashi 
Heart Center, Toyohashi, Japan
Background: Optical coherence tomography (OCT) is a novel imaging technique with 
high resolution, which is able to evaluate microscopic vascular response after drug-
eluting stent implantation. The aim of this study is to evaluate the differences of chronic 
vascular response following coronary stenting between sirolimus-eluting stent (SES) and 
paclitaxel-eluting stent (PES).
Methods: Non-restenotic 60 SESs (56 patients) and 60 PESs (53 patinets) were imaged 
with motorized OCT pull-back system (1 mm/s) at 9-month follow-up and analyzed at 
interval of 1 mm. The stent with malapposed strut observed by intravascular ultrasound at 
the time of stent implantation was excluded from analysis. Neointimal coverage of stent 
struts and the incidence of stent malapposition were evaluated.
Results: A total of 20526 struts were analyzed (10336 SES struts and 10190 PES struts). 
Exposed struts and malapposed struts were observed more frequently in SES group than 
PES group (10.5% vs. 2.3%, p<0.0001, 4.2% vs. 0.7%, p<0.0001). SES also had less 
averaged neointimal thickness compared with PES (101±92μm vs. 179±130μm, p<0.0001).
Conclusions: Although neointimal growth was more strongly suppressed by SES, both 
exposed and malapposed struts were observed more frequently in SES group. This study 
suggested that dual antiplatelet therapy should be recommended for even patients with 
non-restenotic SES at 9-month follow-up.
coronary artery bypass grafting prior to the use of DES for ISR. The target vessel was the 
left anterior descending artery in the majority of patients (59.3%), followed by the right 
coronary artery (25.9%), and left circumﬂex artery (9.6%). The type of stenoses according 
to the Mehran Classiﬁcation were Pattern I (5.2%), Pattern II (33.3%), Pattern III (43.7%) 
and Pattern IV (17.8%). Most patients were treated with 1 DES (77.8%). Cypher, Taxus 
and Endeavor stents were used in 51.1%, 46.7% and 2.2% of the cases respectively. The 
median follow up duration was 38 months (Range from 24 to 72 months). A total of 21 
(16.5%) patients experienced MACE on follow-up of at least 2 years: death 1.6%, MI 5.5% 
and TLR 9.4%. Patients with MACE had longer ISR length (33.6mm vs 25.0mm, p=0.009), 
higher grade stenosis (mean lesion diameter = 0.28mm vs 0.49mm, p=0.04), and vessel 
calciﬁcation [OR = 3.86 (95% CI 1.23 - 12.09)] when compared to those without MACE.
Conclusions: DES implantation is a reasonable long-term treatment for ISR. Our study 
demonstrates a MACE-free rate of 83.5% with median follow up to 38 months. Calciﬁed, 
diffuse ISR with high grade stenoses predispose to clinical failure regardless of preexisting 
cardiovascular risk factors.
3:30 p.m.
2510-632 Off-label and On-label Uses of Sirolimus-eluting Stent: 
Angioscopic Comparison
Masamichi Yano, Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, Takakazu 
Morozumi, Tetsuya Watanabe, Toshinari Onishi, Osamu Iida, Kenji Kawamoto, Fusako 
Sera, Hitoshi Minamiguchi, Kuniyasu Ikeoka, Shin Okamoto, Nobuaki Tanaka, Haruyo 
Yasui, Takayuki Ishihara, Tomoharu Dohi, Seiki Nagata, Kansai Rosai Hospital 
Cardiovascular Division, Amagasaki, Japan
Background: Off-label use of sirolimus-eluting stent (SES) may have an increased risk 
of late stent thrombosis. However, neointimal surfaces following off-label and on-label use 
of SES have not been explored by angioscopy. We compared the angioscopic ﬁndings of 
on-label and off-label uses of SES to explore differences in arterial healing.
Methods: We retrospectively enrolled 44 patients with 70 SES who underwent 
coronary angioscopy between 6 and 12 months after stenting. Neointimal coverage was 
angioscopically compared between off-label and on-label uses. Neointimal coverage was 
graded as complete/incomplete, depending on whether stent struts were embedded by 
the neointima.
Results: Study subjects included 56 off-label and 14 on-label uses. Incomplete coverage 
was more common in off-label use than in on-label use (71% versus 36%, p<0.05). 
Although not statistically signiﬁcant, exposed struts was found in 16 stents in off-label 
use, whereas in only 1 stent in on-label use (29% versus 7%). Incidence of thrombus 
tended to be higher in incomplete coverage than in complete coverage (24% versus 8%). 
Among off-label use, bifurcation lesions were signiﬁcantly associated with exposed struts 
by multivariate analysis (p<0.05).
Conclusion:Compared with on-label use, off-label use of SES was signiﬁcantly 
associated with incomplete coverage. Bifurcation lesions were strongly associated with 
exposed struts.
3:30 p.m.
2510-633 TAXUS ARRIVE Program: The Utility of a 
Comprehensive Drug-Eluting Stent Registry
John M. Lasala, David A. Cox, Keith D. Dawkins, Donald S. Baim, ARRIVE Program 
Participating Physicians, Washington University School of Medicine, St. Louis, MO
Background: Randomized clinical trials (RCT) of drug-eluting stents (DES) generally 
involve highly selected patients (pt) that exclude many treated in routine practice. 
Conversely, registry studies include the broadest pt subsets but lack concurrent controls 
and may lack rigorous ascertainment of endpoints.
Methods: The ARRIVE 1 and 2 Postmarket Surveillance Registries were designed 
to enroll consecutive TAXUS-treated pts with no other inclusion/exclusion criteria at 
procedure start. Data were captured via web-based reporting and veriﬁed against source 
documents for all cardiac events. Clinical monitors assessed an additional 10-20% per 
site sampling of pt to ensure data accuracy and completeness. An independent Clinical 
Events Committee determined the relationship of cardiac events to study device.
Results: Of 7,492 total pts, 64% represented expanded use beyond the simple-use 
(single vessel, single stent) characteristics found in the TAXUS pivotal RCT. Two-year 
follow-up was 94%. ARRIVE simple-use pt outcomes mirrored those of similar pt in the 
RCT TAXUS arms and outcomes for acute myocardial infarction pt were similar to results 
in the HORIZONS-AMI RCT (Table 1).
Conclusion: The close parallels in ﬁndings for simple-use and expanded-use pts between 
ARRIVE and RCT data validate the high event ascertainment in ARRIVE and show that 
a high-quality registry can provide rigorous and reliable data to guide physician decisions 
when analogous RCT data are not available. 
Table 1: Comparison of ARRIVE Subgroup Data with RCT Data
Parameter
TAXUS 
RCTa
TAXUS Arm
ARRIVE Program
Simple-use
Subgroupb
HORIZONS
AMI
TAXUS Armc
ARRIVE
Program 
AMI Subgroupd
Baseline
Characteristics N=1,400 N=2,698 N=2,257 N=954
Male (%) 71.5 65.9 77 66.6
Age (mean) 62.8 63.0 59.9 62.2
Smoker (%) 22.0 24.2 46.3 36.2
Hyperlipidemia (%) 70.1 74.4 42.2 59.7
Hypertension (%) 72.1 75.4 51.2 63.9
Diabetes (%) 25.4 29.8 16.1 24.6
Previous MI (%) 31.6 26.9 9.1 67.1
Outcomes at 1 Year (Kaplan-Meier Analysis)
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3:30 p.m.
2510-637 Does the Therapeutic Option Used for a Drug-eluting 
Stent Failure Impact the Clinical Outcomes?
Gabriel Maluenda, Gilles Lemesle, Itsik Ben-Dor, Sara D. Collins, Asmir Syed, Yanlin 
Li, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell 
F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Treatment of in-stent restenosis (ISR) of drug eluting stents (DES) is 
challenging. There are several therapeutic options for this condition including repeat DES, 
intravascular radiation (IRT) or conventional plain-old balloon angioplasty (POBA), but the 
optimal treatment has not yet been deﬁned. This study aimed to assess the predictors for 
recurrence of DES restenosis and to detect optimal therapeutic strategy.
Methods: A cohort of 476 patients who were previously treated with DES and presented 
with angiographic restenosis was identiﬁed. 266 patients were treated with new-DES 
implantation, 87 with IRT and 123 with POBA. Of these 340 patients completed 12 month 
follow-up. The composite endpoint of death-MI-target lesion revascularization (MACE) 
and target lesion revascularization were assessed up to 1-year follow up.
Results: This population presents a high prevalence of co-morbidities: diabetes 
(44.5%), chronic renal failure (18.9%) and congestive heart failure (17.8%). There was 
not signiﬁcant difference between the 3 groups regarding their baseline clinical and 
angiographic characteristics. The rate of diffuse and proliferative restenosis (length > 20 
mm) at baseline was 22.2% for repeat DES group, 18.4 % for IRT group, and 34.7% for 
POBA. The overall incidence of recurrent DES failure was 13.4 % (n=45). The rate of the 
composite MACE was 14.9% for DES, 19.4% IRB, and 18.0% for POBA (p=0.63). The 
univariate assessment of covariate association with recurrent restenosis up to 1 year 
revealed no predictors, however, chronic renal failure trended towards an association 
(HR: 1.8[0.9-3.3], p=0.074).
Conclusion: Recurrence of ISR after treatment of DES failure is not benign and remains 
challenging independent of the treatment modality. Chronic renal insuﬁciency remains the 
most important adverse prognosis marker for failure of treatment in this population.
3:30 p.m.
2510-638 Frequency and Risk of Noncardiac Surgery After Drug-
Eluting Stent Implantation
Nainesh K. Gandhi, Subhash Banerjee, Emmanouil S. Brilakis, VA North Texas 
Healthcare System, Dallas, TX, University of Texas Southwestern Medical Center, 
Dallas, TX
Background: Limited data exist on the frequency of noncardiac surgery and the incidence 
of perioperative complications after coronary drug-eluting stent (DES) implantation.
Methods: We evaluated the perioperative outcomes of all patients who underwent 
noncardiac surgery after receiving a DES at our institution between 1/2005 and 7/2008.
Results: Of the 823 patients receiving a DES during the study period, subsequent 
noncardiac surgery was required in 131 (16%) patients. Mean age was 60 years and 
96% were men. A total of 191 surgeries were performed (34% general surgery, 18% 
dermatologic, 15% vascular, 8% urologic, 8% orthopedic, 7% head and neck, 5% 
colorectal, 3% ophthalmologic, 2% dental) after a mean and median time of 17 ± 10 and 
15 months, respectively from DES implantation.
A complication occurred in 19 surgeries (10%): excessive bleeding in 11 patients 
(6%), myocardial infarction in 4 patients (2%), acute renal failure in 1 patient (0.5%), 
hypotension and syncope in 1 patient (0.5%) and postoperative death in 2 patients 
(1%). Stent thrombosis occurred in only 1 patient (0.5%). A complication occurred in 3 
of 27 (11%) surgeries done within 6 months vs. 16 of 164 surgeries (10%) done greater 
than 6 months post DES implantation (p=0.83). Clopidogrel was continued during the 
perioperative period in 58 surgeries (30%). A complication occurred in 6 of 58 surgeries 
(10%) in which patients received perioperative clopidogrel vs. 13 of 133 surgeries (10%) 
in which patients did not receive perioperative clopidogrel (P=1.0).
Conclusions: Patients receiving a DES often require noncardiac surgery afterwards. The 
risk of perioperative myocardial infarction or stent thrombosis appears to be low.
3:30 p.m.
2510-639 Prevalence and Predictors of Early and Late Restenosis 
After Sirolimus-Eluting Stent Implantation for De Novo 
Lesion
Kazushige Kadota, Kazuaki Mitsudo, Katsumi Inoue, Tsuyoshi Goto, Satoki Fujii, 
Hiroyuki Yamamoto, Harumi Kato, Naoki Oka, Yasushi Fuku, Shingo Hosogi, Hiroyuki 
Tanaka, Seiji Habara, Daiji Hasegawa, Masao Imai, Suguru Ootsuru, Youji Okamoto, 
Masakazu Miyamoto, Naoki Saito, Kentaro Shibayama, Kurashiki Central Hospital, 
Kurashiki, Japan
Background: Recently, the concern about late restenosis after drug eluting stent 
implantation has emerged. However, the prevalence and predictors of late restenosis after 
Sirolimus-eluting stent (SES) implantation remain unclear. We evaluated the prevalence 
of early and late restenosis after SES implantation for de novo lesion by serial follow-
up angiography (f/u CAG). Methods: From November 2002 to December 2006, 1913 
patients (3025 de novo lesions) were treated with SES exclusively and successfully. Of 
these lesions, 2430 lesions underwent early f/u CAG at 6-8 months after PCI (early f/u 
rate, 80.3%). Of these lesions, 1830 lesions without restenosis underwent late f/u CAG 
at 12 months after early f/u CAG (late f/u rate 82.8 %). Early and late restenosis were 
deﬁned as restenosis at early f/u and restenosis at late f/u without early one respectively. 
Results: Early and late restenosis rate were 9.0 % and 6.3 % respectively. Early and 
late target lesion revascularization (TLR) after SES implantation was 5.9 % and 4.1 % 
respectively. By multivariate analysis, the predictors of early and late restenosis were 
3:30 p.m.
2510-636 Gender-Speciﬁc Outcomes after Paclitaxel-Eluting Stent 
Implantation in Routine Practice
John M. Lasala, David A. Cox, Ruth M. Starzyk, Takahiro Uchida, Keith D. Dawkins, 
Donald S. Baim, ARRIVE Program Investigators, Washington University School of 
Medicine, St. Louis, MO
Background: Pivotal randomized controlled trials (RCT) of drug-eluting stents (DES) have 
included small numbers of women and have been limited to a highly selected patient (pt) 
population excluding many treated in routine practice. Adverse outcomes have not been 
independently correlated with gender in RCT as women and men have derived similar 
beneﬁt through 1 year with DES compared to bare metal stents. This study assessed the 
association of gender with 2-year outcomes in a large cohort of unselected patients.
Methods: TheARRIVE Postmarket Surveillance Program was designed to enroll at procedure 
start consecutive pts treated with the TAXUS Express2 Stent System with no other inclusion/
exclusion criteria. Clinical monitors assessed 100% for cardiac events and an extra 10-20% 
per site sampling of pt to conﬁrm data accuracy and completeness. An independent Clinical 
Events Committee determined the association of cardiac events to study device.
Results: Women, representing 33% of 7,492 analyzed pts, were older with more diabetes 
and by unadjusted analysis had signiﬁcantly higher 1- and 2-year rates for mortality and 
target lesion revascularization (TLR, Table 1). By multivariate analysis, gender was a 
signiﬁcant factor for TLR at 2 years (Male: HR 0.75 [0.63-0.90] P=0.002) but not for death/
cardiac death/MI.
Conclusion: Unlike in pivotal RCT, in the US real-world ARRIVE registry women had 
slightly higher mortality and TLR through 2 years. By multivariate analysis gender was a 
signiﬁcant factor for TLR. 
Table 1: 
ARRIVE Baseline Characteristics and Outcomes in Men and Women
Men Women P-valuea
Baseline Characteristics
Simple Useb 35.2% (1777/5043) 37.6% (921/2449) 0.045
Age 62.92±11.48 (5043) 66.99±11.73 (2449) <0.001
Smoker at baseline 25.0% (1259/5043) 20.6% (505/2449) <0.001
Hypercholesterolemia 76.0% (3833/5043) 75.3% (1844/2449) 0.50
Hypertension 73.3% (3698/5043) 81.4% (1993/2449) <0.001
Diabetes mellitus 30.0% (1511/5043) 35.0% (857/2449) <0.001
Oral medication 22.3% (1125/5043) 24.2% (593/2449) 0.07
Previous MI 38.3% (1929/5043) 32.4% (793/2449) <0.001
Previous stroke 5.4% (270/5043) 8.0% (197/2449) <0.001
Previous CABG 22.6% (1138/5032) 14.9% (364/2439) <0.001
Previous PCI 38.1% (1902/4994) 34.1% (823/2414) 0.001
CHF 6.4% (321/5043) 7.8% (190/2449) 0.03
Multivessel stenting 16.1% (814/5043) 16.1% (394/2449) 0.95
Mean RVD (mm) 3.04±0.42 (5043) 2.95±0.40 (2448) <0.001
Mean lesion length (mm) 15.84±9.01 (5033) 15.33±8.29 (2442) 0.02
Outcomes (Unadjusted Analysis)
1 Year (97% follow-up)
Death 3.2% (157/4884) 4.2% (100/2390) 0.04
Cardiac death 2.0% (97/4884) 2.6% (62/2390) 0.10
MI 2.1% (102/4884) 2.2% (53/2390) 0.72
Q-wave MI 0.7% (34/4884) 0.5% (12/2390) 0.33
TVR 6.3% (310/4884) 7.6% (182/2390) 0.04
TLR 4.6% (225/4884) 6.2% (148/2390) 0.004
ARC ST (deﬁnite/probable)c 1.8% (86/4884) 1.8% (42/2390) 0.99
2 Years (94% follow-up) 
Death 6.1% (288/4706) 7.4% (173/2329) 0.04
Cardiac death 3.4% (161/4706) 4.3% (99/2329) 0.08
MI 3.2% (152/4706) 3.3% (77/2329) 0.87
Q-wave MI 1.1% (52/4706) 0.8% (18/2329) 0.19
TVR 9.8% (461/4706) 10.9% (254/2329) 0.15
TLR 7.2% (341/4706) 8.8% (204/2329) 0.03
ARC ST (deﬁnite/probable) c 2.7% (127/4706) 2.4% (57/2329) 0.53
Values are % (count/sample size) or mean±SD (n)
a: P values are two-sided from Student t -test for continuous variables and from the chi-
square test for binary proportion.
b: Simple-use cases excluded one or more of the following: AMI; bifurcation, 
cardiogenic shock, chronic total occlusion, failed brachytherapy, vein graft stenting, in-
stent restenosis, large vessel (RVD>3.75), left main disease/stenting, long lesion (>28 
mm), moderate/severe calciﬁcation, multivessel stenting, ostial lesion, renal disease, 
severe tortuosity, small vessel (RVD<2.5 mm).
c: Cutlip, et al., Circulation 2007;115:2344
Abbreviations: CABG=coronary artery bypass graft; CHF=congestive heart failure; 
MI=myocardial infarction; PCI=percutaneous coronary intervention; RVD=reference 
vessel diameter; ST=stent thrombosis; TLR/TVR=target lesion/vessel revascularization
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thrombosis among women treated with ZES, late-term composite outcomes of TVF and MACE 
are signiﬁcantly lower in women due to decreased rates of target lesion and target vessel 
revascularization. These ﬁndings inform the need to better understand the interaction of gender 
with safety and efﬁcacy outcomes following percutaneous revascularization with ZES.
1 year 2 years
Female 
(N=608)
Male
(N=1,524) P value
Female 
(N=608)
Male
(N=1,524)
P
value
Cardiac Death 1.0 0.5 0.16 1.4 1.0 0.12
Myocardial Infarction 2.0 2.4 0.17 2.4 2.6 0.34
Target Lesion 
Revascularization 4.8 5.6 0.04 5.8 6.4 0.07
Target Vessel 
Revascularization 6.7 8.7 0.007 8.2 10.4 0.005
ARC Deﬁnite/Probable Stent 
Thrombosis 1.2 0.4 0.13 1.4 0.5 0.06
Major Adverse Cardiac 
Events 7.4 8.3 0.02 8.8 10.2 0.01
Target Vessel Failure 8.5 10.7 0.008 10.0 12.8 0.004
All values expressed as percent.
3:30 p.m.
2510-642 A Risk Score For Predicting Major Adverse 
Cardiovascular Event Within 30 Days After 
Percutaneous Coronary Intervention With Drug-Eluting 
Stent, Results From The STENT Registry
Hiroki Ito, Marcy Nussbaum, James B. Hermiller, Zachary Hodes, Charles A. Simonton, 
St. Vincent Heart Center of Indiana, Indianapolis, IN, Carolinas Heart Institute, Carolinas 
Medical Center, Charlotte, NC
Background: Previous risk models predicting in-hospital major adverse cardiovascular 
event (MACE) after coronary intervention may underestimate actual post-procedure 
complications due to the trend toward early discharge of patients. In addition, these 
studies were not exclusive to drug-eluting stent (DES).
Methods: Using a subset (N 10,679) from the STENT registry, a logistic regression 
model was developed to predict 30day MACE which includes death, myocardial infarction, 
target vessel revascularization and stroke. A risk score was created from the model and 
validated in another subset (3,099).
Results: In the study subset, there was signiﬁcant difference between in-hospital and 
30day MACE 2.0 vs. 4.2% (p <0.01). Univariate analyses comparing patients with vs. 
without 30day MACE showed that female (33.2 vs. 34.1%), mean age (63.2±11.9 vs. 
62.7±11.7years), age q75 years (17.2 vs. 16.5%), diabetes mellitus (33.0 vs. 30.6%), and 
previous coronary bypass surgery (16.7 vs. 15.8%) were not signiﬁcant predictors, which 
contrasts previous studies. The c-statistics of the ﬁnal model were 0.653 and 0.650 in the 
study and validation subset, respectively.
Conclusion: In this large real world registry of DES, in-hospital MACE did not represent 
short-term post-procedure prognosis, and some demographic risk factors were not 
consistent with previous studies. It may be valuable to see if another prediction rule such 
as recursive partitioning ﬁts better in our dataset.
Multivariate predictors of 30day MACE 
Variables in the ﬁnal model Integer score Coefﬁcient OR (95% CI) p value
Hemoglobin <10 4 0.85 2.4 (1.8-3.1) <0.001
Left main disease 3 0.63 1.9 (1.1-3.4) 0.034
Acute congestive heart failure 2 0.49 1.6 (1.1-2.4) 0.017
Shock or cardiac arrest 8 1.75 5.7 (3.4-9.8) <0.001
IABP or cardiopulmonary support 6 1.25 3.5 (2.0-6.3) <0.001
Coronary thrombosis 2 0.47 1.6 (1.0-2.5) 0.039
Ostial lesion 3 0.58 1.8 (1.4-2.4) <0.001
Post-procedure TIMI <3 5 1.14 3.1 (1.6-6.0) <0.001
High ACC/AHA lesion risk 1 0.22 1.3 (1.0-1.5) 0.038
3:30 p.m.
2510-643 Rates of Aspirin and Plavix Resistance Among 
Patients With and Without Deﬁnite Drug-Eluting Stent 
Thrombosis
Ron Waksman, Tina L. Pinto Slottow, Rekha Gavini, Mickey Scheinowitz, Patricia 
Beauzile, Petros Okubagzi, Kimberly Kaneshige, Zhenyi Xue, Rebecca Torguson, Udaya 
Tantry, Augusto Pichard, Lowell Satler, William Suddath, Kenneth Kent, Paul Gurbel, 
Washington Hospital Center, Washington, DC
Background: Drug-eluting stent thrombosis (DEST) has multifactorial causes. Variable 
responsiveness to antiplatelet therapy likely contributes to its pathogenesis.
Methods: Aspirin (ASA) and clopidogrel (CLOP) responsiveness was measured in 26 pts 
(ST group) who experienced angiographically-proven DEST and 15 pts (control group) 
who had not experienced ST at least 1 year following DES implantation. ASA resistance 
was deﬁned as ASA resistance units (ARU) >550 by VerifyNow Aspirin assay. CLOP 
resistance was deﬁned as either P2Y12 response units (PRU) >263 by VerifyNow assay 
or P2Y12 reactivity ratio (PRR) >65% by Biocytex vasodilator-stimulated phosphoprotein 
phosphorylation assay.
Results: Median time to DEST after implant was 17 days (range 0-1312). Clinical 
presentation was STEMI in 77% and acute coronary syndrome in 16%. At the time of ST, 
82% of ST pts were taking ASA and 71% were taking CLOP. More ST pts than controls 
shown in the table. Conclusions: Late restenosis after SES implantation was not a rare 
phenomenon for de novo lesion. There were some differences between the predictors of 
early and late restenosis. These results suggested that the mechanism of early and late 
restenosis could be different.
Predicctors of Early and Late Restenosis
Predictors of Early 
Restenosis
Predicotrs
of Late 
Restenosis
OR 95%CI P Value OR 95%CI P Value
Hemodialysis 5.25 3.00-9.18 <0.0001
Longer
stenting
(>36mm)
2.61 1.33-5.13 0.0055
LMT stenting 2.27 1.49-3.49 0.0002 Saphenous
vein graft 5.43 1.10-26.9 0.0381
Saphenous vein 
graft 7.43 2.28-24.3 0.0009
Diabetes Mellitus 1.71 1.23-2.38 0.0015
Aorto-ostial lesion 3.25 1.51-6.97 0.0026
Bifurcation lesion 1.59 .112-2.26 0.0101
Longer stenting 
(>36mm) 1.81 1.11-2.97 0.0179
3:30 p.m.
2510-640 Drug Eluting Stents (DES) versus Bare Metal Stents 
(BMS) in Octogenarians: A Comparative Outcome 
Analysis
Nitin Mahajan, Ashok Kondur, Rajeev Sudhakar, Vikas Veeranna, Ashutosh Niraj, Luis 
Afonso, Wayne State University, Detroit, MI
Background: Despite the increasing number of elderly, octogenarians (q80 years) are 
underrepresented in percutaneous coronary intervention (PCI) trials. Limited data on 
comparative clinical outcomes following PCI with DES or BMS in octogenarians exist.
Methods: Retrospective screening of 3960 consecutive patients that underwent PCI at 
a tertiary medical center (Jan 2000 -Dec 2006) identiﬁed 220 octogenarians (83.6±3.4 
years) and 376 elderly (<80 yrs) patients (71.3±4.3 years). End points included all cause 
mortality and major adverse cardiovascular outcomes (MACE) deﬁned as recurrent MI, 
CHF, revascularization or death at 30 days and 2 years of follow up. The patients were 
stratiﬁed into 4 groups a) elderly (<80 yrs) DES PCI (n=176), b) octogenarian DES PCI 
(n=146), c) elderly BMS PCI (n=202) and d) octogenarian BMS PCI (n=74).
Results: Cumulative 2 year mortality was higher in octogenarians compared to elderly 
<80 (24% vs. 22% p <0.05). After adjustment of confounding variables, ageq80 years 
remained a signiﬁcant predictor of mortality (hazard ratio 1.33, 95% CI 0.92-1.92) and 
MACE (HR 1.40, 95% CI 1.06-1.85). On multivariable analysis, BMS was associated with 
higher (Figure) MACE (HR 1.31, 95% CI 1.13-1.51 p<0.01), and mortality (HR 2.72, 95% 
CI 1.15-6.51, p=0.02) in octogenarians at 2 years. No differences were seen at 30 days.
Conclusions: Octogenarians have a high mortality risk following PCI. However, compared 
to BMS, DES use confers a signiﬁcant survival beneﬁt and longer MACE free period. 
3:30 p.m.
2510-641 Gender-based Outcomes Following Treatment with 
Zotarolimus-Eluting Stents: Analysis of 6 Clinical Trials
Marcus L. Williams, Ryan A. Brown, Colin M. Barker, Minglei Liu, Laura Mauri, Ian 
Meredith, Jean Fajadet, William Wijns, Paul S. Teirstein, Martin B. Leon, David E. 
Kandzari, Scripps Clinic, La Jolla, CA
Background: Whether outcomes differ according to gender among patients treated with 
zotarolimus-eluting stents (ZES) has not been characterized.
Methods: In a patient level analysis of the Endeavor ZES clinical trials program (N=2,132), 
angiographic and clinical ﬁndings were compared at baseline and over late-term follow-up 
according to gender.
Results: Among 2,132 patients treated with ZES and enrolled in 6 Endeavor clinical 
studies, 608 (28%) were women. Compared with men, women treated with ZES had 
signiﬁcantly older age (P<0.001) and a higher prevalence of diabetes and hypertension 
(P<0.001 for both). Women less commonly had a history of recent (P=0.006) or prior 
myocardial infarction (P<0.001), prior percutaneous coronary revascularization (P=0.009)
and smoking (P<0.001). Reference vessel diameter was signiﬁcantly smaller for women 
compared with men (2.7±0.4 mm versus 2.8±0.5 mm, P<0.001). Risk-adjusted outcomes 
at 1 and 2 years according to gender are represented in the Table.
Conclusion: Despite greater baseline risk and a numerically higher incidence of stent 
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2510-646 Multicenter First-In-Man Study With the Lowest Known 
Dose Elixir Myolimus-Eluting Coronary Stent System 
With Durable Polymer: 12-month Clinical and Six Month 
Angiographic and IVUS Follow-Up
Wolfgang Rutsch, Helmut Schühlen, Bernhard Witzenbichler, Lynn Meredith, Vinayak 
Bhat, John Yan, Peter Fitzgerald, Charité, University Clinic Berlin, Campus Berlin Mitte, 
Department of Cardiology, Berlin, Germany, Stanford Cardiovascular Core Analysis 
Laboratory, Stanford University, Stanford, CA
Background: The Elixir Myolimus-Eluting Stent with Durable Polymer (Elixir Medical, 
Sunnyvale, CA, USA) is comprised of a balloon expandable cobalt chromium alloy 
stent coated with a low, 40 mcg total dose of myolimus, delivered by a thin, single layer 
methacrylate polymer.
Methods: The Elixir Myolimus-Eluting Stent FIM trial evaluated safety and effectiveness 
through a combination of clinical, angiographic, and IVUS endpoints. A total of 15 patients 
with single, de novo coronary artery lesions were enrolled. The primary endpoint was in-
stent late lumen loss assessed by angiography at 6 months. Secondary endpoints included 
acute success, major adverse cardiac events (MACE) and clinically-driven TLR at 1, 6, 9, 
12, 24 months and 6-month binary restenosis and in-stent % volume obstruction.
Results: Acute device success was 100% with a low MACE rate through 9 months (Table 
1). Twelve (12) month clinical follow-up and detailed 6-month angiographic and IVUS data 
will be presented.
Table 1: Major Adverse Cardiac Events
Major Adverse Cardiac Events (MACE) to 9 months
Cardiac Death 0.0% (0/15)
Myocardial Infaction (MI) 6.7% (1/15)
Q-Wave 0.0% (0/15)
Non-Q-Wave 6.7% (1/15)
Target Lesion Revascularization (TLR) 0.0% (0/15)
Cumulative MACE 6.7% (1/15)
Stent Thrombosis 0.0% (0/15)
Conclusion: The Elixir Myolimus-Eluting Stent loaded with the lowest known dose of 
myolimus, in combination with a durable polymer, demonstrated excellent safety and 
effectiveness to 9 months. Clinical data through 12 months and 6 month angiographic 
and IVUS data will be presented.
3:30 p.m.
2510-647 Inﬂuence of Drug-eluting Stent Implantation With Lipid 
Lowering Therapy to the Plaque Regression Located 
Apart From the Stented Segment, Sub-analysis of 
JAPAN-ACS Trial
Yoshihisa Nakagawa, Takeshi Kimura, Takeshi Morimoto, Takafumi Hiro, Katsumi 
Miyauchi, Yukio Ozaki, Masakazu Yamagishi, Tetsu Yamaguchi, Satoshi Saito, Kazuo 
Kimura, Hiroyuki Daida, Masunori Matsuzaki, for the JAPAN-ACS Investigators, Tenri 
Hospital, Tenri, Japan
Background: Location of focal restenosis after drug-eluting stent (DES) implantation 
is more common in proximal-edge than in distal-edge, such a phenomenon was not 
observed with bare metal stent (BMS). It is unclear that the inﬂuence of DES to the plaque 
located apart from the stenting site.
Methods: JAPAN-ACS trial showed a signiﬁcant regression of non-culprit plaque volume 
(PV) with early aggressive lipid lowering therapy for patients with acute coronary syndrome 
(ACS). In this study, PV was measured with intravascular ultrasound at baseline and at 8-12 
months follow-up after stenting for the treatment of culprit plaque. All measured plaques 
were located in proximal or distal of the same coronary arteries of stenting, and at least 5 
mm apart from the stent edge. Percentage change in plaque volume (%change in PV) and 
change in percent plaque volume (change in %PV) were compared between the stent types 
(DES or BMS) and between plaque locations (in proximal or distal of stenting site).
Results: As shown in the table, the plaque located in DES distal had signiﬁcantly larger 
regression of %change in PV of -22.6±11.4%, compared to that of in DES proximal 
(p=0.0064) and in BMS distal (p=0.013). Conclusion: The degree of plaque regression 
with aggressive lipid lowering therapy was larger in the plaque located in DES distal, and 
this data suggest that DES has an inﬂuence to the plaque apart from and located in distal 
of the stented segment.
Plaque Volume Data
variable DESproximal
DES
distal
p value: DES 
proximal vs 
distal
BMS
proximal
BMS
distal
p value: DES 
distal vs BMS 
distal
n 62 18 108 58
PV at baseline(mm3) 56.1
±32.7
40.1
±31.8 0.070
64.6
±31.8
50.0
±30.0 0.23
%PV at beseline (%) 50
±11
52.4
±13 0.42
49.5
±8.8
50.2
±11.1 0.47
PV at follow-up(mm3) 45.8
±28.3
30.5
±23.8 0.039
54.1
±28.9
43.5
±30.0 0.096
%PV at follow-up (%) 44.2
±12.1
41.9
±11.5 0.47
44.3
±9.9
44.4
±11.2 0.41
%change of PV (%) -18.7
±15.2
-22.6
±11.4 0.31
-17.2
±12.9
-15.2
±15.6 0.067
change in %PV (%) -5.78
±6.1
-10.5
±7.36 0.0064
-5.29
±5.45
-5.76
±6.86 0.013
were ASA and CLOP resistant as determined by PRU. There was no difference in CLOP 
resistance by PRR between the ST and control groups. Approximately 40% of ST pts 
were CLOP resistant. 14 pts (early ST) had early DEST (median 6 days after implant) and 
12 (late ST) had late DEST (median 492 days after implant). Rates of ASA and CLOP 
resistance were similar between pts in the early and late ST groups.
Conclusions: Pts who experienced DEST demonstrated signiﬁcantly higher rates of 
CLOP resistance when compared to controls by PRU but not PRR. ASA resistance was 
only present in ST pts. 
Antiplatelet Responsiveness ST (n=26) Control (n=15) p value
Mean ARU 477 ± 89 409 ± 41 0.002
Mean PRU 226 ± 110 173 ± 80 0.023
Mean PRR (VASP) 64 ± 20 53 ± 22 0.11
ASA resistant (%) 23 (6/26) 0 (0/15) 0.07
CLOP resistant (%)
By PRU 40 (10/25) 7 (1/15) 0.03
By PRR 43(9/21) 43 (6/14) --
3:30 p.m.
2510-644 Two-Year Extended Follow-up in Patients Receiving a 
Zotarolimus-eluting Stent in the E-Five Registry
Martin T. Rothman, Ian T. Meredith, Keyur Parikh, Peter Sick, Fausto Feres, Chaim 
Lotan, For the E-FIVE Registry Investigators, The London Chest Hospital, London, 
United Kingdom
Background: The use of drug-eluting stents (DES) for percutaneous coronary intervention 
(PCI) effectively reduces restenosis rates in patients with symptomatic ischemic heart 
disease and de novo coronary artery lesions, however, long-term safety and late stent 
thrombosis (ST) rates remain a concern. The Endeavor zotarolimus-eluting stent (ZES) 
has been found to successfully treat patients with a range of clinical and angiographic 
characteristics. Long-term follow-up in real-world populations is essential to establish the 
safety of the ZES in patients with both simple and complex lesions.
Methods: The E-Five Registry is a prospective, nonrandomized, global registry of 8314 
patients from 188 centers on 4 continents. There were no angiographic or clinical exclusion 
criteria for patients with single or multi-vessel disease amenable to stenting. The primary 
endpoint was rate of major adverse cardiac events (MACE) at 1 year. Compliant centers 
who enrolled at least 40 patients continued to follow a subset of patients through 2-years. 
MACE, myocardial infarction (MI), and ST using ARC criteria were adjudicated by an 
independent Clinical Event Committee.
Results: Twelve month results for 7832 (94.2%) have been reported and revealed a high 
proportion of patients with complex clinical and lesion characteristics (74.4%). The overall 
rate of MACE was 7.5% and late ARC deﬁnite/probable stent thrombosis ( 31 to 365 
days) was 0.4%. The 12-month rates for overall death was 2.4%, cardiac death plus MI 
was 3.0%, and TLR, TVR and TVF were 4.5%, 4.9% and 7.2% respectively. Extended 
two-year follow-up data on approximately 2000 patients will be reported for each of these 
key secondary endpoints.
Conclusions: Long-term follow-up of registry patients with a range of clinical and 
angiographic characteristics will further enhance our understanding of the extended 
effects of ZES treatment for patients undergoing PCI.
3:30 p.m.
2510-645 Long-Term Clinical Impact of Bleeding After 
Percutaneous Coronary Intervention With Drug-Eluting 
Stent In Real World Practice
Jong-Young Lee, Young-Hak Kim, Won-Jang Kim, Sung-Hwan Kim, Sung Sik Kim, 
Myung-Zoon Yi, Duk-Woo Park, Seung-Whan Lee, Sung-Cheol Yun, Cheol Whan Lee, 
Myeong-Ki Hong, Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, 
South Korea
Background: The impact of bleeding or transfusion on long-term clinical outcomes after 
percutaneous coronary intervention (PCI) with drug-eluting stent (DES) is not clear in 
real world practice.
Methods: Consecutive 3,170 patients (mean age of 60 ± 10 years) undergoing PCI with 
DES between February 2003 and March 2006 were enrolled. Occurrence of cardiac 
death, myocardial infarction (MI), bleeding, or transfusion was prospectively evaluated. 
The primary end point was the episode of major bleeding deﬁned as the STEEPLE 
criteria indicating fatal, retroperitoneal, intracranial or intraocular bleeding, bleeding 
requiring any transfusion q 1 unit of packed red cells or whole blood, bleeding causing a 
decrease in hemoglobin of q 3 g/dl (hematocrit q 10%), or bleeding requiring intervention 
or speciﬁc treatment.
Results: Major bleeding occurred in 148 patients (4.7%) during follow-up (median, 
1366 days). Adjusted Cox model was created using the patients’ clinical, procedural and 
angiographic characteristics. Patients with major bleeding had higher incidences of adverse 
outcome (Table). When the patients were stratiﬁed according to the presenting symptom, in 
either acute MI (adjusted HR 3.93, 95% CI 1.64 - 9.42) or angina (adjusted HR 3.18, 95% 
CI 2.05 - 4.93), major bleeding was signiﬁcantly associated with cardiac death.
Conclusions: Bleeding complication is a signiﬁcant predictor of long-term cardiac 
mortality and MI after daily practice of DES placement for either stable or unstable 
patients. 
Outcomes Hazard Ratio (95% CI)
Unadjusted cardiac death 6.16 (3.60 - 10.54)
Unadjusted MI 4.73 (2.39 - 9.34)
Unadjusted cardiac death/MI 5.18 (3.26 - 8.24)
Adjusted cardiac death 3.36 (1.79 - 6.31)
Adjusted MI 3.06 (1.50 - 6.26)
Adjusted cardiac death/MI 3.19 (1.89 - 5.37)
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2511-585 Achieving Door to Balloon Times of Less Than 90 
Minutes for STEMI Patients Transferred for Primary PCI
Bina Ahmed, Stefan Lischke, Faye Straight, Prospero Gogo, Stephen Lefﬂer, Marc 
Kutler, David J. Schneider, Harold L. Dauerman, University of Vermont, Burlington, VT
Background: Recent data from large national registries show that <10% of STEMI 
patients transferred for primary PCI (PPCI) actually meet the door to balloon (D2B) goal 
of <90 minutes, and only one third achieve D2B time of < 120 minutes. We established 
a single point of activation and simpliﬁed pharmacology system to allow rapid transfer of 
STEMI patients for PPCI to meet the D2B goal < 90 minutes. Methods: Per established 
protocol, 33 consecutive patients from February 2007 to August 2008 presenting with 
STEMI to a community hospital in Vermont were transferred 26 miles to our PCI center for 
PPCI. No patients received thrombolysis during this time period. Three time intervals were 
evaluated: door to door time (presentation to ﬁrst hospital to arrival at PCI center); PCI 
delay time (arrival at PCI center to ﬁrst balloon inﬂation) and total D2B time (presentation 
to ﬁrst hospital to ﬁrst balloon inﬂation). Results: The majority of transfers (69%) occurred 
off-hours. All patients received aspirin, clopidogrel and heparin pre-PCI. Mean door to 
door time, PCI delay and total D2B times were 66(40-109), 20 (9-35) and 86 minutes 
(58-129) with 70% of patients achieving D2B of less than 90 minutes and 94% achieving 
D2B < 120 minutes. Conclusions: For patients in a rural setting who present with STEMI, 
transfer of approximately 30 miles for timely PPCI can be achieved in nearly 75% of 
patients using a simpliﬁed activation and pharmacology system. 
3:30 p.m.
2511-586 Low Blood Pressure Is Associated With Increased 
Cardiovascular Morbidity (J-Shaped Curve) in Treated 
Hypertensive Patients With Increased Cardiovascular 
Risk: The VALUE Randomized Trial
Franz H. Messerli, Giuseppe Mancia, Michael A. Weber, Sverre E. Kjeldson, Bjorn 
Holzhauer, Tsushung A. Hua, Dion Zappe, Stevo Julius, St. Luke’s-Roosevelt Hospital 
Center, New York, NY
Background: Previous studies have debated the notion that low blood pressure (BP), 
particularly diastolic, is associated with increased risk for cardiovascular (CV) disease. 
We evaluated the impact of low BP on CV outcomes in a high risk population of 15245 
hypertensive patients almost half of whom had a coronary artery disease (CAD) history.
Methods: In the prospective VALUE study, patients were randomized to valsartan or 
amlodipine regimens and followed for 4.2 years (mean). A Cox proportional hazards 
model was used to evaluate the relationship between average on-treatment BP and 
clinical outcomes. The relationship between BP and CV events was adjusted for baseline 
covariates such as age, BMI, history of CHD, history of stroke, LVH, diabetes mellitus, 
current smoking, high total cholesterol and proteinuria.
Results: Diastolic BP >90 mmHg was associated with increased incidence of the primary 
endpoint (ﬁgure); however, diastolic BP <70 mmHg also was associated with increased 
incidence (J-shaped curve). Similar trends were observed for death, total MI, heart failure 
but not for stroke. Nadir for MI was at a diastolic BP of 76 mmHg and for stroke 60 
mmHg, respectively. The ratio of MI to stroke increased as diastolic BP decreased below 
70 mmHg. In CAD patients the J curve was more pronounced than in patients without 
CAD whereas there was no J curve relationship for stroke regardless of CAD history. 
Also, systolic BPs >140 and <110 mmHg similarly were associated with increased risk 
for primary endpoint.
Conclusion: Patients in BP strata >140/90 mmHg, as well as <110/70 mmHg, were 
at increased risk for adverse outcomes in this hypertensive, high risk population. The 
preponderance of MIs over strokes in low diastolic pressure strata suggests a J-shaped 
curve with regard to diastolic BP and CAD but not with regard to diastolic BP and stroke.
3:30 p.m.
2510-648 Inﬂammatiory Markers Predict Cardiovascular 
Outcomes in Patients Undergoing Coronary Drug 
Eluting Stenting
Kreton Mavromatis, Nima Ghasemzadeh, Konstantinos Aznaouridis, Zohreh Forghani, 
Padi K. Reddy, Christine De Staercke, W. Craig Hooper, Arshed A. Quyyumi, Emory 
University, Atlanta, GA, Atlanta VA Medical Center, Decatur, GA
Abstract: Circulating inﬂammatory markers (IMs) have been associated with outcomes 
in patients with unstable coronary artery disease (CAD). We investigated the association 
of a broad array of IMs and clinical factors on outcomes in patients with stable CAD 
undergoing coronary stenting (CS) with drug eluting stents (DES).
Methods: Stable CAD patients had circulating IMs measured before and after (1 day, 
1 week and 1 month) CS, and were followed for cardiovascular death and myocardial 
infarction (MI) for 23 (range 13-43) months. Patients with inﬂammatory diseases were 
excluded.
Results: 191 patients (male: 84%; age: 61+9 years; DM: 44%; DES 92%) were studied. 
IMs that increased after CS included CRP (158%), Il-6 (273%), MMP-9 (182%), MMP-3 
(143%), MCP-1 (130%), sCD40L (125%) (all p<0.05 vs baseline), and TNF-  (126%)
(p=0.07). Death + MI was increased in patients with higher baseline values of CRP, IL-10, 
IL-6, sCD40L, and MCP-1. (Table) Multivariate analysis including the baseline IMs and 
clinical factors showed only Il-6, Il-10 and sCD40L (p=0.01, 0.07, 0.03 respectively) to 
be independent predictors of death + MI. After CS, only 1 day and 1 week post-CS CRP 
levels correlated with the risk of death + MI.
Conclusion: Higher baseline levels of Il-6, Il-10 and sCD40L, but not clinical factors, 
predict death + MI in patients with stable CAD undergoing CS.
Table. Univariate analysis: Death + MI in stable CAD patients 
Baseline Inﬂammatory Markers (median) Low(< median)
High
(> median) P OR
CRP (2.96) 3.5% 15.1% 0.009 4.86
TNF-  (2.96) 5.7% 12.0% 0.14 2.24
IL-10 (0.31) 14.6% 3.7% 0.018 0.23
IL-6 (1.23) 2.3% 15.4% 0.003 7.59
SCD40L (2964.5) 3.5% 13.7% 0.01 4.37
MCP-1 (128.8) 3.4% 14.2% 0.01 4.66
MMP-3 (9.4) 7.2% 11.2% 0.36 1.62
MMP-9 (76.4) 11.7% 7.1% 0.30 0.57
Age (61) 8.0% 8.6% NS 1.08
Diabetes* 10.4% 6.0% 0.27 0.54
HTN* 6.4% 9.0% 0.64 1.44
HLP* 15% 7.8% 0.28 0.48
Active smoking* 6.2% 14.5% 0.07 2.54
History of MI* 7.0% 10.4% 0.46 1.52
LV Function** 15.3% 7.5% 0.19 0.45
*Data presented as without vs.with the risk factor
** Data presented as EF<40% vs. EF>40%
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3:30 p.m.
2511-584 Temporal Trends and Improved Outcomes of 
Percutaneous Coronary Revascularization in 
Nonagenarians
Aaron Matthew From, Charanjit S. Rihal, Ryan J. Lennon, David R. Holmes, Jr., Abhiram 
Prasad, Mayo Clinic, Rochester, MN
Objectives: There is a paucity of outcomes data among nonagenarians undergoing 
percutaneous coronary intervention (PCI). The aim of this study was to describe the 
clinical characteristics and the outcomes of patients 90 years of age or older who were 
treated with PCI.
Methods: We evaluated the outcomes of all patients 90 years of age or older in the Mayo 
Clinic PCI registry and examined trends over time.
Results: Over a period of 19 years we identiﬁed 138 nonagenarians (66% female; age 
92.2± 2.0 years). Mean duration of hospitalization was 3.7 ± 3.1 days and the median 
follow-up duration was 3.6 years. 91% of patients presented with an acute coronary 
syndrome and underwent urgent or emergent revascularization. Technical success rate 
was 91%. Overall, the frequency of in-hospital death, Q-wave MI, and MACE (composite 
of death, Q-wave MI, urgent or emergent CABG, and cerebrovascular accident) were 
9.4%, 0.7% and 12.3%, respectively. The long term survival of the cohort was not 
signiﬁcantly different than that of an age, gender, and calendar year of birth matched 
Minnesota cohort. The cohort was divided into 2 groups according to the time of their 
intervention: pre 2000 (n=32) and 2000-2006 (n=106). The in-hospital mortality decreased 
markedly:22% to 6% (p=0.006), respectively. Conclusions: Our study demonstrates that 
advanced age alone must not be a contraindication for performing coronary angiography 
and PCI when clear indications are present.
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2511-589 Risk Of Major Adverse Events Associated With Non-
Cardiac Procedures Among Patients With Drug-Eluting 
Coronary Artery Stents
Scott Beach, Charles Salters, Hussam Hamdalla, David Booth, Ahmed Latif, Pareena 
Bilkoo, Debabrata Mukherjee, David Moliterno, Khaled Ziada, VA Medical Center, 
Lexington, KY, University of Kentucky, Lexington, KY
Background: and Objectives. Prolonged dual anti-platelet therapy after use of drug-
eluting stents (DES) represents a clinical challenge when patients subsequently require 
non-cardiac procedures. We sought to evaluate the prevalence of such occurrences, the 
incidence of adverse events, and the current management of anti-platelet therapy at the 
time of these procedures.
Methods. Records of patients who received DES at the Lexington VA Medical Center 
between 1/1/2004 and 12/31/2007 were searched for evidence of planned or performed 
non-cardiac procedures. Adverse cardiac events and/or serious bleeding complications 
during the peri-operative period were recorded.
Results. During the study, 601 patients received DES. Of those, 130 (22%) underwent 
or were planned to undergo a non-cardiac procedure: major procedures in 45 and 
minor procedures in 85 patients. Time from DES implantation to the procedure was 
427 ± 24 days. In 53 (9%) patients, the procedure was within the 1st year. Deﬁnite stent 
thrombosis occurred in 3 (2%) patients: 2 events before minor procedures and 1 after an 
abdominal surgery. Two events were in the 1st year after DES and one after 13 months. 
All resulted in myocardial infarctions; one was eventually fatal. All 3 patients were taken 
off ASA and clopidogrel prior to the procedure. Serious bleeding events were documented 
in 4 (3%) patients on dual anti-platelet therapy that were related to or resulted in non-
cardiac procedures: 1 subarachnoid bleed after carotid surgery, 1 vitreous bleed requiring 
vitrectomy, and 2 GI bleeds requiring transfusion. Peri-procedural management of anti-
platelet therapy was variable: 26 patients stopped both ASA and clopidogrel and 65 patients 
were on ASA alone. Detailed data was not available in the remaining cases.
Conclusions. Non-cardiac procedures following DES implantation are frequent (22% 
overall, 9% within 1 year). Discontinuation of dual anti-platelet therapy before a non-cardiac 
procedure carried a small (2%) but devastating risk of stent thrombosis. Dual therapy 
was associated with a small (3%) risk of serious bleeding. Optimal anti-platelet therapy 
management during non-cardiac procedures after DES needs further prospective study.
3:30 p.m.
2511-590 Staged PCI for Residual Multi-Vessel Disease Following 
Primary PCI Is Associated with Low Mortality
Kurt G. Barringhaus, David D. McManus, Philippe G. Steg, Gilles Montalescot, Frans 
Van de Werf, Jose López-Sendón, Rebecca Dedrick, Joel M. Gore, for the GRACE 
Investigators, University of Massachusetts, Worcester, MA
Background: CABG and PCI are effective means for revascularization of patients with 
multi-vessel coronary artery disease, but previous studies have not focused on treatment 
of patients that ﬁrst undergo primary PCI.
Methods: Among patients enrolled in the Global Registry of Acute Coronary Events 
(GRACE), clinical outcomes for patients presenting with STEMI treated with primary PCI 
were compared according to whether residual stenoses were treated medically, surgically, 
or with repeat PCI. Clinical characteristics and data pertaining to major adverse cardiac 
events during hospitalization and 6 months after discharge were collected.
Results: Of the 2768 patients included, 2375 (85.8%) patients were treated medically, 331 
(12.0%) underwent staged PCI, and 62 (2.2%) underwent CABG following primary PCI. 
Hospital mortality was lowest among patients treated with staged PCI (Medical=3.4%; 
PCI=0.9%; CABG=4.8%; p=0.04) as was the risk adjusted mortality (Odds Ratio: 
PCI=0.26 [0.08-0.86]; p=0.03; CABG=1.81[0.53-6.24]; p=0.35). Patients presenting 
with LAD occlusion as the culprit for primary PCI tended to have a lower mortality when 
residual disease was treated with PCI (Medical=4.0%; PCI=0.7%; CABG=7.7%; n=1304;
p=0.08). Six-month post-discharge mortality (Medical=1.3%; PCI=1.6%; CABG=0.0%; 
p=0.62) and MI (Medical=2.2%; PCI=2.9%; CABG=0.0%; p=0.36) were similar among 
the three groups. However, fewer unplanned catheter-based procedures were performed 
in patients revascularized surgically (Medical=10%; PCI=14%; CABG=1.6%; p=0.01).
Conclusions: The results of this multinational registry suggest that hospital mortality in 
patients who undergo percutaneous revascularization of multivessel coronary disease 
following primary PCI is low. Patients undergoing CABG following primary PCI require 
fewer unplanned catheter-based procedures.
3:30 p.m.
2511-591 Red Blood Cell Storage Duration and Transfusion 
Volume Affects Mortality In Patients Undergoing 
Percutaneous Coronary Intervention (PCI)
Simon D. Robinson, Christian Janssen, Eric B. Fretz, Alexander J. Chase, Brian 
Berry, Anthony J. Della Siega, W. Peter Klinke, J. David Hilton, Victoria Heart Institute 
Foundation, Victoria, BC, Canada, Morriston Cardiac Centre, Swansea, United Kingdom
Background: Despite being widely used to treat blood loss, red blood cell (RBC) 
transfusion has been associated with increased morbidity and mortality. Although the 
reasons for this remain unclear, it may be related to the structural and functional changes 
occurring within RBCs during storage. We investigated whether duration of RBC storage 
was associated with 30 day mortality in patients undergoing PCI.
Methods: We collected data on all RBC transfusions (excluding those related to CABG) 
occurring within 10 days of PCI using an electronic linkage between the British Columbia 
Cardiac Registry (BCCR) and Central Transfusion Registry (CTR). Out of 38,952 cases 
in the BCCR between 1999 and 2005, 909 patients received at least 1 unit of RBC post 
3:30 p.m.
2511-587 Inﬂuence of gender and race on post-percutaneous 
coronary intervention (PCI) outcomes in an open 
cohort of public health system patients
Sandeep Nathan, Steve Attanasio, Amit P. Amin, Arun Kumar, Ravilla Mahidhar, 
University of Chicago Medical Center, Chicago, IL, Cook County Hospital, Chicago, IL
Background: Racial and gender differences inﬂuence various cardiovascular outcomes 
however the impact of these variables on post-PCI outcomes, remains unclear.
Methods: 1,410 consecutive pts undergoing PCI at a large public health system hospital 
(PHS) were analyzed as an open cohort. Pts were included if complete clinical and 
procedural data were available and uniform access to healthcare was provided through 
planned follow-up in the PHS. Pts were grouped based on gender and race and followed 
for occurrence of MACE (death, MI, urgent TVR). Multivariate models were constructed 
and survival data were analyzed via Kaplan-Meier analysis and Log-rank test.
Results: 1,410 pts meeting inclusion criteria (57±10 yrs, 32% female, 46% Black) 
underwent PCI for STEMI (17.1%), NSTEMI (27.9%), unstable angina (26.0%) or stable 
CAD (29.1%) over 56 mos. Clinical follow-up was obtained in 97.2% (n=1,370, mean 1.7 yrs 
± 1.3 yrs). Event-free survival was similar for males and females (83.5% vs 81.9%, p=0.44). 
Black pts evidenced lower MACE-free survival than non-blacks (78.8% vs 85.9%, p<0.001) 
[Figure 1]. After multivariate analysis controlling for all risk and therapy covariates, there was 
a strong trend towards a higher MACE hazard for black pts (p=0.06).
Conclusions: While healthcare disparities exist in PHS pts, gender differences do not 
seem to confer incremental risk in this population. Racial differences however, accounted 
for a trend towards poorer outcomes and warrant further investigation. 
3:30 p.m.
2511-588 Outcomes of Patients with Acute Coronary Syndromes 
and Non-obstructive Coronary Artery Disease: Analysis 
from the Randomized ACUITY Trial
Eugenia Nikolsky, Alexandra Lansky, Roxana Mehran, Adriano Caixeta, George D. 
Dangas, Iulian Benetato Giuran, Walter Desmet, Gregg W. Stone, Columbia University 
Medical Center and the Cardiovascular Research Foundation, New York, NY
Background: Coronary angiography in patients (pts) presenting with acute coronary 
syndromes (ACS) may reveal non-obstructive coronary artery disease (CAD). Outcomes 
of these pts have not been systematically studied. We analyzed data from the randomized 
ACUITY trial to assess outcomes of pts with moderate/high-risk ACS and non-obstructive 
CAD on baseline coronary angiography triaged to medical therapy (Tx).
Methods and Results: Among a total of 6,921 pts with analyzed baseline coronary 
angiogram, non-obstructive CAD (maximal diameter stenosis <50% in any of the major 
epicardial coronary arteries/main branches) was present in 904 (13%) pts (median age: 
57 years; 53% men) triaged to medical Tx. Non ST-segment elevation MI was present in 
35.5% of pts, and the rest had unstable angina. In-hospital composite ischemic outcome* 
occurred rarely (0.2%) [death and unplanned revascularization, one case each]. At 30-day 
F/U, 82.6% of the pts were taking aspirin, 39.8% - thienopyridines, 65.4% - statins, 57.2% 
- B-blockers and 47.3% were taking ACE-inhibitors. Outcomes at F/U are presented in the 
Table. By multivariable analysis, 1-year mortality was predicted by older age (OR=1.13, 
P=0.001), smoking (OR=7.41, P=0.02), and lack of aspirin Tx at 30-day F/U (OR=0.13, 
P=0.007). 
Clinical endpoints, n (%) Follow-up
30 days 1 year
Death 7 (0.8%) 18 (2.1%)
Cardiac death 2 (0.2%) 6 (0.7%)
Q wave myocardial infarction 0 (0.0%) 0 (0.0%)
Non-Q wave myocardial infarction 2 (0.2%) 5 (0.6%)
Unplanned revascularization 2 (0.2%) 14 (1.6%)
Composite ischemic endpoint* 11 (1.2%) 35 (4.0%)
* Death, myocardial infarction or unplanned revascularization
Conclusions: Pts presenting with ACS and non-obstructive CAD have favorable 1-year 
outcomes. However, secondary prevention of CAD is necessary including smoking 
cessation and continued aspirin Tx to improve survival of these pts at 1 year.
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2511-594 Characteristics, Incidence, Management, Immediate and 
Long-Term Outcome of Coronary Artery Perforation 
During PCI in the Current Era Practice: Analysis of 
23,399 PCIs
Ioannis A. Stathopoulos, Marcelo Jimenez, EJ Kwak, Monica Losquadro, Howard 
Cohen, Sriram Iyer, Carlos Ruiz, Gary Roubin, Kirk Garratt, Lenox Hill Hospital, New 
York, NY
Background: Technical improvements permit the performance of PCI reliably and safely.
Yet, adverse events have not been eliminated. Coronary perforation (CP), although rare, 
remains an important complication during PCI.
Methods: Prospectively collected LHH data from 23,399 PCIs performed during an 8-year 
period (1999-2006) identiﬁed 73 CP cases. Records and angiograms were retrospectively 
reviewed. Long term patient survival data (median f/u 2090 days) were secured from the 
USSSDI database. Cox proportional hazard model was applied. An analysis was done to 
determine if incident rates and outcomes differed over time.
Results: CP occurred in 0.31% of PCI patients (pts). Type 1, 2, 3 and 4 occurred in 14%, 
37%, 38% and 3% of CP pts. In 8% of pts the type of CP could not be determined. Mean 
age was 69.48 ± 12.13. Males represented 60.7% of pts. Type C lesions was noted in 
72.6% of the CP and 27.4% were type B. CTOs were 33% of the lesions. PCI target 
vessels were the LAD (43.8%), the LCx (24.7%), the RCA (26%), the RI (2.7%) and grafts 
(2.8%). Vessels were found to be calciﬁed in 84.6% and tortuous in 41.5%. Presumed 
causes of CP were: the balloon (46.6%), the wire (37%), cutting balloon (5.5%), or use 
of other devices (5.4%). In 5.5% no likely cause was identiﬁed. Pericardiocentesis was 
required in 36% of CP. PTFTE stents were deployed in 34% of CP. Coils embolization 
was used in 13%. Emergent cardiac surgery was required in 5%. In hospital mortality 
was 5.5% (of which 75% occured after type 3 CP). CP that occurred during emergent 
PCI was more likely to be complicated by tamponade (p=0.04). Signiﬁcantly more PTFE 
stents were used in the most recent period (2003-2006). Length of stay was signiﬁcantly 
longer in patients with type 2 and 3 CP. Long term survival was similar for all types of CP. 
Furthermore, tamponade did not affect long term survival. Perforation rate decreased in 
the most recent period.
Conclusions: CP rate remains low in the current era practice and decreased over the last 
four years of the study. Non surgical management is associated with a high success rate. 
Tamponade did not affect long term survival.
3:30 p.m.
2511-595 The Obesity Paradox Revisited in a Large 
Contemporary Percutaneous Coronary Intervention 
Database: Overweight and Obese Patient Have Better 
Outcomes
Luis Gruberg, Srihari Naidu, Richard A. Shlofmitz, Sorin Brenner, Allen Jeremias, 
Thomas Pappas, Kevin Marzo, David L. Brown, Stony Brook University Medical Center, 
Stony Brook, NY, Winthrop University Hospital, Mineola, NY
Background: Prior studies have shown that patients with increased body mass index 
(BMI) have better outcomes following percutaneous coronary intervention (PCI)(obesity
paradox). We re-assessed these results in a large contemporary database.
Methods: Baseline clinical, angiographic and procedural characteristics, as well as in-
hospital outcomes were prospectively collected among all patients undergoing elective, 
urgent and emergent PCI at four New York State medical centers. Patients were divided 
into three groups according to BMI: normal BMI <25, overweight with a BMI between 25 
and 30 and obese with a BMI >30. The primary clinical endpoint was freedom from major 
adverse cardiac and cerebrovascular events (MACCE).
Results: A total of 15,116 patients underwent PCI between 1/2004 and 12/2007. 
Overweight and obese patients (83.4%) were more often male, younger and had diabetes 
when compared to normal BMI patients. Rates of anterior wall infarction, shock and left 
ventricular ejection fraction were similar among the three groups. Clinical characteristics 
and in-hospital outcomes including MACCE (death/stroke/re-infarction) rates are shown 
in the Table. 
Normal BMI
(n=2,503) Overweight (n=6,901)
Obese
(n=5,712) p
Age (yrs) 68.0 65.5 66.5 NS
Gender male (%) 59.6 72.1 65.1 <0.05
ST EMI (%) 9.8 8.4 6.7 NS
Diabetes (%) 22.3 26.8 43.2 <0.05
Death (%) 0.9 0.5 0.04 NS
Stroke (%) 0.4 0.2 0.2 NS
Re-infarction (%) 0.3 0.06 0.05 NS
MACCE (%)* 1.6 0.8 0.6 <0.05
Conclusions: Overweight and obese patients still constitute the large majority of patients 
undergoing PCI. These patients have better in-hospital outcomes when compared to 
normal BMI patients. This difference is mainly driven by a lower rate of the individual 
endpoints.
PCI. Mortality was determined from the provincial Vital Statistics records and transfusion 
details compared according to 30 day survival.
Results: Mean transfusion volumes were signiﬁcantly lower in patients surviving 30 days 
(2.8±2.1 vs 3.8±2.9 units, p=0.002). The average storage duration of RBC prior to transfusion was 
25.2±10.0 days. Compared to survivors, patients dying within 30 days more often received blood 
stored for >28 days (65.3 vs 52.9%, p=0.02). In a Cox regression model to adjust for baseline 
risk factors, RBC storage age >28 days (odds ratio 1.71 [95% CI 1.04-2.80], p=0.04) and higher 
transfusion volumes (OR 1.12 [1.03-1.22], p=0.008) both predicted 30 day mortality.
Conclusion: Transfusion of red cells stored for more than 28 days and higher transfusion 
volumes are associated with increased mortality in patients undergoing PCI. Further work 
should assess whether reducing the storage duration of blood improves clinical outcomes 
in those patients requiring transfusion.
3:30 p.m.
2511-592 Lipoprotein-Associated Phospholipase A2 Predicts 
28-Day and 1-Year Adverse Events Following PCI: A 
CREDO Substudy
Herbert D. Aronow, Steven R. Steinhubl, WH Wilson Tang, Danielle Brennan, Robert L. 
Wilensky, Steven P. Marso, Michael Wegner, Eric J. Topol, Michigan Heart & Vascular 
Institute, Ann Arbor, MI
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity predict 
major adverse cardiovascular events (MACE) among patients with established coronary 
artery disease including those with stable and acute coronary syndromes. Little is know about 
the prognostic utility of Lp-PLA2 in the setting of percutaneous coronary intervention (PCI).
Methods: We related pre-procedure Lp-PLA2 mass and activity to 28-day and 1-year 
MACE in 1422 patients who underwent PCI in the Clopidogrel for the Reduction of Events 
during Observation (CREDO) trial. Lp-PLA2 mass was measured with the diaDexus 
PLAC test while activity was measured by the diaDexus Colorimetric Activity Method 
(CAM). Bootstrapping was employed for model selection; 28-day logistic regression and 
1-year Cox proportional hazards models were adjusted for demographic and clinical 
characteristics, clinical presentation and randomization to clopidogrel vs. placebo. Odds 
and hazard ratios were calculated per 1 standard deviation (SD) of Lp-PLA2 levels.
Results: Mean age was 62 years and 28% were women; 15% presented with recent 
myocardial infarction (MI), 54% with unstable angina and 26% with stable angina. Mean 
(SD) Lp-PLA2 mass and activity were 481 (193) ng/mL and 166 (41) nmol/min/mL, 
respectively. Death, MI, stroke or any revascularization occurred in 156 and 388 patients 
at 28 days and 1 year, respectively. Increasing Lp-PLA2 mass and activity levels were 
independent predictors of this endpoint at 28 days (OR 1.22 [95% CI 1.03, 1.44], p=0.019 
and OR 1.20 [95% CI 1.01, 1.43], p=0.044, respectively) but not at 1 year. At 1 year, there 
were 25 patients who died, 129 with death or MI and 109 with non-fatal MI; Lp-PLA2 mass 
independently predicted death (HR 1.48 [95% CI 1.03, 2.13], p=0.035) while Lp-PLA2 
activity independently predicted death or MI (HR 1.25 [95% CI 1.04, 1.50], p=0.015) and 
non-fatal MI (HR 1.27 [95% CI 1.04, 1.55], p=0.017).
Conclusion: Lp-PLA2 mass and activity signiﬁcantly predict the risk of death, MI, stroke 
and any revascularization during the initial 28-days following PCI; Lp-PLA2 mass and 
activity differentially predict the risk of atherothrombotic events 1 year post-PCI.
3:30 p.m.
2511-593 The Association of Serum Uric Acid Levels with 
Outcomes Following Percutaneous Coronary 
Intervention
Daniel B. Spoon, Amir Lerman, Abhiram Prasad, Ryan Lennon, David R. Holmes, Jr., 
Charanjit S. Rihal, Mayo Clinic, Rochester, MN
Background: Serum uric acid may serve as a marker for the activation of oxidative 
stress and may serve as a marker for cardiovascular events. Our goal was to assess the 
association of serum uric acid levels and the outcomes of patients who have undergone 
Percutaneous Coronary Intervention (PCI).
Methods: We preformed a retrospective cohort study of patients who underwent PCIs 
between 1/2000 and 1/2007 at the Mayo Clinic in Rochester MN. Data was retrieved from 
the Cardiac Lab Interventional Clinical Database as well as the medical record. In-hospital 
and long-term mortality, as well as Major Adverse Cardiac Events (MACE) were obtained. 
There were 10632 unique patients who had a PCI and allowed use of their records for 
research. Of these, 1916 had a uric acid measure within 2 years prior to the day of PCI.
Results: Of the 1916 patients in our cohort, 1353 had normal uric acid levels and 563 
had elevated uric acid. Mortality was signiﬁcantly higher in patients with elevated uric 
acid (p=0.034) after adjusting for other risk factors associated with elevated uric acid. 
The adjusted association with mortality/MI was not quite signiﬁcant (p=0.058) and the 
association with MACE was not signiﬁcant (p=0.42)
Conclusions: This study represents the ﬁrst analysis examining the association of uric 
acid levels and outcomes of patients who have undergone PCI. The current study further 
supports a role for uric acid as a participant and/or an independent predictor of increased 
morality in PCI patients.
Multivariable Associations Between Hyperuricemia and Mortality
Variable Hazard Ratio 95% CI P-Value
Elevated Uric Acid 1.291 (1.02,1.63) 0.0338
Diabetes 1.721 (1.37,2.17) <0.0001
CHF on presentation 2.450 (1.94,3.1) <0.0001
Hypertension 0.869 (0.65,1.16) 0.3417
History of MI (>7 days) 1.302 (1.05,1.61) 0.0155
Peripheral Vascular Disease 1.462 (1.12,1.91) 0.0053
Moderate to Severe Renal Disease 1.408 (1.03,1.92) 0.0311
COPD 1.654 (1.29,2.12) <0.0001
CVA/TIA 1.315 (1.02,1.7) 0.0365
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2511-598 Association of Target Lesion Revascularization with 
Outcome in Patients with Sirolimus-Eluting Stent 
Implantation: Insights From j-CYPHER Registry
Kazuhiro Nakao, Mitsuru Abe, Takuya Taniguchi, Futoshi Yamanaka, Nobuhito Yagi, 
Nobuaki Kokubu, Yoichiro Kasahara, Yu Kataoka, Yoritaka Otuka, Takeshi Morimoto, 
Takeshi Kimura, Kazuaki Mitsudo, Hiroshi Nonogi, National Cardiovasculer Center, 
Osaka, Japan
Background: Sirolimus-eluting stents (SESs) reduce restenosis and target lesion 
revascularization (TLR) compared with bare metal stents (BMSs). Although previous 
studies reported BMS restenosis was relatively benign event, the outcome of patients 
with TLR after SES implantation remains unknown at present.
Methods: Design of j-CYPHER registry was multi-center prospective enrollment of 
consecutive patients receiving SES implantation from 37 centers in Japan. From August 2004 
to November 2006, 12812 patients with 17545 lesions were implanted with SES. Among 
10778 patients treated exclusively with SES, we identiﬁed 694 patients referred for TLR within 
1 year after index SES implantation or 9602 patients without TLR followed for 1 year. Among 
patients performed TLR, percutaneous coronary intervention was performed in 674 patients 
and coronary artery bypass grafting in 20 patients. We evaluated the event rates of death, 
myocardial infarction (MI), and cerebrovascular accident (CVA). MI occurring within 24 hours 
after index SES implantation or TLR procedure was excluded in our analysis.
Results: Compare to patients free from TLR, patients with TLR were younger (67.4+-
10.2 vs. 68.4+-10.1, p= 0.01), more likely to be male gender (80.6% vs. 75.1%, p=0.001), 
lower ejection fraction (56.4+-13.4% vs. 58.2+-13.3%, p= 0.001), higher prevalence of 
diabetes (54.2% vs. 39.9%, p<0.0001), and multivessel disease (63.1% vs. 49.1%, p= 
p<0.0001). Among 694 patients performed TLR within 1 year after SES implantation, 
the rates of death, MI, and CVA were 1.9%, 0.0%, and 0.4%, respectively, at 30 days, 
and 11.1%, 1.3%, and 3.8%, respectively, at 1 year. The incidences of cardiac death and 
sudden cardiac death were 1.7% and 0.1%, respectively, at 30 days, and 7.4% and 1.1%, 
respectively, at 1 year. The combined event rate of death, MI, and CVA was 2.3% at 30 
days, and 13.9% at 1 year after TLR. Among 9602 patients without TLR within 1 year after 
SES implantation, the incidences of death, MI, and CVA were 3.8%, 0.7%, and 1.7%, 
respectively, at 1 year after index SES implantation.
Conclusion: TLR within 1 year after SES implantation seemed to be associated with high 
mortality, but low incidences of MI and CVA in our study population.
3:30 p.m.
2511-599 Isolated Elevation in Troponin I Following Elective 
Percutaneous Coronary Intervention Is Predictive of 
Higher Long-Term Mortality
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu 
Wong, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY
Background: Elevations of CK and CK-MB after elective PCI have been associated with 
an increased risk of cardiovascular events during follow-up. However, there is little known 
about the prognostic signiﬁcance of an isolated elevation of troponin I (cTnI) without a 
rise in CK-MB following PCI.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we evaluated the outcomes 
of 1,601 pts who had normal pre-procedure cTnI and CK-MB, underwent elective or urgent 
PCI, and had normal CK-MB after the procedure. Mean follow-up was 24.6 ± 7.6 months.
Results: An elevation in cTnI was observed in 831 pts (51.9%) (median 0.50 ng/ml, range 
0.2 to 52.8 ng/ml). Patients with cTnI elevations had a greater incidence of multivessel 
PCI (17.0% vs. 9.7%, p<0.001). DES were used in 88% of patients. The incidence of in-
hospital MACE (death, CVA, emergent CABG/PCI) was 0.1% vs. 0% (p=1.00) in patients 
with vs. without cTnI elevations, respectively. By 2-years of follow-up, Kaplan-Meier 
survival rates were 94.1% vs. 96.4% (p log rank=0.020) in those with vs. without cTnI 
elevations, respectively (Figure). By multivariate Cox analysis, an elevation in post-PCI 
cTnI (HR 1.68, 95% CI 1.04-2.71, p=0.035) was an independent predictor of increased 
long-term mortality.
Conclusions: An isolated elevation in cTnI with normal CK-MB following non-emergent 
PCI is common and is not associated with more frequent adverse in-hospital outcomes. 
Importantly, patients with an elevated cTnI and normal CK-MB, have a higher long-term 
mortality. 
3:30 p.m.
2511-596 Impact of Mental Health Disorders in U.S. Veterans 
on Cardiovascular Revascularization Strategies and 
Outcomes
Jane T. Luu, Shaun J. Cardozo, Anupama Shivaraju, Dean Ferrera, Herman Kado, Clay 
Shaker, Adhir R. Shroff, John A. Kao, University of Illinois-Chicago, Chicago, IL, Jesse 
Brown Veterans Affairs Medical Center, Chicago, IL
Background: Percutaneous coronary intervention (PCI) requires mandatory antiplatelet 
therapy for up to 1 year. Because medication compliance is critical, many providers are 
hesitant to perform PCI in patients with mental health disease. Currently, 31% of all U.S. 
Veterans are diagnosed with a mental health disorder after active duty; how this impacts 
cardiac revascularization strategies and outcomes is not known.
Methods: All veterans at our institution receiving a PCI (n=487) or CABG (n=140) 
between 2004- 2007 were retrospectively studied. The primary endpoint was a composite 
of death, myocardial infarction, and revascularization at 1 year. PCI was compared to 
CABG, which has no mandatory antiplatelet requirement.
Results: Mental health disease was prevalent in 31.4% of veterans receiving PCI and 
23.6% receiving CABG. There was no difference in major adverse cardiac events after 
revascularization between veterans with mental health disease and those without. This 
was true regardless of revascularization strategy (PCI, p= 0.689; CABG, p= 0.638).
Conclusions: Mental health disorders affect a large number of veterans. We did not ﬁnd an 
association between mental health and cardiovascular outcomes after PCI. The decision to 
pursue PCI in these patients should be individualized, but mental disease should not be a stigma, 
and revascularization with PCI in this population should not be automatically precluded.
Outcomes after Revascularization
Outcomes
PCI
(n=487)
CABG
(n=140)
Mental Disease, 
PCI (n=152)
Control, PCI 
(n=335)
Mental
Disease, 
CABG
(n=33)
Control, CABG 
(n=107)
Death, % n 11.8 (18) 15.5 (52) 13.5 (5) 23.3 (24)
Cardiac Death, % n 0.65 (1) 3.2 (11) 3.0 (1) 1.9 (2)
Myocardial Infarction, 
% n 5.2 (8) 4.4 (16) 3.0 (1) 0.9 (1)
Revascularization, 
% n 18.4 (28) 15.5 (52) 9.1 (3) 3.7 (4)
Total Composite, % n 28.9 (44) 31 (104) 12.1 (4) 5.6 (6)
P-Value for 
Composite Endpoint 0.689 0.638
3:30 p.m.
2511-597 Non-Red Blood Cell Transfusion Is Associated with 
Increased Early Mortality in Patients Undergoing 
Percutaneous Coronary Intervention (PCI)
Simon D. Robinson, Christian Janssen, Eric B. Fretz, Brian Berry, Alex J. Chase, 
Anthony Della Siega, W. Peter Klinke, J. David Hilton, Victoria Heart Insitute Foundation, 
Victoria, BC, Canada
Background: PCI related bleeding is common and may lead to blood transfusion and 
death. Previous work has suggested non red blood cell (RBC) transfusions may be 
harmful in critically ill patients. We investigated whether blood component type was 
related to clinical outcome in patients requiring transfusion following PCI.
Methods: All subjects receiving a transfusion following PCI were identiﬁed using the 
British Columbia Cardiac Registry (BCCR) and BC Central Transfusion Registry (CTR). 
Between 1999 and 2005 there were 38952 PCI cases in the BCCR - 975 (2.5%) of these 
were associated with at least 1 transfusion; patients undergoing CABG following PCI 
were excluded. Patient demographics and transfusion details were compared against 30 
day mortality using the provincial Vital Statistics registry.
Results: The 30 day mortality was 1.3% in the non-transfused and 12.7% in the transfused 
subjects (p<0.001). Baseline characteristics of the transfused patients dying (TD30) and 
surviving 30 days (TLA30) were similar. Over 70% of all transfusions given to survivors were 
RBCs compared to 45% of those given to TD30 (p<0.001). In contrast, patients dying within 30 
days received substantially more plasma and platelet transfusions (p<0.001 for all, Table 1).
Conclusion: In patients requiring transfusion post PCI, use of non-RBC products is 
associated with increased 30 day mortality. Our ﬁndings suggest transfusion of plasma 
and platelets may be detrimental in those at risk of coronary thrombosis.
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Methods: We used data from EVENT, a multicenter registry of patients undergoing PCI 
between July 2004 and June 2006 to examine the association between periprocedural 
ischemic and bleeding complications and 1-year mortality. pMI was deﬁned as a CK-MB value 
>3x the upper limit of normal and was based on routine assessment of cardiac enzyme levels 
(available in 97% of subjects). Post-PCI bleeding was classiﬁed by TIMI criteria.
Results: After excluding patients with elevated pre-PCI CK-MB values or STEMI at 
presentation, the study cohort consisted of 5,961 subjects. Rates of post-PCI bleeding 
and pMI were 3.0% and 7.1%, respectively; 1-year mortality was 2.8% (1.6% cardiac). 
Compared to those without bleeding, subjects with any post-PCI bleeding (combined TIMI 
major and minor) had increased mortality at 1-yr (15.6% vs 2.4%, p<0.0001). Subjects 
with pMI also had increased mortality (5.2% vs 2.7%, p= 0.002). After multivariable 
adjustment, any post-PCI bleeding and pMI were both independently associated with 
mortality at 1-yr (Table).
Conclusions: In a “real-world” setting among unselected patients, both post-PCI bleeding 
of any severity and pMI remain relatively common and are independently associated with 
increased mortality. Continued efforts to reduce both complications are warranted. 
Adjusted Hazard Ratios for the Association of Periprocedural Events with 1-year Mortality
Models Any Bleeding (95% CI) Periprocedural MI (95% CI)
Unadjusted 6.83 (4.55 - 10.24) 2.00 (1.27 - 3.10)
Model 1* 5.81 (3.83 - 8.83) 1.89 (1.20 - 2.95)
Model 2† 3.84 (2.48 - 5.94) 1.87 (1.19 - 2.94)
Fully Adjusted‡ 3.83 (2.48 - 5.90) 1.84 (1.17 - 2.89)
*Model 1: adjusted for age, gender, BMI; †Model 2: model 1+ DM, HTN, hyperlipidemia, 
smoking, CHF, PAD, GFR, prior MI, prior CABG, ACS at presentation; ‡Fully Adjusted: 
model 2 + multivessel CAD, PCI of SVG; PCI of proximal LAD
3:30 p.m.
2511-603 Inﬂuence of gender on long term mortality following 
percutaneous coronary interventions in the present era
SUDHIR RATHORE, Matthew Shaw, Anthony D. Grayson, Mark Jackson, Raphael A. 
Perry, Liverpool Heart and Lung Hospital, Liverpool, United Kingdom
Background: Earlier data has suggested that mortality after percutaneous coronary 
interventions (PCI) was greater for women than men.
Objective: The aim of our study is to evaluate the inﬂuence of gender on long term 
mortality among patients undergoing PCI in the North West of England.
Methods: We conducted a retrospective analysis of prospectively collected data on 9914 
consecutive patients undergoing adult PCI between 1 Aug 2001 and 31 Dec 2003 at all 
centres undertaking PCI in the North West of England. All cause mortality at 30 day, 12 
months and up to ﬁve years was compared by gender.
Results: Of the 9914 patients, 2880 (29%) were women. Women were signiﬁcantly 
older than men (63.2 vs. 59.7, P <0.001) and are more likely to present with unstable 
angina (32.8% vs. 29.6%, P=0.002). Previous bypass surgery (3.8% vs. 8.0%, P< 0.001), 
Ejection fraction < 50% (14.7 vs. 8.2, P<0.001), and multivessel disease (7.5 vs. 10.7, P 
<0.001) were less common among women. AHA type C lesions (39.9 vs. 43.3, P<0.001), 
graft lesions (1.8 vs. 4.4, P <0.001) and multivessel PCI (21.5 vs. 23.3, P=0.04) was also 
less common in women. Stent usage was high with 93%.Using Cox proportional hazard 
analysis to adjust for baseline variables the 30 d mortality was similar in women and men 
(1%) and 12 month mortality was 2.1% in women and 3.0% in men (P= 0.12). Unmatched 
and matched Kaplan Meier survival curve up to5 yrs are shown in Figure 1 &2.
Conclusions: Long term mortality up to 5 years was similar in both genders after 
accounting for baseline factors.
3:30 p.m.
2511-600 Racial Disparities in Percutaneous Coronary 
Intervention In-hospital Outcome: Results from the 
Long Island Angioplasty Network
Luis Gruberg, Srihari S. Naidu, Richard A. Shlofmitz, Sorin Brenner, Allen Jeremias, 
Thomas Pappas, Kevin Marzo, David L. Brown, Winthrop University Hospital, Mineola, 
NY, Stony Brook University Medical Center, Stony Brook, NY
Background: Recent advances in percutaneous coronary intervention (PCI) technique, 
technology and pharmacotherapy have improved in-hospital outcomes. Whether racial 
disparities in PCI outcome persist in the current era remains unclear.
Methods: Baseline demographic, procedural and clinical characteristics, as well as in-
hospital death, myocardial infarction and stroke were prospectively collected among 
consecutive patients undergoing PCI at Winthrop University Hospital and Stony Brook 
Medical Center as part of the Long Island Angioplasty Network. Baseline characteristics 
and in-hospital outcomes were compared across races.
Results: A total of 9,339 patients underwent PCI between January 1, 2004 and December 
31, 2006. 8,349 patients (89.4%) were White, 401 (4.3%) Black, 358 (3.8%) Hispanic, and 
216 (2.3%) Asian. There were no differences between groups with respect to gender, age, 
indication for PCI, hemodynamic instability or shock, ejection fraction, known coronary 
disease, diabetes, lesion location or extent of disease (p=NS for all). In-hospital death 
was highest among Hispanics (1.7%) when compared to Whites (0.4%), Blacks (0.5%) 
and Asians (0.5%). The combined endpoint of in-hospital death, myocardial infarction and 
stroke was likewise two-fold higher among Hispanics (2.2%) when compared to Whites 
(0.9%), Blacks (1.2%) and Asians (1.4%). Due to low absolute event rates, statistical 
signiﬁcance was not reached.
Conclusions: Despite ongoing advances in interventional cardiology, there appear to 
remain signiﬁcant racial disparities in PCI outcome, particularly among Hispanics. Further 
studies are warranted to more fully evaluate this association.
3:30 p.m.
2511-601 Does Peri-Procedural Signiﬁcant Bleeding Impact Long-
Term Mortality in Patients Undergoing Percutaneous 
Coronary Interventions? A Real-World Analysis
Salman A. Haq, Michael Anigobu, Morteza Tavachol, Shehzeen Ahmad, Terrence J. 
Sacchi, Sorin J. Brener, NY Methodist Hospital, Brooklyn, NY
Background: Recent data from randomized clinical trials (RCT) of patients undergoing 
percutaneous coronary interventions (PCI) have highlighted peri- PCI bleeding as an 
independent predictor of short- and long-term mortality, more powerful even than peri-
procedural ischemic events. These patients, because of enrollment in RCT were observed 
with great scrutiny for bleeding complication. We sought to evaluate these ﬁndings in 
patients undergoing PCI in the real-world setting.
Methods: We prospectively evaluated all patients undergoing PCI in our institution 
from April 2004 to December 31, 2007. Signiﬁcant bleeding was deﬁned as a drop in 
hemoglobin of greater than 3 grams or bleeding requiring blood transfusion within 48 
hours of PCI. Mortality data was obtained through the social security death index.
Results: A total of 2509 consecutive patients were evaluated. The mean age was 66+11 years, 
37% had diabetes mellitus and 3.8% had signiﬁcant chronic kidney disease (CKD). The mean 
ejection fraction was 50+12%. Urgent or emergency PCI was performed in 16%. The average 
Hb before PCI was 13.4+3 g% and it declined to 12.6+2 g% after PCI. Signiﬁcant bleeding 
occurred in 11.9%. Of these, 1% had both a drop in Hb >3 g% and required transfusion, an 
equivalent of major bleeding. Death occurred in 5.7% during an average follow-up period of 29 
+ 13 months. By multivariable analysis, signiﬁcant bleeding was not an independent predictor 
of mortality in patients undergoing PCI (p = 0.81, Fig.). Factors predicting mortality were 
increasing age, urgency of procedure, lower ejection fraction, CKD and use of bivalirudin.
Conclusions:This study suggests that signiﬁcant bleeding is not an independent 
predictor of mortality in patients undergoing PCI in routine clinical practice. 
3:30 p.m.
2511-602 Periprocedural Bleeding and Myocardial Infarction are 
Associated with Increased Mortality after PCI: Results 
from the EVENT Registry
Jason B. Lindsey, Steven P. Marso, Michael Pencina, Joshua M. Stolker, Kevin F. 
Kennedy, Charanjit Rihal, Robert N. Piana, Steven L. Goldberg, Donald L. Cutlip, Neal 
S. Kleiman, David J. Cohen, Mid America Heart Institute, Kansas City, MO, Methodist 
DeBakey Heart Center, Houston, TX
Background: In randomized trials, major bleeding after PCI and periprocedural MI (pMI) 
are both associated with increased mortality. Whether similar associations exist among 
unselected PCI patients is unknown.
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STEMI were treated with direct PCI at our medical center. Of these, 123 were enrolled 
into a randomized STEMI PCI trial (ERASE-MI, AMIHOT II, HORIZONS-AMI, or APEX-
AMI). Patients were enrolled if (1) a study was actively enrolling, (2) they met inclusion/
exclusion criteria, (3) study nurse was available, (4) the interventionist thought enrollment 
was appropriate, (5) the patient signed informed consent. We compared patients enrolled 
in a trial (“Enrolled”) to patients not enrolled in a trial (“Not Enrolled”) with respect to D2B 
and cath-lab-arrival-to-balloon time (CL2B). Regression (including 12 demographic and 6 
procedural factors) was used to adjust for time differences in characteristics between the 
Enrolled and the Not Enrolled groups.
Results: Unadjusted times (Table) for D2B and CL2B tended to be shorter for Enrolled 
pts than Not Enrolled pts. The Enrolled and Not Enrolled groups differed in frequency 
of presentation during on- versus off-hours, interventionist performing PCI, and culprit 
artery. After adjustment for these differences, Enrolled versus Not Enrolled pts did not 
differ signiﬁcantly in overall D2B or CL2B (Table). This was true for both pts transferred
from a non-PCI center (n = 423) and patients presenting directly to the PCI center (n 
= 158). Enrollment was 17% during off-hours and 30% during on-hours, although D2B 
times were almost identical for pts presenting on-hours versus off-hours.
Conclusions: In our system, with median D2B well under 90 minutes for non-transferred 
patients, enrollment did not delay D2B or CL2B, either in patients transferred from a non-
PCI center or in patients presenting directly to the PCI center.
Median D2B and Cath Lab to Balloon Times
Transferred 
from Non-
PCI Center,
ENROLLED
(n = 96)
Transferred 
from Non-
PCI Center,
NOT 
ENROLLED
(n = 327)
adjusted
p-value
Presented to 
PCI Center, 
ENROLLED, 
(n = 27)
Presented
to PCI 
Center, 
NOT 
ENROLLED 
(n = 131)
adjusted
p-value
Door-to-
Balloon Time 
(minutes)
104 107 .74 43 56.5 .83
Cath Lab 
Arival to 
Balloon Time 
(minutes)
17 18 .46 17 16 .06
3:30 p.m.
2511-607 Four-year Outcomes of Complex Coronary Intervention 
at a Single, High Volume Center Without On-Site 
Surgical Backup
Najamul H. Ansari, Almas Kherani, Bernadette Speiser, Stephanie Murray, John A. Kao, 
Adhir Ramesh Shroff, Jesse Brown VA Medical Center, Chicago, IL, University of Illinois 
at Chicago Medical Center, Chicago, IL
Objective: Current ACC/AHA Percutaneous Coronary Intervention (PCI) guidelines classify 
PCI without on-site cardiac surgery for elective and primary PCI as class III and IIb /III, 
respectively. Limited data regarding PCI outcomes in a single, high-volume center exists. 
We report the characteristics and outcomes of a consecutive group of unselected patients 
undergoing elective and primary PCI in a center that fulﬁlls the criteria established by the 
ACC/AHA for the Performance of Angioplasty at Hospitals without On-Site Cardiac Surgery.
Methods: From 9/2004 to 9/2008, 729 patients (1081 lesions) were analyzed from a 
database at the Jesse Brown VA Medical Center. Lesions and procedural success were 
classiﬁed according to SCAI/ACC/AHA guidelines. Myocardial infarction (MI) post-PCI 
was deﬁned as troponin-I elevation at or above the level deﬁned as deﬁnite MI.
Results: Lesion types, characteristics and outcomes are shown in Table 1. There were 
no signiﬁcant differences in rates of success, peri-procedural MI or death from the SCAI, 
ACC-NCDR, and NHLBI Registries. There were two deaths in-house after PCI and one 
emergent transfer for CABG after coronary dissection, for which the patient survived.
Conclusion: PCI on predominantly complex (B2/C) coronary lesions without on-site 
surgery was safely performed with complication rates comparable to national averages. The 
established transfer plan was proven successful in the single instance it was required.
Table 1. 
Characteristics and Complications of Lesions
Lesion Type Number Success Myocardial Emergent
Infarction CABG/Death
A 175 (16.2%) 172 (98.2%) 5 (2.9%) 0 (0%)
B1 318 (29.4%) 313 (98.4%) 16 (5.0%) 0 (0%)
B2 323 (29.9%) 313 (96.9%) 17 (5.3%) 0 (0%)
C 262 (24.2%) 214 (81.7%) 16 (6.1%) 2 (0.7%)
Data Missing 3 (0.3%)
Total Lesions 1081 (100%) 1012 (93.6%)
Speciﬁc Lesion Subsets
CTO 68 (6.3%) 46 (67.6%) 2 (2.9%) 0 (0%)
Bifurcation 165 (15.3%) 147 (89.1%) 7 (4.2%) 0 (0%)
STEMI 48 (4.4%) 43 (89.6%) 5 (10.4%) 0 (0%)
SVG/LIMA 76 (7.0%) 68 (89.5%) 6 (7.9%) 0 (0%)
3:30 p.m.
2511-604 Percutaneous Coronary Intervention for Treatment of 
Symptomatic Ischemic Heart Failure With Normal Left 
Ventricular Systolic Function
Scott J. Denardo, Mustafa HM Hassan, Richard S. Schoﬁeld, James A. Hill, Keith E. 
Davis, James E. Tcheng, North Florida/South Georgia Veterans Affairs, Gainesville, FL, 
University of Florida, Gainesville, FL
Background: Current guidelines recommend coronary revascularization for heart failure 
patients (HF pts) with normal left ventricular systolic function (NLVSF) and symptomatic 
or demonstrable myocardial ischemia (Recommendation: Class IIa; Level of Evidence: 
C). However, there are no systematic reports of the outcomes of those pts who actually 
undergo revascularization.
Methods: We assessed outcomes of 160 consecutive pts undergoing revascularization 
using percutaneous coronary intervention (PCI) for treatment of symptomatic ischemic 
HF with NLVSF. Each pt initially received conventional HF medical therapy, and pts were 
selected for study who continued to experience HF symptoms, demonstrate a pulmonary 
capillary wedge pressure of q18mmHg and a left ventricular ejection fraction of q50%.
Results: The technical success rate for PCI was 100%. During the ﬁrst 24 hours, there 
were no major adverse cardiovascular events (MACE: death; Q wave myocardial infarction 
(MI); repeat revascularization). There were 2 (1.3%) non-Q wave MIs, 3 (1.9%) bleeding 
complications, and 2 (1.3%) episodes transient thrombocytopenia. During the ﬁrst 30 
days, there were no MACE and no hospitalizations for medical therapy of decompensated 
HF. During the ﬁrst year, there were 33 (20.6%) MACE: 4 cardiovascular deaths (2.5%); 
2 non-cardiovascular deaths (1.3%); 23 PCIs (14.4%); 4 coronary bypass graft surgeries 
(2.5%). Additionally, there were 11 (6.9%) hospitalizations for decompensated HF. Female 
sex (P=0.019), pre-PCI low diastolic blood pressure (P=0.045), and high cardiac index 
(P=0.028) were each associated with any event at 1 year (MACE or hospitalization). History 
of prior MI (P=0.017) was associated with 1 year death; higher HF class (P=0.011) and high 
pulmonary artery pressures (P=0.045) were each associated with 1 year hospitalization; no 
clinical or hemodynamic variable was associated with repeat revascularization.
Conclusions: PCI for treatment of ischemic HF with NLVSF appears safe and may prove 
efﬁcacious. The HF death and decompensation rates for this cohort at 30 days and 1 year 
post-PCI were substantially lower compared to published reports consisting of medical 
therapy alone.
3:30 p.m.
2511-605 Regionalized Care with STEMI Centers Decreases 
Mortality and Improves Door to Balloon Times
Vikas K. Patel, Samip Vasaiwala, Mladen Vidovich, Adhir Shroff, John Kao, University of 
Illinois at Chicago, Chicago, IL, Advocate Christ Medical Center, Oak Lawn, IL
Background: ACC/AHA guidelines support the use of percutaneous coronary intervention 
(PCI) as the preferred treatment for ST elevation myocardial infarction (STEMI), with a 
goal door to balloon time (D2B) of a 90 minutes. We compared D2B times and mortality 
rates of hospitals participating in regional STEMI networks to hospitals not participating in 
such networks utilizing publicly available data from the Hospital Compare and American 
Heart Association Mission: Lifeline ™ websites.
Methods: Of all 4, 470 hospitals listed on the Hospital Compare website providing D2B 
data for STEMI and mortality data for acute myocardial infarction, those with at least 
10 or more patients were analyzed. STEMI Center hospitals were deﬁned as hospitals 
registered on the Mission: Lifeline™ website. Non-STEMI Center hospitals were deﬁned 
as those without a registered program. A student-t test was used to analyze both the 
mortality and D2B data.
Results: Review of the Mission: Lifeline™ website identiﬁed 92 STEMI Centers, of which 
86 met criteria for mortality analysis and 75 for D2B analysis. Review of the Hospital 
Compare website, after removal of STEMI Centers, left 2,754 Non-STEMI Center 
hospitals providing mortality data and 1,233 providing D2B data. Primary ﬁndings are 
listed in Table 1.
Conclusion: STEMI Centers have signiﬁcantly better D2B times and lower mortality 
rates compared to Non-STEMI hospitals. Our ﬁndings support the formation of dedicated 
STEMI networks for the treatment of patients with STEMI.
Table 1: Mortality and D2B a90 Minute Rates for STEMI and Non-
STEMI Center Hospitals
Variable (%)
Mean ± Standard Deviation P-value
STEMI Centers
(n=86)
Non-STEMI Centers
(n=2754)
Mortality rate 15.80±1.19 16.09±1.16 0.0214
STEMI Centers
(n=75)
Non-STEMI Centers
(n=1233)
D2B a 90 minutes 74±21 69±19 0.021
3:30 p.m.
2511-606 Enrollment in STEMI PCI Trials Is Possible Without 
Increase in Door to Balloon Times
James C. Blankenship, Jennifer A. Sartorius, Deborah K. Zimmerman, Kimberly A. 
Skelding, Kimberly A. Skelding, Thomas A. Scott, Lynn M. Belles, Amy Temple, Peter B. 
Berger, Geisinger Medical Center, Danville, PA
Background: Current guidelines emphasize door-to-balloon times (D2B) under 90 
minutes. Enrollment in randomized trials of STEMI PCI may delay D2B.
Hypothesis: Enrollment in STEMI PCI trials can be accomplished without delaying D2B.
Methods: From 10/17/04 to 12/31/07, 581 patients within 12 hours of the onset of 
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2906-7 Long-Term Outcome After Selective Use of Embolic 
Protection Devices During Saphenous Vein Graft 
Interventions
Shahar Lavi, Joan Ivanov, Clare A. Appleby, Karen Mackie, Eric M. Horlick, Chris 
Overgaard, Peter Seidelin, Douglas Ing, Vlad Dzavik, University Health Network, 
Toronto, Canada
Background: PCI to saphenous vein graft (SVG) is associated with increase risk and it 
is recommended to use embolic protection devices (EPD) in this setting. We tested the 
hypothesis that selective use of these devices is associated with acceptable risk.
Methods: Angiographic and clinical outcome were prospectively obtained from 534 
consecutive patients that underwent PCI to SVGs, with or without EPD from January 
2001 to December 2007 at a large tertiary cardiac referral center. Long term outcome was 
obtained by linkage to provincial registry.
Results: EPD were deployed in 198 of 373 SVGs (53%) that were suitable for deployment 
of a distal EPD. EPD were used more often in ectatic (33% vs 19%, p=0.003), ulcerated 
(17% vs 9%, p=0.03), thrombotic (25% vs 8%, p<0.0001) vein grafts, with longer degenerated 
segments (p=0.002), and in lesions involving the body of the graft (85% vs 66%, p<0.0001). 
In hospital death and myocardial infarction were similar with and without EPD(1.5% vs 1.7%, 
p=0.89, and 2% vs 5%, p=0.11). Long term event free survival was high and similar in both 
groups (ﬁgure). Independent predictors of death included urgency of the procedure (HR=2, 
p=0.027), left ventricular dysfunction (HR=5.5, p<0.0001) and renal dysfunction (HR=2.9, 
p=0.0003). Use of EPD was not a predictor of long term survival.
Conclusions: Selective use of EPD during PCI to SVG is associated with low in hospital 
cardiovascular event rates. Long term outcome is poor and determined by co-morbidities 
whether EPD is used or not.
5:06 p.m.
2906-8 Long-Term Outcomes of Drug Eluting vs. Bare Metal 
Stent Implantation for Patients With Chronic Total 
Coronary Artery Occlusions
Yaling Han, Jian Zhang, Yi Li, Shouli Wang, Quanmin Jing, Shenyang Northern Hospital, 
Shenyang, People’s Republic of China
Background: There are limited data on the efﬁcacy of drug eluting stents (DES) for 
treatment of chronic total occlusions (CTO). The aim of the study was to evaluate the long-
term clinical outcomes of DES implantation for CTO compared with bare metal stents 
(BMS) implantation.
Methods: Between June 1995 and December 2006, a total of 1184 patients with 
successful recanalization of at least one CTO lesions were consecutively registered, 
including 660 (55.7%) received DES and 524 (44.3%) received BMS implantation. All 
patients were followed up to 5 years for occurrence of major adverse cardiac events 
(MACE). Long-term survival rates were estimated with Kaplan-Meier method.
Results: The baseline clinical and angiographic characteristics were comparable between 
the two groups except that patients in DES group received longer dual antiplatelet therapy 
(7.4±2.5 months vs. 1.7±0.8 months). The average follow-up periods were 4.7±0.89 years in 
the BMS group and 3.2±1.3 years in the DES group, respectively. There was no signiﬁcant 
difference in 5-year survival rate between the two groups (90.3% for DES group vs 89.6% 
for BMS group, log-rank P=0.38),but the 5-year TVR-free survival rate in the DES group 
was signiﬁcant higher than that in the BMS group (81.6% vs 73.5%, log rank p<0.001). The 
cumulative MACE-free survival in the DES group was also signiﬁcantly higher than that in 
the BMS group (80.6% vs 71.5%, log-rank p<0.001). The rates of re-admission caused by 
cardiovascular disease (27.0% vs 37.8 %, p<0.001) and the need for CABG were signiﬁcantly 
lower in the DES group (1.5% vs 3.4%, P<0.05). By multivariable analysis, DES implantation 
could signiﬁcantly lower the long-term MACE risk of PCI for CTO patients (HR: 0.492; 95%CI 
0.396~0.656, P<0.001). Heart failure and elderly (q 65-year) were identiﬁed as independent 
predictors of long-term MACE during follow-up.
Conclusions: This study demonstrates the long-term (up to 5 years) efﬁcacy of DES for 
treatment of CTO, which is superior to BMS implantation in reducing the rates of TVR and 
MACE, as well as the need of re-admission and CABG.
I2.ORAL CONTRIBUTIONS
2906
Complex Lesions
Sunday, March 29, 2009, 4:30 p.m.-6:00 p.m.
Orange County Convention Center, Room W414D
4:30 p.m.
2906-5 Rate of Major Cardiac Adverse Events 14 Months After 
Coronary Bifurcation Stenting With Culotte vs. Crush 
Techniques in the Nordic Bifurcation Stent Technique 
Study
Kari Kervinen, Matti Niemelä, Andrejs Erglis, Indulis Kumsars, Michael Maeng, Jens 
F. Lassen, Pål Gunnes, Sindre Stavnes, Jan S. Jensen, Anders Galløe, Inga Narbute, 
Dace Sondore, Evald H. Christiansen, Jan Ravkilde, Terje K. Steigen, Jan Mannsverk, 
Per Thayssen, Knud Nørregaard Hansen, Kari Virtanen, Steffen Helqvist, Saila Vikman, 
Rune Wiseth, Jens Aarøe, Leif Thuesen, University of Oulu, Oulu, Finland, Aarhus 
University Hospital, Aarhus, Denmark
Background:Risk of stent thrombosis and other cardiac adverse events have been 
reported to be increased in bifurcation lesions, especially if a two-stent technique is used. 
Here we report the pre-speciﬁed secondary end-point of 14-month major adverse cardiac 
events (MACE) in patients with bifurcation lesions treated with Culotte versus Crush 
techniques using Sirolimus eluting stents (SES).
Methods:A total of 424 patients with a coronary artery bifurcation lesion were randomized 
to stenting of both main vessel and side branch using culotte or crush techniques. 
Recommended post-procedural clopidogrel treatment duration was 6-12 months. Stent 
thrombosis was deﬁned according to the ARC criteria. MACE was deﬁned as the 
composite of deﬁnite stent thrombosis, cardiac death, non-procedure related myocardial 
infarction and/or target lesion revascularization.
Results:Mortality data was available in 423 (99.8%) patients and clinical follow-up 
data in 417 (98.3%) patients. The two treatment groups were well balanced concerning 
preprocedure patient and lesion related characteristics. After 14 months, the rates of 
MACE were 6.4% versus 8.7% (ns) in the Culotte and Crush treated patients, respectively. 
The individual components of MACE are shown in the table.
Conclusions:Rates of stent thrombosis and MACE were low and similar in patients 
treated with culotte or crush technique using SES in bifurcation lesions.
Crush Culotte p-value
Death, n(%) 6/209 (2,9) 3/214 (1,4) ns
Cardiac death, n(%) 5/209 (2,4) 2/214 (0,9) ns
MI, n(%) 7/206 (3,4) 6/211 (2,8) ns
TLR, n(%) 11/206 (5,3) 10/211 (4,7) ns
Stent thrombosis, n(%) 3/206 (1,5) 6/211 (2,8) ns
4:42 p.m.
2906-6 Long-Term Clinical Outcome and the Efﬁcacy of Final 
Kissing Balloon Technique After Sirolimus-Eluting 
Stent Implantation Using Only Main Branch Stenting 
Technique in Coronary Bifurcation Lesions
Toshihiro Tamura, Kazuaki Mitsudo, Takeshi Kimura, Kazushige Kadota, j-Cypher 
Registry Investigators, Kyoto University Hospital, Kyoto, Japan
Background: Only main branch stenting in coronary bifurcation lesions seems to be 
better clinical outcome compared to the main and side branch stenting also in the 
drug eluting stent era.However the efﬁcacy of ﬁnal kissing balloon(FKB) technique and 
predictor of target lesion revascularization(TLR) after only main branch stenting technique 
remain unclear.
Methods: Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients receiving sirolimus-eluting stent(SES) from 37 centers in Japan. 
Between August 2004 and November 2006, 12824 patients were enrolled in this registry. 
Among them, we identiﬁed 2250 non-LMCA native bifurcation lesions using only SES. Of 
these. 1871 lesions were treated with only main branch stenting(one-stenting) technique. 
We investigated long-term clinical outcome(follow-up period was 525.4±174.8days) and 
efﬁcacy of FKB after implantation of SES with one-stenting technique.
Results: 741 lesions(39.6%) were true bifurcations. Wire protection of side branch before 
main branch stenting was performed in 1461lesions(78.1%) and the FKB was performed 
in 938lesions(50.1%). The incidence of death, TLR and ARC deﬁnite stent thrombosis 
were 5.7%, 7.6% and 0.38%.
In the multivariable analysis, gender, hemodialysis, DM, total stent length and post main 
vessel diameter were the predictor of TLR.
After stent implantation in main branch, 1053 lesions were >50% diameter stenosis 
in side branch. Even among them, there was no signiﬁcant differences regarding TLR 
between the FKB group and non-FKB group(log-lank test; p=0.40).
Conclusions:For SES placement in bifurcation lesions, one-stenting technique suggests 
a good long-term clinical outcome. Gender, hemodialysis, DM, total stent length and post 
main vessel diameter were the only predictor of TLR. Even if the side branch %diameter 
stenosis was more than 50% after main branch stenting, the FKB did not provide the 
beneﬁt regarding TLR.
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2512
PCI - Acute MI
Monday, March 30, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2512-675 Coronary Flow Velocity Pattern Immediately After 
Reperfusion Predicts True Left Ventricular Aneurysm in 
Patients with Acute Anterior Myocardial Infarction Who 
Achieve TIMI Grade 3 Flow
Atsushi Yamamuro, Shuichiro Kaji, Koichi Tamita, Minako Katayama, Makoto Kinoshita, 
Natsuhiko Ehara, Takeshi Kitai, Takafumi Yamane, Yoshimori An, Kite Kim, Syunsuke 
Funakoshi, Noriyuki Kimura, Tomoko Tani, Shigefumi Morioka, Yutaka Furukawa, Kobe 
General Hospital, Kobe, Japan
Background: Aggressive management of acute myocardial infarction (AMI), including prompt 
reperfusion, may diminish the incidence of true left ventricular (LV) aneurysm; however, it has 
been reported that even if successful reperfusion is achieved in epicardial coronary arteries, 
microvascular dysfunction causes insufﬁcient reperfusion of the infracted myocardium, leading 
to LV dysfunction. Recent studies have shown that microvascular damage can be assessed 
quantitatively from coronary ﬂow velocity (CFV) patterns immediately after successful 
reperfusion. The purpose of this study was to examine whether the CFV patterns may predict 
the risk of true LV aneurysm formation in patients with AMI achieving TIMI 3 ﬂow.
Methods: Consecutive 168 patients with ﬁrst anterior AMI who underwent successful 
percutaneous coronary intervention (<50% residual stenosis with TIMI grade 3 ﬂow) 
were subjected to CFV measurement with Doppler guidewires. The CFV spectrum 
provided systolic peak velocity (cm/s, SPV) and diastolic deceleration time (ms, DDT). Left 
ventriculogram obtained 6 months after the infarction was analyzed to measure the LV 
volume index. True LV aneurysm was deﬁned as a deformity of the infarct segment that 
was apparent during diastole as well as during systole, and demonstrated diastolic contour 
abnormality. Patients were divided into the two groups: those subsequently complicated by 
true LV aneurysm (n=26; group 1) and those without true LV aneurysm (n=142; group 2)
Results: CFV analysis showed signiﬁcantly lower SPV (-24 ± 18 vs. 7 ± 21 cm/s; p<0.001) 
and shorter DDT (355 ± 165 vs. 685 ± 191 ms; p<0.001) in group 1 than in group 2. The 
optimal cutoff values to predict true LV aneurysm formation were -20 cm/s for SPV and 
400 ms for DDT (sensitivity=0.77, speciﬁcity=0.85; and sensitivity=0.77, speciﬁcity=0.89, 
respectively). SPV and DDT correlated to the LV end-diastolic volume index obtained 6 
months after AMI (r= -0.63; p<0.001 and r= -0.76; p<0.001, respectively).Conclusions: 
CFV pattern of infarct-related artery immediately after reperfusion predicts true LV 
aneurysm formation, and enables accurate risk stratiﬁcation in patients with anterior AMI 
achieving TIMI grade 3 ﬂow.
9:30 a.m.
2512-676 Prognostic Utility of TIMI Flow After Primary PCI 
in Acute Myocardial Infarction: Insights from the 
HORIZONS-AMI Trial
Adriano Caixeta, Alexandra J. Lansky, Eugenia Nikolsky, Roxana Mehran, George 
D. Dangas, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. Peruga, Bruce Brodie, 
Dariusz Dudek, Ran Kornowski, Hartmann Franz, Helen Parise, Gregg Stone, Columbia 
University Medical Center and the Cardiovascular Research Foundation, New York, NY, 
Adriano Caixeta, New York
Background: Restoration of normal epicardial ﬂow has been strongly related to survival 
following reperfusion therapy during evolving AMI. The prognostic utility of restored 
TIMI ﬂow has not been examined in a large-scale multicenter prospective study after 
contemporary interventional strategies in pts with AMI.
Methods: The HORIZON-AMI trial randomized 3602 pts with STEMI undergoing primary 
PCI to bivalirudin (n=1800) vs. UFH+GPI (n=1802), with a second 3:1 randomization 
in 3006 stent eligible pts to the Taxus stent (N=1348) vs. the bare metal Express stent 
(N=452). An independent angiographic laboratory assessed all angiograms for baseline 
and ﬁnal lesion and ﬂow characteristics. Clinical outcomes including composite major 
adverse cardiovascular events (MACE) (death, reinfarction, ischemic target vessel 
revascularization, and stroke) and stent thrombosis (ARC deﬁnite or probable).
Results: A total of 3,276 lesions were treated with core lab analysis; 2,815 lesions (86%) 
had ﬁnal TIMI 3, 360 (11%) had TIMI 2, and 101 (3%) had TIMI 0/1. The 30-day and 1-year 
outcomes stratiﬁed by the post-procedure TIMI ﬂow are summarized in Table. 
Variable Final TIMI 0/1(N=101)
Final TIMI 2
(N=360)
Final TIMI 3
(N=2815)
P-Value
All Groups
30-day Outcomes
Death 16.8% 4.7% 1.5% <0.0001
Reinfarction 4.0% 1.1% 1.1% 0.04
TVR 10.2% 2.6% 2.3% <0.0001
Stroke 3.0% 0.8% 0.4% 0.001
MACE 26.7% 8.1% 4.1% <0.0001
Stent thrombosis 8.6%% 4.0% 2.0% 0.0005
1-Year Outcomes
Death 19.9% 7.3% 2.8% <0.0001
Reinfarction 13.5% 3.2% 3.8% <0.0001
TVR 15.2% 6.2% 6.8% 0.002
Stroke 3.1% 0.8% 0.9% 0.05
MACE 36.7% 14.3% 10.6% <0.0001
Stent thrombosis 11.4% 4.7% 3.0% 0.0009
5:18 p.m.
2906-9 The Safety and Efﬁcacy of Retrograde Approach 
for Percutaneous Recanalization of Chronic Total 
Occlusions of the Coronary Artery: Toyohashi Heart 
Center Experience From 157 Patients
SUDHIR RATHORE, Hitoshi Matsuo, Mitsuyasu Terashima, Nobuyoshi Tanaka, 
Yoshihisa Kinoshita, Masashi Kimura, Kenya Nasu, Etsuo Tsuchikane, Mariko Ehara, 
Yasushi Asakura, Keiko Asakura, Osamu Katoh, Takahiko Suzuki, Toyohashi Heart 
Center, Toyohashi, Japan
Background: Successful percutaneous coronary intervention (PCI) of chronic total 
occlusion (CTO) has shown improved survival, improvement in LV function and symptom 
relief. Retrograde approach through the collateral channels has become popular recently 
and has a potential to improve the success rate in CTO PCI.
Objective: To deﬁne the safety and efﬁcacy of retrograde approaches used for 
percutaneous recanalization of the CTO PCI in a consecutive series of “real world” 
patients.
Methods: All consecutive patients undergoing CTO PCI of more than 3 months duration 
between 2003 and 2008 by retrograde approach were identiﬁed from dedicated database 
and were evaluated retrospectively.
Results: Total of 157 (17%) out of 925 CTO procedures were attempted in retrograde 
fashion during this period. Septal branch collateral was used in 67.5% and epicardial 
collaterals and saphenous vein grafts were used in 24.8%& and 7.6% cases, respectively. 
The occluded vessel was RCA in 59.2%, LAD in 31.8%, LCx in 7.6% and 0.6% each 
were LMS and vein graft. Collateral channel was crossed by guide wire successfully in 
115(73.2%) cases and the procedure was successful by retrograde approach in 103 
(65.6%) cases. Controlled antegrade and retrograde tracking (CART) was performed in 
64 (40.8%) cases and retrograde wire entered the proximal true lumen in 39(24.8%) 
cases to achieve recanalization. The reasons for failure by retrograde approach was 
inability to cross the collateral channel (48 pts), CART not attempted (2 pts) and inability 
to pass balloon or micro catheter (4 pts). Final procedural success was achieved in 133 
(84.7%) cases. Five patients developed septal perforation, one of which needed coil 
embolisation and rest were managed conservatively. One patient needed emergency 
CABG (0.6%) and, one (0.6%) and ﬁve patients (3.1%) had QMI and NQMI, respectively 
with no in hospital mortality.
Conclusions: Retrograde approach by different strategies is effective in recanalizing CTO 
in previously failed antegrade attempts. As shown here the success rate by retrograde 
approach was 65.6% and ﬁnal success was 85% with low overall adverse events. Further 
studies are needed to evaluate the predictors of retrograde success.
5:30 p.m.
2906-10 Acute Results From the INSPIRE Trial With the Novel 
MGuardTM Stent System Containing a Protection Net to 
Prevent Distal Embolization
Felipe Maia, Sr., Jose Ribamar Costa, Sr., Ricardo Costa, Sr., Vinicius Esteves, Sr., 
Rodolfo Staico, Sr., Galo Maldonado, Sr., Fausto Feres, Sr., Luis Alberto P. Mattos, 
Amanda GMR Souza, J Eduardo Sousa, Sr., Alexandre Abizaid, Sr., Instituto Dante 
Pazzanese de Cardiologia, Sao Paulo, Brazil, Cardiovascular Research Center, Sao 
Paulo, Brazil
Background:Disturbances of coronary ﬂow due to distal embolization of thrombus/
platelet agreggates are associated with worse immediate and long-term prognosis after 
PCI. Treatment of SVG and PCI in the setting of acute coronary syndromes (ACS) are 
often related to this complication. Although protection devices (ﬁlterwires) have been 
shown to reduce distal embolization, they add time and cost to PCI. The newly developed 
balloon-expandable MguardTM stent system is a combination of an ultra-thin polymer 
mesh sleeve attached to the external of a bare metal stent surface designed to provide 
embolic protection during PCI
Methods: Between Nov/2007-Sep/2008, 23 patients were included. Inclusion critirea 
included de novo lesions in SVG or native vessels with angiographic evidence of instability 
with potential to provoke ﬂow disturbance and/or distal embolization. Use of ﬁlterwires 
was not allowed. Primary endpoint included the incidence of MACE (composite of cardiac 
death, non-fatal MI and TLR) up to 30 days of the procedure and TIMI ﬂow right after the 
PCI. Angiographic/ IVUS analysis were performed at independent core laboratories
Results:Mean population age was 63 years and 38% had diabetes. Overall, 55% 
presented with ACS, and 57% of lesions were located in a SVG. The majority of lesions 
had complex morphology including 50% eccentric, 26% thrombus and 20% ulcer. The 
MguardTM stent was successfully delivered in all cases, there was no angiographic/
clinical complications including distal embolization and ﬁnal TIMI-3/blush-3 was achieved 
in 100%. Preprocedural QCA data demonstrated lesion length=8.16±4.8mm, vessel 
size=3.19±0.46mm and diameter stenosis=70.2±9.47%; at ﬁnal procedure, residual 
stenosis was 8.2±3.0mm with acute gain=2.06±0.32mm. There was no cardiac enzimatic 
elevation postprocedural and no MACE up to 30-day follow-up (FU)
Conclusions:In this preliminary evaluation, the MGuardTM device demonstrated excellent 
performance in a highly complex lesion subset, including absence of angiograhpic/
procedural complications and no adverse events up to 30-day FU. Complete six-month 
QCA, IVUS and clinical outcomes will be available during the meeting
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2512-679 The Effect of Intra-coronary Nicorandil prior to 
Reperfusion in Acute ST Segment Elevation Myocardial 
Infarction
Han Cheol Lee, June Kim, June Hong Kim, Kook-Jin Chun, Taek Jong Hong, Yung Woo 
Shin, Pusan National University Hospital, Busan, South Korea
Background: Intravenous nicorandil infusion with percutaneous coronary intervention 
(PCI) has been reported to reduce reperfusion injury events and improve cardiac function 
in patients with an acute myocardial infarction. However, there is limited information on 
the use of intra-coronary nicorandil. A prospective randomized single center study was 
designed to evaluate the efﬁcacy of intra-coronary nicorandil.
Methods: Seventy-three patients with acute ST segment elevation myocardial infarction 
were randomly assigned to the nicorandil group (n=37) or a control group (n=36); all 
patients had a PCI. In the nicorandil group, 4 mg of intra-coronary nicorandil was infused 
directly into the infarct area prior to reperfusion (2 mg before ballooning, 2 mg before 
stenting). The primary study endpoint was a composite of the incidence of a reperfusion 
arrhythmia, no-reﬂow and slow reﬂow. The secondary study endpoint was the post TIMI 
grade and the myocardial blush grade.
Results: The baseline characteristics were similar in both groups. A signiﬁcant difference 
was observed in the primary study endpoint in the nicorandil group compared to the 
control group (p=0.037). The post TIMI grade 3 was signiﬁcantly higher in the nicorandil 
group (p=0.019). The myocardial blush grade 1 was not observed in the nicorandil group; 
however, it was observed in ﬁve patients in the control group (p=0.019).
Conclusion: Intra-coronary nicorandil infusion reduced the occurrence of no reﬂow, slow 
reﬂow, reperfusion arrhythmia and improved the myocardial brush grade and TIMI ﬂow 
during PCI. The results of this study showed that intra-coronary nicorandil improved the 
clinical outcomes in patients with an acute myocardial infarction. 
Nicorandil group
(N=37)
Control group
(N=36) p-value
Thrombus score
3 10(27%) 15(41.7%) 0.281
5 27(73%) 21(58.3%) 0.188
Myocardial Blush grade
1 0 5(13.9%) 0.019
2 11(29.7%) 10(27.8%) 0.854
3 26(70.3%) 21(58.3%) 0.287
Pre/Post TIMI grade
0 1(2.7%) 2(5.6%) 0.538
1 1(2.7%) 4(11.1%) 0.155
2 0 3(8.3%) 0.173
3 35(94.6%) 27(75%) 0.019
Primary endpoint 2(5.4%) 8(22.2%) 0.037
No reﬂow 1(2.7%) 2(5.6%) 0.538
slow reﬂow 1(2.7%) 4(11.1%) 0.155
reperfusion arrhythmia
(VT/VF) 0 2(5.6%) 0.146
re-myocardial infarction 1(2.7%) 0 0.321
Shock 3(8.1%) 2(5.6%) 0.666
9:30 a.m.
2512-680 Coronary Flow Velocity Pattern Immediately After 
Percutaneous Coronary Intervention Predicts 
Left Ventricular Remodeling and Ischemic Mitral 
Regurgitation in Patients with Acute Myocardial 
Infarction
TAKAFUMI YAMANE, Atushi Yamamuro, Yoshimori An, Kite Kim, Takeshi Kitai, Natuhiko 
Ehara, Makoto Kinoshita, Atushi Kobori, Koichi Tamita, Shuichiro Kaji, Tomoko Tani, 
Yutaka Furukawa, Kobe City Medical Center General Hospital, Kobe, Japan
Background: Studies using the Doppler guidewire have shown that coronary ﬂow 
velocity (CFV) pattern in recanalized infarct-related arteries can evaluate microvascular 
dysfunction and predicts recovery of regional left ventricular (LV) function, in-hospital 
complications and long-term cardiac events. The purpose of this study was to examine 
whether the CFV patterns predict the risk of LV remodeling and ischemic mitral 
regurgitation (IMR) in patients with acute myocardial infarction (AMI).
Methods: Consecutive 173 patients with ﬁrst anterior AMI underwent successful PCI 
(<50% residual stenosis with TIMI ﬂow grade 2-3) and coronary ﬂow measurement with the 
Doppler guidewire. We deﬁned microvascular dysfunction as a diastolic deceleration time 
(DDT) a600 ms and the presence of systolic ﬂow reversal. Based on CFV patterns, patients 
were divided into those without microvascular dysfunction (Group 1, n=100) and those with 
microvascular dysfunction (Group 2, n=73). LV end-diastolic volume index (LVEDVI), LV end-
systolic volume index (LVESVI) and the severity of MR were evaluated by echocardiography 
at least 6 months after the infarction. A qualitative index of regurgitant severity was provide 
by the relative size of a regurgitant jet to the receiving chamber on a mild to severe scale. 
IMR was regarded as signiﬁcant when moderate or severe MR was present.
Results: LVEDVI(62.2±20.9 ml/m2 VS 48.0±13.9 ml/m2, p<0.0001) and LVESVI( 34.0±15.8 ml/
m2 VS 21.4±9.33 ml/m2, p<0.0001) were greater in group 2 than in the Group1, and signiﬁcant 
IMR was more frequently observed in Group 2 than in Group 1 (9.7% VS 1.0%, p=0.017).
Conclusions:CFV pattern of infarct-related coronary artery immediately after PCI 
predicts LV remodeling and ischemic mitral regurgitation, and enables accurate risk 
stratiﬁcation in patients with anterior AMI.
Conclusions: In this large-scale contemporary multicenter prospective randomized trial, 
restoration of normal TIMI ﬂow after primary PCI in STEMI was achieved in 86% of lesions 
and was strongly associated not only with markedly lower rates of death, but also of 
reinfarction, TVR, stroke, stent thrombosis and MACE at 30-days and 1-year follow-up.
9:30 a.m.
2512-677 Thin Cap of the Culprit Lesion, as Assessed by Optical 
Coherence Tomography, is Associated with the 
Outcome of Fibrinolytic Therapy in Patients with STEMI
Konstantinos Toutouzas, Maria Riga, Andreas Synetos, Eleutherios Tsiamis, Antonis 
Karanasos, Dimitrios Tousoulis, Elli Stefanadi, Costas Tentolouris, Costas Tsiouﬁs, 
Christodoulos Stefanadis, 1st Cardiology Clinic, University of Athens, Medical School, 
Hippokration Hospital, Athens, Greece
Background: Thrombolysis is successful in approximately 60% of patients (pts) 
with acute ST elevation myocardial infarction (STEMI). There are no data regarding 
the morphology of the culprit plaque, predicting the success of thrombolysis. Optical 
coherence tomography (OCT) can accurately measure the thickness of the ﬁbrous cap of 
the atheromatic plaque. We hypothesized that there is a correlation between the success 
rate of thrombolysis and the cap’s thickness of the culprit lesions (CL) in pts with STEMI.
Methods: We included 21 pts with STEMI (mean age 59.9±5.6 years), who underwent 
thrombolysis with tenecteplase 1-4 hours after the initiation of chest pain. Coronary 
angiography was performed within 24 hours after thrombolysis and TIMI ﬂow was 
observed. Successful thrombolysis was assigned as TIMI ﬂow III. Then all CL were 
investigated with OCT. In cases of complete obstruction, aspiration of the thrombus was 
performed before OCT examination. Fibrous cap thickness at the site of the greatest 
stenosis (FCT) of the CL was measured.
Results: OCT wires were successfully advanced through all lesions. We examined 21 CL 
of 21 pts (100%). In 13 out of 21 pts (61.9%) TIMI ﬂow grade III was achieved. Analysis of 
OCT images showed that mean FCT in all pts was 97±19μm. FCT in pts with successful 
thrombolysis was 116±40μm, whereas in pts with failed thrombolysis FCT was 65±18μm
(p<0.01). After the categorization of the plaques according to plaque thickness (thin 
<65μm; thick >65 μm) we found that 92.3% of pts with successful thrombolysis had thick 
caps, while only 25% of pts with failed thrombolysis had CL with FCT > 65μm (p<0.01).
Conclusions: In pts with STEMI, successful thrombolysis is associated with thicker 
ﬁbrous cap at the site of the greatest lumen stenosis, as measured with OCT. This study 
demonstrates that in pts with STEMI the outcome of the thrombolytic therapy could be 
predicted by speciﬁc morphological characteristics of the culprit lesions.
9:30 a.m.
2512-678 ST-Segment Resolution after Primary Percutaneous 
Intervention is Strongly Associated with Improvement 
of Cardiac Function Only in Anterior Myocardial 
Infarction
Hiroyuki Shibata, Shinichiro Yamada, Takatoshi Hayashi, Yasuyo Yaniguchi, Kazuo 
Mizutani, Sachiyo Iwata, Katsunori Okajima, Akira Shimane, Masahiro Kumada, 
Kensuke Matsumoto, Yasue Tsukishiro, Takumi Inoue, Teishi Kajiya, Himeji 
Cardiovascular Center, Himeji, Japan
Background: Complete ST-segment resolution is well-recognized predictor of good 
myocardial salvage after primary percutaneous coronary intervention (pPCI) for ST 
segment elevation myocardial infarction (STEMI). However, regional difference of effect 
of ST resolution has not been well-evaluated.
Methods: We investigated 264 patients who underwent successful pPCI between 2005 
and 2007 (120 anterior STEMI and 144 non-anterior). ECG-gated 99m-Tc-Tetrofosmin 
(TcTF) and 123-I-BMIPP SPECT were performed between 7-10 days (Acute) and TcTF 
was repeated 3 months (Chronic) after onset. Myocardium was divided into 25 segments 
and segmental score was graded by 5 degrees according to the relative activity (0:normal, 
4:defect). Sum of defect scores (S-DS) were calculated from SPECT, and ejection fraction 
(LVEF) / left ventricular volume from QGS software.
Results: In anterior STEMI, both myocardial perfusion evaluated by TcTF and fatty acid 
metabolism by BMIPP were signiﬁcantly improved in complete ST resolution group. LVEF 
is signiﬁcantly greater in both acute and chronic phase. However, in non anterior STEMI, 
There parameters did not differ signiﬁcantly between complete ST resolution group and 
no/partial ST resolution group.
Conclusions:Complete ST-resolution after primary-PCI was less frequent in anterior STEMI. 
However, it is strongly associated with preserved myocardial perfusion, fatty acid metabolism, 
and ejection fraction, and also prevents from LV remodeling only in anterior STEMI. 
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(P<0.001).
Conclusion: Use of PHECG dramatically reduces FBT and DBT amongst STEMI 
patients undergoing primary PCI within the context of a regional STEMI reperfusion 
strategy. This approach was associated with a 4.9% reduction in inhospital mortality. Use 
of PHECG should be encouraged to improve reperfusion times and reduce mortality in 
STEMI patients.
9:30 a.m.
2512-684 Will Bivalirudin Outperform Heparin Alone During 
Primary PCI for STEMI?
Sanjay Kaul, Babak Azarbal, Prediman K. Shah, George A. Diamond, Cedars-Sinai 
Medical Center, Los Angeles, CA, UCLA Medical Center, Los Angeles, CA
Background: The HORIZON trial reported that in STEMI patients undergoing primary 
PCI, bivalirudin (Bv) signiﬁcantly reduces major bleeding and increases event-freesurvival 
compared to abciximab + heparin (Hep). However, previous trials have failed to yield 
advantage for abciximab + Hep over Hep alone during primary PCI, thereby questioning 
the choice of the comparator in HORIZON.
Objective: Because the addition of abciximab to Hep may potentially increase bleeding 
without improving efﬁcacy, we compared Bv vs Hep alone using an indirect comparison 
(IC). IC have previously been validated for evaluating competing interventions in absence 
of direct comparison.
Methods: Data from abciximab-treated cohort in HORIZON (Bv vs abciximab + Hep) and 
stented cohort in CADILLAC (abciximab + Hep vs Hep) were combined to yield the Bv vs 
Hep risk ratio (RR) according to the formula:
RRBv vs Hep = (RRBv vs abciximab + Hep) x (RRabciximab + Hep vs Hep)
Trials were comparable in terms of patient population, lesion complexity, stent use, 
clopidogrel pretreatment, and outcomes.
Results (Table): Compared with Hep alone, Bv did not signiﬁcantly reduce ischemic 
composite endpoint, mortality, blood transfusion or severe bleeding (all P >0.05).
Conclusion: The results of this IC indicate that Bv did not signiﬁcantly improve efﬁcacy or 
reduce bleeding compared with Hep alone during primary PCI for STEMI. A randomized 
controlled trial directly comparing bivalirudin vs heparin alone during primary PCI is 
warranted. 
Bivalirudin vs Heparin Alone During Primary PCI for STEMI
Endpoints
(30 days)
Bivalirudin
vs
Abciximab + heparin
(HORIZON)
Abciximab + heparin
vs
heparin
(CADILLAC)
Bivalirudin
vs
heparin
(Indirect Comparison)
Death/MI/TVR/CVA 0.91(0.61-1.36)
0.76
(0.44-1.34)
0.69
(0.35-1.37)
All-cause mortality 0.66(0.44-1.00)
1.24
(0.57-2.71)
0.82
(0.34-1.98)
Transfusion rate 0.59(0.39-0.88)
1.21
(0.69-2.12)
0.71
(0.36-1.43)
Severe bleeding 0.73(0.29-1.81)
3.91
(0.44-34.85)
2.85
(0.78-10.42)
MI: reinfarction; TVR = target vessel revascularization for ischemia; severe bleeding 
(GUSTO criterion)
9:30 a.m.
2512-685 Incidence and clinical consequences of distal 
embolization on the coronary angiogram after primary 
percutaneous coronary intervention for ST-elevation 
myocardial infarction.
Marieke L. Fokkema, Pieter J. Vlaar, Tone Svilaas, Mathijs Vogelzang, Diny Amo, Gilles 
F. Diercks, Albert J. Suurmeijer, Felix Zijlstra, University Medical Center Groningen, 
Groningen, The Netherlands
Background: Primary percutaneous coronary intervention (PCI) for ST-elevation 
myocardial infarction (STEMI) may be complicated by distal embolization (DE), which can 
be visible on the angiogram as a distal ﬁlling defect with abrupt cut-off distal to the culprit 
lesion. The aim of this study was to investigate the incidence and clinical consequences 
of angiographically visible DE after primary PCI in STEMI patients treated with triple anti-
platelet therapy.
Methods: DE was analysed as part of the Thrombus Aspiration during Percutaneous coronary 
intervention in Acute myocardial infarction Study as a predeﬁned secondary endpoint.
Results: Angiograms of 880 patients were evaluated for the presence of DE after primary 
PCI. DE was visible on 5.7% of the post-procedural angiograms. DE was associated 
with signiﬁcantly worse outcomes, as shown in table. In patients with DE, the thrombus 
aspirate more often contained erythrocytes (47.1% vs. 15.7%, p<0.001) and the size of 
the aspirated thrombus was larger (p=0.02) compared to patients without DE.
Conclusions: In this patient group with triple anti-platelet therapy, the incidence of 
DE after primary PCI is low, compared to previous reports. Nevertheless, DE is still 
strongly associated with impaired myocardial reperfusion and poor outcome. Thrombus 
composition and size are related to angiographically visible DE after primary PCI.
9:30 a.m.
2512-681 A Non-invasive Strategy for the Treatment of Myocardial 
Infarction is Associated with 1-Year Mortality After 
Correction for Differences in Baseline Characteristics.
Kimberly A. Skelding, Vernon Mascarenas, Peter Berger, Christopher Good, Thomas 
Scott, Jeremy Buckley, Craig Wood, Jennifer Sartorius, James Blankenship, Geisinger 
Medical Center, Danville, PA
Background: Many randomized trials have demonstrated that an invasive strategy for 
myocardial infarction (MI) improves outcome. Data supporting an invasive approach in 
the general population, a much broader population than is enrolled in randomized trials, 
are lacking.
Methods: We queried our electronic medical health record and identiﬁed 3,015 pts 
admitted to a rural tertiary care center who suffered an MI (a CK-MB >3x upper limit of 
normal with a positive relative index) between 1/1/01 to 12/31/06. Multivariate logistic 
regression including 28 baseline clinical variables and risk factors was used to identify 
independent correlates of mortality at one year.
Results: Of the 3,015 pts, 2,066 were treated with an invasive strategy (coronary 
angiography during the initial hospitalization, followed by revascularization if appropriate), 
and 949 pts were not. The overall 1-year mortality rate was 15.7%. After adjusting for 
baseline clinical variables and risk factors, those that received non-invasive therapy were 
4.44 times more likely to die within 1-year (95% CI=[3.45, 5.78], p<0.0001).
Conclusions: Among unselected pts suffering an MI, a non invasive strategy appears to 
be an independent correlate of 1 year mortality, even after adjustment for other measured 
variables.
9:30 a.m.
2512-682 Gender is an Independent Risk Factor for Mortality 
when a Non-Invasive Strategy is Employed in the 
Setting of Acute Myocardial Infarction
Kimberly A. Skelding, Peter Berger, Vernon Mascarenas, Christopher Good, Thomas 
Scott, Jeremy Buckley, Jennifer Sartorius, Craig Wood, James Blankenship, Geisinger 
Medical Center, danville, PA
Background: Gender has been reported to be an independent risk factor for mortality 
following acute myocardial infarction (AMI). However the issue has not been evaluated 
taking into account if and when an invasive strategy was pursued.
Methods: All patients with AMI between January 1, 2001 and December 31, 2006 at 
our center were included. Demographic and clinical characteristics including treatment 
modality and outcomes were captured through a comprehensive electronic medical 
health record. A propensity analysis was incorporated into a logistic regression model to 
determine likelihood of 1-year mortality.
Results: Males (n=1968) were more likely to have a history of smoking (49% vs. 31%, 
p<0.0001); females (n=1047) were older, had more obesity, hypertension, diabetes, 
hyperlipidemia, anemia, and chronic kidney disease (p value <0.0002 for each). After 
adjustment for risk factors, when invasively treated, there was no difference in one-year 
mortality between females to males (OR=0.90, 95% CI 0.63-1.29, p=0.55). However, 
among patients not undergoing an invasive evaluation females had a signiﬁcantly higher 
mortality than males (OR=1.49, 95% CI 1.10-2.01, p=0.010).
Conclusions: Women treated conservatively for AMI are at highest risk for mortality. 
Prospective studies of AMI with increased representation of female patients ought to be 
performed in order to identify cohorts of females who may have a mortality beneﬁt from 
more aggressive therapy.
9:30 a.m.
2512-683 Improvements in Door to Balloon Time with Use of 
Prehospital ECG: The Vancouver Coastal Health 
Experience.
Graham Christopher Wong, Michael Tsang, Michele Perry, Ron G. Carere, Anthony 
Y. Fung, John G. Webb, Monita Sundar, Christopher E. Buller, Krishnan Ramanathan, 
Vancouver Coastal Health Authority, Vancouver, BC, Canada, University of British 
Columbia, Vancouver, BC, Canada
Background: Use of prehospital ECGs (PHECG) has resulted in signiﬁcant improvements 
in ﬁrst medical contact to balloon time (FBT) and door to balloon time (DBT) for patients 
undergoing primary PCI for ST elevation myocardial infarction (STEMI). However, its 
widespread use is limited. Our health care region (Vancouver Coastal Health Authority 
[VCHA]) recently adopted the routine use of PHECG as part of a regional approach to 
STEMI reperfusion. We report on our initial experience with routine use of PHECG for 
STEMI identiﬁcation and subsequent in-ﬁeld redirection of patients for primary PCI.
Methods: VCHA has utilized a region-wide approach to STEMI reperfusion since June 1st,
2007. As part of this program, VCHA has implemented wireless transmission of paramedic 
acquired ECGs for all suspected STEMI patients seen by BC Ambulance Service (BCAS) 
since May 21st 2008. Patients so identiﬁed are redirected from community hospitals in the 
region towards one of 2 PCI capable hospitals. Activation of the cardiac catheterization team 
for primary PCI was made by the emergency department (ED) physicians upon receipt of the 
PHECG and clinical information supporting a diagnosis of STEMI. We compared the median 
ﬁrst medical contact to balloon time (FBT) and hospital door-to-balloon time (DBT) amongst 
consecutive STEMI patients, before (n=68) and after (n= 48) initiating the PHECG program.
Results: Complete clinical and temporal data including was available for 116 patients. 
Patients were well matched for age, % male sex and % age >75 yrs. Use of PHECG was 
associated with a signiﬁcant reduction in FBT (149 vs. 86 min, p< 0.001) and DBT (105 
vs. 46 min, p<0.001). Absolute in hospital mortality was reduced from 13.2% to 8.3% 
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9:30 a.m.
2512-688 Time-to-Treatment in STEMI Patients Undergoing Inter-
hospital Transfer in Massachusetts
Murtuza J. Ali, Zoran S. Nedeljkovic, Katya Zelevinsky, Ann Lovett, Sharon-Lise T. 
Normand, Alice K. Jacobs, Boston University School of Medicine, Boston, MA, Harvard 
Medical School, Boston, MA
Background: Primary percutaneous coronary intervention (PCI) is the preferred 
reperfusion strategy for ST-elevation myocardial infarction (STEMI) if delivered in a timely 
fashion. Because many STEMI patients require inter-hospital transfer to a PCI-capable 
hospital, the importance of time to treatment has gained increased recognition. To study 
the impact of efforts to reduce time to treatment in Massachusetts, we evaluated 6008 
STEMI patients undergoing primary PCI between 2005 and 2007. Methods: We used 
prospectively collected data compiled, audited, and analyzed by the Massachusetts Data 
Analysis Center, the state mandated PCI registry. Results: The mean age of the population 
was 61 years, with 29% women and 6.5% in cardiogenic shock. In patients admitted directly 
to a PCI hospital, mean door-to-balloon (DTB) time decreased from 2005 to 2007, with 
an increase in patients achieving a DTB time a90 minutes (73.2% in 2007). For patients 
requiring inter-hospital transfer, mean DTB time also improved but fewer patients achieved 
total DTB time a90 minutes (8.7% in 2007), as shown in the table below. Most of the delay 
was due to the time required for inter-hospital transfer (102 min in 2007). 
Mean DTB time 
(no transfer)
N=3695
Mean DTB time (with 
inter-hospital transfer)
N=2313
DTB time a
90 minutes
(no transfer)
DTB time a 90 
minutes
(with inter-
hospital transfer)
2005 92.4 min 170.5 min 56.6% 4.5%
2006 87.5 min 159.6 min 62.6% 6.5%
2007 79.3 min 146.1 min 73.2% 8.7%
Conclusion: Although DTB time has improved in STEMI patients in Massachusetts, 
delays still persist primarily in patients requiring transfer to a PCI hospital with < 10% 
achieving the recommended target. The impact of the recently mandated Statewide 
STEMI Triage (Point of Entry) System will require further study.
9:30 a.m.
2512-689 Beneﬁcial Diastolic Effects of Mechanical Left 
Ventricular Unloading by Impella During High-Risk PCI 
and Primary PCI for Acute Myocardial Infarction
Maurice Remmelink, Krischan D. Sjauw, José P. Henriques, Robbert J. de Winter, 
René J. van der Schaaf, Marije M. Vis, Karel T. Koch, Walter J. Paulus, Bas A. de Mol, 
Jan G. Tijssen, Jan J. Piek, Jan Baan, Jr., Academic Medical Center - University of 
Amsterdam, Amsterdam, The Netherlands, VU University Medical Center, Amsterdam, 
The Netherlands
Background: Limited clinical information is available on the direct left ventricular (LV) 
dynamic consequences of LV unloading in patients undergoing high-risk percutaneous 
coronary intervention (PCI) and primary PCI for acute ST-elevation myocardial infarction. 
We studied online LV dynamic effects of mechanical LV unloading during PCI.
Methods: The effects of the Impella LP2.5 device on LV dynamics were studied in 11 
patients (elective high-risk PCI, n=6; primary PCI, n=5). LV pressure and volume were 
continuously assessed by a pressure-conductance catheter at 4 different support levels 
of the Impella, from 0 L/min at baseline to 2.5 L/min at maximal support.
Results: The response to increased LV unloading was not different between both groups 
of patients. The pooled data showed no change on global and systolic LV function during 
increased LV unloading, while diastolic function showed improvement as indicated by an 
increased LV compliance in all patients. There was a decrease in end-diastolic pressure 
from 22±4 to 13±3 mm Hg (p=0.0001), in end-diastolic elastance from 0.134±0.021 to 
0.091±0.021 mm Hg/mL (p=0.009), and in end-diastolic wall stress from 84±18 to 47±13 
mm Hg (p=0.004).
Conclusions: LV unloading decreases end-diastolic wall stress and improves diastolic 
compliance dose-dependently. Our results indicate beneﬁcial LV unloading effects of 
Impella during high-risk and primary PCI.
9:30 a.m.
2512-690 Clinical and Angiographic Factors Predicting 
Development of the No-Reﬂow/Slow Flow Phenomenon 
during Primary Percutaneous Coronary Intervention in 
Acute Myocardial Infarction
Hyoung-Mo Yang, Seung-Jea Tahk, Hong-Seok Lim, Byoung-Joo Choi, So-Yeon Choi, 
Myeong-Ho Yoon, Gyo-Seung Hwang, Jin-Sun Park, Soo-Jin Kang, Joon-Han Shin, 
Ajou University Medical Center, Suwon, South Korea
Background: The development of the no-reﬂow/slow ﬂow phenomenon during 
percutaneous coronary intervention (PCI) is associated with unfavorable outcomes in 
patients with acute myocardial infarction (AMI). We aimed to identify the patient at high 
risk for developing the no-reﬂow/slow ﬂow phenomenon in AMI.
Methods: We studied 122 patients who underwent primary PCI for AMI within 12 hours of 
symptom onset. The patients were divided into the no-reﬂow/slow ﬂow group (thrombolysis 
in myocardial infarction (TIMI) 0,1,2) and reﬂow (TIMI 3) group, and compared clinical, 
Comparison of patients with and without distal embolization on the 
coronary angiogram after PCI
No distal 
embolization
(N = 830)
Distal
embolization
(N = 50) P
Thrombus aspiration (%) 421/830 (50.7) 25/50 (50.0) ns
TIMI ﬂow 3 post PCI (%) 727/830 (87.6) 33/50 (66.0) <.001
MBG 3 post PCI (%) 360/825 (43.6) 2/49 (4.1) <.001
ST-seg. resolution >70% (%) 418/771 (54.2) 9/44 (20.5) <.001
New Q-waves (%) 605/771 (78.5) 42/44 (95.5) .004
9:30 a.m.
2512-686 The Role of Coronary Artery Bypass Grafting in ST-
Segment Elevation Myocardial Infarction: a Substudy 
From the Thrombus Aspiration During Percutaneous 
Coronary Intervention in Acute Myocardial Infarction 
Study
Youlan L. Gu, Iwan C. van der Horst, Yvonne Douglas, Tone Svilaas, Felix Zijlstra, 
University Medical Center Groningen, University of Groningen, Groningen, The 
Netherlands
Background: While primary percutaneous coronary intervention (PCI) is the treatment of 
choice for ST-segment elevation myocardial infarction (STEMI), coronary artery bypass 
grafting (CABG) may be indicated during the acute and subacute phase of STEMI for 
anatomic and ischemic reasons. In this study, we sought to investigate the clinical and 
surgical characteristics and long term outcome of patients treated with CABG within 30 
days after presentation in a contemporary cohort of STEMI patients.
Methods: All 1071 patients enrolled in the Thrombus Aspiration during Percutaneous coronary 
intervention in Acute myocardial infarction Study (TAPAS) were included in this analysis. The 
decision to perform CABG was made by a joint heart team consisting of a clinical cardiologist, 
interventional cardiologist and cardio-thoracic surgeon according to the current guidelines.
Results: CABG was performed in 59 (5.5%) STEMI patients within 30 days of presentation. 
Of these patients, 13 (22%) were operated within 24 hours, 8 (14%) between 1 and 3 
days, and 38 (64%) between 4 and 30 days. Compared with patients not treated with 
CABG, CABG patients had multivessel disease more often (p<0.001), underwent PCI and 
stent implantation less often (70% vs. 95% and 50% vs. 94%, respectively, both p<0.001), 
needed more intra-aortic balloon pump support (33% vs. 5%, p<0.001), and experienced 
more major bleeding (39% vs. 4%, p<0.001). Rethoracotomy was performed in 9/59 (15%) 
patients. When CABG was performed within 3 days, the incidence of rethoracotomy and 
major bleeding was higher than when it was performed after 3 days (33% vs. 5%, p=0.004, 
and 62% vs. 26%, p=0.007). At 1 year follow up, cardiac mortality did not differ between the 
CABG and non-CABG group (1.7% vs. 5.3%, HR 0.31, 95% CI 0.043 - 2.26, p=0.248).
Conclusions: Despite multiple high risk features, and a high incidence of major bleeding 
and rethoracotomy in STEMI patients treated with CABG, especially when it was 
performed within the ﬁrst 3 days after presentation, surgical patients have a favorable 
long term outcome similar to non-surgical patients.
9:30 a.m.
2512-687 Clinical Outcomes of Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction due to Left 
Main Coronary Artery Occlusion
Shingo Sakamoto, Norimasa Taniguchi, Yasuo Sato, Syunsuke Nakajima, Akihiko 
Takahashi, Sakurakai Takahashi Hospital, Kobe, Japan
Background: Acute myocardial infarction (AMI) due to left main coronary artery (LMCA) 
occlusion has a poor prognosis. However, data on the clinical outcome of primary 
percutaneous coronary intervention (PCI) of acute LMCA occlusion has been scarce. The 
purpose of this study was to determine the clinical features and outcomes of patients who 
underwent primary PCI for AMI due to LMCA occlusion.
Methods: Between January 1997 and December 2007, a total of 1219 patients with 
AMI admitted to our hospital. Of these, 37 patients (3.0%) who underwent PCI for LMCA 
occlusion were enrolled. Clinical outcomes were determined by reviewing hospital 
records or via telephone contact. Survival free of all-cause death was estimated by the 
Kaplan-Meier method. A multiple Cox proportional hazard model analysis was performed 
to identify independent variables associated with all-cause death.
Results: Most patients presented with critical hemodynamic status on arrival including 
18 cardiogenic shocks and 8 cardiac arrests. Nineteen patients required percutaneous 
extracorporeal life support to maintain hemodynamic status and 35 patients required 
intra-aortic balloon counter pulsation. Success reperfusion was achieved in 97.3%. 
In-hospital mortality rate was 40.5%. Twenty-two patients (59.5%) survived to hospital 
discharge. During follow-up period, an additional 6 patients died. Multivariate analysis 
showed an independent predictor of all-cause mortality to be cardiopulmonary arrest on 
arrival (RR, 4.39; 95% CI, 1.53 to 12.6; P = 0.01).
Conclusions: Patients with AMI due to LMCA occlusion showed a high mortality, 
however, our data revealed high rate of successful reperfusion and better outcome than 
previous reports. Cardiopulmonary arrest on arrival was the only independent predictor of 
all-cause death. Advanced therapy for the patients with cardiopulmonary arrest on arrival 
may further improve the prognosis.
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Table: Clinical outcomes of the Study Population
Variables, n (%) Dual group(n=1,075 pts)
Triple group
(n=625 pts) P value
In-hospital
Total death 18 (1.7) 8 (1.3) 0.523
Reinfarction 2 (0.2) 3 (0.5) 0.364
Revascularization 18 (1.7) 2 (0.3) 0.013
All MACE 38 (3.5) 13 (2.1) 0.090
TIMI-major bleeding events 1 (0.1) 1 (0.2) 1.000
At 1 month
Total death 20 (1.9) 12 (1.9) 0.939
Reinfarction 8 (0.8) 3 (0.5) 0.755
Revascularization 32 (3.0) 8 (1.3) 0.025
All MACE 60 (5.7) 23 (3.7) 0.076
At 8 months
Total death 26 (2.5) 18 (2.9) 0.562
Reinfarction 12 (1.1) 5 (0.8) 0.528
Revascularization 55 (5.2) 22 (3.6) 0.127
All MACE 93 (8.8) 45 (7.3) 0.292
9:30 a.m.
2512-693 Direct Presentation, Field-Referral, and Interhospital 
Transfer in a Network-Based System for Primary 
Percutaneous Coronary Intervention for ST-Elevation 
Myocardial Infarction Result in Similar 1-Year Mortality
Wichert J. Kuijt, Karel T. Koch, Joost D. Haeck, Niels J. Verouden, José P. Henriques, Jan 
Baan, Jr., René J. Van der Schaaf, Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Mitchell 
W. Krucoff, Robbert J. De Winter, Academic Medical Center-University of Amsterdam, 
Amsterdam, The Netherlands, Duke Clinical Research Institute, Durham, NC
Background: Guidelines describe a systems-based ﬁrst medical contact (FMC) to balloon 
time of 90 minutes as the goal for standard of care in primary percutaneous coronary 
intervention (PCI) for ST-elevation myocardial infarction (STEMI). In our regionalized 
STEMI network, infrastructural measures such as single-call activation of the catherization 
laboratory, short touchdown in the emergency department of referring hospitals, and direct 
ambulance transmission of an electrocardiogram (ECG) have been implemented. We 
investigated whether these measures would lead to guideline adherence and if route of 
presentation had an impact on 1-year mortality in an all-comer STEMI population.
Methods: Data was prospectively acquired in a dedicated database. Between 2000 and 
2006, 2507 patients with a complete dataset underwent primary PCI. Time of symptom 
onset, FMC, call to activate the catherization laboratory, arterial puncture (needle) and 
balloon inﬂation were recorded and time-intervals were calculated for patients presenting 
directly, through interhospital transfer or direct ﬁeld-referral. Field-referral FMC was time 
of acquisition of ambulance ECG.
Results: Time-intervals are medians in minutes with interquartile ranges, in order of direct 
presentation, interhospital transfer, and ﬁeld referral. Time of symptom-onset to FMC was 
90.5 (60-165), 90 (54-155), and 69 (33.5-128) (p<0.001). FMC to call time was 17 (10-34), 
22 (14-40), and 19 (10-36) (p<0.001). Call-to-needle time was 40 (27-49), 50 (40-61), 
and 41 (30-50) (p<0.001). Needle-to-balloon time was 12 (8-19), 13 (9-20), and 15 (11-
23) (p<0.001). Unadjusted 1-year mortality was 9.6% for direct presentation, 9.1% for 
interhospital transfer and 9.3% for ﬁeld-referral (p=0.95). The adjusted hazard ratios for 
route of presentation were 0.95 (p=0.76, 95% CI 0.69-1.31) and 0.77 (p=0.34, 95% CI 
0.45-1.31), respectively.
Conclusion: In STEMI patients, fast reperfusion was achieved in all routes of presentation 
and there was no signiﬁcant difference in unadjusted and adjusted 1-year mortality. These 
results support primary PCI as the preferred treatment in STEMI if these infrastructural 
measures can be successfully implemented.
9:30 a.m.
2512-694 Effect of Gender on Outcome Following Percutaneous 
Coronary Intervention for Acute Myocardial Infarction
Victoria Fratto, Lakshmi Venkitachalam, Faith Selzer, Alice Jacobs, Ruchira Glaser, J. 
Dawn Abbott, Kevin E. Kip, Suresh R. Mulukutla, Sheryl Kesley, Elizabeth M. Holper, 
Oscar C. Marroquin, University of Pittsburgh School of Medicine, Pittsburgh, PA, Center 
for Interventional Cardiology Research, Pittsburgh, PA
Background: Mortality rates from coronary artery disease, speciﬁcally acute myocardial 
infarction (AMI), have decreased over time in men, but not in women. Percutaneous 
coronary intervention (PCI) has proven beneﬁcial for the treatment of AMI, but its impact 
in women is less clear.
Methods: The study population consisted of 2856 patients who underwent PCI for 
AMI enrolled in the National Heart, Lung, and Blood Institute Dynamic Registry in ﬁve 
waves from 1997 to 2006. Gender differences in baseline patient, procedural, and in-
laboratory, echocardiographic, angiographic and procedural parameters.
Results: The incidence of the no-reﬂow/slow ﬂow phenomenon was 31% (38 patients). 
Reperfusion after 6 hours (65.8 vs. 26.2%, p<0.001), the frequency of balloon pre-
dilation q3 times (21.1 vs. 8.3%, p=0.048), q2 stents at culprit vessel (44.7 vs. 20.2%, 
p=0.005), lesion length q20 mm (71.1 vs. 33.3%, p<0.001), troponin-T q0.25 ng/ml (57.9 
vs. 22.6%, p<0.001) were more common in the no-reﬂow/slow ﬂow group. Multivariate 
logistic regression analysis revealed that reperfusion time q6 hours (odds ratio: 5.389, 
p=0.001), lesion length q20 mm (odds ratio: 4.065, p=0.005), and troponin-T q0.25 ng/
ml (odds ratio: 5.178, p=0.001) were independent predictors for developing the no-reﬂow/
slow ﬂow phenomenon.
Conclusions: During primary percutaneous coronary intervention in patients with acute 
myocardial infarction, reperfusion time more than 6 hours, high troponin-T level and 
long lesion length were independent predictors for developing the no-reﬂow/slow ﬂow 
phenomenon.
9:30 a.m.
2512-691 Impact of Clopidogrel Loading Dose on the 
Effectiveness of Bivalirudin in Primary Angioplasty for 
Acute Myocardial Infarction: The HORIZONS-AMI Trial
George D. Dangas, Giulio Guagliumi, Bernhard Witzenbichler, Deepak Bhatt, Frederick 
Feit, Magnus Ohman, S. Chiu Wong, Eugenia Nikolsky, Adriano Caixeta, Helen Parise, 
Alexandra J. Lansky, Roxana Mehran, Gregg W. Stone, Columbia University Medical 
Center and the Cardiovascular Research Foundation, New York, NY
Background. In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared to 
unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced 
30-day rates of major bleeding, reduced cardiac mortality with comparable composite major 
adverse cardiovascular events (MACE), and enhanced freedom from net adverse clinical 
events (NACE; MACE or major bleeding) in pts with AMI undergoing primary PCI. Whether 
the observed effects of Biv are dependent on the clopidogrel loading dose is unknown.
Methods and Results. In HORIZONS, 3602 pts with AMI at 123 centers in 11 countries 
were randomized to Biv (n=1800) vs. UFH+GPI (n=1802). Per protocol, all pts were to 
receive a clopidogrel loading dose in the ER, either 300 mg or 600 mg per the treating 
physician, and randomization was stratiﬁed by this decision. As shown in the table, the 
effects of Biv were independent of the clopidogrel loading dose (interaction p values = 
nonsigniﬁcant for major bleeding, MACE and NACE respectively).
Conclusions. In patients with AMI undergoing primary PCI, Biv monotherapy signiﬁcantly 
reduces major bleeding and net adverse clinical events, independent of the clopidogrel 
loading dose. 
Clopidogrel 300mg Clopidogrel 600mg
Biv
n=569
UFH+GPI
n=584 RR [95%CI]
Biv
N=1097
UFH+GPI
N=1061 RR [95%CI]
Major bleeding 7.5% 11.9% 0.61 [0.41,0.89] 5.0% 8.2% 0.59 [0.42,0.84]
MACE* 13.7% 11.4% 1.22 [0.88,1.70] 10.5% 11.6% 0.90 [0.70,1.16]
NACE** 17.8% 19.4% 0.89 [0.68,1.17] 14.1% 17.4% 0.79 [0.64,0.98]
* MACE = death, reinfarction, ischemic TVR or stroke;
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
9:30 a.m.
2512-692 Triple versus Dual Antiplatelet Therapy in Patients with 
Acute Non-ST-Segment Elevation Myocardial Infarction 
Undergoing Percutaneous Coronary Intervention
Kang Yin Chen, Seung-Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn*, Myung Ho Jeong*, Other 
KAMIR Investigators, Korea University Guro Hospital, Seoul, South Korea, ChonNam 
National University Hospital*, Gwangju, South Korea
Background: Whether the triple antiplatelet therapy is superior to the dual antiplatelet 
therapy in patients (pts) with acute non-ST-segment elevation myocardial infarction 
(NSTEMI) undergoing percutaneous coronary intervention (PCI) is still unclear.
Methods: A total of 1,700 NSTEMI pts undergoing PCI received either dual antiplatelets 
(aspirin plus clopidogrel, Dual group, n=1,075) or triple antiplatelets (aspirin plus 
clopidogrel plus cilostazol, Triple group, n=625) therapy. The patients in Triple group 
received additional cilostazol for 1 month, then, changed to receive dual antiplatelet 
therapy.The bleeding complications and clinical outcomes up to 8 months were compared 
between these two groups.
Results: The baseline characteristics were similar between these two groups. The incidences 
of total death, recurrent MI and major bleeding events were similar between these two groups. 
Triple group showed a lower incidence of in-hospital revascularization, but it was not well 
maintained up to 8 months. Although there was a trend toward lower incidence of All MACE in 
the Triple group at 1 month, but not maintained at 8 months (Table).
Conclusions: Despite numerically lower incidences of early revascularization and 
MACE, the triple antiplatelet therapy appears to be similar to the dual antiplatelet therapy 
in pts with NSTEMI undergoing PCI.
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the other signiﬁcantly narrowed arteries and 217 (73%) had underwent revascularization 
for culprit lesion and the other disease artery were left during the primary percutaneous 
coronary intervention (PCI).
Result: During the 4 years of follow-up, patients with complete revascularization during 
the primary PCI showed the improved long-term mortality as compared to those with 
only culprit intervention ( 4.9 vs. 20.9%, adjusted HR, 0.06, 95% CI 0.01-0.38, P=0.003). 
However, the risk of MI (4.9 versus 7.9 %, adjusted HR, 0.63, 95% CI 0.20-1.94, P=0.42) 
and stent thrombosis (4.9 versus 5.5%, adjusted HR, 0.34, 95% CI 0.06-1.84, P=0.21) 
were similar in the both groups.
Conclusion: In the setting of primary PCI for STEMI with concomitant multivessel 
disease, simultaneous complete revascularization for culprit and non-culprit lesions was 
associated with improved long-term mortality. 
9:30 a.m.
2512-697 Clopidogrel Pretreatment in ST-Elevation Myocardial 
Infarction Patients Transferred for Percutaneous 
Coronary Intervention
David M. Larson, Sue Duval, Scott W. Sharkey, Christopher Solie, Barbara T. Unger, 
Timothy D. Henry, Minneapolis Heart Institute Foundation at Abbott Northwestern 
Hospital, Minneapolis, MN
Background: Pretreatment with clopidogrel prior to percutaneous coronary intervention 
(PCI) reduces ischemic complications, but there are limited data in patients (pts) 
undergoing primary PCI for ST-elevation myocardial infarction (STEMI).
Methods: The Minneapolis Heart Institute at Abbott Northwestern (ANW) performs PCI 
for all STEMI that present directly or are transferred from 35 community hospitals as 
part of the “Level 1 MI” program. Zone 1 hospitals are <60 miles and Zone 2 are 60-210 
miles away from ANW. STEMI pts receive aspirin, unfractionated heparin and clopidogrel 
(600 mg) in the emergency department of the presenting hospital within 15 minutes of 
diagnosis. Zone 2 pts also receive reduced dose ﬁbrinolytic unless contraindicated. This 
analysis included all STEMI pts from 4/03 to 6/08 pretreated with clopidogrel and stratiﬁed 
by zone as a surrogate for pretreatment time. Median door to PCI time was 123 minutes 
in Zone 2, 96 minutes in Zone 1 and 65 minutes at ANW.
Results: There was signiﬁcantly improved coronary patency (TIMI 2/3 ﬂow) and less 
reinfarction at 30 days in pts treated in Zone 2 and 1 compared to ANW with no signiﬁcant 
increase in bleeding and no difference in mortality (Table). 
Reinfarction, 30 
days
Pre-TIMI ﬂow 2/3 
(excluding lytics) Bleeding
Death, 30 
days
ANW 14/371 (3.8%) 122/313 (38.9%) 14/371 (3.8%) 11/371 (3.0%)
Zone 1 9/850 (1.1%) 362/758 (47.8%) 19/850(2.2%) 28/850(3.3%)
Zone 2 6/604 (1%) 57/100 (57%) 21/604 (3.5%) 28/604 (4.6%)
P-value 0.001 0.002 0.23 0.29
Conclusions: STEMI pts who received earlier pretreatment with clopidogrel had 
signiﬁcantly less ischemic complications and improved patency without increased 
bleeding or 30-day mortality. This study supports administration of clopidogrel (600 mg) 
for STEMI pts at the point of ﬁrst medical contact.
9:30 a.m.
2512-698 Impact of Vascular Disease on In-Hospital Mortality 
Following Percutaneous Coronary Intervention for 
Acute Myocardial Infarction
Jignesh Patel, David L. Brown, Stony Brook University Medical Cener, Stony Brook, NY
Background: The impact of vascular disease on the survival of patients presenting with 
acute myocardial infarction (AMI) is not well understood. The purpose of the present study 
is to analyze the effect of vascular disease on in-hospital mortality of patients with AMI 
treated with primary percutaneous coronary intervention (PPCI).
Methods: This retrospective cohort study analyzed all patients undergoing PPCI for 
AMI from 1997-1999 in New York State. Vascular disease was deﬁned as disease of the 
carotid, aorto-iliac or femoral-popliteal circulations. The primary outcome of interest was 
in-hospital mortality.
Results: PPCI was performed in 9015 patients with AMI of whom 529 patients (5.9%) 
had vascular disease. Vascular disease patients were older (69 vs. 60 years, P<0.001) 
and more commonly female (40% vs. 28%, P<0.001). Patients with vascular disease 
were more likely to have diabetes (28% vs. 17%, P<0.001), hypertension (72% vs. 55%, 
P<0.001) or chronic kidney disease (3.6% vs. 0.9%, P< 0.001). A history of stroke (15% 
vs. 3.2%, P<0.001), heart surgery (19% vs. 6%, P<0.001) and heart failure (7.6% vs. 2%, 
hospital outcomes were calculated using Chi-square and Wilcoxon rank-sum tests for 
categorical and continuous variables, respectively. Cumulative one year event rates for 
death, MI, and repeat revascularization (PCI or bypass) were compared using the log 
rank test. Univariate and adjusted risks of one year events for women (reference: men) 
were computed using Cox proportional models. Temporal trends were assessed using the 
interaction term of gender with wave.
Results: Women undergoing PCI for AMI (35.4% of cohort) were older (mean age 65.5 
vs 59.5 years, p<0.001), with a higher prevalence of diabetes (32.8% vs 23.5%, p<0.001), 
hypertension (71.6% vs 58.4%, p<0.001) and congestive heart failure (10.8% vs 7.1%, 
p=0.001) compared to men. Women also presented with more single vessel disease 
(44.8% vs 39.0%, p=0.01) and calciﬁed lesions (27.3% vs 23.4%, p=0.02). In-hospital 
event rates were similar in both groups [death (3.7% women vs 3.2% men, p=0.51), MI 
(1.4% vs 2.0%, p=0.27), emergency bypass surgery (0.4% vs 0.2%, p=0.39)]. Cumulative 
one year event rates were as follows - death (7.1% women vs 6.6% men, p=0.53), MI 
(4.7% both genders), and repeat revascularization (11.7% vs 11.9%, p=0.91). Adjusted 
risks of death, MI and repeat procedures in women were similar to men in the overall 
cohort (non-signiﬁcant hazard ratios were 0.93, 1.08, 1.12, respectively). Interaction of 
gender with wave did not reach statistical signiﬁcance for any event.
Conclusions: Despite more adverse proﬁles at baseline, women treated with PCI for AMI 
experience similar procedural and one year outcomes as men with AMI. These results 
support the continued use of PCI to treat AMI in women and in men.
9:30 a.m.
2512-695 Fibrinolytic Acceleration of STEMI Treatment Coupled 
with Urgent PCI (FAST-PCI) in an Urban Setting 
Improves Infarct Vessel Patency, Decreases Ischemic 
Time, and Reduces Peak Biomarker Levels without a 
Bleeding Penalty
Troy Weirick, Ali Denktas, Vernon Anderson, Richard Smalling, University of Texas at 
Houston, Houston, TX
Background: Although theoretically attractive, the safety and efﬁcacy of pre-hospital 
ﬁbrinolysis prior to planned PCI for acute MI remains uncertain, particularly in an urban 
setting with short transport times. Early trials suggest improved outcomes when ﬁbrinolytic 
therapy was given prior to hospital admission; however, a recent meta-analysis questions 
the safety of ﬁbrinolytic therapy prior to planned PCI.
Methods: From November 2005 thru December 2006, over 200 patients presented to 
a large, urban hospital with presumed STEMI. In this cohort, 131 patients could reliably 
report the time of symptom onset to within six hours of presentation. Forty-nine of these 
patients were part of an ongoing evaluation of pre-hospital reduced-dose ﬁbrinolytic 
therapy prior to planned PCI. Data were analyzed according to treatment strategy, FAST-
PCI vs. primary PCI.
Results: Age and time to presentation are similar in these groups. Measures of early 
target vessel patency signiﬁcantly favor the pre-hospital treated group. Peak biomarker 
levels are reduced in FAST-PCI patients, and mean ischemic time is lower in the lytic 
pretreated group. However, no signiﬁcant difference in bleeding occurred, and there were 
no intracranial bleeds. 
FAST-PCI
(n=49)
Primary PCI
(n=82) P-value
Age (yrs) 57 std +/-12 57 std +/-12 0.97
Time to Presentation (hrs) 2.21 2.17 0.89
Ischemic Time (hrs) 3.0 3.4 0.18
TIMI Flow Pre-procedure (Mean) 2.0 1.3 0.001
TIMI Flow Post-procedure (Mean) 2.9 2.8 0.76
Infarct Artery Patent at Presentation, (TIMI 
Flow 2 or 3) 73% (36/49) 48% (39/82) 0.003
Peak CK, U/L (Mean) 1664 std +/-1809
2431 std+/-
2208 0.04
Peak Troponin-T, ng/dL (Mean) 6.3 8.1 0.19
Average Hb loss (g/dL) 2.5 2.8 0.37
MACE - Death, MI, Stroke (N) 2 5 0.62
Conclusions: In this well-matched, urban population of patients presenting within six 
hours of chest pain onset, FAST-PCI improves infarct artery patency, decreases peak 
biomarker concentrations and reduces ischemic time without increased bleeding 
compared to primary PCI.
9:30 a.m.
2512-696 Long-term Outcomes of Culprit Only versus Complete 
Coronary Revascularization During Primary 
Percutaneous Coronary Intervention
Jeong-Sook Seo, Duk-Woo Park, Sung Sik Kim, Sung-Hwan Kim, Myung-Zoon Yi, 
Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: The optimal percutaneous interventional strategy for dealing with signiﬁcant 
non-culprit lesions in patients presented with acute ST elevation myocardial infarction 
(STEMI) and concomitant multivessel disease remains to be controversial.
Method: A total of 299 patients presented with acute STEMI and multivessel disease 
underwent percutaneous coronary intervention. Among the overall patients, 82 patients 
(27%) underwent simultaneously complete revascularization for culprit, infarct artery and 
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9:30 a.m.
2512-701 Equivalent Improvement of Cardiac Function after 
Late Reperfusion by Primary Percutaneous Coronary 
Intervention for ST-Segment Elevation Myocardial 
Infarction
Shinichiro Yamada, Takatoshi Hayashi, Sachiyo Iwata, Kazuo Mizutani, Yasuyo Taniguchi, 
Masahiro Kumada, Katsumori Okajima, Yasue Tsukishiro, Gaku Kanda, Takumi Inoue, 
Hiroyuki Shibata, Teishi Kajiya, Himeji Cardiovascular Center, Himeji, Japan
Background: Efﬁcacy of primary percutaneous intervention (pPCI) for ST-segment elevation 
myocardial infarction (STEMI) >12 hours after the symptom onset is controversial.
Methods: We investigated 62 consecutive patients with STEMI who had undergone pPCI 
12-48 after symptom onset (Late Reperfusion group). They were compared with age, 
gender and culprit lesion matched patients who received pPCI <6 hours after onset (Early 
Reperfusion). TIMI grade >2 at the time of diagnostic coronary angiography were excluded. 
ECG-gated 99m-Tc-Tetrofosmin (TcTF) and 123-I-BMIPP SPECT were performed between 
7-10 days (Acute) and TcTF was repeated 3 months (Chronic) after onset. Myocardium 
was divided into 25 segments and segmental score was graded by 5 degrees according 
to the relative activity (0:normal, 4:defect). Sum of defect scores (S-DS) were calculated 
from SPECT, and ejection fraction (LVEF) / left ventricular volume from QGS software.
Results: There were no signiﬁcant differences of prevalence of ﬁnal TIMI grade or 
ST resolution between two groups. Baseline myocardial perfusion evaluated by TcTF, 
fatty acid metabolism by BMIPP, LVEF at acute and chronic phase also did not differ 
signiﬁcantly. Only improvement of myocardial perfusion score from acute to chronic phase 
was signiﬁcantly greater in Early Reperfusion group.
Conclusions: Primary PCI for STEMI provides the improvement of cardiac function 
including perfusion, metabolism and wall motion even when performed over 12 hours 
after the onset.
9:30 a.m.
2512-702 Impact of Gender on the Safety and Effectiveness of 
Bivalirudin in Patients with Acute Myocardial Infarction 
Undergoing Primary Angioplasty: The Horizons-AMI 
Trial
Liliana Grinfeld, Alexandra J. Lansky, Jorge Belardi, Bernhard Witzenbichler, Giulio 
Guagliumi, Krzyszto Zmudka, Martin Moeckel, Andrzej Ochala, Witkowski Ruzyllo, Iulian 
Benetato Giuran, Helen Parise, Roxana Mehran, Gregg W. Stone, Columbia University 
Medical Center and the Cardiovascular Research Foundation, New York, NY
Background: In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) vs. unfractionated 
heparin (UFH) + glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced rates of major 
bleeding, comparable composite major adverse cardiovascular events (MACE), and 
enhanced freedom from net adverse clinical events (NACE) in pts with AMI undergoing 
primary PCI. Whether the beneﬁcial effects of biv. are present in women, a high risk group 
after primary PCI in AMI, has not been reported.
Methods and Results: A total of 3602 pts at undergoing primary PCI were randomized to 
Biv (n=1800) vs. UFH+GPI (n=1802). In the entire study population at 1 year Biv compared to 
UFH+GPI resulted in a 39% reduction in major bleeding (5.8% vs. 9.2%, P<0.0001), reduced 
cardiac mortality (2.1% vs. 3.8%, p=0.0.005), similar MACE (11.9% vs. 11.9%, P=1.0), and a 
16% reduction in NACE (15.7% vs. 18.3%, P=0.03). At one year, compared to men, women 
(n=842; 23.4%) had greater rates of major bleeding (11.7% vs. 6.3%, P<0.001), MACE 
(15.5% vs. 10.8%, P=0.002) and NACE (23.5% vs. 15.0%, P<0.0001). Outcomes were 
analyzed according to gender. The impact of Biv was independent of gender.
Conclusions: In patients with AMI undergoing primary PCI, Biv monotherapy signiﬁcantly 
reduces major bleeding and net adverse clinical events, effects which are consistent in women 
and men. However, compared to men, women continue to have worse outcomes at one year 
despite therapies which reduce important complications in the total population studied. 
Female pts 
(n=842)
30-days One Year
Biv
mono
UFH+GPI RR [95%CI] Biv
mono
UFH+GPI RR [95%CI]
Major bleeding 7.5% 12.3% 0.61 [0.40, 0.93] 9.7% 13.6% 0.68 [0.45, 1.02]
MACE* 7.3% 7.4% 0.98 [0.61, 1.58] 16.7% 14.4% 1.15 [0.82, 1.63]
NACE** 13.6% 17.4% 0.78 [0.57, 1.07] 23.3% 23.7% 0.95 [0.71, 1.25]
Cardiac Death 2.2% 4.4% 0.55 [0.26,1.13] 2.7% 5.6% 0.48[0.23,0.97]
* MACE = death, reinfarction, ischemic TVR or stroke;
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
P<0.001) was more common in vascular disease patients. Patients with vascular disease 
were more likely to develop heart failure (23% vs10%, P<0.001), cardiogenic shock (7.6% 
vs. 3.7%, P<0.001) and hemodynamic instability (11% vs. 5.1%, P<0.001). Patients with 
and without vascular disease had similar ejection fractions (37.3% vs. 40.4%, P=NS) 
Vascular disease patients had a longer length of stay (9.6 vs. 6.2 days, P<0.001), higher 
incidence of post-PCI stroke (1.9% vs. 0.6%, P<0.001), access site injury (2.3% vs. 0.8%, 
P<0.001) and acute vessel occlusion (2.5% vs. 0.8%, P<0.001). In-hospital mortality was 
13% for patients with vascular disease vs. 3.8% for patients without vascular disease 
(P<0.001). After multivariate logistic regression analysis, vascular disease remained an 
independent predictor of increased in-hospital mortality (Odds Ratio 2.2, 95% Conﬁdence 
Interval, 1.592 to 2.893, P<0.001).
Conclusion: Vascular disease is independently associated with doubling of the mortality 
risk in patients undergoing PPCI for AMI.
9:30 a.m.
2512-699 Does Coronary Dominance Affect Coronary Blood Flow 
and Mortality after Percutaneous Coronary Intervention 
for Acute Myocardial Infarction?
Jason Golub, Vikas Aggarwal, Dimitrios Bliagos, Seth Sokol, Jaime Ghitelman, Mark 
Menegus, Mark Greenberg, V. S. Srinivas, Monteﬁore Medical Center, Bronx, NY, Albert 
Einstein College of Medicine, Bronx, NY
Background: Coronary dominance is reported to independently predict mortality in 
acute myocardial infarction, although mechanisms underlying this relationship are yet 
to be elucidated. Whereas global ﬂow reductions are noted during myocardial infarction, 
whether coronary dominance inﬂuences global ﬂow in this setting is unknown.
Methods: In 278 patients undergoing primary Percutaneous Coronary Intervention (PCI), 
pre and post corrected TIMI frame count was measured in 159 when either the left anterior 
descending (LAD) or left circumﬂex (LCx) was the infarct related artery (IRA). Global ﬂow 
was calculated as the mean frame count in the LAD & LCx; abnormal ﬂow deﬁned as frame 
count q28. The LCx was Dominant (DLCx) when it supplied the posterior descending artery 
and Non Dominant (NDLCx) otherwise. Statistical comparisons were performed using 
student-t test or suitable non-parametric tests for continious variables and chi-square test 
for categorical variables. Vital Rate ratios were calculated with Mantel-Haenszel methods. 
Multivariate analysis was performed using stepwise logistic regression.
Results: Overall, 27% had DLCx circulation and post-PCI ﬂow improved from 57±16 to 
31±14 frames (P<0.001).However, the improvement among DLCx was less than NDLCx 
(34±10 vs. 27±15, P=0.07).Post-PCI, global ﬂow was normal in 51% and it was achieved 
less often in DLCx than NDLCx circulations (39.5% vs. 55.2%, p=0.08). Regardless of 
the location of IRA, post-PCI ﬂow was slower in the DLCx compared to NDLCx; It was 
37±17 vs. 31±14, P=0.05 for LAD and 43±18vs. 35±26,P=0.02 for LCx as IRA. At 90 
days, normal global ﬂow was associated with decreased mortality [RR 0.19; 95%CI 0.42-
0.90]. Multivariate analysis identiﬁed DLCx (OR 0.35; 0.13-0.98), presence of thrombus, 
(OR 0.25; 0.07-0.84) and normal ﬂow in non-IRA (OR 42.7; 15.4-118.4) as predictors for 
normal global ﬂow post-PCI.
Conclusions: A DLCx independently predicted abnormal global ﬂow, seen in almost 
half the patients, following primary PCI. Since normal global ﬂow was associated with 
lower short term mortality, our results suggest that the effect of coronary dominance on 
mortality is likely to be explained by its effect on global ﬂow.
9:30 a.m.
2512-700 Impaired Coronary Flow in Non-infarct Related Artery 
after Primary Angioplasty for Acute Myocardial 
Infarction: Predictors and clinical outcomes
Vikas Aggarwal, Jason Golub, Dimitrios Bliagos, Swapnil Rajpathak, Nassim Krim, 
Seth Sokol, E.Scott Monrad, Mark Greenberg, V.S Srinivas, Monteﬁore Medical Center, 
Bronx, NY, Jacobi Medical Center, Bronx, NY
Background: Global slowing of epicardial ﬂow has been noted during acute myocardial 
infarction. Although Primary Percutaneous Coronary Intervention (PCI) improves infarct 
related artery (IRA) ﬂow, the frequency of concurrent ﬂow improvement in the non-IRA 
and its effect on clinical outcome is unknown.
Methods: Therefore, using standard techniques, we measured pre and post-PCI corrected 
TIMI frame counts (cTFC) in 159 patients with LAD (left anterior descending) or LCX (left 
circumﬂex) as IRA. Normal ﬂow was deﬁned as cTFC <28 frames and slow ﬂow as cTFC >28 
frames.Statistical comparisons were performed with t-test for continuous and C2 for categorical 
variables. Multivariate analysis was performed using stepwise logistic regression.
Results: Following primary PCI, prevalence of slow ﬂow decreased from 93% to 35% 
(P<0.001) in the IRA and from 67% to 43% (P<0.001)in the non-IRA. In the non-IRA, 
post-PCI cTFC improved from 36.2 ± 13.3 to 30.5 ± 14.5 frames (p <0.001). However, 
36% of patients who achieved normal ﬂow in the IRA post-PCI also had slow ﬂow in the 
non-IRA , wheras 58% failing to achieve normal ﬂow in the IRA had slow ﬂow in the non-
IRA. Patients with slow ﬂow in the non-IRA were older, more were males, had LAD as 
IRA, and had larger infarcts (higher Peak CK-MB and lower ejection fraction) compared to 
those with normal ﬂow in the non-IRA. In multivariable analysis, independent predictors of 
normal post-PCI ﬂow in non-IRA were age <60 yrs (OR 2.38; 95% CI 1.1 - 4.9, p = 0.02), 
female sex (2.24; 1.01-4.99, p=0.05), LCX as IRA (8.64; 2.7 - 27.6, p <0.001) and normal 
ﬂow in the IRA after PCI (4.29; 1.87 - 9.85, p = 0.001). Among patients who achieved 
normal ﬂow in the IRA, 30-day survival was better when non-IRA ﬂow was also normal 
compared to when non-IRA ﬂow was slow (0% vs. 8.1%, P=0.01). However, among those 
with slow ﬂow in the IRA, 30 day outcome was similar in patients with either slow or 
normal ﬂow in the non-IRA (9.4% vs. 13%, P=0.65).
Conclusions: Even in patients with normal ﬂow in the IRA after Primary PCI, those with 
normal ﬂow in the non-IRA recieved additional short term beneﬁt. Whether abnormal ﬂow in 
the non-IRA should be a target for therapy during primary PCI bears further investigation.
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plus clopidogrel plus cilostazol Triple group, n=972) therapy. The pts in Triple group 
received additional cilostazol for 1 month, then, changed to receive dual antiplatelet 
therapy. The clinical outcomes up to 8 months were compared between the two groups.
Results: The baseline characteristics were similar between these two groups. The 
incidence of in-hospital cardiac death was signiﬁcantly lower in Triple group (2.0% vs. 
3.4%, P=0.041) but was not well maintained up to 1 and 8 months. The Triple group showed 
a trend toward lower total death up to 8 months. Both groups had similar incidences of 
in-hospital major bleeding, revascularization and recurrent MI. The Triple group showed 
lower incidences of All MACEs throughout the 8 months’ follow-up (Table).
Conclusions: The triple antiplatelet therapy for 1 month appears to be superior to the 
dual antiplatelet therapy reducing early mortality and MACE without increasing the major 
bleeding events in pts with STEMI undergoing primary PCI.
Table: Clinical outcomes of Study Population 
Variables, n (%) Dual group(n=1,432 pts)
Triple group
(n=972 pts) P value
In-hospital
Total death 54 (3.8) 23 (2.4) 0.055
Revascularization 18 (1.3) 6 (0.6) 0.122
All MACE 80 (5.6) 34 (3.5) 0.018
TIMI-major bleeding 8 (0.6) 2 (0.2) 0.333
At 1 month
Total death 67 (4.9) 32 (3.4) 0.080
Revascularization 34 (2.5) 13 (1.4) 0.064
All MACE 114 (8.3) 51 (5.4) 0.007
At 8 months
Total death 79 (5.8) 39 (4.2) 0.078
Revascularization 82 (6.1) 43 (4.6) 0.133
All MACE 178 (13.2) 89 (9.5) 0.008
9:30 a.m.
2512-706 The Safety and Efﬁcacy of Drug-Eluting Stents 
Compared With Bare-Metal Stents In Patients with 
Acute Myocardial Infarction
Youngkeun Ahn, Myung Ho Jeong, Hae Chang Jeong, Young Jo Kim, Chong Jin Kim, 
Myeong Chan Cho, Chonnam National University Hospital, Gwangju, South Korea
Background: Although drug-eluting stent (DES) limits in-stent restenosis (ISR) and 
target vessel revascularization, their application in acute myocardial infarction is unclear. 
Speciﬁc DES comparisons with BMS for patients with acute MI remains controversial. We 
investigated the safety and efﬁcacy of DES in patients with acute myocardial infarction (MI) 
and compared them with those of bare-metal stents (BMS) in routine clinical practice.
Methods: We recruited patients from 50 high-volume centers with facilities for primary 
percutaneous coronary intervention (PCI). All were participants in the Korea Acute MI 
Registry (KAMIR) from Nov 2005 to Dec 2006. Patients who received at least one DES 
(n=5,563) were retrospectively compared with patients who received at least one or more 
BMS (n=478) during one-year clinical follow-up.
Results: Patients receiving DES had more diabetes mellitus, more left anterior descending 
coronary lesions, and had lower left ventricular ejection fractions. At one-year, composite 
major adverse cardiac events (MACE) were 10.5 % in DES- and 18.0 % in BMS-treated 
patients (p<0.001). The one-year rate of target lesion revascularization was 1.5 % in DES- 
and 4.5 % in BMS- treated patients (p<0.001) and the one-year rate of re-PCI was 3.9 
% in DES- and 6.8 % in BMS-treated patients (p=0.002). In multivariate analysis of all 
clinical and angiographic parameters, multi-vessel disease, use of BMS, door to balloon 
time were the only independent predictors of one-year MACE.
Conclusions: The use of DES in patients with acute MI was safe and associated with 
better one-year clinical outcomes than that of BMS, mainly due to the decreased re-PCI.
9:30 a.m.
2512-707 Incidence and Long-term Outcomes of Plaque Prolapse 
After Stent Implantation in Patients Undergoing 
Primary PCI
Yun-Kyeong Cho, Seung-Ho Hur, Bo-Ram Kim, Shin-Keun Kim, Hong-Won Shin, 
Hyoung-seob Park, Hyuck-jun Yoon, Hyungseop Kim, Chang-Wook Nam, Seong-Wook 
Han, Yoon-Nyun Kim, Kwon-Bae Kim, Division of Cardiology, Department of Internal 
Medicine, Keimyung University, Dongsan Medical Center, Daegu, South Korea
Background: Plaque prolapse (PP) has been reported to be 15 to 20% of cases after 
stenting and has a benign course at long-term follow-up. However, the inﬂuence of PP 
after stent implantation in STEMI patients has yet to be investigated. The aim of this study 
was to evaluate the incidence and long-term outcomes of PP after stenting in patients 
undergoing primary percutaneous coronary intervention (PCI).
Method: The study population consisted of 53 BMS (51 patients) and 87 DES (84 
patients) cases undergoing IVUS examination after primary PCI. PP was deﬁned 
as an intraluminal tissue (thrombus or atheroma) through the stent strut observed by 
IVUS. Patients were divided into two groups according to the presence/ absence of PP. 
Cumulative incidence of major adverse cardiac events (MACE) including death, MI, and 
TLR and stent thrombosis (ST) were evaluated at 1 year after index procedure.
Result: The incidence of PP after stenting was 44.3% (62/140) in patients undergoing 
primary PCI. PP was frequently observed in RCA lesion and presence of intracoronary 
thrombus by coronary angiography (all for p<0.05). The rates of MACE and ST were not 
different between the 2 groups at 1-month and 1-year follow-up (all for P=NS) (Table). By 
multivariate analysis, RCA lesion was the only independent predictor of PP (odds ratio: 
2.25, p=0.033).
9:30 a.m.
2512-703 Extracorporeal Membrane Oxygenation as an Adjunct 
to Primary Percutaneous Coronary Intervention and 
a Bridge to Decision in Acute Coronary Syndromes 
Complicated by Cardiogenic Shock
Pradeep K. Nair, Michael P. Siegenthaler, Oscar C. Marroquin, Christian A. Bermudez, 
William D. Anderson, Robert L. Kormos, Conrad Smith, Joon S. Lee, Marc A. Simon, 
Lakshmi Venkitachalam, Suresh R. Mulukutla, University of Pittsburgh, Pittsburgh, PA
Background: Acute coronary syndromes (ACS) complicated by cardiogenic shock (CS) 
portends a poor prognosis despite advances in early invasive strategies. The role of extracorporeal 
membrane oxygenation (ECMO) as an adjunct to primary percutaneous coronary intervention 
(PCI) and a bridge to clinical stability and decision in this population is unknown.
Methods: Fifteen consecutive patients referred for emergent cardiac catheterization who 
presented with ACS complicated by CS and in whom ECMO was utilized early in their 
course for hemodynamic stabilization were evaluated. The expected mortality at 30 days 
was calculated using a validated scoring system. Primary outcome of observed 30-day 
mortality was then compared to expected mortality using a one-sample binomial test.
Results: Baseline characteristics included a mean age of 55±11 years, 93% male, mean 
arterial pressure 54±13 mmHg, cardiac index 1.8 ± 0.2 L/min/m2, pulmonary capillary 
wedge pressure 29±8 mmHg, and 2.6±0.9 pressors. Ten patients had a cardiac arrest 
either before or during PCI. All patients received an intra-aortic balloon pump but 
remained hemodynamically unstable, necessitating early ECMO utilization. The culprit 
lesion most often involved the left anterior descending coronary artery (53%) while most 
had 2- or 3-vessel disease (93%). Reperfusion was established by PCI in 67% of patients. 
Six patients (40%) had PCI during ECMO support. Mean duration of ECMO support was 
81±68 hours. The observed 30-day mortality in our cohort was lower at 53% compared 
to the calculated expected 30-day mortality of 75% (Z-statistic at 0.05 level:-1.97). Of 
the 8 patients who died, 4 had no neurological recovery post cardiac arrest, requiring 
withdrawal of support. Among survivors of ECMO support (n=12), 41% were bridged 
to a left ventricular assist device, 25% to coronary artery bypass surgery, and 17% to 
recovery. Three patients ultimately received heart transplantation.
Conclusions: ECMO may be an effective adjunct to primary PCI among carefully selected 
patients with ACS complicated by cardiogenic shock. ECMO support may facilitate clinical 
and hemodynamic stability in order to provide time for clinical decision making.
9:30 a.m.
2512-704 Impact of Transfer Delays on Clinical Outcomes in 
Patients Undergoing Primary Percutaneous Coronary 
Intervention for ST-Elevation Myocardial Infarction
Philippe Lachance, Jean-Pierre Déry, Gérald Barbeau, Éric Larose, Josep Rodés-
Cabau, Olivier F. Bertrand, Can M. Nguyen, Bernard Noël, Louis Roy, Guy Proulx, Onil 
Gleeton, Robert De Larochellière, Laval Hospital, Québec, QC, Canada
Background: Shortened treatment delays have been associated with better outcomes 
in patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation 
myocardial infarction (STEMI). Patients presenting to hospital without PCI facilities 
experience longer reperfusion times compared to patients presenting directly to an hospital 
providing on-site primary PCI. The aim of this prospective study was to determine the impact 
of transfer delays on clinical outcomes of patients undergoing primary PCI for STEMI.
Methods: All STEMI patients undergoing primary PCI at a tertiary care center between May 
2006 and June 2007 were included in the study. Treatment delays and clinical outcomes of 
patients presenting directly to the tertiary care center were compared to those of patients 
presenting to hospitals within a radius of 50 km and transferred for primary PCI. The primary 
endpoint was the composite of in-hospital death, myocardial infarction, revascularization, 
and stroke (MACE). One year event-free survival was also evaluated.
Results: During the study period, 199 patients presented directly (Group 1) and 462 
patients were transferred (Group 2). Median door-to-balloon time was 60 (39, 82) minutes 
in group 1 compared to 91.5 (77,123) minutes in group 2 (p<0.0001). In-hospital MACE 
occurred in 21 patients (10.5%) in group 1 compared to 33 patients (7.2%) in group 2 
(p=0.10). There was no difference in the occurrence of in-hospital death (3.5% vs 2.8% 
for group 1 and group 2, respectively, p=0.70). After a median follow-up of 1 year, 30.2% 
of patients in group 1 and 26.5% in group 2 experienced a MACE (p=0.40).
Conclusion: Despite delayed intervention, STEMI patients transferred from nearby 
community hospitals for primary PCI experience in-hospital and long-term clinical outcomes 
similar to those of patients presenting directly to the hospital providing primary PCI.
9:30 a.m.
2512-705 Triple versus Dual Antiplatelet Therapy in Patients with 
Acute ST-Segment Elevation Myocardial Infarction 
Undergoing Primary Percutaneous Coronary 
Intervention
Kang Yin Chen, Seung-Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn*, Myung Ho Jeong*, Other 
KAMIR Investigators, Korea University Guro Hospital, Seoul, South Korea, ChonNam 
National University Hospital*, Gwangju, South Korea
Background: Whether the triple antiplatelet strategy is superior to the dual antiplatelet 
strategy in patients (pts) with acute ST-segment elevation myocardial infarction (STEMI) 
undergoing primary percutaneous coronary intervention (PCI) is still unclear.
Methods: A total of 2,404 STEMI pts underwent primary PCI received either dual 
antiplatelets (aspirin plus clopidogrel, Dual group, n=1,432) or triple antiplatelets (aspirin 
JACC March 10, 2009 ABSTRACTS - Angiography and Interventional Cardiology (i2 Summit)  A61
A
ngiography and Interventional C
ardiology (i2
 S
um
m
it)
I2.POSTER CONTRIBUTIONS
2513
CTA/MRI - - Interventional Aspects
Monday, March 30, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2513-710 Balloon pre-dilatation in percutaneous coronary 
intervention. A cardiovascular magnetic resonance 
imaging and cardiac biomarker study of myocardial 
injury
Didier Locca, Giuseppe Ferrrante, Chiara Bucciarelli-Ducci, Francesca Del Furia, Peter 
Barlis, Agata Grasso, Alessio La manna, Sanjay Prasad, Dudley Pennell, Carlo Di 
Mario, Royal Brompton Hospital, London, United Kingdom
Background: In patients undergoing percutaneous coronary intervention (PCI) 
Troponin elevation is observed in 29-48% of patients in a standard daily practice. Little is 
known about the inﬂuence of balloon pre-dilatation before stent implantation in term of 
myocardial injury. The aim of this study was to assess the impact of balloon pre-dilatation 
in contributing to new areas of late gadolinium enhancement (LGE) measured by CMR 
and post-procedural troponin elevation.
Methods: Patients admitted with stable/unstable angina pectoris or silent ischemia were 
enrolled. LGE CMR scan was performed 24hours pre- and 24 hours post- PCI. Troponin 
I was measured at baseline, 12 and 24 hours after PCI. TIMI ﬂow grade, TIMI perfusion 
myocardial grade (TMPG) (score 0,1,2,3) were assessed before/after balloon dilatation, 
after stenting and at the end of the PCI. No patient with baseline TnI elevation or baseline 
LGE evidence in the territory of the vessel treated was included.
Results: 45 patients had a successful PCI and pre and post CMR scan. Mean age was 
61.6 ± 12.1 years, 73% male, 84% presenting with stable angina. Increased postprocedural 
TnI above the upper normal limit (0.04 ng/ml) occurred in 26 patients (57.7%) 0.51 ng/
ml (0.05-4.93) (min-max). New LGE was detected in 15 patients (33.3%). All were in 
the group with TnI elevation. Patients undergoing pre-dilatation showed more frequent 
elevation of TnI (65.7% vs 14.3%, p=0.03), but no signiﬁcant difference in the occurrence 
of LGE (36.8% vs 14.3%, p=0.39). Pre-dilatation was an independent predictor of TnI 
elevation, after adjusting for the presence of more than one lesion treated per patient and 
the occurrence of a reduction of TMPG score from baseline during PCI (OR 11.4, 95% 
CI (1.2-117.6), p=0.036), although it was not associated with new area of LGE (OR 3.45, 
95% CI (0.4-32.8), p=0.28).
Conclusions: This study demonstrated the accuracy of TnI in identifying potential 
consequences of periprocedural myocardial necrosis after PCI with balloon pre-dilatation. 
Larger studies are needed to assess if pre-dilatation might be associated with LGE 
postprocedural myocardial injury.
9:30 a.m.
2513-711 Detection and evaluation of myocardial bridging with 
multi-detector computed tomography (MDCT), coronary 
angiography (CAG) and myocardial scintigraphy
Osamu Kuboyama, Takeshi Tokunaga, Daisuke Ueshima, Kazuo Kobayashi, Toride 
Kyodo General Hospital, Toride, Japan
Background: Myocardial bridging (MB), a congenital coronary anomaly, is clinical 
condition with several possible manifestations, and its clinical relevance is debated. 
The estimated frequency of MB with CAG was 1.5 to 16%, but it is as high as 80% in 
some autopsy series. It is reported that the proximal segment of MB is more susceptible 
to develop of atherosclerotic lesions because of haemodynamic disturbances. We 
investigated to evaluate the prevalence and characteristics of MB with MDCT, and 
comparative assessment of MB using CAG and myocardial scintigraphy.
Methods: We studied 157 patients (67.0 ± 9.3 years, 108 men), who underwent CT 
angiography and 154 (98%) patients were evaluable. In evaluable 154 patients, 90 
patients with CAG and 92 patients with myocardial scintigarphy by Tl-201 were also 
performed (28 patients were underwent both modalities). We evaluated prevalence and 
location of MB with MDCT and CAG. Atherosclerosis in segment immediately proximal to 
MB in MDCT was assessed. In myocardial scintigraphy, we searched ischemic change 
at the regions of MB
Results: The prevalence of MB was 31.2% (48/154) with MDCT and 6.7% (6/90) with CAG. 
The location of MB in MDCT was 72.9% (35/48) at LAD and 27.1% (13/48) at LCX. Especially, 
the rate of LAD mid-portion was high (66.7%, 32/48). In CAG, all MB were located in LAD 
(6/6). The atherosclerotic plaque in segment immediately proximal to MB was observed in 
68.6% (24/36) at LAD and 15.4% (2/13) at LCX. (P=0.001). At the LAD proximal segment 
without MB, atherosclerotic plaque was observed in 46.7% (49/105). The rate of segment 
with plaque was signiﬁcant higher in segemnet with MB than without MB (P=0.03). In 92 
patients who underwent both MDCT and myocardial scintigraphy, 33 patients showed MB 
and 4 patients indicated ischemic changes. In 4 patients, 3 patients observed severe stenosis 
proximal to MB and only 1 patient (3.0%) indicates ischemic change without plaque.
Conclusion: The rate of myocardial bridging was higher in MDCT than in CAG and we 
frequently observed myocardial bridging at LAD. The incidence of plaque at proximal 
segment to myocardial bridging of LAD was higher. Ischemic change in myocardial 
bridging without atherosclerotic plaque was low.
Conclusion: PP after stenting was detected in 44% of patients undergoing primary 
PCI. The presence/absence of PP was not found to affect short and long term clinical 
outcomes in this patient subset. 
9:30 a.m.
2512-708 Early, Elective Percutaneous Coronary Intervention 
Is Safe and Beneﬁcial After Successful Thrombolytic 
Therapy for Acute Myocardial Infarction
Doo Sun Sim, Myung Ho Jeong, Youngkeun Ahn, Young Jo Kim, Sung Chull Chae, Taek 
Jong Hong, In Whan Seong, In Whan Seong, Jei Keon Chae, Chong Jin Kim, Myeong 
Chan Cho, Ki Bae Seung, Seung Jung Park, Chonnam National University Hospital, 
Gwangju, South Korea
Background: Early, elective PCI after successful thrombolysis is controversial. In case an 
invasive route is chosen, how early a PCI should be performed still remains elusive. The 
aim of this study was to assess the safety and beneﬁts of early, elective percutaneous 
coronary intervention (PCI) after successful thrombolytic therapy for acute myocardial 
infarction (MI).
Methods: Employing data from the Korea Acute Myocardial Infarction Registry (KAMIR; 
November 2005 to June 2007), a total of 383 patients with acute MI who underwent elective 
PCI within two weeks of successful thrombolytic therapy were grouped based on time 
between thrombolysis and PCI: group 1: < 24 hours (N=81, 71 men, 59.5±10.5 years of 
age); group 2: q 24 hours and < 48 hours (N=79, 72 men, 59.5±11.6 years); group 3: q 48 
hours and < 72 hours (N=79, 65 men, 61.0±10.8 years); group 4 > 72 hours (N=144, 109 
men, 61.7±12.8 years). Primary study outcomes include major bleeding complications, in-
hospital death, major adverse cardiac events (MACE: cardiac death, MI, repeat PCI, and 
coronary artery bypass surgery) at one, six and 12 months after the index procedure.
Results: There were no differences between the four groups in the baseline clinical 
characteristics and angiographic ﬁndings. Symptom onset to needle time was similar 
between the four groups: 4.0±3.2 hours in group 1; 5.8±7.4 hours in group 2; 5.4±9.6 
hours in group 3; and 4.4±4.4 hours in group 4, p=0.226. There were no differences in 
the incidence of major bleeding, in-hospital mortality, and one-month outcomes between 
the groups. The rates of composite MACE and repeat PCI at 6 and 12 months were 
signiﬁcantly lower in patients who underwent PCI within 48 hours of thrombolytic therapy, 
compared with those who underwent PCI later (6-month MACE: 0.7% vs. 7.3%, p=0.005; 
6-month repeat PCI: 0% vs. 5.2%, p=0.006; 12-month MACE: 2.2% vs. 8.9%, p=0.017; 
12-month repeat PCI: 0.7% vs. 5.7%, p=0.017).
Conclusion: Early, elective PCI within 48 hours of successful thrombolytic therapy for 
acute MI is safe and more beneﬁcial, compared with PCI performed later.
9:30 a.m.
2512-709 Transfusions after Percutaneous Coronary Intervention 
for Acute Myocardial Infarction Patients are Associated 
with Increased Long Term Mortality: A Statewid 
Registry Study
Tudor Dumitru Vagaonescu, Abel E. Moreyra, Alan C. Wilson, Nora M. Cosgrove, John 
B. Kostis, UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ
Background. Percutaneous coronary intervention (PCI) is the method of choice to 
reestablish coronary ﬂow in acute myocardial infarction (AMI). Anticoagulation used during 
PCI may be associated with bleeding complications requiring, if severe, transfusions. 
Transfusions after PCI have been associated with a grim prognosis and outcome.
Methods. To identify predictors of transfusion during primary PCI for STEMI and its 
consequences on subsequent long term clinical outcomes we performed a retrospective 
analysis of the Myocardial Infarction Data Acquisition System (MIDAS) of the State of 
New Jersey between 2003 and 2004 with subsequent median follow-up over 3 years.
Results. Out of 5588 PCI performed, 207 (3.70%) received transfusions during the index 
hospitalization. Signiﬁcant predictors for transfusion during the index PCI were advanced 
age (p<0.0001), female sex (p=0.002), renal disease (p=0.002) and anemia (p<0.0001) 
on admission. Use of Gp2b/3a during PCI did not predict transfusion (p=0.20). Over a 
median follow-up of 1000 days the patients who were transfused had signiﬁcantly lower 
all cause survival (73.4% vs. 89.5%; p=0.04) than the patients who were not transfused. 
In the Cox multivariate analysis including age, sex, race, diabetes, hypertension, renal 
disease, anemia, cancer, cerebro-vascular disease and left ventricular dysfunction, 
use of Gp2b/3a inhibitors, type of stents used, transfusion during PCI for STEMI (vs. 
non transfusion) was signiﬁcantly correlated with all cause mortality: adjusted HR 1.36 
(1.03-1.83) and non cardiovascular mortality : adjusted HR 1.72 (1.11-2.65), but not with 
cardiovascular mortality: adjusted HR 1.13 (0.75-1.72).
Conclusions. The occurrence of transfusions in the setting of STEMI was associated 
with signiﬁcant increase of 3 year all cause mortality.
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Methods: A total of 452 consecutive coronary CTA examinations were performed 
between July 2007 and June 2008. Of these, 55 patients underwent invasive coronary 
angiography because they have signiﬁcant coronary artery disease. The aortic knob 
calciﬁcation was assessed via chest posteroanterior view. On coronary CTA, plaques 
were classiﬁed into soft plaque, calciﬁed plaque, and mixed plaque. Signiﬁcant coronary 
narrowing was deﬁned as > 60% luminal narrowing.
Results: Aortic knob calciﬁcation was present in 20 patients (36.4%). Presence of 
coronary plaque (100% vs. 80%, p=0.040), multi-vessel disease (65% vs. 28.6%, 
p=0.012), critical coronary stenosis (40% vs. 11.8%, p=0.013), and AHA/ACC B2/C 
lesions (80% vs. 37.1%, p=0.004) were higher in patients with aortic knob calciﬁcation 
than in patients without calciﬁcation. The plaque distribution was as follows: 5.0% soft 
plaques, 40.0% calciﬁed plaques, and 55.0% mixed plaques in patients with aortic knob 
calciﬁcation vs. 39.9% soft plaques, 25.0% calciﬁed plaques, and 35.7% mixed plaques 
in patients without calciﬁcation (p=0.025).
Conclusions: Aortic knob calciﬁcation in patients with coronary artery disease can be a 
marker of more severe coronary artery disease and it may also provide information about 
coronary atherosclerotic plaque composition.
9:30 a.m.
2513-715 Computed Tomography Angiography vs. Coronary 
Angiography: A 3 Dimensional Vessel Feature 
Comparison
Marvin H. Eng, Onno Wink, Philip Li, James Chen, Adam Hansgen, John D. Carroll, Joel 
A. Garcia, University of Colorado Denver, Aurora, CO
Background: Vessel spatial relationships in computed tomography angiograms (CTA) 
and coronary angiograms (CA) have not been rigorously studied, therefore we sought to 
validate CTA 3-dimensional (3D) vessel data against coronary angiography by forward 
projecting 3D CTA based centerlines to standard angiograms.
Methods: An initial validation was performed by comparing CTA datasets and X-rays 
of cardiac phantoms. We then retrospectively analyzed 20 patients undergoing both CA 
and CTA. First, CTA 3D reconstructions were imported into a coronary modeling software 
environment enabling centerline extraction, forward projection, and optimal view map 
generation. Centerline comparison from each dataset was performed via automated 
overlay of their respective centerlines (forward projection) and measuring the root mean 
squared difference (RMS) in error for each CA view. Ofﬂine working view selection using 
the CTA reconstructions versus operator selected working views were then compared in 
terms of foreshortening.
Results: There were minimal differences in the RMS for each vessel (Table 1A). Ofﬂine 
CTA working view selection was found to have less foreshortening compared to operator 
selected views (Table 1B).
Conclusion: The vessel centerline data from CTA is not signiﬁcantly different to that 
of CA. Use of CTA to facilitate pre-procedural PCI working view selection may reduce 
foreshortening. 
9:30 a.m.
2513-716 Four Dimensional, Multidetector Computed 
Tomographic Assessment of Dynamic Changes in 
Coronary Bifurcation Anatomy
John E. Coletta, Pieter Kitslaar, Bruno Bruno Nascimento, Nobuaki Suzuki, Hiram 
Bezerra, Noah Rosenthal, Robert Gilkeson, J. Hans Reiber, Daniel I. Simon, Marco A. 
Costa, University Hosptials Case Medical Center, Cleveland, OH, Leiden University 
Medical Center, Leiden, The Netherlands
Background - Clinical outcomes of percutaneous approaches for bifurcation coronary 
artery disease remain unsatisfactory. Dynamic variation in the three dimensional (3D) 
anatomic conﬁgurations of coronary bifurcations during the cardiac cycle is a potential 
cause of bifurcation coronary device failure.
Methods & Results - We analyzed 10 anonymous technically adequate multidetector 
computed tomography (MDCT) coronary images of the Left Main (LM), Left Anterior 
Descending (LAD), and Left Circumﬂex (LCx) bifurcation. Images were obtained throughout 
the cardiac cycle. RR interval was divided into 10 segments (10% increments). Data was 
cropped in 8 phases to produce a dynamic data set. Angles, deﬁned as (1) LAD-LCx, (2) 
LCx-LM, and (3) LAD-LM, were automatically determined. Each angle was determined in 
3D (x, y, and z planes). We calculated the mean angle for each phase, the range of the 
means (RM) and standard deviation (SD), the absolute variation between each phase, and 
the coefﬁcient of variance (CV=SD/RM). The results of 5 initial cases are shown. 
For all patients, absolute angle variation between cardiac phases varied widely in an 
unpredictable pattern.
Conclusions - This is the ﬁrst report on a novel quantitative method to access coronary 
bifurcation anatomy in 4D (x, y, z axes + time). Our results demonstrate the dynamic 
nature of coronary bifurcation. Future studies are warranted to establish the clinical impact 
of such ﬁndings and potential use of 4D-imaging to guide bifurcation PCI strategies.
9:30 a.m.
2513-712 Coronary Artery Calcium Score for the Use of 
Rotational Atherectomy prior to Sirolimus-eluting Stent 
Implantation
Naoyuki Yokoyama, Kumiko Konno, Hiroyuki Kyouno, Yasunari Ueno, Shigeru Suzuki, 
Ryu Iino, Akiyoshi Miyazawa, Kozuma Ken, Takaaki Isshiki, Teikyo University School of 
Medicine, Tokyo, Japan
Background: Even in the era of drug-eluting stents, Rotational atherectomy device 
(Rotabulator) is an effective tool which modiﬁes calciﬁed lesions to facilitate stent delivery 
and expansion. However, indications of Rotabulator have not yet been ﬁxed as far as 
the levels of calciﬁcation in target lesion are concerned. Coronary artery calcium score 
(CACS) by non-contrast enhanced multi-detector computed tomography (MDCT) can 
quantify calciﬁed coronary plaque. The aim of this study was to evaluate the ability of 
MDCT to measure the levels of calciﬁcation to determine indications of Rotabulator prior 
to sirolimus-eluting stent (SES) implantation.
Methods: A total of 36 patients (mean age 71.5 ± 6.2 years, 21 males) with stable angina 
underwent ECG-triggered MDCT scan (Mx8000 IDT Phillips Medical Systems) prior to SES 
implantation. CACS was measured by Agatston method in each vessel. The target vessels 
with chronic total occlusion or CACS of zero were excluded. Fifty-two calciﬁed lesions (27 in 
LAD, 13 in LCX, 12 in RCA and 3 in LMT) were included. Selection of Rotablator was at the 
operator’s discretion mainly based on the inability to cross IVUS catheter.
Results: Of 52 lesions, 17 were treated by SES implantation after rotablation (Rota+SES). 
SES implantation without rotablator (SES) was performed for 35 lesions. SES implantation 
was angiographically successful in all lesions. CACS of the target vessel in the Rota+SES 
group was signiﬁcantly higher than that in the SES group (586.5±322.5 vs. 264.3±384.0; p 
= 0.004). ROC analysis revealed that CACS of >300 was the best cutoff value for detecting 
the heavily calciﬁed plaque which was required with Rotablator prior to SES implantation. 
Sensitivity and Speciﬁcity in CACS of >300 was 82.4% and 77.8%, respectively. At 8 
months, the target lesion revascularization rate was 5.9% in Rota+SES group vs. 0% in 
SES group (p = ns). Death and non-fatal MI were not occurred in all patients.
Conclusions: CACS of >300 was associated with the heavily calciﬁed vessel which 
needed lesion modiﬁcation with Rotablator. CACS measured by MDCT could be used as 
a novel guidance tool to determine the strategy of PCI for calciﬁed lesions.
9:30 a.m.
2513-713 The Role of 64-Slice Multidetector Computed 
Tomography in Detection of Subclinical Atherosclerosis 
of Coronary Artery
Youngkeun Ahn, Hae Chang Jeong, Young Joon Hong, Doo Sun Sim, Nam Sik Yoon, 
Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Myung Ho Jeong, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National University Hospital, 
Gwangju, South Korea
Background: Multidetector computed tomography (MDCT) has high diagnostic value for 
detecting or excluding coronary artery stenosis in symptomatic patients. But, the role of MDCT 
for routine health examination in asymptomatic patients is not established. We hypothesized 
that MDCT could be a valuable method to detect subclinical coronary artery stenosis.
Methods: In a prospective, single-center, observational study, 1649 volunteers were 
underwent MDCT for routine health examination from Nov 2005 to Apr 2008. 120 patients 
were excluded due to their past history of coronary artery disease, typical chest pain, or 
evidence of myocardial ischemia on laboratory data, electrocardiogram, or echocardiography. 
1529 patients (56.4 ± 8.3 years, 1353 males) were enrolled in our study.
Results: 969 (63.4 %) patients were presented with normal ﬁndings and 560 (36.6 %) 
patients were presented with abnormal ﬁndings in MDCT. The patients with abnormal 
ﬁndings was classiﬁed into two groups, the one was presence of coronary calcium, but 
luminal diameter stenosis of coronary artery < 50 % (n = 508, 33.2 %). These patients were 
treated by medication. And, the other was luminal diameter stenosis of coronary artery 
q 50 %, presence or absence of coronary calcium (n = 52, 3.4 %). These patients were 
underwent conventional coronary angiogram and intravascular ultrasound. 29 patients 
(1.9 %) were presented with insigniﬁcant stenosis or myocardial bridge. These patients 
were treated by medication. 23 patients (1.5 %) were presented with signiﬁcant stenosis. 
17 patients were one vessel, 4 patients two, 2 patients three. The lesion artery was left 
anterior descending artery in 18 patients, left circumﬂex artery 6, and right coronary artery 
6, and left main artery 1. They underwent percutaneous coronary intervention according 
to the basis of the coronary anatomy. The major adverse cardiac events were occurred in 
2 patients during 387.4 ± 252.8 days (mean clinical follow-up period).
Conclusions: The incidence of subclinical signiﬁcant coronary stenosis examined by 
MDCT in general population was 1.5 % in our study. 64-Slice MDCT can be an useful tool 
for noninvasive evaluation of coronary arteries in asymptomatic patients.
9:30 a.m.
2513-714 Impact of aortic knob calciﬁcation on plaque 
composition in patients with coronary artery disease 
using coronary CT angiography
Jae-Sik Jang, Young-Phil Bae, Byoung-Do Lee, Busan St. Mary’s Hospital, Busan, South 
Korea, Busan, South Korea
Background: Atherosclerosis of the aorta has been associated with coronary artery disease. 
There are few data about the inﬂuence of aortic knob calciﬁcation on the severity of coronary 
artery disease and its relationship with coronary plaque composition. We evaluated differences 
in plaque composition and clinical signiﬁcance in coronary artery disease according to the 
presence or absence of aortic knob calciﬁcation using coronary CT angiography (CTA).
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Results: The 518 patients with prior TIA/ CVA were older, more likely to have a history 
of hypertension, hyperlipidemia, and renal dysfunction, while less likely to receive 
glycoprotein IIB/IIIA inhibitors. After adjustment, those with prior TIA/CVA had signiﬁcantly 
higher rates of the primary endpoint (CVD/MI/CVA) (HR 1.30 [1.04-1.64], p=0.02), CVA 
(HR 3.08 [1.89-5.00], p<0.0001), and intracranial hemorrhage (HR 4.10 [1.67-10.07], 
p=0.002). There were signiﬁcant interactions between prior TIA/CVA, treatment and 
outcomes (Fig).
Conclusion: While prasugrel signiﬁcantly reduces the risk for thrombotic events as 
compared to clopidogrel for patients with ACS undergoing PCI, its utility in combination 
with aspirin, in patients with prior TIA/CVA, is limited. These ﬁndings extend previous 
observations of the risk of DAPT for secondary stroke prevention to management of ACS 
in patients with cerebrovascular disease.
9:30 a.m.
2514-719 Bivalirudin Therapy Reduces 30 Day Bleeding 
Complications in Women Undergoing PCI for Acute 
Coronary Syndrome: Results of the REPLACE-2, 
ACUITY and HORIZONS Pooled Analysis
Alexandra J. Lansky, Helen Parise, Liliana Grinfeld, A. Michael Lincoff, Stuart J. 
Pocock, Roxana Mehran, Gregg W. Stone, Columbia University Medical Center and the 
Cardiovascular Research Foundation, New York, NY
Background: Female gender is an independent marker of adverse events and bleeding in 
pts undergoing PCI. In the REPLACE-2, ACUITY and HORIZONS trials, bivalirudin (Biv) 
provided similar rates of ischemic events and signiﬁcantly reduced bleeding compared to 
heparin+GPIIb/IIIa inhibitors (Hep+GPI) in pts with stable and unstable angina, NSTE-ACS, 
and STEMI undergoing PCI. This analysis provides more robust estimates of the impact of 
gender in pts receiving Biv or Hep+GPI across the spectrum of cardiovascular risk.
Methods: The 3 trials randomized pts to Biv or Hep+GPI. We assessed rates of 30-day 
composite ischemia (death, MI, or revascularization), non-CABG TIMI bleeding (major/
minor), and net adverse clinical events (NACE, composite ischemia or protocol-deﬁned 
bleeding) in women undergoing PCI, overall and by randomized treatment.
Results: 3652 (25.5%) of 14,325 pts undergoing PCI were women. Women had similar 
rates of composite ischemia (7.7% vs 7.1% p=0.25) as men, but higher rates of major 
bleeding (6.6% vs 3.8%, p<0.001). In women, Biv vs Hep+GPI resulted in a signiﬁcant 
reduction in 30-day NACE due to reduced major bleeding (Table).
Conclusions: Women had similar rates of 30-day ischemic outcomes as men, but 
signiﬁcantly more bleeding. In women, Biv resulted in signiﬁcantly lower NACE and major 
bleeding than Hep+GPI, with no signiﬁcant difference in composite ischemia. These 
results indicate that Biv is a safe and effective strategy in women undergoing PCI across 
the spectrum of ACS. 
Heparin + GPI
(N=1842)
Bivalirudin
(N=1810) p-value
NACE 15.0 12.4 0.02
Composite ischemia 7.4 7.9 0.61
- Death 1.3 1.1 0.61
- MI 5.3 5.7 0.64
- Revascularization 2.2 3.1 0.06
Non-CABG TIMI bleeding (major + minor) 8.5 4.6 <0.0001
9:30 a.m.
2514-720 Clinical and Angiographic Risk Score to Predict 
Ischemic Outcomes at 1 Year in Acute Coronary 
Syndromes: The ACUITY Risk Score
Alexandra J. Lansky, Kenji Goto, Martin Fahy, JungAh Jung, Eugenia Nikolsky, Magnus 
E. Ohman, Harvey D. White, Michel E. Bertrand, Micheal Lincoff, Jeffrey Moses, Roxana 
Mehran, Gregg W. Stone, Cardiovascular Research Foundation, New York, NY
Background Risk assessment of ACS pts does not take into account angiographic 
factors. We sought to create a practical risk score based on both clinical and angiographic 
criteria to predict cardiac events at 1 year.
Methods The risk model was developed from 7000 ACS pts enrolled in the ACUITY 
angiographic substudy. Logistic regression was used to identify clinical and angiographic 
predictors of death/MI. Based on the Z score value, an integer score was assigned to 
each predictor; the sum comprising the total risk score.
Results Multivariable predictors of 1 year death/MI were determined from 3,740 pts 
with no missing covariates (61% PCI, 14% CABG, 25% medical); death/MI occurred in 
414 pts (11.9%) (table). Death/MI risk increased as the score increased (p<0.0001). Pts 
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2514-717 Cytochrome P450 2C19 loss-of-function polymorphism 
and stent thrombosis following percutaneous coronary 
intervention
Dirk Sibbing, Julia Stegherr, Wolfgang Latz, Werner Koch, Julinda Mehilli, Katharina 
Dorrler, Tanja Morath, Albert Schomig, Adnan Kastrati, Nicolas von Beckerath, 
Deutsches Herzzentrum Munchen, Munich, Germany
Background: Several studies have demonstrated that the mutant *2 allele of the CYP2C19
681G>A loss-of-function polymorphism is associated with diminished metabolization of 
clopidogrel into its active metabolite and an attenuated platelet response to clopidogrel. It 
is not known whether patients carrying the mutant CYP2C19*2 allele have a higher risk 
of stent thrombosis (ST) compared to homozygous CYP2C19*1 wild-type allele carriers 
following percutaneous coronary intervention (PCI). The aim of this study was to assess 
the impact of the CYP2C19 681G>A loss-of-function polymorphism on ST following PCI 
in clopidogrel treated patients. Methods: The study population included 2485 consecutive 
patients undergoing PCI after loading with 600 mg clopidogrel. Genotypes were 
determined with a TaqMan assay. The primary end point of the study was the incidence 
of deﬁnite ST within 30 days after PCI. Results: 1805 (73%) patients were CYP2C19
wild-type homozygotes (*1/*1) and 680 (27%) carried at least one *2 allele (*1/*2 or *2/*2). 
The cumulative incidence of ST was signiﬁcantly higher in CYP2C19*2 allele carriers [10 
(1.5%) in CYP2C19*2 allele carriers vs. 7 (0.4%) in CYP2C19 wild-type homozygotes 
(*1/*1), OR 3.81, 95% CI 1.55-9.36, P=0.003]. The risk of ST was highest in patients 
carrying two of the mutant CYP2C19 alleles (*2/*2 genotype) (P=0.002, test for trend; 
see Figure). Conclusions: CYP2C19*2 carrier status is signiﬁcantly associated with an 
increased risk of ST following PCI. 
9:30 a.m.
2514-718 Lack of Beneﬁt and Evidence for Harm with Prasugrel as 
Compared to Clopidogrel in Patients with a History of 
TIA/CVA Undergoing PCI: Insights from TRITON-TIMI 38
Nihar R. Desai, Elliott M. Antman, Sabina A. Murphy, Stephen D. Wiviott, TIMI Study 
Group, Brigham and Women’s Hospital, Boston, MA
Background: Recent clinical trials of dual anti-platelet therapy (DAPT) for secondary stroke 
prevention have shown limited efﬁcacy and potentially harm. Little is known about the impact 
of DAPT in patients with prior TIA/CVA presenting with ACS and undergoing PCI.
Methods: We compared the effect of DAPT on outcomes in 13608 patients according 
to history of prior TIA/CVA in TRITON-TIMI 38. Logistic regression models were used 
to adjust for baseline differences and formal interaction terms were used to test for 
differential outcomes by treatment assignment.
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9:30 a.m.
2514-722 Impact of Thrombus Aspiration Device use for the 
Treatment of In-stent Thrombosis on Early Patient 
Outcome
Gilles Lemesle, Axel De Labriolle, Laurent Bonello, Gabriel Maluenda, Itsik Ben-Dor, 
Sara D. Collins, Asmir I. Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. 
Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Recent data suggest a beneﬁt with the systematic use of a thrombus 
aspiration device (TAD) for the treatment of ST-elevation myocardial infarction (STEMI). 
Nevertheless, the impact of TAD use for the treatment of stent thrombosis (ST) is 
unknown. This study aimed to analyze the impact of TAD use for the treatment of ST on 
patient outcome.
Methods: From 2003 to 2008, 91 consecutive patients presenting with a ﬁrst deﬁnite ST 
were included. We compared procedural success rates and incidences of the composite 
criteria death-MI-ST at 30 days in patients who beneﬁted from TAD use (TAD group, n=36) 
vs those who did not (No TAD group, n=55).
Results: Baseline characteristics were similar between groups except for body mass 
index: 26.2 vs 29.3 in the TAD and No TAD groups, respectively (p=0.03). The ST 
presented more likely as STEMI in the TAD group: 86% vs 67% (p=0.04). Except for TAD 
use, there was no difference in the treatment therapeutics between groups. The rate of 
procedural success was higher in the TAD group: 89% vs 71% (p=0.04). The incidence of 
the endpoint death-MI-ST was signiﬁcantly lower in the TAD group: 22% vs 47% (p=0.03). 
By multivariate analysis, the TAD use was independently associated with a decrease in 
the composite criteria (HR=0.45, p=0.04).
Conclusion: The use of a TAD as part of the initial strategy for ST treatment is associated 
with a reduced incidence of subsequent death-MI when compared to conventional PCI. 
The use of a TAD should be considered for all patients presenting with ST.
9:30 a.m.
2514-723 Thrombectomy Improves Angiographic Outcome in ST-
Segment Elevation Myocardial Infarction Cases without 
Visible Thrombus: Subanalysis from the VAMPIRE trial.
Hiroyuki Kyono, Ken Kozuma, Yuji Ikari, Kenshi Fujii, Masami Sakurada, Hideki 
Hashimoto, Takaaki Katsuki, Kazuo Kimura, Takahiko Suzuki, Takaaki Isshiki, On behalf 
of the VAMPIRE investigators, Teikyo University Hospital, Tokyo, Japan
Background: The efﬁcacy of thrombus aspiration for STEMI patients who have no 
angiographically visible thrombus during PCI is still unclear. We sought to clarify the 
effectiveness of thrombectomy for this patient subset.
Methods: 355 consecutively enrolled patients in the VAMPIRE (Vacuum Aspiration 
Thrombus Removal) trial were analyzed. This trial was a multicenter prospective 
randomized trial, designed to evaluate the safety and efﬁcacy of thrombus aspiration 
using a thrombus aspiration catheter in patients with STEMI. From this population, 
we analyzed all 65 patients who had coronary stenosis but no visible thrombus. We 
assessed angiographic parameters such as TIMI ﬂow grade, distal embolization, 
Myocardial Blush Grade and corrected TIMI frame count (CTFC) post-procedure with 
thrombectomy compared to without thrombectomy. Results: Thirty one patients did not 
receive thrombectomy (control group) whereas 34 underwent thrombectomy (aspiration 
group). The incidence of TIMI 3 ﬂow, CTFC, and distal embolization post procedure did 
not show a signiﬁcant difference. However, Myocardial Blush Grade 3 post-procedure 
was achieved signiﬁcantly more frequently in aspiration group compared to control group 
(36.7 vs. 52.9%, P=0.013).
Conclusions: Myocardial Blush Grade 3 was obtained more frequently in the aspiration 
group even if visible thrombus did not exist. This ﬁnding suggests that thrombectomy may 
be beneﬁcial to myocardial perfusion beyond the effect of simple thrombus removal. 
were categorized into low (score a10; 1677 pts; 44.8%), moderate (score 11 to 16; 1,295 
pts; 34.6%), and high (score q17; 768 pts; 20.5%) risk, with increasing 1 year death/MI 
(low 5.6%; moderate12.3%; and high 21.1% risk, p=0.0001). The model was validated 
by multiple bootstrap resampling (Hosmer-Lemeshow goodness-of-ﬁt, p=0.65) and c 
statistic=0.68 indicating good risk discrimination. The risk score was validated for pts 
triaged to PCI, CABG and medical therapy (p=0.001).
Conclusions The ACUITY Risk score, derived from 4 clinical and 4 angiographic baseline 
variables, provides reliable predictive risk of 1 year death/MI in pts with ACS undergoing 
early invasive management, and is applicable irrespective of selected treatment strategy.
9:30 a.m.
2514-721 One year follow-up of the Thrombus Aspiration during 
Primary percutaneous coronary intervention in Acute 
non-ST-elevation myocardial infarction Study (TAPAS-II) 
- pilot - trial.
Pieter J. Vlaar, Gilles Diercks, Tone Svilaas, Mathijs Vogelzang, Bart de Smet, Ad 
van den Heuvel, Gillian Jessurun, Eng-Shiong Tan, Albert Suurmeijer, Felix Zijlstra, 
University Medical Center Groningen, Groningen, The Netherlands
Background: Myocardial necrosis in patients with acute coronary syndromes may 
be a sign of microvascular obstruction, owing to spontaneous or intervention-induced 
embolization of atherothrombotic material. Thrombus aspiration results in improved 
myocardial reperfusion in patients undergoing percutaneous coronary intervention (PCI) 
for ST-elevation myocardial infarction. Currently, scarce data on thrombus aspiration in 
patients with Non-ST-elevation myocardial infarction (NSTEMI) are available.
Methods: As part of a prospective cohort study, 70 patients undergoing PCI for NSTEMI 
were treated with thrombus aspiration (Export, Medtronic). Histopathological analysis 
was performed on aspirated material. Vital status at or beyond 1 year after inclusion was 
available for all patients.
Results: Thrombus aspiration was effective in 58 patients (83%), see table. Aspiration 
resulted in a marked reduction of TIMI-thrombus score 4/5 (40% pre- versus 7% post-
aspiration) and increase of the rate of TIMI-ﬂow 3 (36% pre- versus 66% post-aspiration). 
The incidence of Myocardial Blush Grade 3 was 45%. Distal embolization was visible in 3 
patients (4%). At 1 year follow-up, the rate of target vessel revascularization, reinfarction 
and death were 5.7%, 2.9% and 1.4%, respectively.
Conclusions: This study demonstrates that thrombus aspiration in most NSTEMI patients 
is feasible and safe, is associated with a high rate of retrieval of thrombotic material, and 
results in excellent clinical outcome.
Histopathological analysis of aspirated material
Total Age(yrs)
Initial
TIMI
ﬂow
Thrombus 
visible 
on initial 
angiogram
>60 q60 0/1 2/3 no yes
Total -no. 70 31 39 23 47 34 36
Effective 
aspiration - no. 
(%)
58
(83%)
29
(94%)
29
(74%)
21
(91%)
37
(79%) 26 (76%)
32
(89%)
Thrombus White platelet thrombus
44
(76%) 72% 79% 57% 86% 92% 63%
Red
erythrocyte-rich 
thrombus
14
(24%) 28% 21% 43% 14% 8% 38%
Plaque Thrombus with plaque
14
(24%) 28% 21% 33% 19% 15% 31%
Size Small (<0.5mm) 37(64%) 59% 69% 38% 78% 85% 47%
Medium (0.5-
2mm)
10
(17%) 17% 17% 29% 11% 8% 25%
Large (>2mm) 11(19%) 24% 14% 33% 11% 8% 28%
JACC March 10, 2009 ABSTRACTS - Angiography and Interventional Cardiology (i2 Summit)  A65
A
ngiography and Interventional C
ardiology (i2
 S
um
m
it)
Methods: From 2000 to 2007, 2766 consecutive patients, at least 80 years of age, 
underwent PCI with stent implantation. We compared rates of in-hospital bleeding and 
6-month mortality between patients treated by bivalirudin for the PCI (n=1207) and 
patients treated by heparin (n=1559).
Results: The overall in-hospital bleeding and 6-month mortality rates were 4.6% and 
11.8%, respectively. By multivariate logistic regression and after adjustment by propensity 
score analysis, bivalirudin was associated with a signiﬁcant decrease in in-hospital 
bleeding (HR=0.4; p=0.003). By multivariate Cox analysis and after adjustment by 
propensity score analysis, bivalirudin was also associated with a signiﬁcant decrease in 
the 6-month mortality (HR=0.6, p=0.01).
Conclusion: This study shows that bivalirudin use in octogenarians undergoing PCI 
as compared to heparin use was associated with a signiﬁcant decrease in not only in-
hospital bleeding but also in 6-month mortality. These results suggest that bivalirudin use 
is preferable to heparin in such a population.
9:30 a.m.
2514-727 The effect of high dose intracoronary ADenosine 
Administration during Primary percutaneous coronary 
intervention in acute myocardial infarction - a 
randomized controlled Trial (ADAPT).
Marieke L. Fokkema, Pieter J. Vlaar, Mathijs Vogelzang, Youlan L. Gu, Marthe A. 
Kampinga, Bart J. de Smet, Rutger L. Anthonio, Gillian A. Jessurun, Ad F. van den 
Heuvel, Eng-Shiong Tan, Felix Zijlstra, University Medical Center Groningen, Groningen, 
The Netherlands
Background: Coronary microvascular dysfunction is frequently seen in patients with ST-
elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention 
(PCI). Previous studies have documented that the administration of intravenous adenosine 
resulted in an improvement of myocardial perfusion and a reduction in infarct size. The 
effect of intracoronary adenosine during primary PCI has not been investigated in a large 
randomized trial.
Methods: Patients presenting with acute STEMI were randomized to 2 bolus injections of 
intracoronary adenosine (2x 0.12 mg in 20 mL NaCl) or placebo (2x 20 mL NaCl). The ﬁrst 
bolus injection was given before and the second after stenting of the infarct artery. The 
primary endpoint was the incidence of residual ST-segment deviation <0.2 mV 30 to 60 
minutes after procedure. Secondary endpoints were myocardial blush grade (MBG), TIMI 
ﬂow after PCI, ST-segment elevation resolution and outcome at 30 days.
Results: A total of 448 patients were randomized to intracoronary adenosine (N=226) or 
placebo (N=222). The incidence of residual ST-segment deviation <0.2 mV was similar 
in patients treated with adenosine (46.2%) and placebo (52.2%). In addition, secondary 
outcome measurements did not signiﬁcantly differ between the treatment groups, as 
shown in the table.
Conclusion: In patients with STEMI, administration of intracoronary adenosine before 
and after stenting of the infarct artery did not result in improved myocardial perfusion. 
(Trial nr: NTR 1073)
Effect of intracoronary administration of adenosine or placebo on 
myocardial perfusion and outcome
Adenosine
(N = 226)
Placebo
(N = 222) p
Primary end point: ST-
segment deviation <0.2 
mV (%)
96/208 (46.2) 108/207 (52.2) ns
MBG 3 (%) 64/224 (28.6) 77/218 (35.3) ns
TIMI ﬂow 3 (%) 212/225 (94.2) 208/222 (93.7) ns
ST-segment elevation 
resolution >70% (%) 129/189 (68.3) 128/193 (66.3) ns
Mortality at 30 days (%) 3/226 (1.3) 2/222 (0.9) ns
9:30 a.m.
2514-724 Short- and Long-term Outcomes in Patients Undergoing 
Rotational Atherectomy for Complex Coronary Lesions 
in the Current Era of Drug-Eluting Stents
Dmitriy N. Feldman, Robert M. Minutello, Geoffrey Bergman, Issam Moussa, S. Chiu 
Wong, New York Presbyterian Hospital - Weill Cornell Medical Center, New York, NY
Background: Patients requiring rotational atherectomy (RA) for complex calciﬁc coronary 
lesions have been excluded from recent large randomized trials of drug-eluting stents 
(DES). The impact of RA in the current era of DES on short- and long-term outcomes in 
complex coronary lesions is unknown.
Methods: Using the 2004/2005 Cornell Angioplasty Registry, we analyzed 2,504 
consecutive patients undergoing urgent or elective PCI. Patients were divided into 2 
groups: (1) 82 pts (3.3%) undergoing RA; (2) 2422 pts (96.7%) undergoing PCI without 
RA. Patients presenting with an acute MI a24 hours, hemodynamic instability/shock, 
thrombolytic therapy a7 days were excluded. All-cause mortality was obtained for 100% 
of patients, with a mean follow-up of 24.8 ± 7.7 months.
Results: Patients undergoing RA were older (72.3 ± 9.3 vs. 66.6 ±11.8 yrs, p<0.01), more 
frequently had multivessel PCI (23.2% vs. 14.6%, p=0.04), or multilesion PCI (73.2% vs. 
46.7%, p<0.01) performed. Drug-eluting stents were used in 86.8% of PCI; glycoprotein 
IIb/IIIa inhibitors were used in 52.7%. Angiographic success was 99.6% in both groups. 
The incidence of in-hospital death (0% vs. 0.2%, p=1.00) was similar, but the incidence 
of myocardial infarction (14.6% vs. 7.1%, p=0.02), and MACE (death, CVA, emergent 
CABG/PCI, myocardial infarction) (14.6% vs. 7.3%, p=0.03) was higher in the RA group. 
After multivariate analysis, RA was associated with a strong trend towards being an 
independent predictor of post-PCI myocardial infarction (OR 1.87; 95%CI 0.97-3.58, 
p=0.06). However, post-PCI cardiac enzymes elevation did not impact the length of stay 
during hospitalization (2.8 ± 3.3 vs. 2.9 ± 3.7 days, p=ns). By 2-years of follow-up, there 
was no difference in mortality: 4 (4.9%) deaths in the RA+ group vs. 125 (5.2%) deaths in 
the RA- group (HR 0.94; 95%CI 0.35-2.53, p=ns).
Conclusions: Patients undergoing rotational atherectomy in contemporary PCI with drug-
eluting stents have a higher incidence of post-PCI myocardial infarction, but, importantly, a 
good long-term prognosis. These results suggest that a strategy of rotational atherectomy 
and DES is a safe and practical strategy in complex calciﬁc coronary lesions.
9:30 a.m.
2514-725 Predictors of Filter No Reﬂow Prior to Percutaneous 
Coronary Intervention
Takayuki Ishihara, Masaaki Uematsu, Masaki Awata, Takaaki Morozumi, Tetsuya 
Watanabe, Toshinari Onishi, Osamu Iida, Fusako Sera, Hitoshi Minamiguchi, Kenji 
Kawamoto, Masamichi Yano, Kuniyasu Ikeoka, Shin Okamoto, Nobuaki Tanaka, 
Haruyo Yasui, Tomoharu Dohi, Shinsuke Nanto, Seiki Nagata, Kansai Rosai Hospital, 
Amagasaki, Japan
Background: A ﬁlter device is used to avoid microembolization during percutaneous 
coronary intervention (PCI). Under the use of ﬁltering devices, ﬁlter no reﬂow (FNR) occurs 
in one-third of patients. We sought to investigate the predictors of FNR using intravascular 
ultrasound (IVUS). Methods: Between January 2007 and July 2008, PCI assisted with a 
ﬁlter device (Filtrap, NIPRO) and IVUS was performed in 62 patients (mean age 63±12, 
male 83.9%). FNR was deﬁned as reduced ﬂow that is reversible following removal of the 
ﬁlter. Before PCI, we measured reference external elastic membrane cross-sectional area 
(EEM-CSA), reference lumen CSA, calciﬁcation, and echo luminance of plaque by IVUS. 
Plaque burden was deﬁned as (EEM-CSA - lumen CSA) / EEM-CSA. After implantation 
of the stent, we measured minimum stent area (MSA) by IVUS, and evaluated stent 
expansion (MSA / reference lumen CSA). Patients were divided into 2 groups: FNR(+) 
and FNR(-) groups. Results: FNR was found in 23 patients (37%). Signiﬁcant differences 
were not found except for hyperlipidemia (21% versus 51%, P=0.030) and initial TIMI ﬂow 
grade (TIMI 0: 43% versus 30%; TIMI 1 17% versus 3%; TIMI 2: 9% versus 3%; TIMI 3: 
30% versus 64%; P=0.031) in the baseline patient, lesion and procedural characteristics. 
Before PCI, superﬁcial calciﬁcation was more frequent in FNR(+) group (70%) than 
in FNR(-) group (31%, P=0.004) and low echoic plaque tended to be detected more 
frequently in FNR(+) group (48%) than in FNR(-) group (23%, P=0.054). Plaque burden 
and stent expansion were similar between the groups. Reference EEM-CSA and reference 
lumen CSA were smaller in FNR(+) group than in FNR(-) group (reference EEM CSA, 
17.11±4.0mm² versus 20.43±6.2mm²; P=0.026; reference lumen CSA, 8.99±2.7mm² 
versus 11.39±3.7mm² ; P=0.0086, respectively). Conclusions: Superﬁcial calciﬁcation, 
low echoic plaque, small reference EEM-CSA, and small reference lumen CSA assessed 
by IVUS may be predictors of FNR prior to PCI.
9:30 a.m.
2514-726 Impact of Bivalirudin on In-hospital Bleeding and 
6-month Outcomes in Octogenarians Undergoing 
Percutaneous Coronary Intervention
Gilles Lemesle, Axel De Labriolle, Laurent Bonello, Gabriel Maluenda, Asmir I. Syed, 
Sara D. Collins, Itsik Ben-Dor, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. 
Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: Bivalirudin has been identiﬁed as able to prevent bleeding after 
percutaneous coronary intervention (PCI), which is associated with poor outcomes. 
Nevertheless, elderly people who are most susceptible to bleeding and subsequently to 
early and late mortality were excluded from randomized trials. This study aimed to analyze 
the impact of bivalirudin on in-hospital bleeding and 6-month mortality in octogenarians 
undergoing PCI.
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bivalirudin alone. Independent blinded core laboratory analysis was performed in the ﬁrst 
7000 consecutive randomized US patients, 3664 of whom underwent PCI. Major adverse 
cardiac events (MACE) including death, MI, or unplanned revascularization for ischemia 
were compared for component ACC/AHA lesion type by treatment allocation.
Results: In the angiographic subset, a total of 1190 PCI pts were randomized to heparin 
+ GPI, 1254 to bivalirudin + GPI, and 1220 pts received bivalirudin monotherapy. At 30 
days, there were no differences in MACE for any of the complex lesion subgroups based 
on treatment allocation (Figure).
Conclusions: Compared with heparin + GPI or bivalirudin + GPI, bivalirudin monotherapy 
alone achieves similar rates of 30-day MACE across the spectrum of complex lesion types.
9:30 a.m.
2514-731 Safety and Efﬁcacy of Small Molecule Glycoprotein 
IIb/IIIa Inhibitors compared to Abciximab in Patients 
undergoing Primary PCI: A Meta-Analysis of 
Randomized Controlled Trials
Umesh U. Tamhane, Pascal Meier, Paul Michael Grossman, Stanley Chetcuti, Hitinder S. 
Gurm, University of Michigan Medical Center, Ann Arbor, MI
Background: Recent “head to head” clinical trials comparing small molecule glycoprotein 
IIb/IIIa inhibitors (smGPI) with abciximab focused on surrogate endpoints and were not 
adequately powered to detect differences in clinical outcomes. The objective of our meta- 
analysis was to evaluate the survival beneﬁt from smGPI compared to abciximab in ST 
elevation myocardial infarction (STEMI) patients undergoing primary PCI (PPCI).
Methods: Five randomized trials (n=2,138 patients) comparing smGPI (tiroﬁban or 
eptiﬁbatide) with abciximab as an adjunctive therapy to PPCI were included in this meta-
analysis. Summary odds ratios for 30-day death, reinfarction and major bleeding were 
calculated using ﬁxed-effects models.
Results: There were no differences in 30-day mortality (1.9 % for small molecule versus 
2.3% for abciximab, OR 0.84, 95% CI 0.46- 1.55, P =0.58), reinfarction (1.3% versus 
1.2%), or major bleeding (1.7% versus 1.3%) between the two adjunctive strategies. 
There was no signiﬁcant difference in the incidence of death or reinfarction on follow up at 
8 months (3.9% versus 5% and 4.8% versus 4.6% for smGPI compared to abciximab).
Conclusions: In patients undergoing PPCI for STEMI, no difference in outcome could be 
identiﬁed in patients treated with smGPI or abciximab. 
9:30 a.m.
2514-732 Clinical Outcomes of Percutaneous Coronary 
Intervention using Bivalirudin Versus Heparin plus 
Glycoprotein IIb/IIIa Inhibitors in the NHLBI Dynamic 
Registry
Sohah N. Iqbal, Faith Selzer, Frederick Feit, Ruchira Glaser, Suresh R. Mulukutla, 
Robert L. Wilensky, J. Dawn Abbott, David O. Williams, James Slater, New York 
University Langone Medical Center, New York, NY, University of Pittsburgh Medical 
Center, Pittsburgh, PA
Background: In randomized clinical trials, the use of bivalirudin monotherapy in 
percutaneous coronary intervention (PCI), as compared with heparin plus glycoprotein 
IIb/IIIa inhibitors (Hep-GPI), has been shown to reduce bleeding complications, 
while preserving protection from ischemic events. There is less data available on the 
effectiveness of bivalirudin in real world practice. We compared the outcomes of these two 
anticoagulation strategies as used in unrestricted, routine clinical practice.
Methods: Consecutive patients enrolled in 2 recruitment waves in the multi-center, 
prospective cohort study of the National Heart, Lung, and Blood Institute Dynamic 
Registry (2004 and 2006) were studied. Baseline characteristics, in-hospital events, and 
1-year outcomes were compared based on the use of bivalirudin (n = 913) or Hep-GPI (n 
= 1282) during PCI. To account for factors affecting treatment selection bias, a propensity 
score adjustment was performed.
9:30 a.m.
2514-728 Late Outcomes of Elderly Patients with Acute 
Myocardial Infarction Undergoing Primary Angioplasty: 
One Year Results from the HORIZONS-AMI Trial
Dariusz Dudek, Roxana Mehran, Krzyszto Zmudka, Bernhard Witzenbichler, Giulio 
Guagliumi, Jan Z. Peruga, Bruce R. Brodie, Ran Kornowski, Franz Hartmann, Martin , 
Mockel, Andrzej Ochala, Helen Parise, Eugenia Nikolsky, Alexandra J. Lansky, Gregg 
W. Stone, Columbia University Medical Center and the Cardiovascular Research 
Foundation, New York, NY
Background: In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) vs. unfractionated 
heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced rates of major 
bleeding and mortality with comparable composite major adverse cardiovascular events 
(MACE), and enhanced freedom from net adverse clinical events (NACE) in pts with AMI 
undergoing primary PCI at 30 days and 1 year. Whether the beneﬁcial effects of Biv are 
independent of age, an important determinate of outcomes after primary PCI, has not 
been reported.
Methods and Results: A total of 3602 pts at 123 centers in 11 countries with AMI 
undergoing primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802). 
Outcomes were analyzed according to age above or below the median of 60.2 years. 
Compared to young pts, elderly pts had greater (all P values <0.0001) rates of major 
bleeding (9.9% vs. 5.2%), MACE (14.6% vs. 9.3%), cardiac mortality (4.7% vs.1.2%), 
and NACE (21.3% vs. 12.7%). In the entire study population at 1 year Biv compared 
to UFH+GPI resulted in a 39% reduction in major bleeding (5.8% vs. 9.2%, P<0.0001), 
reduced cardiac mortality (2.1% vs. 3.8%, p=0.0.005), similar MACE (11.9% vs. 11.9%, 
P=1.0), and a 16% reduction in NACE (15.7% vs. 18.3%, P=0.03). The impact of Biv was 
independent of age (Table).
Conclusions: At 1 year, elderly pts with AMI undergoing primary PCI beneﬁted from Biv 
monotherapy with signiﬁcant reductions in major bleeding, net adverse clinical events, 
and cardiac mortality. 
Age <=60.2 year
(n=1,808)
Age >60.2 year
(n=1,794)
Biv mono UFH+GPI RR(95% CI) Biv mono UFH+GPI RR(95% CI)
Major
bleeding 3.8% 6.7% 0.56 (0.37,0.84) 7.9% 11.7% 0.66 (0.49, 0.89)
MACE* 10.1% 8.5% 1.20 (0.89, 1.64) 13.9% 15.2% 0.90 (0.71, 1.15)
NACE** 12.3% 13.2% 0.91 (0.70, 1.18) 19.2% 23.2% 0.81 (0.66, 0.99)
Cardiac
death 0.8% 1.6% 0.48 (0.19, 1.18) 3.6% 5.8% 0.61 (0.39, 0.95)
*MACE = death, reinfarction, ischemic TVR or stroke
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
9:30 a.m.
2514-729 One Year Outcomes with Bivalirudin vs. Unfractionated 
Heparin During Percutaneous Coronary Interventions 
in Patients With Stable and Unstable Angina Pectoris
Julinda Mehilli, Adnan Kastrati, Franz-Josef Neumann, Robert A. Byrne, Heinz Joachim 
Buettner, Ahmed A. Khattab, Stefanie Schulz, Juergen Pache, Melchior Seyfarth, Josef 
Dirschinger, Gert Richardt, Albert Schomig, Deutsches Herzzentrum, Munich, Germany
Background: Thirty-day results of the ISAR-REACT 3 trial, showed that bivalirudin 
reduced bleeding compared to unfractionated heparin, although net clinical beneﬁt based 
on the quadruple endpoint was not improved by this drug. However, the 30-day period 
might not be long enough to identify the whole potential beneﬁt with a certain drug. For 
example, reduction of bleeding in the early period may improve the long-term prognosis 
of the treated patients. One year outcomes with bivalirudin vs. unfractionated heparin are 
not evaluated so far.
Methods: In this randomized, double-blind study 4570 biomarker negative patients with 
stable or unstable angina who underwent a percutaneous coronary intervention after 
pretreatment with a 600 mg dose of clopidogrel were enrolled: 2889 patients assigned 
to bivalirudin and 2881 patients to unfractionated heparin. Aim of the present analysis 
is evaluation of one-year outcomes particularly in terms of mortality and myocardial 
infarction and their relation to the early 30-day events.
Results: Results will be available in February 2009.
9:30 a.m.
2514-730 Impact of Bivalirudin Monotherapy on 30-day Outcomes 
in Patients with Acute Coronary Syndromes and 
Complex Coronary Stenoses Undergoing Percutaneous 
Coronary Intervention
Kenji Goto, Alexandra J. Lansky, Ecaterina Cristea, Martin Fahy, Frederick Feit, Magnus 
E. Ohman, Harvey D. White, Karen P. Alexander, Michel E. Bertrand, Walter Desmet, 
Martial Hamon, Roxana Mehran, Gregg W. Stone, Cardiovascular Research Foundation, 
New York, NY
Background: The ACUITY trial demonstrated that among moderate to high risk ACS 
pts undergoing PCI, bivalirudin monotherapy compared to heparin + GP IIb/IIIa inhibitors 
(GPI) achieves similar ischemic outcomes with fewer major bleeding complications. 
Whether these results are generalizable to ACS patients with complex coronary anatomy 
undergoing PCI is unknown.
Methods: ACUITY randomized 13,819 pts with moderate and high risk ACS to heparin 
(unfractionated or low molecular weight heparin) + GPI, vs. bivalirudin + GPI vs. 
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9:30 a.m.
2515-736 Impact of Proton Pump Inhibitors on Platelet Response 
to Clopidogrel Treatment
Dirk Sibbing, Tanja Morath, Julia Stegherr, Siegmund Braun, Martin Hadamitzky, Albert 
Schomig, Adnan Kastrati, Nicolas von Beckerath, Deutsches Herzzentrum Munchen, 
Munich, Germany
Background: Patients receiving dual antiplatelet treatment with aspirin and clopidogrel are 
commonly treated with proton pump inhibitors (PPIs) with the objective of minimizing the 
risk of gastrointestinal bleedings. Adverse effects on the platelet response to clopidogrel 
have been reported solely for the PPI omeprazole. PPIs differ in their metabolization 
properties as well as their potential for drug-drug interactions. Whether other PPIs such 
as pantoprazole or esomeprazole also attenuate the antiplatelet action of clopidogrel is 
unknown. The aim of this study was to investigate the impact of concomitant treatment 
with different PPIs on platelet response to clopidogrel in patients with previous coronary 
stent placement under dual antiplatelet treatment with clopidogrel and aspirin.
Methods: A total of 1000 consecutive patients under clopidogrel treatment and scheduled 
for a control coronary angiography were enrolled in this study. Adenosine diphosphate 
(ADP)-induced platelet aggregation was measured in whole blood with multiple electrode 
platelet aggregometry (MEA) on the Multiplate analyzer. Values of MEA are expressed as 
area under the curve (AUC=AU*min) of arbitrary units (AU).
Results: From the entire study population, 268 (26.8%) patients were under PPI treatment 
at the time point of platelet function testing (pantoprazole, n=162; omeprazole, n=64; 
esomeprazole, n=42). Platelet aggregation (median [interquartile range]) was signiﬁcantly 
higher in patients with omeprazole treatment (295.5 [193.5-571.2] AU*min) compared to 
patients without (n=732) PPI treatment (220.0 [143.8-388.8] AU*min; P=0.001). Platelet 
aggregation was similar in patients with pantoprazole (226.0 [150.0-401.5] AU*min) or 
esomeprazole (209.0 [134.8-384.8] AU*min) treatment compared to patients without PPI 
treatment (P=0.69 and P=0.88, respectively).
Conclusions: Adverse effects of concomitant PPI treatment on platelet response to 
clopidogrel were restricted to the use of omeprazole. No adverse effects on platelet 
response to clopidogrel were observed for pantoprazole or esomeprazole.
9:30 a.m.
2515-737 Less Heparin per Weight is Necessary for Obese 
Patients Undergoing Percutaneous Coronary 
Intervention
Yuichi J. Shimada, Yumiko Kanei, Beth Israel Medical Center, New York, NY
Background: A weight-adjusted bolus heparin of 70 to 100 IU per kg is recommended to 
achieve adequate activated clotting time (ACT) during percutaneous coronary intervention 
(PCI) in ACC/AHA/SCAI Guideline. Since obese patients have lower proportion of lean 
body mass as a percentage of total body weight, heparin dosing based on total body 
weight could cause excessive anticoagulation.
Methods: In 500 consecutive PCI cases in our catheterization laboratory, the amount 
of initial heparin bolus (IU per kg) and ACT (seconds) using Hemochron at 5 minutes 
after heparin administration were retrospectively obtained. We hypothesized that patients 
with more weight requires less heparin per weight to achieve the same goal of ACT, and 
calculated susceptibility to heparin of each individual as the ratio of ACT to heparin dosing 
(IU per kg). Regression analysis was performed to determine relationship between weight 
and susceptibility.
Results: There was a statistically signiﬁcant positive relationship between heparin 
susceptibility (y) and weight (x), showing that patients with more weight required less 
heparin per kilogram to achieve the same goal of ACT (Graph below; y = 0.0603x + 
0.2229; 95% conﬁdence interval of slope, 0.053-0.067>0; P<0.0001. 95% CI for the 
regression line is also shown).
Conclusions: For obese patients undergoing PCI, less heparin per weight should be 
given to avoid excessive anticoagulation.
Results: Patients who received bivalirudin were more likely to be older (65 vs 62 years), 
have more diabetes (38.9% vs 30.2%), and have previous CABG or PCI (53.9% vs 33.6%) 
than Hep-GPI (p < 0.001). Patients who received Hep-GPI were more likely to present 
with an acute MI (46.9% vs 9.7%) (p< 0.001). In the propensity score adjusted model, risk 
for any reported bleeding was signiﬁcantly lower in the patients treated with bivalirudin as 
compared with the Hep-GPI strategy during PCI (adjusted odds ratio [AOR] of 0.20, 95% 
CI 0.10-0.40, p < 0.001) as was bleeding requiring transfusion (AOR of 0.17, 95% CI 0.06-
0.49, p = 0.001). Risk for in-hospital death, myocardial infarction (MI), or CABG was also 
signiﬁcantly lower with bivalirudin therapy (AOR of 0.35, 95% CI 0.14-0.88, p = 0.03). There 
was no difference in risk of 1-year events including death, MI, CABG, or repeat PCI.
Conclusions: Our study demonstrates that in real world clinical practice, after adjusting 
for treatment selection bias, risk of bleeding complications is lower in PCI with bivalirudin 
as compared with Hep-GPI. Though unaccountable imbalances between the two groups 
may be present, there appears to be less in-hospital and similar 1-year ischemic events 
with bivalirudin use.
9:30 a.m.
2514-733 Adverse Cardiac Events with Use of Intracoronary 
Compared to Intravenous Glycoprotein IIb/IIIa Inhibitor 
in Patients with Acute Coronary Syndrome Undergoing 
Percutaneous Coronary Intervention: A Meta-analysis
Amol A. Bahekar, Rohit Bhuriya, Updesh Bedi, Param Puneet Singh, Ahmad Khraisat, 
Janos Molnar, Rohit Arora, Sandeep Khosla, Mount Sinai Hospital, Chicago, IL, 
Rosalind Franklin University, North Chicago, IL
Background: Recent studies have shown that intracoronary (IC) glycoprotein (Gp) IIb/IIIa 
inhibitor may improve myocardial microcirculation and reduce major adverse cardiac events 
(MACE). The aim of this meta-analysis was to assess the effects of IC versus intravenous 
(IV) Gp IIb/IIIa inhibitor bolus administration on the occurrence of MACE up to 6 months.
Methods: Systematic literature search revealed 7 clinical trials (N=2041) comparing IC 
versus IV Gp IIb/IIIa inhibitor in patients with acute coronary syndrome (ACS) undergoing 
percutaneous coronary intervention (PCI). Heterogeneity of the studies was analyzed by 
Cochran’s Q statistics. The Mantel-Haenszel ﬁxed-effect model was used to calculate 
endpoints for outcomes where studies were homogenous and random effect model when 
the studies were heterogenic.
Results: The relative risk (RR) for cardiac deaths decreased signiﬁcantly 0.58; 95% CI: 
0.35 - 0.94 p=0.03 in IC group as compared to IV group. There was a trend towards 
decreased RR of non fatal myocardial infarction(MI) 0.42; 95% CI: 0.08 - 2.25 p=0.31, rate 
of revascularization 0.83; 95% CI: 0.35 - 1.98 p=0.68 and MACE 0.56; 95% CI 0.3-1.06 
p=0.07 in the IC group as compared to IV group but the results were not signiﬁcant.
Conclusions: IC Gp IIb/IIIa inhibitor reduce the RR of cardiac death in addition to 
reducing the trend of non fatal MI & MACE in ACS patients undergoing PCI as compared 
to IV Gp IIb/IIIa inhibitor. Large scale prospective randomized trials are needed to assess 
this beneﬁt further. 
9:30 a.m.
2514-735 Bivalirudin Versus Heparins in Acute Coronary 
Syndrome; with and without Percutaneous Coronary 
Interventions: A Meta-analysis
Sarabjeet Singh, Rohit Arora, Janos Molnar, Param Puneet Singh, Rohit Bhuriya, Amol 
Bahekar, Ahmad Khraisat, Sandeep Khosla, Chicago Medical School and afﬁlated 
Hospitals, Chicago, IL
Background: Heparin provides protection against cardiovascular events with fewer 
bleeding complications. Whether this advantage is consistent is not been fully deﬁned. 
We evaluated cardiac outcomes with bivalirudin versus heparin in management of 
acute coronary syndrome (ACS), including patients undergoing percutaneous coronary 
interventions (PCI).
Methods: Seven randomized controlled trials (BAT, CACHET, REPLACE 1,REPLACE-2, 
ACUITY, HORIZONS-AMI, ISAR-REACT) comparing bivalirudin to heparin were 
identiﬁed. The meta-analysis consisted of 33,629 patients (bivalirudin, 1,9166; heparin, 
1,4463). The combined relative risks (RR) across all the studies and the 95% conﬁdence 
intervals of myocardial infarction (MI), and revascularization (bivalirudin versus heparin) 
were computed with using the Mantel-Haenszel ﬁxed-effect model, while the random 
effect model was used for cardiovascular death and major bleeding.
Results: There were no signiﬁcant differences in patient characteristics between the 
two groups. Compared to heparin, the risk of death, MI, revascularization and composite 
ischemic endpoints were similar with bivalirudin monotherapy. However, the risk of major 
bleeding was signiﬁcantly lower with bivalirudin use p<0.001).
Conclusions: The present meta-analysis suggests that bivalirudin alone is noninferior to 
heparin in reducing composite ischemic endpoints. Additionally, bivalirudin signiﬁcantly 
lowers rate of major bleeding compared with heparin. 
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9:30 a.m.
2515-740 Prognostic Implications of High Platelet Reactivity 
as Deﬁned by Multiple Agonists in Diabetes Mellitus 
Patients on Dual Antiplatelet Therapy
Dominick Angiolillo, Esther Bernardo, Piera Capranzano, Manel Sabate, Pilar Jimenez-
Quevedo, Jose Luis Ferreiro, Fernando Alfonso, Rosana Hernandez, Carlos Macaya, 
Antonio Fernandez-Ortiz, Theodore A. Bass, University of Florida College of Medicine-
Jacksonville, Jacksonville, FL, San Carlos University Hospital, Madrid, Spain
Background: High platelet reactivity (HPR) determined in patients while on dual 
antiplatelet therapy with aspirin and clopidogrel has been associated with an increased 
risk of major adverse cardiovascular events (MACE). Most studies have determined HPR 
using light transmittance aggregometry (LTA) with ADP stimuli. However, if concomitant 
assessment of platelet reactivity using others agonists can better deﬁne patients at an 
increased risk of MACE is unknown.
Methods: LTA with ADP (20 μmol/L) stimuli was used to deﬁne patients with HPR in a total 
of 173 diabetic patients on aspirin and clopidogrel therapy. LTA was also performed with 
the following agonists: collagen (6 μg/ml), epinephrine (20 μmol/L), and TRAP (25 μmol/L). 
Receiver-operating characteristics (ROC) analyses were computed in order to identify the 
best cut-off values of aggregation predicting MACE. MACE (cardiovascular death, acute 
coronary syndrome, stroke) occurring during 2-year follow-up were recorded.
Results: A total of 41 MACE occurred in 34 patients (19.6%) during the 2-year follow-up. 
ROC analysis identiﬁed ADP-induced aggregation >62% to best predict MACE. ROC 
analyses of aggregation values with other agonists (collagen, epinephrine, and TRAP) 
showed epinephrine-induced aggregation as the best to predict MACE for which a cut-
off value >32% was identiﬁed. A total of 37 patients had both ADP and epinephrine 
aggregation above the ROC-deﬁned cut-off values (group 1); 59 patients had only 
one of the aggregation parameters above the ROC-deﬁned cut-off values (group 2); 
the remaining 77 patients had both ADP- and epinephrine-induced aggregation below 
the ROC-deﬁned cut-off values (group 3). The 2-year MACE rate was 43.2%, 13.6%, 
and 13.0% in groups 1, 2, and 3, respectively (p=0.006). After adjustment for multiple 
confounders the hazard ratio for the association of >62% ADP- and >32% epinephrine-
induced aggregation was 3.5 (95% CI 1.8-7.2, p=0.001).
Conclusions: Platelet function proﬁling using multiple agonists activating different 
signaling pathways allows to better discriminate individuals at increased risk of developing 
MACE while on antiplatelet therapy.
9:30 a.m.
2515-741 Clinical Outcomes of Extended Duration of Dual 
Anti-Platelet Therapy After Percutaneous Coronary 
Intervention
Kishore J. Harjai, Pamela Orshaw, Chetan Shenoy, Judith Boura, Guthrie Health 
System, Sayre, PA
Background: It is unknown whether DAP should be continued beyond 12 months after 
successful PCI. We assessed the impact of extended duration of dual-antiplatelet (DAP) 
therapy on long-term outcomes of patients undergoing PCI.
Methods: We identiﬁed 1859 patients who underwent successful native coronary stent 
procedures and survived event-free for >12 months. We assessed the impact of duration 
of DAP therapy [“usual” duration (<12 mon, n=941; 51%) Vs. “extended” duration (>12 
mon; n=918; 49%)] on the combined end-point of death or non-fatal myocardial infarction 
(MI) using actuarial survival analysis and propensity-adjusted multivariate Cox regression 
analysis. Similar analyses were then performed in the 2 stent subsets: BMS (n=835), DES 
(n=1024); and 3 high-risk subsets: diabetics (n=486), patients presenting with MI (n=713), 
and those with ACC/AHA type C lesions (n=717).
Results: Baseline characteristics were as follows: mean age 64±12 years, male 69%, 
diabetic 26%, presentation with MI 38%, ejection fraction 49±12%, mean vessel diameter 
3.1±0.5 mm. Duration of DAP was 4.1±4.1 months in the ‘usual’ group and 27±11 months 
in the ‘extended group (p<0.0001). At a median follow-up of 3.4 years after PCI, the ‘usual’ 
vs. ‘extended’ groups had similar incidence of death or MI (10 vs 9.4%, log rank p=0.83, 
ﬁgure). After multivariate adjustment, ‘extended’ DAP therapy was not associated with 
lower incidence of death or MI than ‘usual DAP’ therapy (adjusted HR=1.01; CI 0.74-1.37, 
p=0.95). Analysis of each of the 5 pre-deﬁned subsets revealed similar results.
Conclusions: In patients who undergo successful native coronary PCI and survive event-
free for at least 12 months, continuation of dual anti-platelet therapy beyond 12-months 
does not confer long-term protection from death or MI. 
9:30 a.m.
2515-738 Comparison of addition of cilostazol versus increasing 
dose of clopidogrel in clopidogrel non-responders after 
drug-eluting stent implantation
Hahn Joo-Yong, Young Bin Song, Sang-Yup Lee, Seung-Hyuk Choi, Jin-Ho Choi, Young Keun 
On, Sang Hoon Lee, Hyeon-Cheol Gwon, Samsung Medical Center, Seoul, South Korea
Background: Previous studies reported that triple antiplatelet therapy including cilostazol 
enhanced inhibition of platelet P2Y12 signaling compared with standard dual antiplatelet 
therapy. However, it is uncertain whether addition of cilostazol is superior to increasing 
dose of clopidogrel in clopidogrel non-responders after drug-eluting stent implantation.
Methods: This was a prospective randomized single-center trial. We enrolled 73 patients 
who showed a poor responsiveness to clopidogrel on standard dual antiplatelet therapy 
(aspirin 100 mg and clopidogrel 75 mg daily) more than 2 weeks. Clopidogrel responsiveness 
was evaluated using VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, CA, USA). 
Patients were considered as clopidogrel non-responder when percent inhibition of P2Y12 
reaction units (PRU) was less than 30%. Thirty-ﬁve patients were randomly assigned to 
receive additional cilostazol (aspirin 100 mg qd + clopidogrel 75 mg qd + cilostazol 100 
mg bid daily: group A) and 38 patients to receive increased clopidogrel (aspirin 100 mg + 
clopidogrel 150 mg daily: group B). The primary endpoint was percent inhibition of PRU on 
follow-up VerifyNow P2Y12 assay at 4 weeks after the randomization. Secondary endpoints 
were PRU at follow-up and change in percent inhibition of PRU and PRU.
Results: Baseline percent inhibition of PRU and PRU was similar between 2 groups 
(13.3±10.5% versus 11.7±9.8%, p=0.50 and 296±54 versus 287±58, p=0.49, 
respectively). At follow-up, percent inhibition of PRU was signiﬁcantly greater in group A 
than in group B (37.0±18.8% versus 27.3±17.1%, p=0.02). Change in percent inhibition 
of PRU was also signiﬁcantly greater in group A compared with group B (23.6±17.6% 
versus 15.6±16.8%, p=0.04). Follow-up PRU and change in PRU showed a favorable 
trend toward group A compared with group B, but without a signiﬁcant difference (212±71 
versus 245±75, p=0.06 and -75±67 versus -51±66, p=0.13, respectively).
Conclusions: Addition of cilostazol on standard dual antiplatelet therapy improved 
clopidogrel responsiveness better than increase in clopidogrel dose in clopidogrel non-
responders after drug-eluting stent implantation.
9:30 a.m.
2515-739 Treatment of Clopidogrel Hypersensitivity Without Drug 
Interruption: Acute and Long-term Outcomes
Kimberly L. Campbell, Rhaguram Mallya, Waseem Jaffrani, John R. Cohn, David L. 
Fischman, Paul Walinsky, Michael P. Savage, Thomas Jefferson University Hospital, 
Philadelphia, PA
Premature discontinuation of dual antiplatelet therapy after PCI is a major predictor of 
stent thrombosis. Clopidogrel hypersensitivity affects 6% of patients and results in drug 
discontinuation in 1.5%. Conventional clopidogrel desensitization protocols require a 
washout period to enable detection of reaction to desensitizing dose. This technique is 
problematic following stent placement since therapy interruption carries signiﬁcant risk of 
stent thrombosis. The goals of the study were to assess a strategy for treating clopidogrel 
hypersensitivity using antihistamines and short-course corticosteroids without drug 
interruption and secondarily to assess long-term outcomes of this strategy. Review of PCI 
performed January 1, 2005 through September 30, 2008 identiﬁed 24 patients treated for 
clopidogrel hypersensitivity. Patients treated for hypersensitivity were followed for 487 ± 
434 days (median 333) to ascertain duration of clopidogrel therapy, frequency of symptom 
recurrence, and incidence of adverse cardiovascular events. The study population 
included 18 males and 6 females with mean age 62 ± 9 years. Indications for PCI included 
STEMI (3), acute coronary syndrome (11), stable angina (1), and positive stress test (9). 
Drug eluting stents were used in 16 patients (67%). Clopidogrel hypersensitivity occurred 
on day 6 ± 2 of therapy. Treatment of hypersensitivity included corticosteroids (19) and 
antihistamines (20) with 15 receiving both. Patients treated with corticosteroids received 
tapering courses for 8 ± 5 days. Treatment of clopidogrel hypersensitivity was successful 
in 21 of 24 patients (87.5%). In these 21 patients, clopidogrel therapy duration was 115 
± 120 days for bare metal stents (median 92) and 511 ± 361 days for drug-eluting stents 
(median 454). During follow-up, there were no deaths, MI, CABG, or stent thrombosis. 
In-stent restenosis required repeat PCI in 3 patients. In conclusion, patients treated for 
clopidogrel hypersensitivity using antihistamines and short-course corticosteroids without 
drug interruption can be successfully maintained on prolonged clopidogrel therapy. This 
strategy confers a low risk of adverse cardiovascular events.
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2515-744 30-day outcomes of patients under anti-vitamin K 
treatment receiving sirolimus-eluting stent implantation 
in the world-wide e-Select Registry
Manel Sabate, Alexander Abizaid, Adrian Banning, Antonio Bartorelli, Vladimir Dzavik, 
Stephen G Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-
Josef Neumann, Christian Spaulding, Stephen Worthley, Philip Urban, Hospital Sant 
Pau, Barcelona, Spain
Background: Patients (pts) under anti-vitamin K (AVK) treatment before the implantation 
of a drug eluting stent remain a therapeutic challenge because of the potential bleeding 
risks associated with dual antiplatelet therapy (DAPT). We sought to identify the risk 
proﬁle and the 30-day outcome of pts under AVK receiving sirolimus-eluting stent (SES) 
in the world-wide e-Select Registry.
Methods: Between 2006 and 2008, 15,217 pts from 321 hospitals in 56 countries 
were prospectively enrolled after implantation of at least one SES (Cypher Select™). 
Monitoring of 20% randomly selected enrolled pts is ongoing. All adverse events are 
adjudicated by an independent critical event committee. The main outcome measure will 
be the incidence of stent thrombosis (ST) at 3 years. Analysis of the subgroup of pts 
under AVK treatment was predeﬁned and data regarding antiplatelet and anticoagulation 
therapy was prospectively collected.
Results: 293 pts (2%) were on AVK at the time of inclusion and were treated for 385 
target lesions with SES. As compared with pts without AVK, these pts were older (68+10
vs. 62+11 years, p<0.001), had had more often prior revascularization (19% vs. 9%; 
p<0.001), myocardial infarction (43% vs. 32%; p<0.001), cerebrovascular accident (15% 
vs. 4%; p<0.001) and, presented a higher incidence of heart failure (19% vs. 4%; p<0.001) 
and comorbid conditions (Charlson comorbidity index >3 in 24.2% vs 10%; p<0.001). 
At 30 days, 98.2% of pts were still on AVK. The percentage of pts on clopidogrel was 
similar between groups (98% vs 98%). However, pts on AVK presented signiﬁcantly less 
usage of aspirin (87% vs. 99%; p<0.001). There was a trend towards an overall higher 
incidence of bleeding at the expense of minor bleeding. The incidence of major bleeding 
and ST were comparably low between groups (0.7% vs. 0.3; p=NS and 0% vs. 0.4%, 
p=NS; respectively).
Conclusions: SES implantation in pts under AVK treatment led the physician to reduce 
the usage of aspirin at 30-day follow-up. However, this was not translated into any hazard 
in terms of major bleeding or ST. Further details on the interaction and discontinuation of 
these drugs at 6-months will be available in March 2009.
9:30 a.m.
2515-745 Dual Antiplatelet Plus Warfarin Therapy Following 
Coronary Stent Placement: An Evaluation of Long-Term 
Outcomes from the Prairie Data Registry
Anna (Moore) Plessa, Robert Trask, Marc Shelton, Gregory Mishkel, Prairie Heart 
Institute at St. John’s Hospital, Springﬁeld, IL, Prairie Education & Research 
Cooperative, Springﬁeld, IL
Background: Dual antiplatelet (DA) therapy with aspirin + clopidogrel is the standard 
of care following coronary stent placement. Patients already on chronic warfarin require 
treatment with dual antiplatelet + warfarin (DA+W) therapy following stent placement. We 
wish to assess morbidity, mortality, and clinical outcomes of DA versus DA+W in the 
“real world”.
Methods: We identiﬁed 3808 consecutive patients who underwent coronary stent 
placement between 1/1/05 and 3/29/08 and met the following criteria: a) this was the 
1st stent procedure during that time; b) DA or DA+W was administered prior to hospital 
discharge. Clinical follow-up was obtained at regular intervals.
Results: DA was administered in 3520 patients, and DA+W in 288. Follow-up was 
obtained on 3519 patients (92.4%) at a mean of 631 ± 328 days. At baseline, the DA+W 
group had signiﬁcantly more co-morbid conditions, including: diabetes (33.3 vs 27.3%, 
p=0.034), congestive heart failure (16.3 vs 4.8%, p<0.001), cerebrovascular disease 
(14.2 vs 7.3%, p<0.001), peripheral vascular disease (13.9 vs 9.0%, p=0.008), and prior 
myocardial infarction (25.3 vs 17.7%, p=0.002). Drug-eluting stents were used more than 
bare metal in the DA group (86.3 vs 79.2%, p=0.002). In-hospital outcomes were similar 
between groups.
Kaplan-Meier 12 Month Event Estimates
DA
(n=3520) DA+W(n=288) p value
At 12 months:
All-cause death 3.0 6.7 0.004
Cardiac death 2.5 3.2 ns
Non-fatal MI 1.5 2.8 ns
Def + prob ST 1.0 1.9 ns
Rehosp for bleeding 5.8 6.8 ns
Conclusion: Although potentially explainable by baseline differences in
co-morbidities, the signiﬁcant increase in 1-year all-cause mortality for DA+W raises 
concerns regarding this practice and warrants further
investigation.
9:30 a.m.
2515-742 Point-of-Care Testing of Platelet Function at the Time of 
Percutaneous Coronary Intervention Identiﬁes Patients 
at Risk for Early Post-Procedure Ischemia
Eric R. Powers, Andrew Fowler, Craig Thieling, Victor Diaz-Gonzales, Mitch Devlin, 
Valerian Fernandes, Robert Leman, Jacob Nunamaker, Bruce Usher, Andrea Boan, 
John Lazarchick, Christopher Nielsen, Randy Goodroe, Medical University of South 
Carolina, Charleston, SC
Background: The relationship between platelet reactivity at the time of PCI and late clinical 
outcomes remains controversial. However, the relationship between platelet reactivity at 
the time of PCI and early post-procedure ischemia has not been previously described. We 
hypothesized that aspirin resistance and low levels of P2Y12 platelet receptor inhibition 
measured using a point-of-care test performed in the catheterization laboratory would 
identify patients at risk for post-procedure ischemia assessed using an intracoronary ECG.
Methods: One-hundred consecutive patients undergoing PCI not treated with a 
glycoprotein IIb/IIIa inhibitor were included. PCI was performed according to standard 
clinical practice. Blood samples were drawn immediately prior to PCI. Aspirin resistance 
and P2Y12 receptor inhibition were assessed using The Ultegra Rapid Platelet Function 
Assay - VerifyNow (Accumetrics) and expressed as aspirin reaction units (ARU) 
and P2Y12 reaction units (PRU). Post-procedure ischemia was assessed using an 
intracoronary ECG and was deﬁned as ST deviation >1mm two minutes following the 
completion of the PCI. Cardiac biomarkers were measured the morning after PCI.
Results: Post-procedure Ischemia was found in 49 of 100 patients. Aspirin resistance 
(ARU > 550) was found in 17 patients and was not associated with post-procedure 
ischemia. A PRU >/= 314 (the median value) was associated with post-procedure 
ischemia (OR 3.89 (1.46, 10.35), p=0.007). The only other predictors of post-procedure 
ischemia were multivessel PCI (OR 6.22 (2.17, 17.85), p=0.001) and stent length (OR 
2.69 (1.02, 7.09), p=0.045). Post-procedure ischemia was associated with an abnormal 
Troponin I the morning after PCI (OR 3.49 (1.25, 9.38), p=0.014).
Conclusions: Post-procedure ischemia following PCI is common and was associated 
with low levels of P2Y12 platelet receptor inhibition, as well as multivessel PCI and 
greater stent length but not aspirin resistance. Thus, pre-procedure point-of-care testing 
of platelet function can identify patients at risk for post-procedure ischemia and allows for 
targeting of these patients for additional anti-platelet therapies.
9:30 a.m.
2515-743 Changing Outcomes and Treatment Strategies for 
Wire Induced Coronary Perforations in the Era of 
Bivalirudin Use
Annapoorna S. Kini, Oana S. Rafael, Kunal Sarkar, Angelica Mares, Madhavi Jakkula, 
Michael C. Kim, Dheeraj Kaplish, Javed Suleman, Prakash Krishnan, Samin K. Sharma, 
Mount Sinai Hospital, NewYork, NY
Background: Technical advances in percutaneous coronary intervention (PCI) have 
facilitated its use in complex lesions like chronic total occlusion and calciﬁed lesions. 
The resultant use of stiff/hydrophilic wires may lead to a higher incidence of coronary 
perforation (CP).
Methods: A single-center retrospective analysis of CP for the last 4 years with review of 
angiograms was performed. Wire perforation (WP) were identiﬁed and classiﬁed based on 
angiographic appearance as: Type I (myocardial stain, with no frank dye extravasation), 
Type II (myocardial fan: dye extravasation to pericardial cavity or cardiac chambers).All 
WP were divided into 2 groups based on anticoagulation used, heparin (group A) and 
bivalirudin (group B).
Results: Incidence of CP was 0.49% (82/16,859) of which 50 (61%) were identiﬁed 
as WP,30 in group A and 20 in group B. All WP occurred in type B2/C lesions 
(100%),commonly with hydrophilic guidewires (70%). All WP in group B responded to 
stopping anticoagulation and prolonged balloon inﬂation. However, type II perforations in 
group A frequently required additional procedures ( pericardiocentesis, coil embolization 
or covered stent graft).(Figure1)
Conclusion: WP is a major cause of CP. With bivalirudin, most WP can be managed 
with discontinuing anticoagulation and balloon inﬂation. WP with heparin often needs 
procedures like pericardiocentesis and coil embolization. Bivalirudin may offer a safer 
alternative for anticoagulation in complex PCI.
Figure 1
Variable
Group A: Heparin (n = 30) Group B: Bivalirudin (n = 20)
P value 
between 
group A 
and B
Type I Type II Combined Type I Type II Combined
Number (%) 12 (40) 18 (60) - 8 (40) 12(60) - 0.82
Pericardiocentesis/
Coil embolization/
Covered stent
0 12(66.6) 12(40) 0 0 0 0.002
Deaths (%) 0 3 (16.7) 3 (10) 0 0 0 0.55
Tamponade (%) 0 6 (33) 6 (20) 0 0 0 0.05
CABG (%) 0 1 (5.5) 1 (3.3) 0 0 0 0.55
MI (%) 1 (8.3) 5 (27.8) 6 (20) 0 0 0 0.23
MACE (%) 1 (8.3) 14 (78) 15 (50) 0 0 0 0.006
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9:30 a.m.
2515-748 Impact of Vascular Closure Devices and Antithrombotic/
Antiplatelet Therapy on Access Site Bleeding. Insights 
from the Acuity Trial
Timothy A. Sanborn, Ramin Ebrahimi, Steven V. Manoukian, Brent T. McLaurin, David 
A. Cox, Frederick Feit, Martial Hamon, Roxana Mehran, Gregg W. Stone, NorthShore 
University HealthSystems, Evanston, IL
Background: The ACUITY Trial demonstrated that bivalirudin monotherapy (BIV) had 
signiﬁcantly reduced rates of major access site bleeding (ASB) compared to heparin 
or bivalirudin plus a glycoprotein IIb/IIIa inhibitor (H + GPI, BIV + GPI). However, it is 
unknown whether vascular closure devices (VCD) had an impact on ASB in this trial. 
Therefore, the incidence of major ASB with and without VCD was examined.
Methods: Major ASB was deﬁned as hemoglobin drop > 3g/dL, retroperitoneal bleeding, 
operation for ASB, or hematoma > 5 cm. Stepwise logistical regression was performed to 
determine whether VCD usage was a predictor of ASB.
Results: Of the 11,278 patients undergoing angiography or percutaneous coronary 
intervention via the femoral approach, 4220 (37.4 %) received a VCD and 7058 (62.6 %) 
did not. Rates of major ASB were lowest with VCD compared to no VCD (2.1% vs. 2.9 %), 
OR (95 % CI) = 0.73 (0.57, 0.94) p = 0.0151) and rates of ASB were lowest in patients 
treated with BIV alone and a VCD (0.6 %). Stepwise logistical regression revealed a trend 
toward VCD usage and reduced ASB (OR 0.78 (95 % CI 0.60-1.03) p = 0.08).
Conclusions: Rates of major ASB were signiﬁcantly lower with the use of a VCD and 
were also lower with the use of BIV compared to GPI containing regimens regardless of 
VCD usage. Lastly, rates of major ASB were lowest in patients who received both BIV and 
a VCD. These results suggest that the combined use of BIV and a VCD may be effective in 
minimizing major ASB in patients with ACS managed with an early invasive strategy. 
Major Access Site Bleeding, (n, %)
Category H + GPI BIV + GPI BIV
VCD 41/1435 (2.9) 40/1344 (3.0) 9/1441 (0.6)
No VCD 81/2320 (3.5) 82/2413 (3.4) 41/2325 (1.8)
BIV vs. H + GPI, BIV + GPI: p < 0.0005
9:30 a.m.
2515-749 Assessment of the pharmacokinetic and 
pharmacodynamic effects of intravenous clopidogrel in 
humans
Daniel Cushing, Raymond Lipicky, Peter Kowey, Christopher Cannon, Michael Adams, 
Warren Cooper, Gerold Mosher, Prism Pharmaceuticals, King of Prussia, PA
Background: Early administration of clopidogrel is recommended prior to diagnostic 
coronary angiography for ACS patients. Such dosing prior to angiography may increase 
bleeding complications if the patient requires CABG. Clopidogrel IV (CIV) is an IV 
formulation of clopidogrel that provides rapid inhibition of platelet aggregation. We present 
a pharmacokinetic (PK) and pharmacodynamic assessment of CIV in humans.
Methods: Healthy volunteers were enrolled in an open-label study and received CIV 
(n=12/dose). Blood samples were taken at baseline, 15 and 30 min, 2, 5 and 24 hr 
after dosing. Platelet aggregation (impedance method) and blood levels of clopidogrel, 
clopdiogrel-carboxylic acid, and the active clopidogrel-thiol metabolite (HPLC method) 
were assessed.
Results: CIV produced dose-dependent inhibition of platelet aggregation (Figure). 
Kaplan-Meier estimates of the cumulative percentage of subjects reaching ﬁrst onset 
of maximum inhibition of q15% was 92% at 15min (300mg). Comparable inhibition was 
observed at 2h for a 300mg oral and IV doses. PK analyses indicated rapid dose-related 
exposure to clopidogrel, clopdiogrel-carboxylic acid, and clopidogrel-thiol. There were no 
serious adverse events or discontinuations. All doses were well tolerated with only mild 
to moderate adverse events.
Conclusion: CIV produced signiﬁcant dose-dependent inhibition of platelet aggregation 
in human subjects with rapid onset (a15min). Further studies are planned.
9:30 a.m.
2515-746 Inﬂuence of Low Dose Aspirin (81 mg) on the Incidence 
of Deﬁnite Stent Thrombosis in Patients Receiving Bare 
Metal and Drug Eluting Stents
Jiang Cui, Amir Lotﬁ, Siddarth Wartak, Jesse Columbo, Scott Mulvey, Mary Davis, Marc 
Schweiger, Gregory R. Giugliano, Baystate Medical Center, Tufts University School of 
Medicine, Springﬁeld, MA
Background: Dual antiplatelet therapy with aspirin plus clopidogrel is the mainstay of 
therapy in patients undergoing percutaneous coronary intervention (PCI). However, the 
optimal dose of aspirin following PCI has not been established.
Methods: Low dose (81mg) aspirin was used as part of a standard dual antiplatelet 
therapy in patients receiving bare metal or drug eluting stents at a large tertiary medical 
center. We retrospectively analyzed 4053 consecutive patients treated with stent 
placement and dual antiplatelet therapy from 01/01/2005 to 12/31/2007. All cases coded 
as stent thrombosis in our PCI database were reviewed and classiﬁed according to the 
ARC deﬁnition of deﬁnite stent thrombosis (DST). The incidence of DST at our institution 
was compared to DST as reported in a large, published cohort of 24 trials and 12973 
patients using a Chi-squared test statistic.
Results: A total of 4053 patients underwent 5871 stent implantations during the study 
period (4534 DES and 1337 BMS). Thirty-four DSTs occurred during the study period (2 
acute (<1 day), 17 subacute (1 day to 30 days), 8 late (30 days to 1 year) and 7 very late 
(>1 year)). The cumulative incidence of DST was 0.47% (95% CI 0.30%-0.73%) at 30 
days and 0.67 % (95% CI 0.46%-0.97%) at 1 year. The incidence of DST was no different 
based on type of stent (0.53% for DES and 0.75% for BMS (p=0.36)). Compared to the 
historic, standard-dose aspirin (162-325mg) cohort, DST in our low dose aspirin (81mg) 
cohort was not signiﬁcantly different at 30 days (0.47% vs 0.7%, p = 0.1) and signiﬁcantly 
lower (0.67% vs 1.1%, p = 0.03) at 1 year.
Conclusion: Low dose aspirin therapy in combination with clopidogrel following 
implantation of either BMS or DES in our cohort does not appear to increase the risk 
of DST compared to a higher dose aspirin regimen. Given the known increased risk 
of bleeding with higher dose aspirin in combination with clopidogrel, low dose aspirin 
appears to be an effective and potentially safer alternative. Conﬁrmation of these results 
deserves further study in a large scale randomized trial.
9:30 a.m.
2515-747 Triple versus Dual Antiplatelet Therapy in Patients with 
Acute Myocardial Infarction Undergoing Percutaneous 
Coronary Intervention
Kang Yin Chen, Seung Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung 
Park, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang 
Gyu Park, Hong Seog Seo, Dong Joo Oh, Young Keun Ahn*, Myung Ho Jeong*, Other 
KAMIR Investigators, Korea University Guro Hospital, Seoul, South Korea, ChonNam 
National University Hospital*, Gwangju, South Korea
Background: Whether the safety and efﬁcacy of triple antiplatelet strategy is superior or 
similar to the dual antiplatelet strategy in patients (pts) with acute myocardial infarction 
(AMI) undergoing percutaneous coronary intervention (PCI) is still unclear.
Methods: A total of 4,892 AMI pts undergoing PCI received either dual antiplatelet 
therapy (aspirin plus clopidogrel, Dual group, n=2,974) or triple antiplatelet therapy 
(aspirin plus clopidogrel plus cilostazol, Triple group, n=1,918). All major adverse cardiac 
events (All MACE) included total death, revascularization, and myocardial re-infarction. 
The bleeding complications and clinical outcomes of in-hospital, 1 and 8 months were 
compared between the two groups.
Results: The baseline characteristics were similar between the two groups. The early 
mortality and revascularization rate were lower in Triple group up to one month and 
all MACE was signiﬁcantly lower up to 8 months. Interestingly, Triple group also had a 
signiﬁcantly lower in-hospital major bleeding (Table). This result might be due to the Triple 
group had less history of peptic ulcer disease (0.4% vs. 0.9%, P=0.034).
Conclusions: Triple antiplatelet therapy appears to be superior in preventing the MACE 
without increasing the major bleeding events in pts with AMI undergoing PCI compared 
with the conventional dual antiplatelet therapy.
Table: Clinical outcomes of study population
Variables, n (%) Dual group(n=2,974 pts)
Triple group
(n= 1,918 pts) P value
In-hospital
Total death 89 (3.0) 34 (1.8) 0.008
Reinfarction 12 (0.4) 9 (0.5) 0.730
Revascularization 41 (1.4) 12 (0.6) 0.013
All MACE 142 (4.8) 55 (2.9) 0.001
TIMI-major bleeding 12 (0.6) 3 (0.2) 0.023
At 1 month
Total death 106 (3.7) 50 (2.7) 0.046
Reinfarction 25 (0.9) 10 (0.5) 0.175
Revascularization 71 (2.5) 26 (1.4) 0.008
All MACE 202 (7.1) 86 (4.6) 0.001
At 8 months
Total death 124 (4.3) 65 (3.5) 0.147
Reinfarction 34 (1.2) 13 (0.7) 0.097
Revascularization 150 (5.2) 75 (4.0) 0.055
All MACE 308 (10.7) 153 (8.2) 0.004
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Penicillin
Sulfa drugs
Ezetimide
Nitrofurantoin
Any drug
3 (12%)
3 (12%)
1 (4%)
1 (4%)
5 (20%)
Concurrent medications
Beta blockers
ACE inhibitors
Aspirin
Calcium channel blockers
17 (68%)
12 (48%)
25 (100%)
4 (16%)
Clopidogrel loading
300 mg
600 mg
None
8 (32%)
7 (28%)
10 (40%)
Stented vessel 
LAD
RCA
Cx
SVG
13 (52%)
5 (20%)
6 (24%)
1 (5%)
Drug eluting stent use 16 (64%)
Hypersensitivity manifestation
Time to 1st symptom, days
Pruritic erythematous rash
Rash Distribution
Face
Neck
Trunk
Limbs
Shortness of breath
Swelling of face or lips
Fever
4±2
25 (100%)
3 (12%)
8 (32%)
25 (100%)
18 (72%)
1 (4%)
2 (8%)
2 (8%)
Complete resolution of symptoms, days 5±2
All values are reported as n (%) or (mean ± SD)
9:30 a.m.
2515-752 Clopidogrel-Induced Antiplatelet Effect Assessment 
by Flow Cytometry and Point-of-Care Based Assays: 
Correlation between VASP and VerifyNow P2Y12 Testing
Piera Capranzano, Jose Luis Ferreiro, Sabrina Sumner, Bhaloo Desai, Ronald K. 
Charlton, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass, Dominick J. Angiolillo, 
University of Florida College of Medicine-Jacksonville, Jacksonville, FL
Background: Flow cytometric assessment of VASP is the most speciﬁc assay to assess 
P2Y12 receptor blockade in clopidogrel treated patients. Nevertheless, VASP analysis 
is time consuming, requires experienced personnel and it is not broadly available. The 
VerifyNow P2Y12 assay is a point-of-care which, similarly to the VASP assay, speciﬁcally 
assesses P2Y12 signaling, by using PGE1 in addition to ADP. However, how these assays 
correlate is unknown.
Methods: Platelet function (n=115) was measured using the VASP and VerifyNow P2Y12
assays according to standard protocols in patients on 75mg/day clopidogrel therapy. 
VASP measurements were used to deﬁne the P2Y12 reactivity index (PRI). The VerifyNow 
P2Y12 results are reported as P2Y12 reaction units (PRU) and percentage inhibition 
(%IPA). Correlation analyses were performed between results obtained with the VASP 
and VerifyNow P2Y12 assays.
Results: Using VASP analysis, the PRI was 54±23. Using the VerifyNow P2Y12 assay, 
PRU and %IPA values were 172±85 and 40±26, respectively. The correlation coefﬁcient 
between PRI and PRU was 0.76 and between PRI and %IPA -0.81 (both p<0.0001). The 
correlation was less strong at higher levels of inhibition (Figure). 
There was a high degree of concordance between these assays in identifying suboptimal 
clopidogrel responders, deﬁned as %IPA<50% and PRI > 50% (kappa 0.83).
Conclusions: A good correlation exists between the VASP and VerifyNow P2Y12 assays 
used to assess clopidogrel-induced antiplatelet effects.
9:30 a.m.
2515-750 Evaluation of a Modiﬁed Light Transmittance 
Aggregometry Protocol to Assess P2Y12 Blockade 
Induced by Clopidogrel
Piera Capranzano, Jose Luis Ferreiro, Sabrina Sumner, Bhaloo Desai, Ronald K. 
Charlton, Lyndon Box, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass, Dominick J. 
Angiolillo, University of Florida College of Medicine-Jacksonville, Jacksonville, FL
Background: Although light transmittance aggregometry (LTA) with ADP stimuli is the 
gold standard to assess clopidogrel effects, this reﬂects both ADP (P2Y1 and P2Y12)
receptors. The P2Y12 reactivity index (PRI) determined by ﬂow cytometric analysis of 
intraplatelet VASP speciﬁcally assesses P2Y12 signaling by using PGE1, which eliminates 
P2Y1 effect, in addition to ADP. The aim of the study was to assess how PRI correlates 
with LTA performed with and without PGE1.
Methods: Blood samples were collected from patients on chronic 75mg/day clopidogrel 
therapy (n=114). PRI was assessed using a commercially available kit. Maximal platelet 
aggregation by LTA was performed with 20 and 5 μmol/L ADP stimuli (“standard”) and was 
repeated in the presence of 5nM PGE1 (“modiﬁed”).
Results: The PRI was 53±24%. Using the standard protocol, 20 and 5 μmol/L ADP-
induced LTA values were 48±16% and 34±14%, and using the modiﬁed protocol, were 
37±20% and 23±16%, respectively. The correlation coefﬁcients between PRI and 20 
μmol/L ADP-induced LTA were 0.76 and 0.82 using the standard and modiﬁed protocols, 
respectively (both p<0.0001; Figure). Improved correlations were also observed with the 
modiﬁed (r=0.72) compared to the standard (r=0.66) protocol with 5 μmol/L ADP. 
Conclusions: Clopidogrel-induced antiplatelet effects assessed by LTA with ADP stimuli 
correlate well with PRI. A modiﬁed protocol in which PGE1 is added to ADP makes the 
assessment more P2Y12 speciﬁc, improving the correlation between assays.
9:30 a.m.
2515-751 Characterization of Clopidogrel Hypersensitivity 
Reactions and Response to Oral Steroids Without 
Clopidogrel Discontinuation
Asim N. Cheema, Atif Mohammad, St. Michael’s Hospital, Toronto, ON, Canada
Background: Hypersensitivity reactions to Clopidogrel (CS) after coronary stenting 
are poorly characterized and present difﬁculty in management. Current treatment 
options include switching to Ticlopidine or Clopidogrel desensitization. In this report, we 
characterize CS and describe our experience with management of these patients using 
oral steroids.
Methods: Since July 2006, all patients with CS after stenting were referred to a Clopidogrel 
allergy clinic for desensitization or initiation and follow up of Ticlopidine therapy. From 
February 2007, all new patients referred received oral steroids after initial evaluation with 
close follow for CS.
Results: From February 2007 to August 2008, a total of 25 patients with CS were seen 
in clinic and completed a 2 week tapering course of prednisone starting at 30 mg BID 
X 5 days. Clinical characteristics are summarized in table. Complete resolution of CS 
was observed in all patients with no recurrence. 2 patients (4%) had normal platelet 
aggregation in response to ADP and were treated with higher dosage of Clopidogrel. Re 
exposure to Clopidogrel produced a recurrence of CS in 3 patients.
Conclusion: CS is characterized by a pruritic erythematous rash on day 3 to 5 in most 
patients. The cutaneous manifestation is not associated with Clopidogrel resistance as 
determined by platelet aggregation assays and can be successfully treated with short 
term course of oral steroids with concurrent Clopidogrel administration.
Baseline Characteristics
Age
Male
BMI
63±10
18 (72%)
27±4
Cardiac risk factors
Diabetes
Hypertension
Dyslipidemia
Prior infarction
11 (44%)
20 (80%)
21 (84%)
8 (32%)
Immunological history 
Asthma
Seasonal allergies
Other environmental agent
0
4 (16%)
5 (20%)
Family history
Drug Allergy
Seasonal Allergy
2 (8%)
4 (16%)
Prior drug reactions
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9:30 a.m.
2515-755 Monitoring of Enoxaparin Anticoagulation Immediately 
Before Catheterization Using a New Point-of-Care test
Johanne SILVAIN, Farzin Beygui, Dominique Costagliola, Ana Pena, Guillaume 
CAYLA, Olivier Barthelemy, Jean-Philippe Collet, Gilles Montalescot, INSTITUT 
DE CARDIOLOGIE - Univ Paris 06 - INSERM U856, PARIS, France, APHP - Pitie-
Salpetriere
Background: : Inadequate anti coagulation in patients undergoing percutaneous 
coronary Intervention (PCI) is associated with the occurrence of ischemic events.
Methods: We sought to assess a new point-of-care test -HEMONOX- in monitoring 
enoxaparin anticoagulation in 296 unselected patients undergoing PCI. Chromogenic 
anti-Xa (AXA), Hemonox Clotting Time (HCT) and activated Partial Prothrombin Time 
(aPTT) were assessed at baseline (T1) and 10’ after IV administration (T2) in patients 
receiving additional enoxaparin.
Results : The patients characteristics were: age:61±14 y/o; male: 75.7%, ACS: 41.3%, BMI 
>30:16.5%; creat cl <60ml/min: 25.2%. The Median (IQR) values were 0.16 (0.17) and 0.89 
(0.28) IU/mL for AXA; 74 (11) and 155 (153) sec for HCT, and 46 (11) and 101 (92) sec 
for aPTT at T1 and T2 time points respectively. HCT strongly correlated with Anti-Xa level 
rho=0.78 (95% CI 0.75-0.82, p<0.0001). When comparing a total of 486 values to discriminate 
patients with AXA >0,5 IU/mL, the area under the receiver operating curve (AUC) (ﬁgure) for 
HCT was 0,95 ± 0,01 (95% IC; 0,93-0,97; p<0,0001) versus 0.89 ± 0,01 (95% IC; 0.86-0.92; 
p<0.0001) for aPTT. The HCT threshold of 80 seconds identiﬁed adequate anticoagulation 
(AXA >0.5 IU/mL) with a 98% sensitivity, 74% speciﬁcity and a likelihood ratio = 3.87.
Conclusion: Hemonox is a reliable point-of care test for monitoring the anticoagulation 
levels of enoxaparin with a high sensitivity to identify adequately anticoagulated patients 
undergoing PCI. 
9:30 a.m.
2515-756 High Doses of Atorvastatin Before PCI in Patient With 
and Without Chronic Statin Therapy
Auguadro Carla, Angeletti Chiara, Manfredi Mariella, Scalise Filippo, Specchia 
Giuseppe, Dept of Cardiology, Policlinico of Monza, Monza, Italy
Background: previous studies documented a beneﬁcial effect of chronic statins’therapy 
on the incidence of periprocedural myocardial injury in patients (pts) undergoing 
percutaneous coronary interventions (PCI). The ﬁrst objective of this study was to verify 
in pts who were not on statins whether high doses of atorvastatin 12 hours before PCI 
reduces the occurrence and the extent of periprocedural myocardial damage. The second 
objective was to assess in pts who were on chronic statin therapy whether the addition of 
high doses of atorvastatin before PCI can potentiate the beneﬁcial effect of these drugs. 
Methods: statins’ pre-treatment was performed with atorvastatin 80mg administered 12 
hours before and 40mg 2 hours before the procedure. In all pts troponin I and CK-MB 
were evaluated in basal condition and 6-12-18-24 hours after PCI. Troponin I levels q 1.0 
ng/ml were considered indicative of post-procedural myocardial injury.
Results: The study population included 282 consecutive pts (215 males, mean age 
65.4±11.4 years) who underwent PCI. 71 pts (G1) received high doses of atorvastatin 
before PCI whereas 211 (G2) did not received atorvastatin. The incidence of TnI > 1.0 
and CK-MB were signiﬁcantly lower in pts who received high doses of atorvastatin (TnI 
13% in G1 and 42% in G2, p=0.008; CK-MB 13% in G1 vs 43% in G2, p=0.009). Also 
the mean peak TnI and CK-MB values were signiﬁcantly lower in G1 pts (TnI: 1.6±6.4 in 
G1 vs 4.8±11 in G2, p=0.02; CK-MB 25.2±39 in G1 vs 54.6±112 in G2, p=0.03). In the 
subogroup of pts who were on chronic statin therapy the addition of atorvastatin before 
PCI did not result in further reduction of TnI and CK-MB elevation.
Conclusions: This study documents that a pre-treatment with high doses of atorvastatin 
12 hours before PCI signiﬁcantly reduce the incidence of periprocedural myocardial 
damage at the time of PCI. On the other hand, the addition of high dose of atorvastatin in 
pts almost on chronic statin therapy did not potentiate the beneﬁcial effects of statins.
9:30 a.m.
2515-757 Platelet Disaggregation: a Novel Parameter of 
Clopidogrel Responsiveness?
Dominick J. Angiolillo, Esther Bernardo, Piera Capranzano, Manel Sabate, Jose Luis 
Ferreiro, Fernando Alfonso, Pilar Jimenez-Quevedo, Rosana Hernandez, Luis A. 
Guzman, Carlos Macaya, Antonio Fernandez-Ortiz, Theodore A. Bass, University 
of Florida College of Medicine-Jacksonville, Jacksonville, FL, San Carlos University 
Hospital, Madrid, Spain
Background: Light transmittance aggregomtery (LTA) using ADP stimuli is the gold 
standard to test for clopidogrel response. However, “maximum” or “late” aggregation values 
have been arbitrarily considered in LTA studies. The aim of this study was to evaluate 
9:30 a.m.
2515-753 Does Transfusion for Major Bleeding After 
Percutaneous Coronary Intervention Impact Clinical 
Outcome in Patients Admitted With Normal Hematocrit?
Gabriel Maluenda, Gilles Lemesle, Asmir Syed, Sara D. Collins, Itsik Ben-Dor, Yanlin 
Li, Rebecca Torguson, Kimberly Kaneshige, Zehnyi Xue, William O. Suddath, Lowell 
F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Transfusion post percutaneous coronary intervention (PCI) has been 
associated with increased mortality and morbidity. Patients (pts) with pre PCI anemia 
are at higher risk for bleeding and transfusion post PCI which can result in an increase 
risk in adverse events. The present study aimed to assess the effect of red blood cell 
(RBC) transfusion post PCI on the incidence of adverse outcomes in a relatively healthy 
population with normal Hematocrit (Hct).
Methods: The records of 3738 pts with normal Hct (> 39% for men, > 36% for women) 
who underwent PCI were reviewed. Pts with cardiogenic shock were excluded. The one-
year clinical outcomes were recorded and compared between pts who did or did not 
receive RBC transfusion.
Results: The 61 (1.6%) pts who required transfusion were older, more female, and had 
more renal failure and prior congestive heart failure. They had more frequently presented 
with acute MI and required intra-aortic balloon pump. Univariate analysis suggested that RBC 
transfusion was linked with death and MI (16.4% vs 3.7%, p<0.001), but after multivariate Cox 
adjustment, RBC transfusion did not persist as an independent predictor (p=0.1) [Table].
Conclusion: In pts with normal Hct, transfusion does not independently predict worse 
1-year outcome. Although in an unselected population RBC transfusion is associated 
with worse outcomes, it is likely that the association with bleeding complications and co-
morbid conditions are accounts for this complications and not the transfusion.
Clinical predictors for death and myocardial infarction at 1-year 
follow up
Univariate Cox Proportional 
Model Multivariate Cox Proportional 
HR 95 % CI p HR 95 % CI p
Age 1.05 1.0-1.1 < 0.001 1.03 1.02-1.05 < 0.001
Male 0.52 0.4-07 < 0.001 0.73 0.50-1.07 0.1
Diabetes Mellitus 2.52 1.8-3.4 < 0.001 2.03 1.39-2.97 < 0.001
Chronic renal failure 4.96 3.2-6.7 < 0.001 2.43 1.56-3.79 < 0.001
Congestive heart failure 4.4 3.1-6.3 < 0.001 2.74 1.80-4.17 < 0.001
IABP use 4.62 2.3-8.4 < 0.001 1.93 0.79-4.71 0.1
Transfusion 5.21 2.7-9.7 < 0.001 1.93 0.81-4.17 0.1
9:30 a.m.
2515-754 Efﬁcacy of Triple Anti-platelet Therapy for Patients with 
Acute Myocardial Infarction Undergoing Drug-eluting 
Stent Implantation
Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko, Shin Eun Lee, Won 
Yu Kang, Soo Hyun Kim, Doo Sun Sim, Nam Sik Yoon, Hyun Ju Youn, Young Joon 
Hong, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun 
Park, Jung Chaee Kang, The Heart Center of Chonnam National University Hospital, 
Gwangju, South Korea, Cardiovascular Research Institute of Chonnam National 
University, Gwangju, South Korea
Background: It has been known that triple anti-platelet therapy prevents restenosis after 
drug-eluting stent (DES) implantation. However, there are few available data on efﬁcacy 
of triple anti-platelet therapy for acute myocardial infarction (AMI).
Methods: We analyzed 784 consecutive patients with AMI undergoing DES implantation 
between Nov 2005 and Feb 2007. We compared clinical outcomes between triple anti-
platelet therapy (group I, n=672: cilostazol adding to aspirin and clopidogrel at least one 
month) and dual anti-platelet therapy (group II, n=112: aspirin and clopidogrel).
Results: Mean ages were higher (62.1±11.86 vs. 59.3±11.61 years, p=0.02) and ST 
elevation MI (STEMI) and TMII ﬂow 0 were more common (69.0% vs. 58.0%, p=0.02; 
42.7% vs. 30.4%, p=0.014) in group I. Group I had lower incidences of 6-month target 
lesion revascularization (TLR) and major adverse cardiac and cerebro-vascular 
events (MACCE) than those of group II (9.0% vs. 18.3% and 12.0% vs. 21.1%, p=0.01 
respectively). In subgroup analysis, lower incidence of 6-month TLR in patients with ACC/
AHA B2 or C lesions and with non-STEMI (9.7% vs. 20.3% and 8.4% vs. 19.1%, p<0.05 
respectively) were observed in group I than in group II. The rate of bleeding complications 
was not different between the two groups. In multivariate analysis, Killip III or IV and triple 
anti-platelet therapy were the independent predictors of 6-month MACCE (HR=2.805; 
95% CI=1.464-5.375, HR=0.497; 95% CI=0.280-0.882).
Conclusions: Triple anti-platelet therapy is safe and efﬁcacious, and prevents MACCE in 
patients with AMI, especially in patients with complex lesions and non-STEMI.
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optimally predict subsequent events. The following predictors were tested by univariate 
analysis (UA): age > 75, gender, ethnicity, body mass index > 30, DM, previous myocardial 
infarction, stroke, peripheral vascular disease, hypertension, hypercholesterolemia, renal 
function, smoking, Canadian Cardiovascular Society (CCS) class, LDL, HDL, triglycerides, 
and use of statins, beta-blockers (BBs), calcium channel blockers (CCBs), ACE inhibitors, 
ARBs, nitrates, or hormone replacement therapy (HRT). Multivariate analysis (MVA) was 
performed using forward stepwise logistical regression with candidate predictors having 
a p value of < 0.15 on UA.
Results: A total of 377 patients were studied. The average age was 66.8 + 10.6 years, 79% 
were male, and 34% had diabetes mellitus (DM). The univariate predictors of HPR entered 
into the MVA were ethnicity (univariate p=0.027), gender (p=0.034), renal dysfunction 
(p=0.041), HRT use (p=0.066). CCS class (p=0.076), BB use (p=0.078), smoking (p=0.11), 
and DM (p=0.11). Independent predictors of HPR were non-Caucasian ethnicity (odds ratio 
[OR] 2.6, 95% conﬁdence interval [CI] 1.3-5.4, p=0.007), female gender (OR 1.8 [95% CI 
1.8- 3.0], p=0.028), and smoking (OR 0.35 [95%CI 0.13-0.96], p=0.04).
Conclusions: In patients on maintenance CLOP, the only independent predictors of HPR 
were ethnicity, gender, and smoking status. Our ﬁndings are consistent with previous 
studies demonstrating a protective effect of smoking on platelet reactivity. We did not 
observe a relationship between HPR and concomitant medications, including CCBs. 
The independent contribution of ethnicity and gender to HPR suggest that HPR is driven 
primarily by genetic mechanisms in non-smokers.
I2.POSTER CONTRIBUTIONS
2516
Experimental Models
Monday, March 30, 2009, 9:30 a.m.-10:30 a.m.
Orange County Convention Center, West Hall D
9:30 a.m.
2516-760 Decrease Of Neointimal Proliferation After Implantation 
of Activated Protein C (Xigris)-Coated Stent In Porcine 
Coronary Arteries
Mariann Gyongyosi, Noemi Nyolczas, Aniko Posa, Zsolt Petrasi, Örs Petnehazy, Dietmar 
Glogar, Medical University of Vienna, Vienna, Austria, University of Kaposvar, Kaposvar, 
Hungary
Background: Activated protein C (APC) an endogenous protein that inhibits inﬂammation 
and thrombosis, promotes ﬁbrinolysis and interrupts coagulation cascade. The aim of our 
study was to investigate the degree of neoinimal hyperplasia after stent implantation in 
pig coronary arteries after implantation of APC-coated stents
Methods: Ten domestic pigs underwent general anaesthesia and coronary angiography 
after loading dose of aspirin (100 mg) and clopidogrel (300 mg) and intravenous heparin. 
Five mg human recombinant APC (Drotrecogin alfa, Xigris, Eli Lilly) was prepared for 70% 
alcohol solution, followed by direct (non-polymeric) coating of 10 Yucon Pearl stents using 
the Translumina stent coating machine (T-SCM 2003) (2.6 ug/mm2 stent surface). The 
APC-coated and bare Yucon stents (BMS) were randomly implanted in the left anterior 
descending and circumﬂex arteries. During the 4-weeks follow-up (FUP), the animals 
were treated daily with dual antiplatelet therapy. After 1-month FUP, the development of 
neointimal hyperplasia was evaluated by angiography and histomorphometry. Coronary 
arteries were stained with mouse anti-human P-selectin antibody with a known cross-
reaction with porcine to identifying activated endothelial cells at the injury site.
Results: There was no procedural complication or allergic reaction. Fibrin deposition 
and adventitial inﬂammation were signiﬁcantly decreased in pigs with APC-coated stents 
as compared with BMS. Endothelialization was complete in both groups. At the FUP, 
signiﬁcantly smaller neointimal area (0.98±0.92 vs 1.44±0.91 mm2, p=0.028) with higher 
lumen area (3.47±0.94 vs 3.06±0.91 mm2, p=0.046) and less %AS (22.2±21.2% vs 
32.1±20.1%, p=0.034) was measured in APC-coated stents as compared with the BMS. 
P-selectin immunostaining revealed signiﬁcantly less prevalence of activated endothelial 
cells in the neointima in the APC-group (4.6±1.9 vs 11.6±4.1/0.28 mm2, p<0.001).
Conclusions: Coating of stent with hrAPC (non-toxic, non-cytostatic drug) reduces 
thrombo-inﬂammatory responses, neointimal proliferation, and in-stent restenosis and 
offers a promising therapy to improve clinical outcomes of coronary stenting.
9:30 a.m.
2516-761 Long-Term Biocompatibility of the Abluminally Coated 
Biolimus A9 Eluting Self Expandable Stent in a Porcine 
Coronary Artery Model
Greg L. Kaluza, Gerard B. Conditt, Armando Tellez, Krzysztof Milewski, Akira Murata, 
Shigenobu Inami, David Wallace-Bradley, Kai Xu, Geng-Hua Yi, Jennifer C. McGregor, 
Brett Trauthen, Frank D. Kolodgie, Renu Virmani, Juan F. Granada, Skirball Center for 
Cardiovascular Research, Cardiovascular Research Foundation, New York, NY, CVPath 
Institute, Inc., Gaithersburg, MD
Background: The AXXESS stent is a novel self-expandable device speciﬁcally designed 
for bifurcation stenting. It is coated with a permanent primer layer consisting of parylene, 
and a bioabsorbable abluminal layer of polylactic acid and Biolimus A9 (~22 μg/mm of 
stent length). In this study, we aimed to determine the safety and vascular biocompatibility 
of the AXXESS Biolimus A9 (AxBA9) self-expandable nitinol stent in comparison to 
Cypher stent out to 180 days in the porcine coronary model.
Methods: A total of 147 coronary arteries in 56 animals were randomized to receive AxBA9, 
Axxess-BMS (AxBMS), Axxess-Parylene (AxP) and Cypher stents (SES). Ten animals were 
platelet disaggregation as a parameter to assess clopidogrel-induced antiplatelet effects.
Methods: LTA was performed using 20 μM/L ADP stimuli in 250 patients on clopidogrel 
75mg/day therapy. Aggregation was measured at peak (Agg
max
) and at 5 min (Agglate). 
Percentage of platelet disaggregation considers both Agg
max
 and Agglate and was deﬁned 
as: 100 x (1 - Agglate/Aggmax). Patients were divided into quartiles of Aggmax to assess 
proﬁles of platelet disaggregation
Results: In the overall population Agg
max
 and Agglate were 51±15% and 42±19%, 
respectively. Agg
max
 quartile distribution (Q) was: Q1: <43% (n=61); Q2: 43-52% (n=63); 
Q3: 52-62% (n=65); Q4: >62% (n=62). The absolute change in platelet aggregation values 
between Agg
max
 and Agglate progressively reduced from the lowest to upper quartile (Q1: 
32±6% vs 21±12%; Q2: 46±2% vs 33±12%; Q3: 56±3% vs 47±8%; Q4: 70±7% vs 
65±9%), indicative of reduced P2Y12 inhibition. In accordance, platelet disaggregation 
was 22±24% in the overall population which reduced from the lowest to upper quartile 
(p<0.0001; Figure). 
Conclusions: Platelet disaggregation is a novel parameter of clopidogrel response 
which, by combining maximal and late aggregation values, may represent a more 
objective determination.
9:30 a.m.
2515-758 Dual Low Response to Acetylsalicylic Acid and 
Clopidogrel Is Associated With PCI-Related Myocardial 
Infarction and Ischemic Events Following Coronary 
Stenting
Parham Eshtehardi, Stephan Windecker, Marcel Zwahlen, Stephane Cook, Michael 
Billinger, Mario Togni, Rolf Vogel, Ali Garachemani, Christian Seiler, Bernhard Meier, 
Otto M. Hess, Peter Wenaweser, Cardiology, Bern University Hospital, Bern, Switzerland
Background: An impaired response to antiplatelet therapy with acetylsalicylic acid (ASA) 
and clopidogrel (CLO) has been associated with adverse cardiovascular events following 
coronary stenting. We investigated whether patients with a low response to ASA (ASA-
LR) or CLO (CLO-LR) are at risk for peri-interventional myocardial infarction (MI) or 
ischemic events during follow-up.
Methods: A total of 219 consecutive patients with stable coronary artery disease or acute 
coronary syndrome excluding ST-elevation myocardial infarction undergoing coronary 
stenting and pre-treated with ASA and CLO but not a glycoprotein IIb/IIIa inhibitor were 
prospectively included. Whole blood impedance platelet aggregometry was performed 
with the Multiplate analyzer to test for platelet aggregation in response to ASA (ASPI-test) 
and CLO (ADP-test) within 12-18 hours following PCI. Patients within the upper quartile 
of the ASPI-test area under the curve (AUC) and ADP-test AUC were deﬁned as ASA-LR 
and CLO-LR, respectively.
Results: Dual ASA-LR and CLO-LR was present in 19 patients (8.6%). PCI-related 
MI, and 30-day cardiac death and MI were more frequent in dual ASA-LR and CLO-LR 
than the other patients (table). In multivariate analysis dual ASA-LR and CLO-LR was 
independently associated with 30-day composite of events (OR 10.08; 95% CI 3.07 to 
38.52, p<0.001).
Conclusion: Dual ASA-LR and CLO-LR is associated with an increase of PCI-related MI 
and the risk for 30-day ischemic events following coronary stenting.
Clinical events during 30-day follow-up.
Total 
population
Dual ASA-LR and 
CLO-LR vs. Controls P value
Number of Patients, n 219 19 vs. 200
PCI-related MI, n (%) 19 (8.7) 5 (26.3) vs. 14 (7.0) 0.004
30-day cardiac death and MI, n (%) 3 (1.4) 2 (10.5) vs.1 (0.5) <0.001
Composite of PCI-related MI and 30-
day cardiac death and MI, n (%) 21 (9.6) 7 (36.8) vs. 14 (7.0) <0.001
9:30 a.m.
2515-759 High Platelet Reactivity On Clopidogrel Is Driven 
Primarily By Non-Modiﬁable Risk Factors
Matthew J. Price, Sarah Endemann, David E. Kandzari, Paul S. Teirstein, Scripps Clinic, 
La Jolla, CA
Background: High platelet reactivity (HPR) on clopidogrel (CLOP) has been associated 
with worse outcomes after percutaneous coronary intervention (PCI). The independent 
contribution of patient characteristics to HPR has not been well examined.
Methods: Patients on maintenance CLOP presenting for elective PCI were enrolled 
prospectively. Platelet reactivity was measured prior to PCI with the VerifyNow P2Y12 
assay. HPR was deﬁned as P2Y12 reaction units > 240, a level previously shown to 
A74  ABSTRACTS - Angiography and Interventional Cardiology (i2 Summit) JACC March 10, 2009
A
ng
io
gr
ap
hy
 a
nd
 I
nt
er
ve
nt
io
na
l C
ar
di
ol
og
y 
(i2
 S
um
m
it)
and in Cypher stents used in distal vessels and/or side branches.
Conclusion: The sheep model allows for adequate simulation of complex stenting 
techniques commonly used clinically in bifurcation setting. AXXESS Biolimus A9 self-
expanding nitinol bifurcation stent overlapped distally with Cypher shows superior 
structural integrity (no fractures) and favorable outcome in comparison to provisional 
T-stenting with Cypher stents out to 180 days in this model. As such, AXXESS stent 
seems an attractive, more anatomically compatible alternative to currently used stenting 
techniques with overlapping conventional stents.
I2.SYMPOSIUM
2624
i2.Complex Patients I: Diabetes, Renal 
Failure, Elderly, CHF
Monday, March 30, 2009, 10:30 a.m.-Noon
Orange County Convention Center, Room W415D
11:30 a.m.
2624-7 Signiﬁcantly Improved Vascular Complication Rates 
Among Women Undergoing PCI: Results From the 
Northern New England PCI Registry
Bina Ahmed, Winthrop D. Piper, David Malenka, Peter VerLee, John Robb, Merle Kellet, 
Michael Hearne, Harold L. Dauerman, University of Vermont, Burlington, VT
Background: Female sex is associated with a higher risk for vascular complications (VC) 
and though the overall incidence of PCI related VC has declined, the impact of this decline 
speciﬁcally in women is unknown. Methods: We studied 13,653 female and 32,334 male 
consecutive cases, from 2002 to 2007, in the Northern New England (NNE) PCI Registry. 
Using multivariate regression, we compared absolute and adjusted rates of VC for women 
versus men over time and report clinical and procedural predictors of VC. VC was deﬁned 
as any access site vessel injury requiring surgical intervention and/or any vascular site 
related bleeding requiring transfusion. Results: The overall risk of a VC was signiﬁcantly 
higher in women versus men (4.5% ± 1.3 vs. 1.6% ± 0.5; p<0.004). Over time there 
was a signiﬁcant (p trend < 0.001) 50% relative decrease in absolute VC rates in both 
women and men (see Figure). After adjustment for differences in baseline characteristics 
between men and women, women remained at a signiﬁcant increased risk in 2007 (OR 
2.6; CI 1.74-3.91). Predictors of increased risk of VC in women included older age, shock, 
renal failure, and larger sheath sizes while the use of routine ﬂuoroscopy in obtaining 
vascular access and of closure devices were protective. Conclusion: Both women and 
men have had a signiﬁcant 50% decline in VC rates over the last 6 years, though women 
remain at a two fold higher risk of VC. Use of routine ﬂuoroscopy and closure devices are 
modiﬁable variables that are protective for both men and women. 
I2.ORAL CONTRIBUTIONS
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2907-5 Impact of Chronic Kidney Disease on One-Year 
Outcomes of Patients With Acute Myocardial Infarction 
Undergoing Primary Angioplasty: Results From the 
HORIZONS AMI Trial
Roxana Mehran, Eugenia Nikolsky, Alexandra Lansky, Bernard Witzenbichler, Giulio 
Guagliumi, Victor Guetta, Harry Suryapranata, Kurt Huber, Jochen Wöehrle, Chris Metzger, 
George D. Dangas, Iulian Benetato Giuran, Helen Parise, Gregg W. Stone, Columbia 
University Medical Center and the Cardiovascular Research Foundation, New York, NY
Background. In HORIZONS-AMI trial, bivalirudin monotherapy (Biv) vs. unfractionated 
heparin (UFH) + GP IIb/IIIa inhibitors (GPI) resulted in reduced rates of major bleeding 
and cardiac death, with comparable rates of composite major adverse cardiovascular 
terminated at 7 days, 15 at 30 days and 16 at 90 days (including 3 for SEM).
Results: At 7 days, SES and AxBA9 featured less endothelial coverage than AxBMS and 
AxP, but all stents were >75% covered, however, SES had signiﬁcantly more uncovered 
struts than any Ax. At 30 days, the neointimal thickness was the lowest in AxBA9. The 
inﬂammation was minimal and the endothelialization nearly complete in all groups. 
Predictably, AxBA9 and SES had more residual ﬁbrin that the other 2 Ax stents. At 90 and 
180 days, the differences between SES and Ax stents were more evident. SES featured 
more luminal obstruction both angiographically (180-day % Diameter Stenosis 4±3% in 
AxBA9, 3±6% in AxBMS, 6±14% in AxP and 24±21% in the SES) and histologically 
(180-day neointimal thickness was the highest in SES (0.38±0.23), closely followed 
by AxP (0.22±0.19), AxBA9 (0.10±0.06) and AxBMS 0.10±0.04 (p=0.001)). This was 
predominatly due to higher prevalence of inﬂammation and granulomas in SES than in 
any Ax stent type,a difference even more pronounced at 180 days. Also, percentage of 
struts with residual ﬁbrin at 90 days was higher in the SES (32.18±5.80%) compared 
to any of the Axxess stent groups (AxBA9= 7.44±9.45%, AxBMS= 0.77±1.85, AxP= 
0.83±2.19, p=0.001); it normalized at 180 days.
Conclusion: In a porcine coronary model up to 180 days, the AXXESS Biolimus A9 
self-expanding nitinol stent demonstrated at least comparable safety and efﬁcacy as the 
benchmark Cypher stent.
9:30 a.m.
2516-762 Vascular Safety of Overlapping Sirolimus-Eluting 
Reservoir Technology Stents in the Porcine Coronary 
Artery Model
G. Sylvester Price, Jean-Martin Lapointe, Andrew Luk, Louis-George Guy, Gary Steese-
Bradley, John Dooley, Campbell Rogers, Cordis Corporation, Warren, NJ, AccelLAB, Inc, 
Boisbriand, QC, Canada
Background: The Conor reservoir technology drug delivery stent platform uses 
biocompatible bioresorbable polymers programmed to erode safely within 90-120 days 
of stenting. Sirolimus has been incorporated into a poly-(lactic-co-glycolic) acid (PLGA) 
polymer matrix similar to that used in previous Conor stents. The sirolimus dose and in 
vivo release kinetics of NEVO™ prototype sirolimus-eluting stents (NEVO™; Menlo Park, 
CA) were tailored to be similar to CYPHER® stents (Cordis Corporation, Warren, NJ). 
Vascular healing of single NEVO™ prototype stents has been reported previously.
Methods: Overlapping pairs of NEVO™ prototype, of bare metal Conor (BMS; empty 
reservoir stents) and of CYPHER® stents were implanted in porcine left anterior descending, 
left circumﬂex and/or right coronary arteries for 30, 90, or 180 days. Quantitative coronary 
angiography, histopathology and histomorphometry were evaluated.
Results: All stents were endothelialized at 30 days. Peri-strut inﬂammation score in 
overlapping NEVO™ stent regions was minimal, and signiﬁcantly lower than in BMS and 
CYPHER® controls at 30 days (NEVO™: 0.11 ± 0.06, CYPHER®: 1.14 ± 0.78, p < 0.05, 
BMS: 0.44 ± 0.13, p < 0.05). Inﬂammation remained minimal at 90 and 180 days; and 
did not differ between groups. There was no evidence of necrosis. As expected, peri-
strut ﬁbrin in overlapping NEVO™ stent regions was signiﬁcantly greater than BMS but 
did not differ from CYPHER® stents at 30 days, and decreased progressively at 90 and 
180 days. A similar pattern was observed in non-overlapping stented regions. Neointimal 
thickness in overlapping NEVO™ stent regions was signiﬁcantly lower than BMS at 30 
days (NEVO™: 0.28 ± 0.05 mm, CYPHER®: 0.41 ± 0.14 mm, BMS: 0.47 ± 0.12 mm, p 
< 0.05). At 90 and 180 days, there was no difference in neointimal thickness between 
stent groups.
Conclusions: NEVO™ prototype reservoir technology sirolimus delivery reduced intimal 
thickening and produced less inﬂammation than BMS, despite the presence at overlap 
sites of double sirolimus and bioresorbable polymer loads.
9:30 a.m.
2516-763 Biolimus A9 Eluting Self Expandable Designated 
Bifurcation Stent in a Sheep Coronary Bifurcation 
Model: Long-Term Comparison to Provisional 
T-Stenting with Cypher Stents
Greg L. Kaluza, Gerard B. Conditt, Armando Tellez, Krzysztof Milewski, Akira Murata, 
Shigenobu Inami, David Wallace-Bradley, Kai Xu, Geng-Hua Yi, Jennifer C. McGregor, 
Brett Trauthen, Frank D. Kolodgie, Renu Virmani, Juan F. Granada, Skirball Center for 
Cardiovascular Research, Cardiovascular Research Foundation, New York, NY, CVPath 
Institute, Inc., Gaithersburg, MD
Background: The AXXESS stent (AxBA9) is a novel self-expandable device aiming at 
a more anatomically correct reconstruction of the bifurcation than the current stenting 
techniques. It has a conical shape covering the entire proximal bifurcation area down to 
the carina, is coated with a bioresorbable abluminal top coat eluting Biolimus A9 (~22 μg/
mm of stent length), and can be complemented with conventional stents in distal parent 
vessel and in side branch.
Methods: This 4-tier study evaluated by angiography and histology the structural 
integrity (fractures) of and arterial response to AxBA9/Cypher bifurcation stenting 
complemented by side branch PTCA or T-stenting vs. conventional Cypher stenting of 
the parent vessel complemented by side branch PTCA or T-stenting. In 45 sheep, 15 and 
30 bifurcations were treated with one of these 4 options and followed up to 90 and 180 
days, respectively.
Results: Collectively, out to 180 days, bifurcations receiving AXXESS/Cypher in the 
parent vessel and side branch PTCA had 0/12 stent fractures, while Cypher with side 
branch PTCA had 4/13 stent fractures. In bifurcations receiving AXXESS/Cypher in the 
parent vessel and side branch Cypher, there were 6/11 stent fractures, involving distal 
or side branch Cyphers only. Whereas, Cypher T-stented with another Cypher had 8/9 
fractures. Fractures generally correlated with stenosis development and resulted in an 
increased incidence of side branch occlusions and aggravated stenosis in overlap areas 
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Results: SVG patients were older (71 vs 61 years), had more renal disease (13.9% vs 6.0%), 
more peripheral arterial disease (22.8% vs 5.6%), more cerebrovascular disease (13.9% vs 
6.1%), more diabetes (40.6% vs 25.5%) more previous MIs (54.2% vs 17.5%), more prior 
PCIs (37.6% vs 16.1%), more history of congestive heart failure (22.9% vs 7.5%), and lower 
mean % ejection fractions (44.3 vs 48.8) as compared with NCA interventions (pa0.01 for 
all). The NCA patients presented more often with ST segment elevation MIs (55% vs 32%, 
p < 0.001). Peri-procedural use of ASA, thienopyridines, and glycoprotein IIb/IIIa inhibitors 
was similar in both groups. Angiographic success rate and stent use were similar, though 
more SVG lesions were treated with direct stenting as compared with NCA lesions (48.6% 
vs 22.5%, p< 0.001). In-hospital death, MI, and CABG were similar in both groups. At one 
year, there was no signiﬁcant difference in repeat revascularization (hazard ratio [HR] = 
0.96, p=0.89) and survival (HR for death = 1.66, p = 0.10), but there was a higher risk of MI 
(10.9% vs 4.7%, HR = 2.24, p = 0.01) in patients who had a SVG intervention.
Conclusions: Patients presenting with acute MI having PCI of SVGs are a higher risk 
population than patients having PCI of NCAs. Despite unfavorable baseline characteristics, 
there was no signiﬁcant difference in in-hospital death or MI. At 1-year mortality is similar, 
but SVG PCI patients had two-fold higher risk for recurrent MI.
11:06 a.m.
2907-8 Abciximab in Patients With Acute Myocardial Infarction: 
One Year Outcomes in the BRAVE-3 Randomized Trial
K. Anette Birkmeier, Julinda Mehilli, Adnan Kastrati, Stefanie Schulz, Werner Moshage, 
Franz Dotzer, Jürgen Pache, Josef Dirschinger, Melchior Seyfarth, Albert Schömig, 
Deutsches Herzzentrum, Technische Universität, Munich, Germany, 1. Medizinische 
Klinik rechts der Isar, Munich, Germany
Background: In the Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Trial, 
abciximab given after loading with 600 mg clopidogrel in patients with ST-elevation 
myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention 
(PPCI) within 24 hours after onset of symptoms was not associated with reduction of 
infarct size and thrombotic complications at 30 days. Previous studies investigating 
abciximab additional to PPCI in the era of ticlopidin therapy, have shown up to 30% 
mortality reduction at one year with abciximab. If this is also the case when abciximab is 
given after loading with 600 mg of clopidogrel is still not kown.
Methods: In BRAVE-3 study, which was a randomized , double-blind, placebo-controlled-
trial, 800 patients with acute STEMI within 24 hours of symptoms onset, all treated with 600 
mg of clopidogrel were assigned to receive either abciximab (=401) or placebo (n=399) 
in the intensive care unit before sent to the catheterization laboratory (96,4% underwent 
PPCI). Aim of the present analysis is assessment of all-cause mortality, recurrent 
myocardial infarction, stroke and reinterventions at one year after randomization.
Results: Results will be available in February 2009 and presented at the meeting.
11:18 a.m.
2907-9 Results of a Randomized Double-Blind Bolus Dose-
Escalating Study Comparing Intracoronary to 
Intravenous Abciximab in Primary PCI : The EASY-MI 
Study.
Olivier F. Bertrand, Josep Rodes-Cabau, Eric Larose, Valérie Gaudreault, Rodrigo 
Bagour, Onil Gleeton, Can M. Nguyen, Guy Proulx, Gérald Barbeau, Bernard Noel, 
Louis Roy, Olivier Costerousse, Robert De Larochellière, Laval Hospital, Quebec Heart-
Lung Institute, Quebec, QC, Canada
Background: Platelet aggregation inhibition (PAI) q 95% has been associated with improved 
outcomes after PCI and GP IIb/IIIa inhibitors. Higher thrombotic burden in MI might require 
higher doses or intracoronary route of abciximab delivery to achieve optimal PAI. Whether 
these novel strategies would reduce myocardial necrosis is currently debated.
Objective: To compare Intracoronary (IC) to Intravenous (IV) routes of abciximab 
administration and to assess 2 bolus-doses : 0.30 mg/kg (bolus-only) vs 0.25 mg/kg bolus 
+ standard 12 h infusion in patients referred for primary-PCI within 6 h of symptoms.
Methods: Using Verify Now (Accumetrics), PAI was assessed at baseline and 10 minutes 
post-bolus. All lesions were treated with Cypher Select® + stents. Assessment of cardiac 
necrosis and microvascular obstruction was performed using magnetic resonance 
imaging (MRI) within 12 hours of the procedure and at 6 months. Quantitative coronary 
analysis was performed after the index procedure and at 6 months.
Results:
Population 
Characteristics
Abciximab bolus dose and route
P0.30 mg/kg ic
(n=25)
0.30 mg/kg iv
(n=25)
0.25 mg/kg ic
(n=28)
0.25 mg/kg iv
(n=27)
Age, yrs 59 ± 9 59 ± 11 59 ± 9 60 ± 7 0.99
Male 18 (72%) 19 (76%) 23 (82%) 24 (89%) 0.45
Symptoms-to-
balloon, min 169 ± 88 188 ± 73 183 ± 58 162 ± 72 0.53
Culprit RCA 15 (63%) 10 (43%) 10 (38%) 18 (67%) 0.37
LAD 7 (29%) 12 (52%) 13 (50%) 8 (30%)
CX 2 (8%) 1 (4%) 3 (12%) 1 (4%)
TIMI ﬂow (initial)
0-1 17 (77%) 17 (77%) 19 (73%) 21 (81%) 0.99
Aspiration catheter 7 (28%) 12 (48%) 10 (36%) 11 (41%) 0.67
Primary End-points:
Mean PAI 10 min, % 94.4 ± 6.1 94.0 ± 4.4 92.0 ± 8.1 94.0 ± 4.8 0.49
q 95% PAI 10 min 15 (60%) 13 (52%) 13 (46%) 15 (56%) 0.79
events (MACE), and enhanced freedom from net adverse clinical events (NACE; MACE 
or major bleeding) at 30 days and 1 year in pts with AMI undergoing primary PCI. Whether 
beneﬁcial effects of Biv are independent of renal function has not been reported.
Methods and Results. A total of 3602 pts at 123 centers with AMI undergoing primary PCI 
were randomized to Biv (n=1800) vs. UFH+GPI (n=1802). At 1 year in entire study population, 
Biv vs. UFH+GPI resulted in a 39% reduction in major bleeding (5.8% vs. 9.2%, P<0.0001), 
43% less cardiac mortality (2.1% vs 3.8%, p=0.005), similar MACE (11.9% vs 11.9%, P=1.0), 
and a 16% reduction in NACE (15.7% vs 18.3%, P=0.03). Outcomes were analyzed according 
to the presence of baseline chronic kidney disease (CKD; calculated creatinine clearance a60 
ml/min). Compared to pts with normal renal function, those with CKD (16% of pts) had greater 
rates (all P-values <0.0001) of major bleeding (16.2% vs 5.9%), MACE (20.8% vs 10.1%), 
cardiac mortality (8.6% vs. 1.8%), and NACE (30.3% vs 13.4%). No signiﬁcant interactions 
were present between renal status and randomization arm (Table).
Conclusions. Patients with CKD and AMI undergoing primary PCI have signiﬁcantly 
higher rates of major bleeding, cardiac mortality, and NACE at 1 year. 
Creatinine clearance >60 ml/min 
(n=2783)
Creatinine clearance a60 ml/min 
(n=554)
Biv mono UFH+GPI RR [95%CI] Biv
mono
UFH+GPI RR [95%CI]
Major
bleeding 4.3% 7.6%
0.50 [0.41, 
0.77] 11.8% 14.7%
0.80 [0.52, 
1.24]
MACE* 10.5% 9.8% 1.06 [0.84, 1.35] 12.6% 10.6%
1.19 [0.75, 
1.88]
NACE** 13.3% 15.4% 0.84 [0.69, 1.02] 21.0% 21.2%
0.99 [0.72, 
1.36]
Cardiac
Death 0.9% 2.6%
0.35 [0.19, 
0.67] 8.1% 9.0%
0.92 [0.51, 
1.63]
* MACE = death, reinfarction, ischemic TVR or stroke;
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
10:42 a.m.
2907-6 Impact on Long-Term Mortality of Mechanical 
Reperfusion in Patients With Acute Myocardial 
Infarction Presenting 12 to 48 Hours From Onset of 
Symptoms
Julinda Mehilli, Gjin Ndrepepa, Adnan Kastrati, David Antoniucci, Albert Schomig, 
Deutsches Herzzentrum, Munich, Germany, 1. Med. Klinik rechts der Isar, Munich, Germany
Background: One-third of patients with acute ST-segment elevation myocardial infarction 
(STEMI) do not receive early reperfusion therapy mostly due to presentation >12 hours 
from the symptom onset and current guidelines do not recommend primary percutaneous 
coronary intervention in such patients (pts). The Beyond 12 hours Reperfusion AlternatiVe 
Evaluation (BRAVE-2) Trial showed that invasive treatment is associated with substantial 
reduction in infarct size in pts with STEMI presenting >12 hours after symptom onset. 
No studies to date have investigated the long-term prognosis after PPCI in such pts. 
Methods: In BRAVE-2 trial 365 pts without persistent symptoms admitted with STEMI 
between 12 and 48 hours from symptom onset were randomly assigned to either an 
invasive treatment (PPCI) (n=182 pts) or a conservative treatment (n=183 pts). Primary 
outcome of the present analysis was 4-year mortality.
Results: At 4 years, signiﬁcantly fewer pts died in invasive than in conservative treatment 
group (Figure). No difference in Kaplan-Meier estimates of myocardial infarction was 
observed (6.8% and 5.6%, RR=1.20, 95% CI 0.52 to 2.78, P=.66). Revascularization of 
the infarct-related artery was performed in 25.8% of pts treated inavsively and 69.1% of 
pts treated conservatively.
Conclusions: Reduction of infarct size and long-term mortality support the use of PPCI 
in pts with STEMI presenting between 12 and 48 hours after onset of symptoms.
10:54 a.m.
2907-7 Presentation and Outcomes After Percutaneous 
Intervention for Acute Myocardial Infarction in the 
NLHBI Dynamic Registry: Saphenous Vein Grafts 
Versus Native Coronary Arteries
Sohah N. Iqbal, Faith Selzer, Srihari S. Naidu, Serge Doucet, David Faxon, Alice Jacobs, 
James Slater, New York Langone Medical Center, New York, NY, University of Pittsburgh 
Medical Center, Pittsburgh, PA
Background: Percutaneous coronary intervention (PCI) of saphenous vein graft (SVG) 
lesions has a higher incidence of adverse events as compared with native coronary artery 
(NCA) interventions. Only limited data have been reported comparing interventions after 
myocardial infarctions (MI) in patients with SVG disease versus NCA lesions.
Methods: Consecutive patients enrolled in 4 recruitment waves (1999 -2006) in the multi-
center prospective cohort study of the National Heart, Lung, and Blood Institute Dynamic 
Registry were studied. Baseline, angiographic and procedural data, in-hospital events, 
and 1-year outcomes of patients treated with PCI for acute MIs were compared based on 
whether the intervention was performed in a SVG (n = 101) or NCA (n = 2245).
A76  ABSTRACTS - Angiography and Interventional Cardiology (i2 Summit) JACC March 10, 2009
A
ng
io
gr
ap
hy
 a
nd
 I
nt
er
ve
nt
io
na
l C
ar
di
ol
og
y 
(i2
 S
um
m
it)
MACE (25.8 vs 25.7%, HR 1.02, 95% CI 0.71-1.49, p=0.90). After subsequent multivariable 
adjustment and/or Propensity-score adjustment, there were no signiﬁcant differences. 
Renal failure (HR 3.28, 95% CI 2.00-5.39, p<0.001) was strongest independent preditors 
of MACE. Besides, Left Ventricular Ejection Fraction(%) (HR 0.99, 95% CI 0.97-1.00, 
p=0.04), IVUS guidance (HR 0.63, 95% CI 0.43-0.91, p=0.01), Total stent length (mm) 
(HR 1.01, 95% CI 1.001-1.02, p=0.03) and Complex bifurcation stenting (q2 stents) 
(HR 1.54, 95% CI 1.02-2.34, p=0.04) were also meaningful independent predictors. The 
cumulative incidence of stent thrombosis (deﬁnite or probable by ARC deﬁnition) were 3 
(0.6%) in the SES group versus 4 (1.6%) in the PES group (p=0.18).
Conclusions:There were no signiﬁcant differences in cumulative rates of death, MI, 
TVR and MACE upto 3 years between patients with unprotected left main disease who 
underwent SES and those who underwent PES. Percutaneous coronary intervention 
with DES (SES or PES), acceptable long-term clinical results can be achieved, with no 
particular safety concerns about treatment of unprotected LM.
2:15 p.m.
2909-6 Long-Term (4 Year) Outcome Following Drug Eluting 
Stent Implantation Versus Coronary Artery Bypass 
Surgery in Unprotected Left Main Coronary Artery 
Lesions
Alaide Chieffo, Valeria Magni, Francesco Maesano, Alfonso Ielasi, Giorgio Bassanelli, 
Matteo Montorfano, Mauro Carlino, Azeem Latib, Cosmo Godino, Angela Ferrari, 
Giuseppe Sangiorgi, Ottavio Alﬁeri, Antonio Colombo, San Raffaele Scientiﬁc Institute, 
Milan, Italy
Background: One-year outcome following drug-eluting stent (DES) implantation versus 
coronary artery by-pass grafting (CABG) in unprotected left main coronary artery (LMCA) 
lesions have been previously reported from our center
Methods: All consecutive patients with an unprotected LMCA stenosis electively treated 
with DES implantation versus CABG in our Center, between March 2002 and July 2004, 
were analysed. Hierarchical study end points were occurrence at 4 years of: death; death 
and/or myocardial infarction (MI); death, MI and/or stroke; target vessel revascularization 
(TVR, deﬁned as any revascularization in left coronary system); and major cardiac 
cerebrovascular events (MACCE). A propensity analysis was performed to adjust for 
baseline differences between the two cohorts.
Results: Two-hundred forty-nine patients were included in the study: 107 were treated with 
PCI and DES implantation and 142 with CABG. At 4 year-clinical follow-up, no difference 
was found between PCI and CABG in the occurrence of death (respectively 12.0% vs. 
14.1%; adjusted OR=0.652; 95% CI=0.254 to 1.620; P=0.42). At adjusted analysis, PCI 
group showed a trend toward a lower occurrence of the composite endpoint of death and 
myocardial infarction (13.0% vs. 19.7%; adjusted OR=0.461; 95% CI=0.180 to 1.088; 
P=0.08). PCI was associated with a lower rate of the composite endpoint of death, MI and/or 
stroke (respectively 14.0% vs. 22.5%; adjusted OR=0.431; 95% CI=0.175 to 0.971; P=0.04). 
Indeed, CABG was correlated to lower TVR (8.4% vs. 28% ; adjusted OR= 5.928; 95% CI= 
1.933- 38.0; p= 0.0003). No difference was detected in the occurrence of MACCE ( in PCI 
36.4% vs. 28.1% in CABG, adjusted OR=1.438; 95% CI=0.754 to 2.766; P=0.3007).
Conclusions: At 4 year-clinical follow-up, in this single-center experience, there was still 
no difference in the occurrence of MACCE between elective PCI with DES implantation and 
CABG in LMCA lesions. There was an advantage of PCI in the composite endpoint of death, 
MI and/or stroke, while a beneﬁt in the need for reintervention was still found in CABG.
2:30 p.m.
2909-7 Systematic Double Stenting Versus Simple Provisional 
T-Stenting for True Bifurcation Lesions of Left Main 
Coronary Artery Disease Using Drug Eluting Stents: 
Multicenter Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Purpose: The purpose of this study is to evaluate the long-term outcomes of systemic double 
stenting and provisional T-stenting technique that were used for treating true bifurcation lesions 
of left main coronary artery (LMT) disease with drug-eluting stents (DES, Sirolimus-eluting 
stent: SES and Paclitaxel-eluting stent: PES). Methods: A prospective Asian multicenter registry 
was set up in ﬁve high volumes Asian centers to evaluate the efﬁcacy DES in the treatment 
of bifurcation lesions of LMT. A total of 507 patients, 507 lesions (male 72.0, mean age 68.9) 
with true bifurcation lesions (deﬁned as a more than 50% stenosis in both LAD and LCX) were 
treated with 2 strategies: Systemic double stenting (n=306) (culotte 79, crush 21, mini-crush 
122, kissing 8, T-stenting 76) and provisional T-stenting (n=201). All patients are evaluated 
immediate and long-term clinical results with 6 and 12 months coronary angiography. Results:
The baseline clinical characteristics between 2 groups were similar. See table for clinical results. 
Conclusion: This study suggests that provisional T-stenting of the side branch is a feasible 
strategy associated with low MACE and low TLR in patients with LMT disease. 
Double stenting Provisional stenting p
Number of patients 306 201 -
30 days MACE (%) 0 0 -
6 months follow-up angiogram
Restenosis (%) 15.7 12.4 NS
TLR (%) 13.1 6.0 0.03
12 months follow-up angiogram
Restenosis (%) 17.0 14.9 NS
TLR (%) 15.0 8.3 0.04
Conclusion: 10 minutes post-bolus, no difference in PAI was observed between standard 
or higher abciximab bolus dosing nor between intracoronary or intravenous delivery. 
Angiographic and MRI analyses will determine whether the standard abciximab infusion 
could be skipped and if intracoronary abciximab provides better myocardial salvage than 
intravenous delivery. Since the last patient was controlled in October 08, complete results 
will be available for presentation.
11:30 a.m.
2907-10 Angiographic Findings and Door to Balloon Times 
at Hospitals With and Without Emergency Medicine 
Physician Cath Lab Activation: Insights From the 
National Cardiovascular Data Registry CathPCI 
Registry and the D2B Alliance
Christopher Regan, Jeptha P. Curtis, Yongfei Wang, Elizabeth Bradley, Harlan Krumholz, 
Yale New Haven Hospital, New Haven, CT
Background: Allowing Emergency Medicine physicians to activate the catheterization lab 
reduces door to balloon (D2B) times. However, many hospitals have concerns that this policy 
would increase rates of inappropriate activation. To assess the overall impact of this strategy, 
we compared angiographic ﬁndings and D2B times of patients undergoing emergency 
catheterization for suspected STEMI at hospitals that did and did not allow EM activation.
Methods: We analyzed data from the NCDR CathPCI Registry to identify patients who 
underwent catheterization for suspected STEMI in hospitals enrolled in the D2B Alliance 
in 2006-7. The hospital’s approach to activating the cath lab was classiﬁed as: cardiology 
alone makes the decision (EM Never), emergency medicine makes the decision 
in consultation with cardiology (EM Sometimes), and emergency medicine makes 
the decision without consultation with cardiology (EM Only). Outcomes, in separate 
models, included presence of signiﬁcant stenosis or total occlusion, performance of 
a revascularization procedure, and proportion of patients with D2B time a90 minutes. 
To assess the independent association of ED activation with outcomes, we performed 
hierarchical multivariable analysis adjusting for demographics, cardiac status, comorbid 
conditions, and hospital characteristics.
Results: A total of 46,825 patients with suspected STEMI underwent catheterization at 513 
CathPCI hospitals. In multivariable analysis, the strategy for activation was not associated 
with signiﬁcant differences in the proportion of patients with a signiﬁcant stenosis, the 
proportion with total occlusion, or the likelihood of undergoing revascularization (Table). In 
contrast, patients treated at “EM Only” hospitals, but not “EM Sometimes” hospitals, were 
more likely than patients treated at “EM Never” hospitals to have D2B times a90 minutes.
Conclusions: A strategy of EM cath lab activation is not associated with higher rates 
of false activation as assessed by measures of angiographic severity and need for 
revascularization. These ﬁndings support more widespread adoption of EM cath lab 
activation for STEMI patients. 
EM Never
(n=17,357)
EM Sometimes
(n=2,868)
EM Only
(n=26,600)
Age (years) 61.0 60.4 60.6
Gender 28.5% 27.5% 28.3%
White 82.6% 83.6% 83.0%
Signiﬁcant Stenosis Ref 1.02 (1.00-1.03) 1.00 (1.00-1.01)
Total Occlusion Ref 1.04 (1.00-1.07) 1.00 (0.98-1.02)
Revascularization Ref 1.02 (0.99-1.03) 1.00 (0.99-1.02)
% D2B a90 min Ref 1.01 (0.91-1.09) 1.08 (1.03-1.12)
I2.ORAL CONTRIBUTIONS
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Left Main
Monday, March 30, 2009, 2:00 p.m.-3:30 p.m.
Orange County Convention Center, Room W314B
2:00 p.m.
2909-5 Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent 
in Unprotected Left Main Coronary Artery Disease 
(MAIN-COMPARE Registry)
Jong-Young Lee, Duk-Woo Park, Won-Jang Kim, Sung Sik Kim, Sung-Hwan Kim, 
Myong-Zoon Yi, Seung-Whan Lee, Young-Hak Kim, Cheol-Whan Lee, Myeong-Ki Hong, 
Seong-Wook Park, Seung-Jung Park, Asan medical center, Seoul, South Korea
Background: This study was aimed to evaluate outcomes of patients with unprotected 
left main coronary artery (LMCA) stenosis who were treated with most commonly used 
drug-eluting stent, Sirolimus-Eluting Stents (SES) and Paclitaxel-Eluting Stents (PES).
Methods: From May 2003 through June 2006, 858 consecutive patients with unprotected 
LMCA stenosis(50%>) in The MAIN-COMPARE registry were treated with SES in 669 
(78%) patients and PES in 189 (22%) patients. Stent selection was decided on operator’s 
discretion. Study end point were death, MI,Target Vessel Revascularization and MACE 
(composite of death, MI or TVR(TLR)).Mean follow-up duration was 864 ± 340 days. 
Procedural success was achieved in all patients.
Results: There were no signiﬁcant differences in cumulative rates upto 3 years of death 
(SES vs PES : 9.1 vs 11.0%, Hazard Ratio 0.88, 95% Conﬁdence Interval 0.49-1.56, 
p=0.66), Myocardial Infarction (7.8 vs 8.0%, HR 0.95, 95% CI 0.54-1.70, p=0.87), Target 
Vessel Revascularization (12.1% vs 10.6%, HR 1.27, 95% CI 0.64-2.51, p=0.49) and 
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3-year clinical event rates _ Pre-PCI endsystolic distal BA
BAa 71° BA=72-92° BAq93°
P value
BAa 71° vs. 
BAq93°
P value
BAa 71° vs. 
BA>71°
All-cause mortality 16.4% 26.4% 36.9% 0.018 0.041
MI 9.8% 0.0% 4.7% 0.338 0.042
TVR 13.1% 23.0% 19.7% 0.297 0.183
Death+MI 20.2 26.4 38.9 0.037 0.102
MACE 28.4% 45.9% 52.6% 0.008 0.011
Log rank test, pairwise comparisons over strata, p<0.05 signiﬁcant. BA values in 
degrees
I2.POSTER CONTRIBUTIONS
2517
PCI - Bifurcations
Monday, March 30, 2009, 3:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
2517-764 Intravascular Ultrasound Findings from the DIVERGE 
Trial: Serial Volumetric Analysis of the Biolimus A9-
Eluting AXXESS Self-Expanding Stent for the Treatment 
of Bifurcation Coronary Lesions
Takao Hasegawa, Junya Ako, Bon-Kwon Koo, Hyeonsoo Chang, Stefan Verheye, 
Joseph Dens, John Ormiston, Dougal McClean, Stephen Worthley, Yasuhiro Honda, 
Peter J. Fitzgerald, Stanford University Medical Center, Stanford, CA
Background: The AXXESS system is a Biolimus A9-eluting self-expanding stent, 
dedicated to the treatment of bifurcation coronary lesions. The aim of this study was to 
assess the efﬁcacy of the AXXESS stent on the treatment of bifurcation coronary lesions 
using serial IVUS.
Methods: Data were obtained from the DIVERGE trial to evaluate the efﬁcacy of the 
combination of AXXESS and sirolimus-eluting (SES) for the treatment of bifurcation 
coronary lesions. Nine-month follow-up IVUS was available in 60 cases, enabling 56 
serial comparisons between post-procedure and follow-up. Volumetric and/or cross-
sectional analyses within both the AXXESS stent and SES and cross-sectional analyses 
at the branch ostia were performed.
Results: At follow up, percent neointimal volume was 4.3 ± 5.0% within the AXXESS 
stent and minimal lumen area of 7.2 ± 2.3 mm2. The self-expanding AXXESS stent 
volume increased 29.7% at follow-up compared with post-procedure (p<0.0001), leading 
to a corresponding 26% increase in lumen volume (p<0.0001). Absolute and relative 
stent volume changes during the follow-up period were greater in more distal part of the 
AXXESS stent, however this late stent enlargement did not exaggerate more neointimal 
growth (Figure). At follow-up, lumen area was 4.0 ± 1.3 mm2 at main branch ostium and 
3.6 ± 1.3 mm2 at side branch ostium.
Conclusion: The combination of the AXXESS and SES demonstrated effective lesion coverage 
with signiﬁcant neointimal suppression in the treatment of coronary bifurcation lesions. 
3:30 p.m.
2517-765 Optical Coherence Tomography (OCT) for evaluation of 
strut healing at coronary bifurcations 6 months after 
deployment.
Hiroyuki Kyono, Giulio Guagliumi, Vasile Sirbu, Noah Rosenthal, Satoko Tahara, 
Giuseppe Musumeci, Antonio Trivisonno, Hiram G. Bezerra, Marco A. Costa, University 
Hospitals Harrington-McLaughlin Heart & Vascular Institute, Cleveland, OH, Ospedali 
Riuniti di Bergamo, Bergamo, Italy
Background: Stent deployment in bifurcation lesions has been associated with a 
higher incidence of stent thrombosis in the drug eluting stent (DES) era. However, the 
mechanisms of this phenomenon are still unclear. We sought to evaluate coverage of 
ﬂoating stent struts located in bifurcated lesions by means of OCT.
Methods: The ODESSA trial was a prospective randomized trial designed to evaluate 
healing of overlapped drug-eluting vs. bare metal stents for de novo coronary artery 
stenosis. All cases underwent OCT imaging at a 6 month follow-up. Strut-level analysis 
was performed by an independent core laboratory. All ﬂoating struts at a bifurcation 
2:45 p.m.
2909-8 Left Main and Three Vessel Disease Stenting in Real 
World Settings: Results From the TAXUS OLYMPIA 
Registry
Oscar A. Mendiz, Martyn R. Thomas, Waqar H. Ahmed, Katrin Leadley, Keith D. 
Dawkins, Fundación Favaloro, Buenos Aires, Argentina, Boston Scientiﬁc Corporation, 
Natick, MA
Background: Stenting of left main coronary artery (LM) or three vessel disease (3VD) 
is a topic of current debate. In the TAXUS OLYMPIA study, a prospective, web-based 
registry of patients (pts) receiving TAXUS Liberté stents, subgroups of LM and 3VD pts 
were enrolled. The outcomes of TAXUS Liberté stenting were examined in these pts.
Methods: OLYMPIA is a multi-center, post-approval registry capturing baseline data and 
outcomes in pts receiving the TAXUS Liberté paclitaxel-eluting stent in real world routine 
interventional cardiology practice. Enrollment and 12-month follow-up in 22,345 pts from 
57 countries has been completed to date. Follow-up data are available for 692 pts with 
LM and 278 pts with 3VD stenting.
Results: Death was highest among pts following LM stenting (4.5%) (Table). The 
composite cardiac event (CE) rate, deﬁned as cardiac death, myocardial infarction, 
or target vessel revascularization (TVR), was similar among pts with LM and 3-vessel 
stenting (7.7% vs 7.6%). In examining component CE, cardiac death was high in pts 
with LM stenting (3.3%) whereas revascularization rates were high in pts with 3-vessel 
stenting (6.5% TVR and 4.7% Target Lesion Revascularization, respectively). The rate of 
cardiac death was lowest in the 3-vessel stenting group (0.7%), even when compared 
with the overall cardiac death rate (1.4%).
Conclusions: These global registry data suggest that the TAXUS Liberté is safe and 
performs well in complex pts with LM and 3VD. 
12-month outcomes of patients receiving TAXUS Liberté stents
Overall
(N=21,126)
LM Stenting*
(N=692)
Three Vessel Stenting**
(N=278)
Death 2.1 4.5 2.2
Composite CE*** 4.4 7.7 7.6
Cardiac Death 1.4 3.3 0.7
MI 0.9 1.6 1.8
TVR (per patient) 3.1 4.8 6.5
TLR (per patient) 2.5 3.3 4.7
ST (per patient) 0.8**** 1.0 1.4
Values reﬂect binary rates.
Outcomes adjudicated by an independent medical reviewer.
Abbreviations: LM=left main coronary artery; RCA=right coronary artery; LAD=left 
anterior descending artery; LCx=left circumﬂex artery; CE=cardiac event; 
MI=myocardial infarction; TVR=target vessel revascularization (reintervention of a target 
vessel); TLR=target lesion revascularization (TAXUS Liberté stent-related reintervention 
of a target vessel); ST=stent thrombosis (angiographically conﬁrmed TAXUS Liberté 
stent thrombosis only)
*LM isolated stenting only
**Includes RCA, LAD, LCx, LM, and grafts
***A composite of cardiac death, MI (including Q- and non Q-wave MI) and 
reintervention of a target vessel (TVR)
****N=21,128 pts
3:00 p.m.
2909-9 Three-Dimensional Bifurcation Angle in Patients 
With Left Main Disease: Impact on Long-Term 
Clinical Outcome Following Percutaneous Coronary 
Intervention
Chrysaﬁos Girasis, Yoshinobu Onuma, Neville Kukreja, Ron van Domburg, Patrick W. 
Serruys, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
Background: Three-dimensional (3-D) quantitative coronary angiography (QCA) provides 
objective data on the bifurcation angle (BA). To appreciate their long-term prognostic 
value, we correlated the BA parameters to the 3-year clinical outcome of the Left Main 
(LM) population of the Thoraxcenter
Methods: Between January 1, 2000 and December 31, 2005, 207 consecutive patients 
underwent PCI for unprotected LM disease; 77 (37.2%) of them due to stable angina, 79 
and 51 for unstable angina and myocardial infarction (MI) respectively. Cineangiograms 
were analyzed with 3-D QCA software (Cardiop-B, Paieon Medical Inc, Israel). The 
proximal BA (between LM and LCx) and the distal BA (between LAD and LCx) were 
computed in enddiastole and endsystole, both pre- and post-PCI. Annual follow-up on 
death and clinical events was collected for 3 years. The primary end-point was all-cause 
mortality. Secondary endpoints included MI, target vessel revascularization (TVR) and 
composite major adverse events (MACE: all-cause death, MI or TVR).
Results: Complete analysis was feasible in 136 (65.7%) patients. Only pre-PCI 
endsystolic distal BA predicted clinical outcome when stratiﬁed into tertiles, with a cut-off 
value of 71 degrees. Mortality and MACE rates were signiﬁcantly lower in the ﬁrst tertile, 
compared either to the third or to the pool of the other two tertiles. (table)
Conclusion: Pre-PCI endsystolic distal BA values wider than 71 degrees confer higher 
long-term mortality and MACE rates after PCI for LM disease. 
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to the proximal [17.6% (297/1682)] or distal segment [10.8% (174/1604] (p<0.0001). The 
highest strut/vessel wall separation distance was detected in quadrant 1 [265 μ median, 
interquartile range (IQR) (180-430 μ)] compared to quadrant 2 [190 μ, IQR (140-255)], 
proximal [190 μ, IQR (160-250)] or distal segment [185 μ, IQR (160-280) ] (p=0.0001).
Conclusions: In coronary bifurcation lesions, strut malapposition is more frequent at the 
bifurcation site and more severe towards the SB origin.
3:30 p.m.
2517-768 Intravascular Ultrasound Evaluation of Complex 
Bifurcation Lesions Treated with Tryton Side-Branch 
Stent in Conjunction with Everolimus-eluting Stents.
Daniela Trabattoni, Franco Fabbiocchi, Piero Montorsi, Stefano Galli, Paolo Ravagnani, 
Alessandro Lualdi, Luca Grancini, Antonio L. Bartorelli, Centro Cardiologico Monzino, 
IRCCS, Milan, Italy
Background: The Tryton Stent (TSBS) was designed to treat complex bifurcation lesions 
(BL). The results of FIM study demonstrated safety and feasibility and low restenosis 
at 6-month angiographic follow-up. Methods: TSBS is a balloon-expandable bare-
metal stent with a distal zone that scaffolds the side-branch ostium and a proximal zone 
consisting of three fronds that terminate in a circumferential band. After deployment in the 
side branch, any stent can be advanced in the main branch across the TSBS proximal 
zone to complete the bifurcation architecture.TSBS was used in conjunction with Xience 
V stents in 9 LAD-diagonal and 1 LCx-obtuse marginal BL. By Medina classiﬁcation, eight 
BL were 1,1,1, one was 1,1,0 and one 0,1,0. The lesion angle was <30° in 5, >30° and 
<45° in 4 and >45° in 1. Kissing balloon was performed in all cases. TSBS results were 
assessed by IVUS in 10 patients (7 men, age 66±11 years) and compared with those 
reported with the “crush” technique. Results: All TSBS and Xience V stents were correctly 
implanted in BL side branch and main vessel. Angiographic and procedural success was 
100%. Table shows the postprocedural IVUS results in comparison to those previously 
published with the “crush” technique in BL. Six-month angiographic and IVUS follow-up 
will be presented. Conclusions: These IVUS results may explain the low restenosis rate 
observed in the FIM study and suggest that TSBS provides a reliable and reproducible 
strategy to stent the side branch and its origin.
Tryton n=10 Crush# n=15
SB ostium MSA 4.71 ±1.05 4.2 ± 1.0
SB distal MSA 4.45 ±1.1 4.5 ± 2.3
SB Stent CSA <4 mm2 21% 55%
SB Stent CSA <5 mm2 66% 90%
SB Dmin/Dmax 0.83 N/A
#JACC 2005;46:599-605
3:30 p.m.
2517-769 First Human Use of the TAXUS Petal Paclitaxel-Eluting 
Bifurcation Stent
John Ormiston, Thierry Lefèvre, Eberhard Grube, Dominic Allocco, Keith Dawkins, 
Donald Baim, Mercy Angiography Unit Ltd, Auckland, New Zealand, Boston Scientiﬁc 
Corporation, Natick, MA
Background: Patients who undergo stenting for the treatment of coronary bifurcation 
lesions have an increased risk of subsequent adverse events compared with patients 
treated for non-bifurcation lesions. The TAXUS Petal paclitaxel-eluting bifurcation stent 
was speciﬁcally designed for the treatment of bifurcation lesions and may result in 
improved outcomes.
The aim of this single-arm, prospective, ﬁrst-in-human study was to evaluate the safety 
and feasibility of this novel bifurcation stent.
Methods: A total of 28 patients with coronary bifurcation lesions were enrolled at three 
sites in Europe and New Zealand. Inclusion criteria were lesion length a20 mm and 
reference vessel diameter (RVD) between 3.0-3.5 mm in the main branch (MB) and lesion 
length a14 mm and RVD between 2.5-3.5 mm in the side branch (SB). Patients with stable 
or unstable angina and who had left ventricular ejection fraction q40 % were eligible for 
inclusion. The primary endpoint was a 30-day composite of death, myocardial infarction 
(MI), and target vessel revascularization (TVR). Complete 30-day results are reported 
below; six month clinical and angiographic follow-up is ongoing and will be available for 
all patients by ACC 2009.
Results: The mean age was 60.9±9.3 years with diabetes mellitus frequency of 17.9%. 
The treated lesion involved an LAD/diagonal bifurcation in 78.6% of patients. RVD, 
measured by an external core lab, was 2.91±0.28 mm in the MB and 2.23±0.33 mm in 
the SB. Seventy-ﬁve percent, 78.6% and 35.7% of patients had signiﬁcant proximal MB, 
distal MB and SB disease, respectively. A Petal stent was successfully implanted in 25/28 
(89.3 %) patients. A SB stent was placed in 25% of patients. Post procedure in-segment 
mean percent diameter stenosis was 23.6±9.1% in the MB and 23.1±13.7% in the SB. 
The rates of death, MI, and TVR at 30 days were 0%, 3.7% (1/27, NQWMI on day 0), and 
0% respectively. No stent thromboses were reported.
Conclusions: Treatment of bifurcation lesions with the TAXUS Petal stent is feasible, with 
good clinical outcomes through 30 days. Further study in a larger number of patients is 
needed to better evaluate outcomes with this device.
segment were classiﬁed for coverage as: Uncovered (U), Covered (C), Proliferative (P), 
deﬁned by tissue extending to an adjacent strut.
Results: 196 jailed bifurcations with 1416 ﬂoating struts from 75 patients (SES: 20, PES: 
22, ZES: 22, Liberte BMS: 11) were analyzed. The average numbers of ﬂoating struts per 
bifurcation were: 7.62 in SES, 8.91 in PES, 5.11 in ZES, and 4.28 in BMS (p=0.090). PES 
showed larger number of uncovered struts (Graph).
Conclusions: This study suggests that delayed coverage at jailed bifurcations occurs 
more frequently in PES than in BMS and other DES platforms. Different DES drug 
properties and retention times might have impact on different levels of strut coverage. 
Coverage of ﬂoating bifurcation struts appears to follow a different pattern than that 
observed in struts deployed in non-bifurcation coronary segments. 
3:30 p.m.
2517-766 Serial Intravascular Ultrasound Analysis of Main and 
Side Branches in Bifurcation Lesions Treated with 
T-Stenting Technique
Hahn Joo-Yong, Young Bin Song, Sang-Yup Lee, Seung-Hyuk Choi, Jin-Ho Choi, Young 
Keun On, Duk Kyung Kim, Sang Hoon Lee, Hyeon-Cheol Gwon, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background: Restenosis rates after percutaneous coronary intervention on bifurcation 
lesions are high. However, the mechanism of restenosis, especially at the ostium of side 
branch (SB), has not been fully elucidated.
Methods and Results: We analyzed 73 bifurcation lesions treated with drug-eluting 
stents by T-stenting technique and with the available post-procedural and 9-month follow-
up intravascular ultrasound images for both main vessel (MV) and SB. Analysis included 
5 distinct locations: MV proximal stent, MV middle area, MV distal stent, SB ostium (<5 
mm distal to the neo-carina), and SB distal stent. Stent expansion was less signiﬁcantly 
in the SB than the MV (6.1±1.9 mm2 versus 4.7±1.8 mm2, P<0.001 and 87.1±20.4% 
versus 97.0±29.1%, P=0.007, respectively). The SB ostium was the most frequent site of 
post-procedural MSA. At the SB ostium, follow-up minimum lumen area (MLA) correlated 
with post-procedural MSA (r=0.81, P<0.001). Percentage of neointimal hyperplasia was 
higher at the SB ostium than the MV proximal, MV distal, and SB distal stent (23.8±18.9% 
versus 13.3±17.3%, 15.4±20.5%, and 12.5±17.2%, P<0.001). Optimal threshold of post-
procedural MSA to predict follow-up MLA q4 mm2 at the SB ostium was 4.83 mm2 yielding 
an area under the curve of 0.88 (95% CI, 0.80 to 0.95).
Conclusions: Both inadequate post-procedural MSA and increased neointimal 
hyperplasia may make the SB ostium the most frequent site of restenosis after coronary 
bifurcation stenting. Our data suggest that obtaining adequate post-procedural MSA is 
crucial in avoiding restenosis at the SB ostium.
3:30 p.m.
2517-767 Stent Strut Apposition in Coronary Bifurcation Lesions 
assessed with Optical Coherence Tomography.
Giuseppe Ferrante, Nandakumar Ramasami, Pawel Tyczynski, Neville Kukreja, Pablo 
Aguiar-Souto, Francesca Del Furia, Peter Barlis, Kevin Beatt, Carlo Di Mario, Royal 
Brompton Hospital, London, United Kingdom, Mayday University Hospital, London, 
United Kingdom
Background: Several techniques have been introduced for the treatment of coronary 
bifurcation lesions, but there is still concern that malapposition may lead to an increased 
risk of late stent thrombosis. Optical coherence tomography (OCT), due to its high spatial 
resolution, allows accurate evaluation of strut apposition.
Methods: Consecutive patients, undergoing elective angioplasty for the treatment of 
coronary bifurcation lesions, with stenting of the main vessel only and kissing balloon 
dilatation of the side branch (simple strategy) or stenting of both main vessel and side 
branch with kissing balloon, were enrolled. Drug eluting stents and dedicated stents for 
the bifurcations: Tryton stent, Tryreme Antares stent were used. OCT was performed with 
a non-occlusive technique, with 1 to 3 mm/sec pullback speed. Cross-sectional images 
were analyzed every 450 microns. Strut apposition was assessed in three segments: 
bifurcation, divided into two 180 degrees quadrants: towards (1) or opposite (2) to the 
origin of the side-branch (SB), proximal segment and distal segment (both extending up 
to 2 mm from the ﬁrst cross-section when the SB is visible). Stent struts were deﬁned as 
malapposed if the strut/vessel wall separation distance was q thickness of the strut.
Results: Twenty-nine patients, 33 bifurcation lesions, Left Anterior Descending-Diagonal 
(18), Left Circumﬂex-Obtuse Marginal (13), Left main (1), Posterior Descending-
Posterolateral (1), 17 treated with the simple strategy, 15 with culotte technique, 1 with 
V-stenting were enrolled. Of 4871 stent struts assessed, 839 (17.2%) were malapposed. 
The prevalence of malapposition was higher in the bifurcation [23.2% (368/1585)] compared 
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2518
PCI - Chronic Total Occlusions
Monday, March 30, 2009, 3:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
2518-772 Clinical Impact of Percutaneous Coronary Intervention 
in Totally Occluded Left Anterior Descending Artery
Cosmo Godino, Roxana Mehran, George D. Dangas, Kotaro Obunai, Martin B. 
Leon, Gregg W. Stone, Jeffrey W. Moses, Somjot Brar, Riccardo Colantonio, Matteo 
Montorfano, Mauro Carlino, Alaide Chieffo, Antonio Colombo, San Raffaele Hospital, 
Milan, Italy, New York Presbyterian-Columbia University Medical Center, New York, NY
Background: The clinical outcome after percutaneous coronary intervention (PCI) of 
chronic total occlusions (CTO) may differ according to the target myocardial distribution. 
We investigated whether PCI of left anterior descending artery (LAD) CTO has a greater 
clinical impact compared to the PCI of non-LAD CTO.
Methods: In a prospective PCI database, we analyzed clinical outcomes in 1,341 
consecutive patients with 1,362 CTO who underwent PCI at three tertiary care centers in 
the US and Italy between January 2000 and May 2007.
Results: Successful PCI was achieved in 921 (67.7%) CTO cases. Of these, stents were 
used in 825 CTO (89.6%), including 555 CTO (60.3%) treated with DES. There were 
no signiﬁcant differences in age, baseline left ventricular function, and history of prior 
myocardial infarction between groups. Kaplan-Meier analysis demonstrated low mortality 
rates during 3-year follow-up in both successful LAD CTO (4.7%) and successful non-LAD 
CTO groups (3.6%)(p=0.51). However, signiﬁcantly higher mortality rate was observed 
in unsuccessful LAD CTO group compared to successful LAD CTO (15.0% vs. 4.7%, 
p=0.02) (Figure) and unsuccessful non-LAD CTO (15.0 vs. 6.0%, p=0.05) groups.
Conclusions: The LAD location appears to be important for clinical outcome after CTO 
PCI. Patients who had unsuccessful PCI of LAD CTO had signiﬁcantly worse outcome 
than those with successful attempt, whereas the same was not detected in non-LAD 
CTO locations. 
3:30 p.m.
2518-773 Procedural and In Hospital Outcomes After 
Percutaneous Coronary Intervention for Chronic Total 
Occlusions of Coronary Arteries - 2002-2008: Impact of 
Novel Guide Wire Techniques
SUDHIR RATHORE, Hitoshi Matsuo, Mitsuyasu Terashima, Masashi Kimura, Yoshihisa 
Kinoshita, Kenya Nasu, Mariko Ehara, Etsuo Tsuchikane, Yasushi Asakura, Osamu 
Katoh, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Objectives: The aim of this study was to examine the procedural success and in-hospital 
outcomes after percutaneous coronary intervention (PCI) for chronic total occlusions 
(CTO) in current era during contemporary practice.
Background: The technique of PCI has improved over time with introduction of novel 
equipment and guide wire crossing techniques. However, there is limited data available 
from contemporary practice in the recent years.
Methods: We evaluated the procedural and in-hospital outcomes in consecutive series 
of 904 procedures between 2002 and 2008 performed at Toyohashi Heart Centre for PCI 
of CTO of > 3 months in duration.
Results: Technical and procedural success were achieved in 87.5% and 86.2% respectively. 
Baseline demographics was similar between successful and failure groups.86% patients 
had previous MI and 15% had previous CABG, and is similar in both groups. Target vessel 
was RCA in 38%, LAD in 28%, LCx in 20% and the branch vessel in 9% of the patients. 
Side branch at CTO site, severe calciﬁcation and severe tortuosity was seen in 15%, 11% 
and 5% cases, respectively. Single antegrade wire was the predominant strategy for guide 
wire crossing, however, retrograde guide wire crossing was used in 7.2% of the cases and 
controlled antegrade and retrograde sub-intimal tracking (CART) in 9.9% of the cases as 
the ﬁnal strategy. Logistic regression analysis identiﬁed severe tortuosity (HR, 2.30; CI, 
1.26-4.18, p=.006) and moderate to severe calciﬁcation (HR, 1.95, CI; 1.19-3.21, p=.008) 
as signiﬁcant predictors of procedural failure. In- hospital MACE (Death, CABG, & QMI) 
occurred in 17(1.9%) and NQMI in 22 (2.4%) of the patients.
3:30 p.m.
2517-770 What is the optimal PCI strategy (two stents vs. 
provisional) for coronary artery bifurcation lesions? 
Meta-analysis of randomized trials
Abdul Hakeem, Faisal M. Khan, Sabha Bhatti, Zainab Samad, Mark H. Eckman, Tarek 
Helmy, University of Cincinnati Hospital, Cincinnati, OH, Duke University Medical 
Center, Durham, NC
Background: To assess the optimal PCI approach for coronary bifurcation lesions 
(CBL), we conducted a meta-analysis of randomized trials comparing two stent (2S) to 
provisional (PS) strategy.
Data Sources: PubMed, Cochrane Registerof Controlled Trials, conference proceedings, 
and Internet-based sources of clinical trials.
Results: Six randomized trials , including 1641 patients met the selection criteria for Meta 
analysis. There were no differences in clinical proﬁle between the two groups. No signiﬁcant 
heterogeneity was found across trials. There was no difference in the reference vessel 
diameters (mm) of main vessel (MV) [2.73+0.41(2S); 2.7+0.44 (PS) (p=0.77)] and side 
branch (SB) [2.31+0.33 (2S); 2.27+0.34 (PS) (p= 0.3)].Incidence of Myocardial infarction 
(MI) was signiﬁcantly higher in the 2 S group compared to PS. (6.7% vs. 3.6%; RR 1.75 
(1.14-2.68); p=0.01) however ,there was no difference in other outcomes between the two 
approaches (2S vs. PS) including total MACE [12.6% vs. 9.6%;RR 1.26 (0.95-1.66);p= 
0.1] , death [1.07% vs. 1.1%;RR 0.93 (0.37 - 2.33);p=0.87,stent thrombosis(ST) (1.8% vs. 
0.8%;RR 1.6(0.65-3.9);p=0.3) target lesion revascularization(TLR) [6% vs. 5.4%;RR 1.1 
( 0.73-1.64);p=0.66] ,MV restenosis [ 4.9% vs. 5%;RR 0.98 (0.58 to 1.67;p=0.93] and SB 
restenosis [13.8% vs. 13.8% ;RR 1 (0.68 - 0.98);p=0.9] at a mean follow up of 9 months.
Conclusion: A 2S strategy for CBL had a signiﬁcantly higher risk of MI compared to PS 
group. Rates of death, ST, restenosis and TLR were similar.
3:30 p.m.
2517-771 Stent deformation and vessel dilation after 
simultaneous kissing stenting in the 3-dimensional 
coronary bifurcation model
Yoshinobu Murasato, Yutaka Hikichi, Masataka Horiuchi, New Yukuhashi Hospital, 
Yukuhashi, Japan, Saga University, Saga, Japan
Background: We investigated how stents expanded in the proximal main vessel (MV) 
after simultaneous kissing stenting (SKS). We also compared the difference between 
SKS and single stenting with kissing balloon inﬂation (SSKB).
Methods: Various SKSs were performed in the 3-dimensional left main coronary artery 
(LMCA) models with the following conditions: same size stents; different size stents; long 
kissing site; 45 and 90 degrees of bifurcation angle. SKS and SSKB techniques were 
compared after the stent implantation in various models of bifurcation angles. The stents 
were analyzed by micro-focus CT or magniﬁed macroscopic inspection.
Results: The lateral position of the two stents was maintained in the low-angle bifurcation model, 
whereas the stents overlapped longitudinally according to the degree of the bifurcation angle 
and ﬁnally becoming an x-shape. When the different size stents were used in the 3-dimensional 
LMCA model, the LCX stent overlapped the LAD stent and was compressed. However, when 
the same size stents were used, the compression was not observed. The long kissing site 
caused the twisting of the stents in the proximal MV area. In each experimental model, SKS 
showed higher values in both short axis distance and dilated area than those in SSKB.
Conclusions: Stent overlap in a high-angle bifurcation leads to a gap formation and 
stent distortion after SKS. SKS has a potential risk of over dilation in the proximal MV 
compared to SSKB.
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3:30 p.m.
2518-776 The Long-Term Outcome for Patients with Chronic 
Total Occlusion Treated with Sirolimus-Eluting 
Stent:Japanese Multi-center Registry
Hiroshi Fujita, Mitsuyasu Terashima, Masaharu Okada, Kunihiro Kosuga, Shigeru 
Nakamura, Tomoko Kobayashi, Ichiro Hamanaka, Etsuo Tsuchikane, Osamu Kato, 
Takahiko Suzuki, Eisho Kyo, Kinzo Ueda, Toyohashi Heart Center, Toyohashi, Aichi, Japan
Background: The long-term outcome for patients following successful percutaneous 
coronary intervention (PCI) of chronic total occlusion (CTO) has not been well examined. 
This multi-center registry was conducted to investigate 2 years outcome for patients with 
CTO treated with DES, compared to BMS.
Methods: A total of 482 patients with CTO lesions (n=500) were treated with either 
Sirolimus-Eluting Stent (SES: n=337) or Bare Metal Stent (BMS: n=163). We compared 
the incidence of MACE (cardiac death, myocardial infarction, congestive heart failure, and 
target lesion revascularization: TLR) at 2 years follow-up between 2 groups.
Results: Overall MACE including TLR at 2-years was less frequent in DES group than that 
in BMS group (16% vs. 33% p < 0.05). The incidence of TLR was signiﬁcantly lower in DES 
group than that in BMS group (12% vs. 31%; p < 0.05). Therefore, incidences of MACE 
without TLR were similar between 2 groups. The probabilities of freedom from MACE at 24 
months were 71% in the BMS group and 89% in the DES group (p < 0.0001). (Figure)
Conclusions:Resulting from decrease in TLR, the introduction of DES in the treatment 
of CTO lesions was associated with reduction of incidence of overall MACE, compared 
to BMS. 
I2.POSTER CONTRIBUTIONS
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Orange County Convention Center, West Hall D
3:30 p.m.
2519-777 Impact of Sirolimus-Eluting Stent and Paclitaxel-Eluting 
Stent on the Outcome of Patients with Sirolimus-
Eluting Stent Failure: Multicenter Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Purpose: To evaluate the Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) 
on the outcome of patients with SES failure (SES-F). Methods: A total of 520 patients 
with 609 SES-F lesions (male 74.8%, mean age 72.1 yrs, LMT 7.1%, LAD 47.6%, LCX 
25.0%, RCA 16.2%, SVG 4.1%) were treated with SES (mean lesion length 26.1±12.6 
mm, mean stent length 31.3±15.9mm) and PES (mean lesion length 28.3±12.2 mm, 
mean stent length 32.9±19.3 mm). We evaluate immediate and long-term clinical results 
by 6 and 12 months angiography. Results: The baseline clinical characteristics between 
2 groups were similar. See table for clinical results. Conclusion: The use of SES and 
PES in patients with restenosis after SES implantation was safe with low complications. 
Patients treated with SES showed lesser rate of restenosis compared with PES. 
SES PES
Number of patients/lesions 256/314 264/295
Procedural success (%) 100 100
MACE at 30 days (%) 0.6 1.1(Stent thrombosis 2 cases)
Proximal reference diameter (mm) 2.96±0.79 2.83±0.80
Minimum lumen diameter post procedure (mm) 2.66±0.90 2.64±0.74
Minimum lumen diameter at 6 months (mm) 2.48±0.80 2.39±0.74
Minimum lumen diameter at 12 months (mm) 2.43±0.79 2.21±0.75
Restenosis rate (%) 7.0 15.2*
Target lesion revascularization (%) 6.6 15.2*
MACE at 12 months (%) 7.0 17.4*
*p<0.05 vs SES
Conclusions: This is the ﬁrst reported large series of patients undergoing PCI for CTO 
of the coronary arteries with improved wire crossing techniques. We have reported 
high success rate in recent years and low complication rates despite the use of more 
aggressive devices and techniques.
3:30 p.m.
2518-774 Drug-Eluting Stents for the Treatment of Chronic Total 
Occlusion: A Comparison with Sirolimus, Paclitaxel, 
Zotarolimus, EPC Capture and Everolimus-Eluting 
Stent: Multicenter Registry in Asia
Sunao Nakamura, Shotaro Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, 
Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo 
Hospital, Chiba, Japan
Aim: The aim of this study is to compare the safety and efﬁcacy of Sirolimus (SES), 
Paclitaxel (PES), Zotarolimus (ZES), EPC capture (ECS) and Everolimus-eluting stent 
(EES) on the outcome of patients with chronic total occlusion (CTO). Methods: A
prospective analysis of 1082 patients with 1183 CTOs (396 SES, 526 PES, 177 ZES, 41 
ECS, 43 EES) in ﬁve high volume Asian centers after successful recanalization of CTO 
was performed. The study endpoints were 30 days and 9 months major adverse cardiac 
events (MACE), 9 months angiographic restenosis and target lesion revascularization 
(TLR). Results: See table for clinical results. Conclusion: The use of drug-eluting stents 
in patients with CTO was safe with low acute complication. Patients treated with SES and 
EES showed lesser rate of restenosis compared with other drug-eluting stents. 
SES PES ZES ECS EES
Number of patients/lesions 365/396 482/526 154/177 39/41 42/43
LAD/LCX/RCA (%) 54/26/20 52/22/26 89/138/50 21/9/9 25/7/11
Procedural success (%) 100 100 100 100 100
MACE at 30 days (%) 0 0.4 0.6 0 0
Proximal reference diameter (mean: mm) 2.86 2.80 2.83 2.90 2.88
Minimum lumen diameter post procedure 
(mean: mm) 2.65 2.54 2.59 2.60 2.68
Minimum lumen diameter at 9 months 
(mean: mm) 2.55 2.33 2.09 2.34 2.59
Restenosis rate at 9 months (%) 4.0* 6.7 12.3 12.8 4.8*
TLR at 9 months (%) 3.6* 6.7 10.4 10.3 2.4*
MACE at 9 months (%) 3.6* 6.7 10.4 10.3 2.4*
*p<0.05 vs ZES, ECS
3:30 p.m.
2518-775 Serial Angiographic Follow-Up after Successful 
Implantation of Sirolimus-Eluting Stent and Paclitaxel-
Eluting Stent for Chronic Total Occlusions: Multicenter 
Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Purpose: To evaluate the long-term efﬁcacy of Sirolimus-eluting stent (SES) and 
Paclitaxel-eluting stent (PES) on the outcome of patients with chronic total occlusions 
(CTO). Methods: A total of 210 patients with 232 CTO lesions (male 70.5%, mean 
age 70.8 yrs, LAD 50.9%, LCX 21.6%, RCA 25.0%, Others 2.5%) were treated with 
SES (102 patients 118 lesions, mean lesion length 36.1±12.9 mm, mean stent length 
41.7±15.6mm) and PES (108 patients 114 lesions, mean lesion length 38.5±12.8 mm, 
mean stent length 43.9±19.5 mm). We conducted follow-up coronary angiogram in all 
patients after successful implantation of SES and PES (9, 12, 18, 24 months respectively) 
Results: The baseline clinical characteristics between 2 groups were similar. See table for 
clinical results. Conclusion: There is a different timing of late catch up phenomenon (late 
lumen loss) of SES and PES (SES: 12-18 months, PES: 9-12 months) after successful 
implantation of SES and PES in patients with chronic total occlusion. Patients treated with 
SES showed lesser loss of minimum lumen diameter compared with PES. 
SES PES
Number of patients/lesions 102/118 108/114
Procedural success (%) 100 100
MACE at 30 days (%)
1.0
(1 Stent 
thrombosis)
0.9
(1 Stent thrombosis)
Proximal reference diameter (mm) 2.87±0.78 2.82±0.84
Minimum lumen diameter post procedure (mm) 2.62±0.77 2.60±0.79
Minimum lumen diameter at 9 months (mm) 2.50±0.80 2.29±0.74*
Minimum lumen diameter at 12 months (mm) 2.49±0.79 2.10±0.75*
Minimum lumen diameter at 18 months (mm) 2.31±0.83 2.08±0.79*
Minimum lumen diameter at 24 months (mm) 2.29±0.76 2.06±0.83*
*p<0.05 vs SES
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Methods: Between May 2002 and May 2008 all consecutive pts treated solely with DES 
were prospectively enrolled in this single center registry and grouped according to their 
“label” status. Pts with STEMI and SVG lesions were excluded. On-label pts had de novo 
lesion <30mm in length, located in a native coronary artery of 2.5 to 3.5mm in diameter. 
All remaining pts were classiﬁed as off-label. The primary goal was the comparison of 
MACE and stent thrombosis (ST). Pts were evaluated at 1, 6 and 12 months and then 
annually up to 6 years.
Results: Most pts were off-label [1,725 (76%) of 2,265]. Complete FU data was obtained 
in 98.3% of the cases (median 3.5 years). During hospitalization, off-lable pts had more 
non-Q wave MI but similar rates of MACE and ST. Survival-free of MACE, TLR and ST 
curves are displayed in the chart. Off-label use of DES was an independent predictor of 
combined MACE (HR 2.5; 95% IC1.7-4.9) but did not impact MI and ST.
Conclusion: In this registry, DES in pts with increased complexity proﬁle (off-label) was 
associated with low rates of MACE (<11%) and ST (<2.0%) in the very long-term FU; 
however, outcomes in this subset are still inferior compared to those with strict indications 
for DES (on-label).
3:30 p.m.
2519-781 Late Outcomes of Bare Metal or Drug-Eluting Stent 
Implantation in Standard and “Off-Label” Lesions
Kishore J. Harjai, Pamela Orshaw, Judith Boura, Daniel Sporn, Guthrie Clinic, Sayre, 
PA, William Beaumont Hospital, Royal Oak, MI
Background: Long-term outcomes from DES- vs. bare-metal stent (BMS) implantation in 
standard and off-label lesions are not available.
Methods: In 2345 patients undergoing PCI for standard (n=1540, 66%) or off-label (805, 34%) 
lesions, we assessed the time to occurrence of death, myocardial infarction (MI), death or MI, 
stent thrombosis, target vessel revascularization (TVR), and major adverse cardiovascular 
events (MACE, deﬁned as composite of all study outcomes). Multivariable differences in 
outcomes between DES vs. BMS were assessed using propensity-adjusted Cox proportional 
hazards regression. To assess the impact of TVR on mortality, we constructed hazard curves 
for mortality in patients who suffered TVR vs. those who did not.
Results: The median duration of follow-up was 3.4 years. Stenting of off-label lesions 
was associated with uniformly worse outcomes than stenting of standard lesions. After 
adjustment for lesion classiﬁcation, propensity to receive DES, and baseline differences, 
the use of DES was associated with statistically signiﬁcant reductions in death, TVR, and 
MACE, without a detrimental impact on MI, death/MI, or stent thrombosis. Time to death 
was similar between patients who suffered TVR versus those who did not.
Conclusions: Compared to BMS, the use of DES is associated with clinical beneﬁt 
in standard and off-label lesions at late follow-up. Reduction in elective TVR does not 
explain the apparent mortality beneﬁt from DES implantation. 
3:30 p.m.
2519-782 Temporal evolution in the Off-Label Use of Drug Eluting 
Stents: Observations from the EVENT Registry
Neal S. Kleiman, Chen-Hsing Yen, Peter B. Berger, John J. Lopez, Htut Win, David J. 
Cohen, Methodist DeBakey Heart and Vascular Center, Houston, TX, Harvard Clinical 
Research Institute, Boston, MA
Background: Since an FDA review in December 2006, there has been concern about 
the implant of drug-eluting stents (DES) for off-label indications. We previously reported 
from the EVENT registry that 54% of pts (excluding STEMI) received off-label DES. More 
recent data allowed us to compare implant practices before and after December 2006.
Methods: EVENT consisted of 4 yearly waves of approximately 2500 unselected pts 
with attempted stent implant from 2004 to 2007 at 61 centers. This analysis excluded 
3:30 p.m.
2519-778 Drug-Eluting Stents for the Treatment of Small Coronary 
Artery with Sirolimus, Paclitaxel, Zotarolimus, EPC 
Capture and Everolimus-Eluting Stent: Multicenter 
Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Aim: The aim of this study is to compare the safety and efﬁcacy of Sirolimus (SES), 
Paclitaxel (PES), Zotarolimus (ZES), EPC capture (ECS) and Everolimus-eluting stent 
(EES) on the outcome of patients with small coronary artery disease. Methods: A
prospective analysis of 1871 patients with small coronary artery stenosis (808 SES, 602 
PES, 219 ZES, 153 ECS, 89 EES) in ﬁve high volume Asian centers after successful 
stenting for small coronary artery stenosis was performed. The study endpoints were 
major adverse events (MACE) at 30 days, 9 months restenosis rate and target lesion 
revascularization (TLR) at 9 months. Results: See table for clinical results. Conclusion:
The use of drug-eluting stents in patients with small coronary artery stenosis was safe and 
feasible. Patients treated with SES and EES showed lesser rate of restenosis compared 
with other drug-eluting stents. 
SES PES ZES ECS EES
Number of patients 808 602 219 153 89
Procedural success (%) 99.8 99.7 100 100 100
Reference diameter (mean: mm) 2.40 2.42 2.37 2.35 2.33
Lesion length (mean: mm) 12.6 11.3 13.7 12.9 18.0
Minimum lumen diameter post procedure (mean: mm) 2.32 2.30 2.28 2.30 2.28
Minimum lumen diameter at 9 months (mean: mm) 2.10 2.01 1.70 1.72 2.10
Restenosis rate at 9 months (%) 7.4* 13.0 20.1 21.6 6.7*
TLR at 9 months (%) 7.4* 11.6 20.1 21.6 4.5*
MACE at 9 months (%) 7.9* 13.0 20.1 21.6 4.5*
*p<0.05 vs ZES, ECS
3:30 p.m.
2519-779 Rotational Atherectomy Prior to the Stenting with 
Sirolimus-Eluting Stent for Diffuse In-Stent Restenosis: 
Multicenter Registry in Asia
Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan
Background: Diffuse in-stent restenosis (D-ISR) is still challenging problem and optimal 
treatment has not been established. Methods: To compare the efﬁcacy and safety of 
stenting with Sirolimus-eluting stent (SES) versus rotational atherectomy (mean burr/
artery ratio 0.70, mean burr size 1.97) prior to stenting with SES for the treatment of 
D-ISR, we assessed baseline clinical and angiographic characteristics, in-hospital and 
12-month major adverse cardiac event (MACE) in 488 consecutive patients. Patients 
were divided into 297 patients, 347 lesions treated with one or more SES and 191 
patients, 243 lesions treated with rotational atherectomy prior to SES. Results: The
baseline clinical characteristics between 2 groups were similar. See table for the clinical 
results. Conclusion: Rotational atherectomy prior to Sirolimus-eluting stent provided an 
advantage in terms of long-term clinical and angiographic outcomes. 
SES Rota+SES p
Number of patients/lesions 297/347 191/243 -
In-hospital Procedural success (%) 100 100 NS
MACE (%) 0 0 NS
Lesion length (mm) 30.5 ± 12.6 29.8 ± 13.8 NS
MLD post procedure (mm) 2.68 ± 0.58 2.80 ± 0.70 NS
12-month MACE (%) 0 0 NS
Angiographic restenosis (%) 12.8 5.2 0.05
Repeat PCI (%) 9.4 3.7 0.05
In-lesion late loss 0.30 ± 0.29 0.10 ± 0.14 0.05
3:30 p.m.
2519-780 Clinical impact of treating complex lesions with drug-
eluting stents: is lesion complexity still a predictor of 
worse outcomes - a long-term analysis (up to 6 years) 
of the DESIRE Registry
Jose de Ribamar Costa Jr, Amanda Sousa, Ricardo A. Costa, Adriana C. Moreira, Galo 
Maldonado, Manuel N. Cano, Mariana T. Carballo, Cantídio Campos, Enilton Egito, 
César Jardim, Otávio Berwanger, J. Eduardo Sousa, Instituto de Ensino e Pesquisa do 
Hospital do Coração, São Paulo, Brazil
Background: The superiority of DES over BMS in reducing repeat lesion revascularization 
has prompted physicians to expand the indications of PCI to very complex scenarios, not 
previously included in RCT. We sought to evaluate the very long-term clinical outcomes 
of DES in the off-label scenario.
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Orange County Convention Center, West Hall D
3:30 p.m.
2520-785 Combined antiplatelet therapy and oral anticoagulation 
for diagnostic and interventional coronary procedures.
Helena Tizon-Marcos, Gerald Barbeau, Olivier Bertand, Jean Rock Boudreault, J-Pierre 
Dery, Onil Gleeton, Bernard Noel, CM Nguyen, Eric Larose, Guy Proulx, josep Rodés-
Cabau, Jacques Rouleau, Guy Rossignol, Stephane Rinfret, Robert De Larochellière, 
Laval Hospital, Quebec, QC, Canada
Background: Based on ACCP guidelines, oral anticoagulation (OA) is usually stopped 
before interventional femoral procedures to avoid bleeding(B) and vascular complications 
(C). Bridging therapies (BT) are often used in patients with intermediate/high risk of 
thromboembolism. However, major B associated with BT and PCI is still high and 
thromboembolic C are abolished.
Objective: Evaluate the safety and feasibility of uninterrupted OA for diagnostic and 
interventional coronary procedures.
Methods: Prospective collection of patients (pts) chronically on OA admitted for acute 
coronary syndrome or stable angina from 12-2005 to 09-2008 who had a percutaneous 
coronary proc. with un-interrupted in OA group (OAG, n=73 pts with 76 procedures) or 
with interrupted OA and INR < 1.8 before procedure (control group, CG, n=22).
Results: Pts in the OAG group were older (71±10 vs 66±11, p=0.05), similar in gender, 
risk factors, CHADS2 score (2 in both groups), tendency for more prior CABG (28% vs 
47%, p=0.06), similar left ventricular ejection fraction (46±14% vs 49±9%, p ns), similar 
indications for OA (atrial ﬁbrillation 58% vs 50%) and similar indications for PCI (unstable 
angina 47% vs 59%, p=0.36). Radial approach was >90% in both groups. INR during 
proc. was 2.4±0.4 in the OAG group and 1.3±0.2 in the CG (p=0.04). Unfractionated 
heparin was used in 28% of OAG and in 95% of CG (p=0.03). ICP was performed in 
47% of cases in OAG and 32% in CG (p=0.19). ICP in the OAG was more complex. No 
statistical differences were found in inhospital outcomes in death (0), per-PCI myocardial 
infarction (4% vs 0), bleeding site C (2.6% vs 0) and stroke (0) between OAG and CG.
Conclusions: Coronary diagnostic or interventional procedures with uninterrupted OA 
may be safe and feasible if radial approach is used as no differences in per-procedural 
and in-hospital outcomes were found between OAG and CG.
3:30 p.m.
2520-786 Impact of Bivalirudin Use on Outcomes in 
Nonagenarians Undergoing Percutaneous Coronary 
Intervention
Gilles Lemesle, Laurent Bonello, Axel De Labriolle, Gabriel Maluenda, Sara D. Collins, 
Itsik Ben-Dor, Asmir I. Syed, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, 
William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. 
Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: With an aging population, nonagenarians constitute an increasing 
percentage of patients with coronary artery disease (CAD). We aimed to determine the 
predictors and outcome of nonagenarians undergoing PCI for symptomatic CAD.
Methods: From 2002 to 2007, 171 consecutive nonagenarians underwent PCI in our 
center. The 6-month rate of major adverse cardiovascular events (MACE) including death, 
myocardial infarction (MI), and target lesion revascularization (TLR) was indexed, as was 
in-hospital bleeding.
Results: The population was 52% female. Nearly 30% of patients had diabetes and 
>25% had renal failure. The mean LVEF was 45%. The clinical presentation was a MI in 
59% of the cases. The in-hospital rate of bleeding was 18%. The 6-month rate of MACE 
was 14% and driven by death: 11%. Bivalirudin use was associated with a 42% decrease 
in in-hospital bleeding (Figure). Clinical presentation as MI or cardiogenic shock was 
associated with high rates of in-hospital death: 19% and 30%, respectively. Predictors 
pts with STEMI or who did not have protocol mandated biomarkers collected. The in-
hospital endpoint was a composite of death, MI (adjudicated), or urgent revascularization. 
Stratiﬁcation as off-label required EF <.25, baseline CK-MB>3x ULN, >1 lesion stented, 
bypass graft target, unprotected LMCA or bifurcation, maximum balloon > 4 mm, stenosis 
= 100%, or total stent length > 36 mm.
Results: In the ﬁrst 2 waves (2004-5) 54% of implants were off-label vs 49% in wave 
4. Within wave 4 (2007), DES were used in 74% off-label and in 72% on-label pts. 
Among off-label pts in waves 1 & 2 vs wave 4, stent length was >36 mm in 54% vs 43%, 
bifurcation lesions were dilated in 26% vs 20%, and lesions were in bypass grafts in 10% 
vs 17%. Within wave 4, pts were more likely to receive a DES than a bare metal stent 
(BMS) for >1 lesion treated (OR 1.9), stent length > 36 mm (OR 2.4), lesion > 30mm (OR 
1.7), bifurcation target (OR 1.9), and more likely to receive a BMS for EF <.35 (OR .55), or 
basal CK >3x nl (OR .4). In waves 1 & 2, death/MI, or UR occurred in 10.9% off-label and 
5% on-label pts (adjusted OR 2.32; 95% CI 1.8, 3.1); in wave 4, the composite occurred 
in 9.2% and 4.1%, respectively, (adjusted OR 2.36; 95% CI 1.6, 3.4)
Conclusions: In 2007 compared with 2004-5, off-label implantation of stents decreased. 
Among pts with off-label indications there appeared to be a slight decrease in lesion 
complexity. Multilesion PCI, long lesions, and bifurcations were more likely to be treated 
with DES while pts with elevated CK-MB, or LV dysfunction were more likely to receive 
BMS. With more selective use of DES compared with earlier years, the absolute risk of 
ischemic complications for off-label use decreased, but the risk compared to on-label use 
was unchanged.
3:30 p.m.
2519-783 Incidence of Early (30-day) Stent Thrombosis in Vein 
Graft Intervention: Results from the AMEthyst Study
Srihari S. Naidu, Mark A. Turco, Janine Lane, Laura Mauri, Jeffrey Popma, Dean J. 
Kereiakes, Winthrop University Hospital, Mineola, NY
Background: The incidence of early stent thrombosis in contemporary saphenous 
vein graft (SVG) intervention remains unknown. Differences between individual drug-
eluting stents (DES), and between DES and bare metal stents (BMS) in this setting, are 
uncertain. AMEthyst is the largest SVG intervention study with routine embolic protection.
Methods: Baseline demographic, procedural and clinical characteristics, as well as 30-
day (early) incidence of stent thrombosis, were recorded on 786 patients undergoing SVG 
stenting. Stent thrombosis was deﬁned as angiographic thrombus or subacute closure at 
time of clinically driven angiographic restudy, or cardiac death. Results: 60.2% (n=473) 
received DES (41.7% Taxus, n=195 and 58.3% Cypher, n=273) and 39.8% (n=313) 
received BMS. Compared to BMS patients, DES patients had lower glycoprotein 2b/3a 
receptor inhibitor use (35.5% vs. 51.1%, p<0.001), smaller reference vessel diameter 
(3.02 mm vs. 3.61 mm, p<0.001) and lower plaque volume (94.4 mm3 vs. 131.3 mm3, 
p<0.001). Compared to Cypher, patients who received Taxus were more likely male 
(82.1% vs. 73.6%, p=0.034) and trended older (70.2 vs. 68.3 years, p=0.053). Early stent 
thrombosis for all patients was 0.5%. Incidence of early stent thrombosis between DES 
and BMS patients did not differ, either prior to (0.4% vs. 0.7%, OR 0.65, p=0.67) or after 
adjustment (adjusted OR 1.10, p=0.93). Similarly, there were no differences in early stent 
thrombosis between Taxus and Cypher, either prior to (0.5% vs. 0.4%, OR 1.37, p=0.83) 
or after adjustment (adjusted OR 2.22, p=0.58). Conclusions: SVG stent thrombosis to 
30 days appears infrequent with no apparent differences between drug-eluting stents and 
bare metal stents, or between different drug-eluting stents.
3:30 p.m.
2519-784 Gender and race speciﬁcs Nationwide trends in the 
utilization of multivessel percutaneous coronary 
intervention (MVPCI) in the United State
Mohammad Reza Movahed, Radhakrishnan Ramaraj, Ramin Ebrahimi, Mazen Jamal, 
Mehrtash Hashemzadeh, The Southern Arizona VA Health Care System and Sarver 
Heart Center, Tucson, CA, AZ
Background: We recently reported increases in the nationwide trends in the utilization of 
Multi Vessel Percutaneous Coronary Intervention (MVPCI). The goal of thisstudy was to 
evaluate this trend based on gender and ethnicity.
Method: The Nationwide Inpatient Sample (NIS) database was utilized to calculate the 
age-adjusted rate for PCI from 1988 to 2004 based on race and gender. Speciﬁc ICD-9-
CM codes for Multi vessel PCI were used to compile the data. Patient demographic data 
was also analyzed from the database.
Results: According to the NIS database, MVPCI was performed in 241,319 patients 
from 1988 to 2004. From 1988, the age-adjusted rate for MPCI gradually increased to 
more than 6 times of 1988 in comparison to 2004. [(3.14 per 100,000 (95%CI=2.52-
3.71) for female and [(9.83 per 100,000 (95%CI=7.7-11.86)] for male population for the 
year1988. In 2004 21.95 per 100,000 (95%CI=18.51-25.40) for female and 60.04 per 
100,000 (95%CI=49.89-70.19) for male population (see ﬁgure). This trend was similar 
across different ethnicities except sudden decrease in MVPCI in the Native American 
population in the recent years.
Conclusion: The utilization of MVPCI has increased to 6 times that of 1988 in the year 
2004, with much of the acceleration in the recent years in most races and both genders. 
The cause of this acceleration is most likely related to advancement in the percutaneous 
coronary interventional techniques. 
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2520-788 Elective Percutaneous Coronary Intervention in the 
Elderly: Lessons From the Euro Heart Survey PCI 
Registry
Timm Bauer, Christian Hamm, Anselm Gitt, Helge Möllmann, Matthias Hochadel, Franz 
Eberli, Ricardo Seabra-Gomes, Franz Weidinger, Jean Marco, Uwe Zeymer, Kerckhoff-
Klinik, Bad Nauheim, Germany, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
Background: The number of elderly patients undergoing elective percutaneous coronary 
intervention (PCI) has been increasing year by year. We evaluated age-related differences 
in clinical characteristics, adjunctive medical treatment, procedural details and in-hospital 
outcomes of patients with stable coronary artery disease (CAD) treated with PCI.
Methods: From 2005 to 2008, 40612 consecutive patients undergoing PCI were 
prospectively enrolled into the PCI-Registry of the Euro Heart Survey Programme (99 
centres in 30 ESC-countries). For the present analysis we examined 19712 patients with 
stable CAD who were divided into two groups: >75 years (n=2747, 13.9%, 78.8 ± 3.1 
years) and a75 years (n=16965, 86.1%, 60.6 ± 9.0 years).
Results: Elderly were more frequently female and had more comorbities, including 
diabetes, hypertension, renal insufﬁciency and a history of stroke and congestive heart 
failure. Coronary pathology was more severe. Among elderly the number of segments 
treated was higher and PCI of the left main stem was more often performed. Vascular 
closure devices were more frequently utilised in older patients, and arterial complications 
were also more prevalent. Guideline adherent adjunctive medication was commonly used 
and no age-related differences could be observed. The incidence of in-hospital death (0.5 
versus 0.2%, p<0.01), major bleedings (0.8 versus 0.4%, p<0.0001) and elevated post 
procedural biochemical markers (5.1 versus 3.2%, p<0.0001) was higher among elderly, 
whereas there were no signiﬁcant differences in the rate of non-fatal reinfarction (0.8 
versus 0.7%), stroke (0.1% respectively) and renal failure requiring dialysis (0.5 versus 
0.3%). Age >75 years was a strong predictor of hospital mortality (OR: 2.37, 95%-CI:1.27-
4.41) by multivariate analysis. At discharge elderly patients were more likely to receive 
clopidogrel, while recommended duration of dual antiplatelet therapy was shorter.
Conclusions: In clinical practice the incidence of hospital complications among elderly 
undergoing elective PCI is low. Nevertheless, they face a higher risk than younger 
patients, strongly inﬂuenced by comorbidities and coronary status.
3:30 p.m.
2520-789 Does Bleeding Impact the Outcomes in Patients 
Admitted Without Anemia After Percutaneous Coronary 
Intervention?
Gabriel Maluenda, Gilles Lemesle, Itsik Ben-Dor, Sara D. Collins, Asmir Syed, Yanlin 
Li, Rebecca Torguson, Kimberly Kaneshige, Zhenyi Xue, William O. Suddath, Lowell 
F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Blood loss after PCI is linked with poor outcomes. Patients (pts) with 
bleeding are more often older and have co-morbidities. This study aimed to assess 
whether post PCI bleeding is associated with adverse outcomes in patients with normal 
baseline hematocrit (Hct).
Methods: 3727 consecutive patients with normal Hct (>39 men, >36 women) underwent 
PCI from 2003 to 2007. Of these, 58 (1.6%) had major bleeding (gastrointestinal bleeding, 
Hct drop >15, major hematoma and q2 red blood cell transfusions) and 1017 (27.3%) 
minor bleeding (Hct drop 5-15). Pts with cardiogenic shock were excluded. Death and 
myocardial infarction (MI) were systematically indexed at 1-year follow-up.
Results: Pts who presented with any bleeding were older and had more renal 
insufﬁciency and history of congestive heart failure. At 1 year, the composite death-
MI was signiﬁcantly lower in the no bleeding group vs the 2 other groups, minor and 
major bleeding: 3.0% vs 5.1% and 19.0% (p=0.003 and p<0.001, respectively). After 
adjustment for known covariates, major bleeding as compared to no bleeding remained 
independently associated with death and MI up to 1 year; however, minor bleeding was 
no longer associated after this adjustment. (Table)
Conclusions: This study showed that major bleeding, but not minor bleeding, predicts 
independently adverse outcomes in this selected, less ill population. This suggests that 
even if major bleeding is more frequent in older and sick pts, major bleeding by itself 
worsens the prognosis.
Clinical predictors for one year composite death and Q-wave 
myocardial infarction
Univariate Cox Proportional 
Model
Multivariate Cox 
Proportional 
HR 95 % CI p HR 95 % CI p
Age 1.0 1.0-1.1 < 0.001 1.0 1.0-1.1 < 0.001
Male gender 0.6 0.5-0.8 0.002 0.8 0.6-1.1 0.202
Diabetes Mellitus 2.2 1.6-3.0 < 0.001 1.8 1.3-2.5 0.001
Chronic renal failure 4.4 3.1-6.1 < 0.001 2.3 1.5-3.3 < 0.001
Congestive heart failure 3.8 2.7-5.4 < 0.001 2.6 1.8-3.7 < 0.001
Acute MI presentation 1.4 0.9-2.1 0.124 1.7 1.1-2.7 0.019
Major Bleeding 6.5 3.6-12.0 < 0.001 1.0 2.1-7.5 < 0.001
Minor Bleeding 1.7 1.3-2.4 0.001 1.3 0.9-1.8 0.341
of 6-month MACE were clinical presentation as MI or cardiogenic shock, renal failure 
and stent length.
Conclusions: Nonagenarians represent a population with a high percentage of females 
and a high incidence of comorbidities. They have logically a worse prognosis than is 
reported in younger patients, with especially high rates of in-hospital bleeding. Bivalirudin 
use should be considered more often in the elderly since it reduces bleeding, and 
improves early outcome.
3:30 p.m.
2520-787 The Effect of Renal Impairment on Outcomes from the 
Real-World EFive Registry
Martin T. Rothman, Ian T. Meredith, Nakul Sinha, Praveen Chandra, Antonio Merchan 
Herrera, Chaim Lotan, For the E-FIVE Registry Investigators, The London Chest 
Hospital, London, United Kingdom
Background: Renal impairment (RI) is a predictor of poor outcome in patients with 
cardiovascular disease, but its inﬂuence in the setting of percutaneous coronary 
intervention (PCI) and stent implantation is not well described. We evaluated clinical 
outcomes in patients with RI from the E-Five Registry.
Methods: E-Five was a prospective, multicenter, nonrandom, global registry of 8314 
patients at 188 centers on 4 continents. All patients with symptomatic coronary artery 
disease amenable to stenting were eligible. Moderate/severe RI was deﬁned as serum 
creatinine (SCr) q140 μmol/L, and mild RI included patients with SCr < 140μmol/L. 
Renal transplant patients were excluded. MACE (death, MI, emergency cardiac bypass 
surgery, or target lesion revascularization [TLR]) and stent thrombosis were adjudicated 
by a Clinical Events Committee. Events at 1 year were compared between groups using 
adjusted logistic regression.
Results: Baseline SCr was available in 6720 patients, and 437 had SCr q140 μmol/L. 
Patients with moderate/severe RI were more often male (81% vs. 76%, p = 0.02); were 
older (68 vs. 63 years), had more diabetes (52% vs. 31%) and hypertension (84% vs. 
68%) (all P<0.001) and were more likely to have a previous MI or revascularization. 
Lesion characteristics were similar. Patients with moderate/severe RI had a higher rate of 
MACE, cardiac death, cardiac death plus MI and late stent thrombosis (Table).
Conclusions: RI is an important risk factor in patients undergoing PCI and stent 
implantation.
1-year Clinical Outcome
Moderate/Severe Renal 
Impairment (SCr q 140 
μmol/L)
N=437
Mild Renal 
Impairment 
(SCr <140 
mol/L)
N=6283
P-Value*
MACE, % (n/N) 13.5 (56/416) 7 (414/5934) 0.003
Death (all), % (n/N) 9.9 (41/416) 1.8 (109/5934) <0.001
Cardiac death, % (n/N) 5.3 (22/416) 1.4 (84/5934) <0.001
MI (all), % (n/N) 2.9 (12/416) 1.5 (89/5934) 0.156
Q-wave MI, % (n/N) 0.7 (3/416) 0.3 (18/5934) 0.304
Non-Q-wave MI, % (n/N) 2.2 (9/416) 1.2 (72/5934) 0.295
Emergent CABG, % (n/N) 0 0
TLR, % (n/N) 4.3 (18/416) 4.5 (269/5934) 0.355
Cardiac death + MI, % (n/N) 6.7 (28/416) 2.7 (159/5934) 0.003
ARC deﬁnite + probable 
stent thrombosis, % (n/N)
0-30 days
31-365 days
2.6 (11/416)
1.4 (6/416)
1.4 (6/416)
1.1 (63/5934)
0.7 (42/5934)
1.0 (22/5934)
0.039
0.347
0.008
*P-values were calculated using logistic regression adjusted for propensity scores for 
RI with no renal transplant [mod/severe creatinineq 140 μmol/l) vs. [mild (creatinine < 
140 μmol/l). Propensity scores were calculated using: sex, age, prior MI, prior PCI, prior 
CABG, diabetes, acute MI (<72hrs), hypertension, hypercholesterolemia, smoking, LAD 
(vs. non-LAD), B2C (vs. AB1), lesion length (q 27mm vs. <27mm), and RVD (> 3.5mm 
vs. a3.5mm).
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2520-792 Impact of Anemia on Long-term All Cause Mortality 
After Percutaneous Coronary Intervention in African-
Americans.
Shyam Poludasu, Jonathan D. Marmur, Jeremy Weedon, Erdal Cavusoglu, SUNY 
Downstate Medical Center, Brooklyn, NY
Background: Anemia has been shown to be an independent predictor of long-term 
mortality after percutaneous coronary intervention (PCI). African Americans are known to 
have lower hemoglobin (Hgb) levels compared to Caucasians. The impact of anemia on 
long-term mortality in African Americans undergoing PCI is unknown.
Methods: We evaluated a total of 715 African Americans (313 with anemia and 402 
without anemia as deﬁned by WHO deﬁnition of anemia [Hgb < 13 g/dl for men; Hgb < 
12 g/dl for women]).
Results: After a median follow up of 3.2 (interquartile range 2.4 to 3.8) years, there were 
a total of 72 (10%) deaths. The survival rate was 84% in the anemic group and 94% in 
the control group (Unadjusted p < 0.001 by log-rank test; hazard ratio [HR]: 2.8). After 
adjustment for baseline clinical and procedural characteristics using a Cox proportional 
hazards model, Hgb as a dichotomous variable was a strong and independent predictor 
of all-cause mortality (adjusted p = 0.003; HR for death: 2.2; 95% conﬁdence interval :
1.3-3.7). Also, when Hgb was analyzed as a categorical variable having three groups 
with empirically determined cutoffs at <10.5, 10.5 to <12.5, and >=12.5 g/dl, the effect 
remained signiﬁcant (p=0.001), with HR of 3.3 for the group with lowest hemoglobin 
when compared to the highest group and HR of 2.1 for the group with Hgb 10.5 to <12.5 
compared to the highest Hgb group.
Conclusion: Baseline hemoglobin is a strong and independent predictor of all-cause 
long-term mortality in African Americans undergoing PCI.
3:30 p.m.
2520-793 Should Patients who Develop Anemia (Hematocrit a
27%) After Percutaneous Coronary Intervention be 
Transfused?
Gabriel Maluenda, Gilles Lemesle, Asmir Syed, Sara D. Collins, Itsik Ben-Dor, Yanlin 
Li, Rebecca Torguson, Kimberly Kaneshige, Zehnyi Xue, William O. Suddath, Lowell 
F. Satler, Kenneth M. Kent, Joseph Lindsay, Augusto D. Pichard, Ron Waksman, 
Washington Hospital Center, Washington, DC
Background: Bleeding and blood transfusion after PCI are associated with higher 
mortality. Some have adopted a hematocrit (Hct) <27% as a threshold for transfusion 
post PCI. However, the impact of red blood cell (RBC) transfusion at this level of Hct 
is unknown. This study aimed to assess whether RBC transfusion at this threshold 
inﬂuences the frequency of adverse outcomes.
Methods: 379 patients whose Hct fell to a27 % after PCI were reviewed. We compared 
the patients who received RBC transfusion to those who did not. Death and myocardial 
infarction (MI) at 1-year follow-up were systematically indexed.
Results: The transfused patients (n = 203, 53.5 %) were more often female and more often 
presented with acute MI and cardiogenic shock. The average nadir Hct was similar for both 
groups (24.1 vs 24.2%). Univariate analysis suggested that those receiving transfusion had 
a greater incidence of death or MI (26.6% vs 17.2%, p = 0.048). After the multivariate Cox 
adjustment, no correlation between transfusion with the endpoint remained (p = 0.7).
Conclusion: This study does not support a beneﬁcial effect of RBC transfusion in such a 
“high risk” population (Hct drop < 27%). There are other stronger predictors that determine 
death and MI at 1-year follow-up.
Clinical predictors for death and myocardial infarction at 1-year follow up
Univariate Cox Proportional 
Model
Multivariate Cox 
Proportional Model
HR 95 % CI p HR 95 % CI p
Age 1.0 1.0-1.1 0.02 1.0 1.0-1.1 0.005
Diabetes Mellitus 1.8 1.2-2.6 0.005 1.9 1.2-3.0 0.003
Chronic renal failure 1.9 1.3-2.8 0.001 1.5 1.0-2.3 0.062
Chronic renal failure 1.9 1.3-2.9 0.001 1.8 1.2-2.7 0.005
Acute MI Presentation 1.7 1.1-2.5 0.01 1.8 1.1-2.8 0.02
Cardiogenic Shock 2.3 1.5-3.5 <0.001 2.0 1.2-3.1 0.004
Transfusion 1.5 1.0-2.1 0.048 1.1 0.7-1.6 0.7
3:30 p.m.
2520-790 Ethnicity and gender based Nationwide trends in the 
utilization of percutaneous coronary intervention (PCI) 
in the United State
Mohammad Reza Movahed, Radhakrishnan Ramaraj, Mazen Jamal, Ramin Ebrahimi, 
Mehrtash Hashemzadeh, The Southern Arizona VA Health Care System and Sarver 
Heart Center, Tucson
Background: We recently reported increases in the nationwide trends in the utilization 
of Percutaneous Coronary Intervention (PCI). The goal of this study was to evaluate this 
trend based on gender and ethnicity using a large data base from 1988 to 2004.
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate the 
age-adjusted rate for PCI from 1988 to 2004. Speciﬁc ICD-9-CM codes for all PCIs were 
used to compile the data. Patient demographic data was also analyzed from the database.
Results: The NIS database contained 1,747,736 patients who had PCI performed from 
1988 to 2004. The From 1988, the age-adjusted rate for all PCI gradually increased to 
more than double until 2001 but remained relatively unchanged (slight decline in last 
few years of the study) until end of the study in 2004 for both gender. [For male in the 
year1988: 117.35 per 100,000 (95%CI=93.08-141.62, p<0.01). For female in 1988: 
39.29 per 100,000 (95%CI=31.49-47.09, p<0.01). For male in the year 2004: 323.09 
per 100,000 (95%CI=268.49-377.68, p<0.01).For female in the year 2004: .131.66 
per 100,000 (95%CI=111.01-152.31, p<0.01). These trends were similar across the 
ethnicities. See ﬁgure.
Conclusion: The utilization of PCI has dramatically increased to more than double from 
1988 to 2001 but remained unchanged thereafter regardless of ethnicity or gender. These 
trends could be related to the approval of drug eluting stents or secondary to improving 
in the secondary prevention. 
3:30 p.m.
2520-791 Safety of Drug-Eluting Stents in Patients with Severe 
Left Ventricular Dysfunction: One Year Data from the 
NHLBI Dynamic Registry
Srihari S. Naidu, Faith Selzer, Helen Vlachos, Elizabeth Holper, Robert L. Wilensky, 
David Holmes, Winthrop University Hospital, Mineola, NY
Background: Patients with left ventricular (LV) dysfunction may be at particular risk for 
ischemic events after percutaneous coronary intervention, including stent thrombosis. We 
utilized the NHLBI Dynamic Registry to evaluate whether drug-eluting stents (DES) are 
safe in patients with signiﬁcant LV dysfunction. Methods: Baseline characteristics, as well 
as in-hospital and one-year outcomes were collected prospectively on 754 consecutive 
patients with ejection fraction < 40% undergoing stent placement during three successive 
Waves of enrollment between 2001 and 2006. BMS patients in Wave 3 (n=257), prior 
to the introduction of DES, were compared to DES patients in Waves 4 and 5 (n=497). 
Results: Mean ejection fraction was similarly reduced (DES 31.6% vs. 31.3%, p=0.58). 
DES patients were more often hypercholesterolemic (77.3% vs. 65.2%, p<0.001) with 
prior stent placement (28.8% vs. 21.0%, p<0.05), while BMS patients were more likely to 
present with positive troponin (62.3% vs. 51.3%, p<0.05), ST-elevation (29.2% vs. 21.5%, 
p<0.05), and prior coronary bypass (24.5% vs. 22.8%, p<0.05). DES lesions were longer 
(17.2 mm vs. 13.0 mm, p<0.001), more frequently calciﬁed (30.7% vs. 18.4%, p<0.001), 
higher lesion class (Type C 30.9% vs. 17.5%, p<0.001), and more often elective (48.5% 
vs. 38.5%, p<0.05). Procedural success was similar (DES 97.6% vs. 95.7%, p=0.16), 
although DES patients more likely had post-procedure troponin elevation (34.1% vs. 
24.1%, p<0.01). In-hospital death (DES 1.8% vs. 2.7%, p=0.41) and the combined 
endpoint death or myocardial infarction (MI, DES 3.6% vs. 4.3%, p=0.66) were similar. 
By one year, cumulative rates and adjusted risk (aHR) of death (DES 9.19 vs. 10.20%, 
p=0.64, aHR 0.65, 95% CI 0.38-1.13) and MI (5.01% vs. 5.88%, p=0.67, aHR 0.88, 
95% CI 0.43-1.79) did not differ, nor did the combined endpoint death or MI (13.06% vs. 
14.94%, p=0.48, aHR 0.76, 95% CI 0.48-1.20). Stent thrombosis in DES patients was 
0.84% at one year. Conclusions: DES appear safe in moderate to severe left ventricular 
dysfunction, with similar procedural, in-hospital and one-year outcome compared to BMS, 
and low incidence of stent thrombosis.
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Conclusions: In the DESIRE registry the negative impact of renal dysfunction was 
considerably minimized by the use of DES, resulting in very low and equivalent rates 
of myocardial infarction, TLR and ST when compared to patients with preserved renal 
condition. We especulate that the higher mortality among these very complex pts may 
reﬂect the severity of their co-morbities.
I2.POSTER CONTRIBUTIONS
2521
Endovascular
Monday, March 30, 2009, 3:30 p.m.-4:30 p.m.
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3:30 p.m.
2521-796 Contrast Induced Nephropathy in Patients Undergoing 
Peripheral Vascular Intervention: Incidence, Risk 
Factors, and Outcomes
Paul Michael Grossman, Khan Munir, Hitinder S. Gurm, Paul G. Bove, Steven K. Wang, 
James M. Fox, Herbert D. Aronow, Timothy J. Nypaver, Arthur Riba, David Share, Mauro 
Moscucci, University of Michigan, Ann Arbor, MI
Background: This study was undertaken to determine the incidence, risk factors and 
outcomes associated with contrast induced nephropathy (CIN) after peripheral vascular 
intervention (PVI).
Methods: Data were analyzed from 3407 PVI cases prospectively collected in a multi-
center database. Patients with prior renal failure were excluded. CIN after PVI was deﬁned 
as an increase in serum creatinine (Cr) from baseline to post-PVI peak Cr of q 0.5 mg/dl. 
A maximum weight and Cr adjusted contrast dose was calculated, (MACD = body weight 
in Kg X 5cc / pre-intervention Cr).
Results: CIN occurred in 3.8% of patients. The MACD was exceeded in 8.1% of the 
total cohort. Renal failure requiring dialysis occurred in 4.8% of CIN patients. CIN was 
associated with exceeding the MACD (13.9% vs. 7.9%, p=0.02) and age > 75 (42.7% 
vs. 34.3%, p=0.05). Clinical characteristics, in-hospital complications and outcomes are 
displayed (table). Independent predictors of CIN (c statistic=0.75) were: Cr clearance 
<30 ml/min (OR 5.3, 95% CI 2.0-13.6, p=0.0006), diabetes (OR 1.5, CI 1.0-2.5, p=0.05), 
anemia (OR 1.7, CI 1.1-2.8, p=0.01), CHF (OR 1.9, CI 1.2-3.0, p=0.009) and CVD (OR 
1.6, CI 1.05-2.5, p=0.03).
Conclusions: CIN after PVI is relatively common and is associated with signiﬁcant 
adverse events. CIN post-PVI is related to preexisting anemia, diabetes, CHF, CVD, lower 
Cr clearance, and exceeding MACD. These data suggest the need to limit CIN post-PVI, 
and to evaluate methods for doing so in multi-center, randomized clinical trials.
Clinical Characteristics, Post-PVI In-Hospital Outcomes and 
Complications
CIN Group Non-CIN group P value
Anemia (%) 63.7 38.5 <0.0001
Diabetes (%) 55.6 41.5 0.002
Congestive heart failure (CHF) (%) 37.1 20.1 <0.0001
Cerebrovascular disease (CVD) (%) 41.9 27.1 0.0003
Death (%) 12.9 0.4 <0.0001
Myocardial Infarction (%) 10.5 0.5 <0.0001
Vascular Complication (%) 29.0 4.1 <0.0001
Transfusion (%) 39.5 6.3 <0.0001
Procedural success (%) 86.3 87.4 0.7
3:30 p.m.
2521-797 Intravascular Ultrasound Imaging in First-In-Man Study 
with Bevacizumab-Eluting Stent. 12 Months Follow Up
Konstantinos Toutouzas, Elli Stefanadi, Andreas Synetos, John Karampelas, Eleutherios 
Tsiamis, Dimitrios Tousoulis, Nicholas Kiphsidze, Christodoulos Stefanadis, 1st Cardiology 
Clinic, University of Athens, Medical School, Hippokration Hospital, Athens, Greece
Background: Bevacizumab is a monoclonal antibody against vascular endothelial 
growth factor (VEGF). Neovascularization of atherosclerotic plaque is mainly mediated 
by VEGF. Previous experimental results with bevacizumab-eluting stent showed inhibition 
of neovascularization in a rabbit atheromatic model. In this study we demonstrate the 
intravascular ultrasound (IVUS) ﬁndings of the ﬁrst-in-man application of these stents.
Methods: Patients with acute coronary syndromes and >2 signiﬁcant coronary 
artery stenoses were included in the study. The culprit lesions were successfully 
treated percutaneously. The targeted non-culprit lesions were 50%). Local delivery of 
bevacizumab was accomplished via BiodivYsio stents, which have a phosphorylcholine 
coating that adsorbs the drug. Patients were discharged under aspirin and clopidogrel 
for 12 months. All patients were scheduled for clinical and angiographic follow-up at 12 
months, and intravascular ultrasound (IVUS) imaging of the target vessel immediately 
after the procedure and at 12 months. IVUS measurements included lumen Area (LA), 
neointimal hyperplasia area (NIHA), stent area (SA) and vessel area (VA).
Results: No acute or subacute thrombosis was observed. IVUS follow-up did not reveal 
any restenosis (50% vessel narrowing). Stent malapposition was not observed in any 
patient. Mean VA (13.3±0.9 vs 13.4±0.9 mm2), mean SA (6.4±0.5 vs 6.4±0.6 mm2) and 
3:30 p.m.
2520-794 Angiographic and clinical outcomes of severe 
calciﬁed lesions requiring rotational atherectomy in 
hemodialysis (HD) and non-hemodialysis patients after 
sirolimus-eluting stent (SES) implantation
Hiroyuki Kyono, Ken Kozuma, Yoshitaka Shiratori, Shuichi Ishikawa, Kumiko Konno, 
Hirosada Yamamoto, Hidenori Watanabe, Akiyoshi Miyazawa, Takeshi Yamakawa, 
Naoyuki Yokoyama, Takaaki Isshiki, Teikyo University Hospital, Tokyo, Japan
Background: Severe calciﬁed lesions and hemodialysis are both predictors for high rates 
of restenosis, even in the drug-eluting stent era. We sought to investigate the angiographic 
and clinical outcome in a population of hemodialysis vs. non-hemodialysis patients with 
severe calciﬁed lesions requiring rotational atherectomy.
Methods: 100 consecutive lesions (28 lesions in HD group, 72 in non-HD group) from 94 
patients that underwent rotational atherectomy prior to SES implantation were analyzed 
post-procedure and at 8 months. Clinical outcomes were assessed out to 8 months. 
Inclusion criteria were calciﬁed lesions with > 270 degrees of superﬁcial calciﬁcation on 
IVUS, lesions that IVUS could not cross, or undilatable lesions.
Results: There were no differences in patient characteristics except for age (HD 64.2±1.7, 
non-HD 72.7±6.99, P=0.003). Both baseline and post-procedure angiographic ﬁndings were 
similar between the two groups, late-loss and binary restenosis at 8 months were signiﬁcantly 
higher in HD group. Also, HD group revealed signiﬁcantly worse clinical outcomes (Table).
Conclusions:Mid-term results of highly complex, severely calciﬁed lesions requiring 
rotational atherectomy in non-HD patients were acceptable. However, in HD patients, 
both angiographic and clinical outcomes were suboptimal in this lesion subset. Further 
approaches for HD patients, beyond plaque debulking and current DES, are warranted.
3:30 p.m.
2520-795 Long-term(80mo) Clinical Follow-up After Drug-eluting 
Stents Implantation in patients with Chronic kidney 
disease in the DESIRE(Drug-Eluting Stents In the REal 
world) Registry
Adriana Moreira, Amanda Sousa, J.Ribamar Costa, Jr., Ricardo Costa, Manuel Cano, 
Galo Maldonado, Fausto Feres, Luciano Cavalcante, Cantidio Campos, Mariana 
Carballo, Abrãao Cury, Otavio Berwanger, Marcos Barbosa, J.Eduardo Sousa, Hospital 
do coração - ASS, São Paulo, Brazil
Background: Chronic renal disease has been consistently shown to be an independent 
predictor of poorer long-term clinical outcomes after percutaneous treatment of coronary 
artery disease, even in DES era. We sought to evaluate the very long-term clinical 
outcomes after DES implantation in this high risk subset in a real world scenario.
Methods and Results: Between May/2002 and Nov/2008, 2,700 pts treated exclusively 
with DES were consecutively enrolled in the non-randomized, single-center DESIRE 
Registry. Recent STEMI (72h), lesions in SVG and patients with < 6months follow-up 
were excluded. The remaining pts (n=1500) were divided into 2 groups according to their 
creatinine clearance: Group I -Clearance <60 (n= 490) and Group II- clearance >60 (n= 
1010). Primary endpoint included combined MACE and stent thrombosis (ST) rate. ST 
was classiﬁed according to ARC deﬁnitions. Clinical follow-up was obtained at 1, 6 and 12 
months and then annually. Follow-up was achieved in 98% of the eligible cohort (median 
3.6 years). Baseline characteristics and late outcomes are displayed in the table. 
Clearance a 60
(n=490)
Clearance >60
(n= 1010) p
Male gender, n(%) 286 (58.4%) 854 (84.55%) < 0.0001
Age (years) 74.3 + 10.2 55.4 + 8.3 <0.0001
Diabetes, n(%) 136 (27.7%) 281 (27.8%) 0.973
Unstable angina, n(%) 171 (34.9%) 296 (29.3%) 0.03
Multivessel disease, n(%) 136 (27.7%) 269 (26.6%) 0.69
St / P ratio , n(%) 1.53 1.54 0.52
Cumulative events (late outcome) , n(%)
Myocardial infarction 17 (3.5%) 27 (2.7%) 0.49
Target lesion revascularization 10 (2.0%) 33 (3.3%) 0.24
Cardiac death 15 (3.1%) 12 (1.2%) 0.019
Major adverse cardiac events 42 (8.6%) 72 (7.2%) 0.376
Stent thrombosis
(ARC deﬁnitions) 5 ( 1.0%) 12 (1.2%) 0.97
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3:30 p.m.
2521-800 Impact of Temporal Cessation of Vasodilators 
on Coronary Artery Spasm as Assessed with 
Intracoronary Acetylcholine Provocation Test
Kang Yin Chen, Seung-Woon Rha, Yong Jian Li, Kanhaiya L. Poddar, Jae Hyoung Park, 
Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, 
Hong Seog Seo, Dong Joo Oh, Korea University Guro Hospital, Seoul, South Korea
Background: Vasodilators are usually temporally stopped before the intracoronary 
acetylcholine (ACh) provocation test, a widely used method for detecting vasospastic 
angina. However, little has been known about the impact of temporal cessation on 
coronary artery spasm (CAS) as assessed with this method.
Methods: A total of 1199 patients (pts) presented with chest pain underwent coronary 
angiography were enrolled. Acetylcholine was injected into left coronary artery in 
incremental doses of 20μg/ min, 50μg/ min and 100μg/ min. Vasodilators were withheld 3 
days before the test. Signiﬁcant CAS was deﬁned as a transient > 70% luminal narrowing 
with concurrent chest pain and/ or ischemic ST-segment change.
Results: After 3-day cessation, pts treated with nitrates, nicorandil, diatiazem and/
or molsidomine had signiﬁcantly higher incidence of CAS than those without previous 
treatment (P<0.001). There was a trend toward signiﬁcantly higher incidence of CAS in 
pts who stopped other calcium channel blockers (CCB) for blood pressure control (35.6% 
vs 29.2%, P=0.055). The incidences of CAS in pts who stopped angiotensin converting 
enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) and beta-blockers were 
similar to those in pts without previous treatment. Multivariate logistic analysis showed 
that the cessation of nitrates, nicorandil and diltiazem was signiﬁcantly associated with 
the higher incidence of CAS, whereas, the cessation of beta-blockers was associated 
with reduced CAS. The cessation of other CCB, ACEI, ARB and trimetazine did not 
signiﬁcantly inﬂuence on the incidence of CAS.
Conclusions: The temporal cessation of antianginal agents for 3 days was independently 
associated with higher incidence of CAS. Therefore, the cessation of antianginal agents 
should be cautious, and the confounding effect of vasodilator should be taken into account 
when we perform the ACh provocation test.
3:30 p.m.
2521-801 Cost Effectiveness of Angiography to Prevent 
Hemodialysis-Access Thrombosis
John A. Bittl, Ocala Heart Institute, Ocala, FL, Munroe Regional Medical Center, Ocala, 
FL
Background: Approximately $1B is spent annually in the U.S. for hemodialysis vascular 
access, but the optimal approach for maintaining the patency of arteriovenous ﬁstulas 
and grafts is unknown. We sought to determine the value of pre-emptive angiography and 
angioplasty to prevent access thrombosis.
Methods: We conducted a cohort-based, cost-effectiveness analysis using data from a 
closed population of 560 hemodialysis patients referred for 1437 radiographic procedures 
during an 8.0-year period. Bottom-up microcosting methods provided measures of supply 
and personnel costs.
Results: Between 1999 and 2007, the rate of invasive surveillance for malfunctioning 
but non-thrombosed hemodialysis accesses rose from 18.8 to 48.3 angiograms per 100 
hemodialysis patients per year (P<0.001). Stenosed accesses undergoing angiographic 
surveillance before thrombosis had a median patency of 348 days (interquartile range 
[IQR] 296, 400 days]), whereas thrombosed accesses undergoing de novo catheter-
based thrombectomy had a median patency of 162 days (IQR 140, 184 days). Expansion 
of the invasive surveillance program was associated with a decline in the annual 
incidence of access thrombosis from 27.8 to 21.6 events per 100 hemodialysis patients 
(P=0.029). The incremental annual cost (in constant 2007 U.S. dollars) to prevent one 
access thrombosis was $14,286 per 100 hemodialysis patients. The estimated annual 
programmatic cost to prevent one access thrombosis in the average-sized cohort of 375 
patients alive at any time was $53,571.
Conclusions: The increased use of angiographic surveillance of non-thrombosed 
hemodialysis accesses may have produced a small reduction in access thrombosis. 
The tradeoff between costs and clinical outcomes in an aggressive screening program 
remains uncertain.
3:30 p.m.
2521-802 Risk of Perforation or Rupture During Percutaneous 
Treatment of Hemodialysis Fistulas and Grafts
John A. Bittl, Ocala Heart Institute, Ocala, FL, Munroe Regional Medical Center, Ocala, FL
Background: Venous stenoses in the outﬂow limb of dialysis ﬁstulas and grafts frequently 
require ultra-high balloon pressure or cutting-balloon angioplasty for optimal dilatation. 
The aim of this study was to analyze the risk and consequences of free perforation or 
rupture of hemodialysis accesses during catheter-based intervention.
Methods: Procedural characteristics and outcomes were analyzed for a consecutive 
series of patients treated by one operator over an 8-year period.
Results: In 1242 consecutive ﬁstulograms referred for catheter-based treatment, free 
perforation or rupture occurred in 11 patients (0.9%). No patient with a perforation or 
rupture died, but 2/11 required transfusion (18.2%), and 8/11 required stenting (72.7%), 
of whom 6 required covered stents (75.0%). Vessel perforation was seen in 3 cases in 
which the balloon catheter was at least 2 mm larger than the diameter of the ﬁstula or graft 
and in 3 separate cases where cutting balloons were used (Figure).
Conclusions: Rupture or perforation is a rare complication during catheter-based 
therapies for dialysis ﬁstulas and grafts. The complication may be avoided by optimal 
balloon selection and sizing. 
mean LA (6.4±0.5 vs 5.6±0.7mm2) were similar after the procedure of stent implantation 
and at follow up (p=NS). Mean NIHA at follow up was 0.8±0.5 mm2 (12.4±7.7%).
Conclusion: IVUS measurements indicate that bevacizumab-eluting stents are effective 
for the treatment of non-culprit de novo lesions in patients suffering from acute coronary 
syndromes.
3:30 p.m.
2521-798 Outcomes of Renal Artery Stenting in Patients With 
Severely Impaired Renal Function
Suresh Ramamurthy, Mubashir Ahmed, Abinet Boku, Samer Shuaib, Tonga Nfor, 
Anthony DeFranco, Anjan Gupta, Tanvir Bajwa, Suhail Allaqaband, Aurora Sinai/Aurora 
St. Luke’s Medical Ctrs, Univ Wisconsin School of Medicine and Public Health-MCC, 
Milwaukee, WI
Background: Optimal management of renal artery stenosis (RAS) in patients with advanced 
renal failure is controversial. Our aim was to assess the effect of renal artery stenting in 
slowing progression to renal failure and in improving blood pressure (BP) control.
Methods: Three hundred nine patients with q70% single or dual RAS were stented 
between January 2002 and June 2007. Patients were grouped into those with creatinine 
< 2mg/dl (mild renal failure) (N=233) and those with creatinine >2.0 mg/dl (advanced 
renal failure) (N=76). Pre and post intervention CR, BP, and number of antihypertensive 
medications were analyzed using T-test.
Results: Mean age was 73±9 yrs. There were more females in the group with mild renal 
failure (65% vs 45%, respectively). There were no signiﬁcant differences between the 
groups for history of diabetes, hyperlidemia, smoking. During mean follow-up of 16 months 
post renal stenting, there was no signiﬁcant change in renal function overall. Blood pressure 
control improved in both groups, but signiﬁcantly more in the advanced renal failure group. 
Mean systolic blood pressure improvement (20 vs 15 mmHg) and diastolic blood pressure 
improvement (11 vs 6 mmHg) was seen in both groups post stenting.
Conclusions: Renal artery stenting for stenosis results in lower blood pressure in 
patients with mild renal failure, and even better blood pressure control in patients with 
advanced renal failure, regardless of any adjunct antihypertensive regimen. 
creatinine < 2 mg/dl pre intervention post intervention p value
systolic BP, mean ± SD 151±27 136±21 <0.0001
diastolic BP, mean ± SD 76±14 70±12 <0.0001
medications, mean ± SD 3±1.5 3±1.5 0.963
creatinine, mean ± SD 1.25±0.33 1.45±0.82 0.001
creatinine q 2 mg/dl pre intervention post intervention p value
systolic BP, mean ± SD 153±28 133±21 <0.0001
diastolic BP, mean ± SD 78±17 67±13 <0.0001
medications, mean ± SD 3.2±1.3 3.2±1.4 0.884
creatinine, mean ± SD 2.79±0.93 2.61±1.46 0.206
3:30 p.m.
2521-799 Longevity of Superior Mesenteric Artery Stents
Athar Saeed, Atif Saeed, Joaquin Solis, Anjan Gupta, Suhail Allaqaband, Tanvir Bajwa, 
Aurora Sinai/Aurora St. Luke’s Medical Ctrs, Univ Wisconsin School of Medicine and 
Public Health-MCC, Milwaukee, WI
Background: Superior mesenteric artery stenosis (SMAS) can lead to incapacitating 
symptoms. Due to the low number of these procedures, there have been few studies that 
look at long-term patency.
Methods: All consecutive patients who underwent angioplasty and stenting of SMAS 
between 1/2003 and 12/2007 were included. All procedures were performed at the same 
center by an experienced interventional cardiologist or interventional radiologist. Patients 
were followed for an average of 22 months and restenosis was monitored both clinically, 
and by ultrasound, angiography, MRA, or CTA.
Results: A total of 28 patients were included. Clinical, angiographic, and procedural data 
are summarized in the table. A total of 32 procedures were performed, with a procedural 
success rate of 100%. In our population, we observed restenosis in 14 out of 32 total 
placed stents. There was a statistically signiﬁcant relationship between restenosis and 
recurrence of symptoms (11/14 of restenosis) (p=0.003 by Yates correction) in contrast to 
no recurrence of symptoms in the patients with patent stents.
Conclusion: Our study showed a 44% rate of restenosis, with a majority of these patients 
showing a recurrence of symptoms, which was shown to be statistically signiﬁcant. In 
addition, stent width (p=0.03) and age (p=0.012) were also deﬁned as independent risk 
factors through multivariate analysis. Larger prospective studies with longer follow-up are 
required. 
ANGIOGRAPHIC, PROCEDURAL AND F/U DATA
Mean ±sd, n(%)
Number of patients 28
Total stents 32
All in stent restenosis 14 (44)
Age 71± 9.7
Stent diameter (mm) 6 ± 0.94
Stent length (mm) 21 ± 9.17
Multi-vessel involvement 23 (72)
Procedural success 25(100)
Symptomatic improvement S/P stenting 100%
Duration of follow-up (m)
Clinical follow-up (mean) 21 months
Diagnostic follow-up (mean) 13.5 months
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Results: In 2,104 patients, median age was 74 years, 37% were women, 29% had prior 
TIA and 28% previous stroke. TIA occurred in 78 (3.7%) patients from the procedure 
through 30-day follow up; 73% of TIAs occurred on or before post-procedure day #1. 
Independent predictors of peri-procedural TIA included age, symptomatic status, number 
of stents implanted, use of GP IIb/IIIa inhibitors and absence of hypertension. The 
incidence of neurological death + stroke in patients who suffered peri-procedural to 30-
day TIA colmpared with those who did not appears below (Table).
Conclusion: Peri-procedural TIA associated with carotid stenting is uncommon and is 
not associated with an increased incidence of the composite 30-day neurological death 
+ stroke. 
30-Day Outcome No Peri-Procedural TIA Peri-Procedural TIA P-Value
Neurological death or stroke 3.6% 6.8% 0.14
3:30 p.m.
2521-805 A Simple Method to Calculate Cerebral Blood Flow 
After Carotid Stenting by Using Carotid Frame Count 
and Guidewire Length
waleed Y. kadro, Yaman Rai Balha, Maya Turkmani, Omar Shiekh Mouss, Tarek Alsaied, 
Hussam Eddin Alrahim, The Golden Cardiovascular Center, Damascus, Syrian Arab 
Republic
Background: The Carotid frame count (CFC) is a relative index of cerebral blood ﬂow 
that measures time by counting the number of frames required for dye to travel from a 
beginning standardized carotid landmark (The point of common carotid artery bifurcation 
into internal and external branches) to an end standardized carotid landmark (The point 
of internal carotid artery bifurcation into anterior and middle cerebral branches) in an 
angiogram ﬁlmed at a known speed frames/s).
Methods: We describe a new method to measure distance along arteries so that absolute 
velocity (length ÷ time) and absolute ﬂow (area × velocity) may be calculated in patients 
undergoing percutaneous carotid stenting (CS). After CS, the guidewire tip is placed at 
the end carotid landmark and a Kelly clamp is placed on the guidewire where it exits the 
Y-adapter. The guidewire tip is then withdrawn to the beginning carotid landmark and 
a second Kelly clamp is placed on the wire where it exits the Y-adapter. The distance 
between the 2 Kelly clamps outside the body is the distance between the beginning and 
the ending anatomic landmarks inside the body. Velocity (cm/s) may be calculated as this 
distance (cm) ÷ carotid frame count (frames) / ﬁlm frame speed (frames/s). Flow ml/s) 
may be calculated by multiplying this velocity (cm/s) and the mean cross-sectional lumen 
area (cm2) along the length of the carotid artery between the two landmarks.
Results: In 25 patients, velocity increased from 9.9 ± 4.5 cm/s before to 14.8 ± 4.3 cm/s 
after CS (p <0.001). For all 25 patients, ﬂow increased from 2.4 ± 0.2 ml/s before to 4.1 ± 
0.3 ml/s after CS (p <0.001).
Conclusions:Distance along carotid arteries (length) can be simply measured using CS 
guidewire. This length may be combined with the Carotid frame count to calculate cerebral 
blood absolute velocity and ﬂow that are sensitive to changes in perfusion.
3:30 p.m.
2521-806 Percutaneous Renal Artery Revascularization 
versus Medical Therapy for Renal Artery Stenosis: A 
Prospective Randomized Trial
Aaron W. Sweeney, Fadi Hage, Raed Aqel, George Phillips, Gilbert Perry, Gilbert 
Zogbi, David Calhoun, University of Alabama at Birmingham, Cardiovascular Disease, 
Birmingham, AL, Birmingham Veterans Affairs Medical Center, Division of Cardiology, 
Birmingham, AL
Background: Renal artery stenosis (RAS) accounts for around 10% of hypertension 
and 20% of end-stage renal disease. Data from randomized studies are lacking on the 
value of percutaneous revascularization (PR) in the management of RAS. We performed 
a prospective randomized trial comparing PR to medical therapy (MT) in patients with 
atherosclerotic RAS.
Hypothesis: Hypertensive patients with signiﬁcant RAS who undergo PR along with MT 
will have better blood pressure control compared to MT alone.
Methods: Adult hypertensive patients on blood pressure medications were eligible for the 
study if they had a central aortic pressure of 135mmHg or more and RAS of 75% or more, 
or RAS of 50% or more with a gradient of no less than 10mmHg across the stenosis on 
renal angiography. Patients were randomized to either PR or MT after renal angiography 
if they provided informed consent.
Results: 71 patients have been randomized out of whom 36 have completed 6 months 
follow-up (19 patients in the PR arm and 17 patients in the MT arm). Both the systolic 
and diastolic blood pressures dropped in the PR arm (128.5 +- 4.3 mmHg versus 142.3 
+- 3.6 mmHg, P<0.05 and 66.2 +- 2.2 versus 72.9 +- 2.0 mmHg, P<0.05) while they did 
not change in the MT arm (134.8 +- 4.1 versus 138.8 +- 3.3 mmHg, P=0.4 and 66.8 +- 2.0 
versus 71.0 +- 3.1 mmHg, P=0.2). Number of BP medications did not signiﬁcantly change 
from baseline to 6 months in both groups. In the MT group, 4 (24%) patients crossed 
over and underwent PR due to failure to achieve target blood pressure at 6 months with 
maximal medical therapy. 1 (6%) patient in the MT group and no patients in the PR group 
were hospitalized for non-protocol related cardiovascular events.
Conclusions: Preliminary ﬁndings from our ongoing randomization trial show that PR can 
lower blood pressure in patients with RAS and hypertension better than MT alone at 6 months. 
This is an on-going study to determine the usefulness of PR in the management of RAS.
3:30 p.m.
2521-803 Carotid Artery Stenting For Signiﬁcant Carotid Stenosis 
in Patients With Contralateral Occlusion: The German 
ALKK CAS - Registry Experience
Rajendra H. Mehta, Ralf Zahn, Matthias Hochadel, Harald Mudra, Thomas Ischinger, 
Karl E. Hauptmann, Jens Jung, Hubert Seggewiss, Uwe Zeymer, Jochen Senges, Duke 
Clinical Research Institute, Durham, NC, Institut für Herzinfarktforschung Ludwigshafen, 
University of Heidelberg, Ludwigshafen, Germany
Background: Data on the safety and efﬁcacy of carotid artery stenting (CAS) in large 
number of patients (pts) with contralateral carotid occlusion (CCO) are less known.
Methods: We studied 3137 pts undergoing CAS enrolled in a German Registry (2000-
2008, 31 sites). We compared the clinical and angiographic features and hospital 
outcomes of pts with and without CCO undergoing CAS.
Results: Of the 3137 pts undergoing CAS, 191 (6.1%) had CCO. Despite similar age of 
the 2 groups, those with CCO had a higher comorbidities, more complex carotid stenosis 
and more focal lesions on the contralateral side on CT imaging. In-hospital events 
including death (1.0% vs 0.5%), ipsilateral major stroke (1.1% vs 1.1%), death or major 
ipsilateral stroke (1.6% vs 1.4%), ipsilateral transient ischemic attack (2.7% vs 2.5%), 
and myocardial infarction (0.4% vs 0.1%) were all low and was not different between pts 
with and without CCO (p>0.05). Outcomes stratiﬁed by symptoms and CCO are shown 
in Table suggesting that most major adverse events were conﬁned to symptomatic pts 
with CCO.
Conclusions: Our data in large number of pts undergoing CAS in contemporary practice 
attest to low risk of periprocedural events among pts with CCO. Most major adverse events 
were conﬁned to symptomatic pts with CCO. This overall low risk of stroke and/or death 
together with its relatively less invasive nature and the ability to maintain uninterrupted 
cerebral perfusion during the procedure should make CAS an attractive option for the 
treatment of these pts.
In-hospital outcomes stratiﬁed by the presence of absence of 
symptoms
Variable
Symptomatic
Patients 
with Carotid 
Occlusion
Symptomatic
Patients 
without
Carotid
Occlusion
P
value
Asymptomatic
Patients 
with Carotid 
Occlusion
Asymptomatic
Patients 
without
Carotid
Occlusion
P value
Ipsilateral 
Transient 
Ischemic
attack
2.2% 2.3% 1.000 3.6% 2.6% 0.475
Ipsilateral 
Major Stroke 2.2% 1.5% 0.646 0% 0.6% 1.000
Contralateral 
Ischemic
Events
3.3% 1.1% 0.096 1.2% 0.4% 0.305
In-hospital
Mortality 2.2% 0.5% 0.103 0% 0.3% 1.000
Ipsilateral 
Major
Stroke or 
In-hospital
Mortality
3.3% 1.8% 0.413 0% 0.8% 1.000
3:30 p.m.
2521-804 Incidence, Predictors and Prognostic Signiﬁcance of 
Peri-Procedural Transient Ischemic Attack Associated 
With Carotid Stenting: Observations From the Cordis 
Carotid Stent Collaborative
Herbert D. Aronow, Hong Wang, Jay S. Yadav, Kenneth Ouriel, Barry T. Katzen, 
Christopher J. Kwolek, Sidney Cohen, Michigan Heart & Vascular Institute, Ann Arbor, MI
Background: Although the incidence of peri-procedural death and stroke with carotid 
stenting has been well characterized, little is known about transient ischemic attack (TIA) 
in this setting.
Methods: We pooled data from 4 Cordis-sponsored carotid stent trials, including the 
Continued Access Registry, CASES, SAPPHIRE and ADVANCE to identify the incidence, 
predictors and prognostic signiﬁcance of TIA within 30 days of the procedure. Independent 
predictors of peri-procedural TIA were determined from stepwise logistic regression. The 
primary endpoint was the 30-day incidence of neurological death + stroke.
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3:30 p.m.
2522-809 Evaluation of Neointimal Coverage of Long-term 
Follow-up Evaluation after Sirolimus-Eluting Stents 
and Paclitaxel-eluting Stents Implantation by Optical 
Coherence Tomography
MIN ZHAO, Jan Minners, Thomas Comberg, Micheal Gick, Klaus Werner, Achim 
Buettner, Franz-Josef Neumann, Heart Center, Bad Krozingen, Germany, Heart Center 
of Beijing Friendship Hospital, Beijing, People’s Republic of China
Background: Drug-eluting stents (DES) inhibit neointimal proliferation which may result 
in uncovered stent struts and predispose to the formation of stent thrombosis. Optimal 
coherence tomography (OCT) is a high-resolution imaging technique which can detect 
neointimal hyperplasia (NIH) in DES.
Methods: Patients who had DES more than 1 year ago and standard dual-antiplatelet therapy 
(long-term aspirin 100mg, clopidogrel 75mg daily for 6 months) after stenting were included. 
We used Modiﬁed OCT (non-occlusive) technique to evaluate the amount of neointimal 
coverage after DES implantation in consecutive stented coronary artery lesions.
Results: 36 DES (18 Sirolimus-Eluting Stent (SES), 18 Paclitaxel-eluting Stent (PES)) in 
29 patients(68.21±12.43 years old, 17 male) were examined by OCT. The average follow up 
period is 642,31±248,94days. Totally 2199 struts in 358 cross-sectional images of 279mm 
single-stented segments were analysed. Mean neointimal thickness of all struts that with 
neointima was 176.31±79.59μM, which were similar in SES and PES (115.09±40.55 μM 
vs. 208.36±64.62 μM, p=0,12). It showed that 22% (483 of 2199) of total struts were still 
exposed without neointima even more than one year after DES implantation. Frequencies 
of non-neointima coverage was 21.15±16.61%, which showed 20.84±12.27% in SES and 
22.17±17.41% in PES (p=0,28). The OCT identiﬁed 1 thrombus in 1 patient in SES group with 
neither abnormal ﬁndings on coronary angiograms nor clinical manifestations in this study.
Conclusions:DES had incomplete neointimal coverage even one year after stent 
implantation but resulted in no clinical events, there was no difference between SES and 
PES. 6 months duration of dual-antiplatelet therapy seems inadequate.
3:30 p.m.
2522-810 Three-Dimensional Bifurcation Angle Analysis in 
Patients With Left Main Disease: a Substudy of the 
SYNergy Between Percutaneous Coronary Intervention 
With TAXus and Cardiac Surgery (SYNTAX) Trial
Chrysaﬁos Girasis, Yoshinobu Onuma, Marie-Claude Morice, Antonio Colombo, David 
R. Holmes, Ted E. Feldman, Keith D. Dawkins, Patrick W. Serruys, Thoraxcenter, 
Erasmus Medical Center, Rotterdam, The Netherlands, Cardialysis BV, Rotterdam, The 
Netherlands
Background: Bifurcation angle (BA) is emerging as an independent predictor of 
outcome after PCI of bifurcation lesions. Three-dimensional (3-D) quantitative coronary 
angiography (QCA) eliminates the shortcomings of 2-D analysis, thus providing reliable 
data. We explore the variables describing the BA of the Left Main (LM) and the impact of 
PCI on this angulation.
Methods: This is a substudy of the SYNergy between percutaneous coronary intervention 
with TAXus and cardiac surgery (SYNTAX) trial. We reviewed the cineangiograms of the 
354 patients with LM disease who were randomized to PCI. Analysis was performed with 
3-D QCA software (Cardiop-B, Paieon Medical Inc, Israel). The proximal BA (between LM 
and LCx) and the distal BA (between LAD and LCx) were computed in enddiastole and 
endsystole, both pre- and post-PCI; the variation of the BA during the heart cycle was 
also determined.
Results: Complete analysis with 3-D QCA was feasible in 266 (75.1%) patients. Post-PCI 
there was a signiﬁcant reduction in the width of the distal angle. The proximal angle was 
not modiﬁed signiﬁcantly (table). During systolic motion there was an enlargement of 
the proximal angle and a reduction of the distal angle (p<0.001 for both). The prognostic 
signiﬁcance of these measurements will be presented at the time of the congress.
Conclusion: Left Main bifurcation angle analysis with 3-D QCA is feasible. PCI affects the 
distal angle, whereas both proximal and distal angles are affected by the heart’s motion. 
Left Main Bifurcation Angles, pre- and post-PCI
Pre-PCI Post-PCI p-value
Diast_prox_BA 106.1 ± 22.0 107.8 ± 21.6 0.142
Syst_prox_BA 113.9 ± 19.8 114.8 ± 19.0 0.409
Var_prox_BA 12.0 ± 9.7 11.0 ± 8.9 0.149
Diast_dist_BA 95.6 ± 23.9 91.0 ± 22.2 <0.001
Syst_dist_BA 86.7 ± 23.1 82.8 ± 21.1 <0.001
Var_dist_BA 11.7 ± 9.7 11.9 ± 9.2 0.737
Student’s t-test, p<0.05 signiﬁcant. Values are in degrees.
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3:30 p.m.
2522-807 Percutaneous Interventions in Unprotected Left 
Main Lesions: Novel Three-Dimensional Imaging and 
Quantitative Analysis Before and After Intervention
Danny Dvir, Abid Assali, Eli Lev, Itsik Ben-Dor, Alexander Battler, Ran Kornowski, Rabin 
Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Background: Difﬁculties in performing percutaneous interventions in unprotected left 
main (LM) may be partly attributable to failure of conventional angiography to properly 
image vessel morphology and plaque distribution. The objective of this study was to 
examine the potential yield of three-dimensional (3D) reconstruction of LM coronary 
lesions.
Methods: 3D reconstruction of the coronary vessels was used to evaluate 302 
angiographic images, before and after stenting, from 62 consecutive patients (age 73.5 ± 
11.3 years) with unprotected LM lesions.
Results: 3D reconstructions signiﬁcantly improved morphological analysis, especially 
for ostial and bifurcation lesions. In cases of bifurcation involvement, lesion length was 
signiﬁcantly longer in the 3D reconstructions than in the 2D images (12.3±4.1 mm vs. 
10.6±4.9 mm, p=0.003). The 3D analysis showed that procedures performed in distal 
LM were associated with a decrease in the bifurcation angle after intervention (from 
82±27º to 72±28º, p=0.01). Elective interventions were associated with signiﬁcantly lower 
mortality than emergent procedures (5% vs. 39% at 6 months).
Conclusions: 3D reconstruction adds insights on the morphology and lesion length of 
unprotected LM lesions, especially those involving the bifurcation, which may make it an 
important tool in planning interventional procedures and evaluating their results.
A. Ostial. B. Shaft C. Distal. D. Bifurcation (note a decrease in the bifurcation angle after 
intervention).
3:30 p.m.
2522-808 Relationship between the change of ﬁbrous cap 
thickness and plaque morphology: Six months 
follow-up study of optical coherence tomography and 
intravascular ultrasound
Ryotaro Yamada, Hiroyuki Okura, Teruyoshi Kume, Takahiro Kawamoto, Yoji Neishi, 
Yoshinori Miyamoto, Akihiro Hayashida, Kiyoshi Yoshida, The Sakakibara Heart Institute 
of Okayama, Okayama, Japan, Kawasaki Medical School, Kurashiki, Japan
Background: Recently, in vivo assessment of a thin ﬁbrous cap has become possible using 
high resolution optical coherence tomography (OCT). The pathological characteristics of 
vulnerable plaque prone to rupture are a positively remodeled vessel, a thin ﬁbrous cap 
(<65μm) with macrophage inﬁltration into the cap and including a large necrotic core. 
Natural course of the ﬁbrous cap and the relationship between serial arterial remodeling 
and changes in ﬁbrous cap thickness is unknown. Therefore, the purpose of this study 
was to evaluate the relationship between changes in ﬁbrous cap thickness and arterial 
remodeling by using OCT and intravasucular ultrasound (IVUS) during 6 months follow-up.
Methods: Three vessel IVUS and OCT examination was performed in 10 patients with 
angina pectoris. Thirteen ﬁbroatheroma (plaque burden > 40 %) were detected by IVUS. 
Fibrous cap thickness of the ﬁbroatheroma was measured by OCT. IVUS and OCT were 
repeated at 6 months follow up.
Results: Fibrous cap thickness was increased during 6 months follow-up 
(70.0±32.2l94.2±41.9μm). Percent change in ﬁbrous cap thickness (%delta cap) was 
correlated negatively (r=-0.645, p=0.041) with the change in external elastic membrane 
cross sectional area (%delta EEM-CSA) (Figure ).
Conclusions: Arterial remodeling may be related to change ﬁbrous cap thickness.
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Results: 111 of 469 STEMI patients had identiﬁable LAD culprit lesions (mean age 
58±14 years, 69% male). Most culprit lesions, 93%, were located in the proximal 50mm 
of the LAD. Overall, culprit lesions were more likely to be located immediately distal to 
bifurcations: 52% within 5mm, 74% within 10mm, 85% within 15mm, p<0.01 (graph). 
Median distance from bifurcation to culprit lesions was 4.6 mm. We observed a positive 
correlation between side branch diameter and the distance from the culprit lesion to the 
bifurcation (r=0.49, p<0.01), with smaller diameter branches having LAD lesions closest 
to the branch artery.
Conclusion: Arterial bifurcations and branch artery diameter inﬂuence location of LAD 
culprit lesions, suggesting that disturbances in wall shear stress are implicated in plaque 
formation and rupture. 
3:30 p.m.
2522-814 A Novel Approach to Quantitative Analysis of 
Intravsacular Optical Coherence Tomography Imaging
Nico Bruining, Kenji Sihan, Charl Botha, Frits Post, Nieves Gonzalo, Evelyn Regar, 
Ronald Hamers, Erasmus MC, Rotterdam, The Netherlands, TU-Delft, Delft, The 
Netherlands
Objectives and Background: Quantitative analysis on intracoronary optical coherence 
tomography (OCT) image data (QOCT) is currently performed by a time-consuming 
manual contour tracing process in many individual OCT images acquired during a 
pullback (frame-based method). In order to get an efﬁcient quantitative analysis process, 
we developed a full-automated lumen contour detection method and evaluated the results 
against those derived by human observers.
Methods: The automated method has been developed using Matlab (The Mathworks, 
Natick, MA, USA) and uses an adapted Canny ﬁlter to detect the lumen borders. The 
process runs fully automated and allows the observer to change individual results in 
case of possible errors. OCT image data, acquirevd with a commercially available system 
(Lighlab imaging, Westford, MA, USA) in 20 randomly selected patients were used for 
this validation study.
Results: A total of 4137 individual OCT images were analyzed. There was no statistical 
signiﬁcant difference in lumen areas between the two methods (5.03±2.16 vs. 5.02±2.21 
mm2, p=0.6; respectively (human vs. automated)). Regression analysis showd a good 
correlation with an R value of 0.99 (Figure). The full automated analysis requires on average 
2-5 seconds per frame and in only 3% of the contour data correction was necessary.
Conclusion: The present study shows that full-automated lumen contour detection in 
OCT images is feasible with only a sparse few frames showing an artifact, which can be 
easily corrected.
.
3:30 p.m.
2522-811 The Use of Transcranial Doppler in the Detection of 
Right-to-Left Shunt in the Catheterization Laboratory
Paul Poommipanit, Hohai Van, Mostafa Shalaby, Jonathan Tobis, UCLA, Los Angeles, CA
The purpose of this study was to determine the sensitivity of different methods of 
detecting right-to-left shunts. Transesophageal echocardiography (TEE) has traditionally 
been the most reliable diagnostic technique for assessment of intracardiac shunts. Some 
patients with a high clinical suspicion for patent foramen ovale (PFO) have inconclusive 
studies, in part due to a lack of cooperation with the Valsalva maneuver from sedation. 
Twenty seven consecutive patients were brought to the cardiac catheterization laboratory 
for PFO closure where simultaneous transcranial Doppler (TCD) and intracardiac 
echocardiography (ICE) were performed. Right atrial pressures were measured at rest, 
with Valsalva and with forced exhalation into a manometer to 40mmHg. Prior to PFO 
closure, the average right atrial pressures were as shown in the table below.
Of the 27 patients who had their PFOs closed, 3 had false-negative TEE studies with 
positive TCD studies. TCD was also more sensitive than intracardiac echo for estimating 
the degree of shunt. This study conﬁrms that inadequate intrathoracic pressures are 
frequently generated with a voluntary Valsalva maneuver, thus conﬁrming a potential 
mechanism for false negative agitated saline transesophageal echocardiograms in the 
assessment of intracardiac shunts.
Right Atrial Pressures
RA Pressure at rest RA Pressure with Valsalva RA Pressure against manometer
6.6 ± 2.7 mm Hg. 22.2 ± 13.6 mmHg* 37.2 ± 6.8 mmHg*
*compared to rest 
(p<0.001) during Valsalva maneuver (p<0.001)
3:30 p.m.
2522-812 Relation Between N-Terminal Pro-B-Type Natriuretic 
Peptide and Coronary Plaque Components in Patients 
with Acute Coronary Syndrome: Virtual Histology-
Intravascular Ultrasound Analysis
Youngkeun Ahn, Young Joon Hong, Doosun Sim, Nam Sik Yoon, Hyun Ju Youn, Kye 
Hun Kim, Hyung Wook Park, Seung Uk Lee, Hyung Wook Park, Ju Han Kim, Myung 
Ho Jeong, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, Chonnam National 
University Hospital, Gwangju, South Korea, Gwangju, South Korea
Background: The N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a sensitive 
indicator of hemodynamic stress and its increased level is associated with higher mortality in 
acute coronary syndrome (ACS) patients. Virtual histology-intravascular ultrasound (VH-IVUS) 
can provide quantitative information on plaque components. We used VH-IVUS to evaluate the 
relation between NT-pro-BNP levels and plaque components in patients with ACS.
Methods: We measured pre-procedural serum NT-pro-BNP levels in 156 ACS patients 
with preserved left ventricular systolic function and normal serum creatinine. VH-IVUS 
classiﬁed the color-coded tissue into four major components: ﬁbrotic; ﬁbro-fatty; dense 
calcium; and necrotic core (NC). Thin-cap ﬁbroatheroma (TCFA) was deﬁned as focal, 
NC-rich (q 10% of the cross-sectional area) plaques being in contact with the lumen in a 
plaque burden q 40%. We divided the patients into two groups according to the NT-pro-
BNP levels [Group I: q 200 pg/ml (n=58) vs. Group II: < 200 pg/ml (n=98)].
Results: The percent area of NC at the minimum lumen site (19.8±13.1% vs. 
15.2±11.1%, p=0.027) and at the largest NC site (24.7±10.3% vs. 19.2±11.4%, p=0.015) 
were signiﬁcantly greater in Group I than in Group II. Percent NC volume was signiﬁcantly 
greater in Group I than in Group II (15.8±8.1% vs. 10.1±9.1%, p=0.008). The total number 
of TCFAs was 38 in group I and 56 in group II. The presence of at least one TCFA (58% 
vs. 38%, p=0.009) and multiple TCFAs (25% vs. 10%, p=0.005) within culprit lesions were 
observed more frequently in Group I than in Group II. The TCFAs were located more in 
proximal in Group I than in Group II [the length from coronary ostium to TCFA: 10.8±7.6 
mm in Group I vs. 25.7±16.3 mm in Group II (p<0.001).] 85% of TCFAs was located within 
20 mm from coronary ostium in Group I; conversely only 36% of TCFAs was located within 
20 mm from coronary ostium in Group II (p<0.001).
Conclusions: VH-IVUS analysis demonstrates that ACS patients with high NT-pro-BNP 
levels had more vulnerable plaque component (more NC-containing lesions and higher 
frequency of culprit lesion TCFAs) and had more proximally located TCFAs.
3:30 p.m.
2522-813 Culprit Lesions in Patients With Anterior ST Elevation 
Myocardial Infarction Are Located Immediately Distal to 
Bifurcations
Ahmad M. Jeroudi, Omar R. Kashlan, Erin M. Galbraith, Eric L. Krivitsky, Michael C. 
McDaniel, Collins A. Kwarteng, Saurabh S. Dhawan, Jin Suo, Don Giddens, John S. 
Douglas, Habib Samady, Emory University, Atlanta, GA, Georgia Institute of Technology, 
Atlanta, GA
Background: Anterior ST elevation myocardial infarction (STEMI) culprit lesions are 
clustered in the proximal left anterior descending artery (LAD). Based on ﬂuid dynamics 
principles, we hypothesized that these culprit lesions are located immediately distal to 
bifurcations where ﬂow is non-laminar.
Methods: Emory University’s contribution to the National Cardiovascular Data Registry 
was queried for STEMIs presenting from January 2006 to July 2008. Culprit lesions were 
deﬁned as site of vessel occlusion or severe stenosis. Quantitative coronary angiography 
was used to measure distance from culprit lesion to LAD ostium and to the nearest 
proximal branch artery >1mm diameter.
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3:30 p.m.
2523-817 Rate of Neointimal Coverage is Different According to
Initial Clinical Presentation and Types of Drug-Eluting
Stents; Optical Coherence Tomography Findings
Jung-Sun Kim, Jung Myung Lee, Jin-Sun Kim, Yong Sung Seo, Sung Il Paik, Young-
Guk Ko, Donghoon Choi, Yangsoo Jang, Namsik Chung, Division of Cardiology, Yonsei 
University, Seoul, South Korea
Background: Acute coronary syndrome (ACS) has a different pathophysiology from 
stable angina (SA) and might has a different pattern of NC. Recently, optical coherence 
tomography (OCT) was introduced in clinical practice and could detect a NC with high 
resolution. Therefore, we compared NC patterns at 9 months after drug eluting stents 
(DES)implantation between ACS and SA using OCT. Method: OCT was performed at 
9-month follow-up with 50 ACS (20 in sirolimus eluting stent (SES), 12 in paclitaxel eluting 
stent (PES) and 18 in zotarolimus eluting stent (ZES)) and 42 SA (15 in SES, 12 in PES 
and 15 in ZES). NIH thickness, percent NIH area and rate of malapposition were measured 
at each stent strut and corss section. Results: In total, 20842 struts in 2180-mm single-
stented segments were analyzed. Overall, NIH thickness and percent NIH area were not 
different between ACS and SA (173 ± 100 vs. 163 ± 125 μm, p = 0.670 and 21 ± 11 vs. 
18 ± 11 %, p =0.447). But rates of stent strut coverage (93.1 vs. 98.3 %, p=0.009, Figure 
1) and rate of malapposition (1.8 vs. 0.4 %, p = 0.002) were signiﬁcantly higher in ACS. 
According to the type of stents, SES has a different pattern of NC according to presence 
of ACS compared to other 2 DESs (Figure 1). Conclusion: Neointimal coverage rate at 
9-month after stent implantation was signiﬁcantly different between ACS and SA and 
especially, SES has a different pattern of NC. Therefore, present study suggested that NC 
might be inﬂuenced by initial clinical presentation and type of DESs.
3:30 p.m.
2523-818 Is An Accurate Evaluation Of The Left Circumﬂex
Ostium From The Left Anterior Descending-Left Main
Possible? An Intravascular Ultrasound Study
Carlos Oviedo, Akiko Maehara, Gary S. Mintz, Damiana Fiscella, Kenichi Tsujita, 
Takashi Kubo, Hiroshi Doi, Celia Castellanos, Junqing Yang, Roxana Mehran, George 
D. Dangas, Martin B. Leon, Gregg W. Stone, Hiroshi Araki, Masahiko Ochiai, Jeffrey W. 
Moses, Cardiovascular Research Foundation - Columbia University Medical Center, 
New York, NY
Treatment of left main (LM) distal bifurcations can depend on ostial left circumﬂex 
(LCX) disease severity. We asked the question whether intravascular ultrasound (IVUS) 
assessment of the LCX ostium requires direct imaging or is accurate from the left anterior 
descending (LAD)-LM pullback.
Methods: In 126 patients with LM bifurcation disease (angiography diameter stenosis 
q50% and IVUS plaque burden (PB) q40%), we analyzed both pullbacks - from the LAD 
and from the LCX. (1) During the main branch pullback (i.e., from the LAD), we evaluated 
the side branch ostium (i.e., of the LCX) by estimating its lumen diameter and presence 
of signiﬁcant plaque. We used 2 cut-offs for signiﬁcant PB: 40% and 70%. (2) We then 
compared this oblique view with direct ostial measurements during LCX pullback. (3) 
Finally, we repeated this process imaging in the ostial LAD from the LCX.
Results: From the LAD, the estimated LCX ostial lumen diameter was 3±0,8mm 
compared to the actual diameter of 2,9±0,6mm. From the LCX, the estimated LAD ostial 
lumen diameter was 2,9±1,1mm vs. the actual diameter of 2,8±0,5mm. However, Bland-
Altman plot (Figure) showed signiﬁcant variation in these comparisons. The oblique 
view assessment of signiﬁcant PB using 2 cut-offs (40% or 70%, Figure) showed good 
sensitivity, but poor speciﬁcity.
Conclusion: IVUS evaluation of the LCX ostium from the LAD-LM (or of the LAD ostium 
from the LCX-LM) is only modestly reliable. For an accurate assessment of the ostium of 
the side branch, direct imaging is necessary. 
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3:30 p.m.
2523-815 Unraveling the Lack of Neointimal Hyperplasia Detected
by Intravascular Ultrasound using Optical Coherence
Tomography: Lack of Spatial Resolution or a True
Biological Effect?
Hiram G. Bezerra, Giulio Guagliumi, O. Valescchi, N. Lortkipanidze, Noah Rosenthal, 
Satoko Tahara, Hiroyuki Kyono, Daniel Simon, Marco A. Costa, University Hospitals 
Harrington-McLaughlin Heart & Vascular Institute, Cleveland, OH, Ospedali Riuniti di 
Bergamo, Bergamo, Italy
Introduction: Intravascular ultrasound (IVUS) frequently depicts absence of neointimal 
hyperplasia(NIH) after drug-eluting stents (DES). Histology studies suggest that IVUS 
may be unable to detect small amounts of NIH. OCT has a 10X higher spatial resolution 
compared with IVUS. The aim of this study was to evaluate the ability of OCT to detect 
NIH and malapposition in stented coronary segments showing no NIH or malapposition 
by IVUS at 6-month post-implantation.
Methods: A subanalysis of the ODESSA trial, a single-center prospective randomized, 
controlled study enrolling patients with long lesions requiring stent in overlap. Patients 
were randomized to drug eluting stents and bare metal stent in a 2:2:2:1 ratio. IVUS 
and OCT analyses were performed by an independent core laboratory. Stented coronary 
segments showing no (zero) NIH and no strut malapposition by IVUS were included. 
Detailed OCT strut level analysis was performed at every 0.3 mm intervals to determine 
NIH area and strut-level NIH thickness and malapposition.
Results: In 75 patients with complete follow-up imaging, 250 stented segments were 
analyzed by IVUS and OCT. Zero NIH and no malapposition were found in 20 segments 
in 11 patients (15%). There were 6968 cross-sections and 43096 struts analyzed by 
OCT. A signiﬁcant correlation was observed between IVUS and OCT for stent lumen 
area r=0.8 (p=0.01). However, OCT measured an average of 0.72 mm2 ± 0.63 of NIH per 
cross section and identiﬁed malapposition in 31% of segments. Indeed, 92.7% ± 15% of 
struts were covered by tissue. The degree of strut coverage varied considerably ranging 
from 35% to 100% coverage. There were no segments with complete absence of strut 
coverage by OCT, in contrast to a homogenous lack of NIH detected by IVUS. Of the 3146 
uncovered strus detected by OCT, 96% were apposed.
Conclusion: All cases without identiﬁable NIH by IVUS have certain amount of tissue 
coverage detected by OCT strut-level analysis. In addition, undetected strut malapposition 
and heterogeneous pattern of strut tissue coverage were depicted by OCT. This study 
supports the need of high resolution imaging such as OCT to properly evaluate local 
vascular responses to potent drug-eluting stents.
3:30 p.m.
2523-816 Black Spot Surrounding Stent Struts Observed by
Optical Coherence Tomography; What Do These
Represent?
Tomohiko Teramoto, Fumiaki Ikeno, Jennifer Lyons, Hiromasa Ootake, Alan C. Yeung, 
Stanford University Cardiovascular Medicine, Stanford, CA
Background: Optical coherence tomography (OCT) has recently merged into the ﬁeld of 
interventional cardiology.We have observed characteristic “black spot” images surrounding 
stent struts using OCT post drug eluting stent (DES) deployment (image 1 left, Arrow 
head). The purpose of this study is to reveal what these “black spot” represent .
Methods: A total of 36 stents (16 bare metal stent (BMS) and 20 DES) were deployed 
in the coronary arteries of 6 pigs. At one month, OCT was performed. The animals were 
then sacriﬁced and histological analysis was performed.
Results: The “black spots” appeared with signiﬁcantly higher frequency in the DES group 
than BMS group (65% (13/20) vs. 19% (3/16), p<0.001). Percent neointimal volume on 
DES group was signiﬁcantly higher in the “black spot” (+) group than “black spot” (-) group 
(45.5±18.3 vs. 27.6±18.9, p=0.05). Upon histological analysis, ﬁbrin was mainly observed 
at the “black spot” site corresponding OCT image. Hyalironic acid and proteoglycan 
were also observed, and in small amounts, neutrophil and macrophage inﬁltration. 
Conclusions: We currently think that these “black spots” surrounding stent struts might 
have some correlation with neointimal hyperplasia post DES deployment. According to 
the histological analysis, it seemed that hyaluronic acid and proteoglycan replaced ﬁbrin. 
The “black spots” seemed to represent the process of ﬁbrin resolution.
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IVUS. In vivo study demonstrated that there was a signiﬁcant correlation between AC by 
OCT and stent expansion (r = -0.59, p = 0.02), but not between AC by IVUS and stent 
expansion (r = -0.40, p = 0.13). AC > 2.0 cm2 could predict stent underexpansion (MSA < 
80% of the reference area) with a sensitivity of 71 % and a speciﬁcity of 78%.
Conclusion: Both OCT and IVUS underestimated AC, but OCT estimates of AC were 
more accurate than those estimated by IVUS. Thus, OCT may be a more useful clinical 
tool to quantify calciﬁed plaque and predict stent expansion.
3:30 p.m.
2523-821 Presence of a Ramus Intermedius is Associated with 
More Proximal LAD Culprit Lesions in Patients with 
Anterior ST Segment Elevation Myocardial Infarctions
Erin Michelle Galbraith, Ahmad M. Jeroudi, Omar R. Kashlan, Eric Krivitsky, Michael 
C. McDaniel, Collins A. Kwarteng, Jin Suo, Don Giddens, Douglas C. Morris, John S. 
Douglas, Habib Samady, Emory University, Atlanta, GA, Georgia Institute of Technology, 
Atlanta, GA
Background: Fluid dynamic principles suggest that left main trifurcations result in 
greater ﬂow disturbances in the very proximal left anterior descending (LAD) artery. We 
hypothesized that in patients presenting with anterior ST elevation myocardial infarction 
(STEMI), the presence of a ramus intermedius (RI) artery is associated with more 
proximal LAD culprit lesions resulting in larger infarcts.
Methods: Emory’s contribution to the National Cardiovascular Data Registry was queried 
for STEMIs presenting from January 2006 to July 2008. Culprit lesions were deﬁned as 
site of occlusion or severe stenosis. A RI was considered present when its diameter was q
1mm. Quantitative coronary angiography was used to measure distance from LAD ostium 
to the culprit lesion in patients with and without RI. Peak troponin-I (TN-I), peak creatinine 
kinase MB (MB), and left ventricular ejection fraction by ventriculography were used as 
markers for infarct size.
Results: Among 469 STEMI patients, 137 had native LAD STEMI. Of these, 111 patients 
had identiﬁable culprit lesions (age 58±14 years, 69% male). Mean distance from LAD 
ostium to culprit lesion was 15.2 ± 11.0 mm in RI patients (n=27) and 27.8 ± 16.7 mm 
in non-RI patients (n=84), p<0.01. Culprit lesions within the LAD were more proximal in 
the RI vs. non-RI patients: 0-10mm: 37% vs. 12%, p<0.01, and 0-20mm: 67% vs. 33%, 
P<0.01. Those with RI tended to have higher peak TN-I values (74 ± 40 ng/ml vs. 60 ± 40 
ng/ml, p<0.13) and were more likely to have peak TN-I values > 90 ng/ml (69% vs. 42%, 
p<0.02) compared to the non-RI patients. Similary, RI patients were more likely to have 
peak MB >200 ng/ml, (67% vs. 43%, p<0.05), with peak MB levels only slightly higher in 
the RI group compared to the non-RI group, 310 ± 250 ng/ml vs. 250 ± 240 ng/ml, p<0.25. 
Left ventricular ejection fraction was not signiﬁcantly lower in patients with RI compared 
to those without RI, 36 ± 10% vs. 39 ± 11%, p<0.26.
Conclusions: In patients presenting with anterior STEMI, RI presence is associated 
with more proximal LAD culprit lesions and a trend towards larger myocardial infarctions. 
These data suggest that coronary anatomy and resulting ﬂow disturbances may have 
important clinical implications.
3:30 p.m.
2523-822 Histopathologic Validation of DICOM based-Ultrasound 
Signal Intensity: An Echoplaque Medical Imaging 
Bench(MIB) study in autopsied coronary arteries
Sang-Wook Kim, Gary S. Mintz, Young-Joon Hong, Sung-Yun Lee, Wang-Soo Lee, 
Hyeong-Joong Kim, Gi-Hwan Kim, Kwang-Je Lee, Tae-Ho Kim, Chee-Jeong Kim, Wang-
Seong Ryu, Neil J. Weissman, Chung-Ang Unversity Hospital, Seoul, South Korea, 
Washington Hospital Center, Washington, DC
We used histopathologically-validated intravascular Ultrasound (IVUS) Virtual Histology 
(VH) to evaluate the accuracy of processed reﬂected grayscale IVUS signal intensity 
to assess plaque composition. Methods. We harvested 123 coronary arteries from 43 
autopsied cases. Greyscale IVUS and VH-IVUS imaging were performed beginning 30mm 
distal to the ostium of each coronary artery. Greyscale IVUS was processed; and the signal 
intensity determined from DICOM-stored images using a new MIB system (Echoplaque 
MIB, Indec, Mountain View, CA, USA). We compared 208 regions of interest (ROIs). 
The accuracy rate was expressed using the interpolation method and 95% conﬁdence 
interval[CI]. Results. Pt age was 49±9.12yrs and 82% were males. Four pts had sudden 
cardiac death and 39 non-cardiac death. The grayscale IVUS signal intensity of dense 
calcium was 215±21.1 (95% CI: 207~223), of ﬁbrosis was 75±17.8 (95% CI: 72~79), and 
of ﬁbrofatty was 55±11.3 (95% CI: 52~59); however, necrotic core had a grayscale signal 
intensity between ﬁbrous and dense calcium - 161±27.4 (95% CI:153~168, ﬁgure). As 
a result of interpolation method, the cut-off value of ﬁbro-fatty was 0 ~ 65, ﬁbrosis was 
65< ~ 105, necrotic core was 105< ~ 187, dense calcium was over 187. MIB greyscale 
had a 78.1% sensitivity and 91.9% speciﬁcity vs histopathology. Conclusion. Plaque 
characterization using DICOM-based grayscale IVUS signal intensity may improve the 
major limitation of greyscale IVUS, its inability to assess plaque composition. 
ROIs PredictiveAccuracy
Sensitivity Speciﬁcity
% 95% CI % 95% CI
FF 43 84.6% 83.7 72.7 94.8 84.8 79.4 90.3
FIBROUS 81 82.7% 64.2 53.8 74.6 94.5 90.5 98.5
NC 54 90.4% 77.8 66.7 88.9 94.8 91.3 98.3
CALCIUM 30 92.3% 86.7 74.5 98.8 93.3 89.6 96.9
3:30 p.m.
2523-819 Oxidative Stress and Inﬂammatory Markers are 
Determinants of Coronary Microvascular Function
Saurabh S. Dhawan, Michael McDaniel, Collins A. Kwarteng, Kwan Lee, Ahmad M. 
Jeroudi, Omar R. Kashlan, Erin M. Galbraith, Vivek Nautiyal, Dean P. Jones, Arshed A. 
Quyyumi, Habib Samady, Emory University School of Medicine, Atlanta, GA
Background: Coronary ﬂow reserve (CFR), deﬁned as the ratio of hyperemic-to-
baseline average peak velocity (APV) and hyperemic microvascular resistance (HMR), 
deﬁned as the ratio of hyperemic distal pressure-to-hyperemic APV are indices of 
coronary microvascular resistance. We hypothesized that increased oxidative stress and 
inﬂammation are associated with lower CFR and higher HMR.
Methods: We performed invasive physiologic evaluation in 33 patients with moderate 
coronary lesions. Measurement of APV at baseline and hyperemia (Hyp-APV) induced 
by 140 mcg/kg/min of intravenous adenosine, CFR, FFR (fractional ﬂow reserve) and 
HMR was performed using a combined pressure and Doppler wire. Four patients with 
signiﬁcant epicardial stenoses (FFR< 0.80) were excluded. Plasma reduced glutathione 
(GSH) and high-sensitivity c-reactive protein (CRP) were measured as biomarkers of 
oxidative stress and inﬂammation, respectively.
Results: Mean age was 56 ± 11 years, 64% were male, 72% had hypertension, 88% 
had hyperlipidemia and 24% had diabetes. GSH correlated positively with CFR (r=0.42, 
p<0.05) [Fig.A] and Hyp-APV (r=0.47, p<0.05) and negatively with HMR (r=-0.42, p<0.05) 
[Fig.B]. CRP correlated negatively with Hyp-APV (r=-0.58, p=0.004) [Fig.C] and positively 
with HMR (r=0.4, p=0.05) [Fig.D].
Conclusions: Increased biomarkers of oxidative stress and inﬂammation are associated 
with reduced coronary microvascular function in patients with non-obstructive coronary 
atherosclerosis. 
3:30 p.m.
2523-820 Quantiﬁcation of Calciﬁed Plaque by Optical Coherence 
Tomography: Ex Vivo Validation and Predictive Value 
for Stent Expansion
Teruyoshi Kume, Hiroyuki Okura, Takahiro Kawamoto, Ryotaro Yamada, Akihiro 
Hayashida, Yoji Neishi, Yoshinori Miyamoto, Koichiro Imai, Kiyoshi Yoshida, Stanford 
University, Palo Alto, CA, Kawasaki Medical School, Kurashiki, Japan
Background: Optical coherence tomography (OCT) can accurately delineate calciﬁed 
plaque without acoustic shadowing. The aims of this OCT study were to evaluate: (1) the 
ability to quantify calciﬁed plaque in ex vivo human coronary arteries; and (2) determine 
the impact of calciﬁed plaque on stent expansion.
Methods: In an ex vivo study, 91 coronary segments from 33 consecutive human 
cadavers were examined. By intravascular ultrasound (IVUS), 32 superﬁcial calciﬁed 
plaques, deﬁned as the leading edge of the acoustic shadowing appears within the 
most shallow 50% of the plaque plus media thickness, were selected and compared 
with corresponding OCT and histological examinations. Area of calciﬁcation (AC) was 
measured by planimetry. For this clinical study, 16 culprit lesions with IVUS-deﬁned 
superﬁcial calciﬁed plaque were enrolled. OCT imaging was performed before intervention 
and AC was measured. Stent expansion was assessed as the minimal stent area (MSA) 
divided by the reference area.
Results: Ex vivo study showed that IVUS signiﬁcantly underestimated AC compared with 
histology (y = 0.39 x + 0.14, r=0.78, p<0.001). Although OCT slightly underestimated AC 
(y = 0.67 x + 0.53, r=0.84, p<0.001), it showed a better correlation with histology than 
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3:30 p.m.
2523-825 The Nonuniform Strut Distribution is Associate with 
Intimal Hyperplasia in Patients with Drug Eluting Steent 
Implantation
Jin Bae Lee, Kee SIk Kim, So Yeon Kim, Young Soo Lee, Jae Kern Ryu, Ji Yong Choi, 
Sung Gug Chang, Daegu Catholic University Medical Center, Daegu, South Korea
Background: There is little data regarding the nonuniform strut distribution(NSD) and 
intimal hyperplasia(IH). The aim of this study was identify the impact of NSD on intimal 
hyperplasia in patients with drug eluting stent (DES) implamtation.
Methods: From January 2006 to May 2007, patients having IVUS guided intervention 
with DES implantation were consecutively registered. NSD was deﬁned as interstrut 
angle > 90°, and NSD segment was deﬁned as any segment observed for more than 
0.5 mm longitudinally. Lesions were graded as follows: grade 1, none or slight intimal 
proliferation(a25%); grade 2, intimal proliferation with no signiﬁcant stenosis (<50%); grade 
3, intimal proliferation with moderate stenosis (q50%); and grade 4, intimal proliferation 
with severe stenosis (q75%). Grade 2, 3 and 4 were considered IH, and Grades 3 and 4 
were considered binary instent restenosis(ISR). NSD after stent implantation and followed 
intimal hyperplasia were assessesd.
Results: We performed IVUS in 120 patients after DES implantation, and 123 stented 
lesions were scanned. Of these, 71 (59.2%) had follow up analysis for intimal hyperplasia. 
The IH was more frequenty occur in NSD patients(with NSD 17.4% vs without NSD 5.2%, 
p=0.045) and The ISR were more frequently occur in NSD patients without statistical 
signiﬁcance(with NSD 15.4% vs without NSD 6.5%, p=0.253).
Conclusions: Patients with NSD after DES implantation have an increased IH rate 
compared to patients without NSD. 
3:30 p.m.
2523-826 Optical Coherence Tomography Analysis of Culprit 
Lesions of Patients with Acute Myocardial Infarction 
in Combination With Intracoronary Thermography: 
Excessive Macrophage Inﬁltration of Thin Fibrous Caps 
are Associated With Increased Local Temperature.
Konstantinos Toutouzas, Maria Riga, Andreas Synetos, Antonis Karanasos, Eleutherios 
Tsiamis, Dimitrios Tousoulis, Costas Tsiouﬁs, John Karampelas, Athanasios Trikas, Elli 
Stefanadi, Christodoulos Stefanadis, 1st Cardiology Clinic, University of Athens, Medical 
School, Hippokration Hospital, Athens, Greece
Purpose: Morphological characteristics of atherosclerotic plaques can be analysed by 
intracoronary optical coherence tomography (OCT) study. Intracoronary thermography 
(ICT) detects the functional situation of the atherosclerotic plaque by quantitative 
measurement of the local temperature. Moreover, OCT images reveal sites of the ﬁbrous 
cap of the lesion with excessive macrophage inﬁltration. In this study we investigated 
the correlation between the morphological characteristics of the culprit lesion (CL) as 
analysed by OCT and its functional characteristics as measured by ICT in patients with 
acute myocardial infarction (AMI).
Methods: We studied 23 CL of 23 pts (20 men, 3 women, mean age 61±14 years) 
with AMI (ST and non-ST segment elevation). ICT and OCT were performed in patients 
undergoing coronary angiography. Temperature difference between the lesion and the 
healthy proximal vessel wall ($4) was measured with a dedicated thermography catheter. 
Thereafter, we measured the minimal thickness of the ﬁbrous cap (mTFC) at CL by OCT. 
Lesions with mTFC < 65 μm were characterized as thin cap plaques, and CL with mTFC 
> 65 μm were characterized as thick cap plaques. The sites in the ﬁbrous cap of CL with 
macrophage inﬁltration were identiﬁed in OCT images.
Results: We analyzed 23 CL. Sixteen CP (69.57%) had increased plaque temperature 
($T> 0.05°C) and 7 CP (30.4%) had low plaque temperature ($T<0.05°C). All CL (100%, 
p<0.01) with low $T had thick cap (mTFC=98±22 μm). Three CL (18.7%) with high $T had 
thick cap (mTFC=78±9μm, p=0.02), while in 13 CL with high $T (80.9%) thin cap plaques 
were observed (mTFC=49±12μm, p=0.02). Among plaques with high $4, 15 (93.8%) had 
macrophage inﬁltration in OCT analysis, while only 1 plaque with low $4 (6.3%) had 
macrophage inﬁltration of its ﬁbrous cap.
Conclusions: In patients with AMI, the majority of culprit lesions with increased 
temperature have thin ﬁbrous caps with excessive macrophage inﬁltration. OCT can 
also give reliable information about the functional characteristics of the atheromatic 
lesions. This study by using a combination of OCT and ICT examinations provides more 
information for the identiﬁcation of high-risk plaques.
3:30 p.m.
2523-823 High Frequency of Abnormal Intraluminal Tissue 
detected by Optical Coherence Tomography (OCT) 
6 months after Deployment of Bare Metal (BMS) and 
Drug-eluting Stents (DES)
Vasile Sirbu, Hiroyuki Kyono, Giulio Guagliumi, Satoko Tahara, Noah Rosenthal, 
Giuseppe B. Zoccai, Teruyoshi Kume, Hiram G. Bezerra, Marco A. Costa, Ospedali 
Riuniti di, Bergamo, Italy, BergamoUniversity Hospitals Harrington-McLaughlin Heart & 
Vascular Institute, Cleveland, OH
Background: Previous reports suggest the ability of OCT to identify intravascular 
thrombus. However, this remains to be determined. We sought to evaluate the prevalence 
and characteristics of abnormal intraluminal tissue (ILT) detected by OCT at 6-month 
follow-up after stent implantation.
Methods: The ODESSA trial was a prospective randomized trial designed to evaluate 
healing of overlapped DES vs. BMS for de novo coronary artery stenosis. All 75 cases (20 
SES, 22 PES, 22 ZES, 11 Liberte BMS) underwent OCT imaging at 6 month follow-up. 
A blinded strut-level analysis was performed at an independent core laboratory. ILT was 
deﬁned as any intraluminal material with >0.25mm protruding into the lumen with light 
backscattering and attached to the vessel wall. ILT was stratiﬁed based on the presence 
or absence of neointimal hyperplasia (NIH).
Results: A total of 252 segments (OLP 86, non-OLP 166) were examined. ILT were found 
in 35 (21.1%) non-OLP and 11 (12.8%) OLP segments (P=0.26). Only SES and PES 
stents had ILT with uncovered struts (graph). BMS showed signiﬁcantly higher incidence 
of ILT than DES. Half of BMS related ILT were observed in segments with severe NIH 
and lumen obstruction.
Conclusions: OCT detected a high incidence of abnormal ILT 6-months after implantation 
of both DES and BMS. Although ILT was deﬁned based on known OCT thrombus 
properties, the clinical and pathological implication remains to be determined. Our results 
also illustrate the challenge in deﬁning intravascular thrombus based on OCT. 
3:30 p.m.
2523-824 PCI causes a Reduction in Microvascular Resistance in 
The Adjacent Vessel Territory
Billal Patel, Paul Browning, George Hart, Michael Fisher, Linda Smith, Royal Liverpool 
University Hospital, Liverpool, United Kingdom, Cardiothoracic Centre, Liverpool, 
United Kingdom
Background: Well developed collaterals play an important role in myocardial perfusion in 
patients with ischaemic heart disease. Coronary stenosis in one vessel is known to affect 
the haemodynamics of ﬂow in the adjacent vessel bed. However the haemodynamic 
effect, of performing PCI in one vessel territory, has on the adjacent vessel bed has 
received little attention.
Methods: We measured the index of microvascular resistance(IMR) in the target vessel 
and a reference vessel (either left anterior descending or circumﬂex artery) using the 
thermodiltion technique and a pressure wire in patients with stable angina and single 
vessel disease. IMR was calculated at maximal hyperaemia during intravenous infusion 
of adenosine at 140ug/kg/min. Fractional ﬂow reserve (FFR) and coronary ﬂow reserve 
(CFR) were also recorded in both vessels before and after PCI. Data is presented as 
mean +/- SEM. Statistical analysis was performed using paired t-test.
Results: 22 patients were included in the study, mean age 61.2. FFR increased in the 
target vessel (0.61+/-0.03 vs 0.91 +/-0.01 p<0.0001). The CFR increased in the target 
vessel in response to PCI. (1.60 +/- 0.16 vs 2.56 +/- 0.28 p <0.001). There was no 
signiﬁcant change in CFR post PCI in the reference vessel (3.04 +/- 0.36 vs 2.67 +/- 0.27 
p=0.22). IMR reduced in response to PCI in the target vessel (31.71+/- 4.23 vs 20.68 +/- 
2.51) and the reference vessel (27.06+/-3.28 vs 21.02+/-2.69 p=0.02).
Conclusions: IMR shows signiﬁcant reductions in both vessel territories, although the 
reduction is to be expected in the target vessel since by performing the angioplasty ﬂow 
will increase and hence a reduction in microvascular resistance would be expected. 
However the reduction in IMR in the reference vessel suggests a global reduction in 
IMR is acheived which is a novel ﬁnding. This data suggests another mechanism may be 
responsible,such as release of vasoactive mediators which are able to further vasodilate 
the microcirculation despite hyperaemia induced by adenosine.
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3:30 p.m.
2523-829 Plaque Characteristics of Thin Cap Fibroatheroma 
evaluated by Optical Coherence Tomography and 
Integrated Backscatter Intravascular Ultrasound
Yoshinori Miyamoto, Hiroyuki Okura, Koichiro Imai, Ken Saito, Kosuke Kagamihara, 
Tomoko Maehama, Noriko Okahashi, Kikuko Obase, Akihiro Hayashida, Yoji Neishi, 
Takahiro Kawamoto, Kiyoshi Yoshida, Kawasaki Medical School, Kurashiki, Japan
Background: The purpose of this study was to assess optical coherence tomography 
(OCT)-derived thin cap ﬁbroatheroma (TCFA) and to investigate plaque characteristics 
of the TCFA by conventional intravascular ultrasound (IVUS) and integrated backscatter 
intravascular ultrasound (IB-IVUS).
Methods: Twenty six coronary lesions from 18 patients with percent diameter stenosis > 
50% were selected and analyzed using both IB-IVUS and OCT. OCT-derived TCFA was 
deﬁned as a presence of thin ﬁbrous cap (< 65 μm) overlying a low-intensity area with diffuse 
border representing a lipid-rich plaque. By conventional IVUS, external elastic membrane
(EEM) cross-sectional area (CSA) and lumen CSA were measured. Plaque plus media 
(P+M) CSA was calculated as EEM minus lumen CSA. Plaque characteristics were further 
assessed by IB-IVUS and classiﬁed as follows: ﬁbrous, mixed, calciﬁcation and lipid.
Results: OCT identiﬁed 9 TCFAs (34.6%). By conventional IVUS, EEM CSA, lumen CSA 
and P+M CSA were signiﬁcantly larger in TCFA than non TCFA. Remodeling index was 
not signiﬁcantly different between TCFA and non-TCFA. By IB-IVUS, % lipid area (=lipid 
area / P+M CSA x 100) was signiﬁcantly higher in TCFA than non-TCFA (62.1 ± 8.3 vs 
46.3 ± 18.9 %, p < 0.05). (Figure)
Conclusions: TCFA by OCT had larger plaque with predominant lipid component 
assessed by IB-IVUS. Combination of these 2 intracoronary imaging modalities may be 
helpful to identify vulnerable coronary plaque. 
3:30 p.m.
2523-830 Frequency of Lipid Core Plaque as Determined by Near-
Infrared Spectroscopy at Target Lesion Sites in Patients 
Undergoing PCI
Philippe L. L’Allier, Jean-Claude Tardif, Simon R. Dixon, Jeffrey W. Moses, John L. 
Petersen, Giora Weisz, Donald E. Cutlip, Mitchell W. Krucoff, James E. Muller, Michael 
J. Hendricks, Stephen T. Sum, Gregg W. Stone, James A. Goldstein, Sergio Waxman, 
InfraReDx, Inc., Burlington, MA, Montreal Heart Institute, Montreal, QC, Canada
Background: Plaque characterization is of great interest to better understand the clinical 
pathophysiology of coronary artery disease. A catheter-based near-infrared spectroscopy 
(NIRS) system (previously validated in autopsy studies) was used to determine lipid core 
plaque (LCP) content of target lesions. The correlation between angiographic ﬁndings and 
NIRS indices of LCP has not been previously studied. The objective was to determine LCP 
content of target lesions and correlation with angiographic characteristics in patients (pts) 
undergoing PCI.
Methods: A retrospective analysis of SPECTACL study data (n=106) was performed to 
determine the prevalence of LCP at the target lesion site. Patients referred for coronary 
angiography were included (stable angina or acute coronary syndrome), and target lesions 
were identiﬁed by angiography combined with clinical data. Single (target) vessel NIRS 
scanning was performed in pts undergoing PCI. A LCP was deﬁned as at least a 2mm 
segment of vessel exhibiting a clear lipid signal in the NIRS image. LCPs were considered 
distinct when separated by at least 6 mm. Angiographic characteristics of individual patients 
and respective target lesions were determined by a central QCA core lab.
Results: A total of 56 pts had NIRS data meeting study endpoint criteria and 
angiographically co-registered target lesions. LCP was detected at the target lesion in 23 
pts (41%). The angiographic characteristics of the target lesions were ACC/AHA lesion 
type B2/C in 28 patients (50%); mean stenosis length was 15.0 mm, mean reference 
vessel diameter was 3.1 mm. LCP positive target lesions tended to be more severe 
(34.8% vs. 21.2%, N.S.), and longer (15.8 vs. 14.2 mm) than LCP negative lesions. Other 
angiographic characteristics associated with instability did not demonstrate differences 
between LCP positive and negative lesions.
Conclusion: LCP occurs in a signiﬁcant proportion of target lesions. LCP status appears 
to be largely independent of conventional angiographic characteristics. The role of the 
identiﬁcation of lesions with LCP content as determined by NIRS in the optimization of 
therapy requires evaluation in clinical studies.
3:30 p.m.
2523-827 Intravascular Ultrasound Appearance of Scattered 
Necrotic Core Pattern as New Index for No-reﬂow 
Phenomenon During Intervention in Acute Coronary 
Syndrome
Kenji Sakata, Hidekazu Ino, Masa-aki Kawashiri, Takao Matsubara, Yoshihide Uno, 
Toshihiko Yasuda, Kenji Miwa, Honin Kanaya, Masakazu Yamagishi, Kanazawa 
University, Kanazawa, Japan, Ishikawa Prefectural Central Hospital, Kanazawa, Japan
Background: No-reﬂow (NRF) observed during interventional procedures in acute 
coronary syndrome (ACS) is associated with poor clinical prognosis. We often observed 
generally scattered necrotic core pattern (SNC) by VH-IVUS in ACS patients with 
NRF during intervention, and the pathological ﬁnding of materials in SNC collected by 
thrombectomy showed mixed thrombi and cholesterol clefts. The aim of this study was to 
evaluate the impact of SNC by VH-IVUS on NRF during intervention in ACS.
Methods: We prospectively studied 38 patients with ACS (30 males, mean age 65.9 ± 13.6 
years) who underwent VH-IVUS before intervention. In addition to conventional VH-IVUS-
derived indices, VH-IVUS plaque component patterns were evaluated. We deﬁned SNC, which 
represents the ruptured thin-cap ﬁbroatheroma derived from VH-IVUS as shown in Figure.
Results: Patients were divided into 2 groups with NRF (n=15) or normal reﬂow (n=23). 
The elastic membrane volume, plaque and media volume and ﬁbrous volume were 
signiﬁcantly greater in NRF than in normal ﬂow (p<0.05). There was no signiﬁcant 
difference in necrotic core volume between two groups. However, the incidence of SNC 
frame was signiﬁcantly higher in NRF than in normal ﬂow (11.7 ± 6.7 vs. 2.0 ± 4.3 frames, 
p<0.0001). Logistic regression analysis showed that the number of SNC frames was the 
most effective index for NRF in ACS patients (odds ratio 2.320, P<0.05).
Conclusion: Increased number of SNC frames with VH-IVUS is highly associated with 
NRF after intervention. 
3:30 p.m.
2523-828 Tissue Characterization of Atherosclerotic Plaque 
in Coronary Artery Bifurcations: an Intravascular 
Ultrasound Radiofrequency Data Analysis in Humans
Seung Hwan Han, Joseph Puma, Hector M. Garcia-Garcia, Kenya Nasu, Pauliina 
Margolis, Martin B. Leon, Amir Lerman, Mayo clinic, Rochester, MN, Gil Hospital, 
Gachon University of Medicine and Science, Incheon, South Korea
Background: Coronary artery bifurcations are prone to atherosclerotic plaque 
accumulation. We assessed compositional characteristics of atherosclerotic plaques in 
coronary artery bifurcations with intravascular ultrasound radio frequency data analysis.
Methods: Using a global virtual histology registry, geometric and compositional 
characteristics of plaque in 3 segments (proximal, distal, and at the bifurcation) of major 
coronary bifurcation sites were analyzed.
Results: : A total of 256 major bifurcation sites were analyzed: left main (LM)-left anterior 
descending artery (LAD), 41; LAD-diagonal artery, 128; left circumﬂex artery-obtuse 
marginal artery, 34; and right coronary artery-acute marginal artery, 53. The percent 
(%) necrotic core at the bifurcation and distal segments at LM-LAD bifurcation sites was 
signiﬁcantly greater than in proximal segments (6.75±5.09%, 7.36±6.01% vs. 4.89±4.78%, 
all p<0.05). In contrast, the % necrotic core in proximal segments of non-LM bifurcation 
sites was signiﬁcantly greater than at the bifurcation and distal segments (8.08±6.21% 
vs. 6.47±5.11%, 6.28±5.05%, all p<0.001). The % necrotic core in proximal and distal 
segments of LM-LAD bifurcation sites was signiﬁcantly correlated with the plaque plus 
media (P+M) burden (r=0.45, p=0.003; r=0.42, p=0.006, respectively). The % necrotic 
core in each segment of non-LM bifurcation sites showed a signiﬁcant positive correlation 
with P+M burden and negative correlation with lumen cross sectional area (0.51ara0.64,
all p<0.001; -0.35ara-0.31, all p<0.001, respectively).
Conclusions: The results demonstrate signiﬁcant differences of plaque composition 
among proximal, distal, at the bifurcation segments of the coronary bifurcations, 
especially according to their anatomical locations (LM-LAD vs. non-LM bifurcations). 
The investigation for the clinical efﬁcacy of the imaging-guided therapeutic approach to 
complex coronary plaques such as bifurcation sites are warranted in the future.
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reevaluated FFR by postischemic diastolic dysfunction after treadmill exercise test with 
strain image derived from 2-dimensional speckle tracking echocardiography.
Methods: In consecutive 33 consecutive patients with signiﬁcant coronary stenosis, 
treadmill stress echocardiography was performed within 1 week of coronary angiography. 
FFR was measured after adenosine infused intravenously.Strain image was acquired in 
the LV midpapillary short-axis view. Radial strain was obtained and peak values of stain 
at the closure of aortic valve (A) and at the one third diastole duration (B) were measured. 
The strain image-diastolic index (SI-DI) was determined as (A-B)/A×100% and used to 
identify regional LV diastolic dysfunction. We deﬁned SI-DI a40% as positive ischemic 
change, and compared FFR with these results.
Results: The result of FFR and diastolic dysfunction was showed in ﬁgure 1. Diastolic 
dysfunction was 75.8% (25 of 33 pts). The sensitivity of FFR <0.83 was 96% , the 
speciﬁcity 87.5%.
Conclusion: In patient with signiﬁcant coronary stenosis, FFR<0.83 was a useful index of 
myocardial ischemia, that is new concept with postischemic diastolic dysfunction.
3:30 p.m.
2523-834 Gender Difference in Vessel Response in Coronary 
Artery Disease Treated with Zotarolimus-Eluting Stents
Daisaku Nakatani, Katsuhisa Waseda, Hiromasa Otake, Bon-Kwon Koo, Ryota Sakurai, 
Akiyoshi Miyazawa, Masao Yamasaki, Junya Ako, Hyeonsoo Chang, Jean Fajadet, 
Richard E. Kuntz, William Wijns, David E. Kandzari, Martin B. Leon, Paul G. Yock, Peter 
J. Fitzgerald, Yasuhiro Honda, Stanford University Medical Center, Palo Alto, CA
Background: Gender difference in outcomes of coronary interventions remains 
controversial in ﬁrst-generation drug-eluting stents. The aim of this study was to examine 
potential gender difference in vessel response following Endeavor zotalolimus-eluting 
stent (ZES) implantation.
Methods: Serial volumetric IVUS analysis was performed in 305 patients (223 Men: 83 
Women) treated with a single ZES for de novo native coronary lesions. Volume index 
(volume/length) was calculated for vessel (VVI), plaque (PVI), neointima (NIV), and 
lumen (LVI). Percent neointimal volume (%NIV) was calculated as (NIV/SVI)×100. Cross-
sectional narrowing (CSN) was deﬁned as neointimal area divided by stent area (%).
Results: Although women had worse baseline characteristics (older age, higher 
prevalence of coronary risk factors, and smaller vessel), max CSN at 8-9 months was 
signiﬁcantly higher in men than in women (Table). %NIV also trended toward larger in 
men, resulting in signiﬁcantly greater LVI loss in men compared with women. Multiple 
regression analysis revealed a correlation of male gender with %max CSN (B=181,
p=0.021) and %NIV (B=0.143, p=0.072).
Conclusion: In patients treated with ZES, neointimal hyperplasia appears to be higher in 
men than in women. However, follow-up lumen dimensions may still be comparable due 
to larger vessel size in men. 
Women Men p
Baseline (BL)
VVI (mm3/mm) 12.4±3.4 14.6±4.3 <0.001
PVI (mm3/mm) 5.6±2.0 7.5±2.8 <0.001
LVI (mm3/mm) 6.8±1.9 7.2±2.1 0.101
Follow-up (FU)
VVI (mm3/mm) 12.6±3.3 14.9±4.2 <0.001
PVI (mm3/mm) 5.8±1.9 7.6±2.6 <0.001
LVI (mm3/mm) 5.7±1.8 6.0±1.9 0.297
%NIV (%) 15.7±10.3 17.8±11.1 0.128
Max CSN (%) 29.2±13.8 33.9±15 0.015
Patients with Max CSN >50% (%) 8.5 14.8 0.151
Changes (FU-BL)
Delta-VVI (mm3/mm) 0.2±0.8 0.1±1.2 0.888
Delta-PVI (mm3/mm) 0.1±0.6 0.1±1.0 0.639
Delta-LVI (mm3/mm) -0.9±1.0 -1.2±1.1 0.028
3:30 p.m.
2523-831 Plaque Vulnerability at Coronary Bifurcations : A Study 
of Virtual Histology Intravascular Ultrasound
Hideo Amano, Division of interventional Cardiology, Cardiovascular Center, Toho 
University Omori Medical Center, Tokyo, Japan
Background: Ruptured plaque is often seen near the bifurcation, and it has been reported 
that endothelial cells near the bifurcation have reduced ability to repair damaged cells. 
However, since plaque properties cannot be discriminated by gray scale intravascular 
ultrasound(IVUS), the volume of vulnerable plaque associated with bifurcation plaque 
is unclear. Since Virtual Histology-IVUS(VH-IVUS) enables classiﬁcation of plaque 
properties, VH was used to study the volume of vulnerable plaque associated with 
bifurcation plaque.
Objectives: To study the volume of vulnerable plaque with respect to the difference with 
bifurcation lesion and non-bifurcation by using VH-IVUS.
Subjects: Subjects were 165 patients with 171 lesions, undergoing stent implantation 
for coronary stenosis and observed by VH-IVUS prior to percutaneous coronary 
intervention.
Methods: 32 lesions revealed at the bifurcation were classiﬁed the bifurcation group, and 
139 lesions that were not revealed at the bifurcation were classiﬁed the non-bifurcation 
group. Site of measurement was 1 slice at the bifurcation for the bifurcation group, and for 
the non-bifurcation group, a mean ratio was obtained by measuring the culprit lesion at 1 
mm intervals. Necrotic core (NC), dense calcium (DC), and NC/DC ratio were calculated 
using VH-IVUS.
Results: The bifurcation group had signiﬁcantly more NC with 14.1±7.2% in the bifurcation 
group and 11.0±6.7% in the non-bifurcation group (p<0.05). There was signiﬁcantly less 
DC in the bifurcation group with 10.3±7.8% in the bifurcation group and 15.3±6.0% in the 
non-bifurcation group (p<0.01). NC/DC was signiﬁcantly higher in the bifurcation group 
with 2.4±2.2 compared to 0.74±0.39 in the non-bifurcation group (p<0.01).
Conclusions: The high vulnerability of plaque at bifurcations was shown from the 
presence of less dense calcium and greater necrotic core by Virtual Histology intravascular 
ultrasound.
3:30 p.m.
2523-832 Long term Clinical Outcomes after Fractional Flow 
Reserve Guided vs. Intravascular Ultrasound Guided 
Percutaneous Coronary Intervention
Chang-Wook Nam, Hong-Won Shin, Yun-Kyeong Cho, Hyoung-Seob Park, Hyuck-Jun 
Yoon, Hyungseop Kim, Seong-Wook Han, Seung-Ho Hur, Yoon-Nyun Kim, Kwon-Bae 
Kim, Division of Cardiology, Department of Internal Medicine, Keimyung University, 
Dongsan Medical Center, Daegu, South Korea
Background: Even though intravascular ultrasound (IVUS) provides 3-D anatomic image 
of coronary artery, it might overestimate real functional signiﬁcance of the coronary lesion 
during percutaneous coronary intervention (PCI). FFR-guided PCI strategy was reported 
to be safe and effective. The aim of this study is to evaluate the safety and efﬁcacy of FFR-
guided PCI strategy compared to IVUS guided PCI in daily practice.
Methods: Four hundred forty four patients (350 patients of IVUS guided, 94 of FFR) were 
consecutively included from Nov. 2006 to June 2007. All patients were divided to IVUS 
guided and FFR guided group. If both procedures were simultaneously used, that patients 
were included to FFR guided group. Major adverse cardiac events (MACE: cardiac death, 
myocardial infarction and target vessel revascularization (TVR)) were assessed at 12 
months after the procedure.
Results: Mean age were higher in FFR guided group than IVUS guided group (63.5±8 
vs. 61.2±10, p=0.021). IVUS guided group had more underwent revascularization therapy, 
also had more implanted stent number than FFR guided group (95.4% vs. 78.7%, p<0.001, 
1.67±1.1 vs. 1.3±1.1, p=0.003). One year clinical follow-up was available in 98.6%. No 
difference was found in 12-month MACE rates between 2 groups (Table). There was no 
death or MI related to the lesions in FFR guided group.
Conclusions:FFR-guided PCI strategy resulted in excellent long-term outcomes, similar 
as IVUS guided PCI. However, FFR-guided strategy reduced the need for PCI.
FFR group IVUS group p value
Cardiac death 0 (0%) 3 (0.9%) 1
Myocardial infarction 0 (0%) 3 (0.9%) 1
Target vessel revascularization 5 (5.3%) 12 (3.5%) 0.38
Cumulative MACE 5 (5.3%) 18 (5.2%) 1
Stent thrombosis 0 (0%) 3 (0.9%) 1
3:30 p.m.
2523-833 Coronary Fractional Flow Reserve less than 0.83 is 
Useful Predictor of Myocardial Ischemia Compared 
with Postischemic Diastolic Dysfunction after Treadmill 
Exercise Stress Test
Motoyoshi Maenaka, Tamaki Suyama, Makoto Imai, Masaki Kawanami, Yasunaka 
Makino, Katsuhisa Ishii, Kansaidenryoku Hospital, Osaka, Japan
Background: In previous studies, coronary fractional ﬂow reserve (FFR) of 0.75 lower 
was proved a useful index of myocardial ischemia. But it is seemed to sever cut-off line. To 
assess whether the coronary artery stenosis is responsible for myocardial ischemia, we 
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3:30 p.m.
2523-837 Relation Between High-Sensitivity C-Reactive Protein 
and Coronary Plaque Components in Patients 
with Acute Coronary Syndrome: Virtual Histology-
Intravascular Ultrasound Analysis
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Jum Suk Ko, Min Goo Lee, Won 
Yu Kang, Shin Eun Lee, Soo Hyun Kim, Doo Sun Sim, Keun Ho Park, Nam Sik Yoon, 
Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, The Heart Center of Chonnam National 
University Hospital, Gwangju, South Korea
Background: An elevated high-sensitivity C-reactive protein (hs-CRP) is associated with 
an increased risk of future ischemic complications in acute coronary syndrome (ACS) 
patients. We used virtual histology-intravascular ultrasound (VH-IVUS) to evaluate the 
relation between hs-CRP levels and plaque components in ACS patients.
Methods: VH-IVUS classiﬁed the color-coded tissue into four major components: ﬁbrotic, 
ﬁbro-fatty, dense calcium, and necrotic core (NC). We divided the patients into two groups 
according to the hs-CRP levels [q 0.5 mg/dl (n=58) vs. < 0.5 mg/dl (n=188)]. Thin-cap 
ﬁbroatheroma (TCFA) was deﬁned as focal, NC-rich (q 10% of the cross-sectional area) 
plaques being in contact with the lumen in a plaque burden q 40%.
Results: Elevated hs-CRP group was more diabetics (36% vs. 16%, p<0.001), and 
had lower ejection fraction (59±8% vs. 63±9%, p=0.011), higher white blood cell counts 
(9869±3110/mm3 vs. 7906±2808/mm3, p<0.001), higher glucose (160±60 mg/dl vs. 
141±45 mg/dl, p=0.029), higher ﬁbrinogen (314±82 mg/dl vs. 275±72 mg/dl, p=0.008), 
and higher N-terminal pro-B-type natriuretic peptide (681±864 pg/ml vs. 213±332 pg/
ml, p<0.001) and longer IVUS lesion (22±13 mm vs. 18±12 mm, p=0.020). The absolute 
and percent areas of NC were signiﬁcantly greater in elevated hs-CRP group at the 
minimum lumen sites (1.40±1.16 mm2 vs. 0.89±0.73 mm2, p=0.008, and 22.1±14.2% 
vs. 17.0±11.4%, p=0.005, respectively) and at the largest NC sites (2.01±1.26 mm2
vs. 1.46±0.98 mm2, p=0.003, and 28.3±10.3% vs. 23.2±11.2%, p=0.002, respectively). 
Absolute and percent NC volumes were signiﬁcantly greater in elevated hs-CRP group 
(25.0±17.0 mm2 vs. 15.2±10.5 mm2, p=0.001, and 20.5±12.5% vs. 15.2±8.7%, p=0.004, 
respectively). The presence of at least one TCFA (62% vs. 35%, p=0.006) and multiple 
TCFAs (26% vs. 11%, p=0.016) within culprit lesions were observed more frequently in 
elevated hs-CRP group.
Conclusions: VH-IVUS analysis demonstrates that ACS patients with elevated hs-CRP 
had more vulnerable plaque component (NC-rich plaques and higher frequency of culprit 
lesion TCFAs) compared with ACS patients with normal hs-CRP.
3:30 p.m.
2523-838 Plaque Characteristics in Culprit Lesions in Diabetic 
Acute Coronary Syndrome Patients: Intravascular 
Ultrasound and Virtual Histology-Intravascular 
Ultrasound Analysis
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Jum Suk Ko, Min Goo Lee, Won 
Yu Kang, Shin Eun Lee, Soo Hyun Kim, Keun Ho Park, Doo Sun Sim, Nam Sik Yoon, 
Hyun Ju Yoon, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, The Heart Center of Chonnam National 
University Hospital, Gwangju, South Korea
Background: Data of the relationship between diabetes mellitus and plaque 
characteristics in acute coronary syndrome (ACS) patients are lacking. The aim of this 
study was to assess the plaque characteristics in culprit lesions in diabetic ACS patients.
Methods: We performed grey-scale intravascular ultrasound (IVUS) analysis in 422 
ACS patients. By subgroup analysis, we assessed the impact of diabetes mellitus on 
IVUS ﬁndings in 112 acute myocardial infarction (AMI) patients with plaque ruptures and 
also evaluated the relationship between diabetes mellitus vs. plaque composition and 
the incidence of thin-cap ﬁbroatheroma (TCFA) using virtual histology (VH)-IVUS in 310 
ACS patients.
Results: High-sensitivity C-reactive protein (hs-CRP) was signiﬁcantly elevated (2.6±3.8 
mg/dl vs. 0.6±1.4 mg/dl, p=0.008), multivessel disease was more common (65% vs. 29%, 
p<0.001), and plaque burden was greater (79.7±9.8 mm2 vs. 74.2±8.9 mm2, p<0.001) 
in diabetic group. In the subgroup analysis in 112 AMI patients with plaque rupture, the 
presence of multiple plaque ruptures (60% vs. 29%, p=0.001) and thrombus (72% vs. 
52%, p=0.032) were more common in diabetic group, and diabetes mellitus was the 
independent predictor of hs-CRP elevation (HR: 3.030, 95% CI: 1.204-7.623, p=0.019) 
and multiple plaque ruptures (HR: 2.984, 95% CI: 1.311-6.792, p=0.009) by multivariate 
analysis. In 310 VH-IVUS subsets, the absolute and % necrotic core volumes were 
signiﬁcantly greater (16.9±15.1 mm3 vs. 11.5±11.4 mm3, p<0.001, and 17.3±9.4% vs. 
13.7±7.5%, p<0.001, respectively), and the presence of at least one TCFA (60% vs. 42%, 
p=0.003) and multiple TCFAs (28% vs. 11%, p<0.001) within culprit lesions were more 
common in diabetic group, and diabetes mellitus was the only independent predictor of 
TCFA by multivariate analysis (HR: 2.139, 95% CI: 1.266-3.613, p=0.004).
Conclusions: Diabetic ACS patients have more plaques, and have characteristics 
of plaque vulnerability and a different composition of plaques, and have elevated 
inﬂammatory status compared with non-diabetics for those presenting with ACS.
3:30 p.m.
2523-835 Angiographic, IVUS and OCT Evaluation of the Long-
term Impact of Coronary Disease Severity at the Site of 
Overlapping Bare Metal and Drug-eluting Stents
SATOKO TAHARA, Hiram Bezerra, Giulio Guagliumi, Hiroyuki Kyono, Noah Rosenthal, 
Vasile Sirbu, Giuseppe Musumeci, Luigi Fioca, Giuseppe B. Zoccai, Daniel Simon, 
Marco A. Costa, University Hospitals Harrington-McLaughlin Heart & Vascular Institute, 
Cleveland, OH, Ospedali Riuniti di Bergamo, Bergamo, Italy
Background: Very long lesions are part of the daily interventional practice and often 
required implantation of overlapping (OLP) stents. Preclinical data suggest potential 
adverse vascular response at the site of OLP drug eluting stents (DES). The impact of 
disease severity at the location of OLP stents is unknown.
Objective: This study aims at evaluating the long-term impact of OLP stents in low grade 
stenosis (LGS) vs. high grade stenosis (HGS) using angiography, IVUS and OCT strut 
level analysis at 6-month follow-up.
Methods: The ODESSA trial was a single-center, prospective, randomized, controlled 
trial. We performed a subanalysis in 71/75 patients with 86 OLP stents (25 Sirolimus-SES, 
24 Paclitaxel-PES, 26 Zotarolimus-ZES eluting stents; and 11 bare metal stents- BMS). 
Angiography, IVUS and OCT analyses were performed at an independent core laboratory. 
Based on angiographic stenosis severity at the site of OLP two groups were generated: 
>70% (HGS) or <70% (LGS). Endpoints were binary restenosis, % neointimal hyperplasia 
(NIH%), and degree of stent coverage by the OCT strut level analysis. Three categories 
were generated by the OCT strut level analysis: covered, uncovered and malapposed.
Results: OLP stents were implanted in 49 segments with HGS and 37 with LGS. Baseline 
characteristics were similar in both groups. Binary restenosis was observed in 9/49 (18%) 
in the HGS vs. 0/37 (0%) in the LGS (p=0.009). Five out of 6 HGS treated with OLP BMS 
had restenosis vs. 4/43 with OLP DES (p=0.01). IVUS and OCT showed similar degree 
of NIH in OLP DES implanted in HGS versus LGS. OCT strut level analysis identiﬁed 
uncovered or malapposed struts more frequently in the LGS vs. HGS groups, 48.6% vs. 
27.1% (p=0.0236), which was driven primarily by a very high incidence of uncovered 
struts in the PES.
Conclusion: Severity of coronary disease at the site of OLP DES did not impact NIH 
response. However, OLP DES and BMS at segments with mild disease were associated 
with higher incidence of uncovered struts by OCT, particularly in patients treated with 
PES. OLP BMS at segments with HGS had a higher proliferative response. Future studies 
are required to guide proper positioning of DES in long lesions requiring stent overlap.
3:30 p.m.
2523-836 Microvascular Dysfunction Immediately after 
Percutaneous Coronary Intervention is Associated with 
Sustained Hemodynamic Abnormalities in Reperfused 
Acute Myocardial Infarction
Takeshi Kitai, Kobe City Medical Center General Hospital, Kobe, Japan
Background: Hemodynamic complications such as congestive heart failure (CHF) and 
cardiogenic shock often result in unfavorable outcomes of patients with acute myocardial 
infarction (AMI). Studies using intravascular Doppler guidewire (DGW) have shown that 
the microvascular dysfunction in infarct-related artery immediately after percutaneous 
coronary intervention (PCI) is an independent predictor of in-hospital mortality and 
morbidity. The aim of this study was to examine whether microvascular dysfunction was 
associated with sustained hemodynamic abnormalities in AMI.
Methods: The study population consisted of 201 consecutive patients with ﬁrst anterior 
AMI successfully treated with PCI. We examined the coronary ﬂow velocity (CFV) pattern 
immediately after PCI using a DGW. In accordance with previous ﬁndings, we deﬁned 
severe microvascular injury as a diastolic deceleration time a600 ms and the presence 
of systolic ﬂow reversal. We measured the pulmonary capirally wedge pressure (PCWP) 
and cardiac output index (CI) by thermodilution using pulmonary artery catheter. Patients 
were divided into the two groups: those with severe microvascular injury (n=74; group 
1) and those without severe microvascular injury (n=127; group 2). Serial hemodynamic 
parameters have been compared between the groups.
Results: The results were shown in the Table. PCWP was signiﬁcantly higher and CI was 
signiﬁcantly lower in group 1 than in group 2 both on the day 1 and 3, despite extensive 
therapy for heart failure. CHF requiring mechanical ventilation or IABP, and in-hospital 
cardiac death occurred more frequently in group 1 than in group 2.
Conclusions: Microvascular dysfunction immediately after successful PCI for AMI was 
associated with sustained hemodynamic abnormalities and high cardiac mortality in AMI.
Results
Group 1 (n=74) Group 2 (n=127 P value
PCWP(day1), mmHg 14.1 ± 6.4 8.8 ± 4.4 <0.01
C.I.(day1), l/min/m2 2.3 ± 0.6 2.6 ± 0.6 <0.01
Forrester 2 or 4(day1), n(%) 21(28) 9(7) <0.01
PCWP(day3), mmHg 13.9 ± 4.7 10.0 ± 3.6 <0.01
C.I.(day3), l/min/m2 2.6 ± 0.5 3.0 ± 0.6 <0.01
Forrester 2 or 4(day3), n(%) 8(11) 4(3) <0.01
CHF requiring mechanical ventilation, n(%) 14(19) 4(3) <0.01
IABP use, n(%) 14(19) 4(3) <0.01
In-hospital death, n(%) 10(14) 0(0) <0.01
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2524
Congenital and Pediatric Intervention
Monday, March 30, 2009, 3:30 p.m.-4:30 p.m.
Orange County Convention Center, West Hall D
3:30 p.m.
2524-841 Hybrid procedures in the management of patients with 
CHD: Results of a multi-institutional registry
Ralf Holzer, Lisa Bergersen, Joanne Chisolm, Sharon Hill, Russel Hirsch, Audrey 
Marshall, Jacqueline Kreutzer, Alistair Phillips, Mark Galantowicz, John Cheatham, 
Nationwide Children’s Hospital, Columbus, OH, Boston Children’s Hospital, Boston, MA
Introduction: Procedural cooperation between cardiac surgeon and interventional 
cardiologist to facilitate interventions, such as device delivery or angioplasty (Hybrid 
procedure) has become increasingly common in the management of patients with CHDz. 
Outcome data on these Hybrid interventions (Hybrids) is limited.
Methods: Data was prospectively collected using a multi-center registry (C3PO). 
Between 02/07 and 09/08, 7 institutions submitted details on 5941 cardiac catheterization 
procedures. Procedural data and adverse events (AE) of 71 Hybrids was evaluated.
Results: The median number of Hybrids per center was 5 (0 to 44). 55/71 (77.5%) Hybrids 
were performed at 2 centers. The median weight was 3.4kg (0.7-86kg). 49/71 (69%) 
cases were performed in patients with single ventricle, while 22/71 (30.9%) cases were 
performed in patients with 2-ventricle circulation. In 12/71 (16.9%) cases, patients were 
on inotropic support and 8/71 (11.2%) cases were performed within 30 days of previous 
cardiac surgery. Hybrids included PDA stent placement (n=41), pulmonary artery stent/
balloon (n=13), BAS (n=7), VSD device closure (n=5), ASD/fenestration device closure 
(n=2), aortic stent/balloon (n=3), other stent/balloon (n=5), pulmonary valvuloplasty (n=1), 
and other procedures (n=5). The median ﬂuoroscopy time was 3.7min (0-74min). 13 AE 
occurred in 11/71 (15.5%) Hybrids. Minor AE were documented in 8/71 (11.3%) cases, 
moderate AE in 3/71 (4.2%) cases, major AE in 1/71 (1.4%) cases, and catastrophic AE 
in 1/71 (1.4%) cases. The type of AE documented included arrhythmias (n=5), hypoxia or 
hypotension (n=2), vessel trauma (n=1), cardiac perforation (n=1), CNS event (n=1), and 
other events (n=3). 6/13 (46.1%) AE were classiﬁed as not preventable, 5/13 (38.5%) AE 
as possibly preventable, and 2/13 (15.4%) AE as preventable.
Conclusion: Hybrids are performed in many centers and include a large spectrum of 
interventions. They are often performed in the early postoperative period or in sick and 
unstable patients. Hybrids are safe with a low incidence of major or preventable adverse 
events. Procedural deﬁnitions of these innovative procedures are required to facilitate 
prospective data collection.
3:30 p.m.
2524-842 Midterm Follow-up after Helex Device Closure of Patent 
Foramen Ovale for Prevention of Paradoxical Embolic 
Events
John F. Rhodes, Jr., Amanda S. Green, Piers C.A. Barker, J. Curt Fudge, Duke 
University Medical Center, Durham, NC
Background: Patients (pts) with a paradoxical embolism as the potential etiology of their 
symptoms are at risk for recurrent events. Closure of a coexistent patent foramen ovale 
(PFO) eliminates paradoxical embolization as a mechanism for recurrence. Although 
midterm follow-up are available for other devices few data are available regarding the 
HELEX. Methods: All pts at a single center who underwent PFO closure using the GORE 
HELEX Septal Occluder between 10/06-10/08 were retrospectively reviewed. Procedures 
were performed as an outpatient using standard technique. All pts had anatomic assessment 
using a “stop-ﬂow” balloon technique and intracardiac echocardiography. All pts were treated 
with Clopidogrel or warfarin for 1 month and aspirin for 6 mos. Follow-up was routinely 
performed at 12-24 hrs, 1month, 6 mos, and yearly including transthoracic echocardiography 
and upper extremity injection of agitated saline at rest and during valsalva. Results: There 
were 108 pts that underwent HELEX PFO device closure during the study period. The 
median age was 54.2 yrs (range: 22.1-75.9). Procedural indication included stroke (n=71), 
multiple transient ischemic attacks (n=23), migraine headache with aura (n=7), systemic 
embolic event (n=3), and systemic hypoxemia (n=4). Although each pt had a PFO; 38 had 
an atrial septal aneurysm (ASA), 9 had additional fenestrations, 3 had Chiari’s network, and 
18 had a tunnel length >18mm. The mean PFO balloon diameter was11.2±3.5mm (range: 
7-20). The device was successfully placed in 107 pts with 1 pt having the device removed 
due to excessive mobility within the ASA. There were no procedure-related adverse events. 
With a Median follow-up of 10.8mos (range: 0.2 - 24) there have been no recurrent embolic 
events and 2 late adverse events including one pt with medically treated arrhythmia and one 
pt with a rash. Overall, 4 pts (3.7%) have a persistent right to left shunt including 3 with trivial 
and 1 with moderate. Conclusions: These data indicate that Helex device PFO closure is 
safe and effective in preventing recurrent paradoxical embolism and should be considered 
an alternate to life-long pharmacologic therapy or other available devices.
3:30 p.m.
2524-843 Do we need to stent discrete (shelf-like) coarctation?
Mohamed Eid Fawzy, Ahmed Fathala, Hani Sergani, Mohammed Kandeel, Amr Badr, 
Abdulaziz Al Ghamdi, Bruce Dunn, King Faisal Specialist Hospital & Research Centre, 
Riyadh, Saudi Arabia
Background: Although the immediate and intermediate-term results of balloon angioplasty 
(BA) for patients with aortic coarctation (AC) have been encouraging, there is paucity of 
3:30 p.m.
2523-839 Visibility and Quantitative Assessment of 
Biodegradable Magnesium Alloy Stents by 
Intravascular Ultrasound and Optical Coherence 
Tomography
Holger Hetterich, Burcu Gül, Andreas König, III, Andreas Schober, Thomas Schiele, Volker 
Klauss, Johannes Rieber, Medizinische Poliklinik, University of Munich, Munich, Germany
Background: Biodegradable magnesium alloy stents (Mg) provide mechanical stability 
for weeks after PCI and demonstrate complete degradation without longterm impairment 
vessel function. Lately feasibility and safety of Mg was demonstrated. Since Mg are not 
visible by angiography, intravascular ultrasound (IVUS) and optical coherence tomography 
(OCT) are two imaging methods used for assessment of stent parameters. The aim of this 
study was to compare IVUS and OCT for the assessment of Mg and to compare the 
ﬁndings to bare metal stents (BMS).
Methods: Four mini pigs (55±7kg) were imaged with ﬂuoroscopy, IVUS and OCT at 
implantation and after 4 weeks. Mg and BMS were randomly distributed in all three coronary 
vessels. Cross sectional images were obtained each millimeter, both by OCT and IVUS. 
Results: 120 cross sections were analyzed by IVUS and OCT. By IVUS the number of 
Mg visible struts per cross section at implantation and harvesting was 6.62±0.83 and 
4.70±1.11 (p=n.s.), strut thickness was 0.22±0.03mm and 0.15±0.03mm (p<0.05). In 
OCT the number of Mg struts was 8.0±1.0 and 6.20±0.8 (p<0.05), strut thickness was 
0.05±0.01mm and 0.06±0.014mm (p<0.001). The values for BMS were similar to those 
for Mg at implantation. OCT was able to detect more struts (p<0.005) but was associated 
with a lower strut thickness (p<0.001) than IVUS, underestimating the original strut 
thickness. A moderate correlation between IVUS and OCT measurements was observed 
for lumen- (r=0.44, p<0.05), stent- (r=0.67, p=0.001) and vessel-area (r=0.71, p<0.05). 
However, all parameters were underestimated by OCT, when compared to IVUS. Blant-
Altmann analysis revealed a mean difference of 0.71mm² for lumen area, 0.18mm² for 
stent area and 0.27mm² for vessel area. The differences between the measurements did 
not vary signiﬁcantly for Mg or BMS. 
Conclusion: Mg can be visualized by IVUS and OCT. Due to the better spatial resolution 
of OCT and the unique imaging characteristics, OCT should be the preferred method for 
qualitative assessment of Mg, e.g. to image the degradation process. Despite the higher 
resolution capacity of OCT, IVUS appears to be superior for quantitative measurements 
of vessel- and stent dimensions of Mg in-vivo.
3:30 p.m.
2523-840 Hypoadiponectinemia Is Associated With Greater 
Atheroma Burden in Reference Segment of Coronary 
Artery
Hideki Kitahara, Yoshio Kobayashi, Issei Komuro, Chiba University Graduate School of 
Medicine, Chiba, Japan
Background: There is little information about relationship between plasma adiponectin 
and plaque burden in reference segment of coronary artery.
Methods: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention 
(PCI) and measurement of plasma high-molecular weight adiponectin were performed 
in 80 patients. Lumen and external elastic membrane (EEM) areas in segment without 
signiﬁcant stenosis (<50% stenosis) were measured at 1-mm intervals; the target lesion 
for PCI including 5-mm proximal and distal references were excluded. Median measured 
length was 23 mm. To compensate the difference in pullback length among coronary 
arteries, normalized total plaque and media volume (TPV) was calculated as TPV 
/ number of slices in pullback × median number of slices in study population. Percent 
plaque and media volume (PPV) was calculated as TPV / £ external elastic membrane 
cross-sectional area × 100. Patients were classiﬁed into 2 groups according to adiponectin 
level: adiponectin q4 μg/mL (n=34) and <4 μg/mL (n=46).
Results: There was no signiﬁcant difference in the incidence of diabetic patients between 
the normal adiponectin group and the hypoadiponectin group (32% vs. 26%, p=0.54). 
Table shows IVUS measurements. There was signiﬁcant correlation between adiponectin 
level and normalized TPV (r=-0.26, p=0.02) and PPV (r=-0.46, p<0.001).
Conclusion: Hypoadiponectinemia may be associated with greater plaque burden in 
reference segment of coronary artery.
Results
Adiponectin level q4 μg/mL <4 μg/mL p Value
Normalized EEM volume (mm3) 280 ± 109 295 ± 114 0.55
Normalized lumen volume (mm3) 172 ± 58 157 ± 65 0.29
Normalized TPV (mm3) 108 ± 59 138 ± 60 0.03
PPV (%) 36.9 ± 8.4 46.2 ± 8.6 <0.001
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0.03, and 28 to 10 mm Hg, p = 0.03, respectively).
Conclusions: The study suggests that pulmonary valvuloplasty in adults using the Inoue 
balloon catheter technique is feasible, safe, and effective.
3:30 p.m.
2524-846 Adverse Event Rates in Congenital Cardiac 
Catheterization - A Multi-center Experience
Lisa Bergersen, Audrey Marshall, Kimberlee Gauvreau, John Moore, Susan Foerster, 
David Balzer, Robert Beekman, Russel Hirsch, William Hellenbrand, Julie Vincent, John 
Cheatham, Ralf Holzer, James Lock, Kathy Jenkins, Children’s Hospital Boston, Boston, MA
Background: Single-center adverse event rates for patients with congenital heart disease 
undergoing cardiac catheterization vary considerably, due to non-comparable standards 
of data inclusion, and highly variable case mix.
Methods: A web based data entry application was developed for the Congenital 
Cardiac Catheterization Outcomes Project (C3PO) which prospectively captured 
case characteristics and adverse events (AE). Validity and completeness of data was 
independently audited. All AE were reviewed by two cardiologists for ﬁnal classiﬁcation 
of event severity.
Results: Between 2/1/07 and 4/30/08, the database captured 630 biopsy, 1099 
hemodynamic, and 2126 interventional cases at 6 participating institutions. The 
median number of cases performed per site was 480 (308 to 1526). The data revealed 
two distinct cath lab practices with 3 institutions performing a higher frequency of 
interventions (excluding biopsies) during a case, 70 to 72% compared to 56 to 57% 
in the others. General anesthesia was used in median 70% of cases, varying from 28 
to 99% between institutions. 22% (range 15 to 26%) of cases were non-electively or 
emergently performed. The median rate of AE reported by institution was 16%, ranging 
from 5 to 18%. For interventional cases the median rate of AE reported by institution was 
19% (7 to 25%) and 10% for hemodynamic cases (6 to 17%). The incidence of adverse 
events was signiﬁcantly higher for interventional compared to hemodynamic cases (20% 
vs 11%, p<0.001), as was the incidence of higher severity adverse events (9% vs 4%, 
p<0.001). Major or catastrophic adverse events occurred in 3% of interventional and 1% 
of hemodynamic cases, p<0.001. Adverse events in biopsy cases were uncommon, 4% 
overall, with <1% considered clinically signiﬁcant.
Conclusions: In this multi-institutional cohort the incidence of AE is higher and includes 
more severe events among interventional cases compared to hemodynamic, and is very 
low among biopsy cases. It is likely that case mix diversity affects institutional AE rates 
and equitable comparisons will require risk adjustment methods.
3:30 p.m.
2524-847 Pediatric Interventional Cardiology in the U.S. is 
Dependent on the Off-Label Use of Approved Medical 
Devices
Jamie S. Sutherell, Russel Hirsch, Robert H. Beekman, III, Cincinnati Children’s Hospital 
Medical Center, Cincinnati, OH
Background: The off-label use of approved medical devices is routine in pediatric 
interventional cardiology, but this practice is not well documented or described. 
Disadvantages of off-label use include: 1) lack of regulatory oversight to assure device 
safety and efﬁcacy; and 2) inability of industry to reﬁne devices for off-label pediatric 
applications. The purpose of this study is to evaluate the current prevalence and nature of 
off-label device use in an active pediatric interventional program.
Methods: A retrospective review of all non-investigational interventional cardiac 
procedures (excluding biopsies and EP ablations) performed at our institution between 
July 1, 2005 and June 30, 2008. Interventions performed were compared to the 
manufacturer’s labeled indications for each device. Multiple coils were counted once.
Results: During this 3-year period 473 patients (median age 4 years) underwent 595 
transcatheter interventions. An approved device was utilized for an off-label application 
in 63% of patients, and in 50% of all interventions performed. The most frequent off-label 
procedures were stent implantations (99% off-label) and balloon dilations (78%).
Device Type Total Interventions On-Label Off-Label
Balloons (Angioplasty, Valvuloplasty) 243 54 (22%) 189 (78%)
Occlusion Devices (Septal, Ductal) 169 156 (92%) 13 (8%)
Embolization Coils 80 57 (71%) 23 (29%)
Stents (Biliary, Coronary, Bronchial) 67 1 (1%) 66 (99%)
Septostomy Catheters 18 18 (100%) 0 (0%)
Other Devices (e.g. IVC Filter, RF Wire, 
Blade, Cutting Balloon) 18 9 (50%) 9 (50%)
Conclusions: In our routine (non-investigational) practice of pediatric interventional 
cardiology, 63% of patients underwent procedures utilizing medical devices for off-label 
indications. These data underscore the need to enhance cardiac device review and 
approval processes in the U.S. to include pediatric applications.
3:30 p.m.
2524-848 Angiojet Rheolytic Thrombectomy in Infants With 
Congenital Heart Disease
Gregory Fleming, Khan Mohammed, Dana Janssen, Thomas Doyle, Vanderbilt 
Children’s Hospital, Nashville, TN
Background: Thrombotic complications after pediatric cardiac surgery can be life 
threatening. Surgical thrombectomy and pharmacologic thrombolysis carry signiﬁcant 
risk in these patients. Angiojet rheolytic thrombectomy (Possis Medical, Minneapolis, MN) 
data on long-term follow-up results. This study evaluated the long-term (up to 22 years) 
follow-up results of BA in adolescent and adult patients with discrete (shelf-like) aortic 
coarctation (AC) and compare the ﬁndings with the reported results of stenting of AC.
Methods: Follow-up data of 58 patients (mean age 24±9 years) undergoing BA 
for discrete AC at median interval of 13.4 years (range 1-22 years) including cardiac 
catheterization, magnetic resonance imaging, and Doppler echocardiography form the 
basis of this study.
Results: No early deaths occurred. Balloon angioplasty produced immediate reduction in 
peak AC gradient from 60±22 mmHg to 8.5±8 mmHg (P<0.0001). Follow-up catheterization 
12 months later revealed a residual gradient of 5±6.4 mmHg (P=0.01). Five patients (8%) 
with suboptimal initial outcome (peak gradient>20 mm Hg) developed restenosis, and 4 
of these had successful repeat angioplasty. Aneurysm developed at the site of dilatation 
in 4 patients (7%). Follow-up magnetic resonance imaging (up to 22 years) revealed no 
new aneurysm. In one patient, the aneurysm increased in size, but no recoarctation or 
appreciable changes in the Doppler gradient across the AC site was noted. The blood 
pressure had normalized without medical treatment in 29 (50%) of the 58 patients.
Conclusions: Long-term results of BA for discrete AC are excellent and compare 
favorably with the reported results of stenting, accordingly stenting is not necessary for 
discrete AC.
3:30 p.m.
2524-844 Balloon Aortic Valvuloplasty in Neonates: a Single-
Center 10-year Experience
Christopher J. Petit, Frank F. Ing, Raphael Mattamal, Alan W. Nugent, Henri Justino, 
Baylor College of Medicine, Houston, TX
Background: Severe aortic valve stenosis in neonates is among the most challenging 
forms of congenital heart disease. Balloon aortic valvuloplasty is the treatment of choice, 
though rates of complications and need for surgical or catheter-based re-intervention 
have been reported to be high. We report a 10 year experience with this procedure.
Methods: The records of all neonates (age <33 days) who underwent balloon aortic 
valvuloplasty at Texas Children’s Hospital from January 1, 1998 to October 30, 2008 were 
reviewed. Pre- and post-procedure echocardiographic, catheterization, and surgical data 
were obtained. Attention was paid to baseline and post-procedure valve gradient, aortic 
and mitral valve insufﬁciency, left ventricular systolic function, and need for repeat cath or 
surgical procedures, including valvotomy, Ross, or prosthetic valve replacement.
Results: 39 neonates underwent valvuloplasty at a mean age of 14.6 (±10.8) days and 
weight of 3.18 (± 0.61) kg. The peak and mean gradients by echo were 78.5 (±28.4) 
and 43.0 (±16.7) mmHg respectively. Catheterization demonstrated pressure gradient 
was 60.0 (±25.8) mmHg, which decreased to 16.5 (±8.5) mmHg following balloon 
valvuloplasty (p<0.01). Aortic insufﬁciency increased from a baseline of 0.17 (±0.38) to 
0.85 (±0.66) based on a 4-point grading system (p<0.01). At a follow-up of 2.7 (± 3.0) 
years, the mean valve gradient by echo was 16.6 (±10.8) mmHg, and aortic insufﬁciency 
1.8 (±0.9). 5 patients (12.8%) underwent repeat valvuloplasty 136 (±58) days following 
the initial catheterization and 4 other patients (10.2%) underwent Ross or prosthetic valve 
replacement. Of three patients who underwent prograde valvuloplasty, 2 experienced 
severe mitral injury, one requiring surgical replacement. Two patients experienced cardiac 
arrest. There were no deaths.
Conclusion: Balloon aortic valvuloplasty is an effective and safe therapy for critical and 
severe neonatal aortic valve stenosis. Aortic valve insufﬁency commonly increases to 
a mild degree following intervention, and rarely, mitral injury can occur with prograde 
approach. Approximately one quarter of neonates will require repeat balloon or surgical 
intervention.
3:30 p.m.
2524-845 Pulmonary Valvuloplasty in Adults Using the Inoue 
Balloon Catheter
Hung Manh Pham, Hieu Lan Nguyen, Quang Ngoc Nguyen, Hung Minh Nguyen, Huong 
Nam Khong, Loi Doan Do, Viet Lan Nguyen, Khai Gia Pham, Hanoi Medical School, 
Hanoi, Viet Nam, Vietnam Heart Insitute, Bachmai Hospital, Hanoi, Viet Nam
Background: Although pulmonary valvular stenosis is not uncommon in adults. There are 
few reports of percutaneous pulmonary valvuloplasty in adults, especially using Inoue balloon. 
OBJECTIVES: This report describes the experience in adult patients undergoing Pulmonary 
valvuloplasty using Inoue balloon and evaluates its effectiveness and tolerance.
Methods: Over an 8-year period (2000-2007), pulmonary valvuloplasty using Inoue 
balloon was considered in 71 adult patients [43 men, 28 women; mean age 28.0 years 
± standard deviation (SD) 10.3; range 16-53 years] with congenital pulmonary valve 
stenosis. Thirty-four patients were asymptomatic with pulmonary systolic murmurs, 
although 36 patients presented with dyspnea. Before the procedure, the peak-to-peak 
transpulmonary valve gradient was 91±40 mmHg SD, with a mean right ventricular 
systolic pressure of 107±41 mmHg SD.
Results: The procedure was technically successful in all patients but one (98.59%). One 
failure because balloon could not pass through pulmonary oriﬁce valve due to very tight 
valve stenosis. Among all patients with technical success all tolerated well and free of 
major complications. The mean right ventricular systolic pressure and the pulmonary 
valvular peak-to-peak systolic gradient decreased from 107±41 to 56±19 mm Hg (p = 
0.001) and 91±40 to 21±7 mm Hg (p = 0.0002), respectively. An infundibular peak-to-peak 
systolic gradient either developed (n = 23) or increased (n = 19). None of these patients 
were treated with beta-adrenergic blockers before or after the valvuloplasty. Incontrast, 
this gradient decreased or did not develop in the remain patients who were on beta- 
blokers before procedures. All patients underwent echo follow up study for 6 - 60 months 
(mean 24) after treatment, and had no evidence of valvular restenosis. The mean right 
ventricular systolic pressure and the mean infundibular peak-to-peak systolic gradient 
decreased, compared to the values immediately after valvuloplasty (56 to 47 mm Hg, p = 
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SBP gradient(mmHg), preprocedure (mean± sd) 23.4 ± 18.4 32.0 ± 21.0 0.08
SBP gradient(mmHg), postprocedure (mean± sd) 6.4 ± 11.3 22.27 ± 17.7 0.001
SBP gradient(mmHg), follow up (mean± sd) 7.0 ± 8.5 5.65 ± 8.9 0.35
Antihypertensives, postprocedure 7/41 25/38 0.0001
Antihypertensives, follow up 3/41 10/38 0.03
7/41 pts in ST group (17%) were treated with an oral anti-hypertensive while 25/38 in SU 
group (71.4%) were treated with IV medication followed by an oral regimen. At time of 
ﬁrst clinic follow up, 3/41 ST pts (7.3%) and 10/38 SU pts (26.3%) continued to require 
antihypertensive medications.
Conclusion: Within 24 hours post procedure, the incidence of paradoxical HTN, the 
SBP gradient and use of antihypertensives were signiﬁcantly higher in the SU group 
as compared to the ST group. By the time of 1st clinic follow up, SBP and SBP gradients 
were comparable for both groups, although the SU group continue to require more use of 
medications to control HTN.
I2.ORAL CONTRIBUTIONS
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4:30 p.m.
2911-5 Late Lumen Enlargement and Plaque Regression 
Following Use of the Bioabsorbable Everolimus 
Eluting Coronary Stent System --- 2-year IVUS and OCT 
Results of the ABSORB Study
Yoshinobu Onuma, Patrick W. Serruys, Evelyn Regar, Hector Garcia-Garcia, Nieves 
Gonzalo, Susan Veldhof, John A. Ormiston, the ABSORB investigators, Thorax center, 
Erasmus MC, Rotterdam, The Netherlands
Background: Metallic drug eluting stents have dramatically reduced restenosis rates 
after percutaneous coronary intervention. However, permanent metallic implants 
may predispose to late stent thrombosis, endothelial dysfunction, hinder surgical 
revascularization and impair coronary imaging with MRI or CT.
Methods: The purpose of the ABSORB Clinical Investigation is to assess the safety and 
performance of the fully absorbable everolimus-eluting stent (BVS EECSS, Abbott Vascular, 
Mountain View, CA) in the treatment of patients with a single de novo native coronary artery 
lesion. Follow-up with multiple imaging modalities including angiography, IVUS, IVUS-VH and 
optical coherence tomography (OCT), were obtained at the 6-month and 2-year time points.
Results: Enrolment of 30 patients at 4 clinical sites in Europe and New Zealand was 
completed in July 2006. At 2-year follow up the device was shown to be safe with no stent 
thromboses or ischemic driven target lesion revascularizations reportetd. The 2-year serial 
angiography demonstrated an acceptable in-stent late loss of 0.46 mm. The 2-year serial 
IVUS and OCT results, summarized below, are consistent in showing early lumen loss to 6 
months, followed by late lumen expansion. IVUS also shows plaque regression at 2 years.
Conclusion: Use of a bioabsorbable everolimus eluting stent is associated with late 
lumen enlargement and late regression of plaque volume, which will be discussed along 
with results from additional imaging endpoints.
IVUS and OCT results
Post procedure 6 months 2 years
Serial IVUS results
Vessel Volume (mm3) 182.92 186.75 183.74
Plaque Volume (mm3) 99.11 116.49 100.73
Lumen Volume (mm3) 82.83 68.98 82.41
Serial OCT results
Lumen volume (mm3) 84.1 58.0 74.1
4:42 p.m.
2911-6 The Prevalence of IVUS-Assessed Vulnerable Plaque 
Increases With Diabetes Duration
Jason B. Lindsey, Joshua M. Stolker, John A. House, Steven P. Marso, Mid America 
Heart Institute, Kansas City
Background: Subjects with diabetes mellitus (DM) are at increased risk for MI. Longer 
duration of DM is associated with adverse cardiovascular (CV) events; however, the 
mechanism for this risk is unknown. Therefore, we describe the relationship between DM 
duration and the frequency of vulnerable plaque, deﬁned as intravascular ultrasound-
Virtual HistologyTM (IVUS-VH)-derived thin cap ﬁbroatheroma (TCFA).
Methods: Subjects were enrolled in an IVUS sub-study of a biomarker and gene banking 
registry. All patients underwent coronary angiography and IVUS-VH. The region of interest 
was the worst 10mm segment (greatest plaque volume over an axial distance of 10mm). 
TCFA was deﬁned as plaque thickness>600 μm and >50% plaque burden with conﬂuent 
necrotic core >14 pixels along the circumference of the lumen on 3 consecutive frames. 
DM duration was assessed by self report
Results: Of 63 diabetic subjects, 51% had DM q10 years. Patients with DM >10 years 
were older and less likely to smoke than those with DM <10 years. In univariate analysis, 
patients with DM >10 years had signiﬁcantly more median (IQR) TCFA than those with 
DM <10 years (52.4% [5.7-77.5] vs 11.5% [0-26.1], p= 0.02). This relationship persisted 
after multivariable adjustment (Figure).
Conclusion: DM duration q10 years is independently associated with increased 
is a percutaneous method of thrombus removal with proven safety and efﬁcacy in adults 
with acute myocardial infarctions, pulmonary embolism, and other indications. We present 
our experience with the Angiojet thrombectomy catheter for percutaneous thrombectomy 
in infants following congenital cardiac surgery.
Methods: We searched our institutional cardiac catheterization database for infants who 
underwent Angiojet thrombectomy, and we reviewed the medical records and angiograms 
of each patient identiﬁed. The Vanderbilt University Institutional Review Board approved 
this study.
Results: Between 11/2005 and 10/2008, ten procedures were performed in eight infants. 
The procedure was performed a mean of 23 days from surgery (range 1 to 76 days). The 
mean age was 74 days (range 1 to 276 days) with a mean weight of 4.3 kg (range 3.0 to 
6.8 kg). All patients had life or limb threatening thrombosis. Indications for thrombectomy 
included severe cyanosis, chronic pleural effusions secondary to extensive venous 
thrombosis, and acute iliac artery thrombosis. Thrombus was evacuated from pulmonary 
arteries in three patients, systemic veins in four patients, a surgical aorto-pulmonary 
shunt in two patients, and an iliac artery in one patient. Balloon angioplasty following 
thrombectomy was performed in 75% of cases. All patients had signiﬁcant improvement 
in ﬂow across the affected area. Two patients required ECMO support at the time of the 
procedure and were successfully weaned from ECMO support following the procedure. 4F 
and 5F catheters were used in all procedures. There was one major complication and three 
minor complications with no procedural related deaths. Survival to discharge was 62.5%.
Conclusions: Angiojet thrombectomy is an effective treatment for life threatening 
postoperative thrombotic complications in infants with congenital heart disease.
3:30 p.m.
2524-849 Left lateral approach to pericardiocentesis in children 
and infants
Frank F. Ing, John Breinholt, Richard O’Brien, Christopher Petit, David Nelson, James 
Mathewson, Texas Children’s Hospital, Houston, TX
Background: Pericardiocentesis in children & infants has traditionally utilized the subxiphoid 
approach originally described by Marfan over 100 years ago. However, the left lateral (LL) 
approach using echocardiographic guidance offers an equally effective but shorter, more 
direct & perhaps safer route, especially for those pericardial effusions (PCE) that are 
loculated &/or posterolaterally located. We report our experience with this approach.
Methods: The records of all pts who underwent pericardiocentesis using the LL approach 
from 1/07 to 9/08 at Texas Children’s Hospital were reviewed. Pt proﬁle included age 
& primary diagnosis. Pre-procedure echocardiographic measurements of the PCE were 
reviewed including size of effusion (mm) seen at the subxiphoid & the posterolateral 
locations. Procedural data included location of entry, depth of needle required to enter the 
pericardium, amount & type of ﬂuid removed, & complications.
Results: 17 pts (19 procedures) underwent this approach during the study period. Median 
age was 8.8 yr (range:1mo-17.25 yr). Presumed etiology was related to blood dycrasias 
(7), post viral (4), post-op (2), and others (4). Mean effusion was 7.8 ± 4.2mm inferiorly 
and 19.3 ± 6.2 mm posterolaterally. Needle entry were all in the LL (15) or peri-apical 
region (2). Depth of needle entry before ﬂuid was reached ranged from 5 to 20 mm. Single 
attempt was successful in 17 of 19 procedures while 2 required an additional attempt due 
to entrance into the pleural space. Amount of ﬂuid drained averaged 220 ± 120 cc. Serous 
ﬂuid was noted in all but 3 (serosanguious). Pericardial drains were left in place in 3. Minor 
complications included a small anterior pneumothorax (1) & inadvertent entrance into 
pleural space (2) without further sequelae. No major complications occurred.
Conclusion: The LL approach for pericardiocentesis is safe & effective when there is a 
signiﬁcant posterolateral PCE. Entrance from skin to pericardium is no more than 2 cm 
thereby minimizing errors related to angle & distance of needle penetration. Rare minor 
complications include pneumothorax and entrance into pleural space. This approach 
should be considered in the majority of pts with PCE.
3:30 p.m.
2524-850 Incidence of Paradoxical Hypertension in Stent vs. 
Surgical Treatment for Coarctation of the Aorta
Priti Patel, Oluwatosin Fatusin, O’Brian Smith, Henri Justino, Frank F. Ing, Texas 
Children’s Hospital, Houston, TX, Baylor College of Medicine, Houston, TX
Background: Paradoxical hypertension (HTN) has been reported following surgical 
(SU) repair of coarctation of the aorta (COA). This complication is not well deﬁned in pts 
following stent (ST) treatment for COA.
Methods: Retrospective chart review was performed of pts who underwent either ST 
or SU treatment for COA from 1/98 to 8/08 at our institution. When adjusted for weight 
>20 kg, 79 pts were identiﬁed for the study (41 pts in the ST & 38 in the SU groups). 
4-extremity systolic blood pressure (SBP) pre & post treatment as well as at 1st clinic 
follow up and use of anti-hypertensive medications were reviewed. SBP was deﬁned 
as the average upper extremity SBP while SBP gradient was deﬁned as the difference 
between the average upper & lower extremity SBP. HTN was deﬁned as SBP q 95th
percentile for age and/or treatment with antihypertensives.
Results: 
Stent Group SurgicalGroup P value
Age (months) (median±range) 183.4 (56.7- 628.9) 119 (55- 237) 0.001
Weight (kg) (median±range) 55.3 (24-100) 31.5 (20- 74.3) 0.02
1st follow up (days) (median±range) 46.5 (6-630) 12 (7-223) 0.001
SBP(mmHg), preprocedure (mean± sd) 134.7 ± 16.0 130.89 ± 17.4 0.37
SBP(mmHg), postprocedure (mean± sd) 124.9 ± 16.4 128.05 ± 15.8 0.006
SBP(mmHg), follow up (mean± sd) 125.15 ± 13.4 109.65 ± 14.3 0.49
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prevalence of vulnerable plaque classiﬁed as TCFA. This ﬁnding may explain the increased 
CV risk associated with longer duration of DM, although further study is warranted. 
4:54 p.m.
2911-7 Virtual Histology Intravascular Ultrasound Analysis 
of Attenuated Plaques Detected by Greyscale 
Intravascular Ultrasound in Patients With Acute 
Coronary Syndromes: A PROSPECT Substudy
Xiaofan Wu, Akiko Maehara, Gary S. Mintz, Takashi Kubo, Hiroshi Doi, Kenichi Tsujita, 
Junqing Yang, Carlos Oviedo, Kai Xu, Yong He, Ning Guo, So-Yeon Choi, Celia 
Castellanos, Jeffrey W. Moses, Marin B. Leon, Bernard De Bruyne, Patrick W. Serruys, 
Gregg W. Stone, Cardiovascular Research Foundation, New York, NY
Background: Noncalciﬁc, attenuated plaque identiﬁed by greyscale intravascular 
ultrasound (IVUS) is often seen in pts with acute coronary syndromes (ACS) and is 
associated with no reﬂow and CK-MB elevation post-PCI; Histopathology in a small 
number of patients has shown cholesterol clefts, microcalciﬁcation, or organized 
thrombus. The causes of this greyscale IVUS appearance are unknown.
Methods: We used virtual histology IVUS (VH-IVUS) to study 102 non-stented segments 
(which included 38 attenuated plaques) in 64 ACS pts from the PROSPECT trial; the 
minimum lumen area site not containing an attenuated plaque was used as control (n=64).
Results: VH-IVUS lesion phenotype included 30 thin-cap ﬁbroatheroma (TCFA), 45 thick 
cap ﬁbroatheroma (ThFA), and 27 pathological intimal thickening (PIT), but no ﬁbrous of 
ﬁbrocalciﬁc plaques. Fibroatheromas - TCFA or -ThFA were more common at the site of 
attenuated plaques than at control sites (97.4% vs 59.4%, P<0.0001) and were associated 
with larger necrotic areas (1.4±0.7mm2 vs 1.1±0.9mm2, P=0.047) (example in the ﬁgure).
Conclusions: One cause of greyscale plaque attenuation appears to be a large amount 
of necrotic core. As a result, noncalciﬁc, attenuated plaque identiﬁed by greyscale IVUS 
indicates the presence of a ﬁbroatherma (TCFA or ThFA) assessed by VH-IVUS. 
5:06 p.m.
2911-8 Predictors of No-Reﬂow After Percutaneous Coronary 
Intervention in Acute Myocardial Infarction Patients 
With Plaque Rupture
Young Joon Hong, Myung Ho Jeong, Yun Ha Choi, Jum Suk Ko, Min Goo Lee, Won 
Yu Kang, Shin Eun Lee, Soo Hyun Kim, Doo Sun Sim, Keun Ho Park, Nam Sik Yoon, 
Hyun Ju Youn, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Youngkeun Ahn, Jeong 
Gwan Cho, Jong Chun Park, Jung Chaee Kang, The Heart Center of Chonnam National 
University Hospital, Gwangju, South Korea
Background: Plaque rupture (PR) and subsequent thrombus formation is the most 
important mechanism leading to an acute myocardial infarction (AMI). Distal embolization 
and no-reﬂow during percutaneous coronary intervention (PCI) carries a poor prognosis 
in AMI patients. It is unclear which factors are associated with no-reﬂow after PCI in AMI 
patients with PR. The aim of this study was to investigate the predictors of the no-reﬂow 
phenomenon after PCI in AMI patients with PR.
Methods: The study group comprised 112 AMI patients who underwent stent implantation 
and pre- and post-PCI IVUS examinations. Angiographic no-reﬂow was deﬁned as TIMI 
ﬂow grade 0, 1, and 2. IVUS ﬁndings included multiple ruptured plaques (PRs separated 
by a >5-mm length of artery containing smooth lumen contours), thrombus (had a 
layered lobulated appearance, evidence of blood ﬂow within the mass, and speckling or 
scintillation), and plaque prolapse (tissue extrusion through the stent struts).
Results: Of 112 patients who underwent pre- and post-stenting IVUS, no-reﬂow was observed 
in 17 patients (15.2%). High-sensitivity C-reactive protein (hs-CRP) was signiﬁcantly higher 
(6.2±6.0 mg/dl vs. 2.2±2.9 mg/dl, p=0.002) and baseline TIMI ﬂow grade was signiﬁcantly 
lower in no-reﬂow group (TIMI ﬂow grade <3: 59% vs. 18%, p<0.001). Lesion site plaque plus 
media area was signiﬁcantly greater (12.9±2.6 mm2 vs. 10.8±4.2 mm2, p=0.009), remodeling 
index was signiﬁcantly higher (1.14±0.17 vs. 1.03±0.20, p=0.031), and the presence of 
IVUS-detected thrombus (88% vs. 56%, p=0.012), culprit lesion multiple plaque ruptures 
(71% vs. 37%, p=0.009), and plaque prolapse (65% vs. 34%, p=0.015) were signiﬁcantly 
more common in no-reﬂow group. In the multivariate analysis, plaque prolapse (HR=33.02; 
95% CI 3.38-322.75, p=0.003), hs-CRP (HR=1.03; 95% CI 1.01-1.05, p=0.013), and culprit 
lesion multiple plaque ruptures (HR=15.73; 95% CI 1.61-153.46, p=0.018) were independent 
predictors of post-PCI no-reﬂow in AMI patients with PR.
Conclusions: Elevated hs-CRP and IVUS-detected multiple plaque ruptures and plaque 
prolapse are associated with post-PCI no-reﬂow in AMI patients with PR.
5:18 p.m.
2911-9 New Index of Microvascular Resistance Reserve for 
Evaluating Residual Myocardial Viability in Patients 
With Prior Myocardial Infarction
Koichi Tamita, Atsushi Yamamuro, Shuichiro Kaji, Minako Katayama, Makoto Kinoshita, 
Natsuhiko Ehara, Takeshi Kitai, Takefumi Yamane, Yoshimori An, Kite Kim, Yutaka 
Furukawa, Takashi Akasaka, Kobe General Hospital, Kobe, Japan, Wakayama Medical 
College, Wakayama, Japan
Background: Fractional ﬂow reserve (FFR) and coronary blood ﬂow velocity reserve 
(CFR) represent physiological quantities used to evaluate coronary lesion severity and 
to make clinical decisions. However, resistive vessel dysfunction may blunt the maximal 
hyperemic response in patients with prior myocardial infarction (MI). The aim of this study 
was to examine the effect of residual viability on intracoronay physiological assessments 
in the infarct-related coronary arteries.
Methods: FFR and CFR were assessed in 52 consecutive patients with 52 intermediate 
coronary lesions (between 40% and 70% diameter stenosis by visual assessment) in 
the infarct-related coronary arteries. Flow-derived microvascular resistance (MVR) was 
calculated as the ratio of mean distal pressure to average peak blood ﬂow velocity. MVR 
reserve (MVRR) was deﬁned as the ratio of MVR at rest to hyperemic MVR. Patients were 
divided into two groups based on residual myocardial viability assessed by thallium-201 
SPECT; 38 patients with viable myocardium and 14 patients with nonviable myocardium 
in the infracted area. Redistribution patterns or residual maximal myocardial activity >50% 
are indices of tissue viability.
Results: Intracoronay physiological assessments showed signiﬁcantly lower hyperemic 
averaged peak blood ﬂow velocity (29.8±10.1 vs 41.7±16.8 cm/s; p=0.016), higher FFR 
(0.88±0.07 vs 0.82±0.09; p=0.026), lower CFR (2.15±0.79 vs 2.78±0.90; p=0.025), higher 
hyperemic MVR (2.63±0.92 vs 1.83±0.75 mmHg/cm/s; p=0.0051), and lower MVRR 
(2.47±1.03 vs 3.50±1.32; p=0.011) in nonviable myocardial group compared with viable 
group. The best cutoff value to predict residual viable myocardium was 2.3 for hyperemic 
MVR (sensitivity=0.89 and speciﬁcity=0.67).
Conclusion: These data indicate that the hemodynamic impact of intermediate coronary 
lesions depends on the amount of residual myocardial viability in patients with prior 
MI. The evaluation of MVR is clinically useful to assess residual myocardial viability in 
patients with prior MI.
5:30 p.m.
2911-10 Near-Infrared Spectroscopic Detection of Lipid-Core 
Coronary Plaques Remote From the Target Lesion in 
Patients Undergoing PCI
James A. Goldstein, Simon R. Dixon, Philippe L. L’Allier, Jeffrey W. Moses, John L. 
Petersen, Donald E. Cutlip, Giora Weisz, Robert D. Saﬁan, Michael J. Hendricks, 
Stephen T. Sum, James E. Muller, Mitchell W. Krucoff, Jean-Claude Tardif, Sergio 
Waxman, Gregg W. Stone, William Beaumont Hospital, Royal Oak, MI, Montreal Heart 
Institute, Montreal, QC, Canada
Background: It has been observed that patients (pts) undergoing PCI often have multiple 
unstable plaques by angiography. A catheter-based near-infrared spectroscopy (NIRS) 
system has recently been cleared by the FDA for detection of LCP. We utilized this NIRS 
system to identify LCP remote from the target lesion that might be associated with a 
higher risk of a subsequent coronary event.
Methods: Scanning NIRS was performed in pts in the SPECTACL study undergoing PCI 
for stable angina or an acute coronary syndrome. Target lesions for PCI were identiﬁed by 
conventional angiography. The target vessel was then analyzed for the presence of LCP 
remote (q10mm) from the target lesion.
Results: NIRS scans of a single vessel were performed in 56 patients. NIRS revealed 
remote LCP in 11 of the 56 pts. The remote LCP was associated with a signiﬁcant 
stenosis (>50% diameter narrowing detected by angiography) in only 2 of the patients; 
in the remaining 9, the remote LCP was not associated with a stenosis and hence not 
detectable by conventional methods.
Conclusions: NIRS results indicate that the occurrence of LCP remote from the 
target lesion, and not associated with stenosis, is a relatively frequent ﬁnding. Figure 
1. Chemogram from a subject enrolled in SPECTACL indicating LCP (yellow) proximal 
and distal (62mm, 50mm, and 2mm locations) at a location remote to the target stenosis 
(green). Angiographically, the vessel diameters at these remote LCP are not narrowed.
